{"sentence": "Concomitant use of digoxin and sympathomimetics increases the risk of cardiac arrhythmias.", "drug1": "digoxin", "drug2": "sympathomimetics", "relation": "EFFECT", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s10", "pair_id": "DDI-DrugBank.d450.s10.p0"}
{"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Hexobarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d457.s0", "pair_id": "DDI-DrugBank.d457.s0.p4"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "ethosuximide", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p15"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "Acetaminophen", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p0"}
{"sentence": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "drug1": "kaolin", "drug2": "chloroquine", "relation": "MECHANISM", "source_file": "Chloroquine_ddi.xml", "sentence_id": "DDI-DrugBank.d429.s0", "pair_id": "DDI-DrugBank.d429.s0.p9"}
{"sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "loop diuretics", "relation": "EFFECT", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s19", "pair_id": "DDI-DrugBank.d46.s19.p4"}
{"sentence": "If antacids are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the antacid.", "drug1": "OMNICEF", "drug2": "antacid", "relation": "ADVISE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s3", "pair_id": "DDI-DrugBank.d420.s3.p5"}
{"sentence": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.", "drug1": "pancreatin", "drug2": "Acarbose", "relation": "MECHANISM", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s4", "pair_id": "DDI-DrugBank.d536.s4.p14"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p30"}
{"sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.", "drug1": "celecoxib", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s8", "pair_id": "DDI-DrugBank.d172.s8.p1"}
{"sentence": "Coadministration of phenytoin with 40 mg SULAR tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.", "drug1": "phenytoin", "drug2": "SULAR", "relation": "MECHANISM", "source_file": "Nisoldipine_ddi.xml", "sentence_id": "DDI-DrugBank.d106.s3", "pair_id": "DDI-DrugBank.d106.s3.p0"}
{"sentence": "Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.", "drug1": "VIRACEPT", "drug2": "astemizole", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s12", "pair_id": "DDI-DrugBank.d340.s12.p0"}
{"sentence": "Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "drug1": "anesthetics", "drug2": "DILAUDID", "relation": "EFFECT", "source_file": "Hydromorphone_ddi.xml", "sentence_id": "DDI-DrugBank.d26.s0", "pair_id": "DDI-DrugBank.d26.s0.p14"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "carbamazepine", "drug2": "resorcinol", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p279"}
{"sentence": "Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.", "drug1": "Clidinium", "drug2": "levodopa", "relation": "EFFECT", "source_file": "Clidinium_ddi.xml", "sentence_id": "DDI-DrugBank.d322.s1", "pair_id": "DDI-DrugBank.d322.s1.p1"}
{"sentence": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.", "drug1": "gentamicin", "drug2": "ibuprofen", "relation": "NONE", "source_file": "Adefovir Dipivoxil_ddi.xml", "sentence_id": "DDI-DrugBank.d244.s0", "pair_id": "DDI-DrugBank.d244.s0.p12"}
{"sentence": "The addition of 540 mg/kg/day of cromolyn sodium (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of isoproterenol (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.", "drug1": "cromolyn sodium", "drug2": "isoproterenol", "relation": "EFFECT", "source_file": "Cromoglicate_ddi.xml", "sentence_id": "DDI-DrugBank.d229.s3", "pair_id": "DDI-DrugBank.d229.s3.p0"}
{"sentence": "Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.", "drug1": "Nabilone", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s1", "pair_id": "DDI-DrugBank.d552.s1.p2"}
{"sentence": "Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.", "drug1": "beta-adrenergic antagonists", "drug2": "alpha-adrenergic stimulants", "relation": "EFFECT", "source_file": "Acebutolol_ddi.xml", "sentence_id": "DDI-DrugBank.d388.s2", "pair_id": "DDI-DrugBank.d388.s2.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "itraconazole", "drug2": "topiramate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p751"}
{"sentence": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "drug1": "fluconazole", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s14", "pair_id": "DDI-DrugBank.d400.s14.p26"}
{"sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "drug1": "vitamin D analogues", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s11", "pair_id": "DDI-DrugBank.d98.s11.p2"}
{"sentence": "A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.", "drug1": "carbamazepine", "drug2": "tetracyclines", "relation": "NONE", "source_file": "Norgestimate_ddi.xml", "sentence_id": "DDI-DrugBank.d360.s1", "pair_id": "DDI-DrugBank.d360.s1.p21"}
{"sentence": "Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.", "drug1": "Thyroid", "drug2": "digoxin", "relation": "ADVISE", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s9", "pair_id": "DDI-DrugBank.d450.s9.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "acetaminophen", "drug2": "temazepam", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p83"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "ethionamide", "drug2": "gold", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p66"}
{"sentence": "Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.", "drug1": "IRESSA", "drug2": "vinorelbine", "relation": "EFFECT", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s8", "pair_id": "DDI-DrugBank.d207.s8.p5"}
{"sentence": "Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.", "drug1": "warfarin", "drug2": "NSAIDs", "relation": "EFFECT", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s22", "pair_id": "DDI-DrugBank.d219.s22.p2"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "loratadine", "drug2": "niacinamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p286"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "benzodiazepines", "drug2": "amiodarone", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p3"}
{"sentence": "1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of phenytoin increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.", "drug1": "phenytoin", "drug2": "Trileptal", "relation": "MECHANISM", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s35", "pair_id": "DDI-DrugBank.d307.s35.p2"}
{"sentence": "Probenecid: Probenecid increases both free and bound ketoprofen by reducing the plasma clearance of ketoprofen to about one-third, as well as decreasing its protein binding.", "drug1": "Probenecid", "drug2": "ketoprofen", "relation": "MECHANISM", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s19", "pair_id": "DDI-DrugBank.d499.s19.p3"}
{"sentence": "Morphine: A literature article reported that when a 60-mg controlled-release morphine capsule was administered 2 hours prior to a 600-mg Neurontin  capsule (N=12), mean gabapentin AUC increased by 44% compared to gabapentin administered without morphine.", "drug1": "morphine", "drug2": "Neurontin", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s26", "pair_id": "DDI-DrugBank.d438.s26.p5"}
{"sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.", "drug1": "Tetracycline", "drug2": "penicillin", "relation": "EFFECT", "source_file": "Dicloxacillin_ddi.xml", "sentence_id": "DDI-DrugBank.d517.s0", "pair_id": "DDI-DrugBank.d517.s0.p1"}
{"sentence": "Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of cobalt on iron absorption and excretion occurred. ", "drug1": "iron", "drug2": "iron", "relation": "NONE", "source_file": "7599505.xml", "sentence_id": "DDI-MedLine.d34.s11", "pair_id": "DDI-MedLine.d34.s11.p4"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "erythromycin", "drug2": "nelfinavir", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p38"}
{"sentence": "Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.", "drug1": "verapamil", "drug2": "diltiazem", "relation": "NONE", "source_file": "Betaxolol_ddi.xml", "sentence_id": "DDI-DrugBank.d489.s7", "pair_id": "DDI-DrugBank.d489.s7.p9"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "estrogen-containing compounds", "drug2": "5-fluorouracil", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p87"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "beta adrenergic blocking agents", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p7"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "MAOIs", "drug2": "fluoxetine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p10"}
{"sentence": "Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ", "drug1": "Amprenavir", "drug2": "rifabutin", "relation": "MECHANISM", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s14", "pair_id": "DDI-MedLine.d3.s14.p0"}
{"sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.", "drug1": "Aprepitant", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s34", "pair_id": "DDI-DrugBank.d382.s34.p0"}
{"sentence": "Withdrawal of rifampin decreased the warfarin requirement by 50%. ", "drug1": "rifampin", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "1115445.xml", "sentence_id": "DDI-MedLine.d116.s4", "pair_id": "DDI-MedLine.d116.s4.p0"}
{"sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.", "drug1": "aluminum hydroxide", "drug2": "antacid", "relation": "NONE", "source_file": "Ethambutol_ddi.xml", "sentence_id": "DDI-DrugBank.d160.s0", "pair_id": "DDI-DrugBank.d160.s0.p5"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "magnesium salicylate", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p8"}
{"sentence": "The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.", "drug1": "loop diuretics", "drug2": "beta-agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s4", "pair_id": "DDI-DrugBank.d284.s4.p5"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "trazodone", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p20"}
{"sentence": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.", "drug1": "bupropion", "drug2": "desipramine", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s14", "pair_id": "DDI-DrugBank.d5.s14.p1"}
{"sentence": "The carbamazepine steady-state Cmin decreased 31% to 5 1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.", "drug1": "carbamazepine", "drug2": "felbamate", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s19", "pair_id": "DDI-DrugBank.d434.s19.p0"}
{"sentence": "- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.", "drug1": "phenytoin", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s14", "pair_id": "DDI-DrugBank.d40.s14.p0"}
{"sentence": "Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.", "drug1": "para-aminosalicylic acid", "drug2": "vitamin B12", "relation": "MECHANISM", "source_file": "Cyanocobalamin_ddi.xml", "sentence_id": "DDI-DrugBank.d39.s1", "pair_id": "DDI-DrugBank.d39.s1.p4"}
{"sentence": "Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.", "drug1": "TNFa-blocking agents", "drug2": "anakinra", "relation": "EFFECT", "source_file": "Infliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d45.s1", "pair_id": "DDI-DrugBank.d45.s1.p1"}
{"sentence": "Caution should be exercised when administering ETOPOPHOS with drugs that are known to inhibit phosphatase activities (e.g., levamisole hydrochloride).", "drug1": "ETOPOPHOS", "drug2": "levamisole hydrochloride", "relation": "ADVISE", "source_file": "Etoposide_ddi.xml", "sentence_id": "DDI-DrugBank.d194.s0", "pair_id": "DDI-DrugBank.d194.s0.p0"}
{"sentence": "If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.", "drug1": "beta blocker", "drug2": "clonidine", "relation": "ADVISE", "source_file": "Atenolol_ddi.xml", "sentence_id": "DDI-DrugBank.d73.s4", "pair_id": "DDI-DrugBank.d73.s4.p0"}
{"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "drug1": "acetylsalicylic acid", "drug2": "Activase", "relation": "INT", "source_file": "Alteplase_ddi.xml", "sentence_id": "DDI-DrugBank.d508.s1", "pair_id": "DDI-DrugBank.d508.s1.p11"}
{"sentence": "Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.", "drug1": "carbamazepine", "drug2": "aripiprazole", "relation": "MECHANISM", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s19", "pair_id": "DDI-DrugBank.d509.s19.p4"}
{"sentence": "Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.", "drug1": "methotrexate", "drug2": "etretinate", "relation": "EFFECT", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s8", "pair_id": "DDI-DrugBank.d353.s8.p2"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "drug1": "epinephrine", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s0", "pair_id": "DDI-DrugBank.d110.s0.p6"}
{"sentence": "Simultaneous administration of SPRYCEL with antacids should be avoided.", "drug1": "SPRYCEL", "drug2": "antacids", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s9", "pair_id": "DDI-DrugBank.d48.s9.p0"}
{"sentence": "Amphetamines may decrease the hypotensive effect of antihypertensives.", "drug1": "Amphetamines", "drug2": "antihypertensives", "relation": "EFFECT", "source_file": "Benzphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d477.s2", "pair_id": "DDI-DrugBank.d477.s2.p0"}
{"sentence": "Concomitant use of calcium supplements and L-lysine may increase calcium absorption", "drug1": "calcium", "drug2": "calcium", "relation": "NONE", "source_file": "L-Lysine_ddi.xml", "sentence_id": "DDI-DrugBank.d344.s0", "pair_id": "DDI-DrugBank.d344.s0.p1"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "barbiturates", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p19"}
{"sentence": "Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;", "drug1": "Phenytoin", "drug2": "phenytoin", "relation": "NONE", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s25", "pair_id": "DDI-DrugBank.d236.s25.p1"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "clofibrate", "drug2": "estrogen-containing compounds", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p63"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "MS Contin", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p34"}
{"sentence": "Albuterol, Antihistamines, antidiabetic drugs, diuretics, digitalis.", "drug1": "antidiabetic drugs", "drug2": "diuretics", "relation": "NONE", "source_file": "Beclomethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d524.s0", "pair_id": "DDI-DrugBank.d524.s0.p7"}
{"sentence": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "ADVISE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s5", "pair_id": "DDI-DrugBank.d400.s5.p0"}
{"sentence": "Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). ", "drug1": "atracurium", "drug2": "gentamycin", "relation": "EFFECT", "source_file": "8542840.xml", "sentence_id": "DDI-MedLine.d90.s7", "pair_id": "DDI-MedLine.d90.s7.p2"}
{"sentence": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "drug1": "FORADIL", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Formoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d103.s3", "pair_id": "DDI-DrugBank.d103.s3.p10"}
{"sentence": "The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .", "drug1": "ENABLEX", "drug2": "ritonavir", "relation": "ADVISE", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s0", "pair_id": "DDI-DrugBank.d459.s0.p2"}
{"sentence": "Concomitant administration of gemfibrozil with Targretin capsules is not recommended.", "drug1": "gemfibrozil", "drug2": "Targretin", "relation": "ADVISE", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s6", "pair_id": "DDI-DrugBank.d467.s6.p0"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "Butalbital", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p4"}
{"sentence": "Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.", "drug1": "carbamazepine", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s22", "pair_id": "DDI-DrugBank.d485.s22.p8"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "monoamine oxidase inhibitors", "drug2": "sulindac", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1225"}
{"sentence": "Aspirin: Concurrent administration of aspirin and flurbiprofen resulted in 50% lower serum flurbiprofen concentrations.", "drug1": "aspirin", "drug2": "flurbiprofen", "relation": "MECHANISM", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s4", "pair_id": "DDI-DrugBank.d529.s4.p3"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "azole antifungals", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p62"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "non-selective beta-adrenergic-blocking agents", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p18"}
{"sentence": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.", "drug1": "diclofenac", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s18", "pair_id": "DDI-DrugBank.d249.s18.p1"}
{"sentence": "The physician should be cautious when administering flurbiprofen to patients taking anticoagulants.", "drug1": "flurbiprofen", "drug2": "anticoagulants", "relation": "ADVISE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s3", "pair_id": "DDI-DrugBank.d529.s3.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "diuretics", "drug2": "paraldehyde", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p204"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "phenytoin", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p23"}
{"sentence": "Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. ", "drug1": "Vitamin E", "drug2": "cypermethrin", "relation": "EFFECT", "source_file": "11137320.xml", "sentence_id": "DDI-MedLine.d126.s6", "pair_id": "DDI-MedLine.d126.s6.p2"}
{"sentence": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "drug1": "aspirin", "drug2": "ketoprofen", "relation": "MECHANISM", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s6", "pair_id": "DDI-DrugBank.d499.s6.p1"}
{"sentence": "Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.", "drug1": "Aprepitant", "drug2": "methylprednisolone", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s13", "pair_id": "DDI-DrugBank.d382.s13.p0"}
{"sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.", "drug1": "heroin", "drug2": "diazepam", "relation": "EFFECT", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s2", "pair_id": "DDI-DrugBank.d514.s2.p3"}
{"sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "drug1": "anticoagulants", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s89", "pair_id": "DDI-DrugBank.d64.s89.p0"}
{"sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "drug1": "bepridil", "drug2": "sparfloxacin", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s18", "pair_id": "DDI-DrugBank.d237.s18.p3"}
{"sentence": "Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.", "drug1": "Lithium", "drug2": "diuretics", "relation": "MECHANISM", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s0", "pair_id": "DDI-DrugBank.d414.s0.p0"}
{"sentence": "Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.", "drug1": "antihistamines", "drug2": "CNS depressant drugs", "relation": "ADVISE", "source_file": "Clemastine_ddi.xml", "sentence_id": "DDI-DrugBank.d309.s1", "pair_id": "DDI-DrugBank.d309.s1.p0"}
{"sentence": "The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. ", "drug1": "rifabutin", "drug2": "rifampin", "relation": "NONE", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s10", "pair_id": "DDI-MedLine.d3.s10.p0"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "macrolide antibiotics", "drug2": "dofetilide", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p11"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "carbamazepine", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p2"}
{"sentence": "Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.", "drug1": "antihypertensive medications", "drug2": "vasodilators", "relation": "EFFECT", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s1", "pair_id": "DDI-DrugBank.d357.s1.p5"}
{"sentence": "Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ", "drug1": "METH", "drug2": "SCH-23390", "relation": "EFFECT", "source_file": "11085305.xml", "sentence_id": "DDI-MedLine.d62.s4", "pair_id": "DDI-MedLine.d62.s4.p0"}
{"sentence": "Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "drug1": "MYOBLOC", "drug2": "curare-like compounds", "relation": "ADVISE", "source_file": "Botulinum Toxin Type B_ddi.xml", "sentence_id": "DDI-DrugBank.d323.s0", "pair_id": "DDI-DrugBank.d323.s0.p1"}
{"sentence": "Methotrexate - There is one report that methotrexate may decrease the possible effectiveness of supplemental L-glutamine for chemotherapy-induced mucositis.", "drug1": "methotrexate", "drug2": "L-glutamine", "relation": "EFFECT", "source_file": "L-Glutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d66.s5", "pair_id": "DDI-DrugBank.d66.s5.p2"}
{"sentence": "Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.", "drug1": "antiarrhythmics", "drug2": "CRIXIVAN", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s59", "pair_id": "DDI-DrugBank.d97.s59.p0"}
{"sentence": "A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.", "drug1": "rifampin", "drug2": "caspofungin", "relation": "MECHANISM", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s10", "pair_id": "DDI-DrugBank.d350.s10.p0"}
{"sentence": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "drug1": "Bezalip", "drug2": "anticoagulants of the coumarin type", "relation": "EFFECT", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s0", "pair_id": "DDI-DrugBank.d291.s0.p8"}
{"sentence": "therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.", "drug1": "nitroglycerin", "drug2": "captopril", "relation": "ADVISE", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s6", "pair_id": "DDI-DrugBank.d175.s6.p1"}
{"sentence": "Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "drug1": "EDECRIN", "drug2": "diuretic", "relation": "NONE", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s7", "pair_id": "DDI-DrugBank.d414.s7.p1"}
{"sentence": "only ibogaine enhances cocaine-induced increases in accumbal dopamine. ", "drug1": "ibogaine", "drug2": "cocaine", "relation": "EFFECT", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s7", "pair_id": "DDI-MedLine.d110.s7.p0"}
{"sentence": "The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.", "drug1": "triazolam", "drug2": "Aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s23", "pair_id": "DDI-DrugBank.d382.s23.p9"}
{"sentence": "Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.", "drug1": "Histamine H2 antagonists", "drug2": "Cimetidine", "relation": "MECHANISM", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s14", "pair_id": "DDI-DrugBank.d143.s14.p0"}
{"sentence": "Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.", "drug1": "Cimetidine", "drug2": "altretamine", "relation": "MECHANISM", "source_file": "Altretamine_ddi.xml", "sentence_id": "DDI-DrugBank.d188.s0", "pair_id": "DDI-DrugBank.d188.s0.p5"}
{"sentence": "In vitro studies have shown no binding displacement between entacapone and other highly bound drugs, such as warfarin, salicylic acid, phenylbutazone, and diazepam.", "drug1": "entacapone", "drug2": "diazepam", "relation": "NONE", "source_file": "Entacapone_ddi.xml", "sentence_id": "DDI-DrugBank.d455.s4", "pair_id": "DDI-DrugBank.d455.s4.p3"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "bupropion", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p211"}
{"sentence": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "drug1": "ketoconazole", "drug2": "valdecoxib", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s28", "pair_id": "DDI-DrugBank.d328.s28.p4"}
{"sentence": "Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.", "drug1": "Bile acid binding resins", "drug2": "hydrocortisone", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s17", "pair_id": "DDI-DrugBank.d345.s17.p1"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "serotoninergic agents", "drug2": "fluvoxamine", "relation": "NONE", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p22"}
{"sentence": "With simultaneous dosing of Vardenafil 20 mg and terazosin 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "drug1": "Vardenafil", "drug2": "terazosin", "relation": "EFFECT", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s30", "pair_id": "DDI-DrugBank.d198.s30.p0"}
{"sentence": "Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).", "drug1": "Ibandronate", "drug2": "antacids", "relation": "ADVISE", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s2", "pair_id": "DDI-DrugBank.d440.s2.p0"}
{"sentence": "Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. ", "drug1": "Acetaminophen", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s9", "pair_id": "DDI-MedLine.d111.s9.p0"}
{"sentence": "Oral Contraceptives Multiple doses of cefditoren pivoxil had no effect on the pharmacokinetics of ethinyl estradiol, the estrogenic component in most oral contraceptives.", "drug1": "Contraceptives", "drug2": "cefditoren pivoxil", "relation": "NONE", "source_file": "Cefditoren_ddi.xml", "sentence_id": "DDI-DrugBank.d550.s0", "pair_id": "DDI-DrugBank.d550.s0.p0"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "benzodiazepines", "drug2": "anticonvulsants", "relation": "EFFECT", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p0"}
{"sentence": "Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.", "drug1": "5-HT3 antiemetics", "drug2": "BUSULFEX", "relation": "NONE", "source_file": "Busulfan_ddi.xml", "sentence_id": "DDI-DrugBank.d72.s1", "pair_id": "DDI-DrugBank.d72.s1.p10"}
{"sentence": "Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.", "drug1": "Dexamethasone", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s0", "pair_id": "DDI-MedLine.d12.s0.p2"}
{"sentence": "Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone. ", "drug1": "TAM", "drug2": "1,25(OH)2D3", "relation": "EFFECT", "source_file": "7654327.xml", "sentence_id": "DDI-MedLine.d53.s4", "pair_id": "DDI-MedLine.d53.s4.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "cimetidine", "drug2": "miconazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p557"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "tetracycline", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p5"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Nizoral", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p14"}
{"sentence": "While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.", "drug1": "estazolam", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s4", "pair_id": "DDI-DrugBank.d338.s4.p0"}
{"sentence": "N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. ", "drug1": "N-methyllevallorphan", "drug2": "morphine", "relation": "EFFECT", "source_file": "7625885.xml", "sentence_id": "DDI-MedLine.d128.s15", "pair_id": "DDI-MedLine.d128.s15.p1"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "anticholinergic", "drug2": "antiarrhythmics", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p6"}
{"sentence": "Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.", "drug1": "Dexamethasone", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s0", "pair_id": "DDI-MedLine.d12.s0.p1"}
{"sentence": "Aspirin: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).", "drug1": "Vardenafil", "drug2": "aspirin", "relation": "NONE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s40", "pair_id": "DDI-DrugBank.d198.s40.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Crixivan", "drug2": "temazepam", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p833"}
{"sentence": "It has been reported that the addition of triamterene to a maintenance schedule of INDOCIN resulted in reversible acute renal failure in two of four healthy volunteers.", "drug1": "triamterene", "drug2": "INDOCIN", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s28", "pair_id": "DDI-DrugBank.d82.s28.p0"}
{"sentence": "In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.", "drug1": "non- steroidal antiinflammatory agent", "drug2": "loop diuretics", "relation": "EFFECT", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s6", "pair_id": "DDI-DrugBank.d414.s6.p0"}
{"sentence": "Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide", "drug1": "lithium", "drug2": "chlorothiazide", "relation": "ADVISE", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s17", "pair_id": "DDI-DrugBank.d46.s17.p0"}
{"sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "drug1": "ZYVOX", "drug2": "serotonergic agents", "relation": "EFFECT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s6", "pair_id": "DDI-DrugBank.d441.s6.p0"}
{"sentence": "The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.", "drug1": "cyclophosphamide", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Cyclophosphamide_ddi.xml", "sentence_id": "DDI-DrugBank.d7.s0", "pair_id": "DDI-DrugBank.d7.s0.p0"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "clarithromycin", "drug2": "telithromycin", "relation": "NONE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p42"}
{"sentence": "Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.", "drug1": "Anagrelide", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s12", "pair_id": "DDI-DrugBank.d75.s12.p0"}
{"sentence": "Since animal studies suggest that the action of barbiturates may be prolonged by therapy with chlorpropamide, barbiturates should be employed with caution.", "drug1": "barbiturates", "drug2": "chlorpropamide", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s7", "pair_id": "DDI-DrugBank.d245.s7.p0"}
{"sentence": "Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.", "drug1": "Diflunisal", "drug2": "hydrochlorothiazide", "relation": "EFFECT", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s6", "pair_id": "DDI-DrugBank.d132.s6.p0"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p1"}
{"sentence": "Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.", "drug1": "multivalent cations", "drug2": "alendronate", "relation": "MECHANISM", "source_file": "Alendronate_ddi.xml", "sentence_id": "DDI-DrugBank.d430.s3", "pair_id": "DDI-DrugBank.d430.s3.p2"}
{"sentence": "Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.", "drug1": "live vaccines", "drug2": "inactivated vaccines", "relation": "NONE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s30", "pair_id": "DDI-DrugBank.d314.s30.p5"}
{"sentence": "Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.", "drug1": "opioids", "drug2": "INAPSINE", "relation": "EFFECT", "source_file": "Droperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d254.s0", "pair_id": "DDI-DrugBank.d254.s0.p13"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "tolbutamide", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p49"}
{"sentence": "Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.", "drug1": "Phenylbutazone", "drug2": "etodolac", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s19", "pair_id": "DDI-DrugBank.d219.s19.p2"}
{"sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "fluoxetine", "drug2": "fluvoxamine", "relation": "NONE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s6", "pair_id": "DDI-DrugBank.d299.s6.p18"}
{"sentence": "There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.", "drug1": "antidepressants", "drug2": "fluoxetine hydrochloride", "relation": "MECHANISM", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s6", "pair_id": "DDI-DrugBank.d202.s6.p1"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "benzodiazepines", "drug2": "nicardipine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p4"}
{"sentence": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.", "drug1": "carbamazepine", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s30", "pair_id": "DDI-DrugBank.d124.s30.p9"}
{"sentence": "Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.", "drug1": "guanethidine", "drug2": "amphetamines", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s0", "pair_id": "DDI-DrugBank.d236.s0.p14"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Tegretol", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p8"}
{"sentence": "Warfarin-Vitamin K can antagonize the effect of warfarin", "drug1": "Warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s8", "pair_id": "DDI-DrugBank.d139.s8.p1"}
{"sentence": "In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.", "drug1": "Angiomax", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Bivalirudin_ddi.xml", "sentence_id": "DDI-DrugBank.d569.s1", "pair_id": "DDI-DrugBank.d569.s1.p1"}
{"sentence": "Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).", "drug1": "tamoxifen", "drug2": "anastrozole", "relation": "ADVISE", "source_file": "Anastrozole_ddi.xml", "sentence_id": "DDI-DrugBank.d195.s7", "pair_id": "DDI-DrugBank.d195.s7.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "colistin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p8"}
{"sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.", "drug1": "dobutamine", "drug2": "lidocaine", "relation": "NONE", "source_file": "Dobutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d274.s3", "pair_id": "DDI-DrugBank.d274.s3.p3"}
{"sentence": "If the TARCEVA dose is adjusted upward, the dose will need to be reduced upon discontinuation of rifampicin or other inducers.", "drug1": "TARCEVA", "drug2": "rifampicin", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s5", "pair_id": "DDI-DrugBank.d456.s5.p0"}
{"sentence": "Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.", "drug1": "HMG-CoA reductase inhibitors", "drug2": "immunosuppressive drugs", "relation": "EFFECT", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s17", "pair_id": "DDI-DrugBank.d165.s17.p0"}
{"sentence": "Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.", "drug1": "PEGASYS", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Peginterferon alfa-2a_ddi.xml", "sentence_id": "DDI-DrugBank.d196.s0", "pair_id": "DDI-DrugBank.d196.s0.p0"}
{"sentence": "Colestipol-Concomitant intake of colestipol and vitamin K may reduce the absorption of vitamin K.", "drug1": "colestipol", "drug2": "vitamin K", "relation": "MECHANISM", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s4", "pair_id": "DDI-DrugBank.d139.s4.p3"}
{"sentence": "Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised: Digoxin elevated digoxin concentrations.", "drug1": "azithromycin", "drug2": "Digoxin", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s13", "pair_id": "DDI-DrugBank.d53.s13.p0"}
{"sentence": "Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with dihydrotachysterol may cause hypercalcemia.", "drug1": "thiazide diuretics", "drug2": "dihydrotachysterol", "relation": "EFFECT", "source_file": "Dihydrotachysterol_ddi.xml", "sentence_id": "DDI-DrugBank.d452.s0", "pair_id": "DDI-DrugBank.d452.s0.p0"}
{"sentence": "Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.", "drug1": "cephalexin", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Cephalexin_ddi.xml", "sentence_id": "DDI-DrugBank.d303.s4", "pair_id": "DDI-DrugBank.d303.s4.p5"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "ritonavir", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p7"}
{"sentence": "Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.", "drug1": "STRATTERA", "drug2": "fluoxetine", "relation": "ADVISE", "source_file": "Atomoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d11.s3", "pair_id": "DDI-DrugBank.d11.s3.p1"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p1"}
{"sentence": "Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.", "drug1": "efavirenz", "drug2": "azithromycin", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s8", "pair_id": "DDI-DrugBank.d53.s8.p1"}
{"sentence": "Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied", "drug1": "Antizol", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Fomepizole_ddi.xml", "sentence_id": "DDI-DrugBank.d228.s2", "pair_id": "DDI-DrugBank.d228.s2.p3"}
{"sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "drug1": "levobupivacaine", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Levobupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d320.s3", "pair_id": "DDI-DrugBank.d320.s3.p0"}
{"sentence": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "drug1": "Bezalip", "drug2": "anticoagulants of the coumarin type", "relation": "NONE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s0", "pair_id": "DDI-DrugBank.d291.s0.p3"}
{"sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "drug1": "haloperidol", "drug2": "dopamine", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s7", "pair_id": "DDI-DrugBank.d325.s7.p4"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "benzodiazepines", "drug2": "MAO inhibitors", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p11"}
{"sentence": "To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.", "drug1": "indinavir", "drug2": "VIDEX", "relation": "ADVISE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s15", "pair_id": "DDI-DrugBank.d43.s15.p2"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "macrolide antibiotics", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p10"}
{"sentence": "Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.", "drug1": "Argatroban", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Argatroban_ddi.xml", "sentence_id": "DDI-DrugBank.d148.s6", "pair_id": "DDI-DrugBank.d148.s6.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "diflunisal", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p16"}
{"sentence": "The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).", "drug1": "captopril", "drug2": "diuretic", "relation": "EFFECT", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s1", "pair_id": "DDI-DrugBank.d175.s1.p0"}
{"sentence": "ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.", "drug1": "ALLEGRA", "drug2": "aluminum", "relation": "ADVISE", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s20", "pair_id": "DDI-DrugBank.d466.s20.p0"}
{"sentence": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "drug1": "Cimetidine", "drug2": "tiagabine", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s15", "pair_id": "DDI-DrugBank.d277.s15.p6"}
{"sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "drug1": "PLETAL", "drug2": "omeprazole", "relation": "ADVISE", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s0", "pair_id": "DDI-DrugBank.d358.s0.p6"}
{"sentence": "Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "drug1": "EQUETROTM", "drug2": "Phenytoin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s13", "pair_id": "DDI-DrugBank.d94.s13.p6"}
{"sentence": "Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.", "drug1": "timolol", "drug2": "guanfacine", "relation": "EFFECT", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s5", "pair_id": "DDI-DrugBank.d507.s5.p5"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "salicylate", "drug2": "Magan", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p30"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "nalidixic acid", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p31"}
{"sentence": "Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.", "drug1": "insulin", "drug2": "hypoglycemic agents", "relation": "NONE", "source_file": "Bepridil_ddi.xml", "sentence_id": "DDI-DrugBank.d137.s7", "pair_id": "DDI-DrugBank.d137.s7.p5"}
{"sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "drug1": "valproic acid", "drug2": "ethosuximide", "relation": "MECHANISM", "source_file": "Ethosuximide_ddi.xml", "sentence_id": "DDI-DrugBank.d205.s0", "pair_id": "DDI-DrugBank.d205.s0.p20"}
{"sentence": "Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.", "drug1": "antacids", "drug2": "anticholinergic agents", "relation": "MECHANISM", "source_file": "Dicyclomine_ddi.xml", "sentence_id": "DDI-DrugBank.d543.s7", "pair_id": "DDI-DrugBank.d543.s7.p0"}
{"sentence": "Phenobarbital: Decreases aspirin effectiveness by enzyme induction.", "drug1": "Phenobarbital", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s6", "pair_id": "DDI-DrugBank.d443.s6.p0"}
{"sentence": "Prior administration of succinylcholine has no clinically important effect on the neuromuscular blocking action of NUROMAX.", "drug1": "succinylcholine", "drug2": "NUROMAX", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s0", "pair_id": "DDI-DrugBank.d267.s0.p0"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "aminosalicylic acid", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p4"}
{"sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "drug1": "eplerenone", "drug2": "fluconazole", "relation": "MECHANISM", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s3", "pair_id": "DDI-DrugBank.d20.s3.p3"}
{"sentence": "Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ", "drug1": "ibogaine", "drug2": "morphine", "relation": "EFFECT", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s6", "pair_id": "DDI-MedLine.d110.s6.p1"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "sertraline", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p6"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "ergotamine", "drug2": "nifedipine", "relation": "NONE", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p14"}
{"sentence": "RESULTS: Sildenafil has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [SSRIs]). ", "drug1": "Sildenafil", "drug2": "selective serotonin reuptake inhibitors", "relation": "NONE", "source_file": "11219477.xml", "sentence_id": "DDI-MedLine.d42.s5", "pair_id": "DDI-MedLine.d42.s5.p0"}
{"sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "drug1": "antipsychotic agents", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s3", "pair_id": "DDI-DrugBank.d186.s3.p1"}
{"sentence": "When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.", "drug1": "BREVIBLOC", "drug2": "morphine", "relation": "MECHANISM", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s6", "pair_id": "DDI-DrugBank.d422.s6.p9"}
{"sentence": "Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.", "drug1": "anastrozole", "drug2": "tamoxifen", "relation": "MECHANISM", "source_file": "Anastrozole_ddi.xml", "sentence_id": "DDI-DrugBank.d195.s8", "pair_id": "DDI-DrugBank.d195.s8.p0"}
{"sentence": "Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.", "drug1": "caffeine", "drug2": "enoxacin", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s4", "pair_id": "DDI-DrugBank.d395.s4.p2"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "bromocriptine", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p9"}
{"sentence": "Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, tacrine, and zileuton).", "drug1": "amitriptyline", "drug2": "zileuton", "relation": "NONE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s30", "pair_id": "DDI-DrugBank.d210.s30.p1"}
{"sentence": "For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.", "drug1": "vitamin K antagonists", "drug2": "nilutamide", "relation": "ADVISE", "source_file": "Nilutamide_ddi.xml", "sentence_id": "DDI-DrugBank.d177.s3", "pair_id": "DDI-DrugBank.d177.s3.p0"}
{"sentence": "Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the tricyclic antidepressants, and clozapine.", "drug1": "dextromethorphan", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s26", "pair_id": "DDI-DrugBank.d480.s26.p3"}
{"sentence": "When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "drug1": "CANCIDAS", "drug2": "dexamethasone", "relation": "ADVISE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s14", "pair_id": "DDI-DrugBank.d350.s14.p3"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "citalopram", "drug2": "dicumarol", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p262"}
{"sentence": "A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.", "drug1": "griseofulvin", "drug2": "ampicillin", "relation": "NONE", "source_file": "Norgestimate_ddi.xml", "sentence_id": "DDI-DrugBank.d360.s1", "pair_id": "DDI-DrugBank.d360.s1.p23"}
{"sentence": "Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.", "drug1": "terfenadine", "drug2": "dirithromycin", "relation": "NONE", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s9", "pair_id": "DDI-DrugBank.d522.s9.p2"}
{"sentence": "The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.", "drug1": "H2 blockers", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s12", "pair_id": "DDI-DrugBank.d48.s12.p1"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "fluoxetine", "drug2": "citalopram", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p16"}
{"sentence": "Antipsychotic drugs such as phenothiazines or haloperidol;", "drug1": "Antipsychotic drugs", "drug2": "haloperidol", "relation": "NONE", "source_file": "Benztropine_ddi.xml", "sentence_id": "DDI-DrugBank.d390.s0", "pair_id": "DDI-DrugBank.d390.s0.p1"}
{"sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.", "drug1": "HYDROXYZINE", "drug2": "BARBITURATES", "relation": "EFFECT", "source_file": "Hydroxyzine_ddi.xml", "sentence_id": "DDI-DrugBank.d308.s0", "pair_id": "DDI-DrugBank.d308.s0.p3"}
{"sentence": "Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status;", "drug1": "isoniazid", "drug2": "disulfiram", "relation": "ADVISE", "source_file": "Disulfiram_ddi.xml", "sentence_id": "DDI-DrugBank.d19.s7", "pair_id": "DDI-DrugBank.d19.s7.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "prednisolone", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p36"}
{"sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "drug1": "carbamazepine", "drug2": "barbiturates", "relation": "NONE", "source_file": "Butabarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d184.s0", "pair_id": "DDI-DrugBank.d184.s0.p28"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Nizoral", "drug2": "theophylline", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p581"}
{"sentence": "Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.", "drug1": "Diphenoxylate HCl", "drug2": "MAO inhibitors", "relation": "INT", "source_file": "Diphenoxylate_ddi.xml", "sentence_id": "DDI-DrugBank.d538.s1", "pair_id": "DDI-DrugBank.d538.s1.p1"}
{"sentence": "In vitro data suggest that itraconazole also markedly inhibits the biotransformation system mainly responsible for the metabolism of cisapride;", "drug1": "itraconazole", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s9", "pair_id": "DDI-DrugBank.d165.s9.p0"}
{"sentence": "Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.", "drug1": "cyclosporine", "drug2": "carvedilol", "relation": "MECHANISM", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s7", "pair_id": "DDI-DrugBank.d269.s7.p2"}
{"sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "drug1": "TNF blocking agents", "drug2": "azathioprine", "relation": "NONE", "source_file": "Abatacept_ddi.xml", "sentence_id": "DDI-DrugBank.d297.s2", "pair_id": "DDI-DrugBank.d297.s2.p38"}
{"sentence": "There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.", "drug1": "insulin", "drug2": "diclofenac", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s11", "pair_id": "DDI-DrugBank.d249.s11.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Neoral", "drug2": "Astramorph", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p747"}
{"sentence": "therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.", "drug1": "nitrates", "drug2": "captopril", "relation": "ADVISE", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s6", "pair_id": "DDI-DrugBank.d175.s6.p2"}
{"sentence": "To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.", "drug1": "delavirdine", "drug2": "VIDEX", "relation": "ADVISE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s15", "pair_id": "DDI-DrugBank.d43.s15.p1"}
{"sentence": "Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.", "drug1": "sedatives", "drug2": "alcohol", "relation": "NONE", "source_file": "Dezocine_ddi.xml", "sentence_id": "DDI-DrugBank.d461.s0", "pair_id": "DDI-DrugBank.d461.s0.p7"}
{"sentence": "Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.", "drug1": "Atromid-S", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Clofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d12.s3", "pair_id": "DDI-DrugBank.d12.s3.p0"}
{"sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.", "drug1": "Carbamazepine", "drug2": "AEDs", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s10", "pair_id": "DDI-DrugBank.d277.s10.p11"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "alprazolam", "drug2": "clarithromycin", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p67"}
{"sentence": "Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;", "drug1": "HEXALEN", "drug2": "cisplatin", "relation": "EFFECT", "source_file": "Altretamine_ddi.xml", "sentence_id": "DDI-DrugBank.d188.s1", "pair_id": "DDI-DrugBank.d188.s1.p0"}
{"sentence": "During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.", "drug1": "Ponstel", "drug2": "furosemide", "relation": "ADVISE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s8", "pair_id": "DDI-DrugBank.d400.s8.p0"}
{"sentence": "With simultaneous dosing of Vardenafil 10 mg and terazosin 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.", "drug1": "Vardenafil", "drug2": "terazosin", "relation": "EFFECT", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s29", "pair_id": "DDI-DrugBank.d198.s29.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "oxolinic acid", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p33"}
{"sentence": "Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "drug1": "aminoglycosides", "drug2": "curare-like compounds", "relation": "NONE", "source_file": "Botulinum Toxin Type A_ddi.xml", "sentence_id": "DDI-DrugBank.d133.s0", "pair_id": "DDI-DrugBank.d133.s0.p3"}
{"sentence": "Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.", "drug1": "rifampin", "drug2": "fludrocortisone acetate", "relation": "MECHANISM", "source_file": "Fludrocortisone_ddi.xml", "sentence_id": "DDI-DrugBank.d526.s17", "pair_id": "DDI-DrugBank.d526.s17.p5"}
{"sentence": "Antiarrhythmics: amiodarone", "drug1": "Antiarrhythmics", "drug2": "amiodarone", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s8", "pair_id": "DDI-DrugBank.d97.s8.p0"}
{"sentence": "Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.", "drug1": "Gastrointestinal acidifying agents", "drug2": "amphetamines", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s0", "pair_id": "DDI-DrugBank.d236.s0.p10"}
{"sentence": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).", "drug1": "famotidine", "drug2": "ranitidine", "relation": "NONE", "source_file": "Diatrizoate_ddi.xml", "sentence_id": "DDI-DrugBank.d293.s0", "pair_id": "DDI-DrugBank.d293.s0.p26"}
{"sentence": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "drug1": "cholestyramine", "drug2": "cerivastatin", "relation": "NONE", "source_file": "Cerivastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d141.s5", "pair_id": "DDI-DrugBank.d141.s5.p1"}
{"sentence": "If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.", "drug1": "pentamidine", "drug2": "HIVID", "relation": "ADVISE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s17", "pair_id": "DDI-DrugBank.d263.s17.p0"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "phenobarbital", "drug2": "calcitriol", "relation": "MECHANISM", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s2", "pair_id": "DDI-DrugBank.d98.s2.p13"}
{"sentence": "In vitro data in human plasma indicate that doxazosin mesylate has no effect on protein binding of digoxin, warfarin, phenytoin or indomethacin.", "drug1": "digoxin", "drug2": "indomethacin", "relation": "NONE", "source_file": "Doxazosin_ddi.xml", "sentence_id": "DDI-DrugBank.d367.s1", "pair_id": "DDI-DrugBank.d367.s1.p6"}
{"sentence": "Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.", "drug1": "flurbiprofen", "drug2": "diuretics", "relation": "ADVISE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s17", "pair_id": "DDI-DrugBank.d529.s17.p1"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "quinolone", "drug2": "calcium", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p6"}
{"sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.", "drug1": "tiagabine", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s12", "pair_id": "DDI-DrugBank.d277.s12.p9"}
{"sentence": "Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.", "drug1": "antihistamines", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s1", "pair_id": "DDI-DrugBank.d448.s1.p0"}
{"sentence": "In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.", "drug1": "non- steroidal antiinflammatory agent", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s6", "pair_id": "DDI-DrugBank.d414.s6.p2"}
{"sentence": "Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.", "drug1": "Sumatriptan", "drug2": "D.H.E. 45", "relation": "EFFECT", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s1", "pair_id": "DDI-DrugBank.d410.s1.p3"}
{"sentence": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "drug1": "Angiotensin II Receptor Antagonists", "drug2": "ARB", "relation": "NONE", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s4", "pair_id": "DDI-DrugBank.d20.s4.p10"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "olanzapine", "drug2": "quetiapine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p904"}
{"sentence": "Severe hypoglycemia has been reported in patients concomitantly receiving azole antifungal agents and oral hypoglycemic agents.", "drug1": "azole antifungal agents", "drug2": "hypoglycemic agents", "relation": "EFFECT", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s26", "pair_id": "DDI-DrugBank.d165.s26.p0"}
{"sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.", "drug1": "heroin", "drug2": "central nervous system depressants", "relation": "EFFECT", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s2", "pair_id": "DDI-DrugBank.d514.s2.p0"}
{"sentence": "In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.\n", "drug1": "prostaglandin F2alpha", "drug2": "oxytocin", "relation": "INT", "source_file": "1113260.xml", "sentence_id": "DDI-MedLine.d17.s0", "pair_id": "DDI-MedLine.d17.s0.p0"}
{"sentence": "Aspirin/Nonsteroidal Antiinflammatory Drugs (NSAIDs)", "drug1": "Aspirin", "drug2": "Nonsteroidal Antiinflammatory Drug", "relation": "NONE", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s8", "pair_id": "DDI-DrugBank.d440.s8.p0"}
{"sentence": "Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .", "drug1": "activated charcoal", "drug2": "leflunomide", "relation": "MECHANISM", "source_file": "Leflunomide_ddi.xml", "sentence_id": "DDI-DrugBank.d41.s0", "pair_id": "DDI-DrugBank.d41.s0.p9"}
{"sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "drug1": "HALDOL", "drug2": "opiates", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s3", "pair_id": "DDI-DrugBank.d186.s3.p7"}
{"sentence": "Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.", "drug1": "Furosemide", "drug2": "tubocurarine", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s4", "pair_id": "DDI-DrugBank.d231.s4.p0"}
{"sentence": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "drug1": "cimetidine", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s11", "pair_id": "DDI-DrugBank.d237.s11.p1"}
{"sentence": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.", "drug1": "apraclonidine", "drug2": "cardiac glycosides", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s8", "pair_id": "DDI-DrugBank.d224.s8.p2"}
{"sentence": "Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.", "drug1": "Ketamine", "drug2": "ketamine", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s13", "pair_id": "DDI-DrugBank.d411.s13.p1"}
{"sentence": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "drug1": "nevirapine", "drug2": "CANCIDAS", "relation": "MECHANISM", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s12", "pair_id": "DDI-DrugBank.d350.s12.p9"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "dicumarol", "drug2": "oxcarbazepine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p555"}
{"sentence": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "drug1": "INSPRA", "drug2": "angiotensin II receptor antagonists", "relation": "EFFECT", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s6", "pair_id": "DDI-DrugBank.d20.s6.p8"}
{"sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.", "drug1": "fluoxetine", "drug2": "aripiprazole", "relation": "MECHANISM", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s8", "pair_id": "DDI-DrugBank.d509.s8.p8"}
{"sentence": "In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.", "drug1": "TIKOSYN", "drug2": "contraceptives", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s33", "pair_id": "DDI-DrugBank.d558.s33.p4"}
{"sentence": "Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.", "drug1": "antihistamines", "drug2": "central nervous system depressants", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s1", "pair_id": "DDI-DrugBank.d448.s1.p3"}
{"sentence": "Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.", "drug1": "thiazides", "drug2": "vitamin D", "relation": "EFFECT", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s5", "pair_id": "DDI-DrugBank.d384.s5.p0"}
{"sentence": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "drug1": "carbamazepine", "drug2": "anticonvulsant", "relation": "NONE", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s7", "pair_id": "DDI-DrugBank.d187.s7.p20"}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "Furosemide", "drug2": "NSAIDs", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s10", "pair_id": "DDI-DrugBank.d328.s10.p0"}
{"sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.", "drug1": "alosetron", "drug2": "telithromycin", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s10", "pair_id": "DDI-DrugBank.d364.s10.p1"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "Vitamin D2", "drug2": "Calcitriol", "relation": "NONE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s0", "pair_id": "DDI-DrugBank.d98.s0.p8"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "drug1": "norepinephrine", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s0", "pair_id": "DDI-DrugBank.d110.s0.p9"}
{"sentence": "Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.", "drug1": "Aspirin", "drug2": "aspirin", "relation": "NONE", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s4", "pair_id": "DDI-DrugBank.d219.s4.p1"}
{"sentence": "In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.", "drug1": "CASODEX", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Bicalutamide_ddi.xml", "sentence_id": "DDI-DrugBank.d266.s0", "pair_id": "DDI-DrugBank.d266.s0.p1"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "insulin", "drug2": "progestogens", "relation": "NONE", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s2", "pair_id": "DDI-DrugBank.d527.s2.p12"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "enflurane", "drug2": "antibiotics", "relation": "NONE", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p12"}
{"sentence": "Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.", "drug1": "aluminum", "drug2": "antacids", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s5", "pair_id": "DDI-DrugBank.d516.s5.p4"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p14"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "MAOI", "drug2": "Ethanol", "relation": "NONE", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p34"}
{"sentence": "Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.", "drug1": "ACTH", "drug2": "amphotericin B", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s2", "pair_id": "DDI-DrugBank.d318.s2.p5"}
{"sentence": "Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ", "drug1": "Amprenavir", "drug2": "rifabutin", "relation": "MECHANISM", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s7", "pair_id": "DDI-MedLine.d3.s7.p0"}
{"sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "drug1": "bexarotene", "drug2": "gemfibrozil", "relation": "NONE", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s2", "pair_id": "DDI-DrugBank.d467.s2.p3"}
{"sentence": "DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.", "drug1": "DOSTINEX", "drug2": "phenothiazines", "relation": "ADVISE", "source_file": "Cabergoline_ddi.xml", "sentence_id": "DDI-DrugBank.d282.s0", "pair_id": "DDI-DrugBank.d282.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "doxycycline", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p596"}
{"sentence": "Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "drug1": "MIDAMOR", "drug2": "non-steroidal anti-inflammatory agents", "relation": "ADVISE", "source_file": "Amiloride_ddi.xml", "sentence_id": "DDI-DrugBank.d356.s5", "pair_id": "DDI-DrugBank.d356.s5.p0"}
{"sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "drug1": "PRECEDEX", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s1", "pair_id": "DDI-DrugBank.d197.s1.p26"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "amikacin", "drug2": "pentamidine", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p32"}
{"sentence": "Therefore, the combination of ketoprofen and probenecid is not recommended.", "drug1": "ketoprofen", "drug2": "probenecid", "relation": "ADVISE", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s20", "pair_id": "DDI-DrugBank.d499.s20.p0"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "antipsychotic drug", "drug2": "antiparkinsonian drug", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p1"}
{"sentence": "Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.", "drug1": "Maalox", "drug2": "gabapentin", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s37", "pair_id": "DDI-DrugBank.d438.s37.p5"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "amitriptyline", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p4"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "clobazam", "drug2": "delavirdine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p297"}
{"sentence": "Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.", "drug1": "beta-blocker", "drug2": "reserpine", "relation": "ADVISE", "source_file": "Carteolol_ddi.xml", "sentence_id": "DDI-DrugBank.d502.s1", "pair_id": "DDI-DrugBank.d502.s1.p0"}
{"sentence": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "drug1": "indinavir", "drug2": "didanosine", "relation": "MECHANISM", "source_file": "11120981.xml", "sentence_id": "DDI-MedLine.d79.s1", "pair_id": "DDI-MedLine.d79.s1.p0"}
{"sentence": "Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.", "drug1": "Proquin XR", "drug2": "omeprazole", "relation": "NONE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s12", "pair_id": "DDI-DrugBank.d123.s12.p9"}
{"sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.", "drug1": "clindamycin", "drug2": "clofibrate", "relation": "NONE", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s13", "pair_id": "DDI-DrugBank.d345.s13.p17"}
{"sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "drug1": "dextran", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s2", "pair_id": "DDI-DrugBank.d488.s2.p20"}
{"sentence": "Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.", "drug1": "Rifampin", "drug2": "CYP3A4", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s47", "pair_id": "DDI-DrugBank.d143.s47.p2"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p16"}
{"sentence": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "drug1": "antacid", "drug2": "TIKOSYN", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s32", "pair_id": "DDI-DrugBank.d558.s32.p59"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "doxycycline", "drug2": "rifampin", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p53"}
{"sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "drug1": "halogenated hydrocarbon anesthetics", "drug2": "dopamine", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s8", "pair_id": "DDI-DrugBank.d325.s8.p4"}
{"sentence": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.", "drug1": "tetracyclines", "drug2": "iron", "relation": "MECHANISM", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s2", "pair_id": "DDI-DrugBank.d500.s2.p4"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "foscarnet", "drug2": "pentamidine", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p39"}
{"sentence": "Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.", "drug1": "alcohol", "drug2": "ethchlorvynol", "relation": "EFFECT", "source_file": "Ethchlorvynol_ddi.xml", "sentence_id": "DDI-DrugBank.d405.s1", "pair_id": "DDI-DrugBank.d405.s1.p2"}
{"sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "drug1": "methotrexate", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s2", "pair_id": "DDI-DrugBank.d114.s2.p19"}
{"sentence": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.", "drug1": "progestin", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Norethindrone_ddi.xml", "sentence_id": "DDI-DrugBank.d306.s0", "pair_id": "DDI-DrugBank.d306.s0.p3"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "adrenocortical steroids", "drug2": "diuretics", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p32"}
{"sentence": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).", "drug1": "Kineret", "drug2": "etanercept", "relation": "EFFECT", "source_file": "Anakinra_ddi.xml", "sentence_id": "DDI-DrugBank.d275.s2", "pair_id": "DDI-DrugBank.d275.s2.p0"}
{"sentence": "Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.", "drug1": "cyclosporine", "drug2": "cyclosporine", "relation": "NONE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s4", "pair_id": "DDI-DrugBank.d217.s4.p0"}
{"sentence": "Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.", "drug1": "diuretics", "drug2": "Lotensin", "relation": "EFFECT", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s0", "pair_id": "DDI-DrugBank.d561.s0.p2"}
{"sentence": "Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.", "drug1": "carbamazepine", "drug2": "exemestane", "relation": "MECHANISM", "source_file": "Exemestane_ddi.xml", "sentence_id": "DDI-DrugBank.d435.s2", "pair_id": "DDI-DrugBank.d435.s2.p8"}
{"sentence": "Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. ", "drug1": "thiabendazole", "drug2": "melarsoprol", "relation": "EFFECT", "source_file": "7496198.xml", "sentence_id": "DDI-MedLine.d97.s8", "pair_id": "DDI-MedLine.d97.s8.p0"}
{"sentence": "Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "drug1": "erythromycin", "drug2": "ergotamine", "relation": "EFFECT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s23", "pair_id": "DDI-DrugBank.d522.s23.p3"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "colistin", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p7"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "procainamide", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p10"}
{"sentence": "The gradual withdrawal of guafacine or a cardioselective beta-blocker could be substituted.", "drug1": "guafacine", "drug2": "cardioselective beta-blocker", "relation": "NONE", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s7", "pair_id": "DDI-DrugBank.d507.s7.p0"}
{"sentence": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.", "drug1": "Intestinal adsorbents", "drug2": "digestive enzyme preparations", "relation": "NONE", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s4", "pair_id": "DDI-DrugBank.d536.s4.p1"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "carbamazepine", "drug2": "6-mercaptopurine", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p273"}
{"sentence": "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.", "drug1": "calcium channel blockers", "drug2": "nitrates", "relation": "EFFECT", "source_file": "Nitroglycerin_ddi.xml", "sentence_id": "DDI-DrugBank.d14.s2", "pair_id": "DDI-DrugBank.d14.s2.p0"}
{"sentence": "The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.", "drug1": "alprazolam", "drug2": "Aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s23", "pair_id": "DDI-DrugBank.d382.s23.p8"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p2"}
{"sentence": "Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.", "drug1": "Coumarin Anticoagulant", "drug2": "lovastatin", "relation": "NONE", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s13", "pair_id": "DDI-DrugBank.d567.s13.p0"}
{"sentence": "The extent to which SSRI-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "drug1": "SSRI", "drug2": "TCA", "relation": "INT", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s18", "pair_id": "DDI-DrugBank.d238.s18.p0"}
{"sentence": "The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.", "drug1": "hydrocodone", "drug2": "hydrocodone", "relation": "NONE", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s2", "pair_id": "DDI-DrugBank.d396.s2.p8"}
{"sentence": "Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.", "drug1": "Fluvoxamine", "drug2": "MAOIs", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s4", "pair_id": "DDI-DrugBank.d76.s4.p0"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "Magan", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p9"}
{"sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "drug1": "midazolam", "drug2": "benzodiazepines", "relation": "NONE", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s6", "pair_id": "DDI-DrugBank.d397.s6.p5"}
{"sentence": "Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.", "drug1": "MAO inhibitors", "drug2": "phenothiazines", "relation": "NONE", "source_file": "Chlorpheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d235.s2", "pair_id": "DDI-DrugBank.d235.s2.p4"}
{"sentence": "Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics.", "drug1": "PRINIVIL", "drug2": "thiazide-type diuretics", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s14", "pair_id": "DDI-DrugBank.d334.s14.p0"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "Aprepitant", "drug2": "troleandomycin", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p3"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Thorazine", "drug2": "Serentil", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p93"}
{"sentence": "DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.", "drug1": "DIAMOX", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s0", "pair_id": "DDI-DrugBank.d368.s0.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "primidone", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p18"}
{"sentence": "Warfarin: Increased INR (International Normalized Ratio) when ARAVA and warfarin were co-administered has been rarely reported.", "drug1": "ARAVA", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Leflunomide_ddi.xml", "sentence_id": "DDI-DrugBank.d41.s16", "pair_id": "DDI-DrugBank.d41.s16.p2"}
{"sentence": "However, LDL-C reduction was greater when atorvastatin and colestipol were coadministered than when either drug was given alone.", "drug1": "atorvastatin", "drug2": "colestipol", "relation": "EFFECT", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s5", "pair_id": "DDI-DrugBank.d140.s5.p0"}
{"sentence": "Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).", "drug1": "TORADOL", "drug2": "alprazolam", "relation": "EFFECT", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s19", "pair_id": "DDI-DrugBank.d3.s19.p8"}
{"sentence": "When estrogen therapy is initiated, a reduction in corticosteroid dosage may be required, and increased amounts may be required when estrogen is terminated.", "drug1": "estrogen", "drug2": "corticosteroid", "relation": "NONE", "source_file": "Fludrocortisone_ddi.xml", "sentence_id": "DDI-DrugBank.d526.s24", "pair_id": "DDI-DrugBank.d526.s24.p0"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenothiazines", "drug2": "succinimides", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p212"}
{"sentence": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "drug1": "nitrates", "drug2": "hydralazine", "relation": "NONE", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s10", "pair_id": "DDI-DrugBank.d107.s10.p27"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "desipramine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p11"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "selegiline hydrochloride", "drug2": "fluvoxamine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p17"}
{"sentence": "The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; ", "drug1": "naloxone", "drug2": "beta-endorphin", "relation": "NONE", "source_file": "3155550.xml", "sentence_id": "DDI-MedLine.d63.s7", "pair_id": "DDI-MedLine.d63.s7.p2"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "pertechnetate", "drug2": "lithium", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p197"}
{"sentence": "Increasing the felbamate dose to 2400 mg/day increased the steadystate valproate Cmin to 96 25 micrograms/mL.", "drug1": "felbamate", "drug2": "valproate", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s25", "pair_id": "DDI-DrugBank.d434.s25.p0"}
{"sentence": "Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin. ", "drug1": "Verapamil", "drug2": "bombesin", "relation": "EFFECT", "source_file": "11125235.xml", "sentence_id": "DDI-MedLine.d133.s5", "pair_id": "DDI-MedLine.d133.s5.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p15"}
{"sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "drug1": "levothyroxine sodium", "drug2": "ferrous sulfate", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s2", "pair_id": "DDI-DrugBank.d411.s2.p10"}
{"sentence": "Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.", "drug1": "bosentan", "drug2": "cyclosporine A", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s13", "pair_id": "DDI-DrugBank.d289.s13.p0"}
{"sentence": "Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.", "drug1": "halofantrine", "drug2": "Mefloquine", "relation": "ADVISE", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s4", "pair_id": "DDI-DrugBank.d220.s4.p0"}
{"sentence": "Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.", "drug1": "Naproxen", "drug2": "propranolol", "relation": "EFFECT", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s9", "pair_id": "DDI-DrugBank.d85.s9.p1"}
{"sentence": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).", "drug1": "Gleevec", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s0", "pair_id": "DDI-DrugBank.d115.s0.p11"}
{"sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "drug1": "asparaginase", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s2", "pair_id": "DDI-DrugBank.d114.s2.p20"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "aminosalicylic acid", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p2"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "MAOIs", "drug2": "venlafaxine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p14"}
{"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "beta blockers", "relation": "EFFECT", "source_file": "Hexobarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d457.s0", "pair_id": "DDI-DrugBank.d457.s0.p6"}
{"sentence": "Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.", "drug1": "Aspirin", "drug2": "probenecid", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s0", "pair_id": "DDI-DrugBank.d443.s0.p4"}
{"sentence": "Carbamazepine: Felbatol  causes a decrease in the steady-state carbamazepine plasma concentrations and an increase in the steady-state carbamazepine epoxide plasma concentration.", "drug1": "Felbatol", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s17", "pair_id": "DDI-DrugBank.d434.s17.p3"}
{"sentence": "There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).", "drug1": "Gleevec", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s2", "pair_id": "DDI-DrugBank.d115.s2.p2"}
{"sentence": "SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.", "drug1": "SUBUTEX", "drug2": "benzodiazepines", "relation": "ADVISE", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s6", "pair_id": "DDI-DrugBank.d380.s6.p1"}
{"sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "drug1": "estrogen", "drug2": "contraceptive", "relation": "NONE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s1", "pair_id": "DDI-DrugBank.d347.s1.p23"}
{"sentence": "Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with SINEQUAN.", "drug1": "MAO inhibitors", "drug2": "SINEQUAN", "relation": "ADVISE", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s20", "pair_id": "DDI-DrugBank.d223.s20.p0"}
{"sentence": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ", "drug1": "naloxone", "drug2": "beta-endorphin", "relation": "EFFECT", "source_file": "3155550.xml", "sentence_id": "DDI-MedLine.d63.s4", "pair_id": "DDI-MedLine.d63.s4.p0"}
{"sentence": "Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.", "drug1": "Chirocaine", "drug2": "anesthetics", "relation": "ADVISE", "source_file": "Levobupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d320.s0", "pair_id": "DDI-DrugBank.d320.s0.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "atorvastatin", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p16"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "phenytoin", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p5"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "thiocyanate", "drug2": "dopamine agonists", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p134"}
{"sentence": "Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.", "drug1": "Cimetidine", "drug2": "zaleplon", "relation": "MECHANISM", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s28", "pair_id": "DDI-DrugBank.d324.s28.p2"}
{"sentence": "Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.", "drug1": "Azlocillin", "drug2": "gentamicin", "relation": "ADVISE", "source_file": "Azlocillin_ddi.xml", "sentence_id": "DDI-DrugBank.d9.s0", "pair_id": "DDI-DrugBank.d9.s0.p2"}
{"sentence": "ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.", "drug1": "ACE-inhibitors", "drug2": "NSAIDs", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s8", "pair_id": "DDI-DrugBank.d328.s8.p0"}
{"sentence": "5-HT3 antagonists: In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron or granisetron.", "drug1": "5-HT3 antagonists", "drug2": "aprepitant", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s7", "pair_id": "DDI-DrugBank.d382.s7.p0"}
{"sentence": "The increase of phenobarbital level, however, is small (15%) when given with Trileptal.", "drug1": "phenobarbital", "drug2": "Trileptal", "relation": "MECHANISM", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s37", "pair_id": "DDI-DrugBank.d307.s37.p0"}
{"sentence": "Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).", "drug1": "Ibandronate", "drug2": "vitamins", "relation": "ADVISE", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s2", "pair_id": "DDI-DrugBank.d440.s2.p1"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "amphotericin B", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p4"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p6"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "rifampin", "drug2": "primidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p40"}
{"sentence": "Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.", "drug1": "acetaminophen", "drug2": "BUSULFEX", "relation": "MECHANISM", "source_file": "Busulfan_ddi.xml", "sentence_id": "DDI-DrugBank.d72.s4", "pair_id": "DDI-DrugBank.d72.s4.p4"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "bacitracin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p4"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p7"}
{"sentence": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "drug1": "citalopram", "drug2": "digoxin", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s9", "pair_id": "DDI-DrugBank.d568.s9.p6"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "Dexbrompheniramine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Brompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d192.s0", "pair_id": "DDI-DrugBank.d192.s0.p0"}
{"sentence": "Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .", "drug1": "cholestyramine", "drug2": "leflunomide", "relation": "MECHANISM", "source_file": "Leflunomide_ddi.xml", "sentence_id": "DDI-DrugBank.d41.s0", "pair_id": "DDI-DrugBank.d41.s0.p8"}
{"sentence": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "drug1": "carbamazepine", "drug2": "CANCIDAS", "relation": "MECHANISM", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s12", "pair_id": "DDI-DrugBank.d350.s12.p18"}
{"sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "drug1": "tranquilizers", "drug2": "sedative-hypnotics", "relation": "NONE", "source_file": "Codeine_ddi.xml", "sentence_id": "DDI-DrugBank.d464.s0", "pair_id": "DDI-DrugBank.d464.s0.p22"}
{"sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "drug1": "ZYVOX", "drug2": "selective serotonin reuptake inhibitors", "relation": "EFFECT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s6", "pair_id": "DDI-DrugBank.d441.s6.p2"}
{"sentence": "When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.", "drug1": "propranolol", "drug2": "naproxen", "relation": "NONE", "source_file": "Nicardipine_ddi.xml", "sentence_id": "DDI-DrugBank.d468.s10", "pair_id": "DDI-DrugBank.d468.s10.p9"}
{"sentence": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).", "drug1": "ranitidine", "drug2": "lansoprazole", "relation": "NONE", "source_file": "Diatrizoate_ddi.xml", "sentence_id": "DDI-DrugBank.d293.s0", "pair_id": "DDI-DrugBank.d293.s0.p31"}
{"sentence": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.", "drug1": "apraclonidine", "drug2": "antihypertensives", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s8", "pair_id": "DDI-DrugBank.d224.s8.p1"}
{"sentence": "Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ", "drug1": "naloxone", "drug2": "beta-endorphin", "relation": "EFFECT", "source_file": "3155550.xml", "sentence_id": "DDI-MedLine.d63.s6", "pair_id": "DDI-MedLine.d63.s6.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "fluoxetine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p9"}
{"sentence": "May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).", "drug1": "beta-adrenergic blocking agents", "drug2": "procainamide", "relation": "NONE", "source_file": "Isoetharine_ddi.xml", "sentence_id": "DDI-DrugBank.d541.s0", "pair_id": "DDI-DrugBank.d541.s0.p4"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "chlorpromazine", "drug2": "Temaril", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p89"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "thioridazine", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p10"}
{"sentence": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "drug1": "Isoniazid", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s7", "pair_id": "DDI-DrugBank.d187.s7.p6"}
{"sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "drug1": "antacids", "drug2": "vitamin D", "relation": "EFFECT", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s15", "pair_id": "DDI-DrugBank.d404.s15.p5"}
{"sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "drug1": "Hydrochlorothiazide", "drug2": "hydrochlorothiazide", "relation": "NONE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s5", "pair_id": "DDI-DrugBank.d132.s5.p1"}
{"sentence": "Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.", "drug1": "VIOXX", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s31", "pair_id": "DDI-DrugBank.d210.s31.p2"}
{"sentence": "Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.", "drug1": "corticosteroids", "drug2": "antidiabetic agents", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s8", "pair_id": "DDI-DrugBank.d314.s8.p2"}
{"sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "drug1": "propranolol", "drug2": "phenytoin", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s11", "pair_id": "DDI-DrugBank.d460.s11.p16"}
{"sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "drug1": "ketoconazole", "drug2": "erythromycin", "relation": "NONE", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s0", "pair_id": "DDI-DrugBank.d358.s0.p7"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chlorpropamide", "drug2": "anesthetics", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p465"}
{"sentence": "Consequently, the effect of iron on the retention of cobalt was lower than on absorption. ", "drug1": "iron", "drug2": "cobalt", "relation": "MECHANISM", "source_file": "7599505.xml", "sentence_id": "DDI-MedLine.d34.s9", "pair_id": "DDI-MedLine.d34.s9.p0"}
{"sentence": "The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.", "drug1": "ethambutol", "drug2": "aluminum hydroxide", "relation": "MECHANISM", "source_file": "Ethambutol_ddi.xml", "sentence_id": "DDI-DrugBank.d160.s0", "pair_id": "DDI-DrugBank.d160.s0.p0"}
{"sentence": "Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. ", "drug1": "gentamicin", "drug2": "99mTc-MDP", "relation": "MECHANISM", "source_file": "7632757.xml", "sentence_id": "DDI-MedLine.d89.s2", "pair_id": "DDI-MedLine.d89.s2.p0"}
{"sentence": "Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "drug1": "Didanosine", "drug2": "norfloxacin", "relation": "ADVISE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s12", "pair_id": "DDI-DrugBank.d217.s12.p3"}
{"sentence": "Amiodarone, disopyramide, lidocaine", "drug1": "disopyramide", "drug2": "lidocaine", "relation": "NONE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s63", "pair_id": "DDI-DrugBank.d270.s63.p2"}
{"sentence": "Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.", "drug1": "Sympathomimetic amines", "drug2": "reserpine", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s2", "pair_id": "DDI-DrugBank.d389.s2.p0"}
{"sentence": "Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.", "drug1": "probenecid", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s0", "pair_id": "DDI-DrugBank.d443.s0.p8"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Dilantin", "drug2": "Crixivan", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p305"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "oxcarbazepine", "drug2": "ziprasidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p942"}
{"sentence": "Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.", "drug1": "5-HT1B/1D agonists", "drug2": "AXERT", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s4", "pair_id": "DDI-DrugBank.d299.s4.p2"}
{"sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.", "drug1": "theophylline", "drug2": "adrenergic agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s3", "pair_id": "DDI-DrugBank.d284.s3.p11"}
{"sentence": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "drug1": "L-methionine", "drug2": "acetaminophen", "relation": "EFFECT", "source_file": "L-Methionine_ddi.xml", "sentence_id": "DDI-DrugBank.d528.s0", "pair_id": "DDI-DrugBank.d528.s0.p7"}
{"sentence": "Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.", "drug1": "FLOLAN", "drug2": "antihypertensive agents", "relation": "EFFECT", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s0", "pair_id": "DDI-DrugBank.d241.s0.p1"}
{"sentence": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .", "drug1": "fluoxetine", "drug2": "carvedilol", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s1", "pair_id": "DDI-DrugBank.d269.s1.p17"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "ZEBETA", "drug2": "verapamil", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p3"}
{"sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "drug1": "acetylsalicylic acid", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s2", "pair_id": "DDI-DrugBank.d488.s2.p14"}
{"sentence": "In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.", "drug1": "Angiomax", "drug2": "heparin", "relation": "EFFECT", "source_file": "Bivalirudin_ddi.xml", "sentence_id": "DDI-DrugBank.d569.s1", "pair_id": "DDI-DrugBank.d569.s1.p0"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "clozapine", "drug2": "encainide", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p6"}
{"sentence": "In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.", "drug1": "buspirone HCl", "drug2": "haloperidol", "relation": "MECHANISM", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s3", "pair_id": "DDI-DrugBank.d463.s3.p0"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "doxorubicin HCL", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p1"}
{"sentence": "Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.", "drug1": "dolasetron mesylate", "drug2": "atenolol", "relation": "MECHANISM", "source_file": "Dolasetron_ddi.xml", "sentence_id": "DDI-DrugBank.d42.s5", "pair_id": "DDI-DrugBank.d42.s5.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "magnesium", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p10"}
{"sentence": "Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.", "drug1": "Theophylline", "drug2": "theophylline", "relation": "NONE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s27", "pair_id": "DDI-DrugBank.d210.s27.p2"}
{"sentence": "Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.", "drug1": "Catecholamine-depleting drugs", "drug2": "beta-blocking agents", "relation": "EFFECT", "source_file": "Acebutolol_ddi.xml", "sentence_id": "DDI-DrugBank.d388.s0", "pair_id": "DDI-DrugBank.d388.s0.p1"}
{"sentence": "When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "drug1": "CANCIDAS", "drug2": "carbamazepine", "relation": "ADVISE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s14", "pair_id": "DDI-DrugBank.d350.s14.p4"}
{"sentence": "- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;", "drug1": "propranolol", "drug2": "metoprolol", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s5", "pair_id": "DDI-DrugBank.d521.s5.p13"}
{"sentence": "Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.", "drug1": "Aspirin", "drug2": "sulfinpyrazone", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s0", "pair_id": "DDI-DrugBank.d443.s0.p5"}
{"sentence": "Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.", "drug1": "anticoagulants", "drug2": "Atromid-S", "relation": "ADVISE", "source_file": "Clofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d12.s0", "pair_id": "DDI-DrugBank.d12.s0.p0"}
{"sentence": "Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;", "drug1": "Anticholinergic agents", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Dicyclomine_ddi.xml", "sentence_id": "DDI-DrugBank.d543.s4", "pair_id": "DDI-DrugBank.d543.s4.p0"}
{"sentence": "Cimetidine: Cimetidine increases nicardipine HCl plasma levels.", "drug1": "Cimetidine", "drug2": "Cimetidine", "relation": "NONE", "source_file": "Nicardipine_ddi.xml", "sentence_id": "DDI-DrugBank.d468.s2", "pair_id": "DDI-DrugBank.d468.s2.p0"}
{"sentence": "Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.", "drug1": "Isocarboxazid", "drug2": "psychotropic agents", "relation": "ADVISE", "source_file": "Isocarboxazid_ddi.xml", "sentence_id": "DDI-DrugBank.d108.s2", "pair_id": "DDI-DrugBank.d108.s2.p0"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "sympathomimetics", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p13"}
{"sentence": "Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.", "drug1": "cinoxacin", "drug2": "caffeine", "relation": "ADVISE", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s5", "pair_id": "DDI-DrugBank.d562.s5.p2"}
{"sentence": "Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7", "drug1": "Edetate calcium disodium", "drug2": "zinc insulin", "relation": "MECHANISM", "source_file": "Edetic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d191.s1", "pair_id": "DDI-DrugBank.d191.s1.p7"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "Acetazolamide", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Astramorph", "drug2": "theophylline", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p932"}
{"sentence": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.", "drug1": "ibuprofen", "drug2": "anticoagulants", "relation": "ADVISE", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s1", "pair_id": "DDI-DrugBank.d415.s1.p9"}
{"sentence": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.", "drug1": "NSAIDs", "drug2": "ACE-inhibitors", "relation": "ADVISE", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s1", "pair_id": "DDI-DrugBank.d219.s1.p0"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "phenothiazines", "drug2": "Type 1C antiarrhythmics", "relation": "NONE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p16"}
{"sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "drug1": "ALPHAGAN P", "drug2": "barbiturates", "relation": "ADVISE", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s0", "pair_id": "DDI-DrugBank.d138.s0.p2"}
{"sentence": "Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.", "drug1": "Corticotropin", "drug2": "ACTH", "relation": "NONE", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s2", "pair_id": "DDI-DrugBank.d318.s2.p3"}
{"sentence": "Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.", "drug1": "FLOLAN", "drug2": "vasodilators", "relation": "EFFECT", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s0", "pair_id": "DDI-DrugBank.d241.s0.p2"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "terfenadine", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p35"}
{"sentence": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "drug1": "vitamin A", "drug2": "acitretin", "relation": "ADVISE", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s12", "pair_id": "DDI-DrugBank.d353.s12.p8"}
{"sentence": "An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.", "drug1": "clonidine", "drug2": "neuroleptic", "relation": "EFFECT", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s6", "pair_id": "DDI-DrugBank.d224.s6.p0"}
{"sentence": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "drug1": "propranolol", "drug2": "propranolol", "relation": "NONE", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s6", "pair_id": "DDI-DrugBank.d81.s6.p1"}
{"sentence": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).", "drug1": "Gleevec", "drug2": "erythromycin", "relation": "ADVISE", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s0", "pair_id": "DDI-DrugBank.d115.s0.p13"}
{"sentence": "Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.", "drug1": "Netilmicin", "drug2": "ethacrynic acid", "relation": "ADVISE", "source_file": "Netilmicin_ddi.xml", "sentence_id": "DDI-DrugBank.d417.s0", "pair_id": "DDI-DrugBank.d417.s0.p2"}
{"sentence": "Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ", "drug1": "naloxone", "drug2": "beta-endorphin", "relation": "EFFECT", "source_file": "3155550.xml", "sentence_id": "DDI-MedLine.d63.s4", "pair_id": "DDI-MedLine.d63.s4.p5"}
{"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Hexobarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d457.s0", "pair_id": "DDI-DrugBank.d457.s0.p2"}
{"sentence": "There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when fluoroquinolones, macrolide antibiotics, or azoles were administered concomitantly.", "drug1": "amiodarone", "drug2": "macrolide antibiotics", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s59", "pair_id": "DDI-DrugBank.d143.s59.p1"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "tricyclic antidepressants", "drug2": "methylphenidate", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p0"}
{"sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "drug1": "anticonvulsant", "drug2": "Mefloquine", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s11", "pair_id": "DDI-DrugBank.d220.s11.p4"}
{"sentence": "Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "NSAIDs", "drug2": "thiazides", "relation": "EFFECT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s11", "pair_id": "DDI-DrugBank.d172.s11.p4"}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "NSAIDs", "drug2": "thiazides", "relation": "EFFECT", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s6", "pair_id": "DDI-DrugBank.d400.s6.p4"}
{"sentence": "Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "drug1": "alcohol", "drug2": "DILAUDID", "relation": "EFFECT", "source_file": "Hydromorphone_ddi.xml", "sentence_id": "DDI-DrugBank.d26.s0", "pair_id": "DDI-DrugBank.d26.s0.p35"}
{"sentence": "Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.", "drug1": "fenofibrate", "drug2": "pravastatin", "relation": "MECHANISM", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s13", "pair_id": "DDI-DrugBank.d283.s13.p1"}
{"sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.", "drug1": "ciprofloxacin", "drug2": "isoniazid", "relation": "NONE", "source_file": "Chlorpheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d235.s4", "pair_id": "DDI-DrugBank.d235.s4.p18"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "amiodarone", "drug2": "ethacrynic acid", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p224"}
{"sentence": "Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "drug1": "Itraconazole", "drug2": "triazolam", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s11", "pair_id": "DDI-DrugBank.d165.s11.p1"}
{"sentence": "Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.", "drug1": "celecoxib", "drug2": "lithium", "relation": "INT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s6", "pair_id": "DDI-DrugBank.d172.s6.p1"}
{"sentence": "Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.", "drug1": "CRIXIVAN", "drug2": "atazanavir", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s26", "pair_id": "DDI-DrugBank.d97.s26.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "azole antifungals", "drug2": "erythromycin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p57"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "lincomycin", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p5"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "thioridazine", "drug2": "triflupromazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p275"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "troleandomycin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p22"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "magnesium", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p24"}
{"sentence": "and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.", "drug1": "Videx", "drug2": "quinolones", "relation": "MECHANISM", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s11", "pair_id": "DDI-DrugBank.d427.s11.p1"}
{"sentence": "Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.", "drug1": "Fluvoxamine", "drug2": "MAOI", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s4", "pair_id": "DDI-DrugBank.d76.s4.p1"}
{"sentence": "Patients treated with Nalfon may be resistant to the effects of loop diuretics.", "drug1": "Nalfon", "drug2": "loop diuretics", "relation": "EFFECT", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s10", "pair_id": "DDI-DrugBank.d154.s10.p0"}
{"sentence": "Adenosine effects are potentiated by dipyridamole.", "drug1": "Adenosine", "drug2": "dipyridamole", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s6", "pair_id": "DDI-DrugBank.d226.s6.p0"}
{"sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "drug1": "anticoagulants", "drug2": "estrogens", "relation": "NONE", "source_file": "Butabarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d184.s0", "pair_id": "DDI-DrugBank.d184.s0.p10"}
{"sentence": "We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.", "drug1": "carbamazepine", "drug2": "tricyclic antidepressant", "relation": "EFFECT", "source_file": "11134454.xml", "sentence_id": "DDI-MedLine.d36.s2", "pair_id": "DDI-MedLine.d36.s2.p0"}
{"sentence": "Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.", "drug1": "Indinavir", "drug2": "didanosine", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s37", "pair_id": "DDI-DrugBank.d97.s37.p0"}
{"sentence": "Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.", "drug1": "tetracyclines", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s6", "pair_id": "DDI-DrugBank.d488.s6.p11"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "methadone", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p11"}
{"sentence": "(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.", "drug1": "steroidal anti-inflammatory agent", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s25", "pair_id": "DDI-DrugBank.d17.s25.p2"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "sirolimus", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p80"}
{"sentence": "Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.", "drug1": "cinoxacin", "drug2": "nonsteroidal anti-inflammatory agents", "relation": "ADVISE", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s13", "pair_id": "DDI-DrugBank.d562.s13.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "morphine", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p31"}
{"sentence": "The vasodilating effects of nitroglycerin may be additive with those of other vasodilators.", "drug1": "nitroglycerin", "drug2": "vasodilators", "relation": "EFFECT", "source_file": "Nitroglycerin_ddi.xml", "sentence_id": "DDI-DrugBank.d14.s0", "pair_id": "DDI-DrugBank.d14.s0.p0"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "Videx", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p34"}
{"sentence": "Coadministration of oral contraceptives, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.", "drug1": "phenytoin", "drug2": "esomeprazole", "relation": "NONE", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s13", "pair_id": "DDI-DrugBank.d29.s13.p8"}
{"sentence": "Colchicine is inhibited by acidifying agents.", "drug1": "Colchicine", "drug2": "acidifying agents", "relation": "MECHANISM", "source_file": "Colchicine_ddi.xml", "sentence_id": "DDI-DrugBank.d146.s0", "pair_id": "DDI-DrugBank.d146.s0.p0"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "drug1": "thiazides", "drug2": "estrogens", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s4", "pair_id": "DDI-DrugBank.d245.s4.p3"}
{"sentence": "It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.", "drug1": "isoniazid", "drug2": "acetaminophen", "relation": "EFFECT", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s3", "pair_id": "DDI-DrugBank.d187.s3.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "allopurinol", "drug2": "oxolinic acid", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p138"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "ZEBETA", "drug2": "benzothiazepine", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p4"}
{"sentence": "If a diuretic is also used, the risk of lithium toxicity may be increased.", "drug1": "diuretic", "drug2": "lithium", "relation": "EFFECT", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s9", "pair_id": "DDI-DrugBank.d561.s9.p0"}
{"sentence": "These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.", "drug1": "zalcitabine", "drug2": "lamivudine", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s7", "pair_id": "DDI-DrugBank.d263.s7.p0"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "benzodiazepines", "drug2": "narcotics", "relation": "EFFECT", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p5"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "tamoxifen", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p16"}
{"sentence": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "drug1": "epinephrine", "drug2": "halothane", "relation": "EFFECT", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s5", "pair_id": "DDI-DrugBank.d247.s5.p2"}
{"sentence": "Therefore, diflunisal and INDOCIN should not be used concomitantly.", "drug1": "diflunisal", "drug2": "INDOCIN", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s2", "pair_id": "DDI-DrugBank.d82.s2.p0"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "Antihistamines", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p1"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "vitamin C", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p21"}
{"sentence": "The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.", "drug1": "catecholamines", "drug2": "Bretylium Tosylate", "relation": "EFFECT", "source_file": "Bretylium_ddi.xml", "sentence_id": "DDI-DrugBank.d180.s1", "pair_id": "DDI-DrugBank.d180.s1.p2"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "thiocyanate", "drug2": "diazepam", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p132"}
{"sentence": "The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)", "drug1": "alcohol", "drug2": "WELLBUTRIN", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s26", "pair_id": "DDI-DrugBank.d5.s26.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "azole antifungals", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p1"}
{"sentence": "In another report, nine patients with breast cancer were reported to have decreased symptoms of methotrexate-related toxicity when given supplemental L-glutamine at a dose of 0.5 gram/kilogram/day.", "drug1": "methotrexate", "drug2": "L-glutamine", "relation": "EFFECT", "source_file": "L-Glutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d66.s6", "pair_id": "DDI-DrugBank.d66.s6.p0"}
{"sentence": "Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.", "drug1": "aripiprazole", "drug2": "quinidine", "relation": "MECHANISM", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s15", "pair_id": "DDI-DrugBank.d509.s15.p4"}
{"sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "drug1": "diflunisal", "drug2": "acenocoumarol", "relation": "EFFECT", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s0", "pair_id": "DDI-DrugBank.d132.s0.p5"}
{"sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.", "drug1": "aspirin", "drug2": "ardeparin", "relation": "EFFECT", "source_file": "Ardeparin_ddi.xml", "sentence_id": "DDI-DrugBank.d105.s0", "pair_id": "DDI-DrugBank.d105.s0.p14"}
{"sentence": "Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. ", "drug1": "cisplatin", "drug2": "thiosulfate", "relation": "NONE", "source_file": "4038510.xml", "sentence_id": "DDI-MedLine.d130.s6", "pair_id": "DDI-MedLine.d130.s6.p1"}
{"sentence": "TRACRIUM should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block.", "drug1": "TRACRIUM", "drug2": "succinylcholine", "relation": "ADVISE", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s10", "pair_id": "DDI-DrugBank.d469.s10.p0"}
{"sentence": "Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).", "drug1": "dextromethorphan", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s1", "pair_id": "DDI-DrugBank.d398.s1.p0"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "chlordiazepoxide", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p4"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "antibiotics", "drug2": "prednisolone", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p162"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "lamotrigine", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p778"}
{"sentence": "Olanzapine: Coadministration of eszopiclone 3 mg and olanzapine 10 mg produced a decrease in DSST scores.", "drug1": "eszopiclone", "drug2": "olanzapine", "relation": "EFFECT", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s3", "pair_id": "DDI-DrugBank.d216.s3.p2"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "non-steroidal anti-inflammatory agents", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p8"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "alprazolam", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p40"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Agenerase", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p24"}
{"sentence": "Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.", "drug1": "aluminum", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s5", "pair_id": "DDI-DrugBank.d516.s5.p5"}
{"sentence": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "drug1": "cimetidine", "drug2": "verografine", "relation": "MECHANISM", "source_file": "7756965.xml", "sentence_id": "DDI-MedLine.d68.s0", "pair_id": "DDI-MedLine.d68.s0.p12"}
{"sentence": "Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.", "drug1": "spironolactone", "drug2": "potassium", "relation": "NONE", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s4", "pair_id": "DDI-DrugBank.d561.s4.p6"}
{"sentence": "When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.", "drug1": "Itraconazole", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s18", "pair_id": "DDI-DrugBank.d165.s18.p0"}
{"sentence": "Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including cyclosporine.", "drug1": "HMG-CoA reductase inhibitors", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s17", "pair_id": "DDI-DrugBank.d165.s17.p1"}
{"sentence": "Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.", "drug1": "Tricyclic antidepressants", "drug2": "guanethidine", "relation": "EFFECT", "source_file": "Cyclobenzaprine_ddi.xml", "sentence_id": "DDI-DrugBank.d150.s2", "pair_id": "DDI-DrugBank.d150.s2.p0"}
{"sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "drug1": "dopamine", "drug2": "beta-adrenergic blocking agents", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s4", "pair_id": "DDI-DrugBank.d325.s4.p0"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "myocardial depressants", "drug2": "diltiazem", "relation": "NONE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p12"}
{"sentence": "Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.", "drug1": "aprepitant", "drug2": "paroxetine", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s43", "pair_id": "DDI-DrugBank.d382.s43.p4"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "Quinidine", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p7"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "dihydroergotamine", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p90"}
{"sentence": "When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed.", "drug1": "diuretic", "drug2": "PRINIVIL", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s3", "pair_id": "DDI-DrugBank.d334.s3.p0"}
{"sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.", "drug1": "tricyclic antidepressants", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s4", "pair_id": "DDI-DrugBank.d238.s4.p3"}
{"sentence": "Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.", "drug1": "Agents with b-blocking properties", "drug2": "hypoglycemics", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s18", "pair_id": "DDI-DrugBank.d269.s18.p8"}
{"sentence": "Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.", "drug1": "Phospholine Iodide", "drug2": "cholinesterase inhibitors", "relation": "EFFECT", "source_file": "Echothiophate Iodide_ddi.xml", "sentence_id": "DDI-DrugBank.d377.s0", "pair_id": "DDI-DrugBank.d377.s0.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "pimozide", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p120"}
{"sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "Felbatol", "drug2": "Felbatol", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s30", "pair_id": "DDI-DrugBank.d434.s30.p10"}
{"sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "drug1": "Factrel", "drug2": "dopamine antagonists", "relation": "EFFECT", "source_file": "Gonadorelin_ddi.xml", "sentence_id": "DDI-DrugBank.d369.s3", "pair_id": "DDI-DrugBank.d369.s3.p1"}
{"sentence": "Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.", "drug1": "Naproxen", "drug2": "gabapentin", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s15", "pair_id": "DDI-DrugBank.d438.s15.p2"}
{"sentence": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "drug1": "WELLBUTRIN", "drug2": "theophylline", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s22", "pair_id": "DDI-DrugBank.d5.s22.p2"}
{"sentence": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.", "drug1": "SSRIs", "drug2": "Imitrex", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s4", "pair_id": "DDI-DrugBank.d423.s4.p4"}
{"sentence": "Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.", "drug1": "Simulect", "drug2": "mycophenolate mofetil", "relation": "MECHANISM", "source_file": "Basiliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d544.s3", "pair_id": "DDI-DrugBank.d544.s3.p1"}
{"sentence": "Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).", "drug1": "CNS depressants", "drug2": "barbiturates", "relation": "NONE", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s0", "pair_id": "DDI-DrugBank.d552.s0.p10"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "Butalbital", "drug2": "sedative-hypnotics", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p7"}
{"sentence": "Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "drug1": "piroxicam", "drug2": "ketorolac tromethamine", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s4", "pair_id": "DDI-DrugBank.d3.s4.p24"}
{"sentence": "Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.", "drug1": "xanthine bronchodilators", "drug2": "sympathomimetic bronchodilators", "relation": "EFFECT", "source_file": "Dyphylline_ddi.xml", "sentence_id": "DDI-DrugBank.d4.s0", "pair_id": "DDI-DrugBank.d4.s0.p2"}
{"sentence": "Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. ", "drug1": "InsP(3)", "drug2": "RR", "relation": "EFFECT", "source_file": "11137703.xml", "sentence_id": "DDI-MedLine.d114.s3", "pair_id": "DDI-MedLine.d114.s3.p0"}
{"sentence": "It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.", "drug1": "dantrolene sodium", "drug2": "verapamil", "relation": "ADVISE", "source_file": "Dantrolene_ddi.xml", "sentence_id": "DDI-DrugBank.d305.s6", "pair_id": "DDI-DrugBank.d305.s6.p1"}
{"sentence": "Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.", "drug1": "Antihistamines", "drug2": "heparin", "relation": "EFFECT", "source_file": "Doxylamine_ddi.xml", "sentence_id": "DDI-DrugBank.d387.s1", "pair_id": "DDI-DrugBank.d387.s1.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "antibiotics", "drug2": "cyclosporine", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p146"}
{"sentence": "Cimetidine: Cimetidine has been demonstrated to interfere with the elimination of other quinolones.", "drug1": "Cimetidine", "drug2": "quinolones", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s12", "pair_id": "DDI-DrugBank.d516.s12.p2"}
{"sentence": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "drug1": "naproxen sodium", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s12", "pair_id": "DDI-DrugBank.d85.s12.p5"}
{"sentence": "Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. ", "drug1": "sirolimus", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "11180036.xml", "sentence_id": "DDI-MedLine.d86.s6", "pair_id": "DDI-MedLine.d86.s6.p2"}
{"sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.", "drug1": "BROVANA", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s6", "pair_id": "DDI-DrugBank.d284.s6.p2"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "antacids", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p68"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "tricyclic antidepressants", "drug2": "fluoxetine", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p2"}
{"sentence": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "drug1": "diclofenac", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s4", "pair_id": "DDI-DrugBank.d249.s4.p0"}
{"sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "drug1": "troleandomycin", "drug2": "nelfinavir", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s2", "pair_id": "DDI-DrugBank.d170.s2.p23"}
{"sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "drug1": "iron supplement", "drug2": "iron", "relation": "NONE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s5", "pair_id": "DDI-DrugBank.d420.s5.p15"}
{"sentence": "INDOCIN has been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.", "drug1": "INDOCIN", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s13", "pair_id": "DDI-DrugBank.d82.s13.p0"}
{"sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "drug1": "ibuprofen", "drug2": "propranolol", "relation": "NONE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s1", "pair_id": "DDI-DrugBank.d431.s1.p35"}
{"sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "nefazodone", "drug2": "cisapride", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s6", "pair_id": "DDI-DrugBank.d237.s6.p4"}
{"sentence": "Warfarin-Vitamin K can antagonize the effect of warfarin", "drug1": "Vitamin K", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s8", "pair_id": "DDI-DrugBank.d139.s8.p2"}
{"sentence": "Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.", "drug1": "Antacids", "drug2": "Aspirin", "relation": "NONE", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s9", "pair_id": "DDI-DrugBank.d443.s9.p0"}
{"sentence": "This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.", "drug1": "ketoconazole", "drug2": "fexofenadine", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s18", "pair_id": "DDI-DrugBank.d466.s18.p3"}
{"sentence": "Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).", "drug1": "Gleevec", "drug2": "benzodiazepines", "relation": "MECHANISM", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s10", "pair_id": "DDI-DrugBank.d115.s10.p0"}
{"sentence": "however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1", "drug1": "pyridoxine", "drug2": "HEXALEN", "relation": "ADVISE", "source_file": "Altretamine_ddi.xml", "sentence_id": "DDI-DrugBank.d188.s2", "pair_id": "DDI-DrugBank.d188.s2.p0"}
{"sentence": "Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.", "drug1": "allopurinol", "drug2": "dicumarol", "relation": "MECHANISM", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s6", "pair_id": "DDI-DrugBank.d413.s6.p4"}
{"sentence": "Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.", "drug1": "BREVIBLOC", "drug2": "dopamine", "relation": "ADVISE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s15", "pair_id": "DDI-DrugBank.d422.s15.p0"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "atenolol", "drug2": "valsartan", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p17"}
{"sentence": "Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. ", "drug1": "4-methylpyrazole", "drug2": "1,3-difluoro-2-propanol", "relation": "EFFECT", "source_file": "11170315.xml", "sentence_id": "DDI-MedLine.d125.s6", "pair_id": "DDI-MedLine.d125.s6.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ethacrynic acid", "drug2": "phenyramidol", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p873"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "aluminum", "drug2": "magnesium", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p23"}
{"sentence": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "drug1": "digoxin", "drug2": "nifedipine", "relation": "INT", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s2", "pair_id": "DDI-DrugBank.d373.s2.p9"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "nefazodone", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p5"}
{"sentence": "Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.", "drug1": "amoxicillin", "drug2": "allopurinol", "relation": "EFFECT", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s16", "pair_id": "DDI-DrugBank.d413.s16.p9"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "salicylates", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p15"}
{"sentence": "The following drug interactions have been identified involving NIZORAL Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: Ketoconazole tablets inhibit the metabolism of terfenadine, resulting in an increased plasma concentration of terfenadine and a delay in the elimination of its acid metabolite.", "drug1": "Ketoconazole", "drug2": "terfenadine", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s3", "pair_id": "DDI-DrugBank.d458.s3.p3"}
{"sentence": "Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.", "drug1": "quinolones", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s2", "pair_id": "DDI-DrugBank.d123.s2.p1"}
{"sentence": "Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.", "drug1": "Probenecid", "drug2": "naproxen", "relation": "MECHANISM", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s10", "pair_id": "DDI-DrugBank.d85.s10.p0"}
{"sentence": "Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.", "drug1": "warfarin", "drug2": "Lodine", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s23", "pair_id": "DDI-DrugBank.d219.s23.p0"}
{"sentence": "Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.", "drug1": "Grepafloxacin", "drug2": "theobromine", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s3", "pair_id": "DDI-DrugBank.d78.s3.p11"}
{"sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "drug1": "dihydroergotamine mesylate", "drug2": "ergotamine", "relation": "NONE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s3", "pair_id": "DDI-DrugBank.d410.s3.p11"}
{"sentence": "In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.", "drug1": "paroxetine", "drug2": "atomoxetine", "relation": "MECHANISM", "source_file": "Atomoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d11.s4", "pair_id": "DDI-DrugBank.d11.s4.p1"}
{"sentence": "- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin", "drug1": "Phenytoin", "drug2": "Dilantin", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s40", "pair_id": "DDI-DrugBank.d179.s40.p0"}
{"sentence": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "drug1": "Vitamin A", "drug2": "acitretin", "relation": "NONE", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s12", "pair_id": "DDI-DrugBank.d353.s12.p3"}
{"sentence": "Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.", "drug1": "cytotoxic agents", "drug2": "allopurinol", "relation": "EFFECT", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s18", "pair_id": "DDI-DrugBank.d413.s18.p5"}
{"sentence": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ", "drug1": "ciprofloxacin", "drug2": "morphine", "relation": "MECHANISM", "source_file": "11210403.xml", "sentence_id": "DDI-MedLine.d124.s1", "pair_id": "DDI-MedLine.d124.s1.p4"}
{"sentence": "Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with ketoprofen and warfarin requires close monitoring of patients on both drugs.", "drug1": "ketoprofen", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s17", "pair_id": "DDI-DrugBank.d499.s17.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "polymyxins", "drug2": "clindamycin", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p61"}
{"sentence": "When Mefloquine is taken concurrently with oral live typhoid vaccines, attenuation of immunization cannot be excluded.", "drug1": "Mefloquine", "drug2": "live typhoid vaccines", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s13", "pair_id": "DDI-DrugBank.d220.s13.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Topamax", "drug2": "Nizoral", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p432"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "pentoxifylline", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p35"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Felbatol", "drug2": "vitamin C", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p493"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "cyclosporine", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p20"}
{"sentence": "A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.", "drug1": "ritonavir", "drug2": "SUSTIVA", "relation": "ADVISE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s42", "pair_id": "DDI-DrugBank.d531.s42.p2"}
{"sentence": "Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. ", "drug1": "tripelennamine", "drug2": "pentazocine", "relation": "EFFECT", "source_file": "3918122.xml", "sentence_id": "DDI-MedLine.d45.s6", "pair_id": "DDI-MedLine.d45.s6.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "triazolam", "drug2": "ziprasidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p1027"}
{"sentence": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.", "drug1": "tetracyclines", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s2", "pair_id": "DDI-DrugBank.d500.s2.p3"}
{"sentence": "Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.", "drug1": "Ethopropazine", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Ethopropazine_ddi.xml", "sentence_id": "DDI-DrugBank.d240.s0", "pair_id": "DDI-DrugBank.d240.s0.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "felbamate", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p16"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "antianxiety agents", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p4"}
{"sentence": "The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.", "drug1": "alcohol", "drug2": "Acamprosate", "relation": "NONE", "source_file": "Acamprosate_ddi.xml", "sentence_id": "DDI-DrugBank.d0.s0", "pair_id": "DDI-DrugBank.d0.s0.p0"}
{"sentence": "ZEBETA should not be combined with other beta-blocking agents.", "drug1": "ZEBETA", "drug2": "beta-blocking agents", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s0", "pair_id": "DDI-DrugBank.d476.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "alprazolam", "drug2": "felodipine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p104"}
{"sentence": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "drug1": "INSPRA", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s1", "pair_id": "DDI-DrugBank.d20.s1.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "disulfiram", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p852"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ranitidine", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1437"}
{"sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "drug1": "Mefloquine", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s9", "pair_id": "DDI-DrugBank.d220.s9.p6"}
{"sentence": "Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.", "drug1": "thiazide diuretics", "drug2": "ergocalciferol", "relation": "EFFECT", "source_file": "Ergocalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d471.s1", "pair_id": "DDI-DrugBank.d471.s1.p0"}
{"sentence": "Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.", "drug1": "lithium", "drug2": "escitalopram", "relation": "EFFECT", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s12", "pair_id": "DDI-DrugBank.d568.s12.p0"}
{"sentence": "Metoprolol - Administration of 20 mg/day LEXAPRO for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg).", "drug1": "LEXAPRO", "drug2": "metoprolol", "relation": "MECHANISM", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s35", "pair_id": "DDI-DrugBank.d568.s35.p4"}
{"sentence": "Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.", "drug1": "bosentan", "drug2": "simvastatin", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s25", "pair_id": "DDI-DrugBank.d289.s25.p5"}
{"sentence": "Lethargy and somnolence have been reported following doses of REVIA and thioridazine.", "drug1": "REVIA", "drug2": "thioridazine", "relation": "EFFECT", "source_file": "Naltrexone_ddi.xml", "sentence_id": "DDI-DrugBank.d346.s3", "pair_id": "DDI-DrugBank.d346.s3.p0"}
{"sentence": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "drug1": "resin", "drug2": "cholestyramine", "relation": "NONE", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s2", "pair_id": "DDI-DrugBank.d566.s2.p16"}
{"sentence": "Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.", "drug1": "tranquilizers", "drug2": "INAPSINE", "relation": "EFFECT", "source_file": "Droperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d254.s0", "pair_id": "DDI-DrugBank.d254.s0.p11"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "acetaminophen", "drug2": "Kaletra", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p71"}
{"sentence": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "drug1": "TRISENOX", "drug2": "diuretics", "relation": "ADVISE", "source_file": "Arsenic trioxide_ddi.xml", "sentence_id": "DDI-DrugBank.d470.s1", "pair_id": "DDI-DrugBank.d470.s1.p2"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Phenothiazines", "drug2": "trifluoperazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p18"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "alfentanil", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p5"}
{"sentence": "The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .", "drug1": "ENABLEX", "drug2": "nelfinavir", "relation": "ADVISE", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s0", "pair_id": "DDI-DrugBank.d459.s0.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "cyclosporine", "drug2": "protease inhibitors", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p716"}
{"sentence": "Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.", "drug1": "Amphetamines", "drug2": "ethosuximide", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s17", "pair_id": "DDI-DrugBank.d236.s17.p2"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "gentamicin", "drug2": "pentamidine", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p27"}
{"sentence": "Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption .", "drug1": "fenofibrate", "drug2": "bile acid binding resin", "relation": "ADVISE", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s12", "pair_id": "DDI-DrugBank.d283.s12.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "lincomycin", "drug2": "sodium colistemethate", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p86"}
{"sentence": "In a single-dose crossover study examining lansoprazole 30 mg and omeprazole 20 mg each administered alone and concomitantly with sucralfate 1 gram, absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with sucralfate.", "drug1": "proton pump inhibitors", "drug2": "sucralfate", "relation": "MECHANISM", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s7", "pair_id": "DDI-DrugBank.d431.s7.p9"}
{"sentence": "- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.", "drug1": "Lithium", "drug2": "bumetanide", "relation": "ADVISE", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s3", "pair_id": "DDI-DrugBank.d331.s3.p5"}
{"sentence": "Acetazolamide increases lithium excretion and the lithium may be decreased.", "drug1": "Acetazolamide", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s12", "pair_id": "DDI-DrugBank.d368.s12.p0"}
{"sentence": "Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.", "drug1": "bosentan", "drug2": "Ortho-Novum", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s6", "pair_id": "DDI-DrugBank.d289.s6.p12"}
{"sentence": "Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.", "drug1": "Thyroxine", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s21", "pair_id": "DDI-DrugBank.d54.s21.p3"}
{"sentence": "Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.", "drug1": "chlorprothixene", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s7", "pair_id": "DDI-DrugBank.d503.s7.p1"}
{"sentence": "Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.\r\n", "drug1": "99mTc-methylene diphosphonate", "drug2": "gentamicin", "relation": "EFFECT", "source_file": "7632757.xml", "sentence_id": "DDI-MedLine.d89.s0", "pair_id": "DDI-MedLine.d89.s0.p0"}
{"sentence": "Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;", "drug1": "Cyclopentolate", "drug2": "carbachol", "relation": "EFFECT", "source_file": "Cyclopentolate_ddi.xml", "sentence_id": "DDI-DrugBank.d298.s0", "pair_id": "DDI-DrugBank.d298.s0.p0"}
{"sentence": "Rifampin: Following concomitant administration of a single dose of ARAVA to subjects receiving multiple doses of rifampin, M1 peak levels were increased (~40%) over those seen when ARAVA was given alone.", "drug1": "ARAVA", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Leflunomide_ddi.xml", "sentence_id": "DDI-DrugBank.d41.s14", "pair_id": "DDI-DrugBank.d41.s14.p3"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "fentanyl", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p129"}
{"sentence": "Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.", "drug1": "Rifampin", "drug2": "nelfinavir", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s32", "pair_id": "DDI-DrugBank.d340.s32.p2"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "caffeine", "drug2": "narcotic analgesic", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p17"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Topamax", "drug2": "clofibrate", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p436"}
{"sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "drug1": "tetracyclines", "drug2": "LEVULAN KERASTICK", "relation": "EFFECT", "source_file": "Aminolevulinic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d379.s1", "pair_id": "DDI-DrugBank.d379.s1.p27"}
{"sentence": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.", "drug1": "psychotropic drugs", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s5", "pair_id": "DDI-DrugBank.d568.s5.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "atorvastatin", "drug2": "vitamin C", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p638"}
{"sentence": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.", "drug1": "Dopamine D2 receptor antagonists", "drug2": "levodopa", "relation": "EFFECT", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s2", "pair_id": "DDI-DrugBank.d47.s2.p4"}
{"sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "drug1": "FACTIVE", "drug2": "omeprazole", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s1", "pair_id": "DDI-DrugBank.d347.s1.p2"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "serotonin reuptake inhibitors", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p40"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Lipitor", "drug2": "Kadian", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p654"}
{"sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "drug1": "carbamazepine", "drug2": "Mefloquine", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s11", "pair_id": "DDI-DrugBank.d220.s11.p13"}
{"sentence": "Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration.", "drug1": "disopyramide", "drug2": "verapamil", "relation": "ADVISE", "source_file": "Disopyramide_ddi.xml", "sentence_id": "DDI-DrugBank.d506.s9", "pair_id": "DDI-DrugBank.d506.s9.p5"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chlorpropamide", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p493"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "cinchophen", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p11"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "ondansetron", "drug2": "ondansetron", "relation": "NONE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p19"}
{"sentence": "Salicylic acid: Combination hormonal contraceptives may increase the clearance of salicylic acid.", "drug1": "hormonal contraceptives", "drug2": "salicylic acid", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s38", "pair_id": "DDI-DrugBank.d485.s38.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "Acetaminophen", "drug2": "alprazolam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p45"}
{"sentence": "Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.", "drug1": "atorvastatin", "drug2": "fluvastatin", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s72", "pair_id": "DDI-DrugBank.d97.s72.p2"}
{"sentence": "Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.", "drug1": "diflunisal", "drug2": "acetaminophen", "relation": "EFFECT", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s14", "pair_id": "DDI-DrugBank.d132.s14.p0"}
{"sentence": "The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.", "drug1": "NIMBEX", "drug2": "succinylcholine", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s1", "pair_id": "DDI-DrugBank.d60.s1.p0"}
{"sentence": "MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.", "drug1": "MAO inhibitors", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s0", "pair_id": "DDI-DrugBank.d492.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "praziquantel", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p32"}
{"sentence": "Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.", "drug1": "clorazepate dipotassium", "drug2": "ethyl alcohol", "relation": "EFFECT", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s1", "pair_id": "DDI-DrugBank.d335.s1.p1"}
{"sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "drug1": "antipsychotic agents", "drug2": "opiates", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s3", "pair_id": "DDI-DrugBank.d186.s3.p3"}
{"sentence": "Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats.\r\n", "drug1": "beta-endorphin", "drug2": "morphine", "relation": "NONE", "source_file": "3155550.xml", "sentence_id": "DDI-MedLine.d63.s0", "pair_id": "DDI-MedLine.d63.s0.p2"}
{"sentence": "Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)", "drug1": "NSAIDs", "drug2": "Warfarin", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s3", "pair_id": "DDI-DrugBank.d568.s3.p1"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "sucralfate", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p13"}
{"sentence": "Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration.", "drug1": "Fluconazole", "drug2": "losartan", "relation": "MECHANISM", "source_file": "Losartan_ddi.xml", "sentence_id": "DDI-DrugBank.d30.s4", "pair_id": "DDI-DrugBank.d30.s4.p0"}
{"sentence": "Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.", "drug1": "WELLBUTRIN", "drug2": "amantadine", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s21", "pair_id": "DDI-DrugBank.d5.s21.p1"}
{"sentence": "In some patients, the administration of a non- steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium- sparing and thiazide diuretics.", "drug1": "non- steroidal antiinflammatory agent", "drug2": "potassium- sparing diuretics", "relation": "EFFECT", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s6", "pair_id": "DDI-DrugBank.d414.s6.p1"}
{"sentence": "Investigations into the effect of acitretin on the protein binding of anticoagulants of the coumarin type (warfarin) revealed no interaction.", "drug1": "acitretin", "drug2": "warfarin", "relation": "NONE", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s14", "pair_id": "DDI-DrugBank.d353.s14.p1"}
{"sentence": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).", "drug1": "Gleevec", "drug2": "clarithromycin", "relation": "ADVISE", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s0", "pair_id": "DDI-DrugBank.d115.s0.p14"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "non-selective beta-adrenergic-blocking agents", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p19"}
{"sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.", "drug1": "heroin", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s2", "pair_id": "DDI-DrugBank.d514.s2.p2"}
{"sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "drug1": "FACTIVE", "drug2": "estrogen", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s1", "pair_id": "DDI-DrugBank.d347.s1.p3"}
{"sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactercidal effect of penicillin and concurrent use of these drugs should be avoided.", "drug1": "bacteriostatic antibiotic", "drug2": "penicillin", "relation": "NONE", "source_file": "Dicloxacillin_ddi.xml", "sentence_id": "DDI-DrugBank.d517.s0", "pair_id": "DDI-DrugBank.d517.s0.p2"}
{"sentence": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.", "drug1": "kaolin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s6", "pair_id": "DDI-DrugBank.d450.s6.p10"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "bacitracin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p18"}
{"sentence": "Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.", "drug1": "proton pump inhibitors", "drug2": "sucralfate", "relation": "ADVISE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s8", "pair_id": "DDI-DrugBank.d431.s8.p0"}
{"sentence": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "drug1": "kaolin", "drug2": "chloroquine", "relation": "NONE", "source_file": "Chloroquine_ddi.xml", "sentence_id": "DDI-DrugBank.d429.s0", "pair_id": "DDI-DrugBank.d429.s0.p6"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "tricyclic antidepressants", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p4"}
{"sentence": "Acetazolamide may increase the effects of other folic acid antagonists.", "drug1": "Acetazolamide", "drug2": "folic acid antagonists", "relation": "EFFECT", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s6", "pair_id": "DDI-DrugBank.d368.s6.p0"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "Cholestyramine", "drug2": "fat soluble vitamins", "relation": "MECHANISM", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s0", "pair_id": "DDI-DrugBank.d98.s0.p27"}
{"sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "drug1": "cyclosporine", "drug2": "quinolone class", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s15", "pair_id": "DDI-DrugBank.d516.s15.p5"}
{"sentence": "Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.", "drug1": "Felbatol", "drug2": "AEDs", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s1", "pair_id": "DDI-DrugBank.d434.s1.p5"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "cimetidine", "drug2": "pentoxifylline", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p563"}
{"sentence": "Aminoglutethimide diminishes the effect of coumarin and warfarin.", "drug1": "coumarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Aminoglutethimide_ddi.xml", "sentence_id": "DDI-DrugBank.d372.s2", "pair_id": "DDI-DrugBank.d372.s2.p2"}
{"sentence": "It may increase excretion of barbiturates, lithium, and ASA and may also increase the toxicity of salicylates.", "drug1": "barbiturates", "drug2": "salicylates", "relation": "NONE", "source_file": "Ethoxzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d286.s1", "pair_id": "DDI-DrugBank.d286.s1.p2"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "skeletal muscle relaxants", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p21"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "naproxen", "drug2": "warfarin sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1274"}
{"sentence": "The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ", "drug1": "MPTP", "drug2": "apomorphine", "relation": "EFFECT", "source_file": "3871245.xml", "sentence_id": "DDI-MedLine.d73.s3", "pair_id": "DDI-MedLine.d73.s3.p1"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p0"}
{"sentence": "There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.", "drug1": "ORENCIA", "drug2": "anakinra", "relation": "ADVISE", "source_file": "Abatacept_ddi.xml", "sentence_id": "DDI-DrugBank.d297.s5", "pair_id": "DDI-DrugBank.d297.s5.p0"}
{"sentence": "Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.", "drug1": "FOSCAVIR", "drug2": "aminoglycosides", "relation": "ADVISE", "source_file": "Foscarnet_ddi.xml", "sentence_id": "DDI-DrugBank.d511.s4", "pair_id": "DDI-DrugBank.d511.s4.p4"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "Pepto-Bismol", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p11"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "iron", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p7"}
{"sentence": "The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.", "drug1": "vardenafil", "drug2": "ritonavir", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s13", "pair_id": "DDI-DrugBank.d198.s13.p0"}
{"sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "drug1": "PRECEDEX", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s1", "pair_id": "DDI-DrugBank.d197.s1.p27"}
{"sentence": "Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.", "drug1": "beta blocker", "drug2": "calcium channel blocker", "relation": "NONE", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s14", "pair_id": "DDI-DrugBank.d81.s14.p5"}
{"sentence": "Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.", "drug1": "bosentan", "drug2": "bosentan", "relation": "NONE", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s31", "pair_id": "DDI-DrugBank.d289.s31.p3"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p0"}
{"sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.", "drug1": "digoxin", "drug2": "hydrochlorothiazide", "relation": "NONE", "source_file": "Acebutolol_ddi.xml", "sentence_id": "DDI-DrugBank.d388.s5", "pair_id": "DDI-DrugBank.d388.s5.p0"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p28"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "ondansetron", "relation": "ADVISE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p25"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "benzodiazepines", "drug2": "nifedipine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p5"}
{"sentence": "MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.", "drug1": "MAO inhibitors", "drug2": "MAOI antidepressants", "relation": "NONE", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s10", "pair_id": "DDI-DrugBank.d236.s10.p0"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "acetaminophen", "drug2": "narcotic analgesic", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p10"}
{"sentence": "Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "drug1": "Hydrochlorothiazide", "drug2": "non-steroidal anti-inflammatory agents", "relation": "ADVISE", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s13", "pair_id": "DDI-DrugBank.d162.s13.p0"}
{"sentence": "Methenamine therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.", "drug1": "amphetamines", "drug2": "methenamine", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s17", "pair_id": "DDI-DrugBank.d158.s17.p2"}
{"sentence": "Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.", "drug1": "diflunisal", "drug2": "acetaminophen", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s11", "pair_id": "DDI-DrugBank.d132.s11.p3"}
{"sentence": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "drug1": "retinoids", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s7", "pair_id": "DDI-MedLine.d12.s7.p12"}
{"sentence": "Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "drug1": "D.H.E. 45", "drug2": "macrolide class", "relation": "MECHANISM", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s5", "pair_id": "DDI-DrugBank.d410.s5.p24"}
{"sentence": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.", "drug1": "diclofenac", "drug2": "prednisolone", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s18", "pair_id": "DDI-DrugBank.d249.s18.p2"}
{"sentence": "Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.", "drug1": "indinavir", "drug2": "ritonavir", "relation": "EFFECT", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s52", "pair_id": "DDI-DrugBank.d97.s52.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "clarithromycin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p3"}
{"sentence": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "drug1": "lithium", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s16", "pair_id": "DDI-DrugBank.d107.s16.p5"}
{"sentence": "for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;", "drug1": "hypoglycemic medications", "drug2": "thiazide diuretic", "relation": "ADVISE", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s18", "pair_id": "DDI-DrugBank.d17.s18.p0"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "LEVSIN", "drug2": "haloperidol", "relation": "EFFECT", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p2"}
{"sentence": "When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "drug1": "CANCIDAS", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s14", "pair_id": "DDI-DrugBank.d350.s14.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "Acetaminophen", "drug2": "felodipine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p61"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "CNS depressants", "drug2": "antianxiety agents", "relation": "NONE", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p14"}
{"sentence": "Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..", "drug1": "cilostazol", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s2", "pair_id": "DDI-DrugBank.d358.s2.p0"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "Phenytoin", "drug2": "calcitriol", "relation": "NONE", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s2", "pair_id": "DDI-DrugBank.d384.s2.p4"}
{"sentence": "Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.", "drug1": "nortriptyline hydrochloride", "drug2": "sympathomimetic drugs", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s9", "pair_id": "DDI-DrugBank.d202.s9.p1"}
{"sentence": "The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.", "drug1": "milrinone", "drug2": "anagrelide", "relation": "EFFECT", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s14", "pair_id": "DDI-DrugBank.d75.s14.p4"}
{"sentence": "Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.", "drug1": "VIOXX", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s27", "pair_id": "DDI-DrugBank.d210.s27.p3"}
{"sentence": "Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.", "drug1": "Phenytoin", "drug2": "acitretin", "relation": "NONE", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s10", "pair_id": "DDI-DrugBank.d353.s10.p0"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "benzodiazepines", "drug2": "ethyl alcohol", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p8"}
{"sentence": "Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "furosemide", "relation": "INT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s7", "pair_id": "DDI-DrugBank.d172.s7.p1"}
{"sentence": "Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.", "drug1": "aminoglycoside", "drug2": "penicillin", "relation": "MECHANISM", "source_file": "Kanamycin_ddi.xml", "sentence_id": "DDI-DrugBank.d57.s1", "pair_id": "DDI-DrugBank.d57.s1.p0"}
{"sentence": "No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil.", "drug1": "Simulect", "drug2": "azathioprine", "relation": "NONE", "source_file": "Basiliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d544.s0", "pair_id": "DDI-DrugBank.d544.s0.p2"}
{"sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "drug1": "calcium channel blockers", "drug2": "loop diuretics", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s35", "pair_id": "DDI-DrugBank.d558.s35.p21"}
{"sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "drug1": "Codeine", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Codeine_ddi.xml", "sentence_id": "DDI-DrugBank.d464.s0", "pair_id": "DDI-DrugBank.d464.s0.p2"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "indomethacin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p33"}
{"sentence": "Apraclonidine should not be used in patients receiving MAO inhibitors..", "drug1": "Apraclonidine", "drug2": "MAO inhibitors", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s0", "pair_id": "DDI-DrugBank.d224.s0.p0"}
{"sentence": "Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.", "drug1": "BREVIBLOC", "drug2": "epinephrine", "relation": "ADVISE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s15", "pair_id": "DDI-DrugBank.d422.s15.p1"}
{"sentence": "Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "drug1": "lithium", "drug2": "lithium", "relation": "NONE", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s15", "pair_id": "DDI-DrugBank.d415.s15.p2"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "benzodiazepines", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p3"}
{"sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "drug1": "itraconazole", "drug2": "bexarotene", "relation": "MECHANISM", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s2", "pair_id": "DDI-DrugBank.d467.s2.p11"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "citalopram", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p5"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "alcohol", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p0"}
{"sentence": "Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.", "drug1": "Ribavirin", "drug2": "stavudine", "relation": "EFFECT", "source_file": "Peginterferon alfa-2a_ddi.xml", "sentence_id": "DDI-DrugBank.d196.s6", "pair_id": "DDI-DrugBank.d196.s6.p7"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "olanzapine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p28"}
{"sentence": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.", "drug1": "metoclopramide", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s6", "pair_id": "DDI-DrugBank.d450.s6.p20"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "clozapine", "drug2": "itraconazole", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p380"}
{"sentence": "Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.", "drug1": "Folic acid", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Leucovorin_ddi.xml", "sentence_id": "DDI-DrugBank.d151.s0", "pair_id": "DDI-DrugBank.d151.s0.p1"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "propafenone", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p14"}
{"sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "drug1": "desipramine hydrochloride", "drug2": "desipramine", "relation": "NONE", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s23", "pair_id": "DDI-DrugBank.d386.s23.p4"}
{"sentence": "Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.", "drug1": "saquinavir", "drug2": "FORTOVASE", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s18", "pair_id": "DDI-DrugBank.d124.s18.p0"}
{"sentence": "Dextromethorphan is a substrate for both CYP2D6 and CYP3A4.", "drug1": "Dextromethorphan", "drug2": "CYP2D6", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s54", "pair_id": "DDI-DrugBank.d143.s54.p0"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "AKINETON", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p16"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Thorazine", "drug2": "thioridazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p102"}
{"sentence": "The immediate release, but not the coat-core formulation of nisoldipine increased plasma quinidine concentrations by about 20%.", "drug1": "nisoldipine", "drug2": "quinidine", "relation": "MECHANISM", "source_file": "Nisoldipine_ddi.xml", "sentence_id": "DDI-DrugBank.d106.s9", "pair_id": "DDI-DrugBank.d106.s9.p0"}
{"sentence": "Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.", "drug1": "WELLBUTRIN", "drug2": "levodopa", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s21", "pair_id": "DDI-DrugBank.d5.s21.p0"}
{"sentence": "Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.", "drug1": "Midazolam", "drug2": "indomethacin", "relation": "EFFECT", "source_file": "11210678.xml", "sentence_id": "DDI-MedLine.d67.s7", "pair_id": "DDI-MedLine.d67.s7.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p5"}
{"sentence": "Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.", "drug1": "Aspirin", "drug2": "phenylbutazone", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s0", "pair_id": "DDI-DrugBank.d443.s0.p6"}
{"sentence": "In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; ", "drug1": "(-)-NANM", "drug2": "naloxone", "relation": "EFFECT", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s8", "pair_id": "DDI-MedLine.d30.s8.p2"}
{"sentence": "It is suggested to monitor both ketoconazole and phenytoin.", "drug1": "ketoconazole", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s23", "pair_id": "DDI-DrugBank.d458.s23.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "itraconazole", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p12"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "scopolamine", "drug2": "lorazepam", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p35"}
{"sentence": "Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.", "drug1": "carbamazepine", "drug2": "lithium", "relation": "EFFECT", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s14", "pair_id": "DDI-DrugBank.d94.s14.p2"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "antihistamines", "drug2": "antihistamines", "relation": "NONE", "source_file": "Dexbrompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d62.s0", "pair_id": "DDI-DrugBank.d62.s0.p35"}
{"sentence": "INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.", "drug1": "Isoniazid", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s25", "pair_id": "DDI-DrugBank.d458.s25.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "protease inhibitors", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p23"}
{"sentence": "however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1", "drug1": "pyridoxine", "drug2": "cisplatin", "relation": "ADVISE", "source_file": "Altretamine_ddi.xml", "sentence_id": "DDI-DrugBank.d188.s2", "pair_id": "DDI-DrugBank.d188.s2.p1"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "itraconazole", "drug2": "nefazodone", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p13"}
{"sentence": "The safety and efficacy of PROLEUKIN in combination with any antineoplastic agents have not been established.", "drug1": "PROLEUKIN", "drug2": "antineoplastic agents", "relation": "NONE", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s3", "pair_id": "DDI-DrugBank.d114.s3.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "nortriptyline", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p27"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "sympathomimetics", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p12"}
{"sentence": "In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.", "drug1": "cyclosporine", "drug2": "caspofungin", "relation": "MECHANISM", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s7", "pair_id": "DDI-DrugBank.d350.s7.p0"}
{"sentence": "Antibiotics (ampicillin, tetracycline): Pregnancy has been reported following concomitant use, however, pharmacokinetic studies have not shown consistent effects with these antibiotics on plasma concentrations of synthetic steroids.", "drug1": "Antibiotics", "drug2": "synthetic steroids", "relation": "NONE", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s8", "pair_id": "DDI-DrugBank.d485.s8.p3"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "iron", "drug2": "ciprofloxacin", "relation": "NONE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p53"}
{"sentence": "- Concomitant use of tricyclic antidepressants may reduce the efficacy of lofexidine.", "drug1": "tricyclic antidepressants", "drug2": "lofexidine", "relation": "EFFECT", "source_file": "Lofexidine_ddi.xml", "sentence_id": "DDI-DrugBank.d454.s4", "pair_id": "DDI-DrugBank.d454.s4.p0"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "lovastatin", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p9"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "p-aminosalicylic acid", "drug2": "b-adrenergic blocking agents", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p39"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "amiodarone", "drug2": "phenytoin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p89"}
{"sentence": "Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.", "drug1": "Uricosuric drugs", "drug2": "sulfinpyrazone", "relation": "NONE", "source_file": "Nitrofurantoin_ddi.xml", "sentence_id": "DDI-DrugBank.d276.s2", "pair_id": "DDI-DrugBank.d276.s2.p1"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "Butalbital", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p5"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "diflunisal", "drug2": "indomethacin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p787"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "ethacrynic acid", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p18"}
{"sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "drug1": "diflunisal", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s0", "pair_id": "DDI-DrugBank.d132.s0.p4"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "propafenone", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p4"}
{"sentence": "We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ", "drug1": "indinavir", "drug2": "indinavir", "relation": "NONE", "source_file": "11120981.xml", "sentence_id": "DDI-MedLine.d79.s2", "pair_id": "DDI-MedLine.d79.s2.p1"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "sumatriptan", "drug2": "sertraline", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p4"}
{"sentence": "ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.", "drug1": "ALLEGRA", "drug2": "magnesium", "relation": "ADVISE", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s20", "pair_id": "DDI-DrugBank.d466.s20.p1"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p1"}
{"sentence": "Given the primary CNS effects of Clozapine, caution is advised in using it concomitantly with other CNS-active drugs or alcohol.", "drug1": "Clozapine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s4", "pair_id": "DDI-DrugBank.d480.s4.p0"}
{"sentence": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "drug1": "cholestyramine", "drug2": "digitalis", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s2", "pair_id": "DDI-DrugBank.d566.s2.p12"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "VIDEX", "drug2": "didanosine", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p75"}
{"sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.", "drug1": "PRECEDEX", "drug2": "opioid", "relation": "ADVISE", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s4", "pair_id": "DDI-DrugBank.d197.s4.p8"}
{"sentence": "The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.", "drug1": "vasopressor", "drug2": "oxytocic drugs", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s12", "pair_id": "DDI-DrugBank.d325.s12.p1"}
{"sentence": "Caution should be used if INDOCIN is administered simultaneously with methotrexate.", "drug1": "INDOCIN", "drug2": "methotrexate", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s12", "pair_id": "DDI-DrugBank.d82.s12.p0"}
{"sentence": "Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.", "drug1": "citalopram", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s7", "pair_id": "DDI-DrugBank.d568.s7.p3"}
{"sentence": "Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.", "drug1": "theophylline", "drug2": "warfarin", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s2", "pair_id": "DDI-DrugBank.d209.s2.p9"}
{"sentence": "Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s12", "pair_id": "DDI-DrugBank.d162.s12.p6"}
{"sentence": "Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.", "drug1": "Venlafaxine", "drug2": "venlafaxine", "relation": "NONE", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s10", "pair_id": "DDI-DrugBank.d324.s10.p3"}
{"sentence": "Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s23", "pair_id": "DDI-DrugBank.d99.s23.p1"}
{"sentence": "Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).", "drug1": "Diphenhydramine hydrochloride", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Diphenhydramine_ddi.xml", "sentence_id": "DDI-DrugBank.d296.s0", "pair_id": "DDI-DrugBank.d296.s0.p3"}
{"sentence": "Antagonism has been demonstrated between clindamycin and erythromycin in vitro.", "drug1": "clindamycin", "drug2": "erythromycin", "relation": "EFFECT", "source_file": "Clindamycin_ddi.xml", "sentence_id": "DDI-DrugBank.d256.s2", "pair_id": "DDI-DrugBank.d256.s2.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anesthetics", "drug2": "warfarin sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1078"}
{"sentence": "Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.", "drug1": "norfloxacin", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s5", "pair_id": "DDI-DrugBank.d217.s5.p4"}
{"sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.", "drug1": "hydroxyurea", "drug2": "allopurinol", "relation": "NONE", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s2", "pair_id": "DDI-DrugBank.d75.s2.p27"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "aluminum", "drug2": "didanosine", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p31"}
{"sentence": "Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "furosemide", "drug2": "thiazides", "relation": "NONE", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s11", "pair_id": "DDI-DrugBank.d219.s11.p2"}
{"sentence": "Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.", "drug1": "erythromycin", "drug2": "cilostazol", "relation": "MECHANISM", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s1", "pair_id": "DDI-DrugBank.d358.s1.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "methylphenidate", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p27"}
{"sentence": "The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.", "drug1": "benzodiazepines", "drug2": "Aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s23", "pair_id": "DDI-DrugBank.d382.s23.p6"}
{"sentence": "Theophylline: Ethinyl estradiol may inhibit the metabolism of theophylline, leading to increased plasma concentrations.", "drug1": "Ethinyl estradiol", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s40", "pair_id": "DDI-DrugBank.d485.s40.p2"}
{"sentence": "Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.", "drug1": "Nonsteroidal Anti-inflammatory Drugs", "drug2": "quinolone", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s19", "pair_id": "DDI-DrugBank.d78.s19.p2"}
{"sentence": "Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.", "drug1": "aspirin", "drug2": "valdecoxib", "relation": "EFFECT", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s4", "pair_id": "DDI-DrugBank.d328.s4.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "anticonvulsants", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p5"}
{"sentence": "Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.", "drug1": "ritonavir", "drug2": "indinavir", "relation": "NONE", "source_file": "Paclitaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d288.s4", "pair_id": "DDI-DrugBank.d288.s4.p10"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "antidepressants", "drug2": "antihistamines", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p34"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "clindamycin", "drug2": "magnesium", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p94"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "quetiapine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p34"}
{"sentence": "A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.", "drug1": "barbiturates", "drug2": "tetracyclines", "relation": "NONE", "source_file": "Norgestimate_ddi.xml", "sentence_id": "DDI-DrugBank.d360.s1", "pair_id": "DDI-DrugBank.d360.s1.p6"}
{"sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "drug1": "cefdinir", "drug2": "iron", "relation": "MECHANISM", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s5", "pair_id": "DDI-DrugBank.d420.s5.p12"}
{"sentence": "The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.", "drug1": "INDOCIN", "drug2": "NSAIDs", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s4", "pair_id": "DDI-DrugBank.d82.s4.p0"}
{"sentence": "Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.", "drug1": "cholestyramine", "drug2": "thyroid hormones", "relation": "ADVISE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s10", "pair_id": "DDI-DrugBank.d54.s10.p0"}
{"sentence": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).", "drug1": "lansoprazole", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s12", "pair_id": "DDI-DrugBank.d431.s12.p3"}
{"sentence": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "drug1": "dexamethasone", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s2", "pair_id": "DDI-MedLine.d12.s2.p3"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "delavirdine", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p177"}
{"sentence": "Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.", "drug1": "NRTIs", "drug2": "zidovudine", "relation": "NONE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s91", "pair_id": "DDI-DrugBank.d531.s91.p4"}
{"sentence": "Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.", "drug1": "ritonavir", "drug2": "VIRACEPT", "relation": "MECHANISM", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s16", "pair_id": "DDI-DrugBank.d340.s16.p4"}
{"sentence": "In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.", "drug1": "MAO inhibitor", "drug2": "disulfiram", "relation": "EFFECT", "source_file": "Isocarboxazid_ddi.xml", "sentence_id": "DDI-DrugBank.d108.s1", "pair_id": "DDI-DrugBank.d108.s1.p0"}
{"sentence": "- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);", "drug1": "Bactrim", "drug2": "Azulfidine", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s3", "pair_id": "DDI-DrugBank.d521.s3.p17"}
{"sentence": "in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.", "drug1": "terfenadine", "drug2": "dirithromycin", "relation": "MECHANISM", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s5", "pair_id": "DDI-DrugBank.d522.s5.p5"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "anticholinergic", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p8"}
{"sentence": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.", "drug1": "intraconazole", "drug2": "budesonide", "relation": "ADVISE", "source_file": "Budesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d144.s1", "pair_id": "DDI-DrugBank.d144.s1.p10"}
{"sentence": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "drug1": "antacids", "drug2": "norfloxacin", "relation": "ADVISE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s11", "pair_id": "DDI-DrugBank.d217.s11.p16"}
{"sentence": "In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.", "drug1": "fluoxetine", "drug2": "atomoxetine", "relation": "MECHANISM", "source_file": "Atomoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d11.s4", "pair_id": "DDI-DrugBank.d11.s4.p3"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "quinine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p20"}
{"sentence": "However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.", "drug1": "escitalopram", "drug2": "desipramine", "relation": "MECHANISM", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s32", "pair_id": "DDI-DrugBank.d568.s32.p5"}
{"sentence": "Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.", "drug1": "amphotericin B", "drug2": "flucytosine", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s7", "pair_id": "DDI-DrugBank.d318.s7.p2"}
{"sentence": "In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.", "drug1": "aminoglycoside", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "Kanamycin_ddi.xml", "sentence_id": "DDI-DrugBank.d57.s0", "pair_id": "DDI-DrugBank.d57.s0.p0"}
{"sentence": "Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.", "drug1": "Digitalis", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s6", "pair_id": "DDI-DrugBank.d488.s6.p8"}
{"sentence": "DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. ", "drug1": "Clarithromycin", "drug2": "simvastatin", "relation": "MECHANISM", "source_file": "11197581.xml", "sentence_id": "DDI-MedLine.d25.s9", "pair_id": "DDI-MedLine.d25.s9.p0"}
{"sentence": "The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.", "drug1": "gemifloxacin", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s6", "pair_id": "DDI-DrugBank.d347.s6.p1"}
{"sentence": "Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.", "drug1": "ketoprofen", "drug2": "warfarin", "relation": "NONE", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s15", "pair_id": "DDI-DrugBank.d499.s15.p2"}
{"sentence": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "drug1": "glucocorticoids", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s10", "pair_id": "DDI-DrugBank.d114.s10.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "amiodarone", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p3"}
{"sentence": "It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.", "drug1": "anticoagulants", "drug2": "disulfiram", "relation": "ADVISE", "source_file": "Disulfiram_ddi.xml", "sentence_id": "DDI-DrugBank.d19.s6", "pair_id": "DDI-DrugBank.d19.s6.p0"}
{"sentence": "Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.", "drug1": "fentanyl", "drug2": "calcium channel blocker", "relation": "EFFECT", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s14", "pair_id": "DDI-DrugBank.d81.s14.p4"}
{"sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "drug1": "Butyrophenones", "drug2": "dopamine", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s7", "pair_id": "DDI-DrugBank.d325.s7.p2"}
{"sentence": "On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. ", "drug1": "neurotensin", "drug2": "tuftsin", "relation": "EFFECT", "source_file": "6545985.xml", "sentence_id": "DDI-MedLine.d131.s4", "pair_id": "DDI-MedLine.d131.s4.p0"}
{"sentence": "Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.", "drug1": "Rifampin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s7", "pair_id": "DDI-DrugBank.d450.s7.p0"}
{"sentence": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "drug1": "buspirone HCl", "drug2": "psychotropic drugs", "relation": "NONE", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s0", "pair_id": "DDI-DrugBank.d463.s0.p7"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "phenytoin", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p4"}
{"sentence": "Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03). ", "drug1": "atracurium", "drug2": "atracurium", "relation": "NONE", "source_file": "8542840.xml", "sentence_id": "DDI-MedLine.d90.s7", "pair_id": "DDI-MedLine.d90.s7.p0"}
{"sentence": "If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.", "drug1": "phenytoin", "drug2": "Norpace", "relation": "MECHANISM", "source_file": "Disopyramide_ddi.xml", "sentence_id": "DDI-DrugBank.d506.s0", "pair_id": "DDI-DrugBank.d506.s0.p0"}
{"sentence": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "drug1": "tolbutamide", "drug2": "Aprepitant", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s18", "pair_id": "DDI-DrugBank.d382.s18.p9"}
{"sentence": "Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.", "drug1": "Rifampin", "drug2": "rifampin", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s32", "pair_id": "DDI-DrugBank.d340.s32.p0"}
{"sentence": "Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ", "drug1": "Sildenafil", "drug2": "short-acting nitrates", "relation": "ADVISE", "source_file": "11213561.xml", "sentence_id": "DDI-MedLine.d1.s5", "pair_id": "DDI-MedLine.d1.s5.p1"}
{"sentence": "Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.", "drug1": "antiretroviral medications", "drug2": "antiretroviral medication", "relation": "NONE", "source_file": "Enfuvirtide_ddi.xml", "sentence_id": "DDI-DrugBank.d535.s1", "pair_id": "DDI-DrugBank.d535.s1.p4"}
{"sentence": "Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.", "drug1": "EQUETROTM", "drug2": "alcohol", "relation": "ADVISE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s18", "pair_id": "DDI-DrugBank.d94.s18.p1"}
{"sentence": "Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "enalapril", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s4", "pair_id": "DDI-DrugBank.d107.s4.p2"}
{"sentence": "Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.", "drug1": "phenytoin", "drug2": "coumarin anticoagulants", "relation": "MECHANISM", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s3", "pair_id": "DDI-DrugBank.d359.s3.p1"}
{"sentence": "In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.", "drug1": "bupropion", "drug2": "desipramine", "relation": "MECHANISM", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s14", "pair_id": "DDI-DrugBank.d5.s14.p0"}
{"sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.", "drug1": "antipsychotics", "drug2": "antianxiety agents", "relation": "NONE", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s0", "pair_id": "DDI-DrugBank.d396.s0.p6"}
{"sentence": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "drug1": "TORADOL", "drug2": "anticoagulants", "relation": "ADVISE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s7", "pair_id": "DDI-DrugBank.d3.s7.p9"}
{"sentence": "The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.", "drug1": "ERGOMAR", "drug2": "vasoconstrictor drugs", "relation": "EFFECT", "source_file": "Ergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d59.s1", "pair_id": "DDI-DrugBank.d59.s1.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "chlorpropamide", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p8"}
{"sentence": "In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.", "drug1": "central nervous system depressants", "drug2": "heroin", "relation": "EFFECT", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s1", "pair_id": "DDI-DrugBank.d514.s1.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "oxyphenbutazone", "drug2": "triclofos sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1310"}
{"sentence": "The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.", "drug1": "alcohol", "drug2": "bromocriptine mesylate", "relation": "EFFECT", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s0", "pair_id": "DDI-DrugBank.d272.s0.p2"}
{"sentence": "Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.", "drug1": "neuroleptics", "drug2": "dopamine agonists", "relation": "ADVISE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s4", "pair_id": "DDI-DrugBank.d357.s4.p0"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "acetaminophen", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p13"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "Benzthiazide", "drug2": "Ibuprofen", "relation": "INT", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p7"}
{"sentence": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "drug1": "CANCIDAS", "drug2": "tacrolimus", "relation": "MECHANISM", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s5", "pair_id": "DDI-DrugBank.d350.s5.p0"}
{"sentence": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .", "drug1": "propafenone", "drug2": "carvedilol", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s1", "pair_id": "DDI-DrugBank.d269.s1.p20"}
{"sentence": "Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin", "drug1": "Antimycobacterial agents", "drug2": "rifabutin", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s7", "pair_id": "DDI-DrugBank.d340.s7.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Sandimmune", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p22"}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "NSAIDs", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s10", "pair_id": "DDI-DrugBank.d328.s10.p3"}
{"sentence": "Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. ", "drug1": "ethanol", "drug2": "disulfiram", "relation": "EFFECT", "source_file": "6537219.xml", "sentence_id": "DDI-MedLine.d81.s2", "pair_id": "DDI-MedLine.d81.s2.p0"}
{"sentence": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.", "drug1": "anticholinergics", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Glycopyrrolate_ddi.xml", "sentence_id": "DDI-DrugBank.d510.s0", "pair_id": "DDI-DrugBank.d510.s0.p6"}
{"sentence": "Aspirin: CELEBREX can be used with low dose aspirin.", "drug1": "CELEBREX", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s13", "pair_id": "DDI-DrugBank.d172.s13.p2"}
{"sentence": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.", "drug1": "Isoflurane", "drug2": "muscle relaxants", "relation": "EFFECT", "source_file": "Isoflurane_ddi.xml", "sentence_id": "DDI-DrugBank.d227.s0", "pair_id": "DDI-DrugBank.d227.s0.p0"}
{"sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "drug1": "hormonal contraceptives", "drug2": "lorazepam", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s17", "pair_id": "DDI-DrugBank.d485.s17.p12"}
{"sentence": "Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.", "drug1": "diuretics", "drug2": "beta2-agonists.", "relation": "EFFECT", "source_file": "Formoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d103.s4", "pair_id": "DDI-DrugBank.d103.s4.p20"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "cyclosporine", "drug2": "Agenerase", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p717"}
{"sentence": "In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.", "drug1": "diuretics", "drug2": "CAMPTOSAR", "relation": "EFFECT", "source_file": "Irinotecan_ddi.xml", "sentence_id": "DDI-DrugBank.d279.s11", "pair_id": "DDI-DrugBank.d279.s11.p2"}
{"sentence": "Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.", "drug1": "Erythromycin", "drug2": "vardenafil", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s5", "pair_id": "DDI-DrugBank.d198.s5.p0"}
{"sentence": "The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.", "drug1": "guanfacine", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s1", "pair_id": "DDI-DrugBank.d507.s1.p0"}
{"sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.", "drug1": "paroxetine", "drug2": "aripiprazole", "relation": "MECHANISM", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s8", "pair_id": "DDI-DrugBank.d509.s8.p9"}
{"sentence": "Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .", "drug1": "propranolol", "drug2": "phenytoin", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s12", "pair_id": "DDI-DrugBank.d460.s12.p10"}
{"sentence": "Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).", "drug1": "Zalcitabine", "drug2": "ZDV", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s1", "pair_id": "DDI-DrugBank.d263.s1.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "quetiapine", "drug2": "triazolam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p985"}
{"sentence": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "drug1": "hydralazine", "drug2": "digoxin", "relation": "NONE", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s10", "pair_id": "DDI-DrugBank.d107.s10.p34"}
{"sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.", "drug1": "antipsychotics", "drug2": "hydrocodone", "relation": "EFFECT", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s0", "pair_id": "DDI-DrugBank.d396.s0.p9"}
{"sentence": "Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.", "drug1": "TRICOR", "drug2": "bile acid binding resin", "relation": "MECHANISM", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s4", "pair_id": "DDI-DrugBank.d283.s4.p5"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "anti-depressants", "drug2": "sparfloxacin", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p3"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "bromocriptine", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p6"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "nonsteroidal anti-inflammatory", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p26"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "caffeine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p18"}
{"sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "drug1": "caffeine", "drug2": "anticoagulant", "relation": "NONE", "source_file": "Levofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d242.s1", "pair_id": "DDI-DrugBank.d242.s1.p9"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "disulfiram", "drug2": "sulindac", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p848"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "halothane", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p11"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "doxycycline", "drug2": "lorazepam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p578"}
{"sentence": "Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. ", "drug1": "zidovudine", "drug2": "zidovudine", "relation": "NONE", "source_file": "11210404.xml", "sentence_id": "DDI-MedLine.d105.s7", "pair_id": "DDI-MedLine.d105.s7.p4"}
{"sentence": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "drug1": "epinephrine", "drug2": "halogenated hydrocarbon general anesthetics", "relation": "EFFECT", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s5", "pair_id": "DDI-DrugBank.d247.s5.p1"}
{"sentence": "Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.", "drug1": "sympathomimetic agents", "drug2": "vasopressor", "relation": "NONE", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s2", "pair_id": "DDI-DrugBank.d441.s2.p7"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "diazepam", "drug2": "itraconazole", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p514"}
{"sentence": "Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.", "drug1": "magnesium", "drug2": "VIDEX", "relation": "EFFECT", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s4", "pair_id": "DDI-DrugBank.d43.s4.p10"}
{"sentence": "No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.", "drug1": "sulfinpyrazone", "drug2": "contraceptives", "relation": "NONE", "source_file": "Acebutolol_ddi.xml", "sentence_id": "DDI-DrugBank.d388.s5", "pair_id": "DDI-DrugBank.d388.s5.p15"}
{"sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "paroxetine", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s3", "pair_id": "DDI-DrugBank.d426.s3.p19"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "lidocaine", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p6"}
{"sentence": "After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.", "drug1": "ketoconazole", "drug2": "loratadine", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s27", "pair_id": "DDI-DrugBank.d458.s27.p0"}
{"sentence": "Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.", "drug1": "thyroid", "drug2": "contraceptives", "relation": "ADVISE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s14", "pair_id": "DDI-DrugBank.d54.s14.p2"}
{"sentence": "Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.", "drug1": "itraconazole", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s9", "pair_id": "DDI-DrugBank.d216.s9.p0"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "alprazolam", "drug2": "nifedipine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p10"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "Phenytoin", "drug2": "Phenobarbital", "relation": "NONE", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s2", "pair_id": "DDI-DrugBank.d404.s2.p0"}
{"sentence": "Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "potassium-sparing diuretics", "relation": "EFFECT", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s12", "pair_id": "DDI-DrugBank.d162.s12.p5"}
{"sentence": "At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.", "drug1": "MAO inhibitor", "drug2": "dexfenfluramine", "relation": "ADVISE", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s2", "pair_id": "DDI-DrugBank.d423.s2.p0"}
{"sentence": "Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.", "drug1": "quinolones", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s0", "pair_id": "DDI-DrugBank.d123.s0.p1"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "aspirin", "drug2": "warfarin", "relation": "NONE", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p35"}
{"sentence": "Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.", "drug1": "cyclosporine", "drug2": "fibrate drugs", "relation": "EFFECT", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s5", "pair_id": "DDI-DrugBank.d283.s5.p3"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "triazolam", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p11"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "bromelains", "drug2": "methyldopa", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p376"}
{"sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "drug1": "dopamine", "drug2": "propranolol", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s4", "pair_id": "DDI-DrugBank.d325.s4.p1"}
{"sentence": "Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ", "drug1": "Barbiturates", "drug2": "coumarin drugs", "relation": "ADVISE", "source_file": "1109248.xml", "sentence_id": "DDI-MedLine.d106.s6", "pair_id": "DDI-MedLine.d106.s6.p1"}
{"sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "drug1": "anticoagulant", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s89", "pair_id": "DDI-DrugBank.d64.s89.p9"}
{"sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "drug1": "potassium-sparing diuretics", "drug2": "spironolactone", "relation": "NONE", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s15", "pair_id": "DDI-DrugBank.d334.s15.p5"}
{"sentence": "Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.", "drug1": "Auranofin", "drug2": "Solganal", "relation": "ADVISE", "source_file": "Auranofin_ddi.xml", "sentence_id": "DDI-DrugBank.d374.s0", "pair_id": "DDI-DrugBank.d374.s0.p1"}
{"sentence": "It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.", "drug1": "CASODEX", "drug2": "coumarin anticoagulants", "relation": "ADVISE", "source_file": "Bicalutamide_ddi.xml", "sentence_id": "DDI-DrugBank.d266.s1", "pair_id": "DDI-DrugBank.d266.s1.p0"}
{"sentence": "Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).", "drug1": "Analgesic", "drug2": "ibuprofen", "relation": "NONE", "source_file": "Doxazosin_ddi.xml", "sentence_id": "DDI-DrugBank.d367.s9", "pair_id": "DDI-DrugBank.d367.s9.p5"}
{"sentence": "The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "drug1": "dextromethorphan hydrobromide", "drug2": "psychotropics", "relation": "EFFECT", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s2", "pair_id": "DDI-DrugBank.d398.s2.p2"}
{"sentence": "FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.", "drug1": "FLUOTHANE", "drug2": "aminoglycosides", "relation": "EFFECT", "source_file": "Halothane_ddi.xml", "sentence_id": "DDI-DrugBank.d74.s0", "pair_id": "DDI-DrugBank.d74.s0.p1"}
{"sentence": "Diflunisal decreased the hyperuricemic effect of furosemide.", "drug1": "Diflunisal", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s8", "pair_id": "DDI-DrugBank.d132.s8.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "clobazam", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p6"}
{"sentence": "Phenylbutazone: Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.", "drug1": "Phenylbutazone", "drug2": "Phenylbutazone", "relation": "NONE", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s19", "pair_id": "DDI-DrugBank.d219.s19.p0"}
{"sentence": "Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.", "drug1": "reserpine", "drug2": "beta-blocking", "relation": "EFFECT", "source_file": "Betaxolol_ddi.xml", "sentence_id": "DDI-DrugBank.d489.s2", "pair_id": "DDI-DrugBank.d489.s2.p0"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "telithromycin", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p10"}
{"sentence": "- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions.", "drug1": "bumetanide", "drug2": "aminoglycoside antibiotics", "relation": "ADVISE", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s0", "pair_id": "DDI-DrugBank.d331.s0.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ibuprofen", "drug2": "naproxen", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p967"}
{"sentence": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).", "drug1": "iodine", "drug2": "antacids", "relation": "NONE", "source_file": "Diatrizoate_ddi.xml", "sentence_id": "DDI-DrugBank.d293.s0", "pair_id": "DDI-DrugBank.d293.s0.p8"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "Aprepitant", "drug2": "nefazodone", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p2"}
{"sentence": "The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion. ", "drug1": "DCG-IV", "drug2": "PCP", "relation": "EFFECT", "source_file": "11085328.xml", "sentence_id": "DDI-MedLine.d104.s4", "pair_id": "DDI-MedLine.d104.s4.p0"}
{"sentence": "Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.", "drug1": "Nevirapine", "drug2": "rifampin", "relation": "ADVISE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s53", "pair_id": "DDI-DrugBank.d270.s53.p0"}
{"sentence": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "drug1": "lomefloxacin", "drug2": "terfenadine", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s23", "pair_id": "DDI-DrugBank.d516.s23.p8"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "lithium", "drug2": "norepinephrine", "relation": "NONE", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p26"}
{"sentence": "Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.", "drug1": "Antacids", "drug2": "quinolones", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s6", "pair_id": "DDI-DrugBank.d562.s6.p1"}
{"sentence": "Calcium Antagonists: After repeated co-administration of Trileptal, the AUC of felodipine was lowered by 28% [90% CI: 20-33].", "drug1": "Trileptal", "drug2": "felodipine", "relation": "MECHANISM", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s45", "pair_id": "DDI-DrugBank.d307.s45.p2"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "rifampin", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p20"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "probenecid", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p5"}
{"sentence": "Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "EFFECT", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s22", "pair_id": "DDI-DrugBank.d99.s22.p0"}
{"sentence": "Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin", "drug1": "(S)-warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s16", "pair_id": "DDI-DrugBank.d216.s16.p9"}
{"sentence": "Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.", "drug1": "Ethoxzolamide", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Ethoxzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d286.s0", "pair_id": "DDI-DrugBank.d286.s0.p3"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "sirolimus", "drug2": "tacrolimus", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p76"}
{"sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "drug1": "omeprazole", "drug2": "cimetidine", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s5", "pair_id": "DDI-DrugBank.d558.s5.p19"}
{"sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "drug1": "diuretics", "drug2": "furosemide", "relation": "NONE", "source_file": "Cefepime_ddi.xml", "sentence_id": "DDI-DrugBank.d378.s1", "pair_id": "DDI-DrugBank.d378.s1.p2"}
{"sentence": "A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.", "drug1": "ritonavir", "drug2": "nevirapine", "relation": "ADVISE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s39", "pair_id": "DDI-DrugBank.d270.s39.p2"}
{"sentence": "This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.", "drug1": "BEXTRA", "drug2": "ACE-inhibitors", "relation": "ADVISE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s9", "pair_id": "DDI-DrugBank.d328.s9.p0"}
{"sentence": "Drug-Drug Interactions: No clinically significant drug interactions have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin.", "drug1": "theophylline", "drug2": "erythromycin", "relation": "NONE", "source_file": "Cetirizine_ddi.xml", "sentence_id": "DDI-DrugBank.d393.s4", "pair_id": "DDI-DrugBank.d393.s4.p3"}
{"sentence": "Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.", "drug1": "NSAIDs", "drug2": "beta-blockers", "relation": "EFFECT", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s9", "pair_id": "DDI-DrugBank.d85.s9.p4"}
{"sentence": "HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.", "drug1": "Indinavir", "drug2": "Vardenafil", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s10", "pair_id": "DDI-DrugBank.d198.s10.p5"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "pentazocine", "drug2": "Levo-Dromoran", "relation": "ADVISE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p20"}
{"sentence": "Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of isradipine on the sixth day showed an increase in isradipine mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).", "drug1": "cimetidine", "drug2": "isradipine", "relation": "MECHANISM", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s7", "pair_id": "DDI-DrugBank.d81.s7.p3"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p0"}
{"sentence": "Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite.", "drug1": "Rifampin", "drug2": "losartan", "relation": "MECHANISM", "source_file": "Losartan_ddi.xml", "sentence_id": "DDI-DrugBank.d30.s1", "pair_id": "DDI-DrugBank.d30.s1.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "alprazolam", "drug2": "praziquantel", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p119"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "lithium", "drug2": "NSAIDs", "relation": "NONE", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p27"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "mefenamic acid", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p25"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "quinidine", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p75"}
{"sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "drug1": "Cyclopropane", "drug2": "catecholamines", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s8", "pair_id": "DDI-DrugBank.d325.s8.p1"}
{"sentence": "These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.", "drug1": "diltiazem", "drug2": "triazolam", "relation": "EFFECT", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s35", "pair_id": "DDI-DrugBank.d565.s35.p1"}
{"sentence": "There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.", "drug1": "anticoagulants", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s8", "pair_id": "DDI-DrugBank.d487.s8.p0"}
{"sentence": "The peripheral vasoconstriction caused by high doses of dopamine HCl is antagonized by alpha-adrenergic blocking agents.", "drug1": "dopamine HCl", "drug2": "alpha-adrenergic blocking agents", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s5", "pair_id": "DDI-DrugBank.d325.s5.p0"}
{"sentence": "Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.", "drug1": "Corticotropin", "drug2": "diuretic", "relation": "EFFECT", "source_file": "Corticotropin_ddi.xml", "sentence_id": "DDI-DrugBank.d25.s0", "pair_id": "DDI-DrugBank.d25.s0.p0"}
{"sentence": "Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ", "drug1": "Haloperidol", "drug2": "PCP", "relation": "EFFECT", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s11", "pair_id": "DDI-MedLine.d30.s11.p1"}
{"sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "drug1": "Sedatives", "drug2": "anesthetics", "relation": "NONE", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s1", "pair_id": "DDI-DrugBank.d197.s1.p11"}
{"sentence": "Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.", "drug1": "bosentan", "drug2": "S-warfarin", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s30", "pair_id": "DDI-DrugBank.d289.s30.p3"}
{"sentence": "Clinical implications of warfarin interactions with five sedatives.\n", "drug1": "warfarin", "drug2": "sedatives", "relation": "INT", "source_file": "1109248.xml", "sentence_id": "DDI-MedLine.d106.s0", "pair_id": "DDI-MedLine.d106.s0.p0"}
{"sentence": "Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.", "drug1": "SULAR", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Nisoldipine_ddi.xml", "sentence_id": "DDI-DrugBank.d106.s4", "pair_id": "DDI-DrugBank.d106.s4.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "antacids", "drug2": "cholestyramine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p71"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p8"}
{"sentence": "Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.", "drug1": "aminoglycoside antibiotics", "drug2": "cephalosporin antibiotics", "relation": "EFFECT", "source_file": "Cefprozil_ddi.xml", "sentence_id": "DDI-DrugBank.d121.s0", "pair_id": "DDI-DrugBank.d121.s0.p0"}
{"sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.", "drug1": "PRECEDEX", "drug2": "hypnotic", "relation": "ADVISE", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s4", "pair_id": "DDI-DrugBank.d197.s4.p7"}
{"sentence": "The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators.", "drug1": "isosorbide mononitrate", "drug2": "vasodilators", "relation": "EFFECT", "source_file": "Isosorbide Mononitrate_ddi.xml", "sentence_id": "DDI-DrugBank.d479.s0", "pair_id": "DDI-DrugBank.d479.s0.p0"}
{"sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.", "drug1": "alcohol", "drug2": "sedatives", "relation": "NONE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s1", "pair_id": "DDI-DrugBank.d224.s1.p13"}
{"sentence": "AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. ", "drug1": "calcium channel blocker", "drug2": "diltiazem", "relation": "NONE", "source_file": "11180036.xml", "sentence_id": "DDI-MedLine.d86.s1", "pair_id": "DDI-MedLine.d86.s1.p5"}
{"sentence": "No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.", "drug1": "digoxin", "drug2": "warfarin", "relation": "NONE", "source_file": "Irbesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d27.s0", "pair_id": "DDI-DrugBank.d27.s0.p3"}
{"sentence": "Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "drug1": "diflunisal", "drug2": "indomethacin", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s20", "pair_id": "DDI-DrugBank.d132.s20.p3"}
{"sentence": "Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.", "drug1": "Levo-Dromoran", "drug2": "MAO inhibitors", "relation": "ADVISE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s3", "pair_id": "DDI-DrugBank.d257.s3.p2"}
{"sentence": "In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.", "drug1": "INDOCIN", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s23", "pair_id": "DDI-DrugBank.d82.s23.p2"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "flecainide", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p5"}
{"sentence": "Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.", "drug1": "VIRACEPT", "drug2": "nelfinavir", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s16", "pair_id": "DDI-DrugBank.d340.s16.p7"}
{"sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.", "drug1": "phenothiazines", "drug2": "antidepressants", "relation": "NONE", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s3", "pair_id": "DDI-DrugBank.d335.s3.p13"}
{"sentence": "Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.", "drug1": "digoxin", "drug2": "nicardipine HCl", "relation": "ADVISE", "source_file": "Nicardipine_ddi.xml", "sentence_id": "DDI-DrugBank.d468.s5", "pair_id": "DDI-DrugBank.d468.s5.p5"}
{"sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "drug1": "TAMBOCOR", "drug2": "TAMBOCOR", "relation": "NONE", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s19", "pair_id": "DDI-DrugBank.d87.s19.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "contraceptives", "drug2": "topiramate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p922"}
{"sentence": "These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.", "drug1": "antibiotics", "drug2": "anticholinesterase", "relation": "ADVISE", "source_file": "Neostigmine_ddi.xml", "sentence_id": "DDI-DrugBank.d498.s1", "pair_id": "DDI-DrugBank.d498.s1.p0"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "antineoplastic agents", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p6"}
{"sentence": "If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.", "drug1": "cyclosporine", "drug2": "diltiazem", "relation": "ADVISE", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s27", "pair_id": "DDI-DrugBank.d565.s27.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "dicumarol", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p13"}
{"sentence": "Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ", "drug1": "Dexamethasone", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s3", "pair_id": "DDI-MedLine.d12.s3.p1"}
{"sentence": "Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.", "drug1": "TRICOR", "drug2": "atorvastatin", "relation": "MECHANISM", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s15", "pair_id": "DDI-DrugBank.d283.s15.p3"}
{"sentence": "Although there is little published information on concomitant administration of lidocaine and Bretylium Tosylate, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.", "drug1": "lidocaine", "drug2": "Bretylium Tosylate", "relation": "NONE", "source_file": "Bretylium_ddi.xml", "sentence_id": "DDI-DrugBank.d180.s3", "pair_id": "DDI-DrugBank.d180.s3.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "magnesium", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p9"}
{"sentence": "We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.", "drug1": "4-methylpyrazole", "drug2": "1,3-difluoro-2-propanol", "relation": "EFFECT", "source_file": "11170315.xml", "sentence_id": "DDI-MedLine.d125.s8", "pair_id": "DDI-MedLine.d125.s8.p0"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "guanethidine", "drug2": "guanadrel", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p69"}
{"sentence": "Steady-state serum concentrations of tricyclic antidepressants are reported to fluctuate significantly when cimetidine is either added or deleted from the drug regimen.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s0", "pair_id": "DDI-DrugBank.d202.s0.p0"}
{"sentence": "Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.", "drug1": "Ibuprofen", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s12", "pair_id": "DDI-DrugBank.d415.s12.p3"}
{"sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "drug1": "Levothyroxine Sodium", "drug2": "aluminum hydoxide", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s2", "pair_id": "DDI-DrugBank.d411.s2.p1"}
{"sentence": "For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.", "drug1": "cholestyramine", "drug2": "vitamin K", "relation": "MECHANISM", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s3", "pair_id": "DDI-DrugBank.d64.s3.p1"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "diazepam", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p5"}
{"sentence": "Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "NSAIDs", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s11", "pair_id": "DDI-DrugBank.d172.s11.p3"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "oxcarbazepine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p30"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "pertechnetate", "drug2": "insulin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p193"}
{"sentence": "Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.", "drug1": "Argatroban", "drug2": "antiplatelet agents", "relation": "EFFECT", "source_file": "Argatroban_ddi.xml", "sentence_id": "DDI-DrugBank.d148.s6", "pair_id": "DDI-DrugBank.d148.s6.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "clofibrate", "drug2": "methylphenidate", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p638"}
{"sentence": "Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. ", "drug1": "Azithromycin", "drug2": "zidovudine", "relation": "MECHANISM", "source_file": "11210404.xml", "sentence_id": "DDI-MedLine.d105.s7", "pair_id": "DDI-MedLine.d105.s7.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "valproate", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p41"}
{"sentence": "The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.", "drug1": "aspirin", "drug2": "fenoprofen", "relation": "MECHANISM", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s0", "pair_id": "DDI-DrugBank.d154.s0.p0"}
{"sentence": "In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).", "drug1": "ENBREL", "drug2": "anakinra", "relation": "EFFECT", "source_file": "Etanercept_ddi.xml", "sentence_id": "DDI-DrugBank.d341.s2", "pair_id": "DDI-DrugBank.d341.s2.p0"}
{"sentence": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "drug1": "sucralfate", "drug2": "norfloxacin", "relation": "ADVISE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s11", "pair_id": "DDI-DrugBank.d217.s11.p18"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "doxycycline", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p14"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "doxycycline", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p4"}
{"sentence": "Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.", "drug1": "aluminum", "drug2": "VIDEX", "relation": "EFFECT", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s4", "pair_id": "DDI-DrugBank.d43.s4.p12"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "clofibrate", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p12"}
{"sentence": "Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).", "drug1": "dorzolamide", "drug2": "carbonic anhydrase inhibitors", "relation": "EFFECT", "source_file": "Dorzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d34.s0", "pair_id": "DDI-DrugBank.d34.s0.p0"}
{"sentence": "The mode of toxic action of the pesticide gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate.\r\n", "drug1": "gliftor", "drug2": "(-)-erythro-fluorocitrate", "relation": "NONE", "source_file": "11170315.xml", "sentence_id": "DDI-MedLine.d125.s0", "pair_id": "DDI-MedLine.d125.s0.p1"}
{"sentence": "However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.", "drug1": "clozapine", "drug2": "fluoxetine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s22", "pair_id": "DDI-DrugBank.d480.s22.p5"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "ergot derivatives", "drug2": "alprazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p112"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "salicylates", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p2"}
{"sentence": "Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.", "drug1": "Propantheline", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s5", "pair_id": "DDI-DrugBank.d450.s5.p1"}
{"sentence": "The effects of ketamine and of Innovar anesthesia on digitalis tolerance in dogs.\r\n", "drug1": "ketamine", "drug2": "Innovar", "relation": "NONE", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s0", "pair_id": "DDI-MedLine.d23.s0.p0"}
{"sentence": "When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.", "drug1": "anticoagulants", "drug2": "FLOLAN", "relation": "EFFECT", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s1", "pair_id": "DDI-DrugBank.d241.s1.p2"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "ondansetron", "relation": "EFFECT", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p9"}
{"sentence": "Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.", "drug1": "rifampin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s18", "pair_id": "DDI-DrugBank.d314.s18.p12"}
{"sentence": "Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.", "drug1": "ketoconazole", "drug2": "cinacalcet", "relation": "MECHANISM", "source_file": "Cinacalcet_ddi.xml", "sentence_id": "DDI-DrugBank.d512.s6", "pair_id": "DDI-DrugBank.d512.s6.p0"}
{"sentence": "To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). ", "drug1": "arginine", "drug2": "theophylline", "relation": "NONE", "source_file": "1116650.xml", "sentence_id": "DDI-MedLine.d74.s2", "pair_id": "DDI-MedLine.d74.s2.p1"}
{"sentence": "Quinolones have been shown to interfere with the metabolism of caffeine.", "drug1": "Quinolones", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s3", "pair_id": "DDI-DrugBank.d427.s3.p0"}
{"sentence": "Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.", "drug1": "rifabutin", "drug2": "VIRACEPT", "relation": "MECHANISM", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s30", "pair_id": "DDI-DrugBank.d340.s30.p4"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "antidepressants", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p0"}
{"sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "drug1": "MONUROL", "drug2": "metoclopramide", "relation": "MECHANISM", "source_file": "Fosfomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d199.s0", "pair_id": "DDI-DrugBank.d199.s0.p3"}
{"sentence": "In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.", "drug1": "warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Irbesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d27.s4", "pair_id": "DDI-DrugBank.d27.s4.p3"}
{"sentence": "In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.", "drug1": "nifedipine", "drug2": "captopril", "relation": "NONE", "source_file": "Iloprost_ddi.xml", "sentence_id": "DDI-DrugBank.d549.s0", "pair_id": "DDI-DrugBank.d549.s0.p4"}
{"sentence": "Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.", "drug1": "Auranofin", "drug2": "gold medication", "relation": "ADVISE", "source_file": "Auranofin_ddi.xml", "sentence_id": "DDI-DrugBank.d374.s0", "pair_id": "DDI-DrugBank.d374.s0.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "influenza virus vaccine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p23"}
{"sentence": "The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.", "drug1": "imipramine", "drug2": "fluoxetine", "relation": "MECHANISM", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s5", "pair_id": "DDI-DrugBank.d77.s5.p1"}
{"sentence": "Nifedipine: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.", "drug1": "nifedipine", "drug2": "nifedipine", "relation": "NONE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s25", "pair_id": "DDI-DrugBank.d198.s25.p5"}
{"sentence": "Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.", "drug1": "calcium", "drug2": "EMCYT", "relation": "MECHANISM", "source_file": "Estramustine_ddi.xml", "sentence_id": "DDI-DrugBank.d481.s0", "pair_id": "DDI-DrugBank.d481.s0.p0"}
{"sentence": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.", "drug1": "bupropion", "drug2": "amantadine", "relation": "EFFECT", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s20", "pair_id": "DDI-DrugBank.d5.s20.p8"}
{"sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "drug1": "phenytoin", "drug2": "levetiracetam", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s11", "pair_id": "DDI-DrugBank.d212.s11.p47"}
{"sentence": "Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).", "drug1": "Skeletal muscle relaxants", "drug2": "skeletal muscle relaxants", "relation": "NONE", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s12", "pair_id": "DDI-DrugBank.d318.s12.p1"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "atorvastatin", "drug2": "didanosine", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p17"}
{"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.", "drug1": "ergotamine", "drug2": "AXERT", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s1", "pair_id": "DDI-DrugBank.d299.s1.p3"}
{"sentence": "Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.", "drug1": "Warfarin", "drug2": "fluvoxamine maleate", "relation": "NONE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s30", "pair_id": "DDI-DrugBank.d76.s30.p0"}
{"sentence": "Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.", "drug1": "digoxin", "drug2": "conivaptan", "relation": "MECHANISM", "source_file": "Conivaptan_ddi.xml", "sentence_id": "DDI-DrugBank.d315.s0", "pair_id": "DDI-DrugBank.d315.s0.p3"}
{"sentence": "Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .", "drug1": "nateglinide", "drug2": "glyburide", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s12", "pair_id": "DDI-DrugBank.d460.s12.p1"}
{"sentence": "Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.", "drug1": "Fenfluramine", "drug2": "methyldopa", "relation": "EFFECT", "source_file": "Fenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d104.s0", "pair_id": "DDI-DrugBank.d104.s0.p2"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "disopyramide", "drug2": "alprazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p42"}
{"sentence": "This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.", "drug1": "ciprofloxacin", "drug2": "antacids", "relation": "ADVISE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s10", "pair_id": "DDI-DrugBank.d123.s10.p0"}
{"sentence": "Other CNS depressant drugs should be used with caution in patients taking fenfluramine, since the effects may be additive.", "drug1": "CNS depressant drugs", "drug2": "fenfluramine", "relation": "ADVISE", "source_file": "Fenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d104.s1", "pair_id": "DDI-DrugBank.d104.s1.p0"}
{"sentence": "Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.", "drug1": "Aspirin", "drug2": "antacids", "relation": "ADVISE", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s9", "pair_id": "DDI-DrugBank.d443.s9.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anesthetics", "drug2": "naproxen", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1057"}
{"sentence": "Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.", "drug1": "sulfur", "drug2": "salicylic acid", "relation": "NONE", "source_file": "Adapalene_ddi.xml", "sentence_id": "DDI-DrugBank.d370.s1", "pair_id": "DDI-DrugBank.d370.s1.p1"}
{"sentence": "Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).", "drug1": "Albendazole sulfoxide", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Albendazole_ddi.xml", "sentence_id": "DDI-DrugBank.d321.s4", "pair_id": "DDI-DrugBank.d321.s4.p3"}
{"sentence": "Meperidine: Amphetamines potentiate the analgesic effect of meperidine.", "drug1": "Amphetamines", "drug2": "meperidine", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s16", "pair_id": "DDI-DrugBank.d158.s16.p2"}
{"sentence": "Lithium: generally should not be given with diuretics.", "drug1": "Lithium", "drug2": "diuretics", "relation": "ADVISE", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s9", "pair_id": "DDI-DrugBank.d162.s9.p0"}
{"sentence": "Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.", "drug1": "nondepolarizing neuromuscular blocking agents", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s13", "pair_id": "DDI-DrugBank.d60.s13.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "bromelains", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p6"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "aspirin", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p12"}
{"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "drug1": "amantadine", "drug2": "benzodiazepines", "relation": "NONE", "source_file": "Dicyclomine_ddi.xml", "sentence_id": "DDI-DrugBank.d543.s0", "pair_id": "DDI-DrugBank.d543.s0.p12"}
{"sentence": "Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.", "drug1": "Fluvoxamine", "drug2": "diazepam", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s19", "pair_id": "DDI-DrugBank.d76.s19.p2"}
{"sentence": "Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.", "drug1": "phenylbutazone", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s3", "pair_id": "DDI-DrugBank.d443.s3.p6"}
{"sentence": "Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.", "drug1": "loratadine", "drug2": "descarboethoxyloratadine", "relation": "NONE", "source_file": "Loratadine_ddi.xml", "sentence_id": "DDI-DrugBank.d258.s1", "pair_id": "DDI-DrugBank.d258.s1.p0"}
{"sentence": "Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ", "drug1": "18-MC", "drug2": "ibogaine", "relation": "NONE", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s15", "pair_id": "DDI-MedLine.d110.s15.p0"}
{"sentence": "Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.", "drug1": "fluvoxamine", "drug2": "alprazolam", "relation": "INT", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s10", "pair_id": "DDI-DrugBank.d76.s10.p2"}
{"sentence": "Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "quinolone antibiotics", "drug2": "calcium", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s12", "pair_id": "DDI-DrugBank.d43.s12.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "lithium", "drug2": "anesthetics", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p114"}
{"sentence": "HEMABATE may augment the activity of other oxytocic agents.", "drug1": "HEMABATE", "drug2": "oxytocic agents", "relation": "EFFECT", "source_file": "Carboprost Tromethamine_ddi.xml", "sentence_id": "DDI-DrugBank.d23.s0", "pair_id": "DDI-DrugBank.d23.s0.p0"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "thyroxine", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p8"}
{"sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.", "drug1": "methylxanthines", "drug2": "adrenergic agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s3", "pair_id": "DDI-DrugBank.d284.s3.p4"}
{"sentence": "- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or", "drug1": "nandrolone", "drug2": "oxandrolone", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s3", "pair_id": "DDI-DrugBank.d179.s3.p9"}
{"sentence": "Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.", "drug1": "nadolol", "drug2": "guanfacine", "relation": "EFFECT", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s5", "pair_id": "DDI-DrugBank.d507.s5.p4"}
{"sentence": "Patients taking disopyramide phosphate and erythromycin concomitantly may develop increased serum concentrations of disopyramide resulting in excessive widening of the QRS complex and/or prolongation of the Q-T interval.", "drug1": "disopyramide phosphate", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Disopyramide_ddi.xml", "sentence_id": "DDI-DrugBank.d506.s7", "pair_id": "DDI-DrugBank.d506.s7.p0"}
{"sentence": "When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced.", "drug1": "amiodarone", "drug2": "flecainide", "relation": "MECHANISM", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s15", "pair_id": "DDI-DrugBank.d87.s15.p0"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "tobramycin", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p1"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "choline salicylate", "drug2": "bismuth subsalicylate", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p66"}
{"sentence": "The zidovudine study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. ", "drug1": "azithromycin", "drug2": "zidovudine", "relation": "NONE", "source_file": "11210404.xml", "sentence_id": "DDI-MedLine.d105.s3", "pair_id": "DDI-MedLine.d105.s3.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chymotrypsin", "drug2": "methyldopa", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p511"}
{"sentence": "Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. ", "drug1": "clindamycin", "drug2": "gentamicin", "relation": "EFFECT", "source_file": "15825309.xml", "sentence_id": "DDI-MedLine.d49.s8", "pair_id": "DDI-MedLine.d49.s8.p0"}
{"sentence": "Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.", "drug1": "phenytoin", "drug2": "exemestane", "relation": "MECHANISM", "source_file": "Exemestane_ddi.xml", "sentence_id": "DDI-DrugBank.d435.s2", "pair_id": "DDI-DrugBank.d435.s2.p6"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "valproate", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p23"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "cyclosporine", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p7"}
{"sentence": "Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.", "drug1": "aluminum", "drug2": "Ibandronate", "relation": "MECHANISM", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s1", "pair_id": "DDI-DrugBank.d440.s1.p6"}
{"sentence": "There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.", "drug1": "erythromycin", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s3", "pair_id": "DDI-DrugBank.d397.s3.p0"}
{"sentence": "Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.", "drug1": "verapamil", "drug2": "Adenocard", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s1", "pair_id": "DDI-DrugBank.d226.s1.p2"}
{"sentence": "Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.", "drug1": "retinoids", "drug2": "acitretin", "relation": "ADVISE", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s12", "pair_id": "DDI-DrugBank.d353.s12.p9"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "Benzthiazide", "drug2": "decongestant drugs", "relation": "INT", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p2"}
{"sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "drug1": "quinolones", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Levofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d242.s1", "pair_id": "DDI-DrugBank.d242.s1.p1"}
{"sentence": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "drug1": "epinephrine", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s2", "pair_id": "DDI-DrugBank.d77.s2.p13"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "phenothiazines classes of antipsychotic agents", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p5"}
{"sentence": "Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.", "drug1": "Cevimeline", "drug2": "beta adrenergic antagonists", "relation": "ADVISE", "source_file": "Cevimeline_ddi.xml", "sentence_id": "DDI-DrugBank.d287.s0", "pair_id": "DDI-DrugBank.d287.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "lorazepam", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p23"}
{"sentence": "Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.", "drug1": "dirithromycin", "drug2": "H 2 -receptor antagonists", "relation": "MECHANISM", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s15", "pair_id": "DDI-DrugBank.d522.s15.p10"}
{"sentence": "Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.", "drug1": "Cardiac glycosides", "drug2": "bepridil hydrochloride", "relation": "EFFECT", "source_file": "Bepridil_ddi.xml", "sentence_id": "DDI-DrugBank.d137.s11", "pair_id": "DDI-DrugBank.d137.s11.p0"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "propranolol", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p2"}
{"sentence": "There was a small increase in plasma concentrations of capecitabine and one metabolite (5-DFCR);", "drug1": "capecitabine", "drug2": "5-DFCR", "relation": "NONE", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s1", "pair_id": "DDI-DrugBank.d88.s1.p0"}
{"sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "drug1": "fentanyl", "drug2": "ritonavir", "relation": "MECHANISM", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s2", "pair_id": "DDI-DrugBank.d170.s2.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "nalidixic acid", "drug2": "pyrazolones", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1240"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "Indocin", "drug2": "Anaprox", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p269"}
{"sentence": "Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol", "drug1": "Tricyclic antidepressants", "drug2": "tramadol", "relation": "EFFECT", "source_file": "Cyclobenzaprine_ddi.xml", "sentence_id": "DDI-DrugBank.d150.s3", "pair_id": "DDI-DrugBank.d150.s3.p0"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "cyclosporine", "drug2": "pimozide", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p47"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Dilantin", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p6"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "quinidine", "drug2": "quinine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1407"}
{"sentence": "Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s24", "pair_id": "DDI-DrugBank.d99.s24.p3"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "Anticonvulsants", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p6"}
{"sentence": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "ADVISE", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s8", "pair_id": "DDI-DrugBank.d334.s8.p0"}
{"sentence": "Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. ", "drug1": "verapamil", "drug2": "bombesin", "relation": "NONE", "source_file": "11125235.xml", "sentence_id": "DDI-MedLine.d133.s4", "pair_id": "DDI-MedLine.d133.s4.p0"}
{"sentence": "Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.", "drug1": "macrolide antibiotics", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s19", "pair_id": "DDI-DrugBank.d314.s19.p4"}
{"sentence": "Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.", "drug1": "enflurane", "drug2": "NUROMAX", "relation": "MECHANISM", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s3", "pair_id": "DDI-DrugBank.d267.s3.p4"}
{"sentence": "Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.", "drug1": "Potassium", "drug2": "Fosinopril sodium", "relation": "NONE", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s3", "pair_id": "DDI-DrugBank.d176.s3.p1"}
{"sentence": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "drug1": "diclofenac", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s2", "pair_id": "DDI-DrugBank.d249.s2.p7"}
{"sentence": "Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.", "drug1": "indinavir", "drug2": "indinavir", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s41", "pair_id": "DDI-DrugBank.d97.s41.p0"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "felbamate", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p17"}
{"sentence": "the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ", "drug1": "naloxone", "drug2": "(-)-NANM", "relation": "EFFECT", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s9", "pair_id": "DDI-MedLine.d30.s9.p0"}
{"sentence": "Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol.", "drug1": "Flurbiprofen", "drug2": "propranolol", "relation": "EFFECT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s8", "pair_id": "DDI-DrugBank.d529.s8.p0"}
{"sentence": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "drug1": "Aprepitant", "drug2": "contraceptive", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s19", "pair_id": "DDI-DrugBank.d382.s19.p6"}
{"sentence": "These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.", "drug1": "STADOL NS", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s7", "pair_id": "DDI-DrugBank.d246.s7.p0"}
{"sentence": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "drug1": "TAXOL", "drug2": "cisplatin", "relation": "EFFECT", "source_file": "Paclitaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d288.s0", "pair_id": "DDI-DrugBank.d288.s0.p9"}
{"sentence": "Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;", "drug1": "lovastatin", "drug2": "erythromycin", "relation": "ADVISE", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s15", "pair_id": "DDI-DrugBank.d397.s15.p0"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "Curariform muscle relaxants", "drug2": "decamethonium", "relation": "NONE", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p3"}
{"sentence": "Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.", "drug1": "Anticholinergic drugs", "drug2": "metoclopramide", "relation": "MECHANISM", "source_file": "Dicyclomine_ddi.xml", "sentence_id": "DDI-DrugBank.d543.s6", "pair_id": "DDI-DrugBank.d543.s6.p0"}
{"sentence": "Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving clonazepam.", "drug1": "antifungal agents", "drug2": "clonazepam", "relation": "ADVISE", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s6", "pair_id": "DDI-DrugBank.d333.s6.p2"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "alfentanil", "drug2": "bromocriptine", "relation": "NONE", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p66"}
{"sentence": "H-2 Antagonists: In studies with human volunteers, co-administration of cimetidine or ranitidine with ibuprofen had no substantive effect on ibuprofen serum concentrations.", "drug1": "ibuprofen", "drug2": "ibuprofen", "relation": "NONE", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s8", "pair_id": "DDI-DrugBank.d415.s8.p5"}
{"sentence": "Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.", "drug1": "indomethacin", "drug2": "captopril", "relation": "EFFECT", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s16", "pair_id": "DDI-DrugBank.d175.s16.p0"}
{"sentence": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "drug1": "Methotrexate", "drug2": "methotrexate", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s13", "pair_id": "DDI-DrugBank.d3.s13.p3"}
{"sentence": "When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.", "drug1": "carbamazepine", "drug2": "aripiprazole", "relation": "NONE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s20", "pair_id": "DDI-DrugBank.d509.s20.p1"}
{"sentence": "- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;", "drug1": "diuretic", "drug2": "Hydrodiuril", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s6", "pair_id": "DDI-DrugBank.d521.s6.p2"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "sucralfate", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p4"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "amiodarone", "drug2": "heparin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p78"}
{"sentence": "Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.", "drug1": "enalapril", "drug2": "thiazide-type diuretics", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s12", "pair_id": "DDI-DrugBank.d107.s12.p2"}
{"sentence": "Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.", "drug1": "acitretin", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s10", "pair_id": "DDI-DrugBank.d353.s10.p3"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "MAOI", "drug2": "Ethanol", "relation": "NONE", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p32"}
{"sentence": "Nifedipine did not alter the plasma levels of Vardenafil when taken in combination.", "drug1": "Nifedipine", "drug2": "Vardenafil", "relation": "NONE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s26", "pair_id": "DDI-DrugBank.d198.s26.p0"}
{"sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.", "drug1": "benzodiazepines", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s3", "pair_id": "DDI-DrugBank.d335.s3.p2"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "anticonvulsants", "drug2": "ethanol", "relation": "NONE", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p13"}
{"sentence": "Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.", "drug1": "antihypertensive drugs", "drug2": "reserpine", "relation": "NONE", "source_file": "Fenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d104.s0", "pair_id": "DDI-DrugBank.d104.s0.p6"}
{"sentence": "The anticoagulant effect of heparin is enhanced by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency.", "drug1": "heparin", "drug2": "antithrombin III", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s3", "pair_id": "DDI-DrugBank.d488.s3.p0"}
{"sentence": "Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. ", "drug1": "Valproic acid", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s12", "pair_id": "DDI-MedLine.d111.s12.p0"}
{"sentence": "If labetalol HCl is used with nitroglycerin in patients with angina pectoris, additional antihypertensive effects may occur.", "drug1": "labetalol HCl", "drug2": "nitroglycerin", "relation": "EFFECT", "source_file": "Labetalol_ddi.xml", "sentence_id": "DDI-DrugBank.d412.s10", "pair_id": "DDI-DrugBank.d412.s10.p0"}
{"sentence": "Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.", "drug1": "veratrum alkaloids", "drug2": "mecamylamine", "relation": "NONE", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s2", "pair_id": "DDI-DrugBank.d389.s2.p8"}
{"sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers", "drug1": "antihistamines", "drug2": "reserpine", "relation": "NONE", "source_file": "Citalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d472.s0", "pair_id": "DDI-DrugBank.d472.s0.p31"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "corticosteroids", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p7"}
{"sentence": "During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.", "drug1": "iloprost", "drug2": "diuretics", "relation": "NONE", "source_file": "Iloprost_ddi.xml", "sentence_id": "DDI-DrugBank.d549.s3", "pair_id": "DDI-DrugBank.d549.s3.p1"}
{"sentence": "Response to sympathomimetic agents may be enhanced by colchicine.", "drug1": "sympathomimetic agents", "drug2": "colchicine", "relation": "EFFECT", "source_file": "Colchicine_ddi.xml", "sentence_id": "DDI-DrugBank.d146.s3", "pair_id": "DDI-DrugBank.d146.s3.p0"}
{"sentence": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "troleandomycin", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s2", "pair_id": "DDI-DrugBank.d237.s2.p12"}
{"sentence": "Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.", "drug1": "glyburide", "drug2": "valdecoxib", "relation": "ADVISE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s35", "pair_id": "DDI-DrugBank.d328.s35.p2"}
{"sentence": "Cimetidine treatment should be stopped during treatment with ELLENCE.", "drug1": "Cimetidine", "drug2": "ELLENCE", "relation": "ADVISE", "source_file": "Epirubicin_ddi.xml", "sentence_id": "DDI-DrugBank.d428.s11", "pair_id": "DDI-DrugBank.d428.s11.p0"}
{"sentence": "While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.", "drug1": "estazolam", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s4", "pair_id": "DDI-DrugBank.d338.s4.p2"}
{"sentence": "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.", "drug1": "ALFENTA", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Alfentanil_ddi.xml", "sentence_id": "DDI-DrugBank.d8.s0", "pair_id": "DDI-DrugBank.d8.s0.p2"}
{"sentence": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "drug1": "zinc", "drug2": "norfloxacin", "relation": "ADVISE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s11", "pair_id": "DDI-DrugBank.d217.s11.p13"}
{"sentence": "- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "drug1": "Bezalip", "drug2": "Bezalip retard", "relation": "NONE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s11", "pair_id": "DDI-DrugBank.d291.s11.p5"}
{"sentence": "The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.", "drug1": "imipramine", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s5", "pair_id": "DDI-DrugBank.d77.s5.p3"}
{"sentence": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "drug1": "valproic acid", "drug2": "phenobarbital", "relation": "EFFECT", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s14", "pair_id": "DDI-MedLine.d111.s14.p14"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p0"}
{"sentence": "Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.", "drug1": "Probenecid", "drug2": "ciprofloxacin", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s15", "pair_id": "DDI-DrugBank.d123.s15.p4"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "Phenytoin", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s2", "pair_id": "DDI-DrugBank.d404.s2.p2"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "ferrous sulfate", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p29"}
{"sentence": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .", "drug1": "paroxetine", "drug2": "carvedilol", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s1", "pair_id": "DDI-DrugBank.d269.s1.p19"}
{"sentence": "Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "drug1": "Enoxacin", "drug2": "methylxanthines", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s2", "pair_id": "DDI-DrugBank.d395.s2.p2"}
{"sentence": "Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.", "drug1": "alcohol", "drug2": "WELLBUTRIN", "relation": "EFFECT", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s25", "pair_id": "DDI-DrugBank.d5.s25.p5"}
{"sentence": "therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.", "drug1": "phenytoin", "drug2": "Itraconazole", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s21", "pair_id": "DDI-DrugBank.d165.s21.p0"}
{"sentence": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.", "drug1": "beta-blockers", "drug2": "lithium carbonate", "relation": "NONE", "source_file": "Decamethonium_ddi.xml", "sentence_id": "DDI-DrugBank.d167.s2", "pair_id": "DDI-DrugBank.d167.s2.p23"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "anticonvulsants", "drug2": "Atromid-S", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p262"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "dapsone", "drug2": "pimozide", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p24"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "anticholinergic", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p7"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "carbamazepine", "drug2": "rifampin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p137"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "b-adrenergic blocking agents", "drug2": "chloral hydrate", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p237"}
{"sentence": "Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.", "drug1": "Lincomycin", "drug2": "neuromuscular blocking agents", "relation": "EFFECT", "source_file": "Lincomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d130.s0", "pair_id": "DDI-DrugBank.d130.s0.p0"}
{"sentence": "Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.", "drug1": "diflunisal", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s25", "pair_id": "DDI-DrugBank.d132.s25.p5"}
{"sentence": "Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.", "drug1": "Exjade", "drug2": "aluminum", "relation": "ADVISE", "source_file": "Deferasirox_ddi.xml", "sentence_id": "DDI-DrugBank.d84.s1", "pair_id": "DDI-DrugBank.d84.s1.p12"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "rifampin", "drug2": "Phenytoin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p39"}
{"sentence": "and Videx , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.", "drug1": "Didanosine", "drug2": "quinolones", "relation": "MECHANISM", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s11", "pair_id": "DDI-DrugBank.d427.s11.p2"}
{"sentence": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "drug1": "sodium carboxymethylcellulose", "drug2": "NaCMC", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s1", "pair_id": "DDI-MedLine.d76.s1.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "niacinamide", "drug2": "propoxyphene", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p308"}
{"sentence": "In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.", "drug1": "theophylline", "drug2": "theophylline", "relation": "NONE", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s13", "pair_id": "DDI-DrugBank.d522.s13.p4"}
{"sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "drug1": "phenytoin", "drug2": "propranolol", "relation": "NONE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s1", "pair_id": "DDI-DrugBank.d431.s1.p40"}
{"sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "drug1": "Ketoconazole", "drug2": "vitamin D", "relation": "MECHANISM", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s8", "pair_id": "DDI-DrugBank.d384.s8.p2"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "desipramine", "drug2": "propafenone", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p68"}
{"sentence": "Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.", "drug1": "Midazolam", "drug2": "metamizol", "relation": "EFFECT", "source_file": "11210678.xml", "sentence_id": "DDI-MedLine.d67.s7", "pair_id": "DDI-MedLine.d67.s7.p1"}
{"sentence": "Ketamine is clinically compatible with the commonly used general and local anesthetic agents when an adequate respiratory exchange is maintained.", "drug1": "Ketamine", "drug2": "anesthetic agents", "relation": "NONE", "source_file": "Ketamine_ddi.xml", "sentence_id": "DDI-DrugBank.d518.s1", "pair_id": "DDI-DrugBank.d518.s1.p0"}
{"sentence": "We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.", "drug1": "carbamazepine", "drug2": "carbamazepine", "relation": "NONE", "source_file": "11134454.xml", "sentence_id": "DDI-MedLine.d36.s2", "pair_id": "DDI-MedLine.d36.s2.p1"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "Lorazepam", "drug2": "benzodiazepines", "relation": "NONE", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p0"}
{"sentence": "Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.", "drug1": "Acetazolamide", "drug2": "quinidine", "relation": "MECHANISM", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s10", "pair_id": "DDI-DrugBank.d368.s10.p0"}
{"sentence": "Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid.", "drug1": "acetaminophen", "drug2": "Isoniazid", "relation": "EFFECT", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s2", "pair_id": "DDI-DrugBank.d187.s2.p2"}
{"sentence": "Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.", "drug1": "amiodarone", "drug2": "protease inhibitor", "relation": "ADVISE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s13", "pair_id": "DDI-DrugBank.d143.s13.p2"}
{"sentence": "The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.", "drug1": "iron", "drug2": "zinc", "relation": "NONE", "source_file": "Lymecycline_ddi.xml", "sentence_id": "DDI-DrugBank.d79.s0", "pair_id": "DDI-DrugBank.d79.s0.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "quinine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p42"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "Motrin", "drug2": "nabumetone", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p82"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "clofibrate", "drug2": "ranitidine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p654"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "Mixed Agonist/Antagonist Opioid Analgesics", "drug2": "Levo-Dromoran", "relation": "NONE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p7"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "anabolic hormones", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p1"}
{"sentence": "Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.", "drug1": "Mineral oil", "drug2": "fat-soluble vitamins", "relation": "MECHANISM", "source_file": "Ergocalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d471.s0", "pair_id": "DDI-DrugBank.d471.s0.p0"}
{"sentence": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "drug1": "digoxin", "drug2": "nifedipine", "relation": "ADVISE", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s2", "pair_id": "DDI-DrugBank.d373.s2.p14"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p32"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "digitoxin", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p3"}
{"sentence": "However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.", "drug1": "iloprost", "drug2": "vasodilators", "relation": "EFFECT", "source_file": "Iloprost_ddi.xml", "sentence_id": "DDI-DrugBank.d549.s1", "pair_id": "DDI-DrugBank.d549.s1.p0"}
{"sentence": "Do not mix TORADOL and morphine in the same syringe.", "drug1": "TORADOL", "drug2": "morphine", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s21", "pair_id": "DDI-DrugBank.d3.s21.p0"}
{"sentence": "Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.", "drug1": "Nabilone", "drug2": "codeine", "relation": "EFFECT", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s1", "pair_id": "DDI-DrugBank.d552.s1.p3"}
{"sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "drug1": "indomethacin", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s2", "pair_id": "DDI-DrugBank.d488.s2.p32"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "influenza virus vaccine", "drug2": "anesthetics", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1020"}
{"sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).", "drug1": "amphotericin", "drug2": "HIVID", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s18", "pair_id": "DDI-DrugBank.d263.s18.p20"}
{"sentence": "Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.", "drug1": "adrenergic agents", "drug2": "epinephrine", "relation": "NONE", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s4", "pair_id": "DDI-DrugBank.d441.s4.p1"}
{"sentence": "Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.", "drug1": "Anafranil", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s24", "pair_id": "DDI-DrugBank.d238.s24.p4"}
{"sentence": "Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.", "drug1": "amprenavir", "drug2": "methadone", "relation": "NONE", "source_file": "Amprenavir_ddi.xml", "sentence_id": "DDI-DrugBank.d437.s9", "pair_id": "DDI-DrugBank.d437.s9.p4"}
{"sentence": "Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.", "drug1": "PAH", "drug2": "procaine", "relation": "EFFECT", "source_file": "Aminohippurate_ddi.xml", "sentence_id": "DDI-DrugBank.d416.s0", "pair_id": "DDI-DrugBank.d416.s0.p1"}
{"sentence": "In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.", "drug1": "buprenorphine", "drug2": "SUBUTEX", "relation": "NONE", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s5", "pair_id": "DDI-DrugBank.d380.s5.p0"}
{"sentence": "Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.", "drug1": "Ribavirin", "drug2": "zidovudine", "relation": "EFFECT", "source_file": "Peginterferon alfa-2a_ddi.xml", "sentence_id": "DDI-DrugBank.d196.s6", "pair_id": "DDI-DrugBank.d196.s6.p8"}
{"sentence": "Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.", "drug1": "ketoconazole", "drug2": "budesonide", "relation": "MECHANISM", "source_file": "Budesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d144.s0", "pair_id": "DDI-DrugBank.d144.s0.p0"}
{"sentence": "Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.", "drug1": "Aminosalicylic acid", "drug2": "Lanoxin", "relation": "MECHANISM", "source_file": "Aminosalicylic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d22.s0", "pair_id": "DDI-DrugBank.d22.s0.p1"}
{"sentence": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "drug1": "antacid", "drug2": "theophylline", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s32", "pair_id": "DDI-DrugBank.d558.s32.p58"}
{"sentence": "Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.", "drug1": "PAH", "drug2": "thiazolesulfone", "relation": "EFFECT", "source_file": "Aminohippurate_ddi.xml", "sentence_id": "DDI-DrugBank.d416.s0", "pair_id": "DDI-DrugBank.d416.s0.p2"}
{"sentence": "However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.", "drug1": "cholestyramine", "drug2": "cerivastatin sodium", "relation": "MECHANISM", "source_file": "Cerivastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d141.s5", "pair_id": "DDI-DrugBank.d141.s5.p0"}
{"sentence": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "drug1": "Bezalip retard", "drug2": "Bezalip retard", "relation": "NONE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s0", "pair_id": "DDI-DrugBank.d291.s0.p5"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "cholestyramine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p8"}
{"sentence": "Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.", "drug1": "Ritonavir", "drug2": "Vardenafil", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s12", "pair_id": "DDI-DrugBank.d198.s12.p0"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "Antihistamines", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p4"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chlorpropamide", "drug2": "quinine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p483"}
{"sentence": "Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.", "drug1": "anakinra", "drug2": "TNF-blocking agents", "relation": "EFFECT", "source_file": "Adalimumab_ddi.xml", "sentence_id": "DDI-DrugBank.d493.s4", "pair_id": "DDI-DrugBank.d493.s4.p0"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "Phenytoin", "drug2": "calcitriol", "relation": "NONE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s2", "pair_id": "DDI-DrugBank.d98.s2.p4"}
{"sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "drug1": "PRINIVIL", "drug2": "spironolactone", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s15", "pair_id": "DDI-DrugBank.d334.s15.p1"}
{"sentence": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.", "drug1": "ritonavir", "drug2": "almotriptan", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s11", "pair_id": "DDI-DrugBank.d299.s11.p11"}
{"sentence": "There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral hypoglycemic agents in the presence of diclofenac that necessitated changes in the doses of such agents.", "drug1": "hypoglycemic agents", "drug2": "diclofenac", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s11", "pair_id": "DDI-DrugBank.d249.s11.p2"}
{"sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "drug1": "neomycin", "drug2": "vitamin B-12", "relation": "MECHANISM", "source_file": "Neomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d330.s2", "pair_id": "DDI-DrugBank.d330.s2.p1"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "efavirenz", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p73"}
{"sentence": "Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "drug1": "sedative-hypnotics", "drug2": "DILAUDID", "relation": "EFFECT", "source_file": "Hydromorphone_ddi.xml", "sentence_id": "DDI-DrugBank.d26.s0", "pair_id": "DDI-DrugBank.d26.s0.p29"}
{"sentence": "- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives", "drug1": "Lofexidine", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Lofexidine_ddi.xml", "sentence_id": "DDI-DrugBank.d454.s0", "pair_id": "DDI-DrugBank.d454.s0.p1"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "phenothiazine derivatives", "drug2": "estrogens", "relation": "NONE", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s2", "pair_id": "DDI-DrugBank.d527.s2.p92"}
{"sentence": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "drug1": "phenobarbital", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s28", "pair_id": "DDI-DrugBank.d434.s28.p14"}
{"sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "drug1": "cholestyramine", "drug2": "ferrous sulfate", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s2", "pair_id": "DDI-DrugBank.d411.s2.p19"}
{"sentence": "H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.", "drug1": "L-histidine", "drug2": "H1 blockers", "relation": "EFFECT", "source_file": "L-Histidine_ddi.xml", "sentence_id": "DDI-DrugBank.d365.s1", "pair_id": "DDI-DrugBank.d365.s1.p7"}
{"sentence": "Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.", "drug1": "probenecid", "drug2": "norfloxacin", "relation": "MECHANISM", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s9", "pair_id": "DDI-DrugBank.d217.s9.p2"}
{"sentence": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "drug1": "EPA", "drug2": "aspirin", "relation": "INT", "source_file": "Icosapent_ddi.xml", "sentence_id": "DDI-DrugBank.d35.s0", "pair_id": "DDI-DrugBank.d35.s0.p0"}
{"sentence": "Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.", "drug1": "Nicotinic Acid", "drug2": "Azole Antifungals", "relation": "NONE", "source_file": "Cerivastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d141.s0", "pair_id": "DDI-DrugBank.d141.s0.p13"}
{"sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "drug1": "phenothiazines", "drug2": "dopamine antagonists", "relation": "NONE", "source_file": "Gonadorelin_ddi.xml", "sentence_id": "DDI-DrugBank.d369.s3", "pair_id": "DDI-DrugBank.d369.s3.p2"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "corticosteroids", "drug2": "diuretics", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p2"}
{"sentence": "The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL.", "drug1": "diuretic", "drug2": "PRINIVIL", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s1", "pair_id": "DDI-DrugBank.d334.s1.p2"}
{"sentence": "Consequently, the combination of methotrexate with acitretin is also contraindicated.", "drug1": "methotrexate", "drug2": "acitretin", "relation": "ADVISE", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s9", "pair_id": "DDI-DrugBank.d353.s9.p0"}
{"sentence": "Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.", "drug1": "ketoconazole", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s8", "pair_id": "DDI-DrugBank.d237.s8.p0"}
{"sentence": "The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. ", "drug1": "CGS 21680", "drug2": "CPA", "relation": "NONE", "source_file": "7746025.xml", "sentence_id": "DDI-MedLine.d51.s3", "pair_id": "DDI-MedLine.d51.s3.p4"}
{"sentence": "This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.", "drug1": "thiosulfate", "drug2": "cisplatin", "relation": "MECHANISM", "source_file": "4038510.xml", "sentence_id": "DDI-MedLine.d130.s8", "pair_id": "DDI-MedLine.d130.s8.p0"}
{"sentence": "The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as zopiclone, triazolopyridazines and others, are also blocked by ROMAZICON.", "drug1": "zopiclone", "drug2": "ROMAZICON", "relation": "EFFECT", "source_file": "Flumazenil_ddi.xml", "sentence_id": "DDI-DrugBank.d234.s6", "pair_id": "DDI-DrugBank.d234.s6.p0"}
{"sentence": "Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.", "drug1": "tacrolimus", "drug2": "bosentan", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s15", "pair_id": "DDI-DrugBank.d289.s15.p0"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p3"}
{"sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "drug1": "levothyroxine sodium", "drug2": "cholestyramine", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s2", "pair_id": "DDI-DrugBank.d411.s2.p8"}
{"sentence": "Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "drug1": "VIOXX", "drug2": "lithium", "relation": "ADVISE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s18", "pair_id": "DDI-DrugBank.d210.s18.p0"}
{"sentence": "Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.", "drug1": "isoniazid", "drug2": "valproate", "relation": "ADVISE", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s14", "pair_id": "DDI-DrugBank.d187.s14.p3"}
{"sentence": "Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).", "drug1": "Antibiotics", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Doxazosin_ddi.xml", "sentence_id": "DDI-DrugBank.d367.s11", "pair_id": "DDI-DrugBank.d367.s11.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "bacitracin", "drug2": "clindamycin", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p52"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "heparin", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p424"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "atenolol", "drug2": "warfarin", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p11"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "antihistamines", "drug2": "levodopa", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p72"}
{"sentence": "Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.", "drug1": "phenobarbital", "drug2": "flecainide", "relation": "MECHANISM", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s13", "pair_id": "DDI-DrugBank.d87.s13.p4"}
{"sentence": "Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;", "drug1": "amitriptyline", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s41", "pair_id": "DDI-DrugBank.d485.s41.p7"}
{"sentence": "Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.\r\n", "drug1": "diltiazem", "drug2": "sirolimus", "relation": "MECHANISM", "source_file": "11180036.xml", "sentence_id": "DDI-MedLine.d86.s0", "pair_id": "DDI-MedLine.d86.s0.p0"}
{"sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "fluoxetine", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s3", "pair_id": "DDI-DrugBank.d426.s3.p14"}
{"sentence": "OBJECTIVES: To examine the effects of acute hydrocortisone pretreatment on the subjective and behavioral effects of d-amphetamine. ", "drug1": "hydrocortisone", "drug2": "d-amphetamine", "relation": "NONE", "source_file": "11271411.xml", "sentence_id": "DDI-MedLine.d38.s3", "pair_id": "DDI-MedLine.d38.s3.p0"}
{"sentence": "Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.", "drug1": "thiazide diuretics", "drug2": "allopurinol", "relation": "NONE", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s12", "pair_id": "DDI-DrugBank.d413.s12.p5"}
{"sentence": "Valproate: Available data suggest that there is no significant effect of valproate on the clearance of Felbatol  at steady state, Therefore, the addition of valproate is not expected to cause a clinically important effect on Felbatol  (felbamate) plasma concentrations.", "drug1": "Felbatol", "drug2": "felbamate", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s32", "pair_id": "DDI-DrugBank.d434.s32.p14"}
{"sentence": "In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine, diltiazem, or captopril.", "drug1": "iloprost", "drug2": "captopril", "relation": "NONE", "source_file": "Iloprost_ddi.xml", "sentence_id": "DDI-DrugBank.d549.s0", "pair_id": "DDI-DrugBank.d549.s0.p2"}
{"sentence": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "drug1": "acetaminophen", "drug2": "theophylline", "relation": "EFFECT", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s14", "pair_id": "DDI-MedLine.d111.s14.p0"}
{"sentence": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.", "drug1": "corticosteroids", "drug2": "amphotericin B", "relation": "ADVISE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s1", "pair_id": "DDI-DrugBank.d314.s1.p3"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "bromocriptine", "drug2": "calcium", "relation": "NONE", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p46"}
{"sentence": "Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.", "drug1": "valdecoxib", "drug2": "Ortho-Novum", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s44", "pair_id": "DDI-DrugBank.d328.s44.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "trimethoprim", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p12"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "midazolam", "drug2": "tramadol", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p858"}
{"sentence": "A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.", "drug1": "Vardenafil", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s8", "pair_id": "DDI-DrugBank.d198.s8.p0"}
{"sentence": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "drug1": "eszopiclone", "drug2": "ethanol", "relation": "NONE", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s0", "pair_id": "DDI-DrugBank.d216.s0.p4"}
{"sentence": "Amphetamines may enhance the effects of tricyclic antidepressants.", "drug1": "Amphetamines", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Benzphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d477.s3", "pair_id": "DDI-DrugBank.d477.s3.p0"}
{"sentence": "Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.", "drug1": "acitretin", "drug2": "tetracyclines", "relation": "EFFECT", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s11", "pair_id": "DDI-DrugBank.d353.s11.p2"}
{"sentence": "Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.", "drug1": "MAOIs", "drug2": "clidinium", "relation": "EFFECT", "source_file": "Clidinium_ddi.xml", "sentence_id": "DDI-DrugBank.d322.s0", "pair_id": "DDI-DrugBank.d322.s0.p5"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "benzocaine", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p5"}
{"sentence": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.", "drug1": "risperidone", "drug2": "levodopa", "relation": "EFFECT", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s2", "pair_id": "DDI-DrugBank.d47.s2.p13"}
{"sentence": "Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.", "drug1": "ethanol", "drug2": "tiagabine", "relation": "ADVISE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s23", "pair_id": "DDI-DrugBank.d277.s23.p1"}
{"sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.", "drug1": "felodipine", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Felodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d316.s14", "pair_id": "DDI-DrugBank.d316.s14.p6"}
{"sentence": "Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;", "drug1": "nelfinavir", "drug2": "ritonavir", "relation": "NONE", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s32", "pair_id": "DDI-DrugBank.d485.s32.p12"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "acetaminophen", "drug2": "chlordiazepoxide", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p14"}
{"sentence": "Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.", "drug1": "ciprofloxacin", "drug2": "sulfonylurea", "relation": "EFFECT", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s3", "pair_id": "DDI-DrugBank.d123.s3.p3"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "fluoxetine", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p9"}
{"sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.", "drug1": "benzodiazepines", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s3", "pair_id": "DDI-DrugBank.d335.s3.p0"}
{"sentence": "Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.\r\n", "drug1": "verapamil", "drug2": "bombesin", "relation": "EFFECT", "source_file": "11125235.xml", "sentence_id": "DDI-MedLine.d133.s0", "pair_id": "DDI-MedLine.d133.s0.p0"}
{"sentence": "Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", "drug1": "Accutane", "drug2": "vitamin A", "relation": "NONE", "source_file": "Isotretinoin_ddi.xml", "sentence_id": "DDI-DrugBank.d163.s0", "pair_id": "DDI-DrugBank.d163.s0.p6"}
{"sentence": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "drug1": "hypnotics", "drug2": "insulin", "relation": "NONE", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s12", "pair_id": "DDI-DrugBank.d507.s12.p28"}
{"sentence": "Potassium-sparing diuretics (spironolactone, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.", "drug1": "spironolactone", "drug2": "amiloride", "relation": "NONE", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s4", "pair_id": "DDI-DrugBank.d561.s4.p4"}
{"sentence": "There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.", "drug1": "theophylline", "drug2": "theophylline", "relation": "NONE", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s1", "pair_id": "DDI-DrugBank.d427.s1.p1"}
{"sentence": "Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "drug1": "Itraconazole", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s11", "pair_id": "DDI-DrugBank.d165.s11.p0"}
{"sentence": "Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. ", "drug1": "reverse transcriptase inhibitors", "drug2": "protease inhibitor", "relation": "NONE", "source_file": "11148572.xml", "sentence_id": "DDI-MedLine.d115.s5", "pair_id": "DDI-MedLine.d115.s5.p2"}
{"sentence": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "drug1": "Aprepitant", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s19", "pair_id": "DDI-DrugBank.d382.s19.p7"}
{"sentence": "INDOCIN can reduce the antihypertensive effects of captopril and losartan.", "drug1": "INDOCIN", "drug2": "captopril", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s35", "pair_id": "DDI-DrugBank.d82.s35.p0"}
{"sentence": "This effect of aspirin (which also lowers serum concentrations of other nonsteroidal anti-inflammatory drugs given with it) has been demonstrated in patients with rheumatoid arthritis (n= 15) as well as normal volunteers (n= 16).", "drug1": "aspirin", "drug2": "nonsteroidal anti-inflammatory drugs", "relation": "NONE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s5", "pair_id": "DDI-DrugBank.d529.s5.p0"}
{"sentence": "Serious toxicity may result if dextromethorphan is coadministered with monoamine oxidase inhibitors (MAOIs).", "drug1": "dextromethorphan", "drug2": "MAOIs", "relation": "EFFECT", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s1", "pair_id": "DDI-DrugBank.d398.s1.p1"}
{"sentence": "Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.", "drug1": "diflunisal", "drug2": "methotrexate", "relation": "ADVISE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s16", "pair_id": "DDI-DrugBank.d132.s16.p2"}
{"sentence": "Auranofin should be avoided by patients with a history of serious reaction to any gold medication, including Solganal and Myochrysine.", "drug1": "Auranofin", "drug2": "Myochrysine", "relation": "ADVISE", "source_file": "Auranofin_ddi.xml", "sentence_id": "DDI-DrugBank.d374.s0", "pair_id": "DDI-DrugBank.d374.s0.p2"}
{"sentence": "The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .", "drug1": "ENABLEX", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s0", "pair_id": "DDI-DrugBank.d459.s0.p1"}
{"sentence": "When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.", "drug1": "ketoconazole", "drug2": "coumarin", "relation": "EFFECT", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s19", "pair_id": "DDI-DrugBank.d458.s19.p2"}
{"sentence": "Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.", "drug1": "phenobarbital", "drug2": "fenoprofen", "relation": "MECHANISM", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s3", "pair_id": "DDI-DrugBank.d154.s3.p0"}
{"sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "drug1": "FACTIVE", "drug2": "calcium carbonate", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s1", "pair_id": "DDI-DrugBank.d347.s1.p0"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "zinc", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p41"}
{"sentence": "Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.", "drug1": "Furosemide", "drug2": "ethacrynic acid", "relation": "ADVISE", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s2", "pair_id": "DDI-DrugBank.d231.s2.p0"}
{"sentence": "Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.", "drug1": "diuretics", "drug2": "fosinopril sodium", "relation": "EFFECT", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s0", "pair_id": "DDI-DrugBank.d176.s0.p2"}
{"sentence": "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.", "drug1": "PROLEUKIN", "drug2": "cis-platinum", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s5", "pair_id": "DDI-DrugBank.d114.s5.p2"}
{"sentence": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "drug1": "cysteine", "drug2": "NaFlu", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s10", "pair_id": "DDI-MedLine.d76.s10.p4"}
{"sentence": "To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.", "drug1": "delavirdine", "drug2": "indinavir", "relation": "NONE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s15", "pair_id": "DDI-DrugBank.d43.s15.p0"}
{"sentence": "The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.", "drug1": "zalcitabine", "drug2": "antacids", "relation": "ADVISE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s23", "pair_id": "DDI-DrugBank.d263.s23.p2"}
{"sentence": "Cytadren accelerates the metabolism of dexamethasone;", "drug1": "Cytadren", "drug2": "dexamethasone", "relation": "MECHANISM", "source_file": "Aminoglutethimide_ddi.xml", "sentence_id": "DDI-DrugBank.d372.s0", "pair_id": "DDI-DrugBank.d372.s0.p0"}
{"sentence": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.", "drug1": "tetracyclines", "drug2": "calcium", "relation": "MECHANISM", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s2", "pair_id": "DDI-DrugBank.d500.s2.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Sporanox", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p15"}
{"sentence": "In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.", "drug1": "bepridil hydrochloride", "drug2": "quinidine", "relation": "NONE", "source_file": "Bepridil_ddi.xml", "sentence_id": "DDI-DrugBank.d137.s9", "pair_id": "DDI-DrugBank.d137.s9.p1"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "norepinephrine", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Bupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d153.s0", "pair_id": "DDI-DrugBank.d153.s0.p7"}
{"sentence": "Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.", "drug1": "rifampin", "drug2": "ZEBETA", "relation": "MECHANISM", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s4", "pair_id": "DDI-DrugBank.d476.s4.p0"}
{"sentence": "Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.", "drug1": "norfloxacin", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s5", "pair_id": "DDI-DrugBank.d217.s5.p3"}
{"sentence": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "drug1": "phenytoin", "drug2": "CANCIDAS", "relation": "MECHANISM", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s12", "pair_id": "DDI-DrugBank.d350.s12.p13"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.", "drug1": "thyroid products", "drug2": "contraceptives", "relation": "NONE", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s4", "pair_id": "DDI-DrugBank.d178.s4.p25"}
{"sentence": "Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)", "drug1": "hydroflumethiazide", "drug2": "nonsteroidal anti-inflammatory agents", "relation": "ADVISE", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s26", "pair_id": "DDI-DrugBank.d17.s26.p0"}
{"sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "drug1": "triazolam", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s12", "pair_id": "DDI-DrugBank.d76.s12.p14"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "phenylbutazone", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p36"}
{"sentence": "Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.", "drug1": "Cephalosporins", "drug2": "cefotetan", "relation": "NONE", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s1", "pair_id": "DDI-DrugBank.d139.s1.p3"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "Aprepitant", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p1"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "nefazodone", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p7"}
{"sentence": "Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.", "drug1": "b-lactam antibiotics", "drug2": "cefditoren pivoxil", "relation": "MECHANISM", "source_file": "Cefditoren_ddi.xml", "sentence_id": "DDI-DrugBank.d550.s4", "pair_id": "DDI-DrugBank.d550.s4.p5"}
{"sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.", "drug1": "felodipine", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Felodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d316.s14", "pair_id": "DDI-DrugBank.d316.s14.p7"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "fenoprofen", "drug2": "indomethacin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p892"}
{"sentence": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.", "drug1": "beta-blocker", "drug2": "clonidine", "relation": "ADVISE", "source_file": "Betaxolol_ddi.xml", "sentence_id": "DDI-DrugBank.d489.s4", "pair_id": "DDI-DrugBank.d489.s4.p5"}
{"sentence": "Two of 16 subjects dosed simultaneously with Vardenafil 10 mg and tamsulosin 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.", "drug1": "Vardenafil", "drug2": "tamsulosin", "relation": "EFFECT", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s33", "pair_id": "DDI-DrugBank.d198.s33.p0"}
{"sentence": "Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.", "drug1": "Anticholinergic agents", "drug2": "anticholinergic medications", "relation": "NONE", "source_file": "Ipratropium_ddi.xml", "sentence_id": "DDI-DrugBank.d51.s2", "pair_id": "DDI-DrugBank.d51.s2.p1"}
{"sentence": "Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin.", "drug1": "TAXOL", "drug2": "cisplatin", "relation": "MECHANISM", "source_file": "Paclitaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d288.s1", "pair_id": "DDI-DrugBank.d288.s1.p2"}
{"sentence": "Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.", "drug1": "indomethacin", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s15", "pair_id": "DDI-DrugBank.d231.s15.p0"}
{"sentence": "No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.", "drug1": "nizatidine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Nizatidine_ddi.xml", "sentence_id": "DDI-DrugBank.d475.s0", "pair_id": "DDI-DrugBank.d475.s0.p4"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p26"}
{"sentence": "Digitalis: Thyroid preparations may potentiate the toxic effects of digitalis.", "drug1": "Thyroid preparations", "drug2": "digitalis", "relation": "EFFECT", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s17", "pair_id": "DDI-DrugBank.d54.s17.p2"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "furosemide", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p25"}
{"sentence": "Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.", "drug1": "diflunisal", "drug2": "phenprocoumon", "relation": "EFFECT", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s0", "pair_id": "DDI-DrugBank.d132.s0.p6"}
{"sentence": "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.", "drug1": "beta-blockers", "drug2": "Tiazac", "relation": "EFFECT", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s1", "pair_id": "DDI-DrugBank.d565.s1.p1"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "Benzthiazide", "drug2": "alcohol", "relation": "INT", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p0"}
{"sentence": "Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.", "drug1": "bupropion", "drug2": "levodopa", "relation": "EFFECT", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s20", "pair_id": "DDI-DrugBank.d5.s20.p7"}
{"sentence": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "drug1": "neomycin sulfate", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Neomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d330.s5", "pair_id": "DDI-DrugBank.d330.s5.p1"}
{"sentence": "There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.", "drug1": "trazodone hydrochloride", "drug2": "Desyrel", "relation": "NONE", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s1", "pair_id": "DDI-DrugBank.d463.s1.p0"}
{"sentence": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "drug1": "Nalfon", "drug2": "salicylates", "relation": "ADVISE", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s2", "pair_id": "DDI-DrugBank.d154.s2.p14"}
{"sentence": "Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.", "drug1": "Itraconazole", "drug2": "busulfan", "relation": "MECHANISM", "source_file": "Busulfan_ddi.xml", "sentence_id": "DDI-DrugBank.d72.s0", "pair_id": "DDI-DrugBank.d72.s0.p0"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "lovastatin", "drug2": "sulfonamides", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p480"}
{"sentence": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "drug1": "felbamate", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s28", "pair_id": "DDI-DrugBank.d434.s28.p7"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "tobramycin", "drug2": "foscarnet", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p20"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "benzodiazepines", "drug2": "cyclosporine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p2"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "alprazolam", "drug2": "erythromycin", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p66"}
{"sentence": "Interaction of ketamine and halothane in rats.\n", "drug1": "ketamine", "drug2": "halothane", "relation": "INT", "source_file": "1115367.xml", "sentence_id": "DDI-MedLine.d16.s0", "pair_id": "DDI-MedLine.d16.s0.p0"}
{"sentence": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "drug1": "Ketoconazole", "drug2": "vardenafil", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s7", "pair_id": "DDI-DrugBank.d198.s7.p0"}
{"sentence": "Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.", "drug1": "androgens", "drug2": "estrogens", "relation": "NONE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s24", "pair_id": "DDI-DrugBank.d54.s24.p8"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "phenothiazines", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p6"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "antipsychotic drug", "drug2": "trihexyphenidyl", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p2"}
{"sentence": "Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. ", "drug1": "Rifampin", "drug2": "amprenavir", "relation": "MECHANISM", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s13", "pair_id": "DDI-MedLine.d3.s13.p0"}
{"sentence": "Loop Diuretics: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.", "drug1": "captopril", "drug2": "captopril", "relation": "NONE", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s22", "pair_id": "DDI-DrugBank.d175.s22.p5"}
{"sentence": "Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).", "drug1": "Diphenhydramine hydrochloride", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Diphenhydramine_ddi.xml", "sentence_id": "DDI-DrugBank.d296.s0", "pair_id": "DDI-DrugBank.d296.s0.p4"}
{"sentence": "If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.", "drug1": "isradipine", "drug2": "cimetidine", "relation": "ADVISE", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s8", "pair_id": "DDI-DrugBank.d81.s8.p0"}
{"sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "drug1": "Diuretic agents", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s16", "pair_id": "DDI-DrugBank.d46.s16.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Agenerase", "drug2": "Theo-Dur", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p817"}
{"sentence": "Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.", "drug1": "Amphetamines", "drug2": "veratrum alkaloids", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s28", "pair_id": "DDI-DrugBank.d236.s28.p2"}
{"sentence": "The drug interaction between warfarin and rifampin is not well known. ", "drug1": "warfarin", "drug2": "rifampin", "relation": "INT", "source_file": "1115445.xml", "sentence_id": "DDI-MedLine.d116.s1", "pair_id": "DDI-MedLine.d116.s1.p0"}
{"sentence": "At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.", "drug1": "dexfenfluramine", "drug2": "MAO inhibitor", "relation": "ADVISE", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s3", "pair_id": "DDI-DrugBank.d423.s3.p0"}
{"sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ", "drug1": "corticosteroids", "drug2": "azathioprine", "relation": "NONE", "source_file": "7635041.xml", "sentence_id": "DDI-MedLine.d11.s4", "pair_id": "DDI-MedLine.d11.s4.p6"}
{"sentence": "Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).", "drug1": "VIDEX", "drug2": "ganciclovir", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s6", "pair_id": "DDI-DrugBank.d43.s6.p3"}
{"sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "drug1": "ALPHAGAN P", "drug2": "sedatives", "relation": "ADVISE", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s0", "pair_id": "DDI-DrugBank.d138.s0.p4"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "monoamine oxidase inhibitors", "drug2": "fluoxetine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p3"}
{"sentence": "Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;", "drug1": "Amphetamines", "drug2": "sympathomimetic agents", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s3", "pair_id": "DDI-DrugBank.d158.s3.p8"}
{"sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "drug1": "butorphanol", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s0", "pair_id": "DDI-DrugBank.d246.s0.p3"}
{"sentence": "Narcotic analgesics may potentiate the hypotensive effects of clonidine.", "drug1": "Narcotic analgesics", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s3", "pair_id": "DDI-DrugBank.d495.s3.p0"}
{"sentence": "The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.", "drug1": "H2 blockers", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s13", "pair_id": "DDI-DrugBank.d48.s13.p4"}
{"sentence": "Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.", "drug1": "5-fluorouracil", "drug2": "leucovorin", "relation": "MECHANISM", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s5", "pair_id": "DDI-DrugBank.d88.s5.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p24"}
{"sentence": "Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.", "drug1": "fluvoxamine", "drug2": "N-desmethyldiazepam", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s20", "pair_id": "DDI-DrugBank.d76.s20.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "dextran", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p687"}
{"sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "drug1": "levothyroxine sodium", "drug2": "aluminum hydoxide", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s2", "pair_id": "DDI-DrugBank.d411.s2.p7"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p7"}
{"sentence": "Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.", "drug1": "phenytoin", "drug2": "fludrocortisone acetate", "relation": "MECHANISM", "source_file": "Fludrocortisone_ddi.xml", "sentence_id": "DDI-DrugBank.d526.s17", "pair_id": "DDI-DrugBank.d526.s17.p4"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "sertraline", "drug2": "paroxetine", "relation": "NONE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s16", "pair_id": "DDI-DrugBank.d238.s16.p12"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "theophylline", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p10"}
{"sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "drug1": "Mefloquine", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s9", "pair_id": "DDI-DrugBank.d220.s9.p3"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "aspirin", "drug2": "magnesium salicylate", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p19"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "bromelains", "drug2": "fenoprofen", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p369"}
{"sentence": "An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. ", "drug1": "perchlorate", "drug2": "pertechnetate", "relation": "MECHANISM", "source_file": "163470.xml", "sentence_id": "DDI-MedLine.d134.s2", "pair_id": "DDI-MedLine.d134.s2.p0"}
{"sentence": "Antacids containing magnesium, aluminum, or calcium;", "drug1": "magnesium", "drug2": "calcium", "relation": "NONE", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s8", "pair_id": "DDI-DrugBank.d427.s8.p4"}
{"sentence": "Therefore, patients on propranolol should be observed when COLESTID Tablets are either added or deleted from a therapeutic regimen.", "drug1": "propranolol", "drug2": "COLESTID", "relation": "ADVISE", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s9", "pair_id": "DDI-DrugBank.d345.s9.p0"}
{"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "theophylline", "relation": "EFFECT", "source_file": "Hexobarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d457.s0", "pair_id": "DDI-DrugBank.d457.s0.p3"}
{"sentence": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.", "drug1": "Antacids", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s6", "pair_id": "DDI-DrugBank.d450.s6.p5"}
{"sentence": "In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.", "drug1": "macrolides", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s11", "pair_id": "DDI-DrugBank.d522.s11.p0"}
{"sentence": "Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.", "drug1": "zopiclone", "drug2": "rifampicin", "relation": "MECHANISM", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s10", "pair_id": "DDI-DrugBank.d216.s10.p2"}
{"sentence": "Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.", "drug1": "doxorubicin", "drug2": "ciprofloxacin", "relation": "NONE", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s7", "pair_id": "DDI-DrugBank.d488.s7.p6"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "perphenazine", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p12"}
{"sentence": "Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.", "drug1": "ephedrine", "drug2": "sympathomimetic bronchodilators", "relation": "EFFECT", "source_file": "Dyphylline_ddi.xml", "sentence_id": "DDI-DrugBank.d4.s0", "pair_id": "DDI-DrugBank.d4.s0.p5"}
{"sentence": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "fluconazole", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s7", "pair_id": "DDI-DrugBank.d237.s7.p7"}
{"sentence": "The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.", "drug1": "norfloxacin", "drug2": "glyburide", "relation": "EFFECT", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s7", "pair_id": "DDI-DrugBank.d217.s7.p3"}
{"sentence": "Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited zalcitabine phosphorylation in a dose dependent manner.", "drug1": "lamivudine", "drug2": "zalcitabine", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s3", "pair_id": "DDI-DrugBank.d263.s3.p2"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "diltiazem", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p185"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "itraconazole", "drug2": "methadone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p738"}
{"sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "drug1": "probenecid", "drug2": "cefdinir", "relation": "MECHANISM", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s4", "pair_id": "DDI-DrugBank.d420.s4.p7"}
{"sentence": "SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.", "drug1": "SUSTIVA", "drug2": "itraconazole", "relation": "MECHANISM", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s79", "pair_id": "DDI-DrugBank.d531.s79.p0"}
{"sentence": "Ethopropazine can interact with chlorpromazine, increasing the metabolism of chlorpromazine.", "drug1": "Ethopropazine", "drug2": "chlorpromazine", "relation": "MECHANISM", "source_file": "Ethopropazine_ddi.xml", "sentence_id": "DDI-DrugBank.d240.s2", "pair_id": "DDI-DrugBank.d240.s2.p0"}
{"sentence": "Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;", "drug1": "Amprenavir", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s32", "pair_id": "DDI-DrugBank.d485.s32.p8"}
{"sentence": "Co-treatment with the potent CYP3A4 inhibitor ketoconazole increases erlotinib AUC by 2/3.", "drug1": "ketoconazole", "drug2": "erlotinib", "relation": "MECHANISM", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s0", "pair_id": "DDI-DrugBank.d456.s0.p0"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "lovastatin", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p8"}
{"sentence": "(Thiazide drugs may increase the responsiveness to tubocurarine.)", "drug1": "Thiazide drugs", "drug2": "tubocurarine", "relation": "EFFECT", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s31", "pair_id": "DDI-DrugBank.d17.s31.p0"}
{"sentence": "Lithium: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.", "drug1": "Lithium", "drug2": "Ibuprofen", "relation": "NONE", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s12", "pair_id": "DDI-DrugBank.d415.s12.p0"}
{"sentence": "If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.", "drug1": "CEFOTAN", "drug2": "aminoglycoside", "relation": "EFFECT", "source_file": "Cefotetan_ddi.xml", "sentence_id": "DDI-DrugBank.d483.s1", "pair_id": "DDI-DrugBank.d483.s1.p0"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "ZEBETA", "drug2": "myocardial depressants", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p0"}
{"sentence": "DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.", "drug1": "digoxin", "drug2": "digoxin", "relation": "NONE", "source_file": "Cerivastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d141.s7", "pair_id": "DDI-DrugBank.d141.s7.p3"}
{"sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. ", "drug1": "magnesium", "drug2": "magnesium", "relation": "NONE", "source_file": "7786695.xml", "sentence_id": "DDI-MedLine.d103.s1", "pair_id": "DDI-MedLine.d103.s1.p11"}
{"sentence": "Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.", "drug1": "calcium-channel-blocking agents", "drug2": "diuretics", "relation": "NONE", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s11", "pair_id": "DDI-DrugBank.d561.s11.p9"}
{"sentence": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "drug1": "valdecoxib", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s28", "pair_id": "DDI-DrugBank.d328.s28.p0"}
{"sentence": "Aspirin: CELEBREX can be used with low dose aspirin.", "drug1": "Aspirin", "drug2": "CELEBREX", "relation": "NONE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s13", "pair_id": "DDI-DrugBank.d172.s13.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p26"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "ethionamide", "drug2": "hydralazine", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p67"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "cinchophen", "drug2": "dextran", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p583"}
{"sentence": "Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.", "drug1": "sulfasalazine", "drug2": "ENBREL", "relation": "EFFECT", "source_file": "Etanercept_ddi.xml", "sentence_id": "DDI-DrugBank.d341.s4", "pair_id": "DDI-DrugBank.d341.s4.p0"}
{"sentence": "Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.", "drug1": "Lithium", "drug2": "lithium", "relation": "NONE", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s5", "pair_id": "DDI-DrugBank.d231.s5.p2"}
{"sentence": "Thus, when ibuprofen and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "drug1": "ibuprofen", "drug2": "lithium", "relation": "ADVISE", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s15", "pair_id": "DDI-DrugBank.d415.s15.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "amitriptyline", "drug2": "itraconazole", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p149"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "adrenocortical steroids", "drug2": "warfarin sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p44"}
{"sentence": "It is recommended that plasma lithium levels be monitored when ketoprofen is coadministered with lithium.", "drug1": "ketoprofen", "drug2": "lithium", "relation": "ADVISE", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s25", "pair_id": "DDI-DrugBank.d499.s25.p2"}
{"sentence": "Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.", "drug1": "probenecid", "drug2": "zalcitabine", "relation": "MECHANISM", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s20", "pair_id": "DDI-DrugBank.d263.s20.p10"}
{"sentence": "Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.", "drug1": "Ephedrine", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s16", "pair_id": "DDI-DrugBank.d314.s16.p3"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "zidovudine", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p28"}
{"sentence": "However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.", "drug1": "UROXATRAL", "drug2": "alpha-blockers", "relation": "ADVISE", "source_file": "Alfuzosin_ddi.xml", "sentence_id": "DDI-DrugBank.d273.s1", "pair_id": "DDI-DrugBank.d273.s1.p0"}
{"sentence": "Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.", "drug1": "Sympathomimetic amines", "drug2": "veratrum alkaloids", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s2", "pair_id": "DDI-DrugBank.d389.s2.p1"}
{"sentence": "Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.", "drug1": "nelfinavir", "drug2": "azithromycin", "relation": "EFFECT", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s1", "pair_id": "DDI-DrugBank.d53.s1.p0"}
{"sentence": "The intake of furosemide and sucralfate should be separated by at least two hours.", "drug1": "furosemide", "drug2": "sucralfate", "relation": "ADVISE", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s12", "pair_id": "DDI-DrugBank.d231.s12.p0"}
{"sentence": "Cimetidine has been shown to increase the bioavailability of labetalol HCl.", "drug1": "Cimetidine", "drug2": "labetalol HCl", "relation": "MECHANISM", "source_file": "Labetalol_ddi.xml", "sentence_id": "DDI-DrugBank.d412.s4", "pair_id": "DDI-DrugBank.d412.s4.p0"}
{"sentence": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "drug1": "aspirin", "drug2": "NSAIDs", "relation": "NONE", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s13", "pair_id": "DDI-DrugBank.d440.s13.p12"}
{"sentence": "FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.", "drug1": "FLUOTHANE", "drug2": "tubocurarine", "relation": "EFFECT", "source_file": "Halothane_ddi.xml", "sentence_id": "DDI-DrugBank.d74.s1", "pair_id": "DDI-DrugBank.d74.s1.p0"}
{"sentence": "Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.", "drug1": "ketoconazole", "drug2": "ciclesonide", "relation": "ADVISE", "source_file": "Ciclesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d362.s5", "pair_id": "DDI-DrugBank.d362.s5.p0"}
{"sentence": "Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.", "drug1": "indinavir", "drug2": "VIDEX", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s14", "pair_id": "DDI-DrugBank.d43.s14.p5"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "flecainide", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p9"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p18"}
{"sentence": "Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.", "drug1": "acetaminophen", "drug2": "Gleevec", "relation": "MECHANISM", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s16", "pair_id": "DDI-DrugBank.d115.s16.p0"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "Flupenthixol", "drug2": "Ethanol", "relation": "EFFECT", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p56"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "LEVSIN", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "EFFECT", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p4"}
{"sentence": "Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.", "drug1": "quinidine", "drug2": "calcium channel blocking agents", "relation": "NONE", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s0", "pair_id": "DDI-DrugBank.d226.s0.p10"}
{"sentence": "Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.", "drug1": "interleukin-1 antagonist", "drug2": "TNF-blocking agent", "relation": "EFFECT", "source_file": "Adalimumab_ddi.xml", "sentence_id": "DDI-DrugBank.d493.s2", "pair_id": "DDI-DrugBank.d493.s2.p5"}
{"sentence": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ", "drug1": "ciprofloxacin", "drug2": "opiate", "relation": "MECHANISM", "source_file": "11210403.xml", "sentence_id": "DDI-MedLine.d124.s1", "pair_id": "DDI-MedLine.d124.s1.p3"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "sumatriptan", "drug2": "escitalopram", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p6"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "amitriptyline", "drug2": "lorazepam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p152"}
{"sentence": "Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.", "drug1": "Enoxacin", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s21", "pair_id": "DDI-DrugBank.d395.s21.p0"}
{"sentence": "Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.", "drug1": "valdecoxib", "drug2": "omeprazole", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s42", "pair_id": "DDI-DrugBank.d328.s42.p0"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p22"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "b-adrenergic blocking agents", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p253"}
{"sentence": "In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.", "drug1": "oxcarbazepine", "drug2": "MHD", "relation": "NONE", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s1", "pair_id": "DDI-DrugBank.d307.s1.p2"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "lovastatin", "drug2": "hydrochlorothiazide", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p5"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "antidepressants", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p0"}
{"sentence": "Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.", "drug1": "nicotine", "drug2": "Clozapine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s15", "pair_id": "DDI-DrugBank.d480.s15.p5"}
{"sentence": "Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.", "drug1": "efavirenz", "drug2": "contraceptives", "relation": "ADVISE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s52", "pair_id": "DDI-DrugBank.d531.s52.p0"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "chloramphenicol", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p4"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "paroxetine", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p4"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "estrogens", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p7"}
{"sentence": "Phenytoin: In a single (400 mg) and multiple dose (400 mg TID) study of Neurontin in epileptic patients (N=8) maintained on phenytoin monotherapy for at least 2 months, gabapentin had no effect on the steady-state trough plasma concentrations of phenytoin and phenytoin had no effect on gabapentin pharmacokinetics.", "drug1": "Phenytoin", "drug2": "phenytoin", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s7", "pair_id": "DDI-DrugBank.d438.s7.p1"}
{"sentence": "Oral Contraceptives: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.", "drug1": "Contraceptives", "drug2": "tiagabine", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s24", "pair_id": "DDI-DrugBank.d277.s24.p0"}
{"sentence": "Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin", "drug1": "VIRACEPT", "drug2": "Antimycobacterial agents", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s7", "pair_id": "DDI-DrugBank.d340.s7.p0"}
{"sentence": "When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ", "drug1": "rifampicin", "drug2": "ofloxacin", "relation": "EFFECT", "source_file": "11137650.xml", "sentence_id": "DDI-MedLine.d8.s6", "pair_id": "DDI-MedLine.d8.s6.p8"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "ibuprofen", "drug2": "Oruvail", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p53"}
{"sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.", "drug1": "NSAIDs", "drug2": "aspirin", "relation": "NONE", "source_file": "Ardeparin_ddi.xml", "sentence_id": "DDI-DrugBank.d105.s0", "pair_id": "DDI-DrugBank.d105.s0.p12"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "colistin", "drug2": "lithium", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p86"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "nefazodone", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p15"}
{"sentence": "Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.", "drug1": "Antihistamines", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s0", "pair_id": "DDI-DrugBank.d389.s0.p2"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "chlorpromazine", "drug2": "Compazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p77"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "nicotinamide", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p17"}
{"sentence": "Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.", "drug1": "Beta-adrenergic receptor antagonists", "drug2": "BROVANA", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s12", "pair_id": "DDI-DrugBank.d284.s12.p1"}
{"sentence": "Ketoconazole: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.", "drug1": "ketoconazole", "drug2": "VIRACEPT", "relation": "MECHANISM", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s22", "pair_id": "DDI-DrugBank.d340.s22.p3"}
{"sentence": "An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.", "drug1": "lithium", "drug2": "ATACAND", "relation": "MECHANISM", "source_file": "Candesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d547.s3", "pair_id": "DDI-DrugBank.d547.s3.p3"}
{"sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "drug1": "phenytoin", "drug2": "Mefloquine", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s11", "pair_id": "DDI-DrugBank.d220.s11.p18"}
{"sentence": "Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.", "drug1": "warfarin", "drug2": "NSAIDs", "relation": "EFFECT", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s13", "pair_id": "DDI-DrugBank.d400.s13.p2"}
{"sentence": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "drug1": "quinolones", "drug2": "didanosine", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s7", "pair_id": "DDI-DrugBank.d562.s7.p4"}
{"sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "drug1": "levothyroxine sodium", "drug2": "sucralfate", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s2", "pair_id": "DDI-DrugBank.d411.s2.p12"}
{"sentence": "Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.", "drug1": "moclobemide", "drug2": "almotriptan", "relation": "MECHANISM", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s2", "pair_id": "DDI-DrugBank.d299.s2.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Phenobarbital", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p7"}
{"sentence": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "drug1": "d-amphetamine", "drug2": "protriptyline", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s8", "pair_id": "DDI-DrugBank.d236.s8.p1"}
{"sentence": "Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.", "drug1": "aluminum hydroxide", "drug2": "ketoprofen", "relation": "NONE", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s3", "pair_id": "DDI-DrugBank.d499.s3.p7"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "anticonvulsant drugs", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p10"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "warfarin", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p90"}
{"sentence": "As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.", "drug1": "NUROMAX", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s6", "pair_id": "DDI-DrugBank.d267.s6.p3"}
{"sentence": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.", "drug1": "phenobarbital", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s30", "pair_id": "DDI-DrugBank.d124.s30.p2"}
{"sentence": "Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.", "drug1": "Grepafloxacin", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s3", "pair_id": "DDI-DrugBank.d78.s3.p10"}
{"sentence": "The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.", "drug1": "benzodiazepines", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s8", "pair_id": "DDI-DrugBank.d338.s8.p3"}
{"sentence": "There have been isolated reports of patients experiencing increases in their prothrombin times when etidronate was added to warfarin therapy.", "drug1": "etidronate", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Etidronic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d327.s0", "pair_id": "DDI-DrugBank.d327.s0.p0"}
{"sentence": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "drug1": "methylprednisolone", "drug2": "Aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s14", "pair_id": "DDI-DrugBank.d382.s14.p1"}
{"sentence": "The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.", "drug1": "cimetidine", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s14", "pair_id": "DDI-DrugBank.d565.s14.p0"}
{"sentence": "Repeated doses of colestipol hydrochloride given prior to a single dose of propranolol in human trials have been reported to decrease propranolol absorption.", "drug1": "colestipol hydrochloride", "drug2": "propranolol", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s5", "pair_id": "DDI-DrugBank.d345.s5.p0"}
{"sentence": "Amiodarone, disopyramide, lidocaine", "drug1": "Amiodarone", "drug2": "lidocaine", "relation": "NONE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s63", "pair_id": "DDI-DrugBank.d270.s63.p1"}
{"sentence": "The concomitant administration of griseofulvin has been reported to reduce the efficacy of oral contraceptives and to increase the incidence of breakthrough bleeding.", "drug1": "griseofulvin", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Griseofulvin_ddi.xml", "sentence_id": "DDI-DrugBank.d83.s2", "pair_id": "DDI-DrugBank.d83.s2.p0"}
{"sentence": "In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when estrogens are started thus increasing thyroid requirements.", "drug1": "levothyroxine", "drug2": "estrogens", "relation": "MECHANISM", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s12", "pair_id": "DDI-DrugBank.d54.s12.p0"}
{"sentence": "Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin", "drug1": "Warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s16", "pair_id": "DDI-DrugBank.d216.s16.p3"}
{"sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "drug1": "TIKOSYN", "drug2": "cimetidine", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s5", "pair_id": "DDI-DrugBank.d558.s5.p6"}
{"sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.", "drug1": "aspirin", "drug2": "iron", "relation": "NONE", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s2", "pair_id": "DDI-DrugBank.d75.s2.p9"}
{"sentence": "Concomitant use of L-phenylalanine and non-selective MAO inhibitors may cause hypertension.", "drug1": "L-phenylalanine", "drug2": "non-selective MAO inhibitors", "relation": "EFFECT", "source_file": "L-Phenylalanine_ddi.xml", "sentence_id": "DDI-DrugBank.d530.s1", "pair_id": "DDI-DrugBank.d530.s1.p0"}
{"sentence": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "drug1": "Aprepitant", "drug2": "norethindrone", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s19", "pair_id": "DDI-DrugBank.d382.s19.p8"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "lovastatin", "drug2": "mitotane", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p473"}
{"sentence": "Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.", "drug1": "quinidine", "drug2": "aripiprazole", "relation": "ADVISE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s16", "pair_id": "DDI-DrugBank.d509.s16.p2"}
{"sentence": "- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.", "drug1": "sulphonylureas", "drug2": "Bezalip retard", "relation": "EFFECT", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s3", "pair_id": "DDI-DrugBank.d291.s3.p2"}
{"sentence": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "drug1": "zinc", "drug2": "Videx", "relation": "NONE", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s7", "pair_id": "DDI-DrugBank.d562.s7.p12"}
{"sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "drug1": "quinolones", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Levofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d242.s1", "pair_id": "DDI-DrugBank.d242.s1.p3"}
{"sentence": "Drug Interactions with Beta-Blockers: Concomitant use of fenoldopam with beta-blockers should be avoided.", "drug1": "fenoldopam", "drug2": "beta-blockers", "relation": "ADVISE", "source_file": "Fenoldopam_ddi.xml", "sentence_id": "DDI-DrugBank.d546.s0", "pair_id": "DDI-DrugBank.d546.s0.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "ibuprofen", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p21"}
{"sentence": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.", "drug1": "Norpace", "drug2": "quinidine", "relation": "NONE", "source_file": "Disopyramide_ddi.xml", "sentence_id": "DDI-DrugBank.d506.s5", "pair_id": "DDI-DrugBank.d506.s5.p2"}
{"sentence": "Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.", "drug1": "loracarbef", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Loracarbef_ddi.xml", "sentence_id": "DDI-DrugBank.d351.s0", "pair_id": "DDI-DrugBank.d351.s0.p7"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "dopamine", "drug2": "somatostatin analogs", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p347"}
{"sentence": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "drug1": "pentobarbital", "drug2": "ouabain", "relation": "EFFECT", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s1", "pair_id": "DDI-MedLine.d23.s1.p21"}
{"sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "drug1": "antidiabetic products", "drug2": "ACE inhibitors", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s1", "pair_id": "DDI-DrugBank.d313.s1.p0"}
{"sentence": "Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines.", "drug1": "Corticosteroids", "drug2": "live attenuated vaccines", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s31", "pair_id": "DDI-DrugBank.d314.s31.p0"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "Tegretol", "drug2": "Prozac", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p91"}
{"sentence": "Furosemide may add to or potentiate the therapeutic effect of other antihypertensive drugs.", "drug1": "Furosemide", "drug2": "antihypertensive drugs", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s6", "pair_id": "DDI-DrugBank.d231.s6.p0"}
{"sentence": "Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.", "drug1": "oxacillin", "drug2": "diclofenac", "relation": "NONE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s19", "pair_id": "DDI-DrugBank.d249.s19.p20"}
{"sentence": "Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. ", "drug1": "allopurinol", "drug2": "cypermethrin", "relation": "EFFECT", "source_file": "11137320.xml", "sentence_id": "DDI-MedLine.d126.s6", "pair_id": "DDI-MedLine.d126.s6.p1"}
{"sentence": "ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.", "drug1": "ISUPREL", "drug2": "halothane", "relation": "ADVISE", "source_file": "Isoproterenol_ddi.xml", "sentence_id": "DDI-DrugBank.d55.s2", "pair_id": "DDI-DrugBank.d55.s2.p1"}
{"sentence": "Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;", "drug1": "Antacids", "drug2": "chloroquine", "relation": "MECHANISM", "source_file": "Chloroquine_ddi.xml", "sentence_id": "DDI-DrugBank.d429.s0", "pair_id": "DDI-DrugBank.d429.s0.p8"}
{"sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "drug1": "acetaminophen", "drug2": "HMG-CoA reductase inhibitors", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s3", "pair_id": "DDI-DrugBank.d209.s3.p25"}
{"sentence": "Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.", "drug1": "cyclosporine", "drug2": "allopurinol sodium", "relation": "MECHANISM", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s22", "pair_id": "DDI-DrugBank.d413.s22.p2"}
{"sentence": "Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.", "drug1": "thyroid", "drug2": "estrogens", "relation": "ADVISE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s14", "pair_id": "DDI-DrugBank.d54.s14.p0"}
{"sentence": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "drug1": "dexamethasone", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s7", "pair_id": "DDI-MedLine.d12.s7.p4"}
{"sentence": "Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.", "drug1": "Erythromycin", "drug2": "erythromycin", "relation": "NONE", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s9", "pair_id": "DDI-DrugBank.d140.s9.p2"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "clozapine", "drug2": "phenothiazines", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p1"}
{"sentence": "The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.", "drug1": "cefdinir", "drug2": "iron", "relation": "MECHANISM", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s11", "pair_id": "DDI-DrugBank.d420.s11.p0"}
{"sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).", "drug1": "methysergide", "drug2": "FROVA", "relation": "ADVISE", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s1", "pair_id": "DDI-DrugBank.d426.s1.p9"}
{"sentence": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.", "drug1": "Robinul", "drug2": "antiparkinson drugs", "relation": "EFFECT", "source_file": "Glycopyrrolate_ddi.xml", "sentence_id": "DDI-DrugBank.d510.s0", "pair_id": "DDI-DrugBank.d510.s0.p2"}
{"sentence": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "drug1": "Felbatol", "drug2": "felbamate", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s36", "pair_id": "DDI-DrugBank.d434.s36.p4"}
{"sentence": "While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.", "drug1": "estazolam", "drug2": "barbiturates", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s4", "pair_id": "DDI-DrugBank.d338.s4.p3"}
{"sentence": "Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.", "drug1": "indomethacin", "drug2": "beta blockers", "relation": "EFFECT", "source_file": "Atenolol_ddi.xml", "sentence_id": "DDI-DrugBank.d73.s6", "pair_id": "DDI-DrugBank.d73.s6.p0"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p3"}
{"sentence": "The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. ", "drug1": "diazepam", "drug2": "indomethacin", "relation": "NONE", "source_file": "11210678.xml", "sentence_id": "DDI-MedLine.d67.s1", "pair_id": "DDI-MedLine.d67.s1.p6"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "Vitamin D3", "drug2": "Cholestyramine", "relation": "NONE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s0", "pair_id": "DDI-DrugBank.d98.s0.p15"}
{"sentence": "Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ", "drug1": "alcohol", "drug2": "alcohol", "relation": "NONE", "source_file": "6536292.xml", "sentence_id": "DDI-MedLine.d54.s8", "pair_id": "DDI-MedLine.d54.s8.p2"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "b-adrenergic blocking agents", "drug2": "sulfonylureas", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p259"}
{"sentence": "FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.", "drug1": "FLEXERIL", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Cyclobenzaprine_ddi.xml", "sentence_id": "DDI-DrugBank.d150.s1", "pair_id": "DDI-DrugBank.d150.s1.p2"}
{"sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "drug1": "vitamin D", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s11", "pair_id": "DDI-DrugBank.d404.s11.p2"}
{"sentence": "Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.", "drug1": "Quinolones", "drug2": "norfloxacin", "relation": "NONE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s5", "pair_id": "DDI-DrugBank.d217.s5.p0"}
{"sentence": "Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.", "drug1": "rifampin", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s24", "pair_id": "DDI-DrugBank.d458.s24.p0"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "Dexbrompheniramine", "drug2": "CNS depressants", "relation": "INT", "source_file": "Dexbrompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d62.s0", "pair_id": "DDI-DrugBank.d62.s0.p1"}
{"sentence": "Phenytoin: Isoniazid may increase serum levels of phenytoin.", "drug1": "Isoniazid", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s9", "pair_id": "DDI-DrugBank.d187.s9.p2"}
{"sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "drug1": "acetaminophen", "drug2": "lidocaine", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s5", "pair_id": "DDI-MedLine.d111.s5.p8"}
{"sentence": "Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.", "drug1": "ABILIFY", "drug2": "Aripiprazole", "relation": "NONE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s24", "pair_id": "DDI-DrugBank.d509.s24.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "delavirdine", "drug2": "risperidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p464"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "isoniazid", "drug2": "quinupristin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p255"}
{"sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "drug1": "Vitamin D", "drug2": "digitalis", "relation": "ADVISE", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s7", "pair_id": "DDI-DrugBank.d384.s7.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "colistin", "drug2": "lithium", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p101"}
{"sentence": "The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.", "drug1": "ranitidine", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s11", "pair_id": "DDI-DrugBank.d237.s11.p2"}
{"sentence": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "drug1": "aspirin", "drug2": "salicylates", "relation": "NONE", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s2", "pair_id": "DDI-DrugBank.d154.s2.p8"}
{"sentence": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "drug1": "Telithromycin", "drug2": "Cyclosporine", "relation": "NONE", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s5", "pair_id": "DDI-DrugBank.d567.s5.p24"}
{"sentence": "If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.", "drug1": "antacid", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s10", "pair_id": "DDI-DrugBank.d48.s10.p0"}
{"sentence": "Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.", "drug1": "phenothiazines", "drug2": "metoclopramide", "relation": "NONE", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s2", "pair_id": "DDI-DrugBank.d272.s2.p5"}
{"sentence": "The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.", "drug1": "Factrel", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Gonadorelin_ddi.xml", "sentence_id": "DDI-DrugBank.d369.s3", "pair_id": "DDI-DrugBank.d369.s3.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "quinine", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p338"}
{"sentence": "Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.", "drug1": "HMG-CoA reductase inhibitors", "drug2": "CRIXIVAN", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s72", "pair_id": "DDI-DrugBank.d97.s72.p8"}
{"sentence": "Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.", "drug1": "carbamazepine", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s30", "pair_id": "DDI-DrugBank.d565.s30.p2"}
{"sentence": "Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.", "drug1": "Boric acid", "drug2": "idoxuridine", "relation": "MECHANISM", "source_file": "Idoxuridine_ddi.xml", "sentence_id": "DDI-DrugBank.d91.s3", "pair_id": "DDI-DrugBank.d91.s3.p0"}
{"sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "drug1": "proton pump inhibitors", "drug2": "dasatinib", "relation": "EFFECT", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s11", "pair_id": "DDI-DrugBank.d48.s11.p17"}
{"sentence": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "drug1": "clonazepam", "drug2": "propantheline", "relation": "MECHANISM", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s3", "pair_id": "DDI-DrugBank.d333.s3.p0"}
{"sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "drug1": "dopamine antagonists", "drug2": "metoclopramide", "relation": "EFFECT", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s3", "pair_id": "DDI-DrugBank.d357.s3.p28"}
{"sentence": "Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.", "drug1": "diuretics", "drug2": "vasodilators", "relation": "NONE", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s0", "pair_id": "DDI-DrugBank.d241.s0.p4"}
{"sentence": "Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.", "drug1": "diltiazem", "drug2": "triazolam", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s33", "pair_id": "DDI-DrugBank.d565.s33.p1"}
{"sentence": "1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.", "drug1": "aripiprazole", "drug2": "antihypertensive agents", "relation": "EFFECT", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s2", "pair_id": "DDI-DrugBank.d509.s2.p0"}
{"sentence": "Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.", "drug1": "Midazolam", "drug2": "morphine", "relation": "EFFECT", "source_file": "11210678.xml", "sentence_id": "DDI-MedLine.d67.s7", "pair_id": "DDI-MedLine.d67.s7.p0"}
{"sentence": "In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; ", "drug1": "(+)-NANM", "drug2": "PCP", "relation": "NONE", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s8", "pair_id": "DDI-MedLine.d30.s8.p3"}
{"sentence": "The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.", "drug1": "benzodiazepines", "drug2": "nefazodone", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s8", "pair_id": "DDI-DrugBank.d338.s8.p0"}
{"sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ", "drug1": "cerulein", "drug2": "3H-spiroperidol", "relation": "NONE", "source_file": "2857100.xml", "sentence_id": "DDI-MedLine.d15.s0", "pair_id": "DDI-MedLine.d15.s0.p6"}
{"sentence": "Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.", "drug1": "Cytosine arabinoside", "drug2": "flucytosine", "relation": "EFFECT", "source_file": "Flucytosine_ddi.xml", "sentence_id": "DDI-DrugBank.d453.s0", "pair_id": "DDI-DrugBank.d453.s0.p1"}
{"sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "Phenytoin", "drug2": "felbamate", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s30", "pair_id": "DDI-DrugBank.d434.s30.p22"}
{"sentence": "Potential for reduction in anticonvulsant and/or efavirenz plasma levels;", "drug1": "anticonvulsant", "drug2": "efavirenz", "relation": "MECHANISM", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s75", "pair_id": "DDI-DrugBank.d531.s75.p0"}
{"sentence": "Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "nefazodone", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s6", "pair_id": "DDI-DrugBank.d237.s6.p3"}
{"sentence": "Certain antibiotic, cisplatin, cyclosporine, diuretic, foscarnet, and vaccines.", "drug1": "foscarnet", "drug2": "vaccines", "relation": "NONE", "source_file": "Bleomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d554.s0", "pair_id": "DDI-DrugBank.d554.s0.p14"}
{"sentence": "Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.", "drug1": "Ethinyl estradiol", "drug2": "prednisolone", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s31", "pair_id": "DDI-DrugBank.d485.s31.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "dextrothyroxine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p14"}
{"sentence": "or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "drug1": "multivitamins", "drug2": "quinolone", "relation": "NONE", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s16", "pair_id": "DDI-DrugBank.d395.s16.p1"}
{"sentence": "Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .", "drug1": "Charcoal", "drug2": "activated charcoal", "relation": "NONE", "source_file": "Leflunomide_ddi.xml", "sentence_id": "DDI-DrugBank.d41.s0", "pair_id": "DDI-DrugBank.d41.s0.p5"}
{"sentence": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "drug1": "tetracycline", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s3", "pair_id": "DDI-DrugBank.d450.s3.p15"}
{"sentence": "There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.", "drug1": "buprenorphine", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s4", "pair_id": "DDI-DrugBank.d380.s4.p0"}
{"sentence": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .", "drug1": "bupropion", "drug2": "phenelzine", "relation": "EFFECT", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s19", "pair_id": "DDI-DrugBank.d5.s19.p4"}
{"sentence": "Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.\r\n", "drug1": "Cypermethrin", "drug2": "allopurinol", "relation": "EFFECT", "source_file": "11137320.xml", "sentence_id": "DDI-MedLine.d126.s0", "pair_id": "DDI-MedLine.d126.s0.p1"}
{"sentence": "Avoid the concomitant use of chlorprothixene and tramadol (Ultram).", "drug1": "tramadol", "drug2": "Ultram", "relation": "NONE", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s3", "pair_id": "DDI-DrugBank.d503.s3.p2"}
{"sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "drug1": "Type 1C antiarrhythmics", "drug2": "propafenone", "relation": "NONE", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s7", "pair_id": "DDI-DrugBank.d223.s7.p12"}
{"sentence": "However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.", "drug1": "buspirone", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s6", "pair_id": "DDI-DrugBank.d463.s6.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "aminoglycosides", "drug2": "procainamide", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p37"}
{"sentence": "Indinavir concentrations may be decreased in the presence of nevirapine.", "drug1": "Indinavir", "drug2": "nevirapine", "relation": "MECHANISM", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s47", "pair_id": "DDI-DrugBank.d97.s47.p0"}
{"sentence": "Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.", "drug1": "statins", "drug2": "lovastatin", "relation": "NONE", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s27", "pair_id": "DDI-DrugBank.d289.s27.p3"}
{"sentence": "Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.", "drug1": "furosemide", "drug2": "acetylsalicylic acid", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s13", "pair_id": "DDI-DrugBank.d231.s13.p0"}
{"sentence": "WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.", "drug1": "verapamil", "drug2": "Calan SR", "relation": "NONE", "source_file": "Colesevelam_ddi.xml", "sentence_id": "DDI-DrugBank.d551.s2", "pair_id": "DDI-DrugBank.d551.s2.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "lamotrigine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p21"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Felbatol", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p11"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p4"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "aminosalicylic acid", "drug2": "cinchophen", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p167"}
{"sentence": "Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.", "drug1": "Mefloquine", "drug2": "chloroquine", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s5", "pair_id": "DDI-DrugBank.d220.s5.p2"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "mitotane", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p517"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "drug1": "thiazides", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s1", "pair_id": "DDI-DrugBank.d536.s1.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "indomethacin", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1017"}
{"sentence": "Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.", "drug1": "SUSTIVA", "drug2": "ritonavir", "relation": "ADVISE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s63", "pair_id": "DDI-DrugBank.d531.s63.p0"}
{"sentence": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "drug1": "NaCMC", "drug2": "NaFlu", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s10", "pair_id": "DDI-MedLine.d76.s10.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "protease inhibitors", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p33"}
{"sentence": "CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ", "drug1": "Macrolide antibiotics", "drug2": "cerivastatin", "relation": "MECHANISM", "source_file": "11197581.xml", "sentence_id": "DDI-MedLine.d25.s12", "pair_id": "DDI-MedLine.d25.s12.p2"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "ranitidine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p19"}
{"sentence": "Quinolones have also been shown to interfere with the metabolism of caffeine.", "drug1": "Quinolones", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s3", "pair_id": "DDI-DrugBank.d562.s3.p0"}
{"sentence": "Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.", "drug1": "diltiazem hydrochloride", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s18", "pair_id": "DDI-DrugBank.d565.s18.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "paraldehyde", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p17"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "valproate", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p7"}
{"sentence": "Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.", "drug1": "cypermethrin", "drug2": "allopurinol", "relation": "EFFECT", "source_file": "11137320.xml", "sentence_id": "DDI-MedLine.d126.s7", "pair_id": "DDI-MedLine.d126.s7.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "alcohol", "drug2": "bromelains", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p59"}
{"sentence": "Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers", "drug1": "Central nervous system depressant", "drug2": "antidepressants", "relation": "NONE", "source_file": "Citalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d472.s0", "pair_id": "DDI-DrugBank.d472.s0.p1"}
{"sentence": "Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.", "drug1": "anticoagulants", "drug2": "Fluvoxamine", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s31", "pair_id": "DDI-DrugBank.d76.s31.p0"}
{"sentence": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "drug1": "d-amphetamine", "drug2": "desipramine", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s8", "pair_id": "DDI-DrugBank.d236.s8.p0"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "antiarrhythmics", "drug2": "antihistamines", "relation": "NONE", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p43"}
{"sentence": "INDOCIN and triamterene should not be administered together.", "drug1": "INDOCIN", "drug2": "triamterene", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s29", "pair_id": "DDI-DrugBank.d82.s29.p0"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "Trilisate", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Felbatol", "drug2": "Prelone", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p487"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "oxyphenbutazone", "drug2": "quinine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1302"}
{"sentence": "Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.", "drug1": "dobutamine", "drug2": "b-blocking drug", "relation": "EFFECT", "source_file": "Dobutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d274.s0", "pair_id": "DDI-DrugBank.d274.s0.p0"}
{"sentence": "Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with 1,3-difluoro-2-propanol. ", "drug1": "(-)-erythro-fluorocitrate", "drug2": "1,3-difluoro-2-propanol", "relation": "NONE", "source_file": "11170315.xml", "sentence_id": "DDI-MedLine.d125.s4", "pair_id": "DDI-MedLine.d125.s4.p2"}
{"sentence": "Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.", "drug1": "Fluconazole", "drug2": "fluconazole", "relation": "NONE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s16", "pair_id": "DDI-DrugBank.d172.s16.p0"}
{"sentence": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.", "drug1": "ibuprofen", "drug2": "coumarin-type anticoagulants", "relation": "EFFECT", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s1", "pair_id": "DDI-DrugBank.d415.s1.p1"}
{"sentence": "However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.", "drug1": "azithromycin", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s4", "pair_id": "DDI-DrugBank.d53.s4.p0"}
{"sentence": "Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.", "drug1": "Warfarin", "drug2": "R warfarin", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s19", "pair_id": "DDI-DrugBank.d212.s19.p1"}
{"sentence": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "drug1": "diclofenac", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s0", "pair_id": "DDI-DrugBank.d249.s0.p4"}
{"sentence": "Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.", "drug1": "anileridine", "drug2": "sedatives", "relation": "ADVISE", "source_file": "Anileridine_ddi.xml", "sentence_id": "DDI-DrugBank.d215.s0", "pair_id": "DDI-DrugBank.d215.s0.p1"}
{"sentence": "In addition, olanzapine is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with risperidone or prolongation of the QT interval. ", "drug1": "olanzapine", "drug2": "risperidone", "relation": "NONE", "source_file": "11217867.xml", "sentence_id": "DDI-MedLine.d83.s11", "pair_id": "DDI-MedLine.d83.s11.p1"}
{"sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.", "drug1": "alosetron", "drug2": "voriconazole", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s10", "pair_id": "DDI-DrugBank.d364.s10.p3"}
{"sentence": "Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).", "drug1": "Nabilone", "drug2": "narcotic analgesics", "relation": "ADVISE", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s0", "pair_id": "DDI-DrugBank.d552.s0.p4"}
{"sentence": "Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7", "drug1": "Steroids", "drug2": "edetate calcium disodium", "relation": "EFFECT", "source_file": "Edetic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d191.s1", "pair_id": "DDI-DrugBank.d191.s1.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p4"}
{"sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.", "drug1": "acetaminophen", "drug2": "furosemide", "relation": "NONE", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s2", "pair_id": "DDI-DrugBank.d75.s2.p13"}
{"sentence": "On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). ", "drug1": "naloxone", "drug2": "morphine", "relation": "EFFECT", "source_file": "3155550.xml", "sentence_id": "DDI-MedLine.d63.s5", "pair_id": "DDI-MedLine.d63.s5.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "amiodarone", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p1"}
{"sentence": "Dexfenfluramine should not be administered with other serotoninergic agents.", "drug1": "Dexfenfluramine", "drug2": "serotoninergic agents", "relation": "ADVISE", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s6", "pair_id": "DDI-DrugBank.d423.s6.p0"}
{"sentence": "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine.", "drug1": "propranolol", "drug2": "propranolol", "relation": "NONE", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s6", "pair_id": "DDI-DrugBank.d81.s6.p7"}
{"sentence": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "drug1": "warfarin", "drug2": "NSAIDs", "relation": "INT", "source_file": "Nabumetone_ddi.xml", "sentence_id": "DDI-DrugBank.d174.s1", "pair_id": "DDI-DrugBank.d174.s1.p2"}
{"sentence": "Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..", "drug1": "thiazide diuretics", "drug2": "allopurinol", "relation": "ADVISE", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s15", "pair_id": "DDI-DrugBank.d413.s15.p0"}
{"sentence": "Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or", "drug1": "Sulfapyridine", "drug2": "Acetaminophen", "relation": "INT", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s1", "pair_id": "DDI-DrugBank.d179.s1.p0"}
{"sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "drug1": "antacids", "drug2": "vitamin D", "relation": "ADVISE", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s15", "pair_id": "DDI-DrugBank.d384.s15.p5"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "probenecid", "drug2": "beta adrenergic blocking agents", "relation": "NONE", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p32"}
{"sentence": "Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.", "drug1": "phenytoin", "drug2": "dexamethasone", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s27", "pair_id": "DDI-DrugBank.d314.s27.p2"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "Magnesium", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p8"}
{"sentence": "While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).", "drug1": "bupropion", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s8", "pair_id": "DDI-DrugBank.d5.s8.p1"}
{"sentence": "The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ", "drug1": "rifampin", "drug2": "warfarin", "relation": "EFFECT", "source_file": "1115445.xml", "sentence_id": "DDI-MedLine.d116.s6", "pair_id": "DDI-MedLine.d116.s6.p0"}
{"sentence": "Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .", "drug1": "dyphylline", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Dyphylline_ddi.xml", "sentence_id": "DDI-DrugBank.d4.s2", "pair_id": "DDI-DrugBank.d4.s2.p0"}
{"sentence": "Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.", "drug1": "sulfonamides", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Ampicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d211.s2", "pair_id": "DDI-DrugBank.d211.s2.p13"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "cyclosporine", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p0"}
{"sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "drug1": "neomycin", "drug2": "5-fluorouracil", "relation": "MECHANISM", "source_file": "Neomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d330.s2", "pair_id": "DDI-DrugBank.d330.s2.p3"}
{"sentence": "The mean QT c interval (msec) was 369 with terfenadine alone and 367 with terfenadine plus dirithromycin.", "drug1": "terfenadine", "drug2": "dirithromycin", "relation": "EFFECT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s7", "pair_id": "DDI-DrugBank.d522.s7.p2"}
{"sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "fluvoxamine", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s3", "pair_id": "DDI-DrugBank.d426.s3.p17"}
{"sentence": "The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.", "drug1": "MAO inhibitors", "drug2": "hydrocodone", "relation": "EFFECT", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s2", "pair_id": "DDI-DrugBank.d396.s2.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Norvir", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p29"}
{"sentence": "ROMAZICON blocks the central effects of benzodiazepines by competitive interaction at the receptor level.", "drug1": "ROMAZICON", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Flumazenil_ddi.xml", "sentence_id": "DDI-DrugBank.d234.s5", "pair_id": "DDI-DrugBank.d234.s5.p0"}
{"sentence": "Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.", "drug1": "magnesium hydroxide", "drug2": "antacid", "relation": "NONE", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s0", "pair_id": "DDI-DrugBank.d88.s0.p9"}
{"sentence": "In well-controlled patients undergoing concurrent therapy with cimetidine, a decrease in the steady-state serum concentrations of tricyclic antidepressants may occur when cime-tidine therapy is discontinued.", "drug1": "cimetidine", "drug2": "tricyclic antidepressants", "relation": "MECHANISM", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s3", "pair_id": "DDI-DrugBank.d202.s3.p0"}
{"sentence": "[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ", "drug1": "cimetidine", "drug2": "iodamide", "relation": "MECHANISM", "source_file": "7756965.xml", "sentence_id": "DDI-MedLine.d68.s0", "pair_id": "DDI-MedLine.d68.s0.p13"}
{"sentence": "Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary", "drug1": "hydroxyurea", "drug2": "uricosuric medication", "relation": "EFFECT", "source_file": "Hydroxyurea_ddi.xml", "sentence_id": "DDI-DrugBank.d16.s2", "pair_id": "DDI-DrugBank.d16.s2.p0"}
{"sentence": "Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.", "drug1": "ampicillin", "drug2": "ampicillin", "relation": "NONE", "source_file": "Ampicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d211.s5", "pair_id": "DDI-DrugBank.d211.s5.p2"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "fluphenazine", "drug2": "Stelazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p124"}
{"sentence": "Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.", "drug1": "COREG", "drug2": "diltiazem", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s16", "pair_id": "DDI-DrugBank.d269.s16.p2"}
{"sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "drug1": "hydroxychloroquine", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s2", "pair_id": "DDI-DrugBank.d488.s2.p35"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "multivitamins", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p6"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "Aprepitant", "drug2": "clarithromycin", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p4"}
{"sentence": "In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.", "drug1": "Vardenafil", "drug2": "tamsulosin", "relation": "EFFECT", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s32", "pair_id": "DDI-DrugBank.d198.s32.p2"}
{"sentence": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "drug1": "Clonidine", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s2", "pair_id": "DDI-DrugBank.d495.s2.p10"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "drug1": "norepinephrine", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s0", "pair_id": "DDI-DrugBank.d110.s0.p10"}
{"sentence": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.", "drug1": "Chlorpromazine", "drug2": "amphetamines", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s12", "pair_id": "DDI-DrugBank.d158.s12.p3"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "Phenytoin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p31"}
{"sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "drug1": "Codeine", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Codeine_ddi.xml", "sentence_id": "DDI-DrugBank.d464.s0", "pair_id": "DDI-DrugBank.d464.s0.p5"}
{"sentence": "Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).", "drug1": "danazol", "drug2": "lovastatin", "relation": "EFFECT", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s11", "pair_id": "DDI-DrugBank.d567.s11.p2"}
{"sentence": "Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.", "drug1": "Warfarin", "drug2": "cefixime", "relation": "EFFECT", "source_file": "Cefixime_ddi.xml", "sentence_id": "DDI-DrugBank.d339.s2", "pair_id": "DDI-DrugBank.d339.s2.p1"}
{"sentence": "Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "drug1": "Fluconazole", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Delavirdine_ddi.xml", "sentence_id": "DDI-DrugBank.d251.s0", "pair_id": "DDI-DrugBank.d251.s0.p20"}
{"sentence": "Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.", "drug1": "rifampin", "drug2": "VIRACEPT", "relation": "MECHANISM", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s32", "pair_id": "DDI-DrugBank.d340.s32.p3"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "drug1": "phenothiazines", "drug2": "estrogens", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s4", "pair_id": "DDI-DrugBank.d245.s4.p27"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "nonsteroidal anti-inflammatory agents", "drug2": "salicylates", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p8"}
{"sentence": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "drug1": "Acarbose", "drug2": "metformin", "relation": "MECHANISM", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s10", "pair_id": "DDI-DrugBank.d536.s10.p2"}
{"sentence": "Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma levels of the tricyclic antidepressants.", "drug1": "cimetidine", "drug2": "tricyclic antidepressants", "relation": "MECHANISM", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s26", "pair_id": "DDI-DrugBank.d386.s26.p0"}
{"sentence": "Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.", "drug1": "contraceptives", "drug2": "nevirapine", "relation": "ADVISE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s26", "pair_id": "DDI-DrugBank.d270.s26.p0"}
{"sentence": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "drug1": "Lithium", "drug2": "ACE inhibitors", "relation": "NONE", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s16", "pair_id": "DDI-DrugBank.d107.s16.p2"}
{"sentence": "Therefore, the combined use of lovastatin with fibrates should generally be avoided.", "drug1": "lovastatin", "drug2": "fibrates", "relation": "ADVISE", "source_file": "Clofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d12.s9", "pair_id": "DDI-DrugBank.d12.s9.p0"}
{"sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "paroxetine", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s6", "pair_id": "DDI-DrugBank.d299.s6.p26"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "alcohol", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "NONE", "source_file": "Brompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d192.s0", "pair_id": "DDI-DrugBank.d192.s0.p12"}
{"sentence": "Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.", "drug1": "Sumatriptan", "drug2": "SSRI", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s16", "pair_id": "DDI-DrugBank.d568.s16.p1"}
{"sentence": "The effect of BREVIBLOC on the duration of succinylcholine-induced neuromuscular blockade was studied in patients undergoing surgery.", "drug1": "BREVIBLOC", "drug2": "succinylcholine", "relation": "NONE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s8", "pair_id": "DDI-DrugBank.d422.s8.p0"}
{"sentence": "It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.", "drug1": "buspirone hydrochloride", "drug2": "MAO inhibitors", "relation": "ADVISE", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s0", "pair_id": "DDI-DrugBank.d463.s0.p0"}
{"sentence": "Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.", "drug1": "diuretics", "drug2": "enalaprilat", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s0", "pair_id": "DDI-DrugBank.d107.s0.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "amiodarone", "drug2": "sulindac", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p253"}
{"sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "drug1": "butyrophenones", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Bupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d153.s4", "pair_id": "DDI-DrugBank.d153.s4.p2"}
{"sentence": "Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).", "drug1": "amphotericin B", "drug2": "skeletal muscle relaxants", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s12", "pair_id": "DDI-DrugBank.d318.s12.p3"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "acetaminophen", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p15"}
{"sentence": "Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.", "drug1": "L-tyrosine", "drug2": "MAO inhibitors", "relation": "EFFECT", "source_file": "L-Tyrosine_ddi.xml", "sentence_id": "DDI-DrugBank.d111.s0", "pair_id": "DDI-DrugBank.d111.s0.p14"}
{"sentence": "Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.", "drug1": "acebutolol", "drug2": "catecholamine depletors", "relation": "ADVISE", "source_file": "Acebutolol_ddi.xml", "sentence_id": "DDI-DrugBank.d388.s1", "pair_id": "DDI-DrugBank.d388.s1.p0"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "Dexbrompheniramine", "drug2": "anticholinergics", "relation": "EFFECT", "source_file": "Brompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d192.s0", "pair_id": "DDI-DrugBank.d192.s0.p3"}
{"sentence": "This indicates that gabapentin does not undergo renal tubular secretion by the pathway that is blocked by probenecid.", "drug1": "gabapentin", "drug2": "probenecid", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s42", "pair_id": "DDI-DrugBank.d438.s42.p0"}
{"sentence": "The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. ", "drug1": "phencyclidine", "drug2": "PCP", "relation": "NONE", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s1", "pair_id": "DDI-MedLine.d30.s1.p5"}
{"sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "drug1": "Lithium", "drug2": "ACE inhibitors", "relation": "NONE", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s6", "pair_id": "DDI-DrugBank.d176.s6.p2"}
{"sentence": "A number of drugs, including ethacrynic acid, have been shown to displace warfarin from plasma protein;", "drug1": "ethacrynic acid", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s4", "pair_id": "DDI-DrugBank.d414.s4.p0"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p23"}
{"sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.", "drug1": "ouabain", "drug2": "ketamine", "relation": "EFFECT", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s2", "pair_id": "DDI-MedLine.d23.s2.p1"}
{"sentence": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.", "drug1": "Robinul", "drug2": "anticholinergics", "relation": "EFFECT", "source_file": "Glycopyrrolate_ddi.xml", "sentence_id": "DDI-DrugBank.d510.s0", "pair_id": "DDI-DrugBank.d510.s0.p0"}
{"sentence": "Alternatives to rifampin should be considered during the course of PCP treatment with MEPRON.", "drug1": "rifampin", "drug2": "MEPRON", "relation": "ADVISE", "source_file": "Atovaquone_ddi.xml", "sentence_id": "DDI-DrugBank.d424.s4", "pair_id": "DDI-DrugBank.d424.s4.p0"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "anticoagulants", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p12"}
{"sentence": "Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.", "drug1": "bosentan", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s23", "pair_id": "DDI-DrugBank.d289.s23.p3"}
{"sentence": "Even though such interactions have not been seen in clinical studies with DynaCirc  (isradipine), an increased volume of circulating fluids might be required if such an interaction were to occur.", "drug1": "DynaCirc", "drug2": "isradipine", "relation": "NONE", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s15", "pair_id": "DDI-DrugBank.d81.s15.p0"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylurea", "drug2": "salicylates", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p1"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "Tylenol", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p1"}
{"sentence": "In 10 otherwise healthy subjects with epilepsy ingesting phenytoin, the steadystate trough (Cmin) phenytoin plasma concentration was 17 5 micrograms/mL.", "drug1": "phenytoin", "drug2": "phenytoin", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s12", "pair_id": "DDI-DrugBank.d434.s12.p0"}
{"sentence": "No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital.", "drug1": "hydrochlorothiazide", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Losartan_ddi.xml", "sentence_id": "DDI-DrugBank.d30.s0", "pair_id": "DDI-DrugBank.d30.s0.p3"}
{"sentence": "Cyclosporine: Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently.", "drug1": "cyclosporine", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s11", "pair_id": "DDI-DrugBank.d314.s11.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "nalidixic acid", "drug2": "quinine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1242"}
{"sentence": "Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.", "drug1": "Coumarin Anticoagulant", "drug2": "warfarin", "relation": "NONE", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s13", "pair_id": "DDI-DrugBank.d567.s13.p1"}
{"sentence": "SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.", "drug1": "SUSTIVA", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s79", "pair_id": "DDI-DrugBank.d531.s79.p1"}
{"sentence": "In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.", "drug1": "rifampin", "drug2": "haloperidol", "relation": "MECHANISM", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s5", "pair_id": "DDI-DrugBank.d186.s5.p5"}
{"sentence": "Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.", "drug1": "diltiazem", "drug2": "cimetidine", "relation": "ADVISE", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s15", "pair_id": "DDI-DrugBank.d565.s15.p0"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "anti-depressants", "drug2": "lithium", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p9"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "opioids", "drug2": "alcohol", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p49"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Lipitor", "drug2": "clofibrate", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p639"}
{"sentence": "Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.", "drug1": "Atromid-S", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "Clofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d12.s3", "pair_id": "DDI-DrugBank.d12.s3.p1"}
{"sentence": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "drug1": "eszopiclone", "drug2": "ethanol", "relation": "EFFECT", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s0", "pair_id": "DDI-DrugBank.d216.s0.p3"}
{"sentence": "Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.", "drug1": "Levetiracetam", "drug2": "topiramate", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s14", "pair_id": "DDI-DrugBank.d212.s14.p2"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "drug1": "anesthetic solutions", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s0", "pair_id": "DDI-DrugBank.d110.s0.p3"}
{"sentence": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "drug1": "FORADIL", "drug2": "monoamine oxidase inhibitors", "relation": "ADVISE", "source_file": "Formoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d103.s3", "pair_id": "DDI-DrugBank.d103.s3.p9"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "diazoxide", "drug2": "naproxen", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p760"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "dezocine", "drug2": "Levo-Dromoran", "relation": "ADVISE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p32"}
{"sentence": "Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.", "drug1": "ketoconazole", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s19", "pair_id": "DDI-DrugBank.d314.s19.p2"}
{"sentence": "Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;", "drug1": "Sensipar", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Cinacalcet_ddi.xml", "sentence_id": "DDI-DrugBank.d512.s7", "pair_id": "DDI-DrugBank.d512.s7.p2"}
{"sentence": "[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ", "drug1": "picrotoxin", "drug2": "phenazepam", "relation": "EFFECT", "source_file": "2857099.xml", "sentence_id": "DDI-MedLine.d27.s0", "pair_id": "DDI-MedLine.d27.s0.p1"}
{"sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "drug1": "phenobarbital", "drug2": "Mefloquine", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s11", "pair_id": "DDI-DrugBank.d220.s11.p16"}
{"sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "drug1": "disopyramide", "drug2": "TAMBOCOR", "relation": "ADVISE", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s19", "pair_id": "DDI-DrugBank.d87.s19.p4"}
{"sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "drug1": "ibuprofen", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s2", "pair_id": "DDI-DrugBank.d488.s2.p29"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "fenoprofen", "drug2": "mefenamic acid", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p895"}
{"sentence": "Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.", "drug1": "Itraconazole", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s15", "pair_id": "DDI-DrugBank.d165.s15.p0"}
{"sentence": "Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied", "drug1": "Antizol", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Fomepizole_ddi.xml", "sentence_id": "DDI-DrugBank.d228.s2", "pair_id": "DDI-DrugBank.d228.s2.p0"}
{"sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "drug1": "Phenothiazines", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Bupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d153.s4", "pair_id": "DDI-DrugBank.d153.s4.p1"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "monoamine oxidase inhibitors", "drug2": "fluvoxamine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p4"}
{"sentence": "However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s8", "pair_id": "DDI-DrugBank.d107.s8.p0"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "phenytoin", "drug2": "CMI", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p20"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "sulfonamides", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p46"}
{"sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "drug1": "disulfiram", "drug2": "nitrites", "relation": "EFFECT", "source_file": "Disulfiram_ddi.xml", "sentence_id": "DDI-DrugBank.d19.s9", "pair_id": "DDI-DrugBank.d19.s9.p5"}
{"sentence": "Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.", "drug1": "ganglionic blocking agents", "drug2": "adrenergic neuron blocking agents", "relation": "NONE", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s11", "pair_id": "DDI-DrugBank.d175.s11.p0"}
{"sentence": "[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ", "drug1": "picrotoxin", "drug2": "amizyl", "relation": "EFFECT", "source_file": "2857099.xml", "sentence_id": "DDI-MedLine.d27.s0", "pair_id": "DDI-MedLine.d27.s0.p3"}
{"sentence": "These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.", "drug1": "warfarin", "drug2": "angiotensin converting enzyme inhibitors", "relation": "NONE", "source_file": "Abciximab_ddi.xml", "sentence_id": "DDI-DrugBank.d532.s2", "pair_id": "DDI-DrugBank.d532.s2.p9"}
{"sentence": "- Lithium: Generally should not be given with diuretics.", "drug1": "Lithium", "drug2": "diuretics", "relation": "ADVISE", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s15", "pair_id": "DDI-DrugBank.d46.s15.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "Acetazolamide", "drug2": "fluvoxamine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p35"}
{"sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "drug1": "Codeine", "drug2": "sedative-hypnotics", "relation": "EFFECT", "source_file": "Codeine_ddi.xml", "sentence_id": "DDI-DrugBank.d464.s0", "pair_id": "DDI-DrugBank.d464.s0.p4"}
{"sentence": "Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.", "drug1": "alosetron", "drug2": "cimetidine", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s5", "pair_id": "DDI-DrugBank.d364.s5.p1"}
{"sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "SSRIs", "drug2": "5-HT1 agonists", "relation": "NONE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s6", "pair_id": "DDI-DrugBank.d299.s6.p12"}
{"sentence": "HMG-CoA Reductase Inhibitors: Simvastatin (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.", "drug1": "Simvastatin", "drug2": "CYP3A4", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s21", "pair_id": "DDI-DrugBank.d143.s21.p3"}
{"sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "drug1": "valproic acid", "drug2": "Mefloquine", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s11", "pair_id": "DDI-DrugBank.d220.s11.p9"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "Chloromycetin", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p3"}
{"sentence": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.", "drug1": "digitalis preparations", "drug2": "colestipol hydrochloride", "relation": "EFFECT", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s14", "pair_id": "DDI-DrugBank.d345.s14.p0"}
{"sentence": "Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.", "drug1": "Ketoconazole", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s22", "pair_id": "DDI-DrugBank.d314.s22.p3"}
{"sentence": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).", "drug1": "caffeine", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Caffeine_ddi.xml", "sentence_id": "DDI-DrugBank.d89.s3", "pair_id": "DDI-DrugBank.d89.s3.p2"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "amikacin", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p3"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p1"}
{"sentence": "Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.", "drug1": "S(-)warfarin", "drug2": "Aprepitant", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s16", "pair_id": "DDI-DrugBank.d382.s16.p9"}
{"sentence": "The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.", "drug1": "adenosine", "drug2": "methylxanthines", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s4", "pair_id": "DDI-DrugBank.d226.s4.p0"}
{"sentence": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).", "drug1": "lansoprazole", "drug2": "ampicillin", "relation": "MECHANISM", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s12", "pair_id": "DDI-DrugBank.d431.s12.p1"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "Butalbital", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p8"}
{"sentence": "However, co-administration of Duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or Duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40-mg oral dose.", "drug1": "magnesium", "drug2": "antacids", "relation": "NONE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s21", "pair_id": "DDI-DrugBank.d548.s21.p11"}
{"sentence": "Antidiabetic Agents: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with quinolones and an antidiabetic agent.", "drug1": "quinolones", "drug2": "antidiabetic agent", "relation": "EFFECT", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s20", "pair_id": "DDI-DrugBank.d78.s20.p2"}
{"sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.", "drug1": "beta2-agonists", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s6", "pair_id": "DDI-DrugBank.d284.s6.p5"}
{"sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.", "drug1": "IOPIDINE", "drug2": "anesthetics", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s1", "pair_id": "DDI-DrugBank.d224.s1.p5"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "lithium", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p25"}
{"sentence": "Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.", "drug1": "amikacin", "drug2": "netilmicin", "relation": "NONE", "source_file": "Azlocillin_ddi.xml", "sentence_id": "DDI-DrugBank.d9.s0", "pair_id": "DDI-DrugBank.d9.s0.p7"}
{"sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.", "drug1": "carbamazepine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s34", "pair_id": "DDI-DrugBank.d382.s34.p9"}
{"sentence": "Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.", "drug1": "lithium", "drug2": "lithium", "relation": "NONE", "source_file": "Candesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d547.s2", "pair_id": "DDI-DrugBank.d547.s2.p4"}
{"sentence": "Ketamine: When administered to patients on a thyroid preparation, this parenteral anesthetic may cause hypertension and tachycardia.", "drug1": "thyroid preparation", "drug2": "anesthetic", "relation": "EFFECT", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s19", "pair_id": "DDI-DrugBank.d54.s19.p2"}
{"sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.", "drug1": "heroin", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s2", "pair_id": "DDI-DrugBank.d514.s2.p1"}
{"sentence": "The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.", "drug1": "enoxacin", "drug2": "ranitidine", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s18", "pair_id": "DDI-DrugBank.d395.s18.p0"}
{"sentence": "Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.", "drug1": "Aprepitant", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s38", "pair_id": "DDI-DrugBank.d382.s38.p3"}
{"sentence": "In some patients, combined use of INDOCIN and diflunisal has been associated with fatal gastrointestinal hemorrhage.", "drug1": "INDOCIN", "drug2": "diflunisal", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s1", "pair_id": "DDI-DrugBank.d82.s1.p0"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "desipramine", "drug2": "metoprolol", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p66"}
{"sentence": "Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..", "drug1": "Sumatriptan", "drug2": "dihydroergotamine mesylate", "relation": "ADVISE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s2", "pair_id": "DDI-DrugBank.d410.s2.p1"}
{"sentence": "Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.", "drug1": "anticoagulants", "drug2": "anticonvulsant", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s89", "pair_id": "DDI-DrugBank.d64.s89.p1"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "clofibrate", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p26"}
{"sentence": "Antacid (Maalox ): Maalox reduced the bioavailability of gabapentin (N=16) by about 20%.", "drug1": "Maalox", "drug2": "Maalox", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s37", "pair_id": "DDI-DrugBank.d438.s37.p3"}
{"sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "drug1": "Codeine", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Codeine_ddi.xml", "sentence_id": "DDI-DrugBank.d464.s0", "pair_id": "DDI-DrugBank.d464.s0.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Dilantin", "drug2": "Invirase", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p307"}
{"sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "drug1": "ranitidine", "drug2": "magnesium hydroxide", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s5", "pair_id": "DDI-DrugBank.d558.s5.p23"}
{"sentence": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "drug1": "atropine", "drug2": "pralidoxime", "relation": "EFFECT", "source_file": "Atropine_ddi.xml", "sentence_id": "DDI-DrugBank.d222.s0", "pair_id": "DDI-DrugBank.d222.s0.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "bacitracin", "drug2": "anesthetics", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p72"}
{"sentence": "We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. ", "drug1": "theophylline", "drug2": "DPCPX", "relation": "NONE", "source_file": "7746025.xml", "sentence_id": "DDI-MedLine.d51.s1", "pair_id": "DDI-MedLine.d51.s1.p6"}
{"sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "drug1": "penicillin V", "drug2": "methotrexate", "relation": "NONE", "source_file": "Neomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d330.s2", "pair_id": "DDI-DrugBank.d330.s2.p5"}
{"sentence": "Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.", "drug1": "benzodiazepine", "drug2": "flumazenil", "relation": "NONE", "source_file": "Flumazenil_ddi.xml", "sentence_id": "DDI-DrugBank.d234.s2", "pair_id": "DDI-DrugBank.d234.s2.p5"}
{"sentence": "Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.", "drug1": "antihistamines", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s1", "pair_id": "DDI-DrugBank.d448.s1.p1"}
{"sentence": "FLUOTHANE augments the action of non-depolarising muscle relaxants and the muscle relaxant effects of aminoglycosides.", "drug1": "FLUOTHANE", "drug2": "non-depolarising muscle relaxant", "relation": "EFFECT", "source_file": "Halothane_ddi.xml", "sentence_id": "DDI-DrugBank.d74.s0", "pair_id": "DDI-DrugBank.d74.s0.p0"}
{"sentence": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "drug1": "EPA", "drug2": "non-steroidal anti-inflammatory drugs", "relation": "INT", "source_file": "Icosapent_ddi.xml", "sentence_id": "DDI-DrugBank.d35.s0", "pair_id": "DDI-DrugBank.d35.s0.p1"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p20"}
{"sentence": "Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.", "drug1": "nondepolarizing neuromuscular blocking agents", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s13", "pair_id": "DDI-DrugBank.d60.s13.p1"}
{"sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "drug1": "Magnesium", "drug2": "vitamin D", "relation": "ADVISE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s15", "pair_id": "DDI-DrugBank.d98.s15.p4"}
{"sentence": "In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.", "drug1": "ciclesonide", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Ciclesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d362.s4", "pair_id": "DDI-DrugBank.d362.s4.p0"}
{"sentence": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).", "drug1": "caffeine", "drug2": "phenobarbital", "relation": "ADVISE", "source_file": "Caffeine_ddi.xml", "sentence_id": "DDI-DrugBank.d89.s3", "pair_id": "DDI-DrugBank.d89.s3.p23"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "topiramate", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p25"}
{"sentence": "Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.", "drug1": "fluvoxamine", "drug2": "diazepam", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s21", "pair_id": "DDI-DrugBank.d76.s21.p0"}
{"sentence": "Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.", "drug1": "Epinephrine", "drug2": "digitalis", "relation": "ADVISE", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s7", "pair_id": "DDI-DrugBank.d247.s7.p0"}
{"sentence": "As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.", "drug1": "NUROMAX", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s6", "pair_id": "DDI-DrugBank.d267.s6.p4"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "carbamazepine", "drug2": "sulfonylureas", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p283"}
{"sentence": "Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.", "drug1": "TORADOL", "drug2": "TORADOL", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s7", "pair_id": "DDI-DrugBank.d3.s7.p2"}
{"sentence": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.", "drug1": "butyrophenones", "drug2": "levodopa", "relation": "EFFECT", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s2", "pair_id": "DDI-DrugBank.d47.s2.p11"}
{"sentence": "Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner. ", "drug1": "estradiol", "drug2": "endotoxin", "relation": "EFFECT", "source_file": "7600639.xml", "sentence_id": "DDI-MedLine.d39.s6", "pair_id": "DDI-MedLine.d39.s6.p0"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "antimuscarinics", "drug2": "amantadine", "relation": "NONE", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p7"}
{"sentence": "Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.", "drug1": "sympathomimetics", "drug2": "beta adrenergic blockers", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s3", "pair_id": "DDI-DrugBank.d389.s3.p1"}
{"sentence": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.", "drug1": "selective serotonin reuptake inhibitors", "drug2": "doxepin", "relation": "MECHANISM", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s16", "pair_id": "DDI-DrugBank.d223.s16.p4"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "MAOIs", "drug2": "paroxetine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p12"}
{"sentence": "Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor.", "drug1": "lithium", "drug2": "ACE inhibitor", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s19", "pair_id": "DDI-DrugBank.d334.s19.p2"}
{"sentence": "Antiepileptic drugs: Potential interactions between Trileptal and other AEDs were assessed in clinical studies.", "drug1": "Antiepileptic drugs", "drug2": "AEDs", "relation": "NONE", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s11", "pair_id": "DDI-DrugBank.d307.s11.p1"}
{"sentence": "Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.", "drug1": "BREVIBLOC", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s10", "pair_id": "DDI-DrugBank.d422.s10.p3"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "skeletal muscle relaxants", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p10"}
{"sentence": "Serum theophylline concentrations increase when grepafloxacin is initiated in a patient maintained on theophylline.", "drug1": "grepafloxacin", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s7", "pair_id": "DDI-DrugBank.d78.s7.p2"}
{"sentence": "Mineral Oil-Concomitant intake of mineral oil and vitamin K may reduce the absorption of vitamin K.", "drug1": "mineral oil", "drug2": "vitamin K", "relation": "MECHANISM", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s5", "pair_id": "DDI-DrugBank.d139.s5.p3"}
{"sentence": "Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).", "drug1": "Kineret", "drug2": "etanercept", "relation": "EFFECT", "source_file": "Anakinra_ddi.xml", "sentence_id": "DDI-DrugBank.d275.s3", "pair_id": "DDI-DrugBank.d275.s3.p0"}
{"sentence": "Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.", "drug1": "Phospholine Iodide", "drug2": "carbamate insecticide", "relation": "EFFECT", "source_file": "Echothiophate Iodide_ddi.xml", "sentence_id": "DDI-DrugBank.d377.s0", "pair_id": "DDI-DrugBank.d377.s0.p3"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "Acetazolamide", "drug2": "protease inhibitors", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p43"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "iodoquinol", "drug2": "metronidazole", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p100"}
{"sentence": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "drug1": "Sulindac", "drug2": "diflunisal", "relation": "NONE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s26", "pair_id": "DDI-DrugBank.d132.s26.p0"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Phenothiazines", "drug2": "Vesprin", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p21"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Trileptal", "drug2": "rifampin", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p424"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "primidone", "drug2": "rifampin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p267"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "atorvastatin", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p0"}
{"sentence": "Interactions for Vitamin B3 (Niacin): Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.", "drug1": "Nicotinic acid", "drug2": "ganglionic blocking agents", "relation": "EFFECT", "source_file": "Niacin_ddi.xml", "sentence_id": "DDI-DrugBank.d542.s0", "pair_id": "DDI-DrugBank.d542.s0.p9"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "flupenthixol", "drug2": "Tricyclic antidepressants", "relation": "NONE", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p44"}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "NSAIDs", "drug2": "thiazides", "relation": "EFFECT", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s10", "pair_id": "DDI-DrugBank.d328.s10.p4"}
{"sentence": "Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.\n", "drug1": "rifabutin", "drug2": "rifampin", "relation": "NONE", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s0", "pair_id": "DDI-MedLine.d3.s0.p2"}
{"sentence": "We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of endotoxin. ", "drug1": "estradiol", "drug2": "endotoxin", "relation": "NONE", "source_file": "7600639.xml", "sentence_id": "DDI-MedLine.d39.s1", "pair_id": "DDI-MedLine.d39.s1.p1"}
{"sentence": "- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.", "drug1": "Lithium", "drug2": "diuretics", "relation": "ADVISE", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s3", "pair_id": "DDI-DrugBank.d331.s3.p4"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "Dexbrompheniramine", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Brompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d192.s0", "pair_id": "DDI-DrugBank.d192.s0.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "antibiotics", "drug2": "quinidine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p344"}
{"sentence": "Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.", "drug1": "VIOXX", "drug2": "methotrexate", "relation": "ADVISE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s22", "pair_id": "DDI-DrugBank.d210.s22.p2"}
{"sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.", "drug1": "IOPIDINE", "drug2": "alcohol", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s1", "pair_id": "DDI-DrugBank.d224.s1.p1"}
{"sentence": "Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.", "drug1": "Agents with b-blocking properties", "drug2": "insulin", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s18", "pair_id": "DDI-DrugBank.d269.s18.p7"}
{"sentence": "Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.", "drug1": "naproxen", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s6", "pair_id": "DDI-DrugBank.d85.s6.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anabolic steroids", "drug2": "prolonged narcotics", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p294"}
{"sentence": "Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.", "drug1": "cephalosporins", "drug2": "aminoglycoside antibiotics", "relation": "EFFECT", "source_file": "Cefoxitin_ddi.xml", "sentence_id": "DDI-DrugBank.d556.s0", "pair_id": "DDI-DrugBank.d556.s0.p0"}
{"sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "drug1": "Keppra", "drug2": "primidone", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s11", "pair_id": "DDI-DrugBank.d212.s11.p6"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "5-fluorouracil", "drug2": "methadone", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p102"}
{"sentence": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "drug1": "digoxin", "drug2": "enalapril", "relation": "NONE", "source_file": "Candesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d547.s0", "pair_id": "DDI-DrugBank.d547.s0.p21"}
{"sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "drug1": "Zarontin", "drug2": "antiepileptic drugs", "relation": "INT", "source_file": "Ethosuximide_ddi.xml", "sentence_id": "DDI-DrugBank.d205.s0", "pair_id": "DDI-DrugBank.d205.s0.p1"}
{"sentence": "Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.", "drug1": "cyclosporine", "drug2": "nicardipine", "relation": "ADVISE", "source_file": "Nicardipine_ddi.xml", "sentence_id": "DDI-DrugBank.d468.s9", "pair_id": "DDI-DrugBank.d468.s9.p0"}
{"sentence": "Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.", "drug1": "warfarin", "drug2": "theophylline", "relation": "NONE", "source_file": "Famotidine_ddi.xml", "sentence_id": "DDI-DrugBank.d203.s2", "pair_id": "DDI-DrugBank.d203.s2.p0"}
{"sentence": "The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.", "drug1": "allopurinol", "drug2": "ampicillin", "relation": "EFFECT", "source_file": "Clavulanate_ddi.xml", "sentence_id": "DDI-DrugBank.d419.s0", "pair_id": "DDI-DrugBank.d419.s0.p0"}
{"sentence": "Aspirin: Concurrent administration of aspirin may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.", "drug1": "aspirin", "drug2": "meclofenamate sodium", "relation": "MECHANISM", "source_file": "Meclofenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d113.s2", "pair_id": "DDI-DrugBank.d113.s2.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "bupropion", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p3"}
{"sentence": "Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.", "drug1": "Bosentan", "drug2": "hypoglycemic agents", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s21", "pair_id": "DDI-DrugBank.d289.s21.p0"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "opioids", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p14"}
{"sentence": "Organic nitrates - L-arginine supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly.", "drug1": "L-arginine", "drug2": "nitrates", "relation": "EFFECT", "source_file": "L-Arginine_ddi.xml", "sentence_id": "DDI-DrugBank.d95.s2", "pair_id": "DDI-DrugBank.d95.s2.p2"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "efavirenz", "drug2": "midazolam", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p67"}
{"sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "Quinolone Antibiotic", "drug2": "ciprofloxacin", "relation": "NONE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s8", "pair_id": "DDI-DrugBank.d43.s8.p2"}
{"sentence": "Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.", "drug1": "Quinolones", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s8", "pair_id": "DDI-DrugBank.d562.s8.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "oxolinic acid", "drug2": "tolbutamide", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1290"}
{"sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "drug1": "anticonvulsants", "drug2": "benzodiazepines", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s3", "pair_id": "DDI-DrugBank.d209.s3.p65"}
{"sentence": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "drug1": "rifampin", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "1115445.xml", "sentence_id": "DDI-MedLine.d116.s3", "pair_id": "DDI-MedLine.d116.s3.p0"}
{"sentence": "Because dopamine is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of dopamine.", "drug1": "dopamine", "drug2": "dopamine", "relation": "NONE", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s0", "pair_id": "DDI-DrugBank.d325.s0.p0"}
{"sentence": "Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.", "drug1": "calcium", "drug2": "alendronate", "relation": "MECHANISM", "source_file": "Alendronate_ddi.xml", "sentence_id": "DDI-DrugBank.d430.s3", "pair_id": "DDI-DrugBank.d430.s3.p1"}
{"sentence": "Concomitant administration of probenecid doubled the AUC for cefprozil.", "drug1": "probenecid", "drug2": "cefprozil", "relation": "MECHANISM", "source_file": "Cefprozil_ddi.xml", "sentence_id": "DDI-DrugBank.d121.s1", "pair_id": "DDI-DrugBank.d121.s1.p0"}
{"sentence": "No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine.", "drug1": "hydrochlorothiazide", "drug2": "nifedipine", "relation": "NONE", "source_file": "Irbesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d27.s0", "pair_id": "DDI-DrugBank.d27.s0.p2"}
{"sentence": "Since bacteriostatic drugs, such as the tetracycline class of antibiotics, may interfere with the bactericidal action of penicillins, it is not advisable to administer these drugs concomitantly.", "drug1": "tetracycline class", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Demeclocycline_ddi.xml", "sentence_id": "DDI-DrugBank.d409.s1", "pair_id": "DDI-DrugBank.d409.s1.p1"}
{"sentence": "These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.", "drug1": "diltiazem", "drug2": "midazolam", "relation": "EFFECT", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s35", "pair_id": "DDI-DrugBank.d565.s35.p0"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "selective serotonin reuptake inhibitors", "drug2": "sertraline", "relation": "NONE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s15", "pair_id": "DDI-DrugBank.d77.s15.p2"}
{"sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "drug1": "Keppra", "drug2": "gabapentin", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s11", "pair_id": "DDI-DrugBank.d212.s11.p2"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "acetaminophen", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p12"}
{"sentence": "Warfarin: When fluvoxamine maleate (50 mg tid) was administered concomitantly with warfarin for two weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged.", "drug1": "fluvoxamine maleate", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s30", "pair_id": "DDI-DrugBank.d76.s30.p3"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "indomethacin", "drug2": "alprazolam", "relation": "NONE", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p31"}
{"sentence": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "drug1": "Morphine", "drug2": "hormonal contraceptives", "relation": "NONE", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s26", "pair_id": "DDI-DrugBank.d485.s26.p0"}
{"sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "drug1": "cyclophosphamide", "drug2": "bleomycin", "relation": "NONE", "source_file": "11148572.xml", "sentence_id": "DDI-MedLine.d115.s2", "pair_id": "DDI-MedLine.d115.s2.p38"}
{"sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "Quinolone Antibiotic", "drug2": "aluminum", "relation": "NONE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s8", "pair_id": "DDI-DrugBank.d43.s8.p6"}
{"sentence": "Patients treated with proton pump inhibitors and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.", "drug1": "proton pump inhibitors", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s6", "pair_id": "DDI-DrugBank.d29.s6.p0"}
{"sentence": "Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.", "drug1": "Corticotropin", "drug2": "amphotericin B", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s2", "pair_id": "DDI-DrugBank.d318.s2.p4"}
{"sentence": "Use in Conjunction with Other Antiepileptic Drugs: The addition of Felbatol  to antiepileptic drugs (AEDs) affects the steady-state plasma concentrations of AEDs.", "drug1": "Felbatol", "drug2": "antiepileptic drugs", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s1", "pair_id": "DDI-DrugBank.d434.s1.p4"}
{"sentence": "Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.", "drug1": "Betaseron", "drug2": "antipyrine", "relation": "MECHANISM", "source_file": "Interferon beta-1b_ddi.xml", "sentence_id": "DDI-DrugBank.d10.s2", "pair_id": "DDI-DrugBank.d10.s2.p0"}
{"sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "drug1": "b-lactam antibiotics", "drug2": "probenecid", "relation": "NONE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s4", "pair_id": "DDI-DrugBank.d420.s4.p4"}
{"sentence": "A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.", "drug1": "INSPRA", "drug2": "eplerenone", "relation": "NONE", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s1", "pair_id": "DDI-DrugBank.d20.s1.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "dextrothyroxine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p728"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "protease inhibitors", "drug2": "quetiapine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p969"}
{"sentence": "Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.", "drug1": "Caffeine", "drug2": "ketoprofen", "relation": "EFFECT", "source_file": "Caffeine_ddi.xml", "sentence_id": "DDI-DrugBank.d89.s4", "pair_id": "DDI-DrugBank.d89.s4.p0"}
{"sentence": "Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.", "drug1": "Amantadine", "drug2": "clidinium", "relation": "EFFECT", "source_file": "Clidinium_ddi.xml", "sentence_id": "DDI-DrugBank.d322.s0", "pair_id": "DDI-DrugBank.d322.s0.p2"}
{"sentence": "Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.", "drug1": "rifampin", "drug2": "Clozapine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s15", "pair_id": "DDI-DrugBank.d480.s15.p7"}
{"sentence": "Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.", "drug1": "propoxyphene", "drug2": "amphetamine", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s23", "pair_id": "DDI-DrugBank.d158.s23.p2"}
{"sentence": "MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.", "drug1": "MAOI antidepressants", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s6", "pair_id": "DDI-DrugBank.d158.s6.p4"}
{"sentence": "Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.", "drug1": "thiazides", "drug2": "vitamin D", "relation": "EFFECT", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s5", "pair_id": "DDI-DrugBank.d98.s5.p0"}
{"sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.", "drug1": "BROVANA", "drug2": "monoamine oxidase inhibitors", "relation": "ADVISE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s6", "pair_id": "DDI-DrugBank.d284.s6.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Neoral", "drug2": "Prelone", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p752"}
{"sentence": "- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.", "drug1": "probenecid", "drug2": "bumetanide", "relation": "EFFECT", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s4", "pair_id": "DDI-DrugBank.d331.s4.p2"}
{"sentence": "- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine", "drug1": "phenytoin", "drug2": "alcohol", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s12", "pair_id": "DDI-DrugBank.d40.s12.p1"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "colistin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p22"}
{"sentence": "Extended Release Tablets: Administration of nifedipine with digoxin increased digoxin levels in 9 of 12 normal volunteers.", "drug1": "digoxin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s3", "pair_id": "DDI-DrugBank.d373.s3.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chymotrypsin", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p521"}
{"sentence": "Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.", "drug1": "narcotics", "drug2": "ketamine", "relation": "EFFECT", "source_file": "Ketamine_ddi.xml", "sentence_id": "DDI-DrugBank.d518.s0", "pair_id": "DDI-DrugBank.d518.s0.p2"}
{"sentence": "The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, theophylline) by patients receiving BROVANA has not been completely evaluated.", "drug1": "methylxanthines", "drug2": "aminophylline", "relation": "NONE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s8", "pair_id": "DDI-DrugBank.d284.s8.p0"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "aluminum", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p16"}
{"sentence": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "drug1": "dexamethasone", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s2", "pair_id": "DDI-MedLine.d12.s2.p2"}
{"sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "antacids", "drug2": "calcium", "relation": "NONE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s8", "pair_id": "DDI-DrugBank.d43.s8.p23"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "adrenocortical steroids", "drug2": "glutethimide", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p34"}
{"sentence": "For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.", "drug1": "cholestyramine", "drug2": "anticoagulants", "relation": "MECHANISM", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s3", "pair_id": "DDI-DrugBank.d64.s3.p0"}
{"sentence": "It is recommended that gabapentin be taken at least 2 hours following Maalox administration.", "drug1": "gabapentin", "drug2": "Maalox", "relation": "ADVISE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s39", "pair_id": "DDI-DrugBank.d438.s39.p0"}
{"sentence": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "drug1": "sodium carboxymethylcellulose", "drug2": "bacitracin", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s1", "pair_id": "DDI-MedLine.d76.s1.p5"}
{"sentence": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "drug1": "terfenadine", "drug2": "lomefloxacin", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s23", "pair_id": "DDI-DrugBank.d516.s23.p5"}
{"sentence": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "drug1": "Cholestytamine", "drug2": "thiazide diuretics", "relation": "MECHANISM", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s7", "pair_id": "DDI-DrugBank.d46.s7.p20"}
{"sentence": "The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.", "drug1": "benzodiazepines", "drug2": "triazolam", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s23", "pair_id": "DDI-DrugBank.d382.s23.p5"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "Cholestyramine", "drug2": "fat soluble vitamins", "relation": "MECHANISM", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s0", "pair_id": "DDI-DrugBank.d404.s0.p27"}
{"sentence": "ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.", "drug1": "ERGAMISOL", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Levamisole_ddi.xml", "sentence_id": "DDI-DrugBank.d381.s0", "pair_id": "DDI-DrugBank.d381.s0.p1"}
{"sentence": "However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.", "drug1": "aspirin", "drug2": "CELEBREX", "relation": "NONE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s14", "pair_id": "DDI-DrugBank.d172.s14.p1"}
{"sentence": "Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.", "drug1": "Caffeine", "drug2": "enoxacin", "relation": "NONE", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s5", "pair_id": "DDI-DrugBank.d395.s5.p1"}
{"sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.", "drug1": "quinidine", "drug2": "aripiprazole", "relation": "MECHANISM", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s8", "pair_id": "DDI-DrugBank.d509.s8.p6"}
{"sentence": "In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin.", "drug1": "terfenadine", "drug2": "erythromycin", "relation": "EFFECT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s12", "pair_id": "DDI-DrugBank.d397.s12.p0"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "monoamine oxidase inhibitors", "drug2": "serotoninergic agents", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p2"}
{"sentence": "In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.", "drug1": "INDOCIN", "drug2": "loop diuretics", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s23", "pair_id": "DDI-DrugBank.d82.s23.p0"}
{"sentence": "H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.", "drug1": "L-histidine", "drug2": "H2 blockers", "relation": "EFFECT", "source_file": "L-Histidine_ddi.xml", "sentence_id": "DDI-DrugBank.d365.s1", "pair_id": "DDI-DrugBank.d365.s1.p8"}
{"sentence": "Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.", "drug1": "antihistamines", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s1", "pair_id": "DDI-DrugBank.d448.s1.p2"}
{"sentence": "Theophylline: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state.", "drug1": "tiagabine", "drug2": "theophylline", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s16", "pair_id": "DDI-DrugBank.d277.s16.p2"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "acetaminophen", "drug2": "procainamide", "relation": "NONE", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p23"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "estrogens", "drug2": "progestogens", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p102"}
{"sentence": "TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects.", "drug1": "digitalis preparations", "drug2": "beta-adrenergic blocking agents", "relation": "NONE", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s1", "pair_id": "DDI-DrugBank.d87.s1.p2"}
{"sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "Felbatol", "drug2": "Felbatol", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s30", "pair_id": "DDI-DrugBank.d434.s30.p28"}
{"sentence": "The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.", "drug1": "imipramine", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s5", "pair_id": "DDI-DrugBank.d77.s5.p0"}
{"sentence": "MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.", "drug1": "MAOI antidepressants", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s10", "pair_id": "DDI-DrugBank.d236.s10.p4"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "atenolol", "drug2": "hydrochlorothiazide", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p15"}
{"sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "drug1": "Opioids", "drug2": "anesthetics", "relation": "NONE", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s1", "pair_id": "DDI-DrugBank.d197.s1.p22"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "phenylbutazone", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p1"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "glucocorticoids", "drug2": "heparin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p390"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "methylphenidate", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1157"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p27"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "ZEBETA", "drug2": "calcium antagonists", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p1"}
{"sentence": "Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.", "drug1": "Mefloquine", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s5", "pair_id": "DDI-DrugBank.d220.s5.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "triazolam", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p40"}
{"sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "drug1": "cimetidine", "drug2": "flecainide", "relation": "NONE", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s7", "pair_id": "DDI-DrugBank.d99.s7.p4"}
{"sentence": "Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.", "drug1": "azathioprine", "drug2": "allopurinol", "relation": "MECHANISM", "source_file": "Azathioprine_ddi.xml", "sentence_id": "DDI-DrugBank.d233.s0", "pair_id": "DDI-DrugBank.d233.s0.p2"}
{"sentence": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "drug1": "dexamethasone", "drug2": "CANCIDAS", "relation": "MECHANISM", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s12", "pair_id": "DDI-DrugBank.d350.s12.p16"}
{"sentence": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.", "drug1": "beta-adrenoceptor blocking agents", "drug2": "non-steroidal antiinflammatory drugs", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s33", "pair_id": "DDI-DrugBank.d82.s33.p0"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "antacids", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p12"}
{"sentence": "Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).", "drug1": "coumarin-derivative anticoagulants", "drug2": "capecitabine", "relation": "ADVISE", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s4", "pair_id": "DDI-DrugBank.d88.s4.p0"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "isoflurane", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p1"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "itraconazole", "drug2": "nicotinamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p264"}
{"sentence": "Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.", "drug1": "chlorprothixene", "drug2": "barbituates", "relation": "EFFECT", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s5", "pair_id": "DDI-DrugBank.d503.s5.p1"}
{"sentence": "Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.", "drug1": "Aspirin", "drug2": "cortico-steroids", "relation": "ADVISE", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s6", "pair_id": "DDI-DrugBank.d487.s6.p0"}
{"sentence": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ", "drug1": "opiate", "drug2": "morphine", "relation": "NONE", "source_file": "11210403.xml", "sentence_id": "DDI-MedLine.d124.s1", "pair_id": "DDI-MedLine.d124.s1.p5"}
{"sentence": "Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).", "drug1": "carbamazepine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s38", "pair_id": "DDI-DrugBank.d307.s38.p0"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "lithium", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p6"}
{"sentence": "Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.", "drug1": "Allopurinol", "drug2": "mercaptopurine", "relation": "MECHANISM", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s2", "pair_id": "DDI-DrugBank.d413.s2.p9"}
{"sentence": "Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.", "drug1": "alosetron", "drug2": "isoniazid", "relation": "EFFECT", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s15", "pair_id": "DDI-DrugBank.d364.s15.p0"}
{"sentence": "Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.", "drug1": "diflunisal", "drug2": "naproxen", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s27", "pair_id": "DDI-DrugBank.d132.s27.p4"}
{"sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "Protease Inhibitors", "drug2": "cisapride", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s12", "pair_id": "DDI-DrugBank.d237.s12.p3"}
{"sentence": "The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.", "drug1": "butalbital", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s0", "pair_id": "DDI-DrugBank.d559.s0.p0"}
{"sentence": "Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.", "drug1": "phenytoin", "drug2": "flecainide", "relation": "MECHANISM", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s13", "pair_id": "DDI-DrugBank.d87.s13.p2"}
{"sentence": "Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.", "drug1": "valdecoxib", "drug2": "diazepam", "relation": "EFFECT", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s49", "pair_id": "DDI-DrugBank.d328.s49.p2"}
{"sentence": "Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.", "drug1": "bromocriptine mesylate", "drug2": "ergot alkaloids", "relation": "ADVISE", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s3", "pair_id": "DDI-DrugBank.d272.s3.p0"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "chlorpromazine", "drug2": "amitriptyline", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p8"}
{"sentence": "Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.", "drug1": "Chloramphenicol", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Ampicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d211.s2", "pair_id": "DDI-DrugBank.d211.s2.p8"}
{"sentence": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "drug1": "macrolide antibiotics", "drug2": "saquinavir", "relation": "NONE", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s2", "pair_id": "DDI-DrugBank.d380.s2.p12"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "glucocorticoids", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p407"}
{"sentence": "Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.", "drug1": "ELSPAR", "drug2": "methotrexate", "relation": "EFFECT", "source_file": "Asparaginase_ddi.xml", "sentence_id": "DDI-DrugBank.d21.s0", "pair_id": "DDI-DrugBank.d21.s0.p0"}
{"sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.", "drug1": "ketamine", "drug2": "fentayl", "relation": "NONE", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s2", "pair_id": "DDI-MedLine.d23.s2.p10"}
{"sentence": "When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.", "drug1": "pralidoxime", "drug2": "atropine", "relation": "EFFECT", "source_file": "Atropine_ddi.xml", "sentence_id": "DDI-DrugBank.d222.s0", "pair_id": "DDI-DrugBank.d222.s0.p9"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p9"}
{"sentence": "This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.", "drug1": "gabapentin", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s31", "pair_id": "DDI-DrugBank.d438.s31.p0"}
{"sentence": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "drug1": "aluminum hydroxide", "drug2": "theophylline", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s32", "pair_id": "DDI-DrugBank.d558.s32.p61"}
{"sentence": "Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.", "drug1": "Carbamazepine", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s22", "pair_id": "DDI-DrugBank.d568.s22.p2"}
{"sentence": "Leucovorin may enhance the toxicity of 5-fluorouracil.", "drug1": "Leucovorin", "drug2": "5-fluorouracil", "relation": "EFFECT", "source_file": "Leucovorin_ddi.xml", "sentence_id": "DDI-DrugBank.d151.s3", "pair_id": "DDI-DrugBank.d151.s3.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chlorpropamide", "drug2": "fenoprofen", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p460"}
{"sentence": "The mean clearances of dofetilide were 16% and 15% lower in patients on thiazide diuretics and inhibitors of tubular organic cation transport, respectively.", "drug1": "dofetilide", "drug2": "thiazide diuretics", "relation": "MECHANISM", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s37", "pair_id": "DDI-DrugBank.d558.s37.p0"}
{"sentence": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "drug1": "colestipol", "drug2": "thiazide diuretics", "relation": "MECHANISM", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s7", "pair_id": "DDI-DrugBank.d46.s7.p23"}
{"sentence": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "Antibiotics", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s2", "pair_id": "DDI-DrugBank.d237.s2.p0"}
{"sentence": "Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.", "drug1": "Phenytoin", "drug2": "Clozapine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s15", "pair_id": "DDI-DrugBank.d480.s15.p2"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "tricyclic antidepressants", "drug2": "barbiturates", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p3"}
{"sentence": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "drug1": "NSAIDs", "drug2": "lithium", "relation": "ADVISE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s12", "pair_id": "DDI-DrugBank.d400.s12.p0"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "coumarins", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p6"}
{"sentence": "In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.", "drug1": "diclofenac", "drug2": "lithium", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s9", "pair_id": "DDI-DrugBank.d249.s9.p0"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "phenytoin", "drug2": "calcitriol", "relation": "MECHANISM", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s2", "pair_id": "DDI-DrugBank.d98.s2.p11"}
{"sentence": "Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ", "drug1": "ibogaine", "drug2": "nicotine", "relation": "EFFECT", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s6", "pair_id": "DDI-MedLine.d110.s6.p2"}
{"sentence": "In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.", "drug1": "quinidine", "drug2": "procainamide", "relation": "NONE", "source_file": "Bepridil_ddi.xml", "sentence_id": "DDI-DrugBank.d137.s9", "pair_id": "DDI-DrugBank.d137.s9.p9"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "methyldopa", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p26"}
{"sentence": "Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.", "drug1": "beta blockers", "drug2": "flecainide", "relation": "EFFECT", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s8", "pair_id": "DDI-DrugBank.d87.s8.p0"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "fluoxetine", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p5"}
{"sentence": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "drug1": "felbamate", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s28", "pair_id": "DDI-DrugBank.d434.s28.p5"}
{"sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "drug1": "Erythromycin", "drug2": "terfenadine", "relation": "MECHANISM", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s10", "pair_id": "DDI-DrugBank.d397.s10.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "alprazolam", "drug2": "glucocorticoids", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p105"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "selegiline hydrochloride", "drug2": "venlafaxine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p20"}
{"sentence": "Concomitant administration of Kerlone with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of warfarin.", "drug1": "warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Betaxolol_ddi.xml", "sentence_id": "DDI-DrugBank.d489.s1", "pair_id": "DDI-DrugBank.d489.s1.p5"}
{"sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "drug1": "anticholinergic compounds", "drug2": "cisapride", "relation": "EFFECT", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s3", "pair_id": "DDI-DrugBank.d237.s3.p6"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "estrogen-containing compounds", "drug2": "phenytoin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p95"}
{"sentence": "In addition, ketoconazole alone can inhibit adrenal corticosteroid synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.", "drug1": "ketoconazole", "drug2": "corticosteroid", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s23", "pair_id": "DDI-DrugBank.d314.s23.p0"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "salicylates", "drug2": "probenecid", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p17"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Tylenol", "drug2": "Invirase", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p112"}
{"sentence": "Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.", "drug1": "sedative", "drug2": "ROMAZICON", "relation": "NONE", "source_file": "Flumazenil_ddi.xml", "sentence_id": "DDI-DrugBank.d234.s12", "pair_id": "DDI-DrugBank.d234.s12.p9"}
{"sentence": "In a small (n=30) combination study of ARAVA with methotrexate, a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients.", "drug1": "ARAVA", "drug2": "methotrexate", "relation": "EFFECT", "source_file": "Leflunomide_ddi.xml", "sentence_id": "DDI-DrugBank.d41.s3", "pair_id": "DDI-DrugBank.d41.s3.p0"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "Flupenthixol", "drug2": "Monoamine oxidase inhibitors", "relation": "INT", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p0"}
{"sentence": "Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;", "drug1": "Sensipar", "drug2": "erythromycin", "relation": "ADVISE", "source_file": "Cinacalcet_ddi.xml", "sentence_id": "DDI-DrugBank.d512.s7", "pair_id": "DDI-DrugBank.d512.s7.p1"}
{"sentence": "The action of colchicine is potentiated by alkalinizing agents.", "drug1": "colchicine", "drug2": "alkalinizing agents", "relation": "MECHANISM", "source_file": "Colchicine_ddi.xml", "sentence_id": "DDI-DrugBank.d146.s1", "pair_id": "DDI-DrugBank.d146.s1.p0"}
{"sentence": "Both the sedative and anticholinergic effects of the major tranquilizers are also additive to those of desipramine.", "drug1": "major tranquilizers", "drug2": "desipramine", "relation": "EFFECT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s24", "pair_id": "DDI-DrugBank.d386.s24.p0"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "anesthetics", "drug2": "barbiturates", "relation": "NONE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p57"}
{"sentence": "Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.", "drug1": "EXTRANEAL", "drug2": "insulin", "relation": "NONE", "source_file": "Icodextrin_ddi.xml", "sentence_id": "DDI-DrugBank.d501.s5", "pair_id": "DDI-DrugBank.d501.s5.p7"}
{"sentence": "Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.", "drug1": "chlorprothixene", "drug2": "anticholinergic drugs", "relation": "ADVISE", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s7", "pair_id": "DDI-DrugBank.d503.s7.p0"}
{"sentence": "Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL.", "drug1": "diuretics", "drug2": "PRINIVIL", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s0", "pair_id": "DDI-DrugBank.d334.s0.p0"}
{"sentence": "Colchicine may increase sensitivity to the CNS depressants.", "drug1": "Colchicine", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Colchicine_ddi.xml", "sentence_id": "DDI-DrugBank.d146.s2", "pair_id": "DDI-DrugBank.d146.s2.p0"}
{"sentence": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "drug1": "amitriptyline HCl", "drug2": "anticholinergic", "relation": "NONE", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s18", "pair_id": "DDI-DrugBank.d99.s18.p5"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "itraconazole", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p37"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "phenytoin", "drug2": "ranitidine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1369"}
{"sentence": "Therefore, indomethacin and diflunisal should not be used concomitantly.", "drug1": "indomethacin", "drug2": "diflunisal", "relation": "ADVISE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s22", "pair_id": "DDI-DrugBank.d132.s22.p0"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "nelfinavir", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p6"}
{"sentence": "Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.", "drug1": "Bosentan", "drug2": "lovastatin", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s27", "pair_id": "DDI-DrugBank.d289.s27.p1"}
{"sentence": "Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.", "drug1": "Diclofenac", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s14", "pair_id": "DDI-DrugBank.d249.s14.p4"}
{"sentence": "The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.", "drug1": "amrinone", "drug2": "anagrelide", "relation": "EFFECT", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s14", "pair_id": "DDI-DrugBank.d75.s14.p11"}
{"sentence": "Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "Lodine", "drug2": "thiazides", "relation": "EFFECT", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s11", "pair_id": "DDI-DrugBank.d219.s11.p1"}
{"sentence": "Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.", "drug1": "cimetidine", "drug2": "zalcitabine", "relation": "MECHANISM", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s20", "pair_id": "DDI-DrugBank.d263.s20.p12"}
{"sentence": "Calcium channel blockers may also have an additive effect when given with TENORMIN .", "drug1": "Calcium channel blockers", "drug2": "TENORMIN", "relation": "EFFECT", "source_file": "Atenolol_ddi.xml", "sentence_id": "DDI-DrugBank.d73.s2", "pair_id": "DDI-DrugBank.d73.s2.p0"}
{"sentence": "Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.", "drug1": "Aspirin", "drug2": "valdecoxib", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s4", "pair_id": "DDI-DrugBank.d328.s4.p2"}
{"sentence": "Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.", "drug1": "uricosuric agents", "drug2": "oxipurinol", "relation": "MECHANISM", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s9", "pair_id": "DDI-DrugBank.d413.s9.p5"}
{"sentence": "Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.", "drug1": "Dipyridamole", "drug2": "cholinesterase inhibitors", "relation": "EFFECT", "source_file": "Dipyridamole_ddi.xml", "sentence_id": "DDI-DrugBank.d505.s4", "pair_id": "DDI-DrugBank.d505.s4.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Felbatol", "drug2": "clofibrate", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p468"}
{"sentence": "Bile acid binding resins may also interfere with the absorption of oral phosphate supplements and hydrocortisone.", "drug1": "Bile acid binding resins", "drug2": "phosphate", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s17", "pair_id": "DDI-DrugBank.d345.s17.p0"}
{"sentence": "Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.", "drug1": "methotrexate", "drug2": "NSAIDs", "relation": "MECHANISM", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s13", "pair_id": "DDI-DrugBank.d3.s13.p4"}
{"sentence": "Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.", "drug1": "esomeprazole", "drug2": "diazepam", "relation": "MECHANISM", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s8", "pair_id": "DDI-DrugBank.d29.s8.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "Antimycobacterial agents", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p7"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "aminoglutethimide", "drug2": "antithyroid drugs", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p6"}
{"sentence": "The concomitant use of diflunisal tablets and other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.", "drug1": "diflunisal", "drug2": "NSAIDs", "relation": "EFFECT", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s23", "pair_id": "DDI-DrugBank.d132.s23.p0"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "ethyl alcohol", "drug2": "scopolamine", "relation": "NONE", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p19"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "valproate", "drug2": "ziprasidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p1030"}
{"sentence": "Digoxin, Methotrexate, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.", "drug1": "Cyclosporine", "drug2": "Diclofenac", "relation": "NONE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s3", "pair_id": "DDI-DrugBank.d249.s3.p7"}
{"sentence": "Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of cimetidine which may result in the loss of the therapeutic efficacy of the tricyclic antidepressant 6.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s27", "pair_id": "DDI-DrugBank.d386.s27.p0"}
{"sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "drug1": "phenobarbital", "drug2": "acetaminophen", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s5", "pair_id": "DDI-MedLine.d111.s5.p52"}
{"sentence": "Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.", "drug1": "Ketoconazole", "drug2": "Isoniazid", "relation": "INT", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s8", "pair_id": "DDI-DrugBank.d187.s8.p2"}
{"sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "drug1": "simethicone", "drug2": "fosinopril", "relation": "MECHANISM", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s9", "pair_id": "DDI-DrugBank.d176.s9.p30"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "Butalbital", "drug2": "chlordiazepoxide", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p6"}
{"sentence": "CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ", "drug1": "Macrolide antibiotics", "drug2": "atorvastatin", "relation": "MECHANISM", "source_file": "11197581.xml", "sentence_id": "DDI-MedLine.d25.s12", "pair_id": "DDI-MedLine.d25.s12.p1"}
{"sentence": "Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.", "drug1": "Naproxen", "drug2": "beta-blockers", "relation": "EFFECT", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s9", "pair_id": "DDI-DrugBank.d85.s9.p2"}
{"sentence": "However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.", "drug1": "quinolones", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s10", "pair_id": "DDI-DrugBank.d78.s10.p0"}
{"sentence": "Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.", "drug1": "HMG-CoA reductase inhibitor", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s17", "pair_id": "DDI-DrugBank.d140.s17.p0"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "thyroid products", "drug2": "sympathomimetics", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p9"}
{"sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "drug1": "sulfonylureas", "drug2": "LEVULAN KERASTICK", "relation": "EFFECT", "source_file": "Aminolevulinic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d379.s1", "pair_id": "DDI-DrugBank.d379.s1.p21"}
{"sentence": "These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.", "drug1": "ethinyl estradiol", "drug2": "contraceptive", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s46", "pair_id": "DDI-DrugBank.d328.s46.p3"}
{"sentence": "Sulfacetamide preparations are incompatible with silver preparations.", "drug1": "Sulfacetamide", "drug2": "silver", "relation": "INT", "source_file": "Sulfacetamide_ddi.xml", "sentence_id": "DDI-DrugBank.d65.s0", "pair_id": "DDI-DrugBank.d65.s0.p0"}
{"sentence": "Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.", "drug1": "fluvoxamine", "drug2": "terbinafine", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s11", "pair_id": "DDI-DrugBank.d76.s11.p0"}
{"sentence": "Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.", "drug1": "Azlocillin", "drug2": "netilmicin", "relation": "ADVISE", "source_file": "Azlocillin_ddi.xml", "sentence_id": "DDI-DrugBank.d9.s0", "pair_id": "DDI-DrugBank.d9.s0.p3"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ranitidine", "drug2": "sulfonamides", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1432"}
{"sentence": "Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.", "drug1": "cyclosporine", "drug2": "quinolone class", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s6", "pair_id": "DDI-DrugBank.d395.s6.p5"}
{"sentence": "Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.", "drug1": "lithium", "drug2": "CELEBREX", "relation": "ADVISE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s20", "pair_id": "DDI-DrugBank.d172.s20.p0"}
{"sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "drug1": "bexarotene", "drug2": "bexarotene", "relation": "NONE", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s2", "pair_id": "DDI-DrugBank.d467.s2.p4"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "clarithromycin", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p2"}
{"sentence": "Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ", "drug1": "diazepam", "drug2": "indomethacin", "relation": "EFFECT", "source_file": "11210678.xml", "sentence_id": "DDI-MedLine.d67.s6", "pair_id": "DDI-MedLine.d67.s6.p1"}
{"sentence": "The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.", "drug1": "zalcitabine", "drug2": "aluminum", "relation": "ADVISE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s23", "pair_id": "DDI-DrugBank.d263.s23.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "clozapine", "drug2": "midazolam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p385"}
{"sentence": "It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. ", "drug1": "neurotensin", "drug2": "enkephalins", "relation": "EFFECT", "source_file": "6545985.xml", "sentence_id": "DDI-MedLine.d131.s3", "pair_id": "DDI-MedLine.d131.s3.p0"}
{"sentence": "Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "loop diuretics", "relation": "EFFECT", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s12", "pair_id": "DDI-DrugBank.d162.s12.p4"}
{"sentence": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "drug1": "fluvoxamine", "drug2": "alprazolam", "relation": "NONE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s17", "pair_id": "DDI-DrugBank.d76.s17.p6"}
{"sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "drug1": "captopril", "drug2": "nateglinide", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s11", "pair_id": "DDI-DrugBank.d460.s11.p29"}
{"sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "drug1": "Ketoconazole", "drug2": "vitamin D", "relation": "MECHANISM", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s8", "pair_id": "DDI-DrugBank.d98.s8.p2"}
{"sentence": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "drug1": "carboxymethylcellulose-cysteine", "drug2": "CMC-Cys", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s1", "pair_id": "DDI-MedLine.d76.s1.p13"}
{"sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "drug1": "magnesium hydroxide", "drug2": "enoxacin", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s17", "pair_id": "DDI-DrugBank.d395.s17.p5"}
{"sentence": "Patients on rifampin should receive 70 mg of CANCIDAS daily.", "drug1": "rifampin", "drug2": "CANCIDAS", "relation": "ADVISE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s11", "pair_id": "DDI-DrugBank.d350.s11.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "polymyxins", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p4"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "MAOIs", "drug2": "fluvoxamine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p11"}
{"sentence": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "drug1": "Trileptal", "drug2": "ethinylestradiol", "relation": "NONE", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s40", "pair_id": "DDI-DrugBank.d307.s40.p5"}
{"sentence": "Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).", "drug1": "Skeletal muscle relaxants", "drug2": "tubocurarine", "relation": "NONE", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s12", "pair_id": "DDI-DrugBank.d318.s12.p2"}
{"sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "drug1": "cephalosporins", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Cefepime_ddi.xml", "sentence_id": "DDI-DrugBank.d378.s1", "pair_id": "DDI-DrugBank.d378.s1.p1"}
{"sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.", "drug1": "narcotic analgesics", "drug2": "hydrocodone", "relation": "EFFECT", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s0", "pair_id": "DDI-DrugBank.d396.s0.p4"}
{"sentence": "Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.", "drug1": "TNF antagonist", "drug2": "ORENCIA", "relation": "EFFECT", "source_file": "Abatacept_ddi.xml", "sentence_id": "DDI-DrugBank.d297.s3", "pair_id": "DDI-DrugBank.d297.s3.p0"}
{"sentence": "Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving terfenadine concomitantly with other macrolide antibiotics.", "drug1": "terfenadine", "drug2": "macrolide antibiotics", "relation": "EFFECT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s10", "pair_id": "DDI-DrugBank.d522.s10.p0"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "benzodiazepines", "drug2": "psychotropic medications", "relation": "EFFECT", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p7"}
{"sentence": "It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.", "drug1": "neurotensin", "drug2": "tuftsin", "relation": "EFFECT", "source_file": "6545985.xml", "sentence_id": "DDI-MedLine.d131.s5", "pair_id": "DDI-MedLine.d131.s5.p0"}
{"sentence": "Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).", "drug1": "Diphenhydramine hydrochloride", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Diphenhydramine_ddi.xml", "sentence_id": "DDI-DrugBank.d296.s0", "pair_id": "DDI-DrugBank.d296.s0.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "alprazolam", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p134"}
{"sentence": "Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.", "drug1": "diltiazem", "drug2": "aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s32", "pair_id": "DDI-DrugBank.d382.s32.p0"}
{"sentence": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "drug1": "NSAIDs", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s12", "pair_id": "DDI-DrugBank.d85.s12.p7"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "lovastatin", "drug2": "digoxin", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p3"}
{"sentence": "However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. ", "drug1": "theophylline", "drug2": "CGS 21680", "relation": "NONE", "source_file": "7746025.xml", "sentence_id": "DDI-MedLine.d51.s4", "pair_id": "DDI-MedLine.d51.s4.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ibuprofen", "drug2": "anesthetics", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p959"}
{"sentence": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.", "drug1": "Imitrex", "drug2": "dihydroergotamine", "relation": "NONE", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s4", "pair_id": "DDI-DrugBank.d423.s4.p8"}
{"sentence": "Although the clinical significance of these effects is not known, caution is advised in the co-administration of beta-agonists with non-potassium sparing diuretics.", "drug1": "beta-agonists", "drug2": "non-potassium sparing diuretics", "relation": "ADVISE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s5", "pair_id": "DDI-DrugBank.d284.s5.p0"}
{"sentence": "(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.", "drug1": "steroidal anti-inflammatory agent", "drug2": "potassium sparing diuretics", "relation": "EFFECT", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s25", "pair_id": "DDI-DrugBank.d17.s25.p1"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "alprazolam", "drug2": "macrolide antibiotics", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p65"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "tetracycline", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p4"}
{"sentence": "If NovoLog is mixed with NPH human insulin, NovoLog should be drawn into the syringe first.", "drug1": "NPH human insulin", "drug2": "NovoLog", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s8", "pair_id": "DDI-DrugBank.d313.s8.p2"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "propafenone", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p8"}
{"sentence": "The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.", "drug1": "olprinone", "drug2": "anagrelide", "relation": "EFFECT", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s14", "pair_id": "DDI-DrugBank.d75.s14.p13"}
{"sentence": "Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.", "drug1": "vitamin B12", "drug2": "folic acid", "relation": "INT", "source_file": "Folic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d425.s1", "pair_id": "DDI-DrugBank.d425.s1.p44"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "anticholinergic", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p5"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "antiparkinsonian drug", "drug2": "amitriptyline", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p11"}
{"sentence": "Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.", "drug1": "Erythromycin", "drug2": "triazolam", "relation": "MECHANISM", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s19", "pair_id": "DDI-DrugBank.d522.s19.p3"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "polymyxins", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p5"}
{"sentence": "Indinavir has been shown to increase plasma levels of combination hormonal contraceptives.", "drug1": "Indinavir", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s34", "pair_id": "DDI-DrugBank.d485.s34.p0"}
{"sentence": "Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides) and theophylline did not affect the pharmacokinetics of TIKOSYN.", "drug1": "estrogens", "drug2": "aluminum hydroxide", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s32", "pair_id": "DDI-DrugBank.d558.s32.p47"}
{"sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "drug1": "aminoglycosides", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s2", "pair_id": "DDI-DrugBank.d114.s2.p5"}
{"sentence": "Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.", "drug1": "indinavir", "drug2": "VIRACEPT", "relation": "MECHANISM", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s14", "pair_id": "DDI-DrugBank.d340.s14.p4"}
{"sentence": "Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.", "drug1": "Sonata", "drug2": "thioridazine", "relation": "EFFECT", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s8", "pair_id": "DDI-DrugBank.d324.s8.p2"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "Arthropan", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p7"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "tiagabine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p38"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "nonsteroidal anti-inflammatory agents", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p0"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "LEVSIN", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p5"}
{"sentence": "Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).", "drug1": "Gleevec", "drug2": "cyclosporine", "relation": "ADVISE", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s9", "pair_id": "DDI-DrugBank.d115.s9.p0"}
{"sentence": "Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.", "drug1": "contraceptives", "drug2": "Estrogens", "relation": "NONE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s17", "pair_id": "DDI-DrugBank.d314.s17.p3"}
{"sentence": "This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.", "drug1": "salicylate", "drug2": "corticosteroid", "relation": "EFFECT", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s5", "pair_id": "DDI-DrugBank.d487.s5.p2"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p3"}
{"sentence": "Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.", "drug1": "benzodiazepines", "drug2": "SUBOXONE", "relation": "ADVISE", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s7", "pair_id": "DDI-DrugBank.d380.s7.p0"}
{"sentence": "Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.", "drug1": "coumarin anticoagulant", "drug2": "lovastatin", "relation": "EFFECT", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s15", "pair_id": "DDI-DrugBank.d567.s15.p0"}
{"sentence": "Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.", "drug1": "Acetazolamide", "drug2": "sodium bicarbonate", "relation": "EFFECT", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s13", "pair_id": "DDI-DrugBank.d368.s13.p0"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "tranquilizers", "drug2": "CNS depressants", "relation": "NONE", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p41"}
{"sentence": "All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. ", "drug1": "amprenavir", "drug2": "rifabutin", "relation": "NONE", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s3", "pair_id": "DDI-MedLine.d3.s3.p0"}
{"sentence": "Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.", "drug1": "zaleplon", "drug2": "promethazine", "relation": "MECHANISM", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s12", "pair_id": "DDI-DrugBank.d324.s12.p3"}
{"sentence": "This allows bitolterol to open air passages, increasing the effectiveness of the steroid.", "drug1": "bitolterol", "drug2": "steroid", "relation": "EFFECT", "source_file": "Bitolterol_ddi.xml", "sentence_id": "DDI-DrugBank.d560.s2", "pair_id": "DDI-DrugBank.d560.s2.p0"}
{"sentence": "Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. ", "drug1": "morphine", "drug2": "dmPGE2", "relation": "EFFECT", "source_file": "7625885.xml", "sentence_id": "DDI-MedLine.d128.s13", "pair_id": "DDI-MedLine.d128.s13.p2"}
{"sentence": "Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.", "drug1": "amitriptyline HCl", "drug2": "anticholinergic", "relation": "EFFECT", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s19", "pair_id": "DDI-DrugBank.d99.s19.p0"}
{"sentence": "Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.", "drug1": "diflunisal", "drug2": "hydrochlorothiazide", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s5", "pair_id": "DDI-DrugBank.d132.s5.p3"}
{"sentence": "CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.", "drug1": "CRIXIVAN", "drug2": "indinavir", "relation": "EFFECT", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s63", "pair_id": "DDI-DrugBank.d97.s63.p0"}
{"sentence": "Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.", "drug1": "Tricyclic Antidepressants", "drug2": "imipramine", "relation": "NONE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s15", "pair_id": "DDI-DrugBank.d54.s15.p1"}
{"sentence": "The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.", "drug1": "Adenocard", "drug2": "digitalis", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s3", "pair_id": "DDI-DrugBank.d226.s3.p0"}
{"sentence": "Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.", "drug1": "Magnesium", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s5", "pair_id": "DDI-DrugBank.d516.s5.p2"}
{"sentence": "Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.", "drug1": "HMG-CoA reductase inhibitor", "drug2": "cimetidine", "relation": "ADVISE", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s17", "pair_id": "DDI-DrugBank.d140.s17.p2"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "alcohol", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p28"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "aminoglycosides", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p1"}
{"sentence": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "drug1": "alprazolam", "drug2": "Fluvoxamine", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s17", "pair_id": "DDI-DrugBank.d76.s17.p7"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "itraconazole", "drug2": "protease inhibitors", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p747"}
{"sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "drug1": "analgesics", "drug2": "HMG-CoA reductase inhibitors", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s3", "pair_id": "DDI-DrugBank.d209.s3.p50"}
{"sentence": "The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy.", "drug1": "SULAR", "drug2": "atenolol", "relation": "EFFECT", "source_file": "Nisoldipine_ddi.xml", "sentence_id": "DDI-DrugBank.d106.s7", "pair_id": "DDI-DrugBank.d106.s7.p0"}
{"sentence": "Phenobarbital: Estimates of steady-state pharmacokinetic parameters for phenobarbital or gabapentin (300 mg TID;", "drug1": "Phenobarbital", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s13", "pair_id": "DDI-DrugBank.d438.s13.p0"}
{"sentence": "Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.", "drug1": "indomethacin", "drug2": "furosemide", "relation": "ADVISE", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s17", "pair_id": "DDI-DrugBank.d231.s17.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "indomethacin", "drug2": "methyldopa", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p992"}
{"sentence": "In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.", "drug1": "enflurane", "drug2": "NIMBEX", "relation": "ADVISE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s9", "pair_id": "DDI-DrugBank.d60.s9.p1"}
{"sentence": "Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.", "drug1": "ketoconazole", "drug2": "astemizole", "relation": "EFFECT", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s5", "pair_id": "DDI-DrugBank.d458.s5.p0"}
{"sentence": "Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.", "drug1": "lamivudine", "drug2": "adefovir dipivoxil", "relation": "NONE", "source_file": "Entecavir_ddi.xml", "sentence_id": "DDI-DrugBank.d295.s1", "pair_id": "DDI-DrugBank.d295.s1.p3"}
{"sentence": "Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by flumazenil.", "drug1": "ROMAZICON", "drug2": "cyclic antidepressants", "relation": "EFFECT", "source_file": "Flumazenil_ddi.xml", "sentence_id": "DDI-DrugBank.d234.s2", "pair_id": "DDI-DrugBank.d234.s2.p0"}
{"sentence": "The effects of allopurinol on didanosine pharmacokinetics in subjects with normal renal function are not known.", "drug1": "allopurinol", "drug2": "didanosine", "relation": "NONE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s3", "pair_id": "DDI-DrugBank.d43.s3.p0"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "amiodarone", "drug2": "dofetilide", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p49"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "tranquilizers", "drug2": "anesthetics", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p64"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "Disalcid", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p5"}
{"sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "drug1": "phenylbutazone", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s2", "pair_id": "DDI-DrugBank.d488.s2.p25"}
{"sentence": "Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.", "drug1": "calcium antagonists", "drug2": "beta-adrenergic blocking agents", "relation": "ADVISE", "source_file": "Betaxolol_ddi.xml", "sentence_id": "DDI-DrugBank.d489.s5", "pair_id": "DDI-DrugBank.d489.s5.p0"}
{"sentence": "During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.", "drug1": "anticoagulants", "drug2": "antipyretics", "relation": "NONE", "source_file": "Iloprost_ddi.xml", "sentence_id": "DDI-DrugBank.d549.s3", "pair_id": "DDI-DrugBank.d549.s3.p12"}
{"sentence": "Antiarrhythmics: bepridil, lidocaine (systemic) and quinidine", "drug1": "lidocaine", "drug2": "quinidine", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s57", "pair_id": "DDI-DrugBank.d97.s57.p5"}
{"sentence": "Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.", "drug1": "metoclopramide", "drug2": "levodopa", "relation": "MECHANISM", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s7", "pair_id": "DDI-DrugBank.d47.s7.p0"}
{"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Hexobarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d457.s0", "pair_id": "DDI-DrugBank.d457.s0.p5"}
{"sentence": "Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.", "drug1": "Lithium carbonate", "drug2": "lithium carbonate", "relation": "NONE", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s15", "pair_id": "DDI-DrugBank.d158.s15.p1"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "meclofenamic acid", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p9"}
{"sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.", "drug1": "beta2-agonists", "drug2": "monoamine oxidase inhibitors", "relation": "ADVISE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s6", "pair_id": "DDI-DrugBank.d284.s6.p4"}
{"sentence": "It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.", "drug1": "CASODEX", "drug2": "anticoagulant", "relation": "ADVISE", "source_file": "Bicalutamide_ddi.xml", "sentence_id": "DDI-DrugBank.d266.s1", "pair_id": "DDI-DrugBank.d266.s1.p1"}
{"sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "sertraline", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s6", "pair_id": "DDI-DrugBank.d299.s6.p27"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p7"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "rifampin", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p8"}
{"sentence": "The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.", "drug1": "desipramine", "drug2": "alprazolam", "relation": "MECHANISM", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s1", "pair_id": "DDI-DrugBank.d131.s1.p2"}
{"sentence": "Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.", "drug1": "hormonal contraceptives", "drug2": "TRACLEER", "relation": "EFFECT", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s8", "pair_id": "DDI-DrugBank.d289.s8.p0"}
{"sentence": "however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.", "drug1": "Lodine", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s6", "pair_id": "DDI-DrugBank.d219.s6.p2"}
{"sentence": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.", "drug1": "SSRIs", "drug2": "dihydroergotamine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s4", "pair_id": "DDI-DrugBank.d423.s4.p6"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "hexobarbital", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p3"}
{"sentence": "In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.", "drug1": "imidazole drugs", "drug2": "coumarin drugs", "relation": "ADVISE", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s20", "pair_id": "DDI-DrugBank.d458.s20.p0"}
{"sentence": "Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin).", "drug1": "nitazoxanide", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Nitazoxanide_ddi.xml", "sentence_id": "DDI-DrugBank.d354.s1", "pair_id": "DDI-DrugBank.d354.s1.p0"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Type 1C antiarrhythmics", "drug2": "flecainide", "relation": "NONE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p53"}
{"sentence": "It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.", "drug1": "cisapride", "drug2": "anticoagulant", "relation": "ADVISE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s5", "pair_id": "DDI-DrugBank.d237.s5.p0"}
{"sentence": "The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s0", "pair_id": "DDI-DrugBank.d85.s0.p0"}
{"sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "drug1": "levobupivacaine", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Levobupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d320.s3", "pair_id": "DDI-DrugBank.d320.s3.p1"}
{"sentence": "Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.", "drug1": "Antithyroid agents", "drug2": "sodium iodide I131", "relation": "EFFECT", "source_file": "Carbimazole_ddi.xml", "sentence_id": "DDI-DrugBank.d213.s3", "pair_id": "DDI-DrugBank.d213.s3.p0"}
{"sentence": "Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.", "drug1": "Fenfluramine", "drug2": "guanethidine", "relation": "EFFECT", "source_file": "Fenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d104.s0", "pair_id": "DDI-DrugBank.d104.s0.p1"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "cannabinoids", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p55"}
{"sentence": "Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).", "drug1": "Diphenhydramine hydrochloride", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Diphenhydramine_ddi.xml", "sentence_id": "DDI-DrugBank.d296.s0", "pair_id": "DDI-DrugBank.d296.s0.p2"}
{"sentence": "Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.", "drug1": "ethoxzolamide", "drug2": "amphotericin B", "relation": "EFFECT", "source_file": "Ethoxzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d286.s2", "pair_id": "DDI-DrugBank.d286.s2.p1"}
{"sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "drug1": "hormonal contraceptives", "drug2": "benzodiazepines", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s17", "pair_id": "DDI-DrugBank.d485.s17.p8"}
{"sentence": "The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.", "drug1": "adenosine", "drug2": "caffeine", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s4", "pair_id": "DDI-DrugBank.d226.s4.p1"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p11"}
{"sentence": "astemizole midazolam, triazolam cisapride ergot derivatives voriconazole", "drug1": "midazolam", "drug2": "cisapride", "relation": "NONE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s11", "pair_id": "DDI-DrugBank.d531.s11.p5"}
{"sentence": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "drug1": "Digoxin", "drug2": "Nimodipine", "relation": "NONE", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s32", "pair_id": "DDI-DrugBank.d289.s32.p0"}
{"sentence": "FLEXERIL may have life-threatening interactions with MAO inhibitors.", "drug1": "FLEXERIL", "drug2": "MAO inhibitors", "relation": "INT", "source_file": "Cyclobenzaprine_ddi.xml", "sentence_id": "DDI-DrugBank.d150.s0", "pair_id": "DDI-DrugBank.d150.s0.p0"}
{"sentence": "While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.", "drug1": "fibrates", "drug2": "gemfibrozil", "relation": "NONE", "source_file": "Clofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d12.s8", "pair_id": "DDI-DrugBank.d12.s8.p0"}
{"sentence": "Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.", "drug1": "alosetron", "drug2": "hydralazine", "relation": "EFFECT", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s15", "pair_id": "DDI-DrugBank.d364.s15.p2"}
{"sentence": "However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "drug1": "fexofenadine hydrochloride", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s1", "pair_id": "DDI-DrugBank.d466.s1.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "cinchophen", "drug2": "diazoxide", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p585"}
{"sentence": "The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .", "drug1": "ENABLEX", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s0", "pair_id": "DDI-DrugBank.d459.s0.p0"}
{"sentence": "ERGAMISOL  (levamisole hydrochloride) has been reported to produce ANTABUSE-like side effects when given concomitantly with alcohol.", "drug1": "levamisole hydrochloride", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Levamisole_ddi.xml", "sentence_id": "DDI-DrugBank.d381.s0", "pair_id": "DDI-DrugBank.d381.s0.p2"}
{"sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.", "drug1": "clarithromycin", "drug2": "verapamil", "relation": "NONE", "source_file": "Chlorpheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d235.s4", "pair_id": "DDI-DrugBank.d235.s4.p35"}
{"sentence": "However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. ", "drug1": "antiretroviral drugs", "drug2": "antineoplastic drugs", "relation": "ADVISE", "source_file": "11148572.xml", "sentence_id": "DDI-MedLine.d115.s14", "pair_id": "DDI-MedLine.d115.s14.p0"}
{"sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "drug1": "Codeine", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Codeine_ddi.xml", "sentence_id": "DDI-DrugBank.d464.s0", "pair_id": "DDI-DrugBank.d464.s0.p1"}
{"sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "drug1": "gemfibrozil", "drug2": "bexarotene", "relation": "MECHANISM", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s2", "pair_id": "DDI-DrugBank.d467.s2.p14"}
{"sentence": "The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day. ", "drug1": "trichlorfon", "drug2": "coumaphos", "relation": "EFFECT", "source_file": "46730.xml", "sentence_id": "DDI-MedLine.d5.s3", "pair_id": "DDI-MedLine.d5.s3.p0"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "perphenazine", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p143"}
{"sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "drug1": "FACTIVE", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s1", "pair_id": "DDI-DrugBank.d347.s1.p1"}
{"sentence": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "drug1": "quinolones", "drug2": "zinc", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s7", "pair_id": "DDI-DrugBank.d562.s7.p2"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "alprazolam", "drug2": "anticonvulsants", "relation": "EFFECT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p6"}
{"sentence": "Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.", "drug1": "Bromocriptine mesylate", "drug2": "butyrophenones", "relation": "INT", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s1", "pair_id": "DDI-DrugBank.d272.s1.p1"}
{"sentence": "Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "drug1": "CNS depressants", "drug2": "DILAUDID", "relation": "EFFECT", "source_file": "Hydromorphone_ddi.xml", "sentence_id": "DDI-DrugBank.d26.s0", "pair_id": "DDI-DrugBank.d26.s0.p34"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "thiazides", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p4"}
{"sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "drug1": "beta blockers", "drug2": "cardiac glycosides", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s35", "pair_id": "DDI-DrugBank.d558.s35.p24"}
{"sentence": "Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.", "drug1": "vasopressor drugs", "drug2": "ergot-type oxytocic drugs", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s3", "pair_id": "DDI-DrugBank.d110.s3.p0"}
{"sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).", "drug1": "antiepileptic drugs", "drug2": "phenytoin", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s18", "pair_id": "DDI-DrugBank.d3.s18.p7"}
{"sentence": "Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.", "drug1": "alcohol", "drug2": "SINEQUAN", "relation": "MECHANISM", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s26", "pair_id": "DDI-DrugBank.d223.s26.p2"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "phenobarbital", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p20"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "antifungals", "drug2": "temazepam", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p521"}
{"sentence": "Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.", "drug1": "ampicillin", "drug2": "allopurinol", "relation": "EFFECT", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s16", "pair_id": "DDI-DrugBank.d413.s16.p8"}
{"sentence": "Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.", "drug1": "ciprofloxacin", "drug2": "Proquin XR", "relation": "NONE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s12", "pair_id": "DDI-DrugBank.d123.s12.p4"}
{"sentence": "Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.", "drug1": "antacids", "drug2": "VIDEX", "relation": "EFFECT", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s4", "pair_id": "DDI-DrugBank.d43.s4.p7"}
{"sentence": "astemizole midazolam, triazolam cisapride ergot derivatives voriconazole", "drug1": "astemizole", "drug2": "triazolam", "relation": "NONE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s11", "pair_id": "DDI-DrugBank.d531.s11.p1"}
{"sentence": "Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ", "drug1": "retinyl acetate", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s4", "pair_id": "DDI-MedLine.d12.s4.p2"}
{"sentence": "Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.", "drug1": "Digoxin", "drug2": "digoxin", "relation": "NONE", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s21", "pair_id": "DDI-DrugBank.d567.s21.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "amitriptyline", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p2"}
{"sentence": "Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.", "drug1": "Isoflurane", "drug2": "NUROMAX", "relation": "MECHANISM", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s3", "pair_id": "DDI-DrugBank.d267.s3.p2"}
{"sentence": "Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "drug1": "erythromycin", "drug2": "ergot alkaloid class", "relation": "NONE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s5", "pair_id": "DDI-DrugBank.d410.s5.p8"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "tramadol", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p39"}
{"sentence": "Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.\r\n", "drug1": "vitamin D", "drug2": "antiestrogens", "relation": "NONE", "source_file": "7654327.xml", "sentence_id": "DDI-MedLine.d53.s0", "pair_id": "DDI-MedLine.d53.s0.p0"}
{"sentence": "Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.", "drug1": "Diclofenac", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s8", "pair_id": "DDI-DrugBank.d249.s8.p4"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "antibiotics", "drug2": "rifadin", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p164"}
{"sentence": "Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.", "drug1": "duloxetine", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s1", "pair_id": "DDI-DrugBank.d548.s1.p0"}
{"sentence": "Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.", "drug1": "alprazolam", "drug2": "sertraline", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s9", "pair_id": "DDI-DrugBank.d131.s9.p3"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "alprazolam", "drug2": "nicardipine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p9"}
{"sentence": "Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.", "drug1": "chloroquine", "drug2": "digitoxin", "relation": "NONE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s16", "pair_id": "DDI-DrugBank.d249.s16.p16"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "lamotrigine", "drug2": "ziprasidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p780"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "quinupristin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p21"}
{"sentence": "Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.", "drug1": "benzodiazepines", "drug2": "SUBUTEX", "relation": "ADVISE", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s7", "pair_id": "DDI-DrugBank.d380.s7.p1"}
{"sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "Phenytoin", "drug2": "Felbatol", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s30", "pair_id": "DDI-DrugBank.d434.s30.p21"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "sulindac", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p47"}
{"sentence": "In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.", "drug1": "oxcarbazepine", "drug2": "contraceptives", "relation": "NONE", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s9", "pair_id": "DDI-DrugBank.d307.s9.p2"}
{"sentence": "Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.", "drug1": "diuretics", "drug2": "hydralazine", "relation": "NONE", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s11", "pair_id": "DDI-DrugBank.d561.s11.p13"}
{"sentence": "Interaction of gentamycin and atracurium in anaesthetised horses.\r\n", "drug1": "gentamycin", "drug2": "atracurium", "relation": "INT", "source_file": "8542840.xml", "sentence_id": "DDI-MedLine.d90.s0", "pair_id": "DDI-MedLine.d90.s0.p0"}
{"sentence": "Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.", "drug1": "COPEGUS", "drug2": "didanosine", "relation": "ADVISE", "source_file": "Peginterferon alfa-2a_ddi.xml", "sentence_id": "DDI-DrugBank.d196.s4", "pair_id": "DDI-DrugBank.d196.s4.p2"}
{"sentence": "While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).", "drug1": "bupropion", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s8", "pair_id": "DDI-DrugBank.d5.s8.p0"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "nortriptyline", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p3"}
{"sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.", "drug1": "platelet aggregation inhibitors", "drug2": "ardeparin", "relation": "EFFECT", "source_file": "Ardeparin_ddi.xml", "sentence_id": "DDI-DrugBank.d105.s0", "pair_id": "DDI-DrugBank.d105.s0.p8"}
{"sentence": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.", "drug1": "selective serotonin reuptake inhibitors", "drug2": "dihydroergotamine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s4", "pair_id": "DDI-DrugBank.d423.s4.p3"}
{"sentence": "When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: Anesthetics, general: exaggeration of the hypotension induced by general anesthetics.", "drug1": "beta-adrenergic receptor blocking agents", "drug2": "Anesthetics", "relation": "INT", "source_file": "Nadolol_ddi.xml", "sentence_id": "DDI-DrugBank.d204.s0", "pair_id": "DDI-DrugBank.d204.s0.p0"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "tamoxifen", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p11"}
{"sentence": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "drug1": "cholestyramine", "drug2": "hydrochlorothiazide", "relation": "MECHANISM", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s5", "pair_id": "DDI-DrugBank.d162.s5.p2"}
{"sentence": "In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 BROVANA -treated subjects received concomitant theophylline at study entry.", "drug1": "BROVANA", "drug2": "BROVANA", "relation": "NONE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s10", "pair_id": "DDI-DrugBank.d284.s10.p0"}
{"sentence": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.", "drug1": "SSRIs", "drug2": "sumatriptan succinate", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s4", "pair_id": "DDI-DrugBank.d423.s4.p5"}
{"sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.", "drug1": "lamivudine", "drug2": "paroxetine", "relation": "NONE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s90", "pair_id": "DDI-DrugBank.d531.s90.p58"}
{"sentence": "In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.", "drug1": "clonidine", "drug2": "guanethidine", "relation": "NONE", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s5", "pair_id": "DDI-DrugBank.d527.s5.p3"}
{"sentence": "Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.", "drug1": "omeprazole", "drug2": "erythromycin", "relation": "NONE", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s1", "pair_id": "DDI-DrugBank.d358.s1.p0"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "multivitamins", "drug2": "Pronestyl", "relation": "NONE", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p96"}
{"sentence": "however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. ", "drug1": "nitrate", "drug2": "sildenafil", "relation": "EFFECT", "source_file": "11219477.xml", "sentence_id": "DDI-MedLine.d42.s9", "pair_id": "DDI-MedLine.d42.s9.p0"}
{"sentence": "Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.", "drug1": "NSAIDs", "drug2": "lisinopril", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s7", "pair_id": "DDI-DrugBank.d334.s7.p1"}
{"sentence": "Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by INDOCIN.", "drug1": "diuretics", "drug2": "INDOCIN", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s32", "pair_id": "DDI-DrugBank.d82.s32.p0"}
{"sentence": "and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.", "drug1": "disulfiram", "drug2": "epinephrine", "relation": "NONE", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s18", "pair_id": "DDI-DrugBank.d99.s18.p3"}
{"sentence": "Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;", "drug1": "imipramine", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s41", "pair_id": "DDI-DrugBank.d485.s41.p10"}
{"sentence": "However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.", "drug1": "acitretin", "drug2": "progestin", "relation": "EFFECT", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s5", "pair_id": "DDI-DrugBank.d353.s5.p0"}
{"sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.", "drug1": "ketoconazole", "drug2": "paroxetine", "relation": "NONE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s8", "pair_id": "DDI-DrugBank.d509.s8.p2"}
{"sentence": "Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.", "drug1": "ZYVOX", "drug2": "dopaminergic agents", "relation": "EFFECT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s2", "pair_id": "DDI-DrugBank.d441.s2.p6"}
{"sentence": "Ritonavir significantly prolonged the half-life of vardenafil to 26 hours.", "drug1": "Ritonavir", "drug2": "vardenafil", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s14", "pair_id": "DDI-DrugBank.d198.s14.p0"}
{"sentence": "MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .", "drug1": "MAO Inhibitors", "drug2": "MAO inhibitor", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s19", "pair_id": "DDI-DrugBank.d5.s19.p1"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "diazepam", "drug2": "insulin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p313"}
{"sentence": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).", "drug1": "methotrexate", "drug2": "methotrexate", "relation": "NONE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s21", "pair_id": "DDI-DrugBank.d210.s21.p4"}
{"sentence": "Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.", "drug1": "antiarrhythmic drugs", "drug2": "procainamide", "relation": "NONE", "source_file": "Disopyramide_ddi.xml", "sentence_id": "DDI-DrugBank.d506.s2", "pair_id": "DDI-DrugBank.d506.s2.p1"}
{"sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "VIDEX", "drug2": "ciprofloxacin", "relation": "ADVISE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s8", "pair_id": "DDI-DrugBank.d43.s8.p7"}
{"sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "drug1": "hormonal contraceptives", "drug2": "oxazepam", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s17", "pair_id": "DDI-DrugBank.d485.s17.p13"}
{"sentence": "Antihypertensive medications, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery", "drug1": "Antihypertensive medications", "drug2": "skeletal-muscle relaxants", "relation": "NONE", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s6", "pair_id": "DDI-DrugBank.d17.s6.p2"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "clarithromycin", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p3"}
{"sentence": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.", "drug1": "charcoal", "drug2": "Acarbose", "relation": "MECHANISM", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s4", "pair_id": "DDI-DrugBank.d536.s4.p8"}
{"sentence": "Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.", "drug1": "estazolam", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s6", "pair_id": "DDI-DrugBank.d338.s6.p1"}
{"sentence": "Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.", "drug1": "Ethoxzolamide", "drug2": "amphetamines", "relation": "EFFECT", "source_file": "Ethoxzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d286.s0", "pair_id": "DDI-DrugBank.d286.s0.p1"}
{"sentence": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.", "drug1": "imipramine", "drug2": "entacapone", "relation": "NONE", "source_file": "Entacapone_ddi.xml", "sentence_id": "DDI-DrugBank.d455.s11", "pair_id": "DDI-DrugBank.d455.s11.p4"}
{"sentence": "In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "loop diuretics", "relation": "EFFECT", "source_file": "Amiloride_ddi.xml", "sentence_id": "DDI-DrugBank.d356.s4", "pair_id": "DDI-DrugBank.d356.s4.p0"}
{"sentence": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "drug1": "Aprepitant", "drug2": "Aprepitant", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s14", "pair_id": "DDI-DrugBank.d382.s14.p8"}
{"sentence": "Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.", "drug1": "Anafranil", "drug2": "anticholinergic", "relation": "ADVISE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s3", "pair_id": "DDI-DrugBank.d238.s3.p0"}
{"sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.", "drug1": "tiagabine", "drug2": "primidone", "relation": "MECHANISM", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s12", "pair_id": "DDI-DrugBank.d277.s12.p10"}
{"sentence": "Cholestyramine increases enterohepatic elimination of amiodarone and may reduce its serum levels and t1/2.", "drug1": "amiodarone", "drug2": "t1", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s56", "pair_id": "DDI-DrugBank.d143.s56.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Sporanox", "drug2": "Prelone", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p605"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "nortriptyline", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p1"}
{"sentence": "(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. ", "drug1": "cephaloridine", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "15830476.xml", "sentence_id": "DDI-MedLine.d29.s2", "pair_id": "DDI-MedLine.d29.s2.p2"}
{"sentence": "Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "drug1": "Cholestyramine", "drug2": "T3", "relation": "MECHANISM", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s8", "pair_id": "DDI-DrugBank.d54.s8.p5"}
{"sentence": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ", "drug1": "phenytoin", "drug2": "drugs", "relation": "NONE", "source_file": "11206048.xml", "sentence_id": "DDI-MedLine.d60.s2", "pair_id": "DDI-MedLine.d60.s2.p5"}
{"sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "drug1": "ketoconazole", "drug2": "bexarotene", "relation": "MECHANISM", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s2", "pair_id": "DDI-DrugBank.d467.s2.p8"}
{"sentence": "Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.\n", "drug1": "glycine", "drug2": "glutamate", "relation": "EFFECT", "source_file": "7794883.xml", "sentence_id": "DDI-MedLine.d20.s0", "pair_id": "DDI-MedLine.d20.s0.p0"}
{"sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.", "drug1": "antipyrine", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Cetirizine_ddi.xml", "sentence_id": "DDI-DrugBank.d393.s0", "pair_id": "DDI-DrugBank.d393.s0.p9"}
{"sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "drug1": "SSRI", "drug2": "TCA", "relation": "INT", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s9", "pair_id": "DDI-DrugBank.d223.s9.p0"}
{"sentence": "Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.", "drug1": "Amphetamines", "drug2": "ethosuximide", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s13", "pair_id": "DDI-DrugBank.d158.s13.p2"}
{"sentence": "In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "drug1": "platelet inhibitors", "drug2": "acetylsalicylic acid", "relation": "NONE", "source_file": "Fondaparinux sodium_ddi.xml", "sentence_id": "DDI-DrugBank.d15.s0", "pair_id": "DDI-DrugBank.d15.s0.p21"}
{"sentence": "Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.", "drug1": "caffeine", "drug2": "enoxacin", "relation": "EFFECT", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s5", "pair_id": "DDI-DrugBank.d395.s5.p2"}
{"sentence": "Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.", "drug1": "botulinum toxin", "drug2": "botulinum toxin", "relation": "EFFECT", "source_file": "Botulinum Toxin Type A_ddi.xml", "sentence_id": "DDI-DrugBank.d133.s2", "pair_id": "DDI-DrugBank.d133.s2.p0"}
{"sentence": "PROSTIN E2 may augment the activity of other oxytocic drugs.", "drug1": "PROSTIN E2", "drug2": "oxytocic drugs", "relation": "EFFECT", "source_file": "Dinoprostone_ddi.xml", "sentence_id": "DDI-DrugBank.d2.s0", "pair_id": "DDI-DrugBank.d2.s0.p0"}
{"sentence": "Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).", "drug1": "WELLBUTRIN", "drug2": "orphenadrine", "relation": "INT", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s3", "pair_id": "DDI-DrugBank.d5.s3.p0"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "insulin", "drug2": "6-mercaptopurine", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p429"}
{"sentence": "Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.", "drug1": "ciprofloxacin", "drug2": "glyburide", "relation": "EFFECT", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s3", "pair_id": "DDI-DrugBank.d123.s3.p4"}
{"sentence": "NSAIDs: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of diclofenac and ibuprofen at concentrations in the clinical range.", "drug1": "NSAIDs", "drug2": "diclofenac", "relation": "NONE", "source_file": "Leflunomide_ddi.xml", "sentence_id": "DDI-DrugBank.d41.s9", "pair_id": "DDI-DrugBank.d41.s9.p0"}
{"sentence": "When Vardenafil dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.", "drug1": "Vardenafil", "drug2": "terazosin", "relation": "EFFECT", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s31", "pair_id": "DDI-DrugBank.d198.s31.p0"}
{"sentence": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "drug1": "NSAIDs", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s2", "pair_id": "DDI-DrugBank.d249.s2.p5"}
{"sentence": "In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.", "drug1": "aspirin", "drug2": "indomethacin", "relation": "MECHANISM", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s3", "pair_id": "DDI-DrugBank.d82.s3.p0"}
{"sentence": "Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.", "drug1": "TCAs", "drug2": "SSRIs", "relation": "ADVISE", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s10", "pair_id": "DDI-DrugBank.d99.s10.p0"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "verapamil", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p15"}
{"sentence": "Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied", "drug1": "Antizol", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Fomepizole_ddi.xml", "sentence_id": "DDI-DrugBank.d228.s2", "pair_id": "DDI-DrugBank.d228.s2.p2"}
{"sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "drug1": "Diuretic agents", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s10", "pair_id": "DDI-DrugBank.d162.s10.p0"}
{"sentence": "INDOCIN can reduce the antihypertensive effects of captopril and losartan.", "drug1": "INDOCIN", "drug2": "losartan", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s35", "pair_id": "DDI-DrugBank.d82.s35.p1"}
{"sentence": "Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.", "drug1": "thioridazine", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Cinacalcet_ddi.xml", "sentence_id": "DDI-DrugBank.d512.s2", "pair_id": "DDI-DrugBank.d512.s2.p5"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "Sucralfate", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p20"}
{"sentence": "Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.", "drug1": "Vitamin D3", "drug2": "arsenate", "relation": "MECHANISM", "source_file": "2981680.xml", "sentence_id": "DDI-MedLine.d82.s8", "pair_id": "DDI-MedLine.d82.s8.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "diazoxide", "drug2": "miconazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p757"}
{"sentence": "Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid in combination with DIFFERIN Gel.", "drug1": "sulfur", "drug2": "DIFFERIN", "relation": "NONE", "source_file": "Adapalene_ddi.xml", "sentence_id": "DDI-DrugBank.d370.s1", "pair_id": "DDI-DrugBank.d370.s1.p2"}
{"sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "drug1": "azathioprine", "drug2": "gold", "relation": "NONE", "source_file": "Abatacept_ddi.xml", "sentence_id": "DDI-DrugBank.d297.s2", "pair_id": "DDI-DrugBank.d297.s2.p46"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "H2-antagonists", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p10"}
{"sentence": "Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.", "drug1": "Anticoagulants", "drug2": "anti-coagulants", "relation": "NONE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s2", "pair_id": "DDI-DrugBank.d529.s2.p2"}
{"sentence": "Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.", "drug1": "aspirin", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s24", "pair_id": "DDI-DrugBank.d314.s24.p8"}
{"sentence": "Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.", "drug1": "Terfenadine", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s7", "pair_id": "DDI-DrugBank.d76.s7.p2"}
{"sentence": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "drug1": "volatile inhalation anesthetics", "drug2": "ALFENTA", "relation": "MECHANISM", "source_file": "Alfentanil_ddi.xml", "sentence_id": "DDI-DrugBank.d8.s3", "pair_id": "DDI-DrugBank.d8.s3.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "antifungals", "drug2": "Nizoral", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p495"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "skeletal muscle relaxants", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p31"}
{"sentence": "ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.", "drug1": "NSAIDs", "drug2": "Angiotensin Converting Enzyme (ACE) inhibitors", "relation": "EFFECT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s9", "pair_id": "DDI-DrugBank.d172.s9.p2"}
{"sentence": "Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ", "drug1": "18-MC", "drug2": "morphine", "relation": "EFFECT", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s9", "pair_id": "DDI-MedLine.d110.s9.p2"}
{"sentence": "Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.", "drug1": "Cimetidine", "drug2": "tricyclic antidepressants", "relation": "MECHANISM", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s21", "pair_id": "DDI-DrugBank.d99.s21.p0"}
{"sentence": "The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;", "drug1": "norethindrone", "drug2": "gabapentin", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s35", "pair_id": "DDI-DrugBank.d438.s35.p0"}
{"sentence": "In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).", "drug1": "cisplatin", "drug2": "cisplatin", "relation": "NONE", "source_file": "Paclitaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d288.s0", "pair_id": "DDI-DrugBank.d288.s0.p6"}
{"sentence": "- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or", "drug1": "oxandrolone", "drug2": "Winstrol", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s3", "pair_id": "DDI-DrugBank.d179.s3.p25"}
{"sentence": "Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.", "drug1": "aspirin", "drug2": "ibuprofen", "relation": "EFFECT", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s2", "pair_id": "DDI-DrugBank.d415.s2.p4"}
{"sentence": "Concurrent use of phenothiazines may antagonize the anorectic effect of diethylpropion.", "drug1": "phenothiazines", "drug2": "diethylpropion", "relation": "EFFECT", "source_file": "Diethylpropion_ddi.xml", "sentence_id": "DDI-DrugBank.d352.s4", "pair_id": "DDI-DrugBank.d352.s4.p0"}
{"sentence": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.", "drug1": "indinavir", "drug2": "budesonide", "relation": "ADVISE", "source_file": "Budesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d144.s1", "pair_id": "DDI-DrugBank.d144.s1.p17"}
{"sentence": "Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.", "drug1": "Noncardioselective beta-blockers", "drug2": "guanfacine", "relation": "EFFECT", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s5", "pair_id": "DDI-DrugBank.d507.s5.p2"}
{"sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).", "drug1": "ergotamine", "drug2": "FROVA", "relation": "ADVISE", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s1", "pair_id": "DDI-DrugBank.d426.s1.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Fortovase", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p26"}
{"sentence": "however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.", "drug1": "anesthetics", "drug2": "muscle relaxants", "relation": "NONE", "source_file": "Flumazenil_ddi.xml", "sentence_id": "DDI-DrugBank.d234.s1", "pair_id": "DDI-DrugBank.d234.s1.p5"}
{"sentence": "- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "drug1": "Perhexiline hydrogen maleate", "drug2": "Bezalip retard", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s11", "pair_id": "DDI-DrugBank.d291.s11.p2"}
{"sentence": "DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.", "drug1": "DOSTINEX", "drug2": "metoclopramide", "relation": "ADVISE", "source_file": "Cabergoline_ddi.xml", "sentence_id": "DDI-DrugBank.d282.s0", "pair_id": "DDI-DrugBank.d282.s0.p3"}
{"sentence": "The concomitant administration of bosentan and cyclosporine A is contraindicated.", "drug1": "bosentan", "drug2": "cyclosporine A", "relation": "ADVISE", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s12", "pair_id": "DDI-DrugBank.d289.s12.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "cyclosporin", "drug2": "lorazepam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p418"}
{"sentence": "It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.", "drug1": "PRINIVIL", "drug2": "lithium", "relation": "ADVISE", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s20", "pair_id": "DDI-DrugBank.d334.s20.p2"}
{"sentence": "Epidural clonidine may prolong the duration of pharmacologic effects of epidural local anesthetics, including both sensory and motor blockade.", "drug1": "clonidine", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s10", "pair_id": "DDI-DrugBank.d495.s10.p0"}
{"sentence": "Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.", "drug1": "sodium bicarbonate", "drug2": "amphetamines", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s4", "pair_id": "DDI-DrugBank.d236.s4.p0"}
{"sentence": "Coumarin Anticoagulants: There have been rare reports of increased prothrombin time in patients taking coumarin anticoagulants to whom nifedipine was administered.", "drug1": "coumarin anticoagulants", "drug2": "nifedipine", "relation": "EFFECT", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s9", "pair_id": "DDI-DrugBank.d373.s9.p2"}
{"sentence": "Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.\r\n", "drug1": "Cypermethrin", "drug2": "vitamin E", "relation": "EFFECT", "source_file": "11137320.xml", "sentence_id": "DDI-MedLine.d126.s0", "pair_id": "DDI-MedLine.d126.s0.p0"}
{"sentence": "In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.", "drug1": "triamterene", "drug2": "dofetilide", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s22", "pair_id": "DDI-DrugBank.d558.s22.p2"}
{"sentence": "Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.", "drug1": "Mefloquine", "drug2": "anticoagulants", "relation": "ADVISE", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s16", "pair_id": "DDI-DrugBank.d220.s16.p0"}
{"sentence": "Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.", "drug1": "Erythromycin", "drug2": "theophylline", "relation": "EFFECT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s0", "pair_id": "DDI-DrugBank.d397.s0.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "polymyxins", "drug2": "lincomycin", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p75"}
{"sentence": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.", "drug1": "ceftazidime", "drug2": "gentamicin", "relation": "NONE", "source_file": "Icodextrin_ddi.xml", "sentence_id": "DDI-DrugBank.d501.s10", "pair_id": "DDI-DrugBank.d501.s10.p26"}
{"sentence": "Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.", "drug1": "Clidinium", "drug2": "ketoconazole", "relation": "EFFECT", "source_file": "Clidinium_ddi.xml", "sentence_id": "DDI-DrugBank.d322.s1", "pair_id": "DDI-DrugBank.d322.s1.p2"}
{"sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.", "drug1": "CANCIDAS", "drug2": "mycophenolate", "relation": "NONE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s3", "pair_id": "DDI-DrugBank.d350.s3.p2"}
{"sentence": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "drug1": "ketamine", "drug2": "Innovar", "relation": "NONE", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s1", "pair_id": "DDI-MedLine.d23.s1.p33"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "acetaminophen", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p11"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "risperidone", "drug2": "triazolam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p994"}
{"sentence": "Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.", "drug1": "Urinary acidifying agents", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s1", "pair_id": "DDI-DrugBank.d236.s1.p2"}
{"sentence": "Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;", "drug1": "Amphetamines", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s19", "pair_id": "DDI-DrugBank.d158.s19.p2"}
{"sentence": "- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);", "drug1": "sulfamethoxazole", "drug2": "Bactrim", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s3", "pair_id": "DDI-DrugBank.d521.s3.p1"}
{"sentence": "Trecator may potentiate the adverse effects of other antituberculous drugs administered concomitantly.", "drug1": "Trecator", "drug2": "antituberculous drugs", "relation": "EFFECT", "source_file": "Ethionamide_ddi.xml", "sentence_id": "DDI-DrugBank.d166.s1", "pair_id": "DDI-DrugBank.d166.s1.p0"}
{"sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.", "drug1": "antianxiety agents", "drug2": "hydrocodone", "relation": "EFFECT", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s0", "pair_id": "DDI-DrugBank.d396.s0.p13"}
{"sentence": "This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).", "drug1": "celecoxib", "drug2": "fluconazole", "relation": "MECHANISM", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s17", "pair_id": "DDI-DrugBank.d172.s17.p0"}
{"sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ", "drug1": "pyreneperone", "drug2": "apomorphine", "relation": "NONE", "source_file": "2857100.xml", "sentence_id": "DDI-MedLine.d15.s0", "pair_id": "DDI-MedLine.d15.s0.p29"}
{"sentence": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "drug1": "Aprepitant", "drug2": "dexamethasone", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s9", "pair_id": "DDI-DrugBank.d382.s9.p18"}
{"sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "drug1": "fexofenadine hydrochloride", "drug2": "Maalox", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s19", "pair_id": "DDI-DrugBank.d466.s19.p9"}
{"sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.", "drug1": "Lithium", "drug2": "lithium", "relation": "NONE", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s18", "pair_id": "DDI-DrugBank.d175.s18.p2"}
{"sentence": "Therefore, patients receiving probenecid will have erroneously low ERPF and Tm PAH values.", "drug1": "probenecid", "drug2": "PAH", "relation": "EFFECT", "source_file": "Aminohippurate_ddi.xml", "sentence_id": "DDI-DrugBank.d416.s3", "pair_id": "DDI-DrugBank.d416.s3.p0"}
{"sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "drug1": "phenothiazines", "drug2": "APOKYN", "relation": "EFFECT", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s3", "pair_id": "DDI-DrugBank.d357.s3.p38"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Kaletra", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p28"}
{"sentence": "Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.", "drug1": "carbamazepine", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s22", "pair_id": "DDI-DrugBank.d568.s22.p5"}
{"sentence": "This may occur because diflunisal competitively displaces coumarins from protein binding sites.", "drug1": "diflunisal", "drug2": "coumarins", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s1", "pair_id": "DDI-DrugBank.d132.s1.p0"}
{"sentence": "Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.", "drug1": "Ponstel", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s0", "pair_id": "DDI-DrugBank.d400.s0.p5"}
{"sentence": "These results suggest that acute dosing with clozapine would not affect behaviors most closely associated with PCP intoxication. ", "drug1": "clozapine", "drug2": "PCP", "relation": "NONE", "source_file": "11114408.xml", "sentence_id": "DDI-MedLine.d135.s6", "pair_id": "DDI-MedLine.d135.s6.p0"}
{"sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "drug1": "antidepressants", "drug2": "Type 1C antiarrhythmics", "relation": "NONE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s15", "pair_id": "DDI-DrugBank.d238.s15.p6"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ethacrynic acid", "drug2": "methylphenidate", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p863"}
{"sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.", "drug1": "lithium", "drug2": "ACE inhibitor", "relation": "EFFECT", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s18", "pair_id": "DDI-DrugBank.d175.s18.p9"}
{"sentence": "Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.", "drug1": "nonsteroidal anti inflammatory drug", "drug2": "quinolone", "relation": "EFFECT", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s19", "pair_id": "DDI-DrugBank.d78.s19.p5"}
{"sentence": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).", "drug1": "lansoprazole", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s12", "pair_id": "DDI-DrugBank.d431.s12.p0"}
{"sentence": "Misonidazole has a complex effect on oral CCNU pharmacokinetics. ", "drug1": "Misonidazole", "drug2": "CCNU", "relation": "MECHANISM", "source_file": "3966974.xml", "sentence_id": "DDI-MedLine.d85.s9", "pair_id": "DDI-MedLine.d85.s9.p0"}
{"sentence": "Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.", "drug1": "phenytoin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s18", "pair_id": "DDI-DrugBank.d314.s18.p7"}
{"sentence": "The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "drug1": "dextromethorphan hydrobromide", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s2", "pair_id": "DDI-DrugBank.d398.s2.p0"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "levodopa", "drug2": "lovastatin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p456"}
{"sentence": "Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ", "drug1": "dexamethasone", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s4", "pair_id": "DDI-MedLine.d12.s4.p1"}
{"sentence": "Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "drug1": "EQUETROTM", "drug2": "primidone", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s13", "pair_id": "DDI-DrugBank.d94.s13.p7"}
{"sentence": "ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.", "drug1": "NSAIDs", "drug2": "Angiotensin Converting Enzyme (ACE) inhibitors", "relation": "EFFECT", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s0", "pair_id": "DDI-DrugBank.d210.s0.p2"}
{"sentence": "Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.", "drug1": "Alcohol", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s1", "pair_id": "DDI-DrugBank.d443.s1.p0"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "somatropin", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p10"}
{"sentence": "Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "drug1": "Felbatol", "drug2": "Felbatol", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s11", "pair_id": "DDI-DrugBank.d434.s11.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "atorvastatin", "drug2": "Lipitor", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p612"}
{"sentence": "It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.", "drug1": "ampicillin", "drug2": "allopurinol", "relation": "EFFECT", "source_file": "Clavulanate_ddi.xml", "sentence_id": "DDI-DrugBank.d419.s1", "pair_id": "DDI-DrugBank.d419.s1.p0"}
{"sentence": "Aspirin: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.", "drug1": "Lodine", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s4", "pair_id": "DDI-DrugBank.d219.s4.p3"}
{"sentence": "Pre-treatment with the CYP3A4 inducer rifampicin decreased erlotinib AUC by about 2/3.", "drug1": "rifampicin", "drug2": "erlotinib", "relation": "MECHANISM", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s2", "pair_id": "DDI-DrugBank.d456.s2.p0"}
{"sentence": "Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.", "drug1": "Phospholine Iodide", "drug2": "succinylcholine", "relation": "EFFECT", "source_file": "Echothiophate Iodide_ddi.xml", "sentence_id": "DDI-DrugBank.d377.s0", "pair_id": "DDI-DrugBank.d377.s0.p1"}
{"sentence": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "drug1": "Multivitamins", "drug2": "norfloxacin", "relation": "ADVISE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s11", "pair_id": "DDI-DrugBank.d217.s11.p4"}
{"sentence": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "drug1": "dopamine HCl", "drug2": "halogenated hydrocarbon anesthetics", "relation": "ADVISE", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s10", "pair_id": "DDI-DrugBank.d325.s10.p1"}
{"sentence": "The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.", "drug1": "benzodiazepines", "drug2": "macrolide antibiotics", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s8", "pair_id": "DDI-DrugBank.d338.s8.p5"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "hydrochlorothiazide", "drug2": "aliskiren", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p55"}
{"sentence": "Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.", "drug1": "quinolone class antimicrobial", "drug2": "fenbufen", "relation": "EFFECT", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s10", "pair_id": "DDI-DrugBank.d562.s10.p1"}
{"sentence": "RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ", "drug1": "diltiazem", "drug2": "sirolimus", "relation": "NONE", "source_file": "11180036.xml", "sentence_id": "DDI-MedLine.d86.s5", "pair_id": "DDI-MedLine.d86.s5.p2"}
{"sentence": "Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.", "drug1": "AEDs", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s11", "pair_id": "DDI-DrugBank.d212.s11.p10"}
{"sentence": "Orlistat-Orlistat may decrease the absorption of vitamin K.", "drug1": "Orlistat", "drug2": "vitamin K", "relation": "MECHANISM", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s6", "pair_id": "DDI-DrugBank.d139.s6.p2"}
{"sentence": "- a diuretic (water pill) such as hydrochlorothiazide (HCTZ, Hydrodiuril), chlorothiazide (Diuril), and others;", "drug1": "HCTZ", "drug2": "Hydrodiuril", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s6", "pair_id": "DDI-DrugBank.d521.s6.p9"}
{"sentence": "Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and metoclopramide are coadministered.", "drug1": "zalcitabine", "drug2": "metoclopramide", "relation": "MECHANISM", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s24", "pair_id": "DDI-DrugBank.d263.s24.p2"}
{"sentence": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "drug1": "miconazole", "drug2": "hypoglycemic agents", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s9", "pair_id": "DDI-DrugBank.d245.s9.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "cimetidine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p10"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "diazepam", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p4"}
{"sentence": "Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.", "drug1": "ATROVENT", "drug2": "anticholinergic", "relation": "ADVISE", "source_file": "Ipratropium_ddi.xml", "sentence_id": "DDI-DrugBank.d51.s3", "pair_id": "DDI-DrugBank.d51.s3.p0"}
{"sentence": "May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;", "drug1": "colestipol", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Bendroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d304.s0", "pair_id": "DDI-DrugBank.d304.s0.p3"}
{"sentence": "Neuroleptic Drugs - L-phenylalanine may potentiate the tardive dyskinesia side reactions of neuroleptic drugs if used concomitantly with them.", "drug1": "Neuroleptic Drugs", "drug2": "L-phenylalanine", "relation": "EFFECT", "source_file": "L-Phenylalanine_ddi.xml", "sentence_id": "DDI-DrugBank.d530.s3", "pair_id": "DDI-DrugBank.d530.s3.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "prolonged narcotics", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1391"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "valproate", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p10"}
{"sentence": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "drug1": "Erythromycin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s3", "pair_id": "DDI-DrugBank.d450.s3.p3"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "vitamin D", "drug2": "Calcidiol", "relation": "NONE", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s0", "pair_id": "DDI-DrugBank.d404.s0.p3"}
{"sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "drug1": "vitamin C", "drug2": "synthetic estrogens", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s14", "pair_id": "DDI-DrugBank.d485.s14.p5"}
{"sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "drug1": "Magnesium", "drug2": "vitamin D", "relation": "ADVISE", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s15", "pair_id": "DDI-DrugBank.d384.s15.p4"}
{"sentence": "Beta-adrenergic blocking agents should be withdrawn at least 48 hours before conducting an arbutamine-mediated stress test.", "drug1": "Beta-adrenergic blocking agents", "drug2": "arbutamine", "relation": "ADVISE", "source_file": "Arbutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d253.s1", "pair_id": "DDI-DrugBank.d253.s1.p0"}
{"sentence": "Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "Lodine", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s11", "pair_id": "DDI-DrugBank.d219.s11.p0"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "nabumetone", "drug2": "oxaprozin", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p273"}
{"sentence": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "drug1": "TRISENOX", "drug2": "thioridazine", "relation": "ADVISE", "source_file": "Arsenic trioxide_ddi.xml", "sentence_id": "DDI-DrugBank.d470.s1", "pair_id": "DDI-DrugBank.d470.s1.p1"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "Antihistamines", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p2"}
{"sentence": "Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s14", "pair_id": "DDI-DrugBank.d529.s14.p5"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "beta adrenergic blocking agents", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p8"}
{"sentence": "H1 and H2 Blockers - Although not reported, L-histidine, via its metabolism to histamine, might decrease the efficacy of H1 and H2 blockers.", "drug1": "H1 Blockers", "drug2": "L-histidine", "relation": "NONE", "source_file": "L-Histidine_ddi.xml", "sentence_id": "DDI-DrugBank.d365.s1", "pair_id": "DDI-DrugBank.d365.s1.p1"}
{"sentence": "Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.", "drug1": "fluvoxamine", "drug2": "astemizole", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s11", "pair_id": "DDI-DrugBank.d76.s11.p1"}
{"sentence": "Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.", "drug1": "Aprepitant", "drug2": "S(-) warfarin", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s4", "pair_id": "DDI-DrugBank.d382.s4.p0"}
{"sentence": "Caution should be used if naproxen is administered concomitantly with methotrexate.", "drug1": "naproxen", "drug2": "methotrexate", "relation": "ADVISE", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s11", "pair_id": "DDI-DrugBank.d85.s11.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Topamax", "drug2": "antifungals", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p430"}
{"sentence": "There have been inconsistent reports regarding the effects of other drugs (e.g., quinine, penicillamine) on serum digoxin concentration.", "drug1": "quinine", "drug2": "penicillamine", "relation": "NONE", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s8", "pair_id": "DDI-DrugBank.d450.s8.p0"}
{"sentence": "The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ", "drug1": "glycine", "drug2": "glutamate", "relation": "EFFECT", "source_file": "7794883.xml", "sentence_id": "DDI-MedLine.d20.s4", "pair_id": "DDI-MedLine.d20.s4.p0"}
{"sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "drug1": "Tetracycline", "drug2": "bacteriostatic antibiotic", "relation": "NONE", "source_file": "Nafcillin_ddi.xml", "sentence_id": "DDI-DrugBank.d261.s0", "pair_id": "DDI-DrugBank.d261.s0.p0"}
{"sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "drug1": "desipramine", "drug2": "chlordiazepoxide", "relation": "EFFECT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s23", "pair_id": "DDI-DrugBank.d386.s23.p31"}
{"sentence": "The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).", "drug1": "hypnotics", "drug2": "antigout drugs", "relation": "NONE", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s12", "pair_id": "DDI-DrugBank.d507.s12.p25"}
{"sentence": "Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.", "drug1": "dipyrone", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s3", "pair_id": "DDI-DrugBank.d443.s3.p9"}
{"sentence": "Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)", "drug1": "clonidine", "drug2": "calcium channel blockers", "relation": "ADVISE", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s7", "pair_id": "DDI-DrugBank.d495.s7.p1"}
{"sentence": "Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "drug1": "erythromycin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s2", "pair_id": "DDI-DrugBank.d397.s2.p0"}
{"sentence": "Chlorthalidone may add to or potentiate the action of other antihypertensive drugs.", "drug1": "Chlorthalidone", "drug2": "antihypertensive drugs", "relation": "EFFECT", "source_file": "Chlorthalidone_ddi.xml", "sentence_id": "DDI-DrugBank.d265.s0", "pair_id": "DDI-DrugBank.d265.s0.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "bacitracin", "drug2": "sodium colistemethate", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p69"}
{"sentence": "Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.", "drug1": "Dipyridamole", "drug2": "adenosine", "relation": "MECHANISM", "source_file": "Dipyridamole_ddi.xml", "sentence_id": "DDI-DrugBank.d505.s2", "pair_id": "DDI-DrugBank.d505.s2.p2"}
{"sentence": "Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.", "drug1": "allopurinol", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s12", "pair_id": "DDI-DrugBank.d413.s12.p3"}
{"sentence": "Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "drug1": "clarithromycin", "drug2": "Rifabutin", "relation": "NONE", "source_file": "Delavirdine_ddi.xml", "sentence_id": "DDI-DrugBank.d251.s0", "pair_id": "DDI-DrugBank.d251.s0.p6"}
{"sentence": "Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.", "drug1": "sodium acid phosphate", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s1", "pair_id": "DDI-DrugBank.d236.s1.p5"}
{"sentence": "Concomitant use of zalcitabine and lamivudine is not recommended.", "drug1": "zalcitabine", "drug2": "lamivudine", "relation": "ADVISE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s9", "pair_id": "DDI-DrugBank.d263.s9.p0"}
{"sentence": "Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.", "drug1": "astemizole", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s7", "pair_id": "DDI-DrugBank.d76.s7.p4"}
{"sentence": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "drug1": "clarithromycin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s3", "pair_id": "DDI-DrugBank.d450.s3.p8"}
{"sentence": "TCAs decrease the hypotensive effect of guanfacine.", "drug1": "TCAs", "drug2": "guanfacine", "relation": "EFFECT", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s4", "pair_id": "DDI-DrugBank.d507.s4.p0"}
{"sentence": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).", "drug1": "ampicillin", "drug2": "iron", "relation": "NONE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s12", "pair_id": "DDI-DrugBank.d431.s12.p7"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "androgens", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p0"}
{"sentence": "Cyclophosphamide treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of succinylcholine chloride.", "drug1": "Cyclophosphamide", "drug2": "succinylcholine chloride", "relation": "EFFECT", "source_file": "Cyclophosphamide_ddi.xml", "sentence_id": "DDI-DrugBank.d7.s2", "pair_id": "DDI-DrugBank.d7.s2.p0"}
{"sentence": "Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.", "drug1": "tiagabine", "drug2": "tiagabine", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s15", "pair_id": "DDI-DrugBank.d277.s15.p9"}
{"sentence": "Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.", "drug1": "halothane", "drug2": "NUROMAX", "relation": "MECHANISM", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s3", "pair_id": "DDI-DrugBank.d267.s3.p5"}
{"sentence": "Elevated plasma levels of theophylline have been reported with concomitant quinolone use.", "drug1": "theophylline", "drug2": "quinolone", "relation": "MECHANISM", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s0", "pair_id": "DDI-DrugBank.d217.s0.p0"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "vitamin D", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p11"}
{"sentence": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.", "drug1": "Aprepitant", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s25", "pair_id": "DDI-DrugBank.d382.s25.p1"}
{"sentence": "The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.", "drug1": "norepinephrine", "drug2": "Bretylium Tosylate", "relation": "EFFECT", "source_file": "Bretylium_ddi.xml", "sentence_id": "DDI-DrugBank.d180.s1", "pair_id": "DDI-DrugBank.d180.s1.p5"}
{"sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "drug1": "lithium", "drug2": "ACE inhibitors", "relation": "NONE", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s7", "pair_id": "DDI-DrugBank.d561.s7.p5"}
{"sentence": "Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.", "drug1": "alprazolam", "drug2": "fluvoxamine", "relation": "EFFECT", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s24", "pair_id": "DDI-DrugBank.d76.s24.p0"}
{"sentence": "Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.", "drug1": "levothyroxine sodium", "drug2": "ketamine", "relation": "EFFECT", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s13", "pair_id": "DDI-DrugBank.d411.s13.p2"}
{"sentence": "Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.", "drug1": "cephalosporins", "drug2": "aminoglycoside antibiotics", "relation": "EFFECT", "source_file": "Cefotaxime_ddi.xml", "sentence_id": "DDI-DrugBank.d100.s0", "pair_id": "DDI-DrugBank.d100.s0.p0"}
{"sentence": "Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.", "drug1": "mycophenolate mofetil", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Basiliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d544.s3", "pair_id": "DDI-DrugBank.d544.s3.p8"}
{"sentence": "Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.", "drug1": "Fosinopril sodium", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s3", "pair_id": "DDI-DrugBank.d176.s3.p5"}
{"sentence": "The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.", "drug1": "REVIA", "drug2": "disulfiram", "relation": "EFFECT", "source_file": "Naltrexone_ddi.xml", "sentence_id": "DDI-DrugBank.d346.s2", "pair_id": "DDI-DrugBank.d346.s2.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "acetaminophen", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "fenoprofen", "drug2": "oxolinic acid", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p903"}
{"sentence": "therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).", "drug1": "lansoprazole", "drug2": "iron", "relation": "MECHANISM", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s12", "pair_id": "DDI-DrugBank.d431.s12.p2"}
{"sentence": "Concomitant use of calcium supplements and L-lysine may increase calcium absorption", "drug1": "calcium", "drug2": "L-lysine", "relation": "MECHANISM", "source_file": "L-Lysine_ddi.xml", "sentence_id": "DDI-DrugBank.d344.s0", "pair_id": "DDI-DrugBank.d344.s0.p0"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "hydrochloroquine", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p24"}
{"sentence": "Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.", "drug1": "cinacalcet", "drug2": "amitriptyline", "relation": "MECHANISM", "source_file": "Cinacalcet_ddi.xml", "sentence_id": "DDI-DrugBank.d512.s3", "pair_id": "DDI-DrugBank.d512.s3.p4"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Gris-PEG", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p13"}
{"sentence": "Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.", "drug1": "Corticosteroids", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s2", "pair_id": "DDI-DrugBank.d443.s2.p0"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "cisapride", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p45"}
{"sentence": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "drug1": "Bezalip", "drug2": "cholestryramine", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s9", "pair_id": "DDI-DrugBank.d291.s9.p2"}
{"sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.", "drug1": "HYDROXYZINE", "drug2": "NARCOTICS", "relation": "EFFECT", "source_file": "Hydroxyzine_ddi.xml", "sentence_id": "DDI-DrugBank.d308.s0", "pair_id": "DDI-DrugBank.d308.s0.p1"}
{"sentence": "The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ", "drug1": "warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "1115445.xml", "sentence_id": "DDI-MedLine.d116.s3", "pair_id": "DDI-MedLine.d116.s3.p2"}
{"sentence": "In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.", "drug1": "MTX", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Infliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d45.s4", "pair_id": "DDI-DrugBank.d45.s4.p2"}
{"sentence": "Phenytoin: Serum phenytoin levels may be increased by aspirin.", "drug1": "phenytoin", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s7", "pair_id": "DDI-DrugBank.d443.s7.p2"}
{"sentence": "Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). ", "drug1": "Morphine", "drug2": "ADL 8-2698", "relation": "EFFECT", "source_file": "11180040.xml", "sentence_id": "DDI-MedLine.d87.s4", "pair_id": "DDI-MedLine.d87.s4.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "Antiarrhythmics", "drug2": "ergot derivatives", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p18"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "tacrolimus", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p84"}
{"sentence": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "drug1": "Isoflurane", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s6", "pair_id": "DDI-DrugBank.d60.s6.p3"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "acyclovir", "drug2": "famotidine", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p49"}
{"sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.", "drug1": "tricyclic antidepressants", "drug2": "CMI", "relation": "EFFECT", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s4", "pair_id": "DDI-DrugBank.d238.s4.p2"}
{"sentence": "The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.", "drug1": "benzodiazepines", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s8", "pair_id": "DDI-DrugBank.d338.s8.p2"}
{"sentence": "Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.", "drug1": "nitroglycerin", "drug2": "INOmax", "relation": "EFFECT", "source_file": "Nitric Oxide_ddi.xml", "sentence_id": "DDI-DrugBank.d183.s2", "pair_id": "DDI-DrugBank.d183.s2.p5"}
{"sentence": "A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)", "drug1": "barbiturates", "drug2": "tetracyclines", "relation": "NONE", "source_file": "Desogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d285.s1", "pair_id": "DDI-DrugBank.d285.s1.p4"}
{"sentence": "Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.", "drug1": "TCAs", "drug2": "SSRIs", "relation": "ADVISE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s19", "pair_id": "DDI-DrugBank.d238.s19.p0"}
{"sentence": "Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.", "drug1": "Cimetidine", "drug2": "tricyclic antidepressants", "relation": "MECHANISM", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s22", "pair_id": "DDI-DrugBank.d223.s22.p2"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "quinine", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p73"}
{"sentence": "Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.", "drug1": "diuretics", "drug2": "enalapril", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s0", "pair_id": "DDI-DrugBank.d107.s0.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "rifabutin", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p8"}
{"sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "potassium-sparing diuretics", "relation": "EFFECT", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s19", "pair_id": "DDI-DrugBank.d46.s19.p5"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "NSAIDs", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p9"}
{"sentence": "In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;", "drug1": "diltiazem", "drug2": "lovastatin", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s37", "pair_id": "DDI-DrugBank.d565.s37.p0"}
{"sentence": "Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.", "drug1": "Valdecoxib", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s20", "pair_id": "DDI-DrugBank.d328.s20.p3"}
{"sentence": "Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).", "drug1": "Nabilone", "drug2": "CNS depressants", "relation": "ADVISE", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s0", "pair_id": "DDI-DrugBank.d552.s0.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "allopurinol", "drug2": "glucagon", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p125"}
{"sentence": "Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.", "drug1": "Lodine", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s7", "pair_id": "DDI-DrugBank.d219.s7.p3"}
{"sentence": "Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.", "drug1": "PEGANONE", "drug2": "coumarin anticoagulants", "relation": "ADVISE", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s6", "pair_id": "DDI-DrugBank.d359.s6.p0"}
{"sentence": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.", "drug1": "tetracyclines", "drug2": "penicillin", "relation": "ADVISE", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s1", "pair_id": "DDI-DrugBank.d500.s1.p2"}
{"sentence": "Morphine: Combination hormonal contraceptives may increase the clearance of morphine.", "drug1": "hormonal contraceptives", "drug2": "morphine", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s26", "pair_id": "DDI-DrugBank.d485.s26.p2"}
{"sentence": "These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.", "drug1": "ketoconazole", "drug2": "fexofenadine", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s17", "pair_id": "DDI-DrugBank.d466.s17.p1"}
{"sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "drug1": "Warfarin", "drug2": "enoxacin", "relation": "NONE", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s23", "pair_id": "DDI-DrugBank.d395.s23.p1"}
{"sentence": "Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.", "drug1": "COUMARIN ANTICOAGULANTS", "drug2": "TRICOR", "relation": "ADVISE", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s0", "pair_id": "DDI-DrugBank.d283.s0.p2"}
{"sentence": "The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.", "drug1": "haloperidol", "drug2": "risperidone", "relation": "NONE", "source_file": "11217867.xml", "sentence_id": "DDI-MedLine.d83.s19", "pair_id": "DDI-MedLine.d83.s19.p0"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "thioxanthene classes of antipsychotic agents", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p6"}
{"sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "drug1": "ALPHAGAN P", "drug2": "CNS depressants", "relation": "ADVISE", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s0", "pair_id": "DDI-DrugBank.d138.s0.p0"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "calcium", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p15"}
{"sentence": "However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.", "drug1": "aspirin", "drug2": "CELEBREX", "relation": "EFFECT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s14", "pair_id": "DDI-DrugBank.d172.s14.p0"}
{"sentence": "Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.", "drug1": "phenytoin", "drug2": "coumarin", "relation": "MECHANISM", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s3", "pair_id": "DDI-DrugBank.d359.s3.p0"}
{"sentence": "The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. ", "drug1": "Fe", "drug2": "cobalt", "relation": "MECHANISM", "source_file": "7599505.xml", "sentence_id": "DDI-MedLine.d34.s8", "pair_id": "DDI-MedLine.d34.s8.p1"}
{"sentence": "Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. ", "drug1": "Misonidazole", "drug2": "CCNU", "relation": "EFFECT", "source_file": "3966974.xml", "sentence_id": "DDI-MedLine.d85.s7", "pair_id": "DDI-MedLine.d85.s7.p0"}
{"sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.", "drug1": "benzodiazepines", "drug2": "antidepressants", "relation": "EFFECT", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s3", "pair_id": "DDI-DrugBank.d335.s3.p4"}
{"sentence": "Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.", "drug1": "Propranolol", "drug2": "nisoldipine", "relation": "EFFECT", "source_file": "Nisoldipine_ddi.xml", "sentence_id": "DDI-DrugBank.d106.s6", "pair_id": "DDI-DrugBank.d106.s6.p0"}
{"sentence": "Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.\r\n", "drug1": "neurotensin", "drug2": "enkephalins", "relation": "EFFECT", "source_file": "6545985.xml", "sentence_id": "DDI-MedLine.d131.s0", "pair_id": "DDI-MedLine.d131.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "felbamate", "drug2": "theophylline", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p648"}
{"sentence": "Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained", "drug1": "chlorothiazide", "drug2": "non-steroidal anti-inflammatory agents", "relation": "ADVISE", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s20", "pair_id": "DDI-DrugBank.d46.s20.p0"}
{"sentence": "Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.", "drug1": "Acetazolamide", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s9", "pair_id": "DDI-DrugBank.d368.s9.p0"}
{"sentence": "Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ", "drug1": "Haloperidol", "drug2": "(+)-NANM", "relation": "EFFECT", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s11", "pair_id": "DDI-MedLine.d30.s11.p0"}
{"sentence": "Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45  (dihydroergotamine mesylate) Injection, USP.", "drug1": "Sumatriptan", "drug2": "dihydroergotamine mesylate", "relation": "EFFECT", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s1", "pair_id": "DDI-DrugBank.d410.s1.p4"}
{"sentence": "Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.", "drug1": "bupropion", "drug2": "hydroxybupropion", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s6", "pair_id": "DDI-DrugBank.d5.s6.p2"}
{"sentence": "Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.", "drug1": "cholestyramine", "drug2": "vitamin K", "relation": "MECHANISM", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s3", "pair_id": "DDI-DrugBank.d139.s3.p3"}
{"sentence": "Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.", "drug1": "bosentan", "drug2": "glyburide", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s19", "pair_id": "DDI-DrugBank.d289.s19.p0"}
{"sentence": "It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .", "drug1": "calcium channel blockers", "drug2": "Nimotop", "relation": "EFFECT", "source_file": "Nimodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d310.s0", "pair_id": "DDI-DrugBank.d310.s0.p0"}
{"sentence": "Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).", "drug1": "enalapril", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s3", "pair_id": "DDI-DrugBank.d107.s3.p4"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "Dexbrompheniramine", "drug2": "anticholinergics", "relation": "INT", "source_file": "Dexbrompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d62.s0", "pair_id": "DDI-DrugBank.d62.s0.p3"}
{"sentence": "While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.", "drug1": "estazolam", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s4", "pair_id": "DDI-DrugBank.d338.s4.p1"}
{"sentence": "The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.", "drug1": "sodium nitroprusside", "drug2": "ganglionic blocking agents", "relation": "EFFECT", "source_file": "Nitroprusside_ddi.xml", "sentence_id": "DDI-DrugBank.d394.s0", "pair_id": "DDI-DrugBank.d394.s0.p1"}
{"sentence": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "drug1": "Amitriptyline", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s2", "pair_id": "DDI-DrugBank.d495.s2.p0"}
{"sentence": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "drug1": "iron", "drug2": "norfloxacin", "relation": "ADVISE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s11", "pair_id": "DDI-DrugBank.d217.s11.p9"}
{"sentence": "Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.", "drug1": "calcium antagonist", "drug2": "verapamil", "relation": "NONE", "source_file": "Labetalol_ddi.xml", "sentence_id": "DDI-DrugBank.d412.s11", "pair_id": "DDI-DrugBank.d412.s11.p2"}
{"sentence": "A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.", "drug1": "hydantoin antiepileptic", "drug2": "phenytoin", "relation": "INT", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s2", "pair_id": "DDI-DrugBank.d359.s2.p0"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "iron", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p34"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "amiodarone", "drug2": "H2-antagonists", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p49"}
{"sentence": "Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.", "drug1": "Mefloquine", "drug2": "quinine", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s5", "pair_id": "DDI-DrugBank.d220.s5.p0"}
{"sentence": "Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.", "drug1": "Paroxetine", "drug2": "Sonata", "relation": "NONE", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s6", "pair_id": "DDI-DrugBank.d324.s6.p0"}
{"sentence": "Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.", "drug1": "Aprepitant", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s36", "pair_id": "DDI-DrugBank.d382.s36.p4"}
{"sentence": "Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.", "drug1": "Amphetamines", "drug2": "veratrum alkaloids", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s24", "pair_id": "DDI-DrugBank.d158.s24.p2"}
{"sentence": "Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.", "drug1": "insulin", "drug2": "EXTRANEAL", "relation": "NONE", "source_file": "Icodextrin_ddi.xml", "sentence_id": "DDI-DrugBank.d501.s5", "pair_id": "DDI-DrugBank.d501.s5.p14"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "selegiline hydrochloride", "drug2": "fluoxetine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p16"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "cyclosporin", "drug2": "delavirdine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p405"}
{"sentence": "A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).", "drug1": "VIDEX", "drug2": "ganciclovir", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s7", "pair_id": "DDI-DrugBank.d43.s7.p2"}
{"sentence": "Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.", "drug1": "Lithium", "drug2": "diuretics", "relation": "ADVISE", "source_file": "Amiloride_ddi.xml", "sentence_id": "DDI-DrugBank.d356.s2", "pair_id": "DDI-DrugBank.d356.s2.p0"}
{"sentence": "Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.", "drug1": "warfarin", "drug2": "lenalidomide", "relation": "NONE", "source_file": "Lenalidomide_ddi.xml", "sentence_id": "DDI-DrugBank.d169.s3", "pair_id": "DDI-DrugBank.d169.s3.p0"}
{"sentence": "Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.", "drug1": "ZYVOX", "drug2": "sympathomimetic agents", "relation": "EFFECT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s2", "pair_id": "DDI-DrugBank.d441.s2.p4"}
{"sentence": "Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.", "drug1": "Tricyclic antidepressants", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s4", "pair_id": "DDI-DrugBank.d495.s4.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "lamotrigine", "drug2": "zonisamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p781"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "sumatriptan", "drug2": "fluoxetine", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p1"}
{"sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "drug1": "ketoconazole", "drug2": "itraconazole", "relation": "NONE", "source_file": "Felodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d316.s1", "pair_id": "DDI-DrugBank.d316.s1.p0"}
{"sentence": "Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.", "drug1": "amphotericin B", "drug2": "pentamidine", "relation": "NONE", "source_file": "Foscarnet_ddi.xml", "sentence_id": "DDI-DrugBank.d511.s4", "pair_id": "DDI-DrugBank.d511.s4.p9"}
{"sentence": "Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.", "drug1": "meclofenamate sodium", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Meclofenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d113.s1", "pair_id": "DDI-DrugBank.d113.s1.p0"}
{"sentence": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "drug1": "diazepam", "drug2": "valdecoxib", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s48", "pair_id": "DDI-DrugBank.d328.s48.p1"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "azole antifungals", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p72"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "isoniazid", "drug2": "vincristine", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p109"}
{"sentence": "Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.", "drug1": "Aspirin", "drug2": "corticosteroids", "relation": "ADVISE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s25", "pair_id": "DDI-DrugBank.d314.s25.p0"}
{"sentence": "- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);", "drug1": "sulfasalazine", "drug2": "Azulfidine", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s3", "pair_id": "DDI-DrugBank.d521.s3.p27"}
{"sentence": "Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.", "drug1": "cephalosporins", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Ceftazidime_ddi.xml", "sentence_id": "DDI-DrugBank.d122.s0", "pair_id": "DDI-DrugBank.d122.s0.p2"}
{"sentence": "Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.", "drug1": "Zidovudine", "drug2": "probenecid", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s2", "pair_id": "DDI-DrugBank.d260.s2.p0"}
{"sentence": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "drug1": "antihypertensives", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s10", "pair_id": "DDI-DrugBank.d114.s10.p20"}
{"sentence": "Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.", "drug1": "Acamprosate", "drug2": "antidepressants", "relation": "EFFECT", "source_file": "Acamprosate_ddi.xml", "sentence_id": "DDI-DrugBank.d0.s6", "pair_id": "DDI-DrugBank.d0.s6.p0"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "perphenazine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p144"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "monoamine oxidase inhibitors", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p16"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "azole antifungal agents", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p21"}
{"sentence": "Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.", "drug1": "Estrogen", "drug2": "ARIMIDEX", "relation": "ADVISE", "source_file": "Anastrozole_ddi.xml", "sentence_id": "DDI-DrugBank.d195.s9", "pair_id": "DDI-DrugBank.d195.s9.p0"}
{"sentence": "Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.", "drug1": "Tadalafil", "drug2": "indinavir", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s90", "pair_id": "DDI-DrugBank.d97.s90.p0"}
{"sentence": "As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.", "drug1": "INDOCIN", "drug2": "lithium", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s18", "pair_id": "DDI-DrugBank.d82.s18.p0"}
{"sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "drug1": "FACTIVE", "drug2": "contraceptive", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s1", "pair_id": "DDI-DrugBank.d347.s1.p5"}
{"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "drug1": "phenytoin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s1", "pair_id": "DDI-DrugBank.d487.s1.p5"}
{"sentence": "Potassium-sparing diuretics (spironolactone, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.", "drug1": "spironolactone", "drug2": "potassium", "relation": "NONE", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s4", "pair_id": "DDI-DrugBank.d176.s4.p6"}
{"sentence": "Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of hypoglycemia.", "drug1": "flurbiprofen", "drug2": "hypoglycemic agents", "relation": "EFFECT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s19", "pair_id": "DDI-DrugBank.d529.s19.p0"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p8"}
{"sentence": "Tinnitus and decreased hearing have been reported in patients concomitantly receiving Itraconazole and quinidine.", "drug1": "Itraconazole", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s28", "pair_id": "DDI-DrugBank.d165.s28.p0"}
{"sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.", "drug1": "ouabain", "drug2": "droperidol", "relation": "EFFECT", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s2", "pair_id": "DDI-MedLine.d23.s2.p2"}
{"sentence": "Vasospastic reactions have been reported with therapeutic doses of ergotamine-containing drugs when co-administered with these antibiotics.", "drug1": "ergotamine", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s6", "pair_id": "DDI-DrugBank.d410.s6.p0"}
{"sentence": "apomorphine - prior ingestion of diphenidol may decrease the emetic response to apomorphine in the treatment of poisoning.", "drug1": "diphenidol", "drug2": "apomorphine", "relation": "EFFECT", "source_file": "Diphenidol_ddi.xml", "sentence_id": "DDI-DrugBank.d120.s2", "pair_id": "DDI-DrugBank.d120.s2.p4"}
{"sentence": "The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.", "drug1": "tetracycline", "drug2": "Penthrane", "relation": "EFFECT", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s5", "pair_id": "DDI-DrugBank.d500.s5.p0"}
{"sentence": "However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin. ", "drug1": "retinyl acetate", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s6", "pair_id": "DDI-MedLine.d12.s6.p0"}
{"sentence": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).", "drug1": "imatinib", "drug2": "Gleevec", "relation": "NONE", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s0", "pair_id": "DDI-DrugBank.d115.s0.p6"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "cyclosporine", "drug2": "valproate", "relation": "NONE", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p16"}
{"sentence": "As with other cephalosporins, high concentrations of cefotetan may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.", "drug1": "cephalosporins", "drug2": "cefotetan", "relation": "NONE", "source_file": "Cefotetan_ddi.xml", "sentence_id": "DDI-DrugBank.d483.s4", "pair_id": "DDI-DrugBank.d483.s4.p0"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "tubocurarine", "drug2": "Coly-Mycin M", "relation": "EFFECT", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p10"}
{"sentence": "Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.", "drug1": "fluvoxamine", "drug2": "cisapride", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s11", "pair_id": "DDI-DrugBank.d76.s11.p2"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "danazol", "drug2": "diltiazem", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p142"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Kadian", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p33"}
{"sentence": "Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;", "drug1": "oxytocics", "drug2": "dinoprost", "relation": "EFFECT", "source_file": "Dinoprost Tromethamine_ddi.xml", "sentence_id": "DDI-DrugBank.d181.s0", "pair_id": "DDI-DrugBank.d181.s0.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "doxycycline", "drug2": "nortriptyline", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p582"}
{"sentence": "In one survey, 2.3% of patients taking labetalol HCl in combination with tricyclic antidepressants experienced tremor, as compared to 0.7% reported to occur with labetalol HCl alone.", "drug1": "labetalol HCl", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Labetalol_ddi.xml", "sentence_id": "DDI-DrugBank.d412.s0", "pair_id": "DDI-DrugBank.d412.s0.p0"}
{"sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "drug1": "erythromycin", "drug2": "cimetidine", "relation": "NONE", "source_file": "Felodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d316.s1", "pair_id": "DDI-DrugBank.d316.s1.p9"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "MAOI", "drug2": "Tricyclic antidepressants", "relation": "NONE", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p29"}
{"sentence": "SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with SSRIs (e. g.", "drug1": "5-HT1 agonists", "drug2": "SSRIs", "relation": "EFFECT", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s7", "pair_id": "DDI-DrugBank.d410.s7.p2"}
{"sentence": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "drug1": "erythromycin", "drug2": "dihydroergotamine", "relation": "EFFECT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s5", "pair_id": "DDI-DrugBank.d397.s5.p1"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "phenothiazines", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p1"}
{"sentence": "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.", "drug1": "PROLEUKIN", "drug2": "interferon-alfa", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s5", "pair_id": "DDI-DrugBank.d114.s5.p4"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "epinephrine", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Bupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d153.s0", "pair_id": "DDI-DrugBank.d153.s0.p6"}
{"sentence": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.", "drug1": "diclofenac", "drug2": "salicylic acid", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s18", "pair_id": "DDI-DrugBank.d249.s18.p0"}
{"sentence": "Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.", "drug1": "carbamazepine", "drug2": "escitalopram", "relation": "MECHANISM", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s23", "pair_id": "DDI-DrugBank.d568.s23.p5"}
{"sentence": "Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.", "drug1": "Anagrelide", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s8", "pair_id": "DDI-DrugBank.d75.s8.p0"}
{"sentence": "Coadministration of entecavir with lamivudine, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.", "drug1": "entecavir", "drug2": "tenofovir disoproxil fumarate", "relation": "NONE", "source_file": "Entecavir_ddi.xml", "sentence_id": "DDI-DrugBank.d295.s1", "pair_id": "DDI-DrugBank.d295.s1.p2"}
{"sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.", "drug1": "steroids", "drug2": "adrenergic agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s3", "pair_id": "DDI-DrugBank.d284.s3.p13"}
{"sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.", "drug1": "primidone", "drug2": "AEDs", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s12", "pair_id": "DDI-DrugBank.d277.s12.p14"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "clozapine", "drug2": "quinidine", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p7"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "chloral hydrate", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p6"}
{"sentence": "Expected to substantially decrease plasma levels of efavirenz;has not been studied in combination with SUSTIVA.", "drug1": "efavirenz", "drug2": "SUSTIVA", "relation": "NONE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s87", "pair_id": "DDI-DrugBank.d531.s87.p0"}
{"sentence": "Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.", "drug1": "Valproate", "drug2": "valproate", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s7", "pair_id": "DDI-DrugBank.d277.s7.p1"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "vancomycin", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p7"}
{"sentence": "Based on anecdotal reports, there may be an interaction between buprenorphine and benzodiazepines.", "drug1": "buprenorphine", "drug2": "benzodiazepines", "relation": "INT", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s3", "pair_id": "DDI-DrugBank.d380.s3.p0"}
{"sentence": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.", "drug1": "isoniazid", "drug2": "levodopa", "relation": "EFFECT", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s2", "pair_id": "DDI-DrugBank.d47.s2.p14"}
{"sentence": "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination.", "drug1": "calcium channel blockers", "drug2": "organic nitrates", "relation": "EFFECT", "source_file": "Isosorbide Mononitrate_ddi.xml", "sentence_id": "DDI-DrugBank.d479.s2", "pair_id": "DDI-DrugBank.d479.s2.p0"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "PABA", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p8"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "chlorpromazine", "drug2": "antiparkinsonian drug", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p5"}
{"sentence": "Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.", "drug1": "dobutamine", "drug2": "nitroprusside", "relation": "EFFECT", "source_file": "Dobutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d274.s2", "pair_id": "DDI-DrugBank.d274.s2.p0"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "thiazides", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p3"}
{"sentence": "Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.", "drug1": "Quinolones", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s8", "pair_id": "DDI-DrugBank.d562.s8.p1"}
{"sentence": "However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.", "drug1": "digoxin", "drug2": "FLOLAN", "relation": "MECHANISM", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s5", "pair_id": "DDI-DrugBank.d241.s5.p1"}
{"sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "drug1": "famotidine", "drug2": "dasatinib", "relation": "EFFECT", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s11", "pair_id": "DDI-DrugBank.d48.s11.p19"}
{"sentence": "Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.", "drug1": "Aspirin", "drug2": "nonsteroidal anti-inflammatory", "relation": "ADVISE", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s4", "pair_id": "DDI-DrugBank.d443.s4.p2"}
{"sentence": "Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.", "drug1": "teniposide", "drug2": "TAXOL", "relation": "ADVISE", "source_file": "Paclitaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d288.s11", "pair_id": "DDI-DrugBank.d288.s11.p2"}
{"sentence": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ", "drug1": "trovafloxacin", "drug2": "opiate", "relation": "MECHANISM", "source_file": "11210403.xml", "sentence_id": "DDI-MedLine.d124.s1", "pair_id": "DDI-MedLine.d124.s1.p1"}
{"sentence": "Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.", "drug1": "Nonsteroidal anti-inflammatory drugs", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s17", "pair_id": "DDI-DrugBank.d132.s17.p0"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "alosetron", "relation": "ADVISE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p29"}
{"sentence": "In an emergency situation when opioid analgesia must be administered to a patient receiving REVIA, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.", "drug1": "REVIA", "drug2": "opioid", "relation": "EFFECT", "source_file": "Naltrexone_ddi.xml", "sentence_id": "DDI-DrugBank.d346.s5", "pair_id": "DDI-DrugBank.d346.s5.p0"}
{"sentence": "Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.", "drug1": "anakinra", "drug2": "HUMIRA", "relation": "EFFECT", "source_file": "Adalimumab_ddi.xml", "sentence_id": "DDI-DrugBank.d493.s4", "pair_id": "DDI-DrugBank.d493.s4.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "pentoxifylline", "drug2": "sulfinpyrazone", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1323"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "anesthetics", "drug2": "antihistamines", "relation": "NONE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p62"}
{"sentence": "The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).", "drug1": "glipizide", "drug2": "fluconazole", "relation": "MECHANISM", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s13", "pair_id": "DDI-DrugBank.d225.s13.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "naproxen", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p32"}
{"sentence": "INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.", "drug1": "INH", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s25", "pair_id": "DDI-DrugBank.d458.s25.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "warfarin sodium", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p53"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "nalidixic acid", "drug2": "pentoxifylline", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1235"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "thyroid products", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p10"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "barbiturates", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p2"}
{"sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "drug1": "Mefloquine", "drug2": "calcium channel blockers", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s9", "pair_id": "DDI-DrugBank.d220.s9.p2"}
{"sentence": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "drug1": "retinyl acetate", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s7", "pair_id": "DDI-MedLine.d12.s7.p7"}
{"sentence": "Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.", "drug1": "Heparin Sodium", "drug2": "heparin", "relation": "NONE", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s7", "pair_id": "DDI-DrugBank.d488.s7.p4"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "dapsone", "drug2": "ribavirin", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p52"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "clobazam", "drug2": "methadone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p311"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "Acetaminophen", "drug2": "nortriptyline", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p71"}
{"sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "drug1": "propranolol", "drug2": "captopril", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s11", "pair_id": "DDI-DrugBank.d460.s11.p11"}
{"sentence": "Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).", "drug1": "TORADOL", "drug2": "thiothixene", "relation": "EFFECT", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s19", "pair_id": "DDI-DrugBank.d3.s19.p7"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "blood thinner", "drug2": "Tegretol", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p5"}
{"sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "drug1": "prednisone", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s1", "pair_id": "DDI-DrugBank.d431.s1.p50"}
{"sentence": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal antiinflammatory drugs including INDOCIN has been reported.", "drug1": "beta-adrenoceptor blocking agents", "drug2": "INDOCIN", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s33", "pair_id": "DDI-DrugBank.d82.s33.p1"}
{"sentence": "Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.", "drug1": "adenosine", "drug2": "dipyridamole", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s7", "pair_id": "DDI-DrugBank.d226.s7.p0"}
{"sentence": "therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.", "drug1": "anticoagulant", "drug2": "Tagamet", "relation": "ADVISE", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s2", "pair_id": "DDI-DrugBank.d171.s2.p0"}
{"sentence": "Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.", "drug1": "alcohol", "drug2": "vitamin B12", "relation": "MECHANISM", "source_file": "Cyanocobalamin_ddi.xml", "sentence_id": "DDI-DrugBank.d39.s1", "pair_id": "DDI-DrugBank.d39.s1.p5"}
{"sentence": "Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .", "drug1": "warfarin", "drug2": "tolbutamide", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s12", "pair_id": "DDI-DrugBank.d460.s12.p24"}
{"sentence": "Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: sertraline and paroxetine.", "drug1": "alprazolam", "drug2": "paroxetine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s9", "pair_id": "DDI-DrugBank.d131.s9.p4"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "benzodiazepines", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p2"}
{"sentence": "Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.", "drug1": "BREVIBLOC", "drug2": "morphine", "relation": "ADVISE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s10", "pair_id": "DDI-DrugBank.d422.s10.p1"}
{"sentence": "In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant theophylline at study entry.", "drug1": "BROVANA", "drug2": "theophylline", "relation": "NONE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s9", "pair_id": "DDI-DrugBank.d284.s9.p2"}
{"sentence": "Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.", "drug1": "L-glutamine", "drug2": "indomethacin", "relation": "EFFECT", "source_file": "L-Glutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d66.s2", "pair_id": "DDI-DrugBank.d66.s2.p3"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "propoxyphene", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p19"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "anticholinergic", "drug2": "antipsychotics", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p4"}
{"sentence": "Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.", "drug1": "nadolol", "drug2": "timolol", "relation": "NONE", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s5", "pair_id": "DDI-DrugBank.d507.s5.p3"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "lincomycin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p6"}
{"sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "drug1": "doxorubicin", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s2", "pair_id": "DDI-DrugBank.d114.s2.p17"}
{"sentence": "Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.", "drug1": "STRATTERA", "drug2": "paroxetine", "relation": "ADVISE", "source_file": "Atomoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d11.s3", "pair_id": "DDI-DrugBank.d11.s3.p0"}
{"sentence": "The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.", "drug1": "succinylcholine", "drug2": "TRACRIUM", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s9", "pair_id": "DDI-DrugBank.d469.s9.p0"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "quinolone", "drug2": "VIDEX", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p5"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "ritonavir", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p4"}
{"sentence": "Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.", "drug1": "MAO inhibitor", "drug2": "escitalopram", "relation": "ADVISE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s10", "pair_id": "DDI-DrugBank.d482.s10.p0"}
{"sentence": "Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.", "drug1": "PEGANONE", "drug2": "Phenurone", "relation": "ADVISE", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s1", "pair_id": "DDI-DrugBank.d359.s1.p0"}
{"sentence": "There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.", "drug1": "CANCIDAS", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s9", "pair_id": "DDI-DrugBank.d350.s9.p0"}
{"sentence": "When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.", "drug1": "antihypertensive drugs", "drug2": "hydralazine", "relation": "EFFECT", "source_file": "Hydralazine_ddi.xml", "sentence_id": "DDI-DrugBank.d31.s1", "pair_id": "DDI-DrugBank.d31.s1.p1"}
{"sentence": "Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.", "drug1": "theophylline", "drug2": "PEGASYS", "relation": "ADVISE", "source_file": "Peginterferon alfa-2a_ddi.xml", "sentence_id": "DDI-DrugBank.d196.s1", "pair_id": "DDI-DrugBank.d196.s1.p2"}
{"sentence": "The clearance of salicylates may be increased with concurrent use of corticosteroids.", "drug1": "salicylates", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s26", "pair_id": "DDI-DrugBank.d314.s26.p0"}
{"sentence": "Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.", "drug1": "Aminosalicylic acid", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Aminosalicylic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d22.s0", "pair_id": "DDI-DrugBank.d22.s0.p0"}
{"sentence": "Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.", "drug1": "hormonal contraceptives", "drug2": "clofibric acid", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s18", "pair_id": "DDI-DrugBank.d485.s18.p2"}
{"sentence": "Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.", "drug1": "calcium blockers", "drug2": "digitalis preparations", "relation": "MECHANISM", "source_file": "Nicardipine_ddi.xml", "sentence_id": "DDI-DrugBank.d468.s4", "pair_id": "DDI-DrugBank.d468.s4.p2"}
{"sentence": "Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).", "drug1": "ENABLEX", "drug2": "thioridazine", "relation": "ADVISE", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s1", "pair_id": "DDI-DrugBank.d459.s1.p1"}
{"sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "drug1": "ACE inhibitors", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s7", "pair_id": "DDI-DrugBank.d561.s7.p9"}
{"sentence": "Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;", "drug1": "Amphetamines", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s3", "pair_id": "DDI-DrugBank.d158.s3.p7"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "Benzthiazide", "drug2": "blood thinner", "relation": "INT", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p1"}
{"sentence": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "drug1": "phenobarbital", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s28", "pair_id": "DDI-DrugBank.d434.s28.p12"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "morphine", "drug2": "theophylline", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p921"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "alprazolam", "drug2": "cyclosporine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p7"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "aminosalicylic acid", "drug2": "chloral hydrate", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p163"}
{"sentence": "Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.", "drug1": "FACTIVE", "drug2": "progesterone", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s1", "pair_id": "DDI-DrugBank.d347.s1.p4"}
{"sentence": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.", "drug1": "phenytoin", "drug2": "clonazepam", "relation": "NONE", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s5", "pair_id": "DDI-DrugBank.d333.s5.p3"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "selegiline hydrochloride", "drug2": "serotoninergic agents", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p15"}
{"sentence": "Aspirin, warfarin, heparin, NSAIDs", "drug1": "warfarin", "drug2": "heparin", "relation": "NONE", "source_file": "Clopidogrel_ddi.xml", "sentence_id": "DDI-DrugBank.d343.s0", "pair_id": "DDI-DrugBank.d343.s0.p3"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "sodium colistemethate", "drug2": "lithium", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p106"}
{"sentence": "These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.", "drug1": "heparin", "drug2": "calcium channel antagonists", "relation": "NONE", "source_file": "Abciximab_ddi.xml", "sentence_id": "DDI-DrugBank.d532.s2", "pair_id": "DDI-DrugBank.d532.s2.p2"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "dalfopristin", "drug2": "nicotinamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p132"}
{"sentence": "No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials.", "drug1": "muscle relaxants", "drug2": "anesthetic agents", "relation": "NONE", "source_file": "Desflurane_ddi.xml", "sentence_id": "DDI-DrugBank.d363.s0", "pair_id": "DDI-DrugBank.d363.s0.p0"}
{"sentence": "Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.", "drug1": "cyclosporine", "drug2": "carvedilol", "relation": "ADVISE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s10", "pair_id": "DDI-DrugBank.d269.s10.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "quinidine", "drug2": "tacrolimus", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p71"}
{"sentence": "Antacids, Sucralfate, Metal Cations, Multivitamins Quinolones form chelates with alkaline earth and transition metal cations.", "drug1": "Sucralfate", "drug2": "Multivitamins", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s0", "pair_id": "DDI-DrugBank.d78.s0.p3"}
{"sentence": "This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. ", "drug1": "rifampin", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "1115445.xml", "sentence_id": "DDI-MedLine.d116.s5", "pair_id": "DDI-MedLine.d116.s5.p0"}
{"sentence": "Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.", "drug1": "progesterone", "drug2": "Accutane", "relation": "EFFECT", "source_file": "Isotretinoin_ddi.xml", "sentence_id": "DDI-DrugBank.d163.s4", "pair_id": "DDI-DrugBank.d163.s4.p4"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "Butalbital", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p3"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "macrolide antibiotics", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p76"}
{"sentence": "- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.", "drug1": "insulin", "drug2": "Bezalip retard", "relation": "EFFECT", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s3", "pair_id": "DDI-DrugBank.d291.s3.p4"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "antifungals", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p12"}
{"sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.", "drug1": "aminophylline", "drug2": "adrenergic agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s3", "pair_id": "DDI-DrugBank.d284.s3.p8"}
{"sentence": "In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s2", "pair_id": "DDI-DrugBank.d202.s2.p0"}
{"sentence": "Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.", "drug1": "furosemide", "drug2": "furosemide", "relation": "NONE", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s17", "pair_id": "DDI-DrugBank.d231.s17.p2"}
{"sentence": "Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.", "drug1": "azathioprine", "drug2": "allopurinol", "relation": "ADVISE", "source_file": "Azathioprine_ddi.xml", "sentence_id": "DDI-DrugBank.d233.s1", "pair_id": "DDI-DrugBank.d233.s1.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "anticonvulsants", "drug2": "Astramorph", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p275"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "TAO", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p11"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p5"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "aminoglycosides", "drug2": "quinidine", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p53"}
{"sentence": "Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.", "drug1": "diuretic", "drug2": "Methotrexate", "relation": "NONE", "source_file": "Folic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d425.s1", "pair_id": "DDI-DrugBank.d425.s1.p39"}
{"sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "drug1": "Codeine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Codeine_ddi.xml", "sentence_id": "DDI-DrugBank.d464.s0", "pair_id": "DDI-DrugBank.d464.s0.p6"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "vitamin D analogues", "drug2": "Vitamin D2", "relation": "NONE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s0", "pair_id": "DDI-DrugBank.d98.s0.p0"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "zafirlukast", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p75"}
{"sentence": "Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.", "drug1": "phenobarbital", "drug2": "efavirenz", "relation": "MECHANISM", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s5", "pair_id": "DDI-DrugBank.d531.s5.p2"}
{"sentence": "Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.", "drug1": "rifampin", "drug2": "haloperidol", "relation": "ADVISE", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s6", "pair_id": "DDI-DrugBank.d186.s6.p0"}
{"sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.", "drug1": "acetaminophen", "drug2": "hydroxyurea", "relation": "NONE", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s2", "pair_id": "DDI-DrugBank.d75.s2.p16"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "benzodiazepines", "drug2": "psychotropic medications", "relation": "EFFECT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p1"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "drug1": "thiazides", "drug2": "sympathomimetics", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s4", "pair_id": "DDI-DrugBank.d245.s4.p7"}
{"sentence": "Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.", "drug1": "live-attenuated vaccines", "drug2": "RAPTIVA", "relation": "ADVISE", "source_file": "Efalizumab_ddi.xml", "sentence_id": "DDI-DrugBank.d44.s2", "pair_id": "DDI-DrugBank.d44.s2.p5"}
{"sentence": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "drug1": "Probenecid", "drug2": "ketorolac", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s9", "pair_id": "DDI-DrugBank.d3.s9.p3"}
{"sentence": "Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "loop diuretics", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s12", "pair_id": "DDI-DrugBank.d162.s12.p8"}
{"sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "drug1": "procarbazine", "drug2": "Eldepryl", "relation": "NONE", "source_file": "L-Tryptophan_ddi.xml", "sentence_id": "DDI-DrugBank.d63.s0", "pair_id": "DDI-DrugBank.d63.s0.p47"}
{"sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "drug1": "Vitamin D", "drug2": "digitalis", "relation": "ADVISE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s7", "pair_id": "DDI-DrugBank.d98.s7.p2"}
{"sentence": "Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.", "drug1": "Pulmozyme", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Dornase Alfa_ddi.xml", "sentence_id": "DDI-DrugBank.d93.s0", "pair_id": "DDI-DrugBank.d93.s0.p3"}
{"sentence": "Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.", "drug1": "etanercept", "drug2": "anakinra", "relation": "EFFECT", "source_file": "Infliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d45.s0", "pair_id": "DDI-DrugBank.d45.s0.p0"}
{"sentence": "The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed. ", "drug1": "fluvoxamine", "drug2": "phenytoin", "relation": "NONE", "source_file": "11206048.xml", "sentence_id": "DDI-MedLine.d60.s2", "pair_id": "DDI-MedLine.d60.s2.p3"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "paroxetine", "drug2": "metoprolol", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p77"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "haloperidol", "drug2": "primidone", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p243"}
{"sentence": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "drug1": "glucocorticoids", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s7", "pair_id": "DDI-MedLine.d12.s7.p11"}
{"sentence": "Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.", "drug1": "Chlorpromazine", "drug2": "amphetamines", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s16", "pair_id": "DDI-DrugBank.d236.s16.p3"}
{"sentence": "ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.", "drug1": "cerivastatin", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Cerivastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d141.s12", "pair_id": "DDI-DrugBank.d141.s12.p2"}
{"sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "drug1": "indomethacin", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s2", "pair_id": "DDI-DrugBank.d114.s2.p10"}
{"sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.", "drug1": "docetaxel", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Docetaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d371.s1", "pair_id": "DDI-DrugBank.d371.s1.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "warfarin sodium", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p22"}
{"sentence": "- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "drug1": "MAO-inhibitors", "drug2": "Bezalip", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s11", "pair_id": "DDI-DrugBank.d291.s11.p3"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "adrenocortical steroids", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p0"}
{"sentence": "Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.", "drug1": "BETAGAN", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Levobunolol_ddi.xml", "sentence_id": "DDI-DrugBank.d252.s0", "pair_id": "DDI-DrugBank.d252.s0.p2"}
{"sentence": "Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.", "drug1": "tetracyclines", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Demeclocycline_ddi.xml", "sentence_id": "DDI-DrugBank.d409.s2", "pair_id": "DDI-DrugBank.d409.s2.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "ethchlorvynol", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p11"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "levothyroxine", "drug2": "warfarin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p801"}
{"sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "drug1": "Mefloquine", "drug2": "beta-adrenergic blocking agents", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s9", "pair_id": "DDI-DrugBank.d220.s9.p1"}
{"sentence": "Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.", "drug1": "almotriptan", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s10", "pair_id": "DDI-DrugBank.d299.s10.p0"}
{"sentence": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "clarithromycin", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s2", "pair_id": "DDI-DrugBank.d237.s2.p7"}
{"sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "drug1": "propranolol", "drug2": "terfenadine", "relation": "NONE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s1", "pair_id": "DDI-DrugBank.d431.s1.p48"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "azole antifungal agents", "drug2": "diltiazem", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p16"}
{"sentence": "Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..", "drug1": "Sumatriptan", "drug2": "D.H.E. 45", "relation": "ADVISE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s2", "pair_id": "DDI-DrugBank.d410.s2.p0"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "nelfinavir", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p8"}
{"sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "drug1": "H2 blockers", "drug2": "dasatinib", "relation": "EFFECT", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s11", "pair_id": "DDI-DrugBank.d48.s11.p14"}
{"sentence": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "drug1": "indinavir", "drug2": "SUBUTEX", "relation": "NONE", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s2", "pair_id": "DDI-DrugBank.d380.s2.p31"}
{"sentence": "Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.", "drug1": "carvedilol", "drug2": "cyclosporine", "relation": "ADVISE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s10", "pair_id": "DDI-DrugBank.d269.s10.p2"}
{"sentence": "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.", "drug1": "ALFENTA", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Alfentanil_ddi.xml", "sentence_id": "DDI-DrugBank.d8.s0", "pair_id": "DDI-DrugBank.d8.s0.p1"}
{"sentence": "Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.", "drug1": "amiodarone", "drug2": "protease inhibitor", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s13", "pair_id": "DDI-DrugBank.d143.s13.p1"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "Lorazepam", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p3"}
{"sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "drug1": "captopril", "drug2": "pravastatin", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s11", "pair_id": "DDI-DrugBank.d460.s11.p22"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "benzodiazepines", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p6"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "phenylbutazone", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p13"}
{"sentence": "Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.", "drug1": "Haloperidol", "drug2": "amphetamines", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s14", "pair_id": "DDI-DrugBank.d158.s14.p2"}
{"sentence": "In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.", "drug1": "serotonin reuptake inhibitor drug", "drug2": "MAOI", "relation": "EFFECT", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s1", "pair_id": "DDI-DrugBank.d76.s1.p1"}
{"sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.", "drug1": "IOPIDINE", "drug2": "opiates", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s1", "pair_id": "DDI-DrugBank.d224.s1.p3"}
{"sentence": "A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.", "drug1": "hydantoin antiepileptic", "drug2": "coumarin anticoagulant", "relation": "INT", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s2", "pair_id": "DDI-DrugBank.d359.s2.p1"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "decamethonium", "drug2": "Coly-Mycin M", "relation": "EFFECT", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p19"}
{"sentence": "Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.", "drug1": "Geocillin", "drug2": "carbenicillin indanyl sodium", "relation": "NONE", "source_file": "Carbenicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d545.s0", "pair_id": "DDI-DrugBank.d545.s0.p0"}
{"sentence": "There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.", "drug1": "trazodone hydrochloride", "drug2": "buspirone HCl", "relation": "EFFECT", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s1", "pair_id": "DDI-DrugBank.d463.s1.p1"}
{"sentence": "In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.", "drug1": "CASODEX", "drug2": "coumarin anticoagulant", "relation": "MECHANISM", "source_file": "Bicalutamide_ddi.xml", "sentence_id": "DDI-DrugBank.d266.s0", "pair_id": "DDI-DrugBank.d266.s0.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "carbamazepine", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p39"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "mirtazapine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p26"}
{"sentence": "It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.", "drug1": "anticoagulants", "drug2": "lovastatin", "relation": "ADVISE", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s16", "pair_id": "DDI-DrugBank.d567.s16.p0"}
{"sentence": "Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.", "drug1": "INAPSINE", "drug2": "CNS depressant drugs", "relation": "ADVISE", "source_file": "Droperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d254.s2", "pair_id": "DDI-DrugBank.d254.s2.p0"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "AKINETON", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p15"}
{"sentence": "Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.", "drug1": "atorvastatin", "drug2": "atorvastatin", "relation": "NONE", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s1", "pair_id": "DDI-DrugBank.d140.s1.p4"}
{"sentence": "Specific Effects of Felbatol  on Other Antiepileptic Drugs Phenytoin: Felbatol  causes an increase in steady-state phenytoin plasma concentrations.", "drug1": "Felbatol", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s11", "pair_id": "DDI-DrugBank.d434.s11.p9"}
{"sentence": "Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.", "drug1": "theophylline", "drug2": "enoxacin", "relation": "EFFECT", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s22", "pair_id": "DDI-DrugBank.d395.s22.p2"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "diazepam", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p329"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Serentil", "drug2": "prochlorperazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p166"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "amitriptyline", "relation": "NONE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p21"}
{"sentence": "astemizole, bepridil, sparfloxacin, and terodiline.", "drug1": "astemizole", "drug2": "terodiline", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s18", "pair_id": "DDI-DrugBank.d237.s18.p2"}
{"sentence": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "drug1": "Erythromycin", "drug2": "felbamate", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s36", "pair_id": "DDI-DrugBank.d434.s36.p2"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "rifampin", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p8"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e. g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "selective serotonin reuptake inhibitors", "drug2": "paroxetine", "relation": "NONE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s15", "pair_id": "DDI-DrugBank.d77.s15.p3"}
{"sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "drug1": "beta-adrenergic blocking agents", "drug2": "metoprolol", "relation": "NONE", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s4", "pair_id": "DDI-DrugBank.d325.s4.p4"}
{"sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "drug1": "HALDOL", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s3", "pair_id": "DDI-DrugBank.d186.s3.p5"}
{"sentence": "Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. ", "drug1": "nevirapine", "drug2": "indinavir", "relation": "NONE", "source_file": "11217868.xml", "sentence_id": "DDI-MedLine.d132.s4", "pair_id": "DDI-MedLine.d132.s4.p6"}
{"sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "drug1": "Proton Pump Inhibitors", "drug2": "H2 blockers", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s11", "pair_id": "DDI-DrugBank.d48.s11.p6"}
{"sentence": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "drug1": "NSAIDs", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s9", "pair_id": "DDI-DrugBank.d400.s9.p3"}
{"sentence": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "drug1": "clozapine", "drug2": "psychotropic drug", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s8", "pair_id": "DDI-DrugBank.d480.s8.p13"}
{"sentence": "Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.", "drug1": "Epinephrine", "drug2": "glycosides", "relation": "ADVISE", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s7", "pair_id": "DDI-DrugBank.d247.s7.p1"}
{"sentence": "In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.", "drug1": "androgens", "drug2": "insulin", "relation": "EFFECT", "source_file": "Fluoxymesterone_ddi.xml", "sentence_id": "DDI-DrugBank.d355.s3", "pair_id": "DDI-DrugBank.d355.s3.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Trileptal", "drug2": "morphine", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p416"}
{"sentence": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "drug1": "nitrous oxide", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s6", "pair_id": "DDI-DrugBank.d60.s6.p10"}
{"sentence": "Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.", "drug1": "adrenaline", "drug2": "FLUOTHANE", "relation": "ADVISE", "source_file": "Halothane_ddi.xml", "sentence_id": "DDI-DrugBank.d74.s2", "pair_id": "DDI-DrugBank.d74.s2.p0"}
{"sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "drug1": "ZYVOX", "drug2": "SSRIs", "relation": "EFFECT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s6", "pair_id": "DDI-DrugBank.d441.s6.p3"}
{"sentence": "Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.", "drug1": "Clozapine", "drug2": "atropine", "relation": "EFFECT", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s9", "pair_id": "DDI-DrugBank.d480.s9.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "dicumarol", "drug2": "olanzapine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p553"}
{"sentence": "The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.", "drug1": "mecamylamine", "drug2": "sympathomimetics", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s3", "pair_id": "DDI-DrugBank.d448.s3.p6"}
{"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "drug1": "Abciximab", "drug2": "Activase", "relation": "EFFECT", "source_file": "Alteplase_ddi.xml", "sentence_id": "DDI-DrugBank.d508.s1", "pair_id": "DDI-DrugBank.d508.s1.p14"}
{"sentence": "The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and levothyroxine sodium.", "drug1": "phenobarbital", "drug2": "levothyroxine sodium", "relation": "NONE", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s7", "pair_id": "DDI-DrugBank.d463.s7.p4"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "antiretroviral nucleoside analogues", "drug2": "nitrofurantoin", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p11"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "celecoxib", "drug2": "ramipril", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p46"}
{"sentence": "Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.", "drug1": "succinylcholine", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s3", "pair_id": "DDI-DrugBank.d60.s3.p3"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "contraceptives", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p29"}
{"sentence": "Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.", "drug1": "benzodiazepines", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s0", "pair_id": "DDI-DrugBank.d18.s0.p2"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "tricyclic antidepressants", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p6"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "ampicillin", "drug2": "Invirase", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p193"}
{"sentence": "Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. ", "drug1": "Cytochalasin D", "drug2": "carbachol", "relation": "EFFECT", "source_file": "11121387.xml", "sentence_id": "DDI-MedLine.d59.s5", "pair_id": "DDI-MedLine.d59.s5.p0"}
{"sentence": "Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices.", "drug1": "NSAIDs", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s1", "pair_id": "DDI-DrugBank.d400.s1.p2"}
{"sentence": "In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.", "drug1": "PCP", "drug2": "PCP", "relation": "NONE", "source_file": "11085328.xml", "sentence_id": "DDI-MedLine.d104.s8", "pair_id": "DDI-MedLine.d104.s8.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "sodium colistemethate", "drug2": "anesthetics", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p107"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "citalopram", "drug2": "fluoxetine", "relation": "NONE", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s8", "pair_id": "DDI-DrugBank.d223.s8.p12"}
{"sentence": "In some patients, the administration of INDOCIN can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics.", "drug1": "INDOCIN", "drug2": "potassium-sparing diuretics", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s23", "pair_id": "DDI-DrugBank.d82.s23.p1"}
{"sentence": "Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.", "drug1": "beta-blocker", "drug2": "reserpine", "relation": "ADVISE", "source_file": "Levobunolol_ddi.xml", "sentence_id": "DDI-DrugBank.d252.s1", "pair_id": "DDI-DrugBank.d252.s1.p0"}
{"sentence": "Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.", "drug1": "Netilmicin", "drug2": "loop diuretics", "relation": "ADVISE", "source_file": "Netilmicin_ddi.xml", "sentence_id": "DDI-DrugBank.d417.s0", "pair_id": "DDI-DrugBank.d417.s0.p0"}
{"sentence": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.", "drug1": "itraconazole", "drug2": "gefitinib", "relation": "MECHANISM", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s4", "pair_id": "DDI-DrugBank.d207.s4.p3"}
{"sentence": "poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .", "drug1": "quinidine", "drug2": "carvedilol", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s1", "pair_id": "DDI-DrugBank.d269.s1.p14"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "levothyroxine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p22"}
{"sentence": "MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics", "drug1": "MAOI", "drug2": "opioid analgesics", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s7", "pair_id": "DDI-DrugBank.d170.s7.p8"}
{"sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.", "drug1": "Anticoagulants", "drug2": "platelet aggregation inhibitors", "relation": "NONE", "source_file": "Ardeparin_ddi.xml", "sentence_id": "DDI-DrugBank.d105.s0", "pair_id": "DDI-DrugBank.d105.s0.p0"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "benzodiazepines", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p4"}
{"sentence": "Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.", "drug1": "phenothiazines", "drug2": "dopamine", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s7", "pair_id": "DDI-DrugBank.d325.s7.p5"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "corticosteroids", "drug2": "dantrolene", "relation": "NONE", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p65"}
{"sentence": "Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.", "drug1": "corticosteroid", "drug2": "inactivated vaccines", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s30", "pair_id": "DDI-DrugBank.d314.s30.p4"}
{"sentence": "Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.", "drug1": "amprenavir", "drug2": "methadone", "relation": "EFFECT", "source_file": "Amprenavir_ddi.xml", "sentence_id": "DDI-DrugBank.d437.s9", "pair_id": "DDI-DrugBank.d437.s9.p3"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "sympathomimetic agents", "drug2": "progestogens", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p58"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p11"}
{"sentence": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.", "drug1": "escitalopram", "drug2": "Celexa", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s39", "pair_id": "DDI-DrugBank.d568.s39.p8"}
{"sentence": "In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.", "drug1": "Angiomax", "drug2": "thrombolytics", "relation": "EFFECT", "source_file": "Bivalirudin_ddi.xml", "sentence_id": "DDI-DrugBank.d569.s1", "pair_id": "DDI-DrugBank.d569.s1.p2"}
{"sentence": "If rifampicin therapy is required, isradipine concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of isradipine.", "drug1": "rifampicin", "drug2": "isradipine", "relation": "MECHANISM", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s10", "pair_id": "DDI-DrugBank.d81.s10.p0"}
{"sentence": "Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.", "drug1": "atorvastatin", "drug2": "erythromycin", "relation": "NONE", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s9", "pair_id": "DDI-DrugBank.d140.s9.p4"}
{"sentence": "In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.", "drug1": "efavirenz", "drug2": "CANCIDAS", "relation": "MECHANISM", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s12", "pair_id": "DDI-DrugBank.d350.s12.p4"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "haloperidol", "drug2": "contraceptives", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p719"}
{"sentence": "Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.", "drug1": "Isoflurane", "drug2": "nondepolarizing muscle relaxants", "relation": "EFFECT", "source_file": "Isoflurane_ddi.xml", "sentence_id": "DDI-DrugBank.d227.s0", "pair_id": "DDI-DrugBank.d227.s0.p1"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "Dexbrompheniramine", "drug2": "alcohol", "relation": "INT", "source_file": "Dexbrompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d62.s0", "pair_id": "DDI-DrugBank.d62.s0.p0"}
{"sentence": "Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ", "drug1": "Sildenafil", "drug2": "long-acting nitrates", "relation": "ADVISE", "source_file": "11213561.xml", "sentence_id": "DDI-MedLine.d1.s5", "pair_id": "DDI-MedLine.d1.s5.p0"}
{"sentence": "Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.", "drug1": "Netilmicin", "drug2": "furosemide", "relation": "ADVISE", "source_file": "Netilmicin_ddi.xml", "sentence_id": "DDI-DrugBank.d417.s0", "pair_id": "DDI-DrugBank.d417.s0.p1"}
{"sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. ", "drug1": "magnesium", "drug2": "magnesium", "relation": "NONE", "source_file": "7786695.xml", "sentence_id": "DDI-MedLine.d103.s1", "pair_id": "DDI-MedLine.d103.s1.p9"}
{"sentence": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.", "drug1": "doxazosin", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Doxazosin_ddi.xml", "sentence_id": "DDI-DrugBank.d367.s4", "pair_id": "DDI-DrugBank.d367.s4.p0"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "antidepressants", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p0"}
{"sentence": "Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.", "drug1": "ketoconazole", "drug2": "VIDEX", "relation": "ADVISE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s5", "pair_id": "DDI-DrugBank.d43.s5.p1"}
{"sentence": "Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "drug1": "erythromycin", "drug2": "ergotamine", "relation": "EFFECT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s5", "pair_id": "DDI-DrugBank.d397.s5.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p13"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "indomethacin", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p22"}
{"sentence": "Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.", "drug1": "Sonata", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s29", "pair_id": "DDI-DrugBank.d324.s29.p0"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "salicylate", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p1"}
{"sentence": "For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters", "drug1": "anticoagulant", "drug2": "Bezalip", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s1", "pair_id": "DDI-DrugBank.d291.s1.p0"}
{"sentence": "Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "drug1": "nonsteroial anti-inflammatory drugs", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s18", "pair_id": "DDI-DrugBank.d132.s18.p3"}
{"sentence": "Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.", "drug1": "Antizol", "drug2": "ethanol", "relation": "MECHANISM", "source_file": "Fomepizole_ddi.xml", "sentence_id": "DDI-DrugBank.d228.s0", "pair_id": "DDI-DrugBank.d228.s0.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "ranitidine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p43"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "drug1": "thiazides", "drug2": "phenothiazines", "relation": "NONE", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s1", "pair_id": "DDI-DrugBank.d536.s1.p2"}
{"sentence": "The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.", "drug1": "potassium-sparing antihypertensives", "drug2": "NSAIDs", "relation": "EFFECT", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s11", "pair_id": "DDI-DrugBank.d20.s11.p0"}
{"sentence": "Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.", "drug1": "Digitalis", "drug2": "Bretylium Tosylate", "relation": "EFFECT", "source_file": "Bretylium_ddi.xml", "sentence_id": "DDI-DrugBank.d180.s0", "pair_id": "DDI-DrugBank.d180.s0.p0"}
{"sentence": "The risk of a potential interaction between NovoSeven and coagulation factor concentrates has not been adequately evaluated in preclinical or clinical studies.", "drug1": "NovoSeven", "drug2": "coagulation factor", "relation": "NONE", "source_file": "Coagulation factor VIIa_ddi.xml", "sentence_id": "DDI-DrugBank.d221.s0", "pair_id": "DDI-DrugBank.d221.s0.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "vitamin K", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p9"}
{"sentence": "Selegiline: Combination hormonal contraceptives may increase the serum concentration of selegiline.", "drug1": "Combination hormonal contraceptives", "drug2": "selegiline", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s39", "pair_id": "DDI-DrugBank.d485.s39.p2"}
{"sentence": "METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. ", "drug1": "everolimus", "drug2": "prednisone", "relation": "NONE", "source_file": "11180038.xml", "sentence_id": "DDI-MedLine.d140.s2", "pair_id": "DDI-MedLine.d140.s2.p1"}
{"sentence": "Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.", "drug1": "INDOCIN", "drug2": "digoxin", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s22", "pair_id": "DDI-DrugBank.d82.s22.p0"}
{"sentence": "Diuretics: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.", "drug1": "Diuretics", "drug2": "diuretics", "relation": "NONE", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s0", "pair_id": "DDI-DrugBank.d176.s0.p0"}
{"sentence": "Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.", "drug1": "tetracyclines", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Ampicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d211.s2", "pair_id": "DDI-DrugBank.d211.s2.p14"}
{"sentence": "Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. ", "drug1": "Etofibrate", "drug2": "heparin", "relation": "EFFECT", "source_file": "11166779.xml", "sentence_id": "DDI-MedLine.d44.s6", "pair_id": "DDI-MedLine.d44.s6.p0"}
{"sentence": "It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.", "drug1": "ethambutol", "drug2": "antacids", "relation": "NONE", "source_file": "Ethambutol_ddi.xml", "sentence_id": "DDI-DrugBank.d160.s1", "pair_id": "DDI-DrugBank.d160.s1.p1"}
{"sentence": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "drug1": "NaFlu", "drug2": "insulin", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s1", "pair_id": "DDI-MedLine.d76.s1.p26"}
{"sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "drug1": "eplerenone", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s3", "pair_id": "DDI-DrugBank.d20.s3.p2"}
{"sentence": "Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ", "drug1": "estradiol", "drug2": "noradrenaline", "relation": "EFFECT", "source_file": "11213358.xml", "sentence_id": "DDI-MedLine.d102.s5", "pair_id": "DDI-MedLine.d102.s5.p0"}
{"sentence": "The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.", "drug1": "midazolam", "drug2": "Aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s23", "pair_id": "DDI-DrugBank.d382.s23.p3"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "adrenocortical steroids", "drug2": "ethchlorvynol", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p33"}
{"sentence": "Antineoplastic agents (e. g., nitrogen mustard, etc.) should be given concomitantly only with great caution.", "drug1": "Antineoplastic agents", "drug2": "nitrogen mustard", "relation": "NONE", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s1", "pair_id": "DDI-DrugBank.d318.s1.p0"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "antidepressants", "drug2": "Type 1C antiarrhythmics", "relation": "NONE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p16"}
{"sentence": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.", "drug1": "ketoconazole", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s2", "pair_id": "DDI-DrugBank.d487.s2.p2"}
{"sentence": "Upon administration of 10 mg of Vardenafil with 800 mg TID indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.", "drug1": "Vardenafil", "drug2": "indinavir", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s37", "pair_id": "DDI-DrugBank.d198.s37.p0"}
{"sentence": "HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.", "drug1": "TRICOR", "drug2": "HMG-CoA reductase inhibitors", "relation": "ADVISE", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s3", "pair_id": "DDI-DrugBank.d283.s3.p2"}
{"sentence": "Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.", "drug1": "vitamin D analogues", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s11", "pair_id": "DDI-DrugBank.d384.s11.p2"}
{"sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "drug1": "valproic acid", "drug2": "phenobarbital", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s5", "pair_id": "DDI-MedLine.d111.s5.p75"}
{"sentence": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.", "drug1": "allopurinol", "drug2": "chlorpropamide", "relation": "MECHANISM", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s20", "pair_id": "DDI-DrugBank.d413.s20.p9"}
{"sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.", "drug1": "digitalis preparations", "drug2": "morphine", "relation": "NONE", "source_file": "Dobutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d274.s3", "pair_id": "DDI-DrugBank.d274.s3.p18"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "diltiazem", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p61"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "barbiturates", "drug2": "CMI", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p19"}
{"sentence": "Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.", "drug1": "quinolones", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s14", "pair_id": "DDI-DrugBank.d562.s14.p2"}
{"sentence": "Lymphocytopenia has been reported in patients receiving CAMPTOSAR, and it is possible that the administration of dexamethasone as antiemetic prophylaxis may have enhanced the likelihood of this effect.", "drug1": "CAMPTOSAR", "drug2": "dexamethasone", "relation": "EFFECT", "source_file": "Irinotecan_ddi.xml", "sentence_id": "DDI-DrugBank.d279.s3", "pair_id": "DDI-DrugBank.d279.s3.p0"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "granisetron", "relation": "ADVISE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p26"}
{"sentence": "Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.", "drug1": "Probenecid", "drug2": "ciprofloxacin", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s15", "pair_id": "DDI-DrugBank.d123.s15.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Atromid-S", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p19"}
{"sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "drug1": "barbiturates", "drug2": "barbiturates", "relation": "NONE", "source_file": "Butabarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d184.s0", "pair_id": "DDI-DrugBank.d184.s0.p68"}
{"sentence": "Long Acting Nitrates: Nifedipine may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.", "drug1": "Nitrates", "drug2": "nitrates", "relation": "NONE", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s1", "pair_id": "DDI-DrugBank.d373.s1.p1"}
{"sentence": "Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.", "drug1": "Antihistamines", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s0", "pair_id": "DDI-DrugBank.d389.s0.p1"}
{"sentence": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.", "drug1": "nonsteroidal anti-inflammatory agents", "drug2": "coumarin-type anticoagulants", "relation": "EFFECT", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s1", "pair_id": "DDI-DrugBank.d415.s1.p4"}
{"sentence": "Treatment with entacapone coadministered with levodopa/dopa decarboxylase inhibitor does not change these effects.", "drug1": "entacapone", "drug2": "levodopa", "relation": "NONE", "source_file": "Entacapone_ddi.xml", "sentence_id": "DDI-DrugBank.d455.s6", "pair_id": "DDI-DrugBank.d455.s6.p0"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "glucocorticoids", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p8"}
{"sentence": "Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.", "drug1": "Azlocillin", "drug2": "amikacin", "relation": "ADVISE", "source_file": "Azlocillin_ddi.xml", "sentence_id": "DDI-DrugBank.d9.s0", "pair_id": "DDI-DrugBank.d9.s0.p0"}
{"sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.", "drug1": "IOPIDINE", "drug2": "CNS depressants", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s1", "pair_id": "DDI-DrugBank.d224.s1.p0"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "enflurane", "drug2": "aminoglycosides", "relation": "NONE", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p13"}
{"sentence": "Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.", "drug1": "retinyl acetate", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s0", "pair_id": "DDI-MedLine.d12.s0.p3"}
{"sentence": "Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.", "drug1": "Sumatriptan", "drug2": "selective serotonin reuptake inhibitor", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s16", "pair_id": "DDI-DrugBank.d568.s16.p0"}
{"sentence": "Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.", "drug1": "TRACLEER", "drug2": "glyburide", "relation": "ADVISE", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s18", "pair_id": "DDI-DrugBank.d289.s18.p0"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "multivitamins", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p9"}
{"sentence": "Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.", "drug1": "Quinolones", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s5", "pair_id": "DDI-DrugBank.d427.s5.p2"}
{"sentence": "Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.", "drug1": "Heparin", "drug2": "heparin", "relation": "NONE", "source_file": "Argatroban_ddi.xml", "sentence_id": "DDI-DrugBank.d148.s0", "pair_id": "DDI-DrugBank.d148.s0.p3"}
{"sentence": "Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.", "drug1": "iodine", "drug2": "Carbimazole", "relation": "NONE", "source_file": "Carbimazole_ddi.xml", "sentence_id": "DDI-DrugBank.d213.s0", "pair_id": "DDI-DrugBank.d213.s0.p6"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "corticosteroids", "drug2": "salbutamol", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p5"}
{"sentence": "Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.", "drug1": "ketoconazole", "drug2": "cisapride", "relation": "EFFECT", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s8", "pair_id": "DDI-DrugBank.d165.s8.p0"}
{"sentence": "The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ", "drug1": "ruthenium red", "drug2": "InsP(3)", "relation": "NONE", "source_file": "11137703.xml", "sentence_id": "DDI-MedLine.d114.s1", "pair_id": "DDI-MedLine.d114.s1.p2"}
{"sentence": "Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.", "drug1": "clonidine", "drug2": "agents with b-blocking properties", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s4", "pair_id": "DDI-DrugBank.d269.s4.p2"}
{"sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "drug1": "belladonna alkaloids", "drug2": "cisapride", "relation": "EFFECT", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s3", "pair_id": "DDI-DrugBank.d237.s3.p8"}
{"sentence": "The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate.", "drug1": "nitrofurantoin", "drug2": "magnesium trisilicate", "relation": "MECHANISM", "source_file": "Nitrofurantoin_ddi.xml", "sentence_id": "DDI-DrugBank.d276.s1", "pair_id": "DDI-DrugBank.d276.s1.p0"}
{"sentence": "Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.", "drug1": "Auranofin", "drug2": "Cuprimine", "relation": "ADVISE", "source_file": "Auranofin_ddi.xml", "sentence_id": "DDI-DrugBank.d374.s1", "pair_id": "DDI-DrugBank.d374.s1.p2"}
{"sentence": "Anticoagulants, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.", "drug1": "corticosteroids", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s6", "pair_id": "DDI-DrugBank.d314.s6.p3"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "amiodarone", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p48"}
{"sentence": "Warfarin: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.", "drug1": "celecoxib", "drug2": "warfarin", "relation": "NONE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s22", "pair_id": "DDI-DrugBank.d172.s22.p3"}
{"sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "drug1": "fexofenadine hydrochloride", "drug2": "antacid", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s19", "pair_id": "DDI-DrugBank.d466.s19.p8"}
{"sentence": "Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.", "drug1": "phenothiazines", "drug2": "levodopa", "relation": "EFFECT", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s2", "pair_id": "DDI-DrugBank.d47.s2.p8"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "VIDEX", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p14"}
{"sentence": "Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.", "drug1": "NSAIDs", "drug2": "lithium", "relation": "EFFECT", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s18", "pair_id": "DDI-DrugBank.d219.s18.p0"}
{"sentence": "Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.", "drug1": "Chloramphenicol", "drug2": "beta-lactam antibiotics", "relation": "EFFECT", "source_file": "Ceftazidime_ddi.xml", "sentence_id": "DDI-DrugBank.d122.s3", "pair_id": "DDI-DrugBank.d122.s3.p0"}
{"sentence": "Close supervision and careful adjustment of dosage are required when Anafranil is administered with anticholinergic or sympathomimetic drugs.", "drug1": "Anafranil", "drug2": "sympathomimetic drugs", "relation": "ADVISE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s3", "pair_id": "DDI-DrugBank.d238.s3.p1"}
{"sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "drug1": "H2 Blockers", "drug2": "famotidine", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s11", "pair_id": "DDI-DrugBank.d48.s11.p3"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;", "drug1": "TRACRIUM", "drug2": "enflurane", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s0", "pair_id": "DDI-DrugBank.d469.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "haloperidol", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p19"}
{"sentence": "The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.", "drug1": "benzodiazepines", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s8", "pair_id": "DDI-DrugBank.d338.s8.p1"}
{"sentence": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "drug1": "Amitriptyline", "drug2": "barbiturates", "relation": "NONE", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s2", "pair_id": "DDI-DrugBank.d495.s2.p3"}
{"sentence": "Therefore, concurrent use of aspirin and ketoprofen is not recommended.", "drug1": "aspirin", "drug2": "ketoprofen", "relation": "ADVISE", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s8", "pair_id": "DDI-DrugBank.d499.s8.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "protease inhibitors", "drug2": "risperidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p970"}
{"sentence": "Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination.", "drug1": "carbamazepine", "drug2": "flecainide", "relation": "MECHANISM", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s13", "pair_id": "DDI-DrugBank.d87.s13.p5"}
{"sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "drug1": "cefdinir", "drug2": "iron", "relation": "MECHANISM", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s5", "pair_id": "DDI-DrugBank.d420.s5.p14"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "calcium channel blockers", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p15"}
{"sentence": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "drug1": "diclofenac", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s5", "pair_id": "DDI-DrugBank.d249.s5.p4"}
{"sentence": "Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.", "drug1": "antacids", "drug2": "diflunisal", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s9", "pair_id": "DDI-DrugBank.d132.s9.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "lithium", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p11"}
{"sentence": "Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.", "drug1": "levamisole", "drug2": "warfarin sodium", "relation": "ADVISE", "source_file": "Levamisole_ddi.xml", "sentence_id": "DDI-DrugBank.d381.s2", "pair_id": "DDI-DrugBank.d381.s2.p0"}
{"sentence": "The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ", "drug1": "ketamine", "drug2": "halothane", "relation": "MECHANISM", "source_file": "1115367.xml", "sentence_id": "DDI-MedLine.d16.s5", "pair_id": "DDI-MedLine.d16.s5.p0"}
{"sentence": "Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.", "drug1": "cimetidine", "drug2": "IRESSA", "relation": "MECHANISM", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s7", "pair_id": "DDI-DrugBank.d207.s7.p5"}
{"sentence": "Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.", "drug1": "Vardenafil", "drug2": "alpha-blocker", "relation": "ADVISE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s35", "pair_id": "DDI-DrugBank.d198.s35.p0"}
{"sentence": "Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.", "drug1": "phenytoin", "drug2": "aminopyrine", "relation": "NONE", "source_file": "Famotidine_ddi.xml", "sentence_id": "DDI-DrugBank.d203.s2", "pair_id": "DDI-DrugBank.d203.s2.p10"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "flecainide", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p15"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "succinimides", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p17"}
{"sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "drug1": "hormonal contraceptives", "drug2": "chlordiazepoxide", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s17", "pair_id": "DDI-DrugBank.d485.s17.p10"}
{"sentence": "Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.", "drug1": "chloroquine", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s16", "pair_id": "DDI-DrugBank.d94.s16.p4"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "Phenytoin", "drug2": "triazolam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p952"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "mefenamic acid", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p10"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "5-fluorouracil", "drug2": "glucocorticoids", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p99"}
{"sentence": "The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.", "drug1": "guanfacine", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s1", "pair_id": "DDI-DrugBank.d507.s1.p1"}
{"sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "fluvoxamine", "drug2": "paroxetine", "relation": "NONE", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s3", "pair_id": "DDI-DrugBank.d426.s3.p15"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "carbamazepine", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p12"}
{"sentence": "When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.", "drug1": "antihypertensive drugs", "drug2": "diazoxide", "relation": "EFFECT", "source_file": "Hydralazine_ddi.xml", "sentence_id": "DDI-DrugBank.d31.s1", "pair_id": "DDI-DrugBank.d31.s1.p0"}
{"sentence": "The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.", "drug1": "proton pump inhibitors", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s12", "pair_id": "DDI-DrugBank.d48.s12.p2"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "drug1": "corticosteroids", "drug2": "sympathomimetics", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s4", "pair_id": "DDI-DrugBank.d245.s4.p24"}
{"sentence": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.", "drug1": "prednisolone", "drug2": "warfarin", "relation": "NONE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s18", "pair_id": "DDI-DrugBank.d249.s18.p9"}
{"sentence": "As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY", "drug1": "alcohol", "drug2": "ABILIFY", "relation": "ADVISE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s28", "pair_id": "DDI-DrugBank.d509.s28.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ibuprofen", "drug2": "quinidine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p976"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "didanosine", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p44"}
{"sentence": "Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ", "drug1": "naloxone", "drug2": "morphine", "relation": "EFFECT", "source_file": "3155550.xml", "sentence_id": "DDI-MedLine.d63.s6", "pair_id": "DDI-MedLine.d63.s6.p1"}
{"sentence": "Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.", "drug1": "eprosartan", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Eprosartan_ddi.xml", "sentence_id": "DDI-DrugBank.d525.s2", "pair_id": "DDI-DrugBank.d525.s2.p0"}
{"sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "drug1": "magnesium hydroxide", "drug2": "fosinopril", "relation": "MECHANISM", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s9", "pair_id": "DDI-DrugBank.d176.s9.p25"}
{"sentence": "A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.", "drug1": "NovoLog", "drug2": "NPH human insulin", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s7", "pair_id": "DDI-DrugBank.d313.s7.p0"}
{"sentence": "ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.", "drug1": "NSAIDs", "drug2": "ACE-inhibitors", "relation": "EFFECT", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s0", "pair_id": "DDI-DrugBank.d219.s0.p2"}
{"sentence": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.", "drug1": "colestipol hydrochloride", "drug2": "digitoxin", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s14", "pair_id": "DDI-DrugBank.d345.s14.p4"}
{"sentence": "The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. ", "drug1": "non-nucleoside reverse transcriptase inhibitor", "drug2": "protease inhibitor", "relation": "NONE", "source_file": "11217868.xml", "sentence_id": "DDI-MedLine.d132.s1", "pair_id": "DDI-MedLine.d132.s1.p2"}
{"sentence": "A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.", "drug1": "diclofenac", "drug2": "hypoglycemic agents", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s13", "pair_id": "DDI-DrugBank.d249.s13.p1"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "ergot derivatives", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p114"}
{"sentence": "Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.", "drug1": "lithium", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s18", "pair_id": "DDI-DrugBank.d334.s18.p5"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "itraconazole", "drug2": "zonisamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p758"}
{"sentence": "Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.", "drug1": "Panretin", "drug2": "DEET", "relation": "ADVISE", "source_file": "Alitretinoin_ddi.xml", "sentence_id": "DDI-DrugBank.d392.s0", "pair_id": "DDI-DrugBank.d392.s0.p0"}
{"sentence": "Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.", "drug1": "calcium channel blockers", "drug2": "digoxin", "relation": "EFFECT", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s12", "pair_id": "DDI-DrugBank.d450.s12.p2"}
{"sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "drug1": "SSRI", "drug2": "TCA", "relation": "INT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s11", "pair_id": "DDI-DrugBank.d386.s11.p0"}
{"sentence": "Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "drug1": "Digitalis", "drug2": "digoxin", "relation": "NONE", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s2", "pair_id": "DDI-DrugBank.d373.s2.p3"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "zinc", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p8"}
{"sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "drug1": "acetaminophen", "drug2": "valproic acid", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s5", "pair_id": "DDI-MedLine.d111.s5.p61"}
{"sentence": "Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).", "drug1": "OCs", "drug2": "macrolide antibiotics", "relation": "NONE", "source_file": "Adinazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d449.s2", "pair_id": "DDI-DrugBank.d449.s2.p6"}
{"sentence": "The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed", "drug1": "TRICOR", "drug2": "immunosuppressants", "relation": "ADVISE", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s6", "pair_id": "DDI-DrugBank.d283.s6.p0"}
{"sentence": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "carbamazepine", "drug2": "Felbatol", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s31", "pair_id": "DDI-DrugBank.d434.s31.p12"}
{"sentence": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "drug1": "cyclosporin A", "drug2": "etoposide", "relation": "MECHANISM", "source_file": "Etoposide_ddi.xml", "sentence_id": "DDI-DrugBank.d194.s1", "pair_id": "DDI-DrugBank.d194.s1.p0"}
{"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Hexobarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d457.s0", "pair_id": "DDI-DrugBank.d457.s0.p0"}
{"sentence": "The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. ", "drug1": "alcohol", "drug2": "3-hydroxy-1,4-benzodiazepine", "relation": "MECHANISM", "source_file": "9120829.xml", "sentence_id": "DDI-MedLine.d113.s5", "pair_id": "DDI-MedLine.d113.s5.p0"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "antineoplastic agents", "drug2": "clofibrate", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p4"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "fluoxetine", "drug2": "paroxetine", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p14"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "influenza virus vaccine", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1047"}
{"sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "drug1": "Mefloquine", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s9", "pair_id": "DDI-DrugBank.d220.s9.p5"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "acyclovir", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p16"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "Quinidine", "drug2": "itraconazole", "relation": "NONE", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p4"}
{"sentence": "Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.", "drug1": "warfarin-type anticoagulant", "drug2": "griseofulvin", "relation": "ADVISE", "source_file": "Griseofulvin_ddi.xml", "sentence_id": "DDI-DrugBank.d83.s0", "pair_id": "DDI-DrugBank.d83.s0.p0"}
{"sentence": "In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.", "drug1": "aspirin", "drug2": "nizatidine", "relation": "MECHANISM", "source_file": "Nizatidine_ddi.xml", "sentence_id": "DDI-DrugBank.d475.s3", "pair_id": "DDI-DrugBank.d475.s3.p1"}
{"sentence": "In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.", "drug1": "disulfiram", "drug2": "nitrite", "relation": "EFFECT", "source_file": "Disulfiram_ddi.xml", "sentence_id": "DDI-DrugBank.d19.s9", "pair_id": "DDI-DrugBank.d19.s9.p0"}
{"sentence": "- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.", "drug1": "Indomethacin", "drug2": "bumetanide", "relation": "EFFECT", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s7", "pair_id": "DDI-DrugBank.d331.s7.p4"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "ethionamide", "drug2": "lovastatin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p376"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "loratadine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p14"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "procainamide", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p12"}
{"sentence": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "drug1": "retinyl acetate", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s7", "pair_id": "DDI-MedLine.d12.s7.p8"}
{"sentence": "Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.", "drug1": "aluminum/magnesium hydroxide antacids", "drug2": "famotidine", "relation": "NONE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s90", "pair_id": "DDI-DrugBank.d531.s90.p23"}
{"sentence": "Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.", "drug1": "Valdecoxib", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s24", "pair_id": "DDI-DrugBank.d328.s24.p2"}
{"sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).", "drug1": "TORADOL", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s18", "pair_id": "DDI-DrugBank.d3.s18.p5"}
{"sentence": "Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.", "drug1": "probenecid", "drug2": "penciclovir", "relation": "MECHANISM", "source_file": "Famciclovir_ddi.xml", "sentence_id": "DDI-DrugBank.d112.s0", "pair_id": "DDI-DrugBank.d112.s0.p0"}
{"sentence": "Digoxin: Enoxacin may raise serum digoxin levels in some individuals.", "drug1": "Enoxacin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s7", "pair_id": "DDI-DrugBank.d395.s7.p2"}
{"sentence": "Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.", "drug1": "Chlorpropamide", "drug2": "allopurinol", "relation": "MECHANISM", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s20", "pair_id": "DDI-DrugBank.d413.s20.p4"}
{"sentence": "Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.", "drug1": "atorvastatin", "drug2": "contraceptive", "relation": "MECHANISM", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s10", "pair_id": "DDI-DrugBank.d140.s10.p4"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "antacids", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p2"}
{"sentence": "Nicotine: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.", "drug1": "Nicotine", "drug2": "ergot", "relation": "EFFECT", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s4", "pair_id": "DDI-DrugBank.d410.s4.p2"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "triazolam", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p135"}
{"sentence": "The AUC and Cmax of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium.", "drug1": "warfarin", "drug2": "cerivastatin sodium", "relation": "NONE", "source_file": "Cerivastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d141.s10", "pair_id": "DDI-DrugBank.d141.s10.p0"}
{"sentence": "Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.", "drug1": "ammonium chloride", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s0", "pair_id": "DDI-DrugBank.d158.s0.p1"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "alprazolam", "drug2": "isoniazid", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p64"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "opioids", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p4"}
{"sentence": "Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ", "drug1": "18-MC", "drug2": "morphine", "relation": "EFFECT", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s6", "pair_id": "DDI-MedLine.d110.s6.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Tegretol", "drug2": "Nizoral", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p365"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "angiotensin-converting enzyme inhibitors", "drug2": "zidovudine", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p64"}
{"sentence": "- Lofexidine may enhance the effects of anti-hypertensive drug therapy", "drug1": "Lofexidine", "drug2": "anti-hypertensive drug", "relation": "EFFECT", "source_file": "Lofexidine_ddi.xml", "sentence_id": "DDI-DrugBank.d454.s2", "pair_id": "DDI-DrugBank.d454.s2.p0"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p9"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "quinolone", "drug2": "antacids", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p3"}
{"sentence": "Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.", "drug1": "quinolone class antimicrobial", "drug2": "nonsteroidal anti-inflammatory drug", "relation": "EFFECT", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s10", "pair_id": "DDI-DrugBank.d562.s10.p0"}
{"sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "drug1": "desipramine", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s23", "pair_id": "DDI-DrugBank.d386.s23.p30"}
{"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "drug1": "phenobarbital", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s1", "pair_id": "DDI-DrugBank.d487.s1.p2"}
{"sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.", "drug1": "PRECEDEX", "drug2": "anesthetic", "relation": "ADVISE", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s4", "pair_id": "DDI-DrugBank.d197.s4.p5"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "drug1": "norepinephrine", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s0", "pair_id": "DDI-DrugBank.d110.s0.p11"}
{"sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.", "drug1": "alosetron", "drug2": "clarithromycin", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s10", "pair_id": "DDI-DrugBank.d364.s10.p0"}
{"sentence": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "drug1": "secobarbital", "drug2": "glutethimide", "relation": "NONE", "source_file": "1109248.xml", "sentence_id": "DDI-MedLine.d106.s1", "pair_id": "DDI-MedLine.d106.s1.p11"}
{"sentence": "In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.", "drug1": "indomethacin", "drug2": "diflunisal", "relation": "EFFECT", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s21", "pair_id": "DDI-DrugBank.d132.s21.p0"}
{"sentence": "Terfenadine: No clinically significant changes occurred in heart rate or corrected QT intervals, or in terfenadine metabolite or lomefloxacin pharmacokinetics, during concurrent administration of lomefloxacin and terfenadine at steady-state in 28 healthy males.", "drug1": "lomefloxacin", "drug2": "terfenadine", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s23", "pair_id": "DDI-DrugBank.d516.s23.p9"}
{"sentence": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "drug1": "Heparin", "drug2": "ketorolac tromethamine", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s1", "pair_id": "DDI-DrugBank.d3.s1.p16"}
{"sentence": "If any signs or symptoms occur physicians should consider discontinuation of either one or both agents (ZYVOX or concomitant serotonergic agents).", "drug1": "ZYVOX", "drug2": "serotonergic agents", "relation": "ADVISE", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s8", "pair_id": "DDI-DrugBank.d441.s8.p0"}
{"sentence": "Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.", "drug1": "benzodiazepines", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s0", "pair_id": "DDI-DrugBank.d18.s0.p1"}
{"sentence": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "drug1": "ketamine", "drug2": "ouabain", "relation": "EFFECT", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s1", "pair_id": "DDI-MedLine.d23.s1.p10"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "choline salicylate", "drug2": "Arthropan", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p63"}
{"sentence": "In Europe, Nimotop  was observed to occasionally intensify the effect of antihypertensive compounds taken concomitantly by patients suffering from hypertension;", "drug1": "Nimotop", "drug2": "antihypertensive compounds", "relation": "EFFECT", "source_file": "Nimodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d310.s1", "pair_id": "DDI-DrugBank.d310.s1.p0"}
{"sentence": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "drug1": "norethindrone acetate", "drug2": "ethinyl estradiol", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s33", "pair_id": "DDI-DrugBank.d438.s33.p12"}
{"sentence": "When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.", "drug1": "agents with b-blocking properties", "drug2": "clonidine", "relation": "ADVISE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s5", "pair_id": "DDI-DrugBank.d269.s5.p0"}
{"sentence": "Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.", "drug1": "antihistamines", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Clemastine_ddi.xml", "sentence_id": "DDI-DrugBank.d309.s0", "pair_id": "DDI-DrugBank.d309.s0.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "cimetidine", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p564"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "chlordiazepoxide", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p2"}
{"sentence": "Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.", "drug1": "L-phenylalanine", "drug2": "selective MAO inhibitor", "relation": "NONE", "source_file": "L-Phenylalanine_ddi.xml", "sentence_id": "DDI-DrugBank.d530.s2", "pair_id": "DDI-DrugBank.d530.s2.p3"}
{"sentence": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.", "drug1": "valdecoxib", "drug2": "glyburide", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s33", "pair_id": "DDI-DrugBank.d328.s33.p0"}
{"sentence": "Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.", "drug1": "fibrate", "drug2": "lovastatin", "relation": "EFFECT", "source_file": "Clofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d12.s6", "pair_id": "DDI-DrugBank.d12.s6.p0"}
{"sentence": "Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.", "drug1": "Nonsteroidal anti-inflammatory agents", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s24", "pair_id": "DDI-DrugBank.d314.s24.p3"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "propafenone", "drug2": "quinidine", "relation": "NONE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p32"}
{"sentence": "CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ", "drug1": "Macrolide antibiotics", "drug2": "simvastatin", "relation": "MECHANISM", "source_file": "11197581.xml", "sentence_id": "DDI-MedLine.d25.s12", "pair_id": "DDI-MedLine.d25.s12.p4"}
{"sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "Antiepileptic Drugs", "drug2": "felbamate", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s30", "pair_id": "DDI-DrugBank.d434.s30.p4"}
{"sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "drug1": "nitrates", "drug2": "vardenafil", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s22", "pair_id": "DDI-DrugBank.d198.s22.p3"}
{"sentence": "The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.", "drug1": "tolbutamide", "drug2": "Atromid-S", "relation": "EFFECT", "source_file": "Clofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d12.s5", "pair_id": "DDI-DrugBank.d12.s5.p0"}
{"sentence": "There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use.", "drug1": "nifedipine", "drug2": "diltiazem", "relation": "NONE", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s20", "pair_id": "DDI-DrugBank.d87.s20.p2"}
{"sentence": "EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.", "drug1": "EDECRIN", "drug2": "cephalosporin antibiotics", "relation": "EFFECT", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s2", "pair_id": "DDI-DrugBank.d414.s2.p1"}
{"sentence": "Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).", "drug1": "aspirin", "drug2": "acetaminophen", "relation": "NONE", "source_file": "Argatroban_ddi.xml", "sentence_id": "DDI-DrugBank.d148.s2", "pair_id": "DDI-DrugBank.d148.s2.p16"}
{"sentence": "Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "drug1": "iron", "drug2": "sucralfate", "relation": "NONE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s11", "pair_id": "DDI-DrugBank.d217.s11.p8"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "nonsteroidal anti-inflammatory agents", "drug2": "probenecid", "relation": "NONE", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p13"}
{"sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "fluoxetine", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s6", "pair_id": "DDI-DrugBank.d299.s6.p21"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "haloperidol", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p14"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Trileptal", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p9"}
{"sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "drug1": "butyrophenones", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Lidocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d564.s1", "pair_id": "DDI-DrugBank.d564.s1.p2"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "somatropin", "drug2": "progestogens", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p97"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "clozapine", "drug2": "Type 1C antiarrhythmics", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p3"}
{"sentence": "The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.", "drug1": "beta-adrenergic blocking agents", "drug2": "digitalis", "relation": "EFFECT", "source_file": "Levobunolol_ddi.xml", "sentence_id": "DDI-DrugBank.d252.s4", "pair_id": "DDI-DrugBank.d252.s4.p0"}
{"sentence": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "drug1": "erythromycin", "drug2": "fentanyl", "relation": "MECHANISM", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s3", "pair_id": "DDI-DrugBank.d170.s3.p3"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "buprenorphine", "drug2": "Levo-Dromoran", "relation": "ADVISE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p34"}
{"sentence": "The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.", "drug1": "eszopiclone", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s7", "pair_id": "DDI-DrugBank.d216.s7.p0"}
{"sentence": "Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.", "drug1": "cephalosporins", "drug2": "aminoglycoside antibiotics", "relation": "EFFECT", "source_file": "Ceftazidime_ddi.xml", "sentence_id": "DDI-DrugBank.d122.s0", "pair_id": "DDI-DrugBank.d122.s0.p0"}
{"sentence": "Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.", "drug1": "tiagabine", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s11", "pair_id": "DDI-DrugBank.d277.s11.p3"}
{"sentence": "Some drugs/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of CYP3A4 (enzyme induction).", "drug1": "drugs", "drug2": "amiodarone", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s45", "pair_id": "DDI-DrugBank.d143.s45.p0"}
{"sentence": "A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.", "drug1": "diltiazem", "drug2": "cyclosporine", "relation": "INT", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s25", "pair_id": "DDI-DrugBank.d565.s25.p0"}
{"sentence": "The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ", "drug1": "desmethyldiltiazem", "drug2": "sirolimus", "relation": "NONE", "source_file": "11180036.xml", "sentence_id": "DDI-MedLine.d86.s7", "pair_id": "DDI-MedLine.d86.s7.p7"}
{"sentence": "Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.", "drug1": "indinavir", "drug2": "SUSTIVA", "relation": "MECHANISM", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s38", "pair_id": "DDI-DrugBank.d531.s38.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "methadone", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p24"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "sildenafil", "drug2": "zidovudine", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p109"}
{"sentence": "During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.", "drug1": "TAMBOCOR", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s2", "pair_id": "DDI-DrugBank.d87.s2.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "methyldopa", "drug2": "methylphenidate", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1107"}
{"sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "drug1": "isocarboxazid", "drug2": "L-tryptophan", "relation": "NONE", "source_file": "L-Tryptophan_ddi.xml", "sentence_id": "DDI-DrugBank.d63.s0", "pair_id": "DDI-DrugBank.d63.s0.p20"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "phenytoin", "drug2": "diazepam", "relation": "NONE", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p22"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Dilantin", "drug2": "morphine", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p311"}
{"sentence": "Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. ", "drug1": "Azithromycin", "drug2": "zidovudine", "relation": "MECHANISM", "source_file": "11210404.xml", "sentence_id": "DDI-MedLine.d105.s7", "pair_id": "DDI-MedLine.d105.s7.p1"}
{"sentence": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "drug1": "allopurinol", "drug2": "mercaptopurine", "relation": "ADVISE", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s4", "pair_id": "DDI-DrugBank.d413.s4.p18"}
{"sentence": "Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.", "drug1": "enalapril", "drug2": "digoxin", "relation": "NONE", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s10", "pair_id": "DDI-DrugBank.d107.s10.p14"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "bismuth subsalicylate", "drug2": "Pepto-Bismol", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p77"}
{"sentence": "Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.", "drug1": "saquinavir", "drug2": "VIRACEPT", "relation": "MECHANISM", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s18", "pair_id": "DDI-DrugBank.d340.s18.p6"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "Indocin", "drug2": "Aleve", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p271"}
{"sentence": "No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.", "drug1": "tricyclic antidepressant", "drug2": "entacapone", "relation": "NONE", "source_file": "Entacapone_ddi.xml", "sentence_id": "DDI-DrugBank.d455.s11", "pair_id": "DDI-DrugBank.d455.s11.p1"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "cholestyramine", "drug2": "contraceptives", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p178"}
{"sentence": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "drug1": "diclofenac", "drug2": "digoxin", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s5", "pair_id": "DDI-DrugBank.d249.s5.p2"}
{"sentence": "Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.", "drug1": "aliskiren", "drug2": "furosemide", "relation": "MECHANISM", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s9", "pair_id": "DDI-DrugBank.d533.s9.p3"}
{"sentence": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "drug1": "Imidazoles", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s8", "pair_id": "DDI-DrugBank.d318.s8.p0"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "estrogen-containing compounds", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p5"}
{"sentence": "Nevertheless, caution is indicated in the co-administration of T.A. with any of the SSRIs and also in switching from one class to the other.", "drug1": "T.A.", "drug2": "SSRIs", "relation": "ADVISE", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s12", "pair_id": "DDI-DrugBank.d386.s12.p0"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "quinolone", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p2"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "corticosteroids", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p5"}
{"sentence": "In vitro data suggest that itraconazole, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.", "drug1": "itraconazole", "drug2": "astemizole", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s5", "pair_id": "DDI-DrugBank.d165.s5.p1"}
{"sentence": "Therefore, concurrent use of Trileptal with hormonal contraceptives may render these contraceptives less effective.", "drug1": "Trileptal", "drug2": "hormonal contraceptives", "relation": "EFFECT", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s43", "pair_id": "DDI-DrugBank.d307.s43.p0"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "fluoxetine", "drug2": "CMI", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p17"}
{"sentence": "Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.", "drug1": "rifampicin", "drug2": "phenytoin", "relation": "NONE", "source_file": "Exemestane_ddi.xml", "sentence_id": "DDI-DrugBank.d435.s2", "pair_id": "DDI-DrugBank.d435.s2.p0"}
{"sentence": "Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.", "drug1": "Quinolones", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s5", "pair_id": "DDI-DrugBank.d217.s5.p1"}
{"sentence": "Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. ", "drug1": "methaqualone", "drug2": "anticoagulant agents", "relation": "INT", "source_file": "1109248.xml", "sentence_id": "DDI-MedLine.d106.s8", "pair_id": "DDI-MedLine.d106.s8.p2"}
{"sentence": "Warfarin-Vitamin K can antagonize the effect of warfarin", "drug1": "Warfarin", "drug2": "Vitamin K", "relation": "NONE", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s8", "pair_id": "DDI-DrugBank.d139.s8.p0"}
{"sentence": "Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Nevirapine may decrease plasma levels of combination hormonal contraceptives;", "drug1": "Nevirapine", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s27", "pair_id": "DDI-DrugBank.d485.s27.p5"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "sumatriptan", "drug2": "citalopram", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p5"}
{"sentence": "Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.", "drug1": "rifampin", "drug2": "efavirenz", "relation": "MECHANISM", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s5", "pair_id": "DDI-DrugBank.d531.s5.p4"}
{"sentence": "Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.", "drug1": "Buforin II", "drug2": "minocycline", "relation": "EFFECT", "source_file": "11152438.xml", "sentence_id": "DDI-MedLine.d47.s4", "pair_id": "DDI-MedLine.d47.s4.p1"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "disopyramide", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p44"}
{"sentence": "Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects", "drug1": "Accutane", "drug2": "vitamin A", "relation": "EFFECT", "source_file": "Isotretinoin_ddi.xml", "sentence_id": "DDI-DrugBank.d163.s0", "pair_id": "DDI-DrugBank.d163.s0.p4"}
{"sentence": "FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.", "drug1": "FLEXERIL", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Cyclobenzaprine_ddi.xml", "sentence_id": "DDI-DrugBank.d150.s1", "pair_id": "DDI-DrugBank.d150.s1.p0"}
{"sentence": "Alpha-blockers: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.", "drug1": "Vardenafil", "drug2": "terazosin", "relation": "EFFECT", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s28", "pair_id": "DDI-DrugBank.d198.s28.p2"}
{"sentence": "Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.", "drug1": "Fluvoxamine", "drug2": "alosetron", "relation": "MECHANISM", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s3", "pair_id": "DDI-DrugBank.d364.s3.p0"}
{"sentence": "Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.", "drug1": "Felbamate", "drug2": "gestodene", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s38", "pair_id": "DDI-DrugBank.d434.s38.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Crixivan", "drug2": "rifadin", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p831"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "fenoprofen", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p921"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "coumarins", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p5"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "phenyramidol", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p37"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p2"}
{"sentence": "Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.", "drug1": "Coumarin Anticoagulants", "drug2": "capecitabine", "relation": "NONE", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s3", "pair_id": "DDI-DrugBank.d88.s3.p0"}
{"sentence": "Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials.", "drug1": "Beta-adrenergic blocking agents", "drug2": "beta-adrenergic blocking agents", "relation": "NONE", "source_file": "Ibutilide_ddi.xml", "sentence_id": "DDI-DrugBank.d68.s5", "pair_id": "DDI-DrugBank.d68.s5.p0"}
{"sentence": "On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.", "drug1": "amiodarone", "drug2": "digitalis", "relation": "ADVISE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s24", "pair_id": "DDI-DrugBank.d143.s24.p0"}
{"sentence": "Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.", "drug1": "FOSCAVIR", "drug2": "pentamidine", "relation": "ADVISE", "source_file": "Foscarnet_ddi.xml", "sentence_id": "DDI-DrugBank.d511.s4", "pair_id": "DDI-DrugBank.d511.s4.p6"}
{"sentence": "Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "drug1": "piroxicam", "drug2": "phenytoin", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s4", "pair_id": "DDI-DrugBank.d3.s4.p23"}
{"sentence": "Potassium-depleting diuretics are a major contributing factor to digitalis toxicity.", "drug1": "Potassium-depleting diuretics", "drug2": "digitalis", "relation": "EFFECT", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s0", "pair_id": "DDI-DrugBank.d450.s0.p0"}
{"sentence": "Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability. ", "drug1": "Cholestyramine", "drug2": "fluvastatin", "relation": "MECHANISM", "source_file": "19489169.xml", "sentence_id": "DDI-MedLine.d119.s15", "pair_id": "DDI-MedLine.d119.s15.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "risperidone", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p995"}
{"sentence": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.", "drug1": "carbamazepine", "drug2": "Clozapine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s18", "pair_id": "DDI-DrugBank.d480.s18.p5"}
{"sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "drug1": "antacids", "drug2": "fosinopril", "relation": "MECHANISM", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s9", "pair_id": "DDI-DrugBank.d176.s9.p44"}
{"sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "drug1": "quinidine", "drug2": "theophylline", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s5", "pair_id": "DDI-MedLine.d111.s5.p77"}
{"sentence": "Cyclosporine - L-arginine may counteract the antinaturetic effect of cyclosporin.", "drug1": "L-arginine", "drug2": "cyclosporin", "relation": "EFFECT", "source_file": "L-Arginine_ddi.xml", "sentence_id": "DDI-DrugBank.d95.s0", "pair_id": "DDI-DrugBank.d95.s0.p2"}
{"sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "drug1": "desipramine hydrochloride", "drug2": "sedative", "relation": "EFFECT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s23", "pair_id": "DDI-DrugBank.d386.s23.p2"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p8"}
{"sentence": "Increasing the felbamate dose to 1800 mg/day in six of these subjects increased the steady-state phenytoin Cmin to 25 7 micrograms/mL.", "drug1": "felbamate", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s14", "pair_id": "DDI-DrugBank.d434.s14.p0"}
{"sentence": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "drug1": "fluconazole", "drug2": "lovastatin", "relation": "NONE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s14", "pair_id": "DDI-DrugBank.d400.s14.p25"}
{"sentence": "In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.", "drug1": "AED", "drug2": "oxcarbazepine", "relation": "MECHANISM", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s1", "pair_id": "DDI-DrugBank.d307.s1.p0"}
{"sentence": "A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.", "drug1": "lopinavir", "drug2": "nevirapine", "relation": "ADVISE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s39", "pair_id": "DDI-DrugBank.d270.s39.p1"}
{"sentence": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "drug1": "FLOLAN", "drug2": "digoxin", "relation": "NONE", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s3", "pair_id": "DDI-DrugBank.d241.s3.p9"}
{"sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "drug1": "phenytoin", "drug2": "valproic acid", "relation": "NONE", "source_file": "Ethosuximide_ddi.xml", "sentence_id": "DDI-DrugBank.d205.s0", "pair_id": "DDI-DrugBank.d205.s0.p18"}
{"sentence": "Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).", "drug1": "carbonic anhydrase inhibitors", "drug2": "salicylate", "relation": "NONE", "source_file": "Dorzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d34.s0", "pair_id": "DDI-DrugBank.d34.s0.p2"}
{"sentence": "In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.", "drug1": "ciprofloxacin", "drug2": "didanosine", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s11", "pair_id": "DDI-DrugBank.d43.s11.p0"}
{"sentence": "As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin", "drug1": "losartan", "drug2": "indomethacin", "relation": "EFFECT", "source_file": "Losartan_ddi.xml", "sentence_id": "DDI-DrugBank.d30.s9", "pair_id": "DDI-DrugBank.d30.s9.p4"}
{"sentence": "Concomitant administration of alosetron and fluvoxamine is contraindicated.", "drug1": "alosetron", "drug2": "fluvoxamine", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s4", "pair_id": "DDI-DrugBank.d364.s4.p0"}
{"sentence": "Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.", "drug1": "Fluconazole", "drug2": "celecoxib", "relation": "NONE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s16", "pair_id": "DDI-DrugBank.d172.s16.p1"}
{"sentence": "Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.", "drug1": "magnesium hydroxide", "drug2": "Maalox", "relation": "NONE", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s0", "pair_id": "DDI-DrugBank.d88.s0.p10"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "antidepressants", "drug2": "imipramine", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p17"}
{"sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.", "drug1": "ciprofloxacin", "drug2": "diclofenac", "relation": "NONE", "source_file": "Chlorpheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d235.s4", "pair_id": "DDI-DrugBank.d235.s4.p14"}
{"sentence": "Studies in humans show that the absorption of chlorothiazide as reflected in urinary excretion is markedly decreased even when administered one hour before colestipol hydrochloride.", "drug1": "chlorothiazide", "drug2": "colestipol hydrochloride", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s10", "pair_id": "DDI-DrugBank.d345.s10.p0"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "amlodipine", "drug2": "aliskiren", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p65"}
{"sentence": "Nitrofurantoin interferes with the therapeutic action of nalidixic acid.", "drug1": "Nitrofurantoin", "drug2": "nalidixic acid", "relation": "EFFECT", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s7", "pair_id": "DDI-DrugBank.d427.s7.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "vitamin C", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p43"}
{"sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "drug1": "Rifampin", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s36", "pair_id": "DDI-DrugBank.d485.s36.p4"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "bismuth subsalicylate", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p10"}
{"sentence": "It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.", "drug1": "TCA", "drug2": "TCA", "relation": "NONE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s21", "pair_id": "DDI-DrugBank.d77.s21.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "buspirone", "drug2": "quetiapine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p244"}
{"sentence": "Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. ", "drug1": "Loperamide", "drug2": "dmPGE2", "relation": "EFFECT", "source_file": "7625885.xml", "sentence_id": "DDI-MedLine.d128.s13", "pair_id": "DDI-MedLine.d128.s13.p1"}
{"sentence": "Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).", "drug1": "enalapril", "drug2": "antihypertensive agents", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s3", "pair_id": "DDI-DrugBank.d107.s3.p1"}
{"sentence": "Iron salts may reduce the bioavailability of carbidopa and levodopa.", "drug1": "Iron", "drug2": "carbidopa", "relation": "MECHANISM", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s5", "pair_id": "DDI-DrugBank.d47.s5.p0"}
{"sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "SSRIs", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s3", "pair_id": "DDI-DrugBank.d426.s3.p10"}
{"sentence": "The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (oxymetazoline), but the rate of absorption is decreased.", "drug1": "nasal vasoconstrictor", "drug2": "oxymetazoline", "relation": "NONE", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s13", "pair_id": "DDI-DrugBank.d246.s13.p2"}
{"sentence": "Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other s metabolism.", "drug1": "Phenothiazine-related compounds", "drug2": "beta-adrenergic blocking agents", "relation": "MECHANISM", "source_file": "Levobunolol_ddi.xml", "sentence_id": "DDI-DrugBank.d252.s5", "pair_id": "DDI-DrugBank.d252.s5.p0"}
{"sentence": "The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.", "drug1": "ciprofloxacin", "drug2": "didanosine", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s10", "pair_id": "DDI-DrugBank.d43.s10.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "tetracycline", "drug2": "atorvastatin", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p221"}
{"sentence": "Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.", "drug1": "cyclosporine", "drug2": "TRICOR", "relation": "EFFECT", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s5", "pair_id": "DDI-DrugBank.d283.s5.p4"}
{"sentence": "In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.", "drug1": "cerivastatin sodium", "drug2": "cholestyramine", "relation": "MECHANISM", "source_file": "Cerivastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d141.s4", "pair_id": "DDI-DrugBank.d141.s4.p0"}
{"sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "drug1": "ethosuximide", "drug2": "antiepileptic drugs", "relation": "INT", "source_file": "Ethosuximide_ddi.xml", "sentence_id": "DDI-DrugBank.d205.s0", "pair_id": "DDI-DrugBank.d205.s0.p6"}
{"sentence": "The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. ", "drug1": "theophylline", "drug2": "CGS 21680", "relation": "EFFECT", "source_file": "7746025.xml", "sentence_id": "DDI-MedLine.d51.s3", "pair_id": "DDI-MedLine.d51.s3.p0"}
{"sentence": "These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.", "drug1": "methotrexate", "drug2": "ELSPAR", "relation": "ADVISE", "source_file": "Asparaginase_ddi.xml", "sentence_id": "DDI-DrugBank.d21.s1", "pair_id": "DDI-DrugBank.d21.s1.p0"}
{"sentence": "Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).", "drug1": "ketoconazole", "drug2": "digoxin", "relation": "NONE", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s12", "pair_id": "DDI-DrugBank.d29.s12.p4"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "contraceptives", "drug2": "rifampin", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p68"}
{"sentence": "Likewise, gabapentin pharmacokinetics were unaltered by carbamazepine administration.", "drug1": "gabapentin", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s10", "pair_id": "DDI-DrugBank.d438.s10.p0"}
{"sentence": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "drug1": "d-amphetamine", "drug2": "tricyclics", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s4", "pair_id": "DDI-DrugBank.d158.s4.p2"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "pimozide", "drug2": "alprazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p118"}
{"sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "drug1": "ALPHAGAN P", "drug2": "anesthetics", "relation": "ADVISE", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s0", "pair_id": "DDI-DrugBank.d138.s0.p5"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "nonsteroidal anti-inflammatory agents", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p5"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p15"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "phenytoin", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s2", "pair_id": "DDI-DrugBank.d384.s2.p9"}
{"sentence": "In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.", "drug1": "serotonin reuptake inhibitor drug", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s1", "pair_id": "DDI-DrugBank.d76.s1.p0"}
{"sentence": "Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.", "drug1": "acitretin", "drug2": "glibenclamide", "relation": "EFFECT", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s1", "pair_id": "DDI-DrugBank.d353.s1.p4"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "dextran", "drug2": "monoamine oxidase inhibitors", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p681"}
{"sentence": "However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in etodolac-treated patients receiving concomitant warfarin therapy.", "drug1": "etodolac", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s26", "pair_id": "DDI-DrugBank.d219.s26.p0"}
{"sentence": "Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.", "drug1": "Sympathomimetic amines", "drug2": "mecamylamine", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s2", "pair_id": "DDI-DrugBank.d389.s2.p3"}
{"sentence": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "drug1": "oxygen", "drug2": "furosemide", "relation": "NONE", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s3", "pair_id": "DDI-DrugBank.d241.s3.p40"}
{"sentence": "Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.", "drug1": "Indinavir", "drug2": "amprenavir", "relation": "MECHANISM", "source_file": "Amprenavir_ddi.xml", "sentence_id": "DDI-DrugBank.d437.s5", "pair_id": "DDI-DrugBank.d437.s5.p0"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "carbamazepine", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p11"}
{"sentence": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "drug1": "Clozapine", "drug2": "benzodiazepine", "relation": "NONE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s8", "pair_id": "DDI-DrugBank.d480.s8.p3"}
{"sentence": "Dolasetron mesylate did not inhibit the antitumor activity of four chemotherapeutic agents (cisplatin, 5-fluorouracil, doxorubicin, cyclophosphamide) in four murine models.", "drug1": "cisplatin", "drug2": "5-fluorouracil", "relation": "NONE", "source_file": "Dolasetron_ddi.xml", "sentence_id": "DDI-DrugBank.d42.s7", "pair_id": "DDI-DrugBank.d42.s7.p9"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "anticholinergic", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p3"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "epinephrine", "drug2": "norepinephrine", "relation": "NONE", "source_file": "Bupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d153.s0", "pair_id": "DDI-DrugBank.d153.s0.p4"}
{"sentence": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "drug1": "Imidazoles", "drug2": "miconazole", "relation": "NONE", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s8", "pair_id": "DDI-DrugBank.d318.s8.p1"}
{"sentence": "A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to insulin or oral hypoglycemic agents.", "drug1": "diclofenac", "drug2": "insulin", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s13", "pair_id": "DDI-DrugBank.d249.s13.p0"}
{"sentence": "Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.", "drug1": "heparin sodium", "drug2": "dicumarol", "relation": "ADVISE", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s1", "pair_id": "DDI-DrugBank.d488.s1.p0"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "ergotamine", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p89"}
{"sentence": "Barbiturates, phenytoin, or rifampin increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes.", "drug1": "Barbiturates", "drug2": "fludrocortisone acetate", "relation": "MECHANISM", "source_file": "Fludrocortisone_ddi.xml", "sentence_id": "DDI-DrugBank.d526.s17", "pair_id": "DDI-DrugBank.d526.s17.p2"}
{"sentence": "However, in a well-controlled study of patients with lymphoma on combination therapy, allopurinol did not increase the marrow toxicity of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechlorethamine.", "drug1": "allopurinol", "drug2": "cyclophosphamide", "relation": "NONE", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s19", "pair_id": "DDI-DrugBank.d413.s19.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "felbamate", "drug2": "topiramate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p649"}
{"sentence": "Death due to fulminant pancreatitis possibly related to intravenous pentamidine and HIVID has been reported.", "drug1": "pentamidine", "drug2": "HIVID", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s16", "pair_id": "DDI-DrugBank.d263.s16.p0"}
{"sentence": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ", "drug1": "carboxymethylcellulose-cysteine", "drug2": "NaFlu", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s1", "pair_id": "DDI-MedLine.d76.s1.p15"}
{"sentence": "In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.", "drug1": "warfarin", "drug2": "piroxicam", "relation": "NONE", "source_file": "Fondaparinux sodium_ddi.xml", "sentence_id": "DDI-DrugBank.d15.s1", "pair_id": "DDI-DrugBank.d15.s1.p6"}
{"sentence": "Cyclosporine: Combination hormonal contraceptives may inhibit the metabolism of cyclosporine, leading to increased plasma concentrations;", "drug1": "hormonal contraceptives", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s19", "pair_id": "DDI-DrugBank.d485.s19.p2"}
{"sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "drug1": "antacids", "drug2": "vitamin D", "relation": "ADVISE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s15", "pair_id": "DDI-DrugBank.d98.s15.p5"}
{"sentence": "When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.", "drug1": "duloxetine", "drug2": "desipramine", "relation": "MECHANISM", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s8", "pair_id": "DDI-DrugBank.d548.s8.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "trimethoprim", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p51"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "alcohol", "drug2": "miconazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p82"}
{"sentence": "Adrenergic blockers: Adrenergic blockers are inhibited by amphetamines.", "drug1": "Adrenergic blockers", "drug2": "amphetamines", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s3", "pair_id": "DDI-DrugBank.d236.s3.p2"}
{"sentence": "Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;", "drug1": "ritonavir", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s32", "pair_id": "DDI-DrugBank.d485.s32.p14"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "cimetidine", "drug2": "quinupristin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p93"}
{"sentence": "In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.", "drug1": "amiloride", "drug2": "dofetilide", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s22", "pair_id": "DDI-DrugBank.d558.s22.p5"}
{"sentence": "Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis.", "drug1": "anticholinesterase agents", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s4", "pair_id": "DDI-DrugBank.d314.s4.p2"}
{"sentence": "Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.", "drug1": "fentanyl", "drug2": "beta blocker", "relation": "EFFECT", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s14", "pair_id": "DDI-DrugBank.d81.s14.p3"}
{"sentence": "A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.", "drug1": "lopinavir", "drug2": "SUSTIVA", "relation": "ADVISE", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s42", "pair_id": "DDI-DrugBank.d531.s42.p1"}
{"sentence": "Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.", "drug1": "Lithium", "drug2": "Valdecoxib", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s20", "pair_id": "DDI-DrugBank.d328.s20.p0"}
{"sentence": "Quinidine: Immediate Release Capsules: There have been rare reports of an interaction between quinidine and nifedipine (with a decreased plasma level of quinidine).", "drug1": "quinidine", "drug2": "nifedipine", "relation": "MECHANISM", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s8", "pair_id": "DDI-DrugBank.d373.s8.p3"}
{"sentence": "As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.", "drug1": "adenosine", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s9", "pair_id": "DDI-DrugBank.d226.s9.p0"}
{"sentence": "Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. ", "drug1": "nitrosourea", "drug2": "misonidazole", "relation": "NONE", "source_file": "3966974.xml", "sentence_id": "DDI-MedLine.d85.s1", "pair_id": "DDI-MedLine.d85.s1.p2"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "serotoninergic agents", "drug2": "sertraline", "relation": "NONE", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p24"}
{"sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "drug1": "Digitalis", "drug2": "digitalis", "relation": "NONE", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s7", "pair_id": "DDI-DrugBank.d404.s7.p1"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "bacitracin", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p3"}
{"sentence": "MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.", "drug1": "furazolidone", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s10", "pair_id": "DDI-DrugBank.d236.s10.p5"}
{"sentence": "Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.", "drug1": "angiotensin converting enzyme inhibitors", "drug2": "azathioprine", "relation": "EFFECT", "source_file": "Azathioprine_ddi.xml", "sentence_id": "DDI-DrugBank.d233.s3", "pair_id": "DDI-DrugBank.d233.s3.p2"}
{"sentence": "Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide) enhanced hypokalemia.", "drug1": "benzothiadiazines", "drug2": "ethacrynic acid", "relation": "NONE", "source_file": "Fludrocortisone_ddi.xml", "sentence_id": "DDI-DrugBank.d526.s1", "pair_id": "DDI-DrugBank.d526.s1.p7"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "sulfonamides", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p18"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "cetirizine", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p2"}
{"sentence": "Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.", "drug1": "rifampin", "drug2": "bexarotene", "relation": "MECHANISM", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s3", "pair_id": "DDI-DrugBank.d467.s3.p2"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "Butalbital", "drug2": "narcotic analgesic", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p2"}
{"sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "drug1": "aluminum hydroxide", "drug2": "fosinopril", "relation": "MECHANISM", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s9", "pair_id": "DDI-DrugBank.d176.s9.p19"}
{"sentence": "Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;", "drug1": "Tricyclic antidepressants", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s41", "pair_id": "DDI-DrugBank.d485.s41.p3"}
{"sentence": "Sodium cephalothin may enhance the nephrotoxicity of Coly-Mycin M Parenteral.", "drug1": "Sodium cephalothin", "drug2": "Coly-Mycin M", "relation": "EFFECT", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s3", "pair_id": "DDI-DrugBank.d250.s3.p0"}
{"sentence": "Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ", "drug1": "iron", "drug2": "cobalt", "relation": "MECHANISM", "source_file": "7599505.xml", "sentence_id": "DDI-MedLine.d34.s7", "pair_id": "DDI-MedLine.d34.s7.p0"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "monoamine oxidase inhibitors", "drug2": "paroxetine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p5"}
{"sentence": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.", "drug1": "quinidine", "drug2": "selective serotonin reuptake inhibitors", "relation": "NONE", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s16", "pair_id": "DDI-DrugBank.d223.s16.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "vitamin K", "drug2": "ethchlorvynol", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p186"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "caffeine", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p20"}
{"sentence": "Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.", "drug1": "fluoxetine", "drug2": "alprazolam", "relation": "MECHANISM", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s5", "pair_id": "DDI-DrugBank.d131.s5.p7"}
{"sentence": "In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.", "drug1": "clonazepam", "drug2": "propantheline", "relation": "MECHANISM", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s3", "pair_id": "DDI-DrugBank.d333.s3.p14"}
{"sentence": "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of eplerenone with an NSAID has not been conducted.", "drug1": "eplerenone", "drug2": "NSAID", "relation": "NONE", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s10", "pair_id": "DDI-DrugBank.d20.s10.p5"}
{"sentence": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "drug1": "TRISENOX", "drug2": "amphotericin B", "relation": "ADVISE", "source_file": "Arsenic trioxide_ddi.xml", "sentence_id": "DDI-DrugBank.d470.s1", "pair_id": "DDI-DrugBank.d470.s1.p3"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Sparine", "drug2": "trifluoperazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p249"}
{"sentence": "Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.", "drug1": "Beta-adrenergic blocking drugs", "drug2": "captopril", "relation": "EFFECT", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s12", "pair_id": "DDI-DrugBank.d175.s12.p0"}
{"sentence": "Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.", "drug1": "ARAVA", "drug2": "rifampin", "relation": "ADVISE", "source_file": "Leflunomide_ddi.xml", "sentence_id": "DDI-DrugBank.d41.s15", "pair_id": "DDI-DrugBank.d41.s15.p2"}
{"sentence": "In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "drug1": "warfarin", "drug2": "phenytoin", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s11", "pair_id": "DDI-DrugBank.d460.s11.p51"}
{"sentence": "Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.", "drug1": "ketoconazole", "drug2": "cisapride", "relation": "EFFECT", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s8", "pair_id": "DDI-DrugBank.d458.s8.p0"}
{"sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.", "drug1": "NON-NARCOTIC ANALGESICS", "drug2": "BARBITURATES", "relation": "NONE", "source_file": "Hydroxyzine_ddi.xml", "sentence_id": "DDI-DrugBank.d308.s0", "pair_id": "DDI-DrugBank.d308.s0.p9"}
{"sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.", "drug1": "diuretics", "drug2": "adrenergic agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s3", "pair_id": "DDI-DrugBank.d284.s3.p14"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "clozapine", "drug2": "carbamazepine", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "tramadol", "drug2": "ziprasidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p1023"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "quinolone", "drug2": "zinc", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p8"}
{"sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.", "drug1": "voriconazole", "drug2": "itraconazole", "relation": "NONE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s10", "pair_id": "DDI-DrugBank.d364.s10.p14"}
{"sentence": "There have been greater than two-fold increases of previously stable plasma levels of tricyclic antidepressants when fluoxetine has been administered in combination with these agents.", "drug1": "tricyclic antidepressants", "drug2": "fluoxetine", "relation": "MECHANISM", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s28", "pair_id": "DDI-DrugBank.d386.s28.p0"}
{"sentence": "Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.", "drug1": "capecitabine", "drug2": "phenprocoumon", "relation": "EFFECT", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s3", "pair_id": "DDI-DrugBank.d88.s3.p6"}
{"sentence": "Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.", "drug1": "ascorbic acid", "drug2": "amphetamines", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s0", "pair_id": "DDI-DrugBank.d236.s0.p20"}
{"sentence": "Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.", "drug1": "cephalosporins", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Ceftazidime_ddi.xml", "sentence_id": "DDI-DrugBank.d122.s0", "pair_id": "DDI-DrugBank.d122.s0.p1"}
{"sentence": "There have been reports of theophylline-related side effects in patients on concomitant therapy with quinolones and theophylline.", "drug1": "quinolones", "drug2": "theophylline", "relation": "EFFECT", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s1", "pair_id": "DDI-DrugBank.d427.s1.p2"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "metronidazole", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p9"}
{"sentence": "Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.", "drug1": "linezolid", "drug2": "adrenergic", "relation": "INT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s1", "pair_id": "DDI-DrugBank.d441.s1.p0"}
{"sentence": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "drug1": "lithium", "drug2": "TORADOL", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s12", "pair_id": "DDI-DrugBank.d3.s12.p4"}
{"sentence": "In one controlled clinical study, the ureidopenicillins, including piperacillin, were reported to prolong the action of vecuronium.", "drug1": "piperacillin", "drug2": "vecuronium", "relation": "EFFECT", "source_file": "Piperacillin_ddi.xml", "sentence_id": "DDI-DrugBank.d462.s3", "pair_id": "DDI-DrugBank.d462.s3.p0"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "central nervous system depressants", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p0"}
{"sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "drug1": "ketoconazole", "drug2": "cimetidine", "relation": "NONE", "source_file": "Felodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d316.s1", "pair_id": "DDI-DrugBank.d316.s1.p2"}
{"sentence": "In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of coumarin by fondaparinux (200 m m M i.e., 350 mg/L) was 17-28%.", "drug1": "coumarin", "drug2": "fondaparinux", "relation": "MECHANISM", "source_file": "Fondaparinux sodium_ddi.xml", "sentence_id": "DDI-DrugBank.d15.s4", "pair_id": "DDI-DrugBank.d15.s4.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Gris-PEG", "drug2": "theophylline", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p552"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "thyroid products", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p11"}
{"sentence": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.", "drug1": "ketoconazole", "drug2": "budesonide", "relation": "ADVISE", "source_file": "Budesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d144.s1", "pair_id": "DDI-DrugBank.d144.s1.p5"}
{"sentence": "Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.", "drug1": "amphotericin B", "drug2": "nelfinavir", "relation": "NONE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s3", "pair_id": "DDI-DrugBank.d350.s3.p10"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "asparaginase", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p2"}
{"sentence": "When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.", "drug1": "lansoprazole", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s3", "pair_id": "DDI-DrugBank.d431.s3.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "amiodarone", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p69"}
{"sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.", "drug1": "CNS depressants", "drug2": "hydrocodone", "relation": "EFFECT", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s0", "pair_id": "DDI-DrugBank.d396.s0.p16"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p1"}
{"sentence": "No drug interaction studies have been conducted for COLAZAL, however the use of orally administered antibiotics could, theoretically, interfere with the release of mesalamine in the colon.", "drug1": "antibiotics", "drug2": "mesalamine", "relation": "NONE", "source_file": "Balsalazide_ddi.xml", "sentence_id": "DDI-DrugBank.d486.s0", "pair_id": "DDI-DrugBank.d486.s0.p2"}
{"sentence": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "drug1": "decongestants", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s2", "pair_id": "DDI-DrugBank.d77.s2.p4"}
{"sentence": "ACE-inhibitors:Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors.", "drug1": "NSAIDs", "drug2": "ACE-inhibitors", "relation": "EFFECT", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s8", "pair_id": "DDI-DrugBank.d328.s8.p2"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "MAOI", "drug2": "flupenthixol", "relation": "EFFECT", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p30"}
{"sentence": "The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.", "drug1": "quinidine", "drug2": "antihistamines", "relation": "NONE", "source_file": "Dicyclomine_ddi.xml", "sentence_id": "DDI-DrugBank.d543.s0", "pair_id": "DDI-DrugBank.d543.s0.p18"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p10"}
{"sentence": "In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.", "drug1": "INSPRA", "drug2": "enalapril", "relation": "EFFECT", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s7", "pair_id": "DDI-DrugBank.d20.s7.p1"}
{"sentence": "The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. ", "drug1": "cobalt", "drug2": "Fe", "relation": "NONE", "source_file": "7599505.xml", "sentence_id": "DDI-MedLine.d34.s1", "pair_id": "DDI-MedLine.d34.s1.p2"}
{"sentence": "Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and TNF blocking agents did not influence abatacept clearance.", "drug1": "MTX", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Abatacept_ddi.xml", "sentence_id": "DDI-DrugBank.d297.s1", "pair_id": "DDI-DrugBank.d297.s1.p1"}
{"sentence": "Lithium: Nonsteroidal anti-inflammatory agents have been reported to increase steadystate plasma lithium levels.", "drug1": "Nonsteroidal anti-inflammatory agents", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s24", "pair_id": "DDI-DrugBank.d499.s24.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Invirase", "drug2": "Kadian", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p859"}
{"sentence": "Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, sedatives, tranquilizers).", "drug1": "antiemetics", "drug2": "tranquilizers", "relation": "NONE", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s1", "pair_id": "DDI-DrugBank.d114.s1.p13"}
{"sentence": "Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.", "drug1": "Estrogens", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s17", "pair_id": "DDI-DrugBank.d314.s17.p5"}
{"sentence": "Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.", "drug1": "itraconazole", "drug2": "VIDEX", "relation": "ADVISE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s5", "pair_id": "DDI-DrugBank.d43.s5.p2"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "fentanyl", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p62"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "Aprepitant", "drug2": "nelfinavir", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p6"}
{"sentence": "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.", "drug1": "ALFENTA", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Alfentanil_ddi.xml", "sentence_id": "DDI-DrugBank.d8.s0", "pair_id": "DDI-DrugBank.d8.s0.p4"}
{"sentence": "Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.", "drug1": "indinavir", "drug2": "indinavir", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s4", "pair_id": "DDI-DrugBank.d97.s4.p2"}
{"sentence": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.", "drug1": "carbamazepine", "drug2": "clonazepam", "relation": "MECHANISM", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s5", "pair_id": "DDI-DrugBank.d333.s5.p5"}
{"sentence": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.", "drug1": "quinolones", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s4", "pair_id": "DDI-DrugBank.d347.s4.p0"}
{"sentence": "Griseofulvin: Griseofulvin may induce the metabolism of combination hormonal contraceptives causing menstrual changes;", "drug1": "Griseofulvin", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s23", "pair_id": "DDI-DrugBank.d485.s23.p2"}
{"sentence": "Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.", "drug1": "ketoconazole", "drug2": "astemizole", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s4", "pair_id": "DDI-DrugBank.d165.s4.p4"}
{"sentence": "Using calcium acetate with digitalis glycosides (heart medicine) may cause hypercalcemia (too much calcium in the blood), which could increase the chance of developing an irregular heartbeat.", "drug1": "calcium acetate", "drug2": "digitalis glycosides", "relation": "EFFECT", "source_file": "Calcium Acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d494.s1", "pair_id": "DDI-DrugBank.d494.s1.p0"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "chloramphenicol", "drug2": "para-aminobenzoic acid", "relation": "NONE", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p43"}
{"sentence": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).", "drug1": "caffeine", "drug2": "caffeine", "relation": "NONE", "source_file": "Caffeine_ddi.xml", "sentence_id": "DDI-DrugBank.d89.s3", "pair_id": "DDI-DrugBank.d89.s3.p3"}
{"sentence": "however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.", "drug1": "ranitidine", "drug2": "ceftibuten", "relation": "MECHANISM", "source_file": "Ceftibuten_ddi.xml", "sentence_id": "DDI-DrugBank.d32.s7", "pair_id": "DDI-DrugBank.d32.s7.p1"}
{"sentence": "In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.", "drug1": "methylxanthines", "drug2": "adenosine", "relation": "ADVISE", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s5", "pair_id": "DDI-DrugBank.d226.s5.p1"}
{"sentence": "Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.", "drug1": "diltiazem", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s33", "pair_id": "DDI-DrugBank.d565.s33.p0"}
{"sentence": "conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).", "drug1": "diethylpropion", "drug2": "guanethidine", "relation": "INT", "source_file": "Diethylpropion_ddi.xml", "sentence_id": "DDI-DrugBank.d352.s3", "pair_id": "DDI-DrugBank.d352.s3.p1"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "hypnotics", "drug2": "opioids", "relation": "NONE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p42"}
{"sentence": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.", "drug1": "phenytoin", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s30", "pair_id": "DDI-DrugBank.d124.s30.p6"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "epinephrine", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Lidocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d564.s0", "pair_id": "DDI-DrugBank.d564.s0.p5"}
{"sentence": "Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.", "drug1": "thiazides", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s5", "pair_id": "DDI-DrugBank.d236.s5.p2"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p0"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "butyrophenone classes of antipsychotic agents", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p7"}
{"sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "drug1": "Erythromycin", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s6", "pair_id": "DDI-DrugBank.d397.s6.p1"}
{"sentence": "In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.", "drug1": "cimetidine", "drug2": "tricyclic antidepressant", "relation": "MECHANISM", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s25", "pair_id": "DDI-DrugBank.d223.s25.p5"}
{"sentence": "Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. ", "drug1": "Sodium thiosulfate", "drug2": "cisplatin", "relation": "EFFECT", "source_file": "4038510.xml", "sentence_id": "DDI-MedLine.d130.s2", "pair_id": "DDI-MedLine.d130.s2.p0"}
{"sentence": "Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "ibuprofen", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s9", "pair_id": "DDI-DrugBank.d415.s9.p3"}
{"sentence": "Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.", "drug1": "metoclopramide", "drug2": "metoclopramide", "relation": "NONE", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s7", "pair_id": "DDI-DrugBank.d47.s7.p1"}
{"sentence": "Probenecid: The oral combination of probenecid before intramuscular injection of PIPRACIL produces an increase in piperacillin peak serum level of about 30%.", "drug1": "probenecid", "drug2": "PIPRACIL", "relation": "MECHANISM", "source_file": "Piperacillin_ddi.xml", "sentence_id": "DDI-DrugBank.d462.s5", "pair_id": "DDI-DrugBank.d462.s5.p3"}
{"sentence": "In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism.", "drug1": "escitalopram", "drug2": "escitalopram", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s31", "pair_id": "DDI-DrugBank.d568.s31.p5"}
{"sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "drug1": "Cisapride", "drug2": "sotalol", "relation": "ADVISE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s14", "pair_id": "DDI-DrugBank.d237.s14.p3"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "cisapride", "drug2": "disopyramide", "relation": "NONE", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p70"}
{"sentence": "Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.", "drug1": "agents with b-blocking properties", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s3", "pair_id": "DDI-DrugBank.d269.s3.p1"}
{"sentence": "Intravenous ranitidine was shown to double the bioavailability of oral alendronate.", "drug1": "ranitidine", "drug2": "alendronate", "relation": "MECHANISM", "source_file": "Alendronate_ddi.xml", "sentence_id": "DDI-DrugBank.d430.s0", "pair_id": "DDI-DrugBank.d430.s0.p0"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "contraceptives", "drug2": "quinidine", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p69"}
{"sentence": "Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.", "drug1": "Cimetidine", "drug2": "chloroquine", "relation": "MECHANISM", "source_file": "Chloroquine_ddi.xml", "sentence_id": "DDI-DrugBank.d429.s2", "pair_id": "DDI-DrugBank.d429.s2.p2"}
{"sentence": "However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.", "drug1": "leucovorin", "drug2": "methotrexate", "relation": "EFFECT", "source_file": "Leucovorin_ddi.xml", "sentence_id": "DDI-DrugBank.d151.s2", "pair_id": "DDI-DrugBank.d151.s2.p0"}
{"sentence": "Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients.", "drug1": "Beta-blockers", "drug2": "beta-agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s13", "pair_id": "DDI-DrugBank.d284.s13.p0"}
{"sentence": "Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.", "drug1": "Paroxetine", "drug2": "duloxetine", "relation": "MECHANISM", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s4", "pair_id": "DDI-DrugBank.d548.s4.p0"}
{"sentence": "The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). ", "drug1": "estradiol", "drug2": "endotoxin", "relation": "MECHANISM", "source_file": "7600639.xml", "sentence_id": "DDI-MedLine.d39.s3", "pair_id": "DDI-MedLine.d39.s3.p0"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "Type 1C antiarrhythmics", "drug2": "encainide", "relation": "NONE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p28"}
{"sentence": "Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.", "drug1": "Lithium", "drug2": "diuretics", "relation": "ADVISE", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s5", "pair_id": "DDI-DrugBank.d231.s5.p0"}
{"sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "drug1": "quinolones", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Levofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d242.s1", "pair_id": "DDI-DrugBank.d242.s1.p4"}
{"sentence": "A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and nimodipine at 90 mg/day.", "drug1": "cimetidine", "drug2": "nimodipine", "relation": "MECHANISM", "source_file": "Nimodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d310.s3", "pair_id": "DDI-DrugBank.d310.s3.p2"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "blood thinner", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p4"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "antibiotics", "drug2": "thyroid drugs", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p351"}
{"sentence": "Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.", "drug1": "statins", "drug2": "TRACLEER", "relation": "ADVISE", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s29", "pair_id": "DDI-DrugBank.d289.s29.p0"}
{"sentence": "Rifampin: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.", "drug1": "rifampin", "drug2": "MEPRON", "relation": "MECHANISM", "source_file": "Atovaquone_ddi.xml", "sentence_id": "DDI-DrugBank.d424.s3", "pair_id": "DDI-DrugBank.d424.s3.p3"}
{"sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "drug1": "fentanyl", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s2", "pair_id": "DDI-DrugBank.d170.s2.p1"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Phenothiazines", "drug2": "Sparine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p13"}
{"sentence": "Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. ", "drug1": "anticoagulant", "drug2": "trichlorfon", "relation": "NONE", "source_file": "46730.xml", "sentence_id": "DDI-MedLine.d5.s1", "pair_id": "DDI-MedLine.d5.s1.p9"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "glucocorticoids", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p18"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "astemizole", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p24"}
{"sentence": "Cimetidine increased the AUC of epirubicin by 50%.", "drug1": "Cimetidine", "drug2": "epirubicin", "relation": "MECHANISM", "source_file": "Epirubicin_ddi.xml", "sentence_id": "DDI-DrugBank.d428.s10", "pair_id": "DDI-DrugBank.d428.s10.p0"}
{"sentence": "Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.", "drug1": "salicylates", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s3", "pair_id": "DDI-DrugBank.d231.s3.p0"}
{"sentence": "Ketoconazole (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.", "drug1": "vardenafil", "drug2": "Vardenafil", "relation": "NONE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s7", "pair_id": "DDI-DrugBank.d198.s7.p2"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "felbamate", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p2"}
{"sentence": "Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.", "drug1": "valproate", "drug2": "isoniazid", "relation": "MECHANISM", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s13", "pair_id": "DDI-DrugBank.d187.s13.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Felbatol", "drug2": "morphine", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p481"}
{"sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "drug1": "antipsychotic agents", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s3", "pair_id": "DDI-DrugBank.d186.s3.p2"}
{"sentence": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.", "drug1": "neomycin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s6", "pair_id": "DDI-DrugBank.d450.s6.p17"}
{"sentence": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "drug1": "Clonidine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s2", "pair_id": "DDI-DrugBank.d495.s2.p9"}
{"sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "drug1": "aluminum hydroxide", "drug2": "cimetidine", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s5", "pair_id": "DDI-DrugBank.d558.s5.p31"}
{"sentence": "Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.", "drug1": "diflunisal", "drug2": "anticoagulants", "relation": "ADVISE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s2", "pair_id": "DDI-DrugBank.d132.s2.p0"}
{"sentence": "Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine", "drug1": "dihydroergotamine", "drug2": "ergonovine", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s10", "pair_id": "DDI-DrugBank.d97.s10.p0"}
{"sentence": "Doxylamine may enhance the effects of epinephrine.", "drug1": "Doxylamine", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Doxylamine_ddi.xml", "sentence_id": "DDI-DrugBank.d387.s2", "pair_id": "DDI-DrugBank.d387.s2.p0"}
{"sentence": "Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. ", "drug1": "caffeine", "drug2": "acetaminophen", "relation": "NONE", "source_file": "3969689.xml", "sentence_id": "DDI-MedLine.d55.s1", "pair_id": "DDI-MedLine.d55.s1.p5"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "trimethoprim", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p117"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "phenothiazines", "drug2": "lorazepam", "relation": "NONE", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p25"}
{"sentence": "In Study 1, patients with colorectal cancer were given irinotecan/5-FU/leucovorin (bolus-IFL) with or without AVASTIN.", "drug1": "irinotecan", "drug2": "leucovorin", "relation": "NONE", "source_file": "Bevacizumab_ddi.xml", "sentence_id": "DDI-DrugBank.d312.s1", "pair_id": "DDI-DrugBank.d312.s1.p1"}
{"sentence": "It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.", "drug1": "fluvoxamine", "drug2": "anagrelide", "relation": "MECHANISM", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s10", "pair_id": "DDI-DrugBank.d75.s10.p0"}
{"sentence": "In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "potassium-sparing diuretics", "relation": "EFFECT", "source_file": "Amiloride_ddi.xml", "sentence_id": "DDI-DrugBank.d356.s4", "pair_id": "DDI-DrugBank.d356.s4.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "allopurinol", "drug2": "diflunisal", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p121"}
{"sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.", "drug1": "Anticoagulants", "drug2": "ardeparin", "relation": "EFFECT", "source_file": "Ardeparin_ddi.xml", "sentence_id": "DDI-DrugBank.d105.s0", "pair_id": "DDI-DrugBank.d105.s0.p4"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Sporanox", "drug2": "Agenerase", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p592"}
{"sentence": "Coadministration of terfenadine with Itraconazole has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.", "drug1": "terfenadine", "drug2": "Itraconazole", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s3", "pair_id": "DDI-DrugBank.d165.s3.p0"}
{"sentence": "There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam.", "drug1": "loxapine", "drug2": "lorazepam", "relation": "EFFECT", "source_file": "Loxapine_ddi.xml", "sentence_id": "DDI-DrugBank.d504.s0", "pair_id": "DDI-DrugBank.d504.s0.p0"}
{"sentence": "Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.", "drug1": "Quinolones", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s19", "pair_id": "DDI-DrugBank.d123.s19.p4"}
{"sentence": "In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.", "drug1": "nonsteroidal anti-inflammatory agents", "drug2": "folic acid", "relation": "NONE", "source_file": "Infliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d45.s4", "pair_id": "DDI-DrugBank.d45.s4.p4"}
{"sentence": "Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.", "drug1": "Auranofin", "drug2": "Depen", "relation": "ADVISE", "source_file": "Auranofin_ddi.xml", "sentence_id": "DDI-DrugBank.d374.s1", "pair_id": "DDI-DrugBank.d374.s1.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "chloral hydrate", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p7"}
{"sentence": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "drug1": "iron supplements", "drug2": "OMNICEF", "relation": "ADVISE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s6", "pair_id": "DDI-DrugBank.d420.s6.p1"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "imipramine", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p2"}
{"sentence": "There is no information regarding the effect on lamivudine pharmacokinetics of higher doses of TMP/SMX such as those used to treat Pneumocystis carinii pneumonia.", "drug1": "TMP", "drug2": "SMX", "relation": "NONE", "source_file": "Lamivudine_ddi.xml", "sentence_id": "DDI-DrugBank.d71.s3", "pair_id": "DDI-DrugBank.d71.s3.p2"}
{"sentence": "Caution should also be applied for other sympathomimetics, and for aminophylline and theophylline and tricyclic antidepressants, which may also precipitate arrhythmias.", "drug1": "sympathomimetics", "drug2": "theophylline", "relation": "NONE", "source_file": "Halothane_ddi.xml", "sentence_id": "DDI-DrugBank.d74.s4", "pair_id": "DDI-DrugBank.d74.s4.p1"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p13"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "trimethoprim", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1482"}
{"sentence": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "drug1": "NSAIDs", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s15", "pair_id": "DDI-DrugBank.d219.s15.p3"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "drug1": "anesthetic solutions", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s0", "pair_id": "DDI-DrugBank.d110.s0.p4"}
{"sentence": "Other quinolones have demonstrated moderate to marked interference with the metabolism of caffeine, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of caffeine.", "drug1": "quinolones", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s11", "pair_id": "DDI-DrugBank.d516.s11.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p5"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "nonsteroidal anti-inflammatory agents", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p4"}
{"sentence": "Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy;", "drug1": "quinidine", "drug2": "flecainide", "relation": "MECHANISM", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s16", "pair_id": "DDI-DrugBank.d87.s16.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p42"}
{"sentence": "The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.", "drug1": "triacetyloleandomycin", "drug2": "ergotamine", "relation": "MECHANISM", "source_file": "Ergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d59.s0", "pair_id": "DDI-DrugBank.d59.s0.p2"}
{"sentence": "A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.", "drug1": "barbiturates", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Norgestimate_ddi.xml", "sentence_id": "DDI-DrugBank.d360.s1", "pair_id": "DDI-DrugBank.d360.s1.p2"}
{"sentence": "While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.", "drug1": "phenytoin", "drug2": "estazolam", "relation": "NONE", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s4", "pair_id": "DDI-DrugBank.d338.s4.p11"}
{"sentence": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "drug1": "retinyl acetate", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s2", "pair_id": "DDI-MedLine.d12.s2.p6"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "sulfamethoxazole", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p13"}
{"sentence": "Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.", "drug1": "Warfarin", "drug2": "anticoagulant", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s24", "pair_id": "DDI-DrugBank.d516.s24.p1"}
{"sentence": "Thus, probenecid should not be administered concurrently with bumetanide.", "drug1": "probenecid", "drug2": "bumetanide", "relation": "ADVISE", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s6", "pair_id": "DDI-DrugBank.d331.s6.p0"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p7"}
{"sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "drug1": "sulphonylureas", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s35", "pair_id": "DDI-DrugBank.d558.s35.p41"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;", "drug1": "anticoagulant", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s30", "pair_id": "DDI-DrugBank.d64.s30.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "bromelains", "drug2": "phenytoin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p388"}
{"sentence": "There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.", "drug1": "PGF2alpha", "drug2": "oxytocin", "relation": "EFFECT", "source_file": "1113260.xml", "sentence_id": "DDI-MedLine.d17.s9", "pair_id": "DDI-MedLine.d17.s9.p0"}
{"sentence": "Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.", "drug1": "Bismuth subsalicylate", "drug2": "enoxacin", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s0", "pair_id": "DDI-DrugBank.d395.s0.p4"}
{"sentence": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "drug1": "rifabutin", "drug2": "CRIXIVAN", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s84", "pair_id": "DDI-DrugBank.d97.s84.p0"}
{"sentence": "Caution should be exercised if tacrolimus and bosentan are used together.", "drug1": "tacrolimus", "drug2": "bosentan", "relation": "ADVISE", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s16", "pair_id": "DDI-DrugBank.d289.s16.p0"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "propafenone", "drug2": "quinidine", "relation": "NONE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p32"}
{"sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.", "drug1": "Phenobarbital", "drug2": "AEDs", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s12", "pair_id": "DDI-DrugBank.d277.s12.p4"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p2"}
{"sentence": "Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.", "drug1": "androgens", "drug2": "methandrostenolone", "relation": "NONE", "source_file": "Fludrocortisone_ddi.xml", "sentence_id": "DDI-DrugBank.d526.s19", "pair_id": "DDI-DrugBank.d526.s19.p5"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "serotonin reuptake inhibitors", "drug2": "SSRIs", "relation": "NONE", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s8", "pair_id": "DDI-DrugBank.d99.s8.p0"}
{"sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "drug1": "Nardil", "drug2": "Eldepryl", "relation": "NONE", "source_file": "L-Tryptophan_ddi.xml", "sentence_id": "DDI-DrugBank.d63.s0", "pair_id": "DDI-DrugBank.d63.s0.p41"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "enflurane", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p0"}
{"sentence": "The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .", "drug1": "ENABLEX", "drug2": "clarithromycin", "relation": "ADVISE", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s0", "pair_id": "DDI-DrugBank.d459.s0.p4"}
{"sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "ardeparin", "relation": "EFFECT", "source_file": "Ardeparin_ddi.xml", "sentence_id": "DDI-DrugBank.d105.s0", "pair_id": "DDI-DrugBank.d105.s0.p11"}
{"sentence": "Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.", "drug1": "sodium acid phosphate", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s0", "pair_id": "DDI-DrugBank.d158.s0.p2"}
{"sentence": "The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ", "drug1": "desipramine", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "7798493.xml", "sentence_id": "DDI-MedLine.d94.s12", "pair_id": "DDI-MedLine.d94.s12.p2"}
{"sentence": "The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.", "drug1": "ENABLEX", "drug2": "anticholinergic agents", "relation": "EFFECT", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s2", "pair_id": "DDI-DrugBank.d459.s2.p0"}
{"sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "drug1": "fentanyl", "drug2": "itraconazole", "relation": "MECHANISM", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s2", "pair_id": "DDI-DrugBank.d170.s2.p2"}
{"sentence": "When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.", "drug1": "STADOL NS", "drug2": "sumatriptan", "relation": "MECHANISM", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s5", "pair_id": "DDI-DrugBank.d246.s5.p0"}
{"sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "drug1": "Atorvastatin", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s16", "pair_id": "DDI-DrugBank.d485.s16.p4"}
{"sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "drug1": "Anesthetics", "drug2": "sedatives", "relation": "NONE", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s1", "pair_id": "DDI-DrugBank.d197.s1.p5"}
{"sentence": "Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).", "drug1": "Acarbose", "drug2": "digoxin", "relation": "NONE", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s8", "pair_id": "DDI-DrugBank.d536.s8.p1"}
{"sentence": "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.", "drug1": "PROLEUKIN", "drug2": "antineoplastic agents", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s5", "pair_id": "DDI-DrugBank.d114.s5.p0"}
{"sentence": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "drug1": "oxyphenbutazone", "drug2": "androgens", "relation": "MECHANISM", "source_file": "Fluoxymesterone_ddi.xml", "sentence_id": "DDI-DrugBank.d355.s2", "pair_id": "DDI-DrugBank.d355.s2.p0"}
{"sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "indinavir", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s12", "pair_id": "DDI-DrugBank.d237.s12.p5"}
{"sentence": "The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.", "drug1": "diuretic", "drug2": "fosinopril sodium", "relation": "EFFECT", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s1", "pair_id": "DDI-DrugBank.d176.s1.p0"}
{"sentence": "Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.", "drug1": "Azlocillin", "drug2": "tobramycin", "relation": "ADVISE", "source_file": "Azlocillin_ddi.xml", "sentence_id": "DDI-DrugBank.d9.s0", "pair_id": "DDI-DrugBank.d9.s0.p4"}
{"sentence": "The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. ", "drug1": "GL", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "10319155.xml", "sentence_id": "DDI-MedLine.d84.s4", "pair_id": "DDI-MedLine.d84.s4.p0"}
{"sentence": "Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.", "drug1": "Indinavir", "drug2": "didanosine", "relation": "ADVISE", "source_file": "11120981.xml", "sentence_id": "DDI-MedLine.d79.s5", "pair_id": "DDI-MedLine.d79.s5.p0"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p19"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "ergot alkaloids", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p87"}
{"sentence": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).", "drug1": "cimetidine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Caffeine_ddi.xml", "sentence_id": "DDI-DrugBank.d89.s3", "pair_id": "DDI-DrugBank.d89.s3.p17"}
{"sentence": "Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.", "drug1": "sulfinpyrazone", "drug2": "nitrofurantoin", "relation": "MECHANISM", "source_file": "Nitrofurantoin_ddi.xml", "sentence_id": "DDI-DrugBank.d276.s2", "pair_id": "DDI-DrugBank.d276.s2.p5"}
{"sentence": "include terfenadine, astemizole, cisapride, midazolam, and triazolam.", "drug1": "midazolam", "drug2": "triazolam", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s16", "pair_id": "DDI-DrugBank.d78.s16.p9"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "dolasetron", "relation": "ADVISE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p27"}
{"sentence": "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.", "drug1": "PROLEUKIN", "drug2": "tamoxifen", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s5", "pair_id": "DDI-DrugBank.d114.s5.p3"}
{"sentence": "The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.", "drug1": "cilostazol", "drug2": "anagrelide", "relation": "EFFECT", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s14", "pair_id": "DDI-DrugBank.d75.s14.p14"}
{"sentence": "Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.", "drug1": "Erythromycin", "drug2": "Ketoconazole", "relation": "NONE", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s0", "pair_id": "DDI-DrugBank.d466.s0.p0"}
{"sentence": "Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.", "drug1": "Valdecoxib", "drug2": "S-warfarin", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s24", "pair_id": "DDI-DrugBank.d328.s24.p1"}
{"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "drug1": "phenobarbital", "drug2": "phenytoin", "relation": "NONE", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s1", "pair_id": "DDI-DrugBank.d487.s1.p0"}
{"sentence": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.", "drug1": "acetaminophen", "drug2": "caffeine", "relation": "EFFECT", "source_file": "3969689.xml", "sentence_id": "DDI-MedLine.d55.s4", "pair_id": "DDI-MedLine.d55.s4.p0"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "bromocriptine", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p3"}
{"sentence": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "drug1": "TIKOSYN", "drug2": "verapamil", "relation": "MECHANISM", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s7", "pair_id": "DDI-DrugBank.d558.s7.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "miconazole", "drug2": "sulfonamides", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1201"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "Vitamin D2", "drug2": "Vitamin D3", "relation": "NONE", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s0", "pair_id": "DDI-DrugBank.d404.s0.p7"}
{"sentence": "Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ", "drug1": "indinavir", "drug2": "indinavir", "relation": "NONE", "source_file": "11120981.xml", "sentence_id": "DDI-MedLine.d79.s1", "pair_id": "DDI-MedLine.d79.s1.p1"}
{"sentence": "Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.", "drug1": "Probenecid", "drug2": "zalcitabine", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s20", "pair_id": "DDI-DrugBank.d263.s20.p3"}
{"sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "drug1": "desipramine hydrochloride", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s23", "pair_id": "DDI-DrugBank.d386.s23.p1"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "quinidine", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p75"}
{"sentence": "Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.\r\n", "drug1": "MPTP", "drug2": "methamphetamine", "relation": "NONE", "source_file": "3871245.xml", "sentence_id": "DDI-MedLine.d73.s0", "pair_id": "DDI-MedLine.d73.s0.p2"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "salsalate", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p4"}
{"sentence": "When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.", "drug1": "amiloride", "drug2": "angiotensin-converting enzyme inhibitor", "relation": "EFFECT", "source_file": "Amiloride_ddi.xml", "sentence_id": "DDI-DrugBank.d356.s0", "pair_id": "DDI-DrugBank.d356.s0.p0"}
{"sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "drug1": "fexofenadine hydrochloride", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s19", "pair_id": "DDI-DrugBank.d466.s19.p7"}
{"sentence": "In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "drug1": "acetylsalicylic acid", "drug2": "fondaparinux sodium", "relation": "NONE", "source_file": "Fondaparinux sodium_ddi.xml", "sentence_id": "DDI-DrugBank.d15.s0", "pair_id": "DDI-DrugBank.d15.s0.p29"}
{"sentence": "Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.", "drug1": "HMG-CoA reductase inhibitors", "drug2": "Fentanyl", "relation": "ADVISE", "source_file": "Daptomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d337.s3", "pair_id": "DDI-DrugBank.d337.s3.p5"}
{"sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "Selective serotonin reuptake inhibitors", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s3", "pair_id": "DDI-DrugBank.d426.s3.p5"}
{"sentence": "Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "drug1": "lithium", "drug2": "insulin", "relation": "EFFECT", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s3", "pair_id": "DDI-DrugBank.d527.s3.p8"}
{"sentence": "In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.", "drug1": "androgens", "drug2": "insulin", "relation": "EFFECT", "source_file": "Dromostanolone_ddi.xml", "sentence_id": "DDI-DrugBank.d129.s3", "pair_id": "DDI-DrugBank.d129.s3.p0"}
{"sentence": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "drug1": "dofetilide", "drug2": "dofetilide", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s7", "pair_id": "DDI-DrugBank.d558.s7.p5"}
{"sentence": "Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).", "drug1": "enalapril", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s3", "pair_id": "DDI-DrugBank.d107.s3.p2"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "tacrolimus", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "lincomycin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p20"}
{"sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "drug1": "acetaminophen", "drug2": "theophylline", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s5", "pair_id": "DDI-MedLine.d111.s5.p59"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "topiramate", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p37"}
{"sentence": "In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.", "drug1": "nifedipine", "drug2": "Vardenafil", "relation": "EFFECT", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s27", "pair_id": "DDI-DrugBank.d198.s27.p0"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "quinolone", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "risperidone", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p35"}
{"sentence": "Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;", "drug1": "lopinavir", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s32", "pair_id": "DDI-DrugBank.d485.s32.p11"}
{"sentence": "Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.", "drug1": "iodine", "drug2": "iodine", "relation": "NONE", "source_file": "Carbimazole_ddi.xml", "sentence_id": "DDI-DrugBank.d213.s0", "pair_id": "DDI-DrugBank.d213.s0.p5"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "serotoninergic agents", "drug2": "venlafaxine", "relation": "NONE", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p25"}
{"sentence": "Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.", "drug1": "Phenothiazines", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Lidocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d564.s1", "pair_id": "DDI-DrugBank.d564.s1.p1"}
{"sentence": "Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.", "drug1": "phenobarbital", "drug2": "AEDs", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s12", "pair_id": "DDI-DrugBank.d277.s12.p13"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p10"}
{"sentence": "Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.", "drug1": "Aminosalicylic acid", "drug2": "vitamin B12", "relation": "MECHANISM", "source_file": "Aminosalicylic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d22.s2", "pair_id": "DDI-DrugBank.d22.s2.p0"}
{"sentence": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.", "drug1": "ritonavir", "drug2": "budesonide", "relation": "ADVISE", "source_file": "Budesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d144.s1", "pair_id": "DDI-DrugBank.d144.s1.p14"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "sulfinpyrazone", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p45"}
{"sentence": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "drug1": "COREG", "drug2": "diltiazem", "relation": "ADVISE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s17", "pair_id": "DDI-DrugBank.d269.s17.p6"}
{"sentence": "Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.", "drug1": "dopamine", "drug2": "metoprolol", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s4", "pair_id": "DDI-DrugBank.d325.s4.p2"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "magnesium", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p29"}
{"sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "drug1": "ranitidine", "drug2": "aluminum hydroxide", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s5", "pair_id": "DDI-DrugBank.d558.s5.p22"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "fenoprofen", "drug2": "tolbutamide", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p919"}
{"sentence": "Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.", "drug1": "cefditoren pivoxil", "drug2": "antacids", "relation": "ADVISE", "source_file": "Cefditoren_ddi.xml", "sentence_id": "DDI-DrugBank.d550.s1", "pair_id": "DDI-DrugBank.d550.s1.p0"}
{"sentence": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "drug1": "NSAID", "drug2": "digoxin", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s5", "pair_id": "DDI-DrugBank.d249.s5.p9"}
{"sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "drug1": "omeprazole", "drug2": "ranitidine", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s5", "pair_id": "DDI-DrugBank.d558.s5.p15"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "azole antifungal agents", "drug2": "cannabinoids", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p15"}
{"sentence": "MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.", "drug1": "MAO inhibitors", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Diphenhydramine_ddi.xml", "sentence_id": "DDI-DrugBank.d296.s1", "pair_id": "DDI-DrugBank.d296.s1.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "adrenocortical steroids", "drug2": "cholestyramine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p30"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "indomethacin", "drug2": "naproxen", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p260"}
{"sentence": "The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.", "drug1": "azathioprine", "drug2": "muromonab-CD3", "relation": "NONE", "source_file": "Basiliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d544.s5", "pair_id": "DDI-DrugBank.d544.s5.p8"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "barbiturates", "drug2": "nonsteroidal anti-inflammatory", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p81"}
{"sentence": "Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.", "drug1": "calcium", "drug2": "Ibandronate", "relation": "MECHANISM", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s1", "pair_id": "DDI-DrugBank.d440.s1.p3"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "p-aminosalicylic acid", "drug2": "lithium", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p52"}
{"sentence": "- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine", "drug1": "phenytoin", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s12", "pair_id": "DDI-DrugBank.d40.s12.p0"}
{"sentence": "Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.", "drug1": "phenytoin", "drug2": "BUSULFEX", "relation": "NONE", "source_file": "Busulfan_ddi.xml", "sentence_id": "DDI-DrugBank.d72.s3", "pair_id": "DDI-DrugBank.d72.s3.p3"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "AKINETON", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p13"}
{"sentence": "NSAIDs may decrease the hemodynamic effects of hydralazine;", "drug1": "NSAIDs", "drug2": "hydralazine", "relation": "EFFECT", "source_file": "Hydralazine_ddi.xml", "sentence_id": "DDI-DrugBank.d31.s7", "pair_id": "DDI-DrugBank.d31.s7.p0"}
{"sentence": "Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.", "drug1": "ciprofloxacin", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s0", "pair_id": "DDI-DrugBank.d123.s0.p2"}
{"sentence": "Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.", "drug1": "anticoagulants", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s88", "pair_id": "DDI-DrugBank.d64.s88.p1"}
{"sentence": "Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.", "drug1": "ABILIFY", "drug2": "alcohol", "relation": "ADVISE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s0", "pair_id": "DDI-DrugBank.d509.s0.p4"}
{"sentence": "Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.", "drug1": "antibiotics", "drug2": "vitamins", "relation": "NONE", "source_file": "Dornase Alfa_ddi.xml", "sentence_id": "DDI-DrugBank.d93.s0", "pair_id": "DDI-DrugBank.d93.s0.p6"}
{"sentence": "Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.", "drug1": "flurbiprofen", "drug2": "furosemide", "relation": "ADVISE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s17", "pair_id": "DDI-DrugBank.d529.s17.p0"}
{"sentence": "Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "drug1": "Beta-blockers", "drug2": "insulin", "relation": "EFFECT", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s3", "pair_id": "DDI-DrugBank.d313.s3.p3"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "indomethacin", "drug2": "Aleve", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p263"}
{"sentence": "Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.", "drug1": "BREVIBLOC", "drug2": "digoxin", "relation": "ADVISE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s10", "pair_id": "DDI-DrugBank.d422.s10.p0"}
{"sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.", "drug1": "tricyclic antidepressants", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s4", "pair_id": "DDI-DrugBank.d238.s4.p1"}
{"sentence": "Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable", "drug1": "phenytoin", "drug2": "phenobarbital", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s15", "pair_id": "DDI-DrugBank.d40.s15.p0"}
{"sentence": "Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.", "drug1": "Theophylline", "drug2": "theophylline", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s6", "pair_id": "DDI-DrugBank.d78.s6.p1"}
{"sentence": "The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.", "drug1": "lymecycline", "drug2": "iron", "relation": "MECHANISM", "source_file": "Lymecycline_ddi.xml", "sentence_id": "DDI-DrugBank.d79.s0", "pair_id": "DDI-DrugBank.d79.s0.p0"}
{"sentence": "These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.", "drug1": "erythromycin", "drug2": "fexofenadine", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s17", "pair_id": "DDI-DrugBank.d466.s17.p2"}
{"sentence": "Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. ", "drug1": "pyrilamine", "drug2": "phenyltoloxamine", "relation": "NONE", "source_file": "2578597.xml", "sentence_id": "DDI-MedLine.d57.s2", "pair_id": "DDI-MedLine.d57.s2.p18"}
{"sentence": "Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.", "drug1": "Clozapine", "drug2": "fluvoxamine", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s23", "pair_id": "DDI-DrugBank.d480.s23.p0"}
{"sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "drug1": "alprazolam", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s12", "pair_id": "DDI-DrugBank.d76.s12.p11"}
{"sentence": "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.", "drug1": "ALFENTA", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Alfentanil_ddi.xml", "sentence_id": "DDI-DrugBank.d8.s0", "pair_id": "DDI-DrugBank.d8.s0.p0"}
{"sentence": "In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.", "drug1": "cimetidine", "drug2": "flecainide", "relation": "MECHANISM", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s14", "pair_id": "DDI-DrugBank.d87.s14.p0"}
{"sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.", "drug1": "benzodiazepines", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s3", "pair_id": "DDI-DrugBank.d335.s3.p3"}
{"sentence": "Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.", "drug1": "atorvastatin", "drug2": "CRIXIVAN", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s72", "pair_id": "DDI-DrugBank.d97.s72.p4"}
{"sentence": "In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.", "drug1": "digoxin", "drug2": "ertapenem", "relation": "NONE", "source_file": "Ertapenem_ddi.xml", "sentence_id": "DDI-DrugBank.d329.s4", "pair_id": "DDI-DrugBank.d329.s4.p4"}
{"sentence": "It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.", "drug1": "Vardenafil", "drug2": "erythromycin", "relation": "ADVISE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s6", "pair_id": "DDI-DrugBank.d198.s6.p0"}
{"sentence": "Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.", "drug1": "BUSULFEX", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Busulfan_ddi.xml", "sentence_id": "DDI-DrugBank.d72.s3", "pair_id": "DDI-DrugBank.d72.s3.p0"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "probenecid", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p4"}
{"sentence": "Rifampin and warfarin: a drug interaction.\r\n", "drug1": "Rifampin", "drug2": "warfarin", "relation": "INT", "source_file": "1115445.xml", "sentence_id": "DDI-MedLine.d116.s0", "pair_id": "DDI-MedLine.d116.s0.p0"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "AKINETON", "drug2": "meperidine", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p10"}
{"sentence": "The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.", "drug1": "Acamprosate", "drug2": "alcohol", "relation": "NONE", "source_file": "Acamprosate_ddi.xml", "sentence_id": "DDI-DrugBank.d0.s0", "pair_id": "DDI-DrugBank.d0.s0.p3"}
{"sentence": "Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).", "drug1": "rifampin", "drug2": "Gleevec", "relation": "MECHANISM", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s6", "pair_id": "DDI-DrugBank.d115.s6.p0"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "non-steroidal anti-inflammatory drugs", "drug2": "hydrochloroquine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p14"}
{"sentence": "Opioids are strong central nervous system depressants, but regular users develop physiological tolerance allowing gradually increased dosages.", "drug1": "Opioids", "drug2": "central nervous system depressants", "relation": "NONE", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s0", "pair_id": "DDI-DrugBank.d514.s0.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "miconazole", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p29"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "phenobarbital", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p21"}
{"sentence": "Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.", "drug1": "etodolac", "drug2": "phenylbutazone", "relation": "ADVISE", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s20", "pair_id": "DDI-DrugBank.d219.s20.p0"}
{"sentence": "These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.", "drug1": "anticoagulants", "drug2": "sulfinpyrazone", "relation": "NONE", "source_file": "Enoxaparin_ddi.xml", "sentence_id": "DDI-DrugBank.d474.s1", "pair_id": "DDI-DrugBank.d474.s1.p5"}
{"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "drug1": "rifampin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s1", "pair_id": "DDI-DrugBank.d487.s1.p7"}
{"sentence": "In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.", "drug1": "SUSTIVA", "drug2": "clarithromycin", "relation": "EFFECT", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s29", "pair_id": "DDI-DrugBank.d531.s29.p0"}
{"sentence": "Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.", "drug1": "digoxin", "drug2": "hydralazine", "relation": "NONE", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s11", "pair_id": "DDI-DrugBank.d561.s11.p14"}
{"sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.", "drug1": "furosemide", "drug2": "hydroxyurea", "relation": "NONE", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s2", "pair_id": "DDI-DrugBank.d75.s2.p20"}
{"sentence": "In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.", "drug1": "clozapine", "drug2": "paroxetine", "relation": "NONE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s19", "pair_id": "DDI-DrugBank.d480.s19.p1"}
{"sentence": "Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ", "drug1": "phenobarbital", "drug2": "quinidine", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s2", "pair_id": "DDI-MedLine.d111.s2.p9"}
{"sentence": "Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.", "drug1": "ciprofloxacin", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s2", "pair_id": "DDI-DrugBank.d123.s2.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "ampicillin", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p3"}
{"sentence": "If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.", "drug1": "chlorprothixene", "drug2": "opioids", "relation": "EFFECT", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s2", "pair_id": "DDI-DrugBank.d503.s2.p9"}
{"sentence": "Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;", "drug1": "Amphetamines", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s25", "pair_id": "DDI-DrugBank.d236.s25.p2"}
{"sentence": "The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;", "drug1": "CMI", "drug2": "haloperidol", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s5", "pair_id": "DDI-DrugBank.d238.s5.p0"}
{"sentence": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.", "drug1": "digoxin", "drug2": "digitoxin", "relation": "NONE", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s14", "pair_id": "DDI-DrugBank.d345.s14.p5"}
{"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "drug1": "vitamin K antagonists", "drug2": "Activase", "relation": "EFFECT", "source_file": "Alteplase_ddi.xml", "sentence_id": "DDI-DrugBank.d508.s1", "pair_id": "DDI-DrugBank.d508.s1.p8"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "delavirdine", "drug2": "desipramine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p440"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "phenothiazines", "drug2": "quinidine", "relation": "NONE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p20"}
{"sentence": "Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.", "drug1": "Vardenafil", "drug2": "indinavir", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s93", "pair_id": "DDI-DrugBank.d97.s93.p0"}
{"sentence": "Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.", "drug1": "sirolimus", "drug2": "diltiazem", "relation": "ADVISE", "source_file": "11180036.xml", "sentence_id": "DDI-MedLine.d86.s9", "pair_id": "DDI-MedLine.d86.s9.p0"}
{"sentence": "Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.", "drug1": "ethoxzolamide", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Ethoxzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d286.s2", "pair_id": "DDI-DrugBank.d286.s2.p0"}
{"sentence": "Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.", "drug1": "beta-adrenergic blocking agents", "drug2": "calcium antagonist", "relation": "EFFECT", "source_file": "Betaxolol_ddi.xml", "sentence_id": "DDI-DrugBank.d489.s6", "pair_id": "DDI-DrugBank.d489.s6.p0"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "oxaprozin", "drug2": "naproxen", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p286"}
{"sentence": "Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.", "drug1": "lithium", "drug2": "CELEBREX", "relation": "MECHANISM", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s19", "pair_id": "DDI-DrugBank.d172.s19.p7"}
{"sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "drug1": "desipramine hydrochloride", "drug2": "psychotropic agents", "relation": "EFFECT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s23", "pair_id": "DDI-DrugBank.d386.s23.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "carbamazepine", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p125"}
{"sentence": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "drug1": "d-amphetamine", "drug2": "desipramine", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s4", "pair_id": "DDI-DrugBank.d158.s4.p0"}
{"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "drug1": "phenytoin", "drug2": "corticosteroid", "relation": "ADVISE", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s1", "pair_id": "DDI-DrugBank.d487.s1.p6"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "meprobamate", "drug2": "rifampin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p252"}
{"sentence": "Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.", "drug1": "beta-adrenergic-blocking agents", "drug2": "diuretics", "relation": "NONE", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s11", "pair_id": "DDI-DrugBank.d561.s11.p6"}
{"sentence": "In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.", "drug1": "TAMBOCOR", "drug2": "propranolol", "relation": "MECHANISM", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s3", "pair_id": "DDI-DrugBank.d87.s3.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "sodium colistemethate", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p23"}
{"sentence": "Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.", "drug1": "Cholestyramine", "drug2": "T4", "relation": "MECHANISM", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s8", "pair_id": "DDI-DrugBank.d54.s8.p4"}
{"sentence": "Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.", "drug1": "warfarin", "drug2": "enoxacin", "relation": "ADVISE", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s25", "pair_id": "DDI-DrugBank.d395.s25.p0"}
{"sentence": "Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.", "drug1": "Paroxetine", "drug2": "paroxetine", "relation": "NONE", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s6", "pair_id": "DDI-DrugBank.d324.s6.p1"}
{"sentence": "Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "drug1": "clonidine", "drug2": "insulin", "relation": "EFFECT", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s3", "pair_id": "DDI-DrugBank.d527.s3.p6"}
{"sentence": "ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.", "drug1": "anesthetics", "drug2": "sympathomimetic amines", "relation": "NONE", "source_file": "Isoproterenol_ddi.xml", "sentence_id": "DDI-DrugBank.d55.s2", "pair_id": "DDI-DrugBank.d55.s2.p4"}
{"sentence": "A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.", "drug1": "phenytoin", "drug2": "coumarin anticoagulant", "relation": "NONE", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s2", "pair_id": "DDI-DrugBank.d359.s2.p2"}
{"sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "Protease Inhibitors", "drug2": "cisapride", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s12", "pair_id": "DDI-DrugBank.d237.s12.p2"}
{"sentence": "- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.", "drug1": "Probenecid", "drug2": "probenecid", "relation": "NONE", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s4", "pair_id": "DDI-DrugBank.d331.s4.p0"}
{"sentence": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "drug1": "STRATTERA", "drug2": "albuterol", "relation": "ADVISE", "source_file": "Atomoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d11.s0", "pair_id": "DDI-DrugBank.d11.s0.p4"}
{"sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.", "drug1": "heroin", "drug2": "Valium", "relation": "EFFECT", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s2", "pair_id": "DDI-DrugBank.d514.s2.p4"}
{"sentence": "Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.", "drug1": "tetracyclines", "drug2": "anticoagulant", "relation": "ADVISE", "source_file": "Demeclocycline_ddi.xml", "sentence_id": "DDI-DrugBank.d409.s0", "pair_id": "DDI-DrugBank.d409.s0.p0"}
{"sentence": "Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.", "drug1": "neomycin sulfate", "drug2": "coumarin", "relation": "EFFECT", "source_file": "Neomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d330.s5", "pair_id": "DDI-DrugBank.d330.s5.p0"}
{"sentence": "Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.", "drug1": "Theophylline", "drug2": "theophylline", "relation": "NONE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s16", "pair_id": "DDI-DrugBank.d123.s16.p3"}
{"sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "drug1": "propoxyphene", "drug2": "sulfonamide antibiotics", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s1", "pair_id": "DDI-DrugBank.d313.s1.p48"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "bumetanide", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p21"}
{"sentence": "Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.", "drug1": "carbamazepine", "drug2": "aripiprazole", "relation": "MECHANISM", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s7", "pair_id": "DDI-DrugBank.d509.s7.p0"}
{"sentence": "RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. ", "drug1": "fluvoxamine", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "11180037.xml", "sentence_id": "DDI-MedLine.d99.s9", "pair_id": "DDI-MedLine.d99.s9.p0"}
{"sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "drug1": "phenobarbital", "drug2": "rifampin", "relation": "NONE", "source_file": "Levobupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d320.s3", "pair_id": "DDI-DrugBank.d320.s3.p7"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "AKINETON", "drug2": "antipsychotics", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p12"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "bromelains", "drug2": "warfarin sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p403"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "alprazolam", "drug2": "ethanol", "relation": "EFFECT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p8"}
{"sentence": "Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.", "drug1": "propoxyphene", "drug2": "alprazolam", "relation": "MECHANISM", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s6", "pair_id": "DDI-DrugBank.d131.s6.p0"}
{"sentence": "Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ", "drug1": "diazepam", "drug2": "metamizol", "relation": "EFFECT", "source_file": "11210678.xml", "sentence_id": "DDI-MedLine.d67.s6", "pair_id": "DDI-MedLine.d67.s6.p0"}
{"sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "drug1": "Mefloquine", "drug2": "anti-arrhythmic", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s9", "pair_id": "DDI-DrugBank.d220.s9.p0"}
{"sentence": "Interaction of clindamycin and gentamicin in vitro.\n", "drug1": "clindamycin", "drug2": "gentamicin", "relation": "INT", "source_file": "15825309.xml", "sentence_id": "DDI-MedLine.d49.s0", "pair_id": "DDI-MedLine.d49.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "diazepam", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p12"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "diflunisal", "drug2": "pyrazolones", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p805"}
{"sentence": "Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.", "drug1": "protease inhibitor", "drug2": "saquinavir", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s18", "pair_id": "DDI-DrugBank.d124.s18.p5"}
{"sentence": "Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "EFFECT", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s1", "pair_id": "DDI-DrugBank.d202.s1.p0"}
{"sentence": "Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone.", "drug1": "diazepam", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Dantrolene_ddi.xml", "sentence_id": "DDI-DrugBank.d305.s2", "pair_id": "DDI-DrugBank.d305.s2.p1"}
{"sentence": "Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "INT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s7", "pair_id": "DDI-DrugBank.d172.s7.p4"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "alprazolam", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p62"}
{"sentence": "Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.", "drug1": "Ibuprofen", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s5", "pair_id": "DDI-DrugBank.d415.s5.p4"}
{"sentence": "Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.", "drug1": "astemizole", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s6", "pair_id": "DDI-DrugBank.d458.s6.p0"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "metoclopramide", "drug2": "sulfonylureas", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p514"}
{"sentence": "Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.", "drug1": "phenytoin", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s3", "pair_id": "DDI-DrugBank.d29.s3.p7"}
{"sentence": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "drug1": "aspirin", "drug2": "ginkgo", "relation": "NONE", "source_file": "Icosapent_ddi.xml", "sentence_id": "DDI-DrugBank.d35.s0", "pair_id": "DDI-DrugBank.d35.s0.p5"}
{"sentence": "Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.", "drug1": "ranitidine", "drug2": "IRESSA", "relation": "MECHANISM", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s7", "pair_id": "DDI-DrugBank.d207.s7.p4"}
{"sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ", "drug1": "pyreneperone", "drug2": "3H-spiroperidol", "relation": "NONE", "source_file": "2857100.xml", "sentence_id": "DDI-MedLine.d15.s0", "pair_id": "DDI-MedLine.d15.s0.p28"}
{"sentence": "Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.", "drug1": "barbiturates", "drug2": "ketamine", "relation": "EFFECT", "source_file": "Ketamine_ddi.xml", "sentence_id": "DDI-DrugBank.d518.s0", "pair_id": "DDI-DrugBank.d518.s0.p1"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "Type 1C antiarrhythmics", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p13"}
{"sentence": "In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.", "drug1": "theophylline", "drug2": "cetirizine", "relation": "MECHANISM", "source_file": "Cetirizine_ddi.xml", "sentence_id": "DDI-DrugBank.d393.s2", "pair_id": "DDI-DrugBank.d393.s2.p0"}
{"sentence": "Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.", "drug1": "Lithium carbonate", "drug2": "amphetamines", "relation": "NONE", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s19", "pair_id": "DDI-DrugBank.d236.s19.p0"}
{"sentence": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "drug1": "furosemide", "drug2": "FLOLAN", "relation": "MECHANISM", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s3", "pair_id": "DDI-DrugBank.d241.s3.p46"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "quinolone", "drug2": "sucralfate", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p4"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "rifampin", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p38"}
{"sentence": "The pharmacokinetics and protein binding of fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Cerebyx were concurrently administered in single submaximal doses.", "drug1": "phenytoin", "drug2": "Cerebyx", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s4", "pair_id": "DDI-DrugBank.d40.s4.p6"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "felbamate", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p16"}
{"sentence": "Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.", "drug1": "bromocriptine mesylate", "drug2": "metoclopramide", "relation": "EFFECT", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s2", "pair_id": "DDI-DrugBank.d272.s2.p2"}
{"sentence": "In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.", "drug1": "Nitrates", "drug2": "nitrates", "relation": "NONE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s22", "pair_id": "DDI-DrugBank.d198.s22.p0"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "Benzthiazide", "drug2": "lithium", "relation": "INT", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p3"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "Relafen", "drug2": "Daypro", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p280"}
{"sentence": "Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.", "drug1": "MAOIs", "drug2": "ethchlorvynol", "relation": "EFFECT", "source_file": "Ethchlorvynol_ddi.xml", "sentence_id": "DDI-DrugBank.d405.s1", "pair_id": "DDI-DrugBank.d405.s1.p5"}
{"sentence": "When other antiplatelet agents or anticoagulants are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.", "drug1": "antiplatelet agents", "drug2": "FLOLAN", "relation": "EFFECT", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s1", "pair_id": "DDI-DrugBank.d241.s1.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "oxyphenbutazone", "drug2": "sulindac", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1307"}
{"sentence": "Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.", "drug1": "STADOL NS", "drug2": "nasal vasoconstrictor", "relation": "EFFECT", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s14", "pair_id": "DDI-DrugBank.d246.s14.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "nefazodone", "drug2": "protease inhibitors", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p298"}
{"sentence": "Chlorthalidone and related drugs may increase the responsiveness to tubocurarine.", "drug1": "Chlorthalidone", "drug2": "tubocurarine", "relation": "EFFECT", "source_file": "Chlorthalidone_ddi.xml", "sentence_id": "DDI-DrugBank.d265.s7", "pair_id": "DDI-DrugBank.d265.s7.p0"}
{"sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "drug1": "acetaminophen", "drug2": "valproic acid", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s5", "pair_id": "DDI-MedLine.d111.s5.p56"}
{"sentence": "Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.", "drug1": "tacrolimus", "drug2": "vancomycin", "relation": "NONE", "source_file": "Adefovir Dipivoxil_ddi.xml", "sentence_id": "DDI-DrugBank.d244.s0", "pair_id": "DDI-DrugBank.d244.s0.p35"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "dopamine agonists", "drug2": "insulin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p354"}
{"sentence": "In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present. ", "drug1": "phenobarbital sodium", "drug2": "coumaphos", "relation": "EFFECT", "source_file": "46730.xml", "sentence_id": "DDI-MedLine.d5.s4", "pair_id": "DDI-MedLine.d5.s4.p0"}
{"sentence": "Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.", "drug1": "Clonidine hydrochloride", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s1", "pair_id": "DDI-DrugBank.d495.s1.p1"}
{"sentence": "Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ", "drug1": "estradiol", "drug2": "noradrenaline", "relation": "EFFECT", "source_file": "11213358.xml", "sentence_id": "DDI-MedLine.d102.s6", "pair_id": "DDI-MedLine.d102.s6.p0"}
{"sentence": "The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.", "drug1": "midazolam", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s34", "pair_id": "DDI-DrugBank.d565.s34.p1"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "dapsone", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p30"}
{"sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "drug1": "antacid", "drug2": "fexofenadine", "relation": "NONE", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s19", "pair_id": "DDI-DrugBank.d466.s19.p19"}
{"sentence": "Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.", "drug1": "chlorprothixene", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s5", "pair_id": "DDI-DrugBank.d503.s5.p0"}
{"sentence": "Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.", "drug1": "Norpace", "drug2": "quinidine", "relation": "MECHANISM", "source_file": "Disopyramide_ddi.xml", "sentence_id": "DDI-DrugBank.d506.s5", "pair_id": "DDI-DrugBank.d506.s5.p0"}
{"sentence": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "drug1": "diclofenac", "drug2": "methotrexate", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s5", "pair_id": "DDI-DrugBank.d249.s5.p3"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "meprobamate", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p15"}
{"sentence": "Concurrent administration of low-dose dopamine HCl and diuretic agents may produce an additive or potentiating effect on urine flow.", "drug1": "dopamine HCl", "drug2": "diuretic agents", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s2", "pair_id": "DDI-DrugBank.d325.s2.p0"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "5HT3 Antagonists", "drug2": "granisetron", "relation": "NONE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p5"}
{"sentence": "If iron supplements are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the supplement.", "drug1": "iron supplements", "drug2": "OMNICEF", "relation": "NONE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s6", "pair_id": "DDI-DrugBank.d420.s6.p0"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "amitriptyline", "drug2": "phenothiazines", "relation": "NONE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p41"}
{"sentence": "Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.", "drug1": "valproate", "drug2": "tiagabine", "relation": "MECHANISM", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s13", "pair_id": "DDI-DrugBank.d277.s13.p14"}
{"sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "drug1": "barbiturates", "drug2": "divalproex sodium", "relation": "NONE", "source_file": "Butabarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d184.s0", "pair_id": "DDI-DrugBank.d184.s0.p63"}
{"sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "drug1": "diuretics", "drug2": "quinolone anti-infectives", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s3", "pair_id": "DDI-DrugBank.d209.s3.p109"}
{"sentence": "Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.", "drug1": "bromocriptine mesylate", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s2", "pair_id": "DDI-DrugBank.d272.s2.p0"}
{"sentence": "However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im. ", "drug1": "halothane", "drug2": "ketamine", "relation": "MECHANISM", "source_file": "1115367.xml", "sentence_id": "DDI-MedLine.d16.s3", "pair_id": "DDI-MedLine.d16.s3.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "quinidine", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p2"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "vitamin D", "drug2": "Cholestyramine", "relation": "NONE", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s0", "pair_id": "DDI-DrugBank.d404.s0.p5"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "pimozide", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p69"}
{"sentence": "Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.", "drug1": "TCAs", "drug2": "SSRIs", "relation": "ADVISE", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s10", "pair_id": "DDI-DrugBank.d223.s10.p0"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "rifampin", "drug2": "vitamin D", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p74"}
{"sentence": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.", "drug1": "nonsteroidal anti-inflammatory agents", "drug2": "ibuprofen", "relation": "NONE", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s1", "pair_id": "DDI-DrugBank.d415.s1.p5"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "palonosetron", "relation": "NONE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p15"}
{"sentence": "The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.", "drug1": "adenosine", "drug2": "theophylline", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s4", "pair_id": "DDI-DrugBank.d226.s4.p2"}
{"sentence": "If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.", "drug1": "steroid", "drug2": "bitolterol", "relation": "ADVISE", "source_file": "Bitolterol_ddi.xml", "sentence_id": "DDI-DrugBank.d560.s1", "pair_id": "DDI-DrugBank.d560.s1.p0"}
{"sentence": "Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.", "drug1": "morphine", "drug2": "succinylcholine", "relation": "NONE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s10", "pair_id": "DDI-DrugBank.d422.s10.p7"}
{"sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).", "drug1": "aminoglycosides", "drug2": "HIVID", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s18", "pair_id": "DDI-DrugBank.d263.s18.p25"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "antidepressants", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p0"}
{"sentence": "Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.", "drug1": "Sildenafil", "drug2": "indinavir", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s87", "pair_id": "DDI-DrugBank.d97.s87.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "amitriptyline", "drug2": "tiagabine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p167"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "ketoprofen", "drug2": "Orudis KT", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p130"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "troleandomycin", "drug2": "zileuton", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p347"}
{"sentence": "This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.", "drug1": "fluvoxamine", "drug2": "fluvoxamine", "relation": "NONE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s17", "pair_id": "DDI-DrugBank.d76.s17.p0"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "antidepressants", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p10"}
{"sentence": "Edema has been reported in patients concomitantly receiving Itraconazole and dihydropyridine calcium channel blockers.", "drug1": "Itraconazole", "drug2": "dihydropyridine calcium channel blockers", "relation": "EFFECT", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s29", "pair_id": "DDI-DrugBank.d165.s29.p0"}
{"sentence": "Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.", "drug1": "pseudoephedrine", "drug2": "kaolin", "relation": "MECHANISM", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s6", "pair_id": "DDI-DrugBank.d448.s6.p2"}
{"sentence": "The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;", "drug1": "furosemide", "drug2": "colestipol hydrochloride", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s11", "pair_id": "DDI-DrugBank.d345.s11.p8"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Sporanox", "drug2": "morphine", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p599"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "caffeine", "drug2": "sedative-hypnotics", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p22"}
{"sentence": "- Drugs that may either increase or decrease plasma phenytoin concentrations include: phenobarbital, vaiproic acid, and sodium valproate.", "drug1": "phenytoin", "drug2": "sodium valproate", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s14", "pair_id": "DDI-DrugBank.d40.s14.p1"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "insulin", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s2", "pair_id": "DDI-DrugBank.d527.s2.p0"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "benzodiazepines", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p10"}
{"sentence": "Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.", "drug1": "dihydroergotamine mesylate", "drug2": "peripheral vasoconstrictors", "relation": "EFFECT", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s0", "pair_id": "DDI-DrugBank.d410.s0.p5"}
{"sentence": "Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.", "drug1": "methotrexate", "drug2": "ciprofloxacin", "relation": "ADVISE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s7", "pair_id": "DDI-DrugBank.d123.s7.p0"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "itraconazole", "drug2": "dasatinib", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p32"}
{"sentence": "However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.", "drug1": "quinolone antimicrobial", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s10", "pair_id": "DDI-DrugBank.d78.s10.p5"}
{"sentence": "Antihistamines may partially counteract the anticoagulation effects of heparin or warfarin.", "drug1": "Antihistamines", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Doxylamine_ddi.xml", "sentence_id": "DDI-DrugBank.d387.s1", "pair_id": "DDI-DrugBank.d387.s1.p1"}
{"sentence": "Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.", "drug1": "cinoxacin", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s8", "pair_id": "DDI-DrugBank.d562.s8.p3"}
{"sentence": "Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. ", "drug1": "endotoxin", "drug2": "endotoxin", "relation": "NONE", "source_file": "7600639.xml", "sentence_id": "DDI-MedLine.d39.s2", "pair_id": "DDI-MedLine.d39.s2.p2"}
{"sentence": "Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.", "drug1": "Naproxen", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s12", "pair_id": "DDI-DrugBank.d85.s12.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "methadone", "drug2": "tiagabine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p838"}
{"sentence": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.", "drug1": "quinidine", "drug2": "doxepin", "relation": "MECHANISM", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s16", "pair_id": "DDI-DrugBank.d223.s16.p2"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p25"}
{"sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.", "drug1": "colestipol hydrochloride", "drug2": "clindamycin", "relation": "NONE", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s13", "pair_id": "DDI-DrugBank.d345.s13.p1"}
{"sentence": "Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;", "drug1": "Amphetamines", "drug2": "tricyclic", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s7", "pair_id": "DDI-DrugBank.d236.s7.p7"}
{"sentence": "Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.", "drug1": "Cholestyramine", "drug2": "Cholestyramine", "relation": "NONE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s10", "pair_id": "DDI-DrugBank.d314.s10.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "procainamide", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p13"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "triazolam", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p11"}
{"sentence": "Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.", "drug1": "bosentan", "drug2": "cyclosporine A", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s11", "pair_id": "DDI-DrugBank.d289.s11.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "ethosuximide", "drug2": "praziquantel", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p616"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "clarithromycin", "drug2": "nefazodone", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p45"}
{"sentence": "Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.", "drug1": "probenecid", "drug2": "ertapenem", "relation": "ADVISE", "source_file": "Ertapenem_ddi.xml", "sentence_id": "DDI-DrugBank.d329.s3", "pair_id": "DDI-DrugBank.d329.s3.p0"}
{"sentence": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.", "drug1": "ketoconazole", "drug2": "gefitinib", "relation": "MECHANISM", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s4", "pair_id": "DDI-DrugBank.d207.s4.p1"}
{"sentence": "Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.", "drug1": "Beta-blockers", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s10", "pair_id": "DDI-DrugBank.d114.s10.p19"}
{"sentence": "Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.", "drug1": "HUMORSOL", "drug2": "anticholinesterase agents", "relation": "INT", "source_file": "Demecarium bromide_ddi.xml", "sentence_id": "DDI-DrugBank.d149.s0", "pair_id": "DDI-DrugBank.d149.s0.p1"}
{"sentence": "In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.", "drug1": "ciprofloxacin", "drug2": "VIDEX", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s9", "pair_id": "DDI-DrugBank.d43.s9.p2"}
{"sentence": "Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).", "drug1": "Nabilone", "drug2": "psychoactive drugs", "relation": "ADVISE", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s0", "pair_id": "DDI-DrugBank.d552.s0.p0"}
{"sentence": "Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.", "drug1": "diazepam", "drug2": "fluvoxamine", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s25", "pair_id": "DDI-DrugBank.d76.s25.p0"}
{"sentence": "Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.", "drug1": "Cholestyramine", "drug2": "cholestyramine", "relation": "NONE", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s3", "pair_id": "DDI-DrugBank.d139.s3.p0"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "VIDEX", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p9"}
{"sentence": "Drug Interaction During Pregnancy: Cromolyn sodium and isoproterenol were studied following subcutaneous injections in pregnant mice.", "drug1": "Cromolyn sodium", "drug2": "isoproterenol", "relation": "NONE", "source_file": "Cromoglicate_ddi.xml", "sentence_id": "DDI-DrugBank.d229.s0", "pair_id": "DDI-DrugBank.d229.s0.p0"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "phenylbutazone", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p35"}
{"sentence": "Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.", "drug1": "bepridil hydrochloride", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Bepridil_ddi.xml", "sentence_id": "DDI-DrugBank.d137.s4", "pair_id": "DDI-DrugBank.d137.s4.p2"}
{"sentence": "Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.", "drug1": "Ortho-Novum", "drug2": "ethinyl estradiol", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s44", "pair_id": "DDI-DrugBank.d328.s44.p4"}
{"sentence": "Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.", "drug1": "colestipol hydrochloride", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s14", "pair_id": "DDI-DrugBank.d345.s14.p3"}
{"sentence": "Chlorthalidone and related drugs may decrease arterial responsiveness to norepinephrine.", "drug1": "Chlorthalidone", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "Chlorthalidone_ddi.xml", "sentence_id": "DDI-DrugBank.d265.s8", "pair_id": "DDI-DrugBank.d265.s8.p0"}
{"sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.", "drug1": "felodipine", "drug2": "anticonvulsant", "relation": "MECHANISM", "source_file": "Felodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d316.s14", "pair_id": "DDI-DrugBank.d316.s14.p5"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "opioids", "drug2": "sedatives", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p42"}
{"sentence": "Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ", "drug1": "retinyl acetate", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s3", "pair_id": "DDI-MedLine.d12.s3.p2"}
{"sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "drug1": "indinavir", "drug2": "tenofovir disoproxil fumarate", "relation": "NONE", "source_file": "Emtricitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d375.s0", "pair_id": "DDI-DrugBank.d375.s0.p6"}
{"sentence": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "drug1": "sympathomimetic amine", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s2", "pair_id": "DDI-DrugBank.d77.s2.p11"}
{"sentence": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "drug1": "lithium", "drug2": "TORADOL", "relation": "MECHANISM", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s12", "pair_id": "DDI-DrugBank.d3.s12.p5"}
{"sentence": "The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).", "drug1": "vasodilators", "drug2": "milrinone", "relation": "NONE", "source_file": "Nesiritide_ddi.xml", "sentence_id": "DDI-DrugBank.d239.s2", "pair_id": "DDI-DrugBank.d239.s2.p8"}
{"sentence": "Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.", "drug1": "Iodine", "drug2": "Carbimazole", "relation": "EFFECT", "source_file": "Carbimazole_ddi.xml", "sentence_id": "DDI-DrugBank.d213.s0", "pair_id": "DDI-DrugBank.d213.s0.p1"}
{"sentence": "Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.", "drug1": "TORADOL", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s9", "pair_id": "DDI-DrugBank.d3.s9.p4"}
{"sentence": "In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.", "drug1": "VIOXX", "drug2": "benazepril", "relation": "EFFECT", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s1", "pair_id": "DDI-DrugBank.d210.s1.p1"}
{"sentence": "Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.\r\n", "drug1": "Misonidazole", "drug2": "CCNU", "relation": "EFFECT", "source_file": "3966974.xml", "sentence_id": "DDI-MedLine.d85.s0", "pair_id": "DDI-MedLine.d85.s0.p0"}
{"sentence": "Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.", "drug1": "xanthine derivatives", "drug2": "beta2-agonists.", "relation": "EFFECT", "source_file": "Formoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d103.s4", "pair_id": "DDI-DrugBank.d103.s4.p17"}
{"sentence": "Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.", "drug1": "clorazepate dipotassium", "drug2": "hexobarbital", "relation": "EFFECT", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s1", "pair_id": "DDI-DrugBank.d335.s1.p0"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "AKINETON", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p11"}
{"sentence": "The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.", "drug1": "imipramine", "drug2": "alprazolam", "relation": "MECHANISM", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s1", "pair_id": "DDI-DrugBank.d131.s1.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "clofibrate", "drug2": "oxyphenbutazone", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p645"}
{"sentence": "Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.", "drug1": "STADOL NS", "drug2": "butorphanol", "relation": "NONE", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s11", "pair_id": "DDI-DrugBank.d246.s11.p0"}
{"sentence": "Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.", "drug1": "aspirin", "drug2": "VIOXX", "relation": "EFFECT", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s3", "pair_id": "DDI-DrugBank.d210.s3.p3"}
{"sentence": "Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.", "drug1": "Aprepitant", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s25", "pair_id": "DDI-DrugBank.d382.s25.p0"}
{"sentence": "Cimetidine reduces the clearance of ALFENTA.", "drug1": "Cimetidine", "drug2": "ALFENTA", "relation": "MECHANISM", "source_file": "Alfentanil_ddi.xml", "sentence_id": "DDI-DrugBank.d8.s4", "pair_id": "DDI-DrugBank.d8.s4.p0"}
{"sentence": "Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.", "drug1": "Adrenergic blockers", "drug2": "amphetamines", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s2", "pair_id": "DDI-DrugBank.d158.s2.p2"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "cyclosporine", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p1"}
{"sentence": "During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.", "drug1": "diuretics", "drug2": "cardiac glycosides", "relation": "NONE", "source_file": "Iloprost_ddi.xml", "sentence_id": "DDI-DrugBank.d549.s3", "pair_id": "DDI-DrugBank.d549.s3.p15"}
{"sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "drug1": "Ketoconazole", "drug2": "vitamin D", "relation": "MECHANISM", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s8", "pair_id": "DDI-DrugBank.d404.s8.p2"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p1"}
{"sentence": "When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.", "drug1": "theophylline", "drug2": "grepafloxacin", "relation": "ADVISE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s8", "pair_id": "DDI-DrugBank.d78.s8.p7"}
{"sentence": "Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.", "drug1": "diflunisal", "drug2": "acetaminophen", "relation": "ADVISE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s13", "pair_id": "DDI-DrugBank.d132.s13.p2"}
{"sentence": "Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.", "drug1": "Clonidine", "drug2": "sedating drugs", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s2", "pair_id": "DDI-DrugBank.d495.s2.p11"}
{"sentence": "Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.", "drug1": "erythromycin", "drug2": "ALFENTA", "relation": "MECHANISM", "source_file": "Alfentanil_ddi.xml", "sentence_id": "DDI-DrugBank.d8.s3", "pair_id": "DDI-DrugBank.d8.s3.p7"}
{"sentence": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "drug1": "Phenobarbital", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s28", "pair_id": "DDI-DrugBank.d434.s28.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "itraconazole", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p20"}
{"sentence": "Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.", "drug1": "cimetidine", "drug2": "gabapentin", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s29", "pair_id": "DDI-DrugBank.d438.s29.p2"}
{"sentence": "Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.", "drug1": "antihistamines", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Clemastine_ddi.xml", "sentence_id": "DDI-DrugBank.d309.s0", "pair_id": "DDI-DrugBank.d309.s0.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "antifungals", "drug2": "prednisolone", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p517"}
{"sentence": "Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.", "drug1": "omeprazole", "drug2": "cilostazol", "relation": "MECHANISM", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s1", "pair_id": "DDI-DrugBank.d358.s1.p1"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "clindamycin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p7"}
{"sentence": "In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; ", "drug1": "ouabain", "drug2": "PTX", "relation": "EFFECT", "source_file": "2857198.xml", "sentence_id": "DDI-MedLine.d56.s2", "pair_id": "DDI-MedLine.d56.s2.p0"}
{"sentence": "Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.", "drug1": "iodine", "drug2": "Carbimazole", "relation": "EFFECT", "source_file": "Carbimazole_ddi.xml", "sentence_id": "DDI-DrugBank.d213.s0", "pair_id": "DDI-DrugBank.d213.s0.p9"}
{"sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "drug1": "PRECEDEX", "drug2": "opioids", "relation": "EFFECT", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s1", "pair_id": "DDI-DrugBank.d197.s1.p29"}
{"sentence": "Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.", "drug1": "tacrolimus", "drug2": "Itraconazole", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s16", "pair_id": "DDI-DrugBank.d165.s16.p4"}
{"sentence": "Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.", "drug1": "alpha-adrenergic blocking agents", "drug2": "beta-adrenergic blocking agents", "relation": "NONE", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s6", "pair_id": "DDI-DrugBank.d325.s6.p2"}
{"sentence": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "cisapride", "drug2": "cisapride", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s7", "pair_id": "DDI-DrugBank.d237.s7.p14"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p41"}
{"sentence": "Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.", "drug1": "Aprepitant", "drug2": "dexamethasone", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s9", "pair_id": "DDI-DrugBank.d382.s9.p11"}
{"sentence": "Two percent of patients treated concurrently with ENBREL  and anakinra developed neutropenia (ANC   1 x 109/L).", "drug1": "ENBREL", "drug2": "anakinra", "relation": "EFFECT", "source_file": "Etanercept_ddi.xml", "sentence_id": "DDI-DrugBank.d341.s3", "pair_id": "DDI-DrugBank.d341.s3.p0"}
{"sentence": "Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.", "drug1": "Cimetidine", "drug2": "probenecid", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s20", "pair_id": "DDI-DrugBank.d263.s20.p5"}
{"sentence": "It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.", "drug1": "ethambutol", "drug2": "aluminum hydroxide", "relation": "ADVISE", "source_file": "Ethambutol_ddi.xml", "sentence_id": "DDI-DrugBank.d160.s1", "pair_id": "DDI-DrugBank.d160.s1.p0"}
{"sentence": "These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).", "drug1": "cholestyramine", "drug2": "erythromycin", "relation": "NONE", "source_file": "Entacapone_ddi.xml", "sentence_id": "DDI-DrugBank.d455.s10", "pair_id": "DDI-DrugBank.d455.s10.p6"}
{"sentence": "Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.", "drug1": "cephalosporins", "drug2": "aminoglycosides", "relation": "EFFECT", "source_file": "Ceftizoxime_ddi.xml", "sentence_id": "DDI-DrugBank.d33.s0", "pair_id": "DDI-DrugBank.d33.s0.p2"}
{"sentence": "Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.", "drug1": "cefamandole", "drug2": "cefazolin", "relation": "NONE", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s1", "pair_id": "DDI-DrugBank.d139.s1.p26"}
{"sentence": "The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.", "drug1": "triazolam", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s34", "pair_id": "DDI-DrugBank.d565.s34.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "glucagon", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p20"}
{"sentence": "A dose adjustment is not needed when zidovudine is administered with VIRACEPT.", "drug1": "zidovudine", "drug2": "VIRACEPT", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s27", "pair_id": "DDI-DrugBank.d340.s27.p0"}
{"sentence": "In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. ", "drug1": "antiestrogen", "drug2": "TAM", "relation": "NONE", "source_file": "7654327.xml", "sentence_id": "DDI-MedLine.d53.s3", "pair_id": "DDI-MedLine.d53.s3.p4"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "Dexbrompheniramine", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "EFFECT", "source_file": "Brompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d192.s0", "pair_id": "DDI-DrugBank.d192.s0.p5"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "sertraline", "drug2": "risperidone", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p93"}
{"sentence": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "drug1": "Bezalip retard", "drug2": "cholestryramine", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s9", "pair_id": "DDI-DrugBank.d291.s9.p6"}
{"sentence": "However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).", "drug1": "Argatroban", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Argatroban_ddi.xml", "sentence_id": "DDI-DrugBank.d148.s4", "pair_id": "DDI-DrugBank.d148.s4.p0"}
{"sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "drug1": "antacid", "drug2": "fosinopril", "relation": "MECHANISM", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s9", "pair_id": "DDI-DrugBank.d176.s9.p12"}
{"sentence": "This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.", "drug1": "CELEBREX", "drug2": "ACE-inhibitors", "relation": "ADVISE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s10", "pair_id": "DDI-DrugBank.d172.s10.p0"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "caffeine", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p19"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "sulfonamides", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p3"}
{"sentence": "Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.", "drug1": "amphotericin B", "drug2": "leukocyte transfusions", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s14", "pair_id": "DDI-DrugBank.d318.s14.p2"}
{"sentence": "Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ", "drug1": "Amprenavir", "drug2": "25-O-desacetylrifabutin", "relation": "MECHANISM", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s7", "pair_id": "DDI-MedLine.d3.s7.p1"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "norfloxacin", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p70"}
{"sentence": "Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.", "drug1": "NSAIDs", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s14", "pair_id": "DDI-DrugBank.d249.s14.p5"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "delavirdine", "drug2": "itraconazole", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p449"}
{"sentence": "Iron salts may reduce the bioavailability of carbidopa and levodopa.", "drug1": "Iron", "drug2": "levodopa", "relation": "MECHANISM", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s5", "pair_id": "DDI-DrugBank.d47.s5.p1"}
{"sentence": "When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.", "drug1": "carbamazepine", "drug2": "aripiprazole", "relation": "ADVISE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s22", "pair_id": "DDI-DrugBank.d509.s22.p0"}
{"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.", "drug1": "methysergide", "drug2": "AXERT", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s1", "pair_id": "DDI-DrugBank.d299.s1.p9"}
{"sentence": "- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.", "drug1": "Bumetanide", "drug2": "antihypertensive drugs", "relation": "EFFECT", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s9", "pair_id": "DDI-DrugBank.d331.s9.p2"}
{"sentence": "- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted", "drug1": "tricyclic antidepressants", "drug2": "Cerebyx", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s17", "pair_id": "DDI-DrugBank.d40.s17.p0"}
{"sentence": "Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. ", "drug1": "pentazocine", "drug2": "tripelennamine", "relation": "EFFECT", "source_file": "3918122.xml", "sentence_id": "DDI-MedLine.d45.s5", "pair_id": "DDI-MedLine.d45.s5.p2"}
{"sentence": "Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.", "drug1": "REVIA", "drug2": "opioid", "relation": "EFFECT", "source_file": "Naltrexone_ddi.xml", "sentence_id": "DDI-DrugBank.d346.s4", "pair_id": "DDI-DrugBank.d346.s4.p0"}
{"sentence": "Acetazolamide may elevate cyclosporine levels.", "drug1": "Acetazolamide", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s14", "pair_id": "DDI-DrugBank.d368.s14.p0"}
{"sentence": "Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).", "drug1": "TORADOL", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s8", "pair_id": "DDI-DrugBank.d3.s8.p4"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "encainide", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p6"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Kaletra", "drug2": "morphine", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p872"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "erythromycin", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p212"}
{"sentence": "Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.", "drug1": "dasatinib", "drug2": "dasatinib", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s3", "pair_id": "DDI-DrugBank.d48.s3.p0"}
{"sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "drug1": "Quinolones", "drug2": "R-warfarin", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s23", "pair_id": "DDI-DrugBank.d395.s23.p5"}
{"sentence": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "itraconazole", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s7", "pair_id": "DDI-DrugBank.d237.s7.p10"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Lipitor", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p17"}
{"sentence": "Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.", "drug1": "cytotoxic", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s2", "pair_id": "DDI-DrugBank.d114.s2.p14"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "cyclosporin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p9"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "alprazolam", "drug2": "psychotropic medications", "relation": "EFFECT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p5"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "calcium", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p4"}
{"sentence": "- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.", "drug1": "Indomethacin", "drug2": "bumetanide", "relation": "MECHANISM", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s7", "pair_id": "DDI-DrugBank.d331.s7.p3"}
{"sentence": "Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.", "drug1": "cinoxacin", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s8", "pair_id": "DDI-DrugBank.d562.s8.p4"}
{"sentence": "Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.", "drug1": "Cholestyramine", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s10", "pair_id": "DDI-DrugBank.d314.s10.p2"}
{"sentence": "Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.", "drug1": "nortriptyline hydrochloride", "drug2": "anticholinergic drugs", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s9", "pair_id": "DDI-DrugBank.d202.s9.p0"}
{"sentence": "Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.", "drug1": "Aprepitant", "drug2": "contraceptives", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s21", "pair_id": "DDI-DrugBank.d382.s21.p0"}
{"sentence": "The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.", "drug1": "uricosuric agents", "drug2": "allopurinol", "relation": "MECHANISM", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s10", "pair_id": "DDI-DrugBank.d413.s10.p0"}
{"sentence": "Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or", "drug1": "Sulfapyridine", "drug2": "Tylenol", "relation": "INT", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s1", "pair_id": "DDI-DrugBank.d179.s1.p1"}
{"sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "drug1": "cefdinir", "drug2": "iron supplement", "relation": "NONE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s5", "pair_id": "DDI-DrugBank.d420.s5.p11"}
{"sentence": "Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.", "drug1": "HUMORSOL", "drug2": "succinylcholine", "relation": "INT", "source_file": "Demecarium bromide_ddi.xml", "sentence_id": "DDI-DrugBank.d149.s0", "pair_id": "DDI-DrugBank.d149.s0.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "chymotrypsin", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p9"}
{"sentence": "ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. ", "drug1": "ADL-8-2698", "drug2": "opioid", "relation": "EFFECT", "source_file": "11180040.xml", "sentence_id": "DDI-MedLine.d87.s1", "pair_id": "DDI-MedLine.d87.s1.p1"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "lithium", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p10"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "AKINETON", "drug2": "narcotic analgesics", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p9"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "hexobarbital", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p1"}
{"sentence": "May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;", "drug1": "cholestyramine", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Bendroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d304.s0", "pair_id": "DDI-DrugBank.d304.s0.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "nortriptyline", "drug2": "risperidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p889"}
{"sentence": "In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.", "drug1": "aminoglycoside", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Kanamycin_ddi.xml", "sentence_id": "DDI-DrugBank.d57.s0", "pair_id": "DDI-DrugBank.d57.s0.p1"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "benzodiazepines", "drug2": "ergotamine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p1"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "troleandomycin", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p10"}
{"sentence": "Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.", "drug1": "Diuretics", "drug2": "beta2-agonists.", "relation": "NONE", "source_file": "Formoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d103.s4", "pair_id": "DDI-DrugBank.d103.s4.p14"}
{"sentence": "This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.", "drug1": "probenecid", "drug2": "bumetanide", "relation": "MECHANISM", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s5", "pair_id": "DDI-DrugBank.d331.s5.p0"}
{"sentence": "Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.", "drug1": "lithium", "drug2": "ACE inhibitors", "relation": "MECHANISM", "source_file": "Candesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d547.s2", "pair_id": "DDI-DrugBank.d547.s2.p7"}
{"sentence": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "drug1": "NSAIDs", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s9", "pair_id": "DDI-DrugBank.d400.s9.p4"}
{"sentence": "OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.", "drug1": "calcium-channel blockers", "drug2": "NSAIDs", "relation": "NONE", "source_file": "Cerivastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d141.s13", "pair_id": "DDI-DrugBank.d141.s13.p17"}
{"sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "drug1": "Erythromycin", "drug2": "triazolam", "relation": "MECHANISM", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s6", "pair_id": "DDI-DrugBank.d397.s6.p0"}
{"sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "SSRIs", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s6", "pair_id": "DDI-DrugBank.d299.s6.p17"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "meperidine", "drug2": "phenothiazines", "relation": "NONE", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p24"}
{"sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "drug1": "phenothiazines", "drug2": "LEVULAN KERASTICK", "relation": "EFFECT", "source_file": "Aminolevulinic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d379.s1", "pair_id": "DDI-DrugBank.d379.s1.p24"}
{"sentence": "Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin. ", "drug1": "atracurium", "drug2": "gentamycin", "relation": "EFFECT", "source_file": "8542840.xml", "sentence_id": "DDI-MedLine.d90.s8", "pair_id": "DDI-MedLine.d90.s8.p2"}
{"sentence": "Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.", "drug1": "BEXTRA", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s26", "pair_id": "DDI-DrugBank.d328.s26.p2"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "chloramphenicol", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p2"}
{"sentence": "Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "drug1": "ergot alkaloid class", "drug2": "macrolide class", "relation": "MECHANISM", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s5", "pair_id": "DDI-DrugBank.d410.s5.p21"}
{"sentence": "The use of dextromethorphan hydrobromide may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "drug1": "dextromethorphan hydrobromide", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s2", "pair_id": "DDI-DrugBank.d398.s2.p1"}
{"sentence": "It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.", "drug1": "ketamine", "drug2": "halothane", "relation": "EFFECT", "source_file": "1115367.xml", "sentence_id": "DDI-MedLine.d16.s6", "pair_id": "DDI-MedLine.d16.s6.p0"}
{"sentence": "As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.", "drug1": "potassium-sparing diuretics", "drug2": "spironolactone", "relation": "NONE", "source_file": "Losartan_ddi.xml", "sentence_id": "DDI-DrugBank.d30.s8", "pair_id": "DDI-DrugBank.d30.s8.p0"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "disulfiram", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p6"}
{"sentence": "Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.", "drug1": "anakinra", "drug2": "TNF-blocking agent", "relation": "EFFECT", "source_file": "Adalimumab_ddi.xml", "sentence_id": "DDI-DrugBank.d493.s2", "pair_id": "DDI-DrugBank.d493.s2.p4"}
{"sentence": "Avoid the concomitant use of chlorprothixene and tramadol (Ultram).", "drug1": "chlorprothixene", "drug2": "tramadol", "relation": "ADVISE", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s3", "pair_id": "DDI-DrugBank.d503.s3.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "salicylates", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p44"}
{"sentence": "Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.", "drug1": "fexofenadine hydrochloride", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s19", "pair_id": "DDI-DrugBank.d466.s19.p6"}
{"sentence": "Of particular importance, sufficient time must elapse before initiating TCAtreatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).", "drug1": "TCA", "drug2": "fluoxetine", "relation": "ADVISE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s20", "pair_id": "DDI-DrugBank.d238.s20.p0"}
{"sentence": "Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.", "drug1": "ipratropium bromide", "drug2": "anticholinergic medications", "relation": "EFFECT", "source_file": "Ipratropium_ddi.xml", "sentence_id": "DDI-DrugBank.d51.s2", "pair_id": "DDI-DrugBank.d51.s2.p2"}
{"sentence": "Rifampin: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.", "drug1": "VIOXX", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s25", "pair_id": "DDI-DrugBank.d210.s25.p3"}
{"sentence": "Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.", "drug1": "theophylline", "drug2": "lansoprazole", "relation": "ADVISE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s5", "pair_id": "DDI-DrugBank.d431.s5.p0"}
{"sentence": "If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.", "drug1": "AXERT", "drug2": "SSRI", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s7", "pair_id": "DDI-DrugBank.d299.s7.p0"}
{"sentence": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.", "drug1": "phenobarbital", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s30", "pair_id": "DDI-DrugBank.d124.s30.p3"}
{"sentence": "Chlorprothixene may increase the plasma-level of concomitantly given lithium.", "drug1": "Chlorprothixene", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s0", "pair_id": "DDI-DrugBank.d503.s0.p0"}
{"sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "drug1": "photosensitizing agents", "drug2": "LEVULAN KERASTICK", "relation": "EFFECT", "source_file": "Aminolevulinic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d379.s1", "pair_id": "DDI-DrugBank.d379.s1.p6"}
{"sentence": "Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "drug1": "clonidine", "drug2": "insulin", "relation": "EFFECT", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s3", "pair_id": "DDI-DrugBank.d313.s3.p6"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "clonazepam", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p365"}
{"sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.", "drug1": "Aprepitant", "drug2": "aprepitant", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s34", "pair_id": "DDI-DrugBank.d382.s34.p3"}
{"sentence": "In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, dextromethorphan, and methotrexate.", "drug1": "Cordarone", "drug2": "dextromethorphan", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s62", "pair_id": "DDI-DrugBank.d143.s62.p1"}
{"sentence": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "drug1": "ethanol", "drug2": "ethanol", "relation": "NONE", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s0", "pair_id": "DDI-DrugBank.d216.s0.p5"}
{"sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "drug1": "chloroquine", "drug2": "leflunomide", "relation": "NONE", "source_file": "Abatacept_ddi.xml", "sentence_id": "DDI-DrugBank.d297.s2", "pair_id": "DDI-DrugBank.d297.s2.p53"}
{"sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).", "drug1": "aminoglycosides", "drug2": "zalcitabine", "relation": "MECHANISM", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s18", "pair_id": "DDI-DrugBank.d263.s18.p26"}
{"sentence": "A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.", "drug1": "cisapride", "drug2": "ketoconazole", "relation": "EFFECT", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s9", "pair_id": "DDI-DrugBank.d237.s9.p0"}
{"sentence": "Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.", "drug1": "pimozide", "drug2": "citalopram", "relation": "EFFECT", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s13", "pair_id": "DDI-DrugBank.d568.s13.p7"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "pure agonist opioid analgesic", "drug2": "Levo-Dromoran", "relation": "ADVISE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p35"}
{"sentence": "Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.", "drug1": "indomethacin", "drug2": "MIDAMOR", "relation": "EFFECT", "source_file": "Amiloride_ddi.xml", "sentence_id": "DDI-DrugBank.d356.s6", "pair_id": "DDI-DrugBank.d356.s6.p1"}
{"sentence": "Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.", "drug1": "valdecoxib", "drug2": "fluconazole", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s28", "pair_id": "DDI-DrugBank.d328.s28.p1"}
{"sentence": "MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.", "drug1": "MAO inhibitors", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s1", "pair_id": "DDI-DrugBank.d389.s1.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "cyclosporin", "drug2": "ethosuximide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p410"}
{"sentence": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "sertraline", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s3", "pair_id": "DDI-DrugBank.d426.s3.p20"}
{"sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).", "drug1": "foscarnet", "drug2": "HIVID", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s18", "pair_id": "DDI-DrugBank.d263.s18.p23"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p38"}
{"sentence": "Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.", "drug1": "dolasetron", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Dolasetron_ddi.xml", "sentence_id": "DDI-DrugBank.d42.s1", "pair_id": "DDI-DrugBank.d42.s1.p3"}
{"sentence": "Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.", "drug1": "naratriptan", "drug2": "5-HT1 agonists", "relation": "ADVISE", "source_file": "Naratriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d478.s3", "pair_id": "DDI-DrugBank.d478.s3.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "nortriptyline", "drug2": "quetiapine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p888"}
{"sentence": "Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.", "drug1": "Antacids", "drug2": "pseudoephedrine", "relation": "MECHANISM", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s6", "pair_id": "DDI-DrugBank.d448.s6.p0"}
{"sentence": "It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. ", "drug1": "MPTP", "drug2": "pargyline", "relation": "EFFECT", "source_file": "3871245.xml", "sentence_id": "DDI-MedLine.d73.s2", "pair_id": "DDI-MedLine.d73.s2.p0"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "salicylates", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p1"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "LEVSIN", "drug2": "amantadine", "relation": "EFFECT", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p1"}
{"sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "drug1": "sulfonamides", "drug2": "LEVULAN KERASTICK", "relation": "EFFECT", "source_file": "Aminolevulinic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d379.s1", "pair_id": "DDI-DrugBank.d379.s1.p26"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "caffeine", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p23"}
{"sentence": "Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.", "drug1": "Fexofenadine", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s2", "pair_id": "DDI-DrugBank.d466.s2.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "protease inhibitors", "drug2": "Kadian", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p789"}
{"sentence": "Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.", "drug1": "beta-blockers", "drug2": "clonidine", "relation": "ADVISE", "source_file": "Betaxolol_ddi.xml", "sentence_id": "DDI-DrugBank.d489.s4", "pair_id": "DDI-DrugBank.d489.s4.p0"}
{"sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "drug1": "Cisapride", "drug2": "antiarrhythmics", "relation": "ADVISE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s14", "pair_id": "DDI-DrugBank.d237.s14.p0"}
{"sentence": "The potential for increased sedation when guanfacine is given with other CNS-depressant drug should be appreciated.", "drug1": "guanfacine", "drug2": "CNS-depressant drug", "relation": "EFFECT", "source_file": "Guanfacine_ddi.xml", "sentence_id": "DDI-DrugBank.d507.s0", "pair_id": "DDI-DrugBank.d507.s0.p0"}
{"sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "drug1": "levobupivacaine", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Levobupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d320.s3", "pair_id": "DDI-DrugBank.d320.s3.p3"}
{"sentence": "When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.", "drug1": "warfarin", "drug2": "naproxen", "relation": "NONE", "source_file": "Nicardipine_ddi.xml", "sentence_id": "DDI-DrugBank.d468.s10", "pair_id": "DDI-DrugBank.d468.s10.p16"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "anticholinergic", "drug2": "meperidine", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p2"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "cabergoline", "drug2": "lithium", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p90"}
{"sentence": "Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ", "drug1": "Physostigmine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "6536292.xml", "sentence_id": "DDI-MedLine.d54.s8", "pair_id": "DDI-MedLine.d54.s8.p0"}
{"sentence": "Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.", "drug1": "Cyclosporine", "drug2": "TRICOR", "relation": "NONE", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s5", "pair_id": "DDI-DrugBank.d283.s5.p2"}
{"sentence": "Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril.", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s7", "pair_id": "DDI-DrugBank.d334.s7.p0"}
{"sentence": "Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.", "drug1": "vaccines", "drug2": "corticosteroid", "relation": "ADVISE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s32", "pair_id": "DDI-DrugBank.d314.s32.p0"}
{"sentence": "Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation", "drug1": "streptokinase", "drug2": "REFLUDAN", "relation": "NONE", "source_file": "Lepirudin_ddi.xml", "sentence_id": "DDI-DrugBank.d52.s0", "pair_id": "DDI-DrugBank.d52.s0.p2"}
{"sentence": "Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.", "drug1": "GL", "drug2": "cefazolin", "relation": "EFFECT", "source_file": "10319155.xml", "sentence_id": "DDI-MedLine.d84.s5", "pair_id": "DDI-MedLine.d84.s5.p0"}
{"sentence": "The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.", "drug1": "zalcitabine", "drug2": "magnesium", "relation": "ADVISE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s23", "pair_id": "DDI-DrugBank.d263.s23.p0"}
{"sentence": "Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.", "drug1": "valdecoxib", "drug2": "fluconazole", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s29", "pair_id": "DDI-DrugBank.d328.s29.p0"}
{"sentence": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "drug1": "diclofenac", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s4", "pair_id": "DDI-DrugBank.d249.s4.p2"}
{"sentence": "Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .", "drug1": "doxapram", "drug2": "monoamine oxidase inhibiting drugs", "relation": "EFFECT", "source_file": "Doxapram_ddi.xml", "sentence_id": "DDI-DrugBank.d332.s0", "pair_id": "DDI-DrugBank.d332.s0.p1"}
{"sentence": "Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).", "drug1": "Isocarboxazid", "drug2": "disulfiram", "relation": "ADVISE", "source_file": "Isocarboxazid_ddi.xml", "sentence_id": "DDI-DrugBank.d108.s0", "pair_id": "DDI-DrugBank.d108.s0.p1"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "cisplatin", "drug2": "phenytoin", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p39"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "fluphenazine", "drug2": "Trilafon", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p114"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "Lorazepam", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p2"}
{"sentence": "Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.", "drug1": "antihistamines", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s6", "pair_id": "DDI-DrugBank.d488.s6.p14"}
{"sentence": "In vitro, buspirone may displace less firmly bound drugs like digoxin.", "drug1": "buspirone", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s8", "pair_id": "DDI-DrugBank.d463.s8.p0"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "drug1": "diuretics", "drug2": "contraceptives", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s4", "pair_id": "DDI-DrugBank.d245.s4.p13"}
{"sentence": "Furosemide may decrease arterial responsiveness to norepinephrine.", "drug1": "Furosemide", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s8", "pair_id": "DDI-DrugBank.d231.s8.p0"}
{"sentence": "Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.", "drug1": "Warfarin", "drug2": "warfarin", "relation": "NONE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s19", "pair_id": "DDI-DrugBank.d123.s19.p2"}
{"sentence": "Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.", "drug1": "Nevirapine", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s36", "pair_id": "DDI-DrugBank.d270.s36.p0"}
{"sentence": "No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.", "drug1": "aspirin", "drug2": "warfarin", "relation": "NONE", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s13", "pair_id": "DDI-DrugBank.d345.s13.p16"}
{"sentence": "Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.", "drug1": "Duloxetine", "drug2": "thioridazine", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s11", "pair_id": "DDI-DrugBank.d548.s11.p2"}
{"sentence": "However, co  administration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine.", "drug1": "fexofenadine hydrochloride", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Fexofenadine_ddi.xml", "sentence_id": "DDI-DrugBank.d466.s1", "pair_id": "DDI-DrugBank.d466.s1.p0"}
{"sentence": "Bromocriptine mesylate may interact with dopamine antagonists, butyrophenones, and certain other agents.", "drug1": "Bromocriptine mesylate", "drug2": "dopamine antagonists", "relation": "INT", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s1", "pair_id": "DDI-DrugBank.d272.s1.p0"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "Lorazepam", "drug2": "MAO inhibitors", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p4"}
{"sentence": "Ketoconazole: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.", "drug1": "ketoconazole", "drug2": "lapatinib", "relation": "MECHANISM", "source_file": "Lapatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d135.s7", "pair_id": "DDI-DrugBank.d135.s7.p2"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "pentamidine", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p6"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "thiazide diuretics", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p13"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "Antacids", "drug2": "didanosine", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p6"}
{"sentence": "Interactions of cobalt and iron in absorption and retention.\r\n", "drug1": "cobalt", "drug2": "iron", "relation": "MECHANISM", "source_file": "7599505.xml", "sentence_id": "DDI-MedLine.d34.s0", "pair_id": "DDI-MedLine.d34.s0.p0"}
{"sentence": "With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.", "drug1": "phenytoin", "drug2": "theophylline", "relation": "EFFECT", "source_file": "3967572.xml", "sentence_id": "DDI-MedLine.d7.s4", "pair_id": "DDI-MedLine.d7.s4.p0"}
{"sentence": "Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.", "drug1": "Barbiturates", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "Hexobarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d457.s0", "pair_id": "DDI-DrugBank.d457.s0.p1"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "disulfiram", "drug2": "iodoquinol", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p58"}
{"sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "drug1": "levothyroxine sodium", "drug2": "sodium polystyrene sulfonate", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s2", "pair_id": "DDI-DrugBank.d411.s2.p11"}
{"sentence": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "drug1": "digoxin", "drug2": "FLOLAN", "relation": "MECHANISM", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s3", "pair_id": "DDI-DrugBank.d241.s3.p49"}
{"sentence": "Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.", "drug1": "clorazepate dipotassium", "drug2": "chlorpromazine", "relation": "EFFECT", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s1", "pair_id": "DDI-DrugBank.d335.s1.p2"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "coumarin", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p2"}
{"sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "drug1": "combination hormonal contraceptives", "drug2": "caffeine", "relation": "EFFECT", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s43", "pair_id": "DDI-DrugBank.d485.s43.p5"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "Ethanol", "drug2": "Flupenthixol", "relation": "NONE", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p51"}
{"sentence": "If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.", "drug1": "diuretic", "drug2": "PRINIVIL", "relation": "ADVISE", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s2", "pair_id": "DDI-DrugBank.d334.s2.p0"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "furosemide", "drug2": "valsartan", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p34"}
{"sentence": "Ranitidine also has no effect on eprosartan pharmacokinetics.", "drug1": "Ranitidine", "drug2": "eprosartan", "relation": "NONE", "source_file": "Eprosartan_ddi.xml", "sentence_id": "DDI-DrugBank.d525.s3", "pair_id": "DDI-DrugBank.d525.s3.p0"}
{"sentence": "(Concurrent use with thiazide diuretics may enhance the possibility of digitalis toxicity associated with hypokalemia.)", "drug1": "thiazide diuretics", "drug2": "digitalis", "relation": "EFFECT", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s12", "pair_id": "DDI-DrugBank.d17.s12.p0"}
{"sentence": "Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.", "drug1": "Ketoconazole", "drug2": "alosetron", "relation": "MECHANISM", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s8", "pair_id": "DDI-DrugBank.d364.s8.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "efavirenz", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p4"}
{"sentence": "In patients receiving HCTZ alone, dofetilide AUC increased by 27% and Cmax by 21%.", "drug1": "HCTZ", "drug2": "dofetilide", "relation": "MECHANISM", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s14", "pair_id": "DDI-DrugBank.d558.s14.p0"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "propafenone", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p28"}
{"sentence": "Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.", "drug1": "central nervous system depressants", "drug2": "hydroxyzine", "relation": "ADVISE", "source_file": "Hydroxyzine_ddi.xml", "sentence_id": "DDI-DrugBank.d308.s1", "pair_id": "DDI-DrugBank.d308.s1.p0"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p8"}
{"sentence": "Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.", "drug1": "MAO inhibitors", "drug2": "dopamine HCl", "relation": "ADVISE", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s1", "pair_id": "DDI-DrugBank.d325.s1.p0"}
{"sentence": "The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide", "drug1": "irbesartan", "drug2": "hydrochlorothiazide", "relation": "NONE", "source_file": "Irbesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d27.s5", "pair_id": "DDI-DrugBank.d27.s5.p1"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "aminoglycosides", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p0"}
{"sentence": "Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.", "drug1": "paclitaxel", "drug2": "doxorubicin", "relation": "MECHANISM", "source_file": "Paclitaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d288.s5", "pair_id": "DDI-DrugBank.d288.s5.p5"}
{"sentence": "Furosemide: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of furosemide.", "drug1": "Furosemide", "drug2": "furosemide", "relation": "NONE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s7", "pair_id": "DDI-DrugBank.d132.s7.p2"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "estrogens", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p4"}
{"sentence": "Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.", "drug1": "Amphetamines", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s14", "pair_id": "DDI-DrugBank.d236.s14.p2"}
{"sentence": "Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.", "drug1": "cimetidine", "drug2": "gabapentin", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s30", "pair_id": "DDI-DrugBank.d438.s30.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "terfenadine", "drug2": "ergot derivatives", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p63"}
{"sentence": "More than 600 Parkinsons disease patients in clinical trials have used selegiline in combination with entacapone and levodopa/dopa decarboxylase inhibitor.", "drug1": "selegiline", "drug2": "entacapone", "relation": "NONE", "source_file": "Entacapone_ddi.xml", "sentence_id": "DDI-DrugBank.d455.s8", "pair_id": "DDI-DrugBank.d455.s8.p0"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "monoamine oxidase inhibitors", "drug2": "venlafaxine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p7"}
{"sentence": "Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.", "drug1": "Vardenafil", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s9", "pair_id": "DDI-DrugBank.d198.s9.p2"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "isoniazid", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p12"}
{"sentence": "Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.", "drug1": "digoxin", "drug2": "VAPRISOL", "relation": "MECHANISM", "source_file": "Conivaptan_ddi.xml", "sentence_id": "DDI-DrugBank.d315.s1", "pair_id": "DDI-DrugBank.d315.s1.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Astramorph", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p32"}
{"sentence": "However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.", "drug1": "Tagamet", "drug2": "Theo-Dur", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s4", "pair_id": "DDI-DrugBank.d171.s4.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "midazolam", "drug2": "triazolam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p859"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "Cisplatin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p0"}
{"sentence": "Cocaine sometimes proves to be fatal when used in combination with heroin.", "drug1": "Cocaine", "drug2": "heroin", "relation": "EFFECT", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s4", "pair_id": "DDI-DrugBank.d514.s4.p0"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "ondansetron", "relation": "NONE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p12"}
{"sentence": "Anticholinergic agents: Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications.", "drug1": "Anticholinergic agents", "drug2": "ipratropium bromide", "relation": "NONE", "source_file": "Ipratropium_ddi.xml", "sentence_id": "DDI-DrugBank.d51.s2", "pair_id": "DDI-DrugBank.d51.s2.p0"}
{"sentence": "Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.", "drug1": "methotrexate", "drug2": "ciprofloxacin", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s5", "pair_id": "DDI-DrugBank.d123.s5.p3"}
{"sentence": "- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or", "drug1": "Anabolic steroids", "drug2": "oxymetholone", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s3", "pair_id": "DDI-DrugBank.d179.s3.p4"}
{"sentence": "When INDOCIN is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased.", "drug1": "INDOCIN", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s9", "pair_id": "DDI-DrugBank.d82.s9.p0"}
{"sentence": "Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.", "drug1": "dolasetron", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Dolasetron_ddi.xml", "sentence_id": "DDI-DrugBank.d42.s1", "pair_id": "DDI-DrugBank.d42.s1.p4"}
{"sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "drug1": "salicylates", "drug2": "sulfonamide antibiotics", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s1", "pair_id": "DDI-DrugBank.d313.s1.p51"}
{"sentence": "Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.", "drug1": "Praziquantel", "drug2": "praziquantel", "relation": "NONE", "source_file": "Albendazole_ddi.xml", "sentence_id": "DDI-DrugBank.d321.s1", "pair_id": "DDI-DrugBank.d321.s1.p0"}
{"sentence": "The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.", "drug1": "nevirapine", "drug2": "antithrombotic agent", "relation": "NONE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s9", "pair_id": "DDI-DrugBank.d270.s9.p0"}
{"sentence": "Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.", "drug1": "nicotine", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s6", "pair_id": "DDI-DrugBank.d488.s6.p13"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "NSAIDs", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p10"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "glucagon", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p939"}
{"sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "drug1": "Benzodiazepines", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s12", "pair_id": "DDI-DrugBank.d76.s12.p8"}
{"sentence": "Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.", "drug1": "Alcohol", "drug2": "SINEQUAN", "relation": "NONE", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s26", "pair_id": "DDI-DrugBank.d223.s26.p1"}
{"sentence": "Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.", "drug1": "troleandomycin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s2", "pair_id": "DDI-DrugBank.d487.s2.p1"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "aminoglycosides", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p4"}
{"sentence": "Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.", "drug1": "phenytoin", "drug2": "quinidine", "relation": "NONE", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s3", "pair_id": "DDI-DrugBank.d29.s3.p6"}
{"sentence": "Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.", "drug1": "atorvastatin", "drug2": "aliskiren", "relation": "MECHANISM", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s3", "pair_id": "DDI-DrugBank.d533.s3.p0"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "drug1": "phenothiazines", "drug2": "contraceptives", "relation": "NONE", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s1", "pair_id": "DDI-DrugBank.d536.s1.p32"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "lincomycin", "drug2": "quinidine", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p76"}
{"sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "drug1": "eplerenone", "drug2": "verapamil", "relation": "MECHANISM", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s3", "pair_id": "DDI-DrugBank.d20.s3.p1"}
{"sentence": "Plasma concentrations of azole antifungal agents are reduced when given concurrently with isoniazid.", "drug1": "azole antifungal agents", "drug2": "isoniazid", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s24", "pair_id": "DDI-DrugBank.d165.s24.p0"}
{"sentence": "Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. ", "drug1": "fluoxetine", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "11213850.xml", "sentence_id": "DDI-MedLine.d46.s13", "pair_id": "DDI-MedLine.d46.s13.p0"}
{"sentence": "Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.", "drug1": "Digoxin", "drug2": "Adenocard", "relation": "EFFECT", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s1", "pair_id": "DDI-DrugBank.d226.s1.p1"}
{"sentence": "However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.", "drug1": "PRECEDEX", "drug2": "sedative", "relation": "ADVISE", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s4", "pair_id": "DDI-DrugBank.d197.s4.p6"}
{"sentence": "Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.", "drug1": "pseudoephedrine", "drug2": "digitalis", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s5", "pair_id": "DDI-DrugBank.d448.s5.p0"}
{"sentence": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "drug1": "Nalfon", "drug2": "Nalfon", "relation": "NONE", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s2", "pair_id": "DDI-DrugBank.d154.s2.p12"}
{"sentence": "Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.", "drug1": "Clonidine", "drug2": "clonidine", "relation": "NONE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s4", "pair_id": "DDI-DrugBank.d269.s4.p0"}
{"sentence": "Theophylline: Twelve healthy male volunteers were administered one 200-mg ceftibuten capsule twice daily for 6 days.", "drug1": "Theophylline", "drug2": "ceftibuten", "relation": "NONE", "source_file": "Ceftibuten_ddi.xml", "sentence_id": "DDI-DrugBank.d32.s0", "pair_id": "DDI-DrugBank.d32.s0.p0"}
{"sentence": "Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.", "drug1": "Tricyclic antidepressants", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s3", "pair_id": "DDI-DrugBank.d138.s3.p0"}
{"sentence": "Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.", "drug1": "quinolones", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s16", "pair_id": "DDI-DrugBank.d123.s16.p5"}
{"sentence": "Cimetidine: A study in 6 healthy volunteers has shown a significant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of cimetidine at 1000 mg per day and nifedipine at 40 mg per day.", "drug1": "cimetidine", "drug2": "nifedipine", "relation": "MECHANISM", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s11", "pair_id": "DDI-DrugBank.d373.s11.p5"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "benzodiazepines", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p9"}
{"sentence": "Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.", "drug1": "SSRIs", "drug2": "doxepin", "relation": "MECHANISM", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s16", "pair_id": "DDI-DrugBank.d223.s16.p5"}
{"sentence": "Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.", "drug1": "Azlocillin", "drug2": "ciprofloxacin", "relation": "ADVISE", "source_file": "Azlocillin_ddi.xml", "sentence_id": "DDI-DrugBank.d9.s0", "pair_id": "DDI-DrugBank.d9.s0.p1"}
{"sentence": "Probenecid depresses tubular secretion of certain weak acids such as PAH.", "drug1": "Probenecid", "drug2": "PAH", "relation": "MECHANISM", "source_file": "Aminohippurate_ddi.xml", "sentence_id": "DDI-DrugBank.d416.s2", "pair_id": "DDI-DrugBank.d416.s2.p0"}
{"sentence": "Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.", "drug1": "Furosemide", "drug2": "succinylcholine", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s4", "pair_id": "DDI-DrugBank.d231.s4.p1"}
{"sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "drug1": "PRINIVIL", "drug2": "triamterene", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s15", "pair_id": "DDI-DrugBank.d334.s15.p2"}
{"sentence": "However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis.", "drug1": "Xigris", "drug2": "Xigris", "relation": "NONE", "source_file": "Drotrecogin alfa_ddi.xml", "sentence_id": "DDI-DrugBank.d190.s1", "pair_id": "DDI-DrugBank.d190.s1.p0"}
{"sentence": "Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.", "drug1": "fenofibrate", "drug2": "atorvastatin", "relation": "MECHANISM", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s15", "pair_id": "DDI-DrugBank.d283.s15.p1"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "isoniazid", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p74"}
{"sentence": "Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.", "drug1": "sympathomimetics", "drug2": "MAO inhibitors", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s3", "pair_id": "DDI-DrugBank.d389.s3.p0"}
{"sentence": "Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;", "drug1": "FOSCAVIR", "drug2": "pentamidine", "relation": "EFFECT", "source_file": "Foscarnet_ddi.xml", "sentence_id": "DDI-DrugBank.d511.s1", "pair_id": "DDI-DrugBank.d511.s1.p0"}
{"sentence": "Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.", "drug1": "rifampin", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s41", "pair_id": "DDI-DrugBank.d565.s41.p0"}
{"sentence": "Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.", "drug1": "probenecid", "drug2": "acyclovir", "relation": "MECHANISM", "source_file": "Aciclovir_ddi.xml", "sentence_id": "DDI-DrugBank.d200.s0", "pair_id": "DDI-DrugBank.d200.s0.p0"}
{"sentence": "Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.", "drug1": "Albuterol", "drug2": "albuterol", "relation": "NONE", "source_file": "Atomoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d11.s0", "pair_id": "DDI-DrugBank.d11.s0.p3"}
{"sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "drug1": "ALPHAGAN P", "drug2": "alcohol", "relation": "ADVISE", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s0", "pair_id": "DDI-DrugBank.d138.s0.p1"}
{"sentence": "Cimetidine: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.", "drug1": "cimetidine", "drug2": "rofecoxib", "relation": "MECHANISM", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s10", "pair_id": "DDI-DrugBank.d210.s10.p2"}
{"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.", "drug1": "ergot-type medications", "drug2": "naratriptan", "relation": "ADVISE", "source_file": "Naratriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d478.s1", "pair_id": "DDI-DrugBank.d478.s1.p6"}
{"sentence": "Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "drug1": "Didanosine", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Delavirdine_ddi.xml", "sentence_id": "DDI-DrugBank.d251.s0", "pair_id": "DDI-DrugBank.d251.s0.p13"}
{"sentence": "Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.", "drug1": "retinyl acetate", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s0", "pair_id": "DDI-MedLine.d12.s0.p4"}
{"sentence": "Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.", "drug1": "capecitabine", "drug2": "coumarin-derivative anticoagulants", "relation": "EFFECT", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s3", "pair_id": "DDI-DrugBank.d88.s3.p4"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "lincomycin", "drug2": "anesthetics", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p74"}
{"sentence": "The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.", "drug1": "enoximone", "drug2": "anagrelide", "relation": "EFFECT", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s14", "pair_id": "DDI-DrugBank.d75.s14.p8"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "sulfonamides", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p12"}
{"sentence": "Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.", "drug1": "beta-adrenergic blocking agents", "drug2": "calcium antagonists", "relation": "ADVISE", "source_file": "Levobunolol_ddi.xml", "sentence_id": "DDI-DrugBank.d252.s2", "pair_id": "DDI-DrugBank.d252.s2.p0"}
{"sentence": "Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.", "drug1": "rifampin", "drug2": "zaleplon", "relation": "MECHANISM", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s16", "pair_id": "DDI-DrugBank.d324.s16.p0"}
{"sentence": "Elevated serum levels of cyclosporine have been reported with the concomitant use of some quinolones and cyclosporine.", "drug1": "quinolones", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s13", "pair_id": "DDI-DrugBank.d427.s13.p2"}
{"sentence": "These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.", "drug1": "lead", "drug2": "alcohol", "relation": "EFFECT", "source_file": "6536282.xml", "sentence_id": "DDI-MedLine.d93.s9", "pair_id": "DDI-MedLine.d93.s9.p0"}
{"sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "drug1": "spironolactone", "drug2": "potassium", "relation": "NONE", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s15", "pair_id": "DDI-DrugBank.d334.s15.p11"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "antimuscarinics", "drug2": "antihistamines", "relation": "NONE", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p12"}
{"sentence": "Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.", "drug1": "Ephedrine", "drug2": "Ephedrine", "relation": "NONE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s16", "pair_id": "DDI-DrugBank.d314.s16.p0"}
{"sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.", "drug1": "IOPIDINE", "drug2": "sedatives", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s1", "pair_id": "DDI-DrugBank.d224.s1.p4"}
{"sentence": "Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.", "drug1": "Nimodipine", "drug2": "bosentan", "relation": "NONE", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s32", "pair_id": "DDI-DrugBank.d289.s32.p12"}
{"sentence": "Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.", "drug1": "Epinephrine", "drug2": "isoproterenol", "relation": "ADVISE", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s2", "pair_id": "DDI-DrugBank.d247.s2.p1"}
{"sentence": "The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract.", "drug1": "nitrofurantoin", "drug2": "Norfloxacin", "relation": "EFFECT", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s10", "pair_id": "DDI-DrugBank.d217.s10.p2"}
{"sentence": "Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.", "drug1": "tetracyclines", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s2", "pair_id": "DDI-DrugBank.d500.s2.p1"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "central nervous system depressants", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p23"}
{"sentence": "Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.", "drug1": "theophylline", "drug2": "quinolones", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s0", "pair_id": "DDI-DrugBank.d562.s0.p0"}
{"sentence": "MAO inhibitors prolong and intensify the effects of antihistamines.", "drug1": "MAO inhibitors", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s0", "pair_id": "DDI-DrugBank.d448.s0.p0"}
{"sentence": "Influence of Trileptal on AED Concentration (Mean change, 90% Confidence Interval)", "drug1": "Trileptal", "drug2": "AED", "relation": "NONE", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s16", "pair_id": "DDI-DrugBank.d307.s16.p0"}
{"sentence": "Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.", "drug1": "Sonata", "drug2": "warfarin", "relation": "NONE", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s35", "pair_id": "DDI-DrugBank.d324.s35.p4"}
{"sentence": "Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.", "drug1": "fluconazole", "drug2": "celecoxib", "relation": "MECHANISM", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s16", "pair_id": "DDI-DrugBank.d172.s16.p2"}
{"sentence": "Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.", "drug1": "PEGANONE", "drug2": "phenacemide", "relation": "ADVISE", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s1", "pair_id": "DDI-DrugBank.d359.s1.p1"}
{"sentence": "Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.", "drug1": "phenobarbital", "drug2": "exemestane", "relation": "MECHANISM", "source_file": "Exemestane_ddi.xml", "sentence_id": "DDI-DrugBank.d435.s2", "pair_id": "DDI-DrugBank.d435.s2.p9"}
{"sentence": "Administration of phenytoin to patients receiving dopamine HCl has been reported to lead to hypotension and bradycardia.", "drug1": "phenytoin", "drug2": "dopamine HCl", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s13", "pair_id": "DDI-DrugBank.d325.s13.p0"}
{"sentence": "Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.", "drug1": "diltiazem hydrochloride", "drug2": "propranolol", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s8", "pair_id": "DDI-DrugBank.d565.s8.p0"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "lovastatin", "drug2": "warfarin", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p1"}
{"sentence": "Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.", "drug1": "Folic acid", "drug2": "primidone", "relation": "EFFECT", "source_file": "Leucovorin_ddi.xml", "sentence_id": "DDI-DrugBank.d151.s0", "pair_id": "DDI-DrugBank.d151.s0.p2"}
{"sentence": "Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.", "drug1": "Corticosteroids", "drug2": "amphotericin B", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s2", "pair_id": "DDI-DrugBank.d318.s2.p2"}
{"sentence": "ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.", "drug1": "ISUPREL", "drug2": "anesthetics", "relation": "ADVISE", "source_file": "Isoproterenol_ddi.xml", "sentence_id": "DDI-DrugBank.d55.s2", "pair_id": "DDI-DrugBank.d55.s2.p0"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "Antihistamines", "drug2": "antianxiety agents", "relation": "EFFECT", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p5"}
{"sentence": "Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.", "drug1": "Macrolide antibiotics", "drug2": "corticosteroid", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s3", "pair_id": "DDI-DrugBank.d314.s3.p2"}
{"sentence": "Pregnancy estrogens and estrogen-containing oral contraceptives increase TBg concentrations.", "drug1": "estrogens", "drug2": "estrogen", "relation": "NONE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s27", "pair_id": "DDI-DrugBank.d54.s27.p0"}
{"sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.", "drug1": "alosetron", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s10", "pair_id": "DDI-DrugBank.d364.s10.p4"}
{"sentence": "If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.", "drug1": "beta blockers", "drug2": "clonidine", "relation": "ADVISE", "source_file": "Atenolol_ddi.xml", "sentence_id": "DDI-DrugBank.d73.s5", "pair_id": "DDI-DrugBank.d73.s5.p5"}
{"sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "drug1": "acetylsalicylic acid", "drug2": "benzodiazepines", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s3", "pair_id": "DDI-DrugBank.d209.s3.p32"}
{"sentence": "Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.", "drug1": "theophylline", "drug2": "diuretics", "relation": "NONE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s3", "pair_id": "DDI-DrugBank.d284.s3.p10"}
{"sentence": "It would be expected that laxative use during therapy with CAMPTOSAR would worsen the incidence or severity of diarrhea, but this has not been studied.", "drug1": "laxative", "drug2": "CAMPTOSAR", "relation": "EFFECT", "source_file": "Irinotecan_ddi.xml", "sentence_id": "DDI-DrugBank.d279.s10", "pair_id": "DDI-DrugBank.d279.s10.p0"}
{"sentence": "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with Tiazac.", "drug1": "digitalis", "drug2": "Tiazac", "relation": "EFFECT", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s1", "pair_id": "DDI-DrugBank.d565.s1.p2"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "narcotics", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p28"}
{"sentence": "Aminoglutethimide: Aminoglutethimide may diminish adrenal suppression by corticosteroids.", "drug1": "Aminoglutethimide", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s0", "pair_id": "DDI-DrugBank.d314.s0.p2"}
{"sentence": "However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.", "drug1": "metformin", "drug2": "Acarbose", "relation": "MECHANISM", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s10", "pair_id": "DDI-DrugBank.d536.s10.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "buspirone", "drug2": "doxycycline", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p224"}
{"sentence": "Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.", "drug1": "carbamazepine", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s18", "pair_id": "DDI-DrugBank.d314.s18.p10"}
{"sentence": "Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).", "drug1": "esomeprazole", "drug2": "iron", "relation": "MECHANISM", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s12", "pair_id": "DDI-DrugBank.d29.s12.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chlorpropamide", "drug2": "influenza virus vaccine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p464"}
{"sentence": "Avoid the concomitant use of chlorprothixene and tramadol (Ultram).", "drug1": "chlorprothixene", "drug2": "Ultram", "relation": "ADVISE", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s3", "pair_id": "DDI-DrugBank.d503.s3.p1"}
{"sentence": "This may indicate that ibuprofen could enhance the toxicity of methotrexate.", "drug1": "ibuprofen", "drug2": "methotrexate", "relation": "EFFECT", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s6", "pair_id": "DDI-DrugBank.d415.s6.p0"}
{"sentence": "Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).", "drug1": "verapamil", "drug2": "HMG-CoA reductase inhibitor class", "relation": "EFFECT", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s12", "pair_id": "DDI-DrugBank.d567.s12.p9"}
{"sentence": "Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.", "drug1": "tricyclic antidepressant", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s24", "pair_id": "DDI-DrugBank.d223.s24.p0"}
{"sentence": "In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.", "drug1": "salicylate", "drug2": "ketorolac", "relation": "MECHANISM", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s3", "pair_id": "DDI-DrugBank.d3.s3.p0"}
{"sentence": "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.", "drug1": "quinolones", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Levofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d242.s1", "pair_id": "DDI-DrugBank.d242.s1.p0"}
{"sentence": "Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.", "drug1": "Warfarin", "drug2": "VIOXX", "relation": "NONE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s31", "pair_id": "DDI-DrugBank.d210.s31.p0"}
{"sentence": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "drug1": "Isoniazid", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s7", "pair_id": "DDI-DrugBank.d187.s7.p9"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "diazoxide", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p15"}
{"sentence": "In post-marketing experience, bleeding has been reported in patients on concomitant treatment with anticoagulants and INDOCIN.", "drug1": "anticoagulants", "drug2": "INDOCIN", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s7", "pair_id": "DDI-DrugBank.d82.s7.p0"}
{"sentence": "Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. ", "drug1": "neomycin", "drug2": "ACTH", "relation": "EFFECT", "source_file": "6100240.xml", "sentence_id": "DDI-MedLine.d2.s1", "pair_id": "DDI-MedLine.d2.s1.p1"}
{"sentence": "Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.", "drug1": "Chloramphenicol", "drug2": "ceftazidime", "relation": "EFFECT", "source_file": "Ceftazidime_ddi.xml", "sentence_id": "DDI-DrugBank.d122.s3", "pair_id": "DDI-DrugBank.d122.s3.p1"}
{"sentence": "- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "drug1": "Perhexiline hydrogen maleate", "drug2": "Bezalip", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s11", "pair_id": "DDI-DrugBank.d291.s11.p1"}
{"sentence": "Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.", "drug1": "Colchicine", "drug2": "vitamin B12", "relation": "MECHANISM", "source_file": "Cyanocobalamin_ddi.xml", "sentence_id": "DDI-DrugBank.d39.s1", "pair_id": "DDI-DrugBank.d39.s1.p2"}
{"sentence": "Potential drug interactions for doxylamine include, increased sedation if doxylamine is combined with other CNS depressant drugs.", "drug1": "doxylamine", "drug2": "CNS depressant drugs", "relation": "EFFECT", "source_file": "Doxylamine_ddi.xml", "sentence_id": "DDI-DrugBank.d387.s0", "pair_id": "DDI-DrugBank.d387.s0.p2"}
{"sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "drug1": "PLETAL", "drug2": "erythromycin", "relation": "ADVISE", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s0", "pair_id": "DDI-DrugBank.d358.s0.p5"}
{"sentence": "When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.", "drug1": "Bezalip retard", "drug2": "anticoagulants of the coumarin type", "relation": "EFFECT", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s0", "pair_id": "DDI-DrugBank.d291.s0.p9"}
{"sentence": "Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of doxepin (75 mg/day).", "drug1": "tolazamide", "drug2": "doxepin", "relation": "EFFECT", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s28", "pair_id": "DDI-DrugBank.d223.s28.p2"}
{"sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "drug1": "Benzodiazepines", "drug2": "midazolam", "relation": "NONE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s12", "pair_id": "DDI-DrugBank.d76.s12.p6"}
{"sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "drug1": "griseofulvin", "drug2": "LEVULAN KERASTICK", "relation": "EFFECT", "source_file": "Aminolevulinic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d379.s1", "pair_id": "DDI-DrugBank.d379.s1.p12"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "zonisamide", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p44"}
{"sentence": "Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;", "drug1": "norethindrone", "drug2": "norethindrone", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s19", "pair_id": "DDI-DrugBank.d382.s19.p19"}
{"sentence": "In the case that you are taking digoxin while taking aminosalicylic acid, higher doses of digoxin may be needed.", "drug1": "digoxin", "drug2": "aminosalicylic acid", "relation": "ADVISE", "source_file": "Aminosalicylic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d22.s1", "pair_id": "DDI-DrugBank.d22.s1.p0"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "Aprepitant", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anabolic steroids", "drug2": "naproxen", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p287"}
{"sentence": "CANCIDAS has no effect on the pharmacokinetics of itraconazole, amphotericin B, or the active metabolite of mycophenolate.", "drug1": "itraconazole", "drug2": "amphotericin B", "relation": "NONE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s4", "pair_id": "DDI-DrugBank.d350.s4.p2"}
{"sentence": "A study of interaction between BREVIBLOC and warfarin showed that concomitant administration of BREVIBLOC and warfarin does not alter warfarin plasma levels.", "drug1": "BREVIBLOC", "drug2": "warfarin", "relation": "NONE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s2", "pair_id": "DDI-DrugBank.d422.s2.p8"}
{"sentence": "Effect of diazepam and midazolam on the antinociceptive effect of morphine, metamizol and indomethacin in mice.", "drug1": "midazolam", "drug2": "indomethacin", "relation": "NONE", "source_file": "11210678.xml", "sentence_id": "DDI-MedLine.d67.s0", "pair_id": "DDI-MedLine.d67.s0.p6"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "phenothiazines", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p14"}
{"sentence": "The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive.", "drug1": "TAMBOCOR", "drug2": "propranolol", "relation": "EFFECT", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s6", "pair_id": "DDI-DrugBank.d87.s6.p0"}
{"sentence": "In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.", "drug1": "ZEBETA", "drug2": "clonidine", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s2", "pair_id": "DDI-DrugBank.d476.s2.p2"}
{"sentence": "Theophylline: The effect of steady-state fluvoxamine l50 mg bid on the pharmacokinetics of a single dose of Theophylline (375 mg) as 442 mg aminophylline was evaluated in 12 healthy non-smoking, male volunteers.", "drug1": "Theophylline", "drug2": "aminophylline", "relation": "NONE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s26", "pair_id": "DDI-DrugBank.d76.s26.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anabolic steroids", "drug2": "ranitidine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p298"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p10"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "antibiotics", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p355"}
{"sentence": "The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.", "drug1": "diuretic", "drug2": "Lotensin", "relation": "ADVISE", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s1", "pair_id": "DDI-DrugBank.d561.s1.p2"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "terbutaline", "drug2": "isoniazid", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p77"}
{"sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "drug1": "Antacids", "drug2": "antacid", "relation": "NONE", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s9", "pair_id": "DDI-DrugBank.d176.s9.p0"}
{"sentence": "Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.", "drug1": "digitoxin", "drug2": "antithyroid agents", "relation": "MECHANISM", "source_file": "Carbimazole_ddi.xml", "sentence_id": "DDI-DrugBank.d213.s1", "pair_id": "DDI-DrugBank.d213.s1.p2"}
{"sentence": "When taken orally , imidazole compounds like ketoconazole may enhance the anticoagulant effect of coumarin-like drugs.", "drug1": "imidazole compounds", "drug2": "coumarin", "relation": "EFFECT", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s19", "pair_id": "DDI-DrugBank.d458.s19.p1"}
{"sentence": "Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.\n", "drug1": "Fluvoxamine", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "11180037.xml", "sentence_id": "DDI-MedLine.d99.s0", "pair_id": "DDI-MedLine.d99.s0.p0"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenylbutazone", "drug2": "tolbutamide", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p219"}
{"sentence": "- Methyldopa (e.g., Aldomet) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood", "drug1": "methyldopa", "drug2": "sulfapyridine", "relation": "EFFECT", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s39", "pair_id": "DDI-DrugBank.d179.s39.p5"}
{"sentence": "In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.", "drug1": "Nalfon", "drug2": "steroid", "relation": "ADVISE", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s11", "pair_id": "DDI-DrugBank.d154.s11.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "astemizole", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p4"}
{"sentence": "The in vitro interaction between nevirapine and the antithrombotic agent warfarin is complex.", "drug1": "nevirapine", "drug2": "warfarin", "relation": "INT", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s9", "pair_id": "DDI-DrugBank.d270.s9.p1"}
{"sentence": "Antidepressants (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.", "drug1": "Antidepressants", "drug2": "tricyclic", "relation": "NONE", "source_file": "Arbutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d253.s3", "pair_id": "DDI-DrugBank.d253.s3.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "cisapride", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p12"}
{"sentence": "Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.", "drug1": "Beta blockers", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Atenolol_ddi.xml", "sentence_id": "DDI-DrugBank.d73.s3", "pair_id": "DDI-DrugBank.d73.s3.p0"}
{"sentence": "Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).", "drug1": "ENABLEX", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s1", "pair_id": "DDI-DrugBank.d459.s1.p2"}
{"sentence": "Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.", "drug1": "NSAIDs", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s7", "pair_id": "DDI-DrugBank.d219.s7.p4"}
{"sentence": "ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.\r\n", "drug1": "ADL 8-2698", "drug2": "morphine", "relation": "EFFECT", "source_file": "11180040.xml", "sentence_id": "DDI-MedLine.d87.s0", "pair_id": "DDI-MedLine.d87.s0.p0"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "NSAIDs", "drug2": "Aleve", "relation": "NONE", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p33"}
{"sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "drug1": "halogenated hydrocarbon anesthetics", "drug2": "catecholamines", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s8", "pair_id": "DDI-DrugBank.d325.s8.p3"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "gallamine", "drug2": "Coly-Mycin M", "relation": "EFFECT", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p17"}
{"sentence": "Naproxen had no effect on plasma levels of diflunisal.", "drug1": "Naproxen", "drug2": "diflunisal", "relation": "NONE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s28", "pair_id": "DDI-DrugBank.d132.s28.p0"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "spironolactone", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p42"}
{"sentence": "Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.", "drug1": "selective serotonin reuptake inhibitor", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s16", "pair_id": "DDI-DrugBank.d568.s16.p4"}
{"sentence": "However, iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents.", "drug1": "iloprost", "drug2": "antihypertensive agents", "relation": "EFFECT", "source_file": "Iloprost_ddi.xml", "sentence_id": "DDI-DrugBank.d549.s1", "pair_id": "DDI-DrugBank.d549.s1.p1"}
{"sentence": "Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.", "drug1": "warfarin", "drug2": "ketorolac tromethamine", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s4", "pair_id": "DDI-DrugBank.d3.s4.p12"}
{"sentence": "Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.", "drug1": "Vardenafil", "drug2": "ritonavir", "relation": "ADVISE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s15", "pair_id": "DDI-DrugBank.d198.s15.p0"}
{"sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.", "drug1": "tricyclic antidepressants", "drug2": "adrenergic agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s6", "pair_id": "DDI-DrugBank.d284.s6.p9"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "nefazadone", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p66"}
{"sentence": "Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.", "drug1": "Antihistamines", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s0", "pair_id": "DDI-DrugBank.d389.s0.p0"}
{"sentence": "Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.", "drug1": "non-depolarizing muscle relaxants", "drug2": "piperacillin", "relation": "EFFECT", "source_file": "Piperacillin_ddi.xml", "sentence_id": "DDI-DrugBank.d462.s4", "pair_id": "DDI-DrugBank.d462.s4.p0"}
{"sentence": "Dimenhydrinate may decrease emetic response to apomorphine.", "drug1": "Dimenhydrinate", "drug2": "apomorphine", "relation": "EFFECT", "source_file": "Dimenhydrinate_ddi.xml", "sentence_id": "DDI-DrugBank.d96.s0", "pair_id": "DDI-DrugBank.d96.s0.p1"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "sulfonamides", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p2"}
{"sentence": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.", "drug1": "sulfasalazine", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s6", "pair_id": "DDI-DrugBank.d450.s6.p14"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "dextran", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p13"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylurea", "drug2": "probenecid", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p4"}
{"sentence": "Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.", "drug1": "Epinephrine", "drug2": "sympathomimetic drugs", "relation": "ADVISE", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s2", "pair_id": "DDI-DrugBank.d247.s2.p0"}
{"sentence": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "drug1": "quinolones", "drug2": "Videx", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s7", "pair_id": "DDI-DrugBank.d562.s7.p3"}
{"sentence": "Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.", "drug1": "acetazolamide", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s5", "pair_id": "DDI-DrugBank.d236.s5.p1"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "glutethimide", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p12"}
{"sentence": "After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.", "drug1": "interferon beta-1a", "drug2": "TYSABRI", "relation": "MECHANISM", "source_file": "Natalizumab_ddi.xml", "sentence_id": "DDI-DrugBank.d232.s0", "pair_id": "DDI-DrugBank.d232.s0.p1"}
{"sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "drug1": "D.H.E. 45", "drug2": "propranolol", "relation": "NONE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s3", "pair_id": "DDI-DrugBank.d410.s3.p6"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "alprazolam", "drug2": "ergotamine", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p6"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "corticotropin", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p6"}
{"sentence": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "drug1": "nitrous oxide", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s6", "pair_id": "DDI-DrugBank.d60.s6.p11"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Stelazine", "drug2": "trimeprazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p292"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "polymyxins", "drug2": "procainamide", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p67"}
{"sentence": "Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.", "drug1": "chloroprocaine", "drug2": "sulfonamide drug", "relation": "ADVISE", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s5", "pair_id": "DDI-DrugBank.d110.s5.p0"}
{"sentence": "Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.", "drug1": "Anti-arrhythmics", "drug2": "bepridil hydrochloride", "relation": "EFFECT", "source_file": "Bepridil_ddi.xml", "sentence_id": "DDI-DrugBank.d137.s10", "pair_id": "DDI-DrugBank.d137.s10.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "prolonged narcotics", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p39"}
{"sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "drug1": "PRINIVIL", "drug2": "amiloride", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s15", "pair_id": "DDI-DrugBank.d334.s15.p3"}
{"sentence": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).", "drug1": "caffeine", "drug2": "cimetidine", "relation": "ADVISE", "source_file": "Caffeine_ddi.xml", "sentence_id": "DDI-DrugBank.d89.s3", "pair_id": "DDI-DrugBank.d89.s3.p1"}
{"sentence": "Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.", "drug1": "dapsone", "drug2": "glutethimide", "relation": "NONE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s13", "pair_id": "DDI-DrugBank.d263.s13.p44"}
{"sentence": "The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.", "drug1": "EMTRIVA", "drug2": "tenofovir disoproxil fumarate", "relation": "NONE", "source_file": "Emtricitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d375.s0", "pair_id": "DDI-DrugBank.d375.s0.p3"}
{"sentence": "conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).", "drug1": "diethylpropion", "drug2": "antihypertensive drugs", "relation": "INT", "source_file": "Diethylpropion_ddi.xml", "sentence_id": "DDI-DrugBank.d352.s3", "pair_id": "DDI-DrugBank.d352.s3.p0"}
{"sentence": "Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.", "drug1": "Indinavir", "drug2": "indinavir", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s14", "pair_id": "DDI-DrugBank.d340.s14.p0"}
{"sentence": "In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.", "drug1": "methylxanthines", "drug2": "adenosine", "relation": "ADVISE", "source_file": "Adenosine_ddi.xml", "sentence_id": "DDI-DrugBank.d226.s5", "pair_id": "DDI-DrugBank.d226.s5.p0"}
{"sentence": "(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. ", "drug1": "penicillins", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "15830476.xml", "sentence_id": "DDI-MedLine.d29.s2", "pair_id": "DDI-MedLine.d29.s2.p1"}
{"sentence": "Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.", "drug1": "INDOCIN", "drug2": "anticoagulants", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s8", "pair_id": "DDI-DrugBank.d82.s8.p0"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "anesthetics", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p4"}
{"sentence": "Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.", "drug1": "sucralfate", "drug2": "quinolones", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s6", "pair_id": "DDI-DrugBank.d562.s6.p2"}
{"sentence": "When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.", "drug1": "probenecid", "drug2": "ertapenem", "relation": "MECHANISM", "source_file": "Ertapenem_ddi.xml", "sentence_id": "DDI-DrugBank.d329.s0", "pair_id": "DDI-DrugBank.d329.s0.p5"}
{"sentence": "Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.", "drug1": "penicillin", "drug2": "tetracyclines", "relation": "NONE", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s1", "pair_id": "DDI-DrugBank.d500.s1.p0"}
{"sentence": "The potential effects of INDOCIN and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently.", "drug1": "INDOCIN", "drug2": "potassium-sparing diuretics", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s31", "pair_id": "DDI-DrugBank.d82.s31.p0"}
{"sentence": "Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).", "drug1": "propranolol", "drug2": "atenolol", "relation": "NONE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s7", "pair_id": "DDI-DrugBank.d529.s7.p5"}
{"sentence": "Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.", "drug1": "clozapine", "drug2": "benzodiazepine", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s8", "pair_id": "DDI-DrugBank.d480.s8.p12"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "Benzthiazide", "drug2": "NSAIDs", "relation": "INT", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p5"}
{"sentence": "EDECRIN may increase the ototoxic potential of other drugs such as aminoglycoside and some cephalosporin antibiotics.", "drug1": "EDECRIN", "drug2": "aminoglycoside", "relation": "EFFECT", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s2", "pair_id": "DDI-DrugBank.d414.s2.p0"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "Benzthiazide", "drug2": "norepinephrine", "relation": "INT", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p4"}
{"sentence": "Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system", "drug1": "Benazepril", "drug2": "beta-adrenergic blockers", "relation": "EFFECT", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s12", "pair_id": "DDI-DrugBank.d561.s12.p1"}
{"sentence": "however, in a study of 12 normal subjects, concurrent administration of aspirin decreased ketoprofen protein binding and increased ketoprofen plasma clearance from 0.07 L/kg/h without aspirin to 0.11 L/kg/h with aspirin.", "drug1": "aspirin", "drug2": "ketoprofen", "relation": "MECHANISM", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s6", "pair_id": "DDI-DrugBank.d499.s6.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "desipramine", "drug2": "Phenytoin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p493"}
{"sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "drug1": "PRINIVIL", "drug2": "potassium", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s15", "pair_id": "DDI-DrugBank.d334.s15.p4"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "fluoxetine", "drug2": "sulfonamides", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p173"}
{"sentence": "Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.\r\n", "drug1": "simvastatin", "drug2": "clarithromycin", "relation": "EFFECT", "source_file": "11197581.xml", "sentence_id": "DDI-MedLine.d25.s0", "pair_id": "DDI-MedLine.d25.s0.p0"}
{"sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "phenytoin", "drug2": "Felbatol", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s30", "pair_id": "DDI-DrugBank.d434.s30.p33"}
{"sentence": "Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.", "drug1": "corticosteroid", "drug2": "live vaccines", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s30", "pair_id": "DDI-DrugBank.d314.s30.p3"}
{"sentence": "(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and thiazide diuretics.", "drug1": "steroidal anti-inflammatory agent", "drug2": "loop diuretics", "relation": "EFFECT", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s25", "pair_id": "DDI-DrugBank.d17.s25.p0"}
{"sentence": "In clinical trials in patients undergoing PTCA/PCI, co-administration of Angiomax with heparin, warfarin, thrombolytics or glycoprotein IIb/IIIa inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications.", "drug1": "heparin", "drug2": "thrombolytics", "relation": "NONE", "source_file": "Bivalirudin_ddi.xml", "sentence_id": "DDI-DrugBank.d569.s1", "pair_id": "DDI-DrugBank.d569.s1.p4"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "pertechnetate", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p202"}
{"sentence": "FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.", "drug1": "FLEXERIL", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Cyclobenzaprine_ddi.xml", "sentence_id": "DDI-DrugBank.d150.s1", "pair_id": "DDI-DrugBank.d150.s1.p1"}
{"sentence": "Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.", "drug1": "aluminum hydroxide", "drug2": "enoxacin", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s17", "pair_id": "DDI-DrugBank.d395.s17.p4"}
{"sentence": "Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.", "drug1": "Probenecid", "drug2": "ampicillin", "relation": "MECHANISM", "source_file": "Ampicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d211.s5", "pair_id": "DDI-DrugBank.d211.s5.p0"}
{"sentence": "Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..", "drug1": "epinephrine", "drug2": "cyclopropane", "relation": "EFFECT", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s5", "pair_id": "DDI-DrugBank.d247.s5.p0"}
{"sentence": "Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.", "drug1": "Erythromycin", "drug2": "benzodiazepines", "relation": "EFFECT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s6", "pair_id": "DDI-DrugBank.d397.s6.p2"}
{"sentence": "Although ROMAZICON exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a benzodiazepine agonist can give rise to convulsions in epileptic patients.", "drug1": "ROMAZICON", "drug2": "benzodiazepine", "relation": "EFFECT", "source_file": "Flumazenil_ddi.xml", "sentence_id": "DDI-DrugBank.d234.s4", "pair_id": "DDI-DrugBank.d234.s4.p0"}
{"sentence": "Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.", "drug1": "Urinary acidifying", "drug2": "amphetamines", "relation": "MECHANISM", "source_file": "Benzphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d477.s5", "pair_id": "DDI-DrugBank.d477.s5.p0"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p6"}
{"sentence": "Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.", "drug1": "Trileptal", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s36", "pair_id": "DDI-DrugBank.d307.s36.p0"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "anticholinergic", "drug2": "narcotic analgesics", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p1"}
{"sentence": "Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.", "drug1": "Tetracycline", "drug2": "penicillin", "relation": "EFFECT", "source_file": "Nafcillin_ddi.xml", "sentence_id": "DDI-DrugBank.d261.s0", "pair_id": "DDI-DrugBank.d261.s0.p1"}
{"sentence": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "drug1": "NSAIDs", "drug2": "Ibandronate", "relation": "ADVISE", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s13", "pair_id": "DDI-DrugBank.d440.s13.p14"}
{"sentence": "Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.", "drug1": "digoxin", "drug2": "antithyroid agents", "relation": "MECHANISM", "source_file": "Carbimazole_ddi.xml", "sentence_id": "DDI-DrugBank.d213.s1", "pair_id": "DDI-DrugBank.d213.s1.p1"}
{"sentence": "Since iloprost inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants.", "drug1": "iloprost", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Iloprost_ddi.xml", "sentence_id": "DDI-DrugBank.d549.s2", "pair_id": "DDI-DrugBank.d549.s2.p0"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "metoprolol", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p12"}
{"sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "drug1": "hormonal contraceptives", "drug2": "diazepam", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s17", "pair_id": "DDI-DrugBank.d485.s17.p11"}
{"sentence": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).", "drug1": "antacids", "drug2": "ranitidine", "relation": "NONE", "source_file": "Diatrizoate_ddi.xml", "sentence_id": "DDI-DrugBank.d293.s0", "pair_id": "DDI-DrugBank.d293.s0.p17"}
{"sentence": "Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).", "drug1": "TORADOL", "drug2": "psychoactive drugs", "relation": "EFFECT", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s19", "pair_id": "DDI-DrugBank.d3.s19.p5"}
{"sentence": "Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.", "drug1": "agents with b-blocking properties", "drug2": "reserpine", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s3", "pair_id": "DDI-DrugBank.d269.s3.p0"}
{"sentence": "The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.", "drug1": "benzodiazepines", "drug2": "isoniazide", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s8", "pair_id": "DDI-DrugBank.d338.s8.p4"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "procainamide", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p27"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "anticonvulsants", "drug2": "temazepam", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p283"}
{"sentence": "Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.", "drug1": "Lodine", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s7", "pair_id": "DDI-DrugBank.d219.s7.p2"}
{"sentence": "Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.", "drug1": "Erythromycin", "drug2": "triazolam", "relation": "EFFECT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s19", "pair_id": "DDI-DrugBank.d522.s19.p4"}
{"sentence": "Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.", "drug1": "carbamazepine", "drug2": "lapatinib", "relation": "MECHANISM", "source_file": "Lapatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d135.s8", "pair_id": "DDI-DrugBank.d135.s8.p2"}
{"sentence": "In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Amiloride_ddi.xml", "sentence_id": "DDI-DrugBank.d356.s4", "pair_id": "DDI-DrugBank.d356.s4.p2"}
{"sentence": "MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.", "drug1": "furazolidone", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s6", "pair_id": "DDI-DrugBank.d158.s6.p5"}
{"sentence": "Warfarin: Meclofenamate sodium enhances the effect of warfarin.", "drug1": "Warfarin", "drug2": "Meclofenamate sodium", "relation": "EFFECT", "source_file": "Meclofenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d113.s0", "pair_id": "DDI-DrugBank.d113.s0.p0"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "iron", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p5"}
{"sentence": "Compounds that have been tested in man include antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.", "drug1": "digoxin", "drug2": "warfarin", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s2", "pair_id": "DDI-DrugBank.d209.s2.p6"}
{"sentence": "Sildenafil citrate - Theoretically, L-arginine supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.", "drug1": "L-arginine", "drug2": "sildenafil citrate", "relation": "EFFECT", "source_file": "L-Arginine_ddi.xml", "sentence_id": "DDI-DrugBank.d95.s3", "pair_id": "DDI-DrugBank.d95.s3.p2"}
{"sentence": "There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.", "drug1": "furosemide", "drug2": "NSAIDs", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s14", "pair_id": "DDI-DrugBank.d231.s14.p0"}
{"sentence": "Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.", "drug1": "Medroxyprogesterone Acetate", "drug2": "medroxyprogesterone acetate", "relation": "NONE", "source_file": "L-Histidine_ddi.xml", "sentence_id": "DDI-DrugBank.d365.s0", "pair_id": "DDI-DrugBank.d365.s0.p1"}
{"sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "drug1": "Diuretic agents", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s16", "pair_id": "DDI-DrugBank.d46.s16.p1"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p28"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "drug1": "diuretics", "drug2": "nicotinic acid", "relation": "NONE", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s1", "pair_id": "DDI-DrugBank.d536.s1.p17"}
{"sentence": "Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.", "drug1": "Ketoprofen", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s22", "pair_id": "DDI-DrugBank.d499.s22.p4"}
{"sentence": "Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.", "drug1": "nitric oxide donor compounds", "drug2": "nitroglycerin", "relation": "NONE", "source_file": "Nitric Oxide_ddi.xml", "sentence_id": "DDI-DrugBank.d183.s2", "pair_id": "DDI-DrugBank.d183.s2.p1"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "opioids", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p24"}
{"sentence": "During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). ", "drug1": "amiodarone", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "3964797.xml", "sentence_id": "DDI-MedLine.d61.s4", "pair_id": "DDI-MedLine.d61.s4.p0"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "Advil", "drug2": "Anaprox", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p107"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "delavirdine", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p167"}
{"sentence": "While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.", "drug1": "estazolam", "drug2": "estazolam", "relation": "MECHANISM", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s4", "pair_id": "DDI-DrugBank.d338.s4.p4"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Prelone", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p37"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p8"}
{"sentence": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "drug1": "WELLBUTRIN", "drug2": "antidepressants", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s22", "pair_id": "DDI-DrugBank.d5.s22.p1"}
{"sentence": "Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.", "drug1": "Argatroban", "drug2": "thrombolytics", "relation": "EFFECT", "source_file": "Argatroban_ddi.xml", "sentence_id": "DDI-DrugBank.d148.s6", "pair_id": "DDI-DrugBank.d148.s6.p1"}
{"sentence": "Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.", "drug1": "Bosentan", "drug2": "statins", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s27", "pair_id": "DDI-DrugBank.d289.s27.p0"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "chlorpromazine", "drug2": "trihexyphenidyl", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p6"}
{"sentence": "Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.", "drug1": "phenelzine sulfate", "drug2": "MAO inhibitors", "relation": "NONE", "source_file": "L-Tyrosine_ddi.xml", "sentence_id": "DDI-DrugBank.d111.s0", "pair_id": "DDI-DrugBank.d111.s0.p11"}
{"sentence": "Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.", "drug1": "cisapride", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s7", "pair_id": "DDI-DrugBank.d76.s7.p5"}
{"sentence": "[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ", "drug1": "picrotoxin", "drug2": "diazepam", "relation": "EFFECT", "source_file": "2857099.xml", "sentence_id": "DDI-MedLine.d27.s0", "pair_id": "DDI-MedLine.d27.s0.p0"}
{"sentence": "Phenytoin: Etodolac has no apparent pharmacokinetic interaction when administered with phenytoin.", "drug1": "Phenytoin", "drug2": "Etodolac", "relation": "NONE", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s21", "pair_id": "DDI-DrugBank.d219.s21.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "fluconazole", "drug2": "sildenafil", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p78"}
{"sentence": "Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.", "drug1": "EQUETROTM", "drug2": "centrally acting drugs", "relation": "ADVISE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s18", "pair_id": "DDI-DrugBank.d94.s18.p0"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p9"}
{"sentence": "Gentamicin - Methionine may protect against the ototoxic effects of gentamicin.", "drug1": "Methionine", "drug2": "gentamicin", "relation": "EFFECT", "source_file": "L-Methionine_ddi.xml", "sentence_id": "DDI-DrugBank.d528.s2", "pair_id": "DDI-DrugBank.d528.s2.p2"}
{"sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "drug1": "phenylbutazone", "drug2": "indomethacin", "relation": "NONE", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s2", "pair_id": "DDI-DrugBank.d488.s2.p22"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "Pronestyl", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p11"}
{"sentence": "Quinolones, including nalidixic acid, may enhance the effects of the oral anticoagulant warfarin or its derivatives.", "drug1": "nalidixic acid", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s5", "pair_id": "DDI-DrugBank.d427.s5.p4"}
{"sentence": "The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.", "drug1": "reserpine", "drug2": "sympathomimetics", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s3", "pair_id": "DDI-DrugBank.d448.s3.p8"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "indinavir", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p6"}
{"sentence": "Digoxin: In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin.", "drug1": "Digoxin", "drug2": "digoxin", "relation": "NONE", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s13", "pair_id": "DDI-DrugBank.d499.s13.p1"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "nicotine", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p9"}
{"sentence": "On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.", "drug1": "erythromycin", "drug2": "bexarotene", "relation": "MECHANISM", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s2", "pair_id": "DDI-DrugBank.d467.s2.p13"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "metoclopramide", "drug2": "somatostatin analogs", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p512"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Sandimmune", "drug2": "theophylline", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p777"}
{"sentence": "Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.", "drug1": "Methadone", "drug2": "nevirapine", "relation": "ADVISE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s42", "pair_id": "DDI-DrugBank.d270.s42.p7"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "sodium colistemethate", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p9"}
{"sentence": "Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.", "drug1": "Antacid", "drug2": "atorvastatin", "relation": "NONE", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s1", "pair_id": "DDI-DrugBank.d140.s1.p0"}
{"sentence": "Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.", "drug1": "Robinul", "drug2": "potassium chloride", "relation": "MECHANISM", "source_file": "Glycopyrrolate_ddi.xml", "sentence_id": "DDI-DrugBank.d510.s1", "pair_id": "DDI-DrugBank.d510.s1.p0"}
{"sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.", "drug1": "docetaxel", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Docetaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d371.s1", "pair_id": "DDI-DrugBank.d371.s1.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p11"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "nifedipine", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p3"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "lorazepam", "drug2": "zonisamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p824"}
{"sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.", "drug1": "alcohol", "drug2": "hydrocodone", "relation": "EFFECT", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s0", "pair_id": "DDI-DrugBank.d396.s0.p18"}
{"sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.", "drug1": "rifampin", "drug2": "carbamazepine", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s34", "pair_id": "DDI-DrugBank.d382.s34.p5"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "trihexyphenidyl", "drug2": "amitriptyline", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p13"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylurea", "drug2": "sulfonamides", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p2"}
{"sentence": "Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.", "drug1": "alosetron", "drug2": "protease inhibitors", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s10", "pair_id": "DDI-DrugBank.d364.s10.p2"}
{"sentence": "Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.", "drug1": "quinidine", "drug2": "dehydroaripiprazole", "relation": "NONE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s15", "pair_id": "DDI-DrugBank.d509.s15.p8"}
{"sentence": "Non-steroidal anti-inflammatory agents: Seizures have been reported in patients taking enoxacin concomitantly with the nonsteroidal anti-inflammatory drug fenbufen.", "drug1": "enoxacin", "drug2": "fenbufen", "relation": "EFFECT", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s9", "pair_id": "DDI-DrugBank.d395.s9.p4"}
{"sentence": "The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "drug1": "codeine", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s0", "pair_id": "DDI-DrugBank.d398.s0.p1"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "lincomycin", "drug2": "colistin", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p70"}
{"sentence": "Agents Increasing Serum Potassium: Enalapril and enalapril IV attenuate potassium loss caused by thiazide-type diuretics.", "drug1": "Enalapril", "drug2": "thiazide-type diuretics", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s12", "pair_id": "DDI-DrugBank.d107.s12.p1"}
{"sentence": "Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ", "drug1": "retinyl acetate", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s2", "pair_id": "DDI-MedLine.d12.s2.p5"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p0"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "barbiturates", "drug2": "psychotropic medications", "relation": "NONE", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p29"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "5HT3 Antagonists", "drug2": "ondansetron", "relation": "NONE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p1"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "quinidine", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p9"}
{"sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "drug1": "antipsychotic agents", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s3", "pair_id": "DDI-DrugBank.d186.s3.p4"}
{"sentence": "Ethopropazine may interact with alcohol or other CNS depressants, causing increased sedative effects.", "drug1": "Ethopropazine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Ethopropazine_ddi.xml", "sentence_id": "DDI-DrugBank.d240.s0", "pair_id": "DDI-DrugBank.d240.s0.p0"}
{"sentence": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.", "drug1": "digoxin", "drug2": "hydrochlorothiazide", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s7", "pair_id": "DDI-DrugBank.d533.s7.p26"}
{"sentence": "Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.", "drug1": "Itraconazole", "drug2": "hypoglycemic agents", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s27", "pair_id": "DDI-DrugBank.d165.s27.p0"}
{"sentence": "Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.", "drug1": "Metoclopramide", "drug2": "fosfomycin", "relation": "NONE", "source_file": "Fosfomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d199.s0", "pair_id": "DDI-DrugBank.d199.s0.p2"}
{"sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.", "drug1": "glyburide", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s8", "pair_id": "DDI-DrugBank.d172.s8.p6"}
{"sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "drug1": "neomycin", "drug2": "penicillin V", "relation": "MECHANISM", "source_file": "Neomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d330.s2", "pair_id": "DDI-DrugBank.d330.s2.p0"}
{"sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "drug1": "b-lactam antibiotics", "drug2": "cefdinir", "relation": "MECHANISM", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s4", "pair_id": "DDI-DrugBank.d420.s4.p5"}
{"sentence": "NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.", "drug1": "NSAIDs", "drug2": "cyclosporine", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s15", "pair_id": "DDI-DrugBank.d82.s15.p0"}
{"sentence": "Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release. ", "drug1": "ouabain", "drug2": "PTX", "relation": "EFFECT", "source_file": "2857198.xml", "sentence_id": "DDI-MedLine.d56.s8", "pair_id": "DDI-MedLine.d56.s8.p0"}
{"sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "drug1": "erythromycin", "drug2": "cisapride", "relation": "EFFECT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s13", "pair_id": "DDI-DrugBank.d397.s13.p0"}
{"sentence": "The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.", "drug1": "18-MC", "drug2": "ibogaine", "relation": "NONE", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s16", "pair_id": "DDI-MedLine.d110.s16.p0"}
{"sentence": "The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.", "drug1": "ERGOMAR", "drug2": "triacetyloleandomycin", "relation": "MECHANISM", "source_file": "Ergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d59.s0", "pair_id": "DDI-DrugBank.d59.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "citalopram", "drug2": "cyclosporin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p258"}
{"sentence": "Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.", "drug1": "Depen", "drug2": "Cuprimine", "relation": "NONE", "source_file": "Auranofin_ddi.xml", "sentence_id": "DDI-DrugBank.d374.s1", "pair_id": "DDI-DrugBank.d374.s1.p5"}
{"sentence": "Acetazolamide may prevent the urinary antiseptic effect of methenamine.", "drug1": "Acetazolamide", "drug2": "methenamine", "relation": "EFFECT", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s11", "pair_id": "DDI-DrugBank.d368.s11.p0"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "5HT3 antagonist class", "relation": "ADVISE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p24"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p30"}
{"sentence": "Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either methotrexate or Kineret when the two agents were administered together.", "drug1": "methotrexate", "drug2": "Kineret", "relation": "NONE", "source_file": "Anakinra_ddi.xml", "sentence_id": "DDI-DrugBank.d275.s1", "pair_id": "DDI-DrugBank.d275.s1.p0"}
{"sentence": "Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.", "drug1": "NSAIDs", "drug2": "Ponstel", "relation": "NONE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s0", "pair_id": "DDI-DrugBank.d400.s0.p3"}
{"sentence": "The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.", "drug1": "tricyclic antidepressants", "drug2": "hydrocodone", "relation": "EFFECT", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s2", "pair_id": "DDI-DrugBank.d396.s2.p4"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "chlordiazepoxide", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p7"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "Lorazepam", "drug2": "antidepressants", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p5"}
{"sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "drug1": "HALDOL", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s3", "pair_id": "DDI-DrugBank.d186.s3.p6"}
{"sentence": "Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.", "drug1": "ketoconazole", "drug2": "cisapride", "relation": "ADVISE", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s9", "pair_id": "DDI-DrugBank.d458.s9.p0"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "alfentanil", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p12"}
{"sentence": "In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.", "drug1": "PRINIVIL", "drug2": "indomethacin", "relation": "NONE", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s9", "pair_id": "DDI-DrugBank.d334.s9.p1"}
{"sentence": "Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.", "drug1": "histamine H2-receptor antagonists", "drug2": "IRESSA", "relation": "MECHANISM", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s7", "pair_id": "DDI-DrugBank.d207.s7.p2"}
{"sentence": "Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.", "drug1": "ketoconazole", "drug2": "zaleplon", "relation": "MECHANISM", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s22", "pair_id": "DDI-DrugBank.d324.s22.p0"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "Calcidiol", "drug2": "Cholestyramine", "relation": "NONE", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s0", "pair_id": "DDI-DrugBank.d404.s0.p23"}
{"sentence": "therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.", "drug1": "VIRACEPT", "drug2": "terfenadine", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s11", "pair_id": "DDI-DrugBank.d340.s11.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "delavirdine", "drug2": "methadone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p453"}
{"sentence": "In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.", "drug1": "aminoglycoside", "drug2": "cephalosporins", "relation": "EFFECT", "source_file": "Kanamycin_ddi.xml", "sentence_id": "DDI-DrugBank.d57.s0", "pair_id": "DDI-DrugBank.d57.s0.p2"}
{"sentence": "It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.", "drug1": "digoxin", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s18", "pair_id": "DDI-DrugBank.d458.s18.p0"}
{"sentence": "Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.", "drug1": "mefloquine", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s16", "pair_id": "DDI-DrugBank.d94.s16.p5"}
{"sentence": "Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "azoles", "relation": "EFFECT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s0", "pair_id": "DDI-DrugBank.d225.s0.p1"}
{"sentence": "Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.", "drug1": "Vitamin D", "drug2": "digitalis", "relation": "ADVISE", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s7", "pair_id": "DDI-DrugBank.d404.s7.p2"}
{"sentence": "Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.", "drug1": "ouabain", "drug2": "Innovar", "relation": "EFFECT", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s2", "pair_id": "DDI-MedLine.d23.s2.p0"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "protease inhibitors", "drug2": "TIKOSYN", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p31"}
{"sentence": "Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.", "drug1": "sympathomimetic amines", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Benzphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d477.s0", "pair_id": "DDI-DrugBank.d477.s0.p0"}
{"sentence": "Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.", "drug1": "lorazepam", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s0", "pair_id": "DDI-DrugBank.d18.s0.p4"}
{"sentence": "Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.", "drug1": "Theophylline", "drug2": "ciprofloxacin", "relation": "NONE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s16", "pair_id": "DDI-DrugBank.d123.s16.p1"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p16"}
{"sentence": "Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).", "drug1": "ENABLEX", "drug2": "flecainide", "relation": "ADVISE", "source_file": "Darifenacin_ddi.xml", "sentence_id": "DDI-DrugBank.d459.s1", "pair_id": "DDI-DrugBank.d459.s1.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "disopyramide", "drug2": "alfentanyl", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p41"}
{"sentence": "INOmax has been administered with tolazoline, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.", "drug1": "INOmax", "drug2": "dobutamine", "relation": "NONE", "source_file": "Nitric Oxide_ddi.xml", "sentence_id": "DDI-DrugBank.d183.s1", "pair_id": "DDI-DrugBank.d183.s1.p2"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "sildenafil", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p9"}
{"sentence": "Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.", "drug1": "NSAIDs", "drug2": "anticoagulant", "relation": "NONE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s2", "pair_id": "DDI-DrugBank.d249.s2.p6"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "delavirdine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p6"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "phenytoin", "drug2": "calcitriol", "relation": "MECHANISM", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s2", "pair_id": "DDI-DrugBank.d384.s2.p11"}
{"sentence": "The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.", "drug1": "proton pump inhibitors", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s13", "pair_id": "DDI-DrugBank.d48.s13.p5"}
{"sentence": "There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.", "drug1": "cisapride", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s13", "pair_id": "DDI-DrugBank.d397.s13.p5"}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "furosemide", "drug2": "thiazides", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s10", "pair_id": "DDI-DrugBank.d328.s10.p5"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "niacinamide", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p16"}
{"sentence": "This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.", "drug1": "Mefloquine", "drug2": "H1-blocking agents", "relation": "EFFECT", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s9", "pair_id": "DDI-DrugBank.d220.s9.p4"}
{"sentence": "Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.", "drug1": "triazolam", "drug2": "midazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s23", "pair_id": "DDI-DrugBank.d124.s23.p5"}
{"sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.", "drug1": "docetaxel", "drug2": "troleandomycin", "relation": "MECHANISM", "source_file": "Docetaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d371.s1", "pair_id": "DDI-DrugBank.d371.s1.p4"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "amiodarone", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p1"}
{"sentence": "In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.", "drug1": "warfarin", "drug2": "rofecoxib", "relation": "EFFECT", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s32", "pair_id": "DDI-DrugBank.d210.s32.p0"}
{"sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "ritonavir", "drug2": "cisapride", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s12", "pair_id": "DDI-DrugBank.d237.s12.p8"}
{"sentence": "Ibuprofen - L-arginine may increase the absorption of ibuprofen if taken concomitantly.", "drug1": "L-arginine", "drug2": "ibuprofen", "relation": "MECHANISM", "source_file": "L-Arginine_ddi.xml", "sentence_id": "DDI-DrugBank.d95.s1", "pair_id": "DDI-DrugBank.d95.s1.p2"}
{"sentence": "The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;", "drug1": "tetracycline", "drug2": "colestipol hydrochloride", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s11", "pair_id": "DDI-DrugBank.d345.s11.p4"}
{"sentence": "Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.", "drug1": "enoxacin", "drug2": "bismuth subsalicylate", "relation": "ADVISE", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s1", "pair_id": "DDI-DrugBank.d395.s1.p0"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "warfarin", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p12"}
{"sentence": "Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of FORADIL.", "drug1": "sympathomimetic agents", "drug2": "FORADIL", "relation": "EFFECT", "source_file": "Formoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d103.s2", "pair_id": "DDI-DrugBank.d103.s2.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "polymyxins", "drug2": "anesthetics", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p81"}
{"sentence": "Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.", "drug1": "glutamic acid HCl", "drug2": "amphetamines", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s0", "pair_id": "DDI-DrugBank.d236.s0.p19"}
{"sentence": "(Thiazides may decrease arterial responsiveness to norepinephrine.", "drug1": "Thiazides", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s28", "pair_id": "DDI-DrugBank.d17.s28.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p1"}
{"sentence": "Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).", "drug1": "Gleevec", "drug2": "pimozide", "relation": "ADVISE", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s9", "pair_id": "DDI-DrugBank.d115.s9.p1"}
{"sentence": "Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).", "drug1": "Diphenhydramine hydrochloride", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Diphenhydramine_ddi.xml", "sentence_id": "DDI-DrugBank.d296.s0", "pair_id": "DDI-DrugBank.d296.s0.p1"}
{"sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.", "drug1": "heroin", "drug2": "methadone", "relation": "EFFECT", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s2", "pair_id": "DDI-DrugBank.d514.s2.p5"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "niacinamide", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p312"}
{"sentence": "Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.", "drug1": "oxyphenbutazone", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s3", "pair_id": "DDI-DrugBank.d443.s3.p8"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p27"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "LEVSIN", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p3"}
{"sentence": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "drug1": "anesthetics", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s2", "pair_id": "DDI-DrugBank.d77.s2.p8"}
{"sentence": "Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).", "drug1": "Phenothiazines", "drug2": "phenothiazine", "relation": "NONE", "source_file": "Piperazine_ddi.xml", "sentence_id": "DDI-DrugBank.d326.s0", "pair_id": "DDI-DrugBank.d326.s0.p1"}
{"sentence": "Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).", "drug1": "Nabilone", "drug2": "alcohol", "relation": "ADVISE", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s0", "pair_id": "DDI-DrugBank.d552.s0.p2"}
{"sentence": "Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.", "drug1": "INSPRA", "drug2": "lithium", "relation": "ADVISE", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s9", "pair_id": "DDI-DrugBank.d20.s9.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "pyrazolones", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p40"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "cimetidine", "drug2": "nicotinamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p89"}
{"sentence": "Concomitant use of barbiturates usually depresses griseofulvin activity and may necessitate raising the dosage.", "drug1": "barbiturates", "drug2": "griseofulvin", "relation": "EFFECT", "source_file": "Griseofulvin_ddi.xml", "sentence_id": "DDI-DrugBank.d83.s1", "pair_id": "DDI-DrugBank.d83.s1.p0"}
{"sentence": "Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.", "drug1": "celecoxib", "drug2": "fluconazole", "relation": "INT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s6", "pair_id": "DDI-DrugBank.d172.s6.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Tylenol", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "pentoxifylline", "drug2": "warfarin sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1331"}
{"sentence": "This decrease in bioavailability was about 5% when gabapentin was administered 2 hours after Maalox.", "drug1": "gabapentin", "drug2": "Maalox", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s38", "pair_id": "DDI-DrugBank.d438.s38.p0"}
{"sentence": "It is desirable to monitor TCAplasma levels whenever an agent of the tricyclic antidepressant class including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).", "drug1": "TCA", "drug2": "Anafranil", "relation": "NONE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s23", "pair_id": "DDI-DrugBank.d238.s23.p1"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "isoniazid", "drug2": "thyroid hormones", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p86"}
{"sentence": "Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ", "drug1": "Amprenavir", "drug2": "25-O-desacetylrifabutin", "relation": "MECHANISM", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s14", "pair_id": "DDI-MedLine.d3.s14.p1"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "chloramphenicol", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p3"}
{"sentence": "Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.", "drug1": "rifabutin", "drug2": "efavirenz", "relation": "MECHANISM", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s5", "pair_id": "DDI-DrugBank.d531.s5.p5"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p0"}
{"sentence": "Antacids: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of meclofenamate sodium.", "drug1": "aluminum hydroxide", "drug2": "meclofenamate sodium", "relation": "NONE", "source_file": "Meclofenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d113.s7", "pair_id": "DDI-DrugBank.d113.s7.p4"}
{"sentence": "Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells. ", "drug1": "Flavoridin", "drug2": "contortrostatin", "relation": "EFFECT", "source_file": "10978746.xml", "sentence_id": "DDI-MedLine.d69.s5", "pair_id": "DDI-MedLine.d69.s5.p0"}
{"sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "ritonavir", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s12", "pair_id": "DDI-DrugBank.d237.s12.p7"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "anesthetics", "drug2": "procainamide", "relation": "NONE", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p65"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "diflunisal", "drug2": "triclofos sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p815"}
{"sentence": "Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.", "drug1": "dexamethasone", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s30", "pair_id": "DDI-DrugBank.d124.s30.p8"}
{"sentence": "Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.", "drug1": "iron", "drug2": "Ibandronate", "relation": "MECHANISM", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s1", "pair_id": "DDI-DrugBank.d440.s1.p9"}
{"sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "drug1": "butorphanol", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s0", "pair_id": "DDI-DrugBank.d246.s0.p1"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "salicylates", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p14"}
{"sentence": "Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.", "drug1": "zaleplon", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s20", "pair_id": "DDI-DrugBank.d324.s20.p0"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Sparine", "drug2": "trimeprazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p253"}
{"sentence": "At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.", "drug1": "VIOXX", "drug2": "aspirin", "relation": "NONE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s6", "pair_id": "DDI-DrugBank.d210.s6.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "antibiotics", "drug2": "tolbutamide", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p352"}
{"sentence": "Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.", "drug1": "Ocupress", "drug2": "beta-adrenergic blocking agent", "relation": "ADVISE", "source_file": "Carteolol_ddi.xml", "sentence_id": "DDI-DrugBank.d502.s0", "pair_id": "DDI-DrugBank.d502.s0.p0"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "dopamine agonists", "drug2": "iodine-containing compounds", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p355"}
{"sentence": "Anafranil should not be used with MAO inhibitors.", "drug1": "Anafranil", "drug2": "MAO inhibitors", "relation": "ADVISE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s2", "pair_id": "DDI-DrugBank.d238.s2.p0"}
{"sentence": "Starlix is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of tolbutamide.", "drug1": "Starlix", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s1", "pair_id": "DDI-DrugBank.d460.s1.p0"}
{"sentence": "Even so dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.", "drug1": "dextromethorphan", "drug2": "valdecoxib", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s19", "pair_id": "DDI-DrugBank.d328.s19.p0"}
{"sentence": "Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.", "drug1": "diltiazem", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s30", "pair_id": "DDI-DrugBank.d565.s30.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "haloperidol", "drug2": "methadone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p714"}
{"sentence": "When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. ", "drug1": "ouabain", "drug2": "phentolamine", "relation": "EFFECT", "source_file": "2857198.xml", "sentence_id": "DDI-MedLine.d56.s5", "pair_id": "DDI-MedLine.d56.s5.p0"}
{"sentence": "Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.", "drug1": "Haloperidol", "drug2": "amphetamines", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s18", "pair_id": "DDI-DrugBank.d236.s18.p2"}
{"sentence": "Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.", "drug1": "norepinephrine", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s2", "pair_id": "DDI-DrugBank.d77.s2.p14"}
{"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.", "drug1": "dihydroergotamine", "drug2": "AXERT", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s1", "pair_id": "DDI-DrugBank.d299.s1.p8"}
{"sentence": "RAPTIVA should not be used with other immunosuppressive drugs.", "drug1": "RAPTIVA", "drug2": "immunosuppressive drugs", "relation": "ADVISE", "source_file": "Efalizumab_ddi.xml", "sentence_id": "DDI-DrugBank.d44.s1", "pair_id": "DDI-DrugBank.d44.s1.p0"}
{"sentence": "Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.", "drug1": "reserpine", "drug2": "ZEBETA", "relation": "EFFECT", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s1", "pair_id": "DDI-DrugBank.d476.s1.p1"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "antiparkinsonian drug", "drug2": "tricyclic antidepressant", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p10"}
{"sentence": "Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ", "drug1": "iron", "drug2": "cobalt", "relation": "MECHANISM", "source_file": "7599505.xml", "sentence_id": "DDI-MedLine.d34.s7", "pair_id": "DDI-MedLine.d34.s7.p1"}
{"sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "drug1": "finasteride", "drug2": "HMG-CoA reductase inhibitors", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s3", "pair_id": "DDI-DrugBank.d209.s3.p11"}
{"sentence": "Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.", "drug1": "Epinephrine", "drug2": "guanethidine", "relation": "EFFECT", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s9", "pair_id": "DDI-DrugBank.d247.s9.p0"}
{"sentence": "Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "drug1": "ergot alkaloid class", "drug2": "antibiotics", "relation": "NONE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s5", "pair_id": "DDI-DrugBank.d410.s5.p20"}
{"sentence": "Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.", "drug1": "NaFlu", "drug2": "insulin", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s10", "pair_id": "DDI-MedLine.d76.s10.p8"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "thyroid drugs", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p48"}
{"sentence": "Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.", "drug1": "diuretics", "drug2": "captopril", "relation": "EFFECT", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s0", "pair_id": "DDI-DrugBank.d175.s0.p4"}
{"sentence": "Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.", "drug1": "ZYVOX", "drug2": "antidepressants", "relation": "EFFECT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s6", "pair_id": "DDI-DrugBank.d441.s6.p1"}
{"sentence": "Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.", "drug1": "reserpine", "drug2": "beta-blocking agent", "relation": "EFFECT", "source_file": "Atenolol_ddi.xml", "sentence_id": "DDI-DrugBank.d73.s0", "pair_id": "DDI-DrugBank.d73.s0.p0"}
{"sentence": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.", "drug1": "warfarin", "drug2": "fosinopril", "relation": "NONE", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s12", "pair_id": "DDI-DrugBank.d176.s12.p53"}
{"sentence": "Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.", "drug1": "phenobarbital", "drug2": "bexarotene", "relation": "MECHANISM", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s3", "pair_id": "DDI-DrugBank.d467.s3.p5"}
{"sentence": "When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.", "drug1": "amphotericin B", "drug2": "Antineoplastic agents", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s0", "pair_id": "DDI-DrugBank.d318.s0.p0"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "grepafloxacin", "drug2": "codeine", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p66"}
{"sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.", "drug1": "docetaxel", "drug2": "terfenadine", "relation": "MECHANISM", "source_file": "Docetaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d371.s1", "pair_id": "DDI-DrugBank.d371.s1.p1"}
{"sentence": "Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.", "drug1": "non-steroidal anti-inflammatory drugs", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s14", "pair_id": "DDI-DrugBank.d82.s14.p0"}
{"sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "drug1": "ACE inhibitors", "drug2": "beta blockers", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s35", "pair_id": "DDI-DrugBank.d558.s35.p2"}
{"sentence": "If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.", "drug1": "magnesium hydroxide", "drug2": "TIKOSYN", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s5", "pair_id": "DDI-DrugBank.d558.s5.p34"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "aminosalicylic acid", "drug2": "furosemide", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p71"}
{"sentence": "Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.", "drug1": "INVIRASE", "drug2": "ritonavir", "relation": "ADVISE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s28", "pair_id": "DDI-DrugBank.d124.s28.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "anabolic steroids", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p4"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "multivitamin preparations", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p38"}
{"sentence": "In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.", "drug1": "warfarin", "drug2": "digoxin", "relation": "NONE", "source_file": "Irbesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d27.s4", "pair_id": "DDI-DrugBank.d27.s4.p1"}
{"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.", "drug1": "ergotamine", "drug2": "naratriptan", "relation": "ADVISE", "source_file": "Naratriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d478.s1", "pair_id": "DDI-DrugBank.d478.s1.p3"}
{"sentence": "Increases in prothrombin time have been noted in patients receiving long- term warfarin therapy after flutamide was initiated.", "drug1": "warfarin", "drug2": "flutamide", "relation": "EFFECT", "source_file": "Flutamide_ddi.xml", "sentence_id": "DDI-DrugBank.d442.s0", "pair_id": "DDI-DrugBank.d442.s0.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "didanosine", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p63"}
{"sentence": "Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity.", "drug1": "Cerubidine", "drug2": "doxorubicin", "relation": "EFFECT", "source_file": "Daunorubicin_ddi.xml", "sentence_id": "DDI-DrugBank.d69.s0", "pair_id": "DDI-DrugBank.d69.s0.p0"}
{"sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "drug1": "fluoxetine", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s1", "pair_id": "DDI-DrugBank.d313.s1.p34"}
{"sentence": "Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.", "drug1": "carbamazepine", "drug2": "doxycycline", "relation": "MECHANISM", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s4", "pair_id": "DDI-DrugBank.d500.s4.p4"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "antidepressants", "drug2": "flecainide", "relation": "NONE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p18"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Neoral", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p21"}
{"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "drug1": "dipyridamole", "drug2": "Activase", "relation": "EFFECT", "source_file": "Alteplase_ddi.xml", "sentence_id": "DDI-DrugBank.d508.s1", "pair_id": "DDI-DrugBank.d508.s1.p13"}
{"sentence": "acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ", "drug1": "acetaminophen", "drug2": "theophylline", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s5", "pair_id": "DDI-MedLine.d111.s5.p0"}
{"sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "drug1": "fentanyl", "drug2": "nelfinavir", "relation": "MECHANISM", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s2", "pair_id": "DDI-DrugBank.d170.s2.p5"}
{"sentence": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.", "drug1": "selective serotonin reuptake inhibitors", "drug2": "Imitrex", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s4", "pair_id": "DDI-DrugBank.d423.s4.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "oxyphenbutazone", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p34"}
{"sentence": "Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.", "drug1": "magnesium trisilicate", "drug2": "nitrofurantoin", "relation": "MECHANISM", "source_file": "Nitrofurantoin_ddi.xml", "sentence_id": "DDI-DrugBank.d276.s0", "pair_id": "DDI-DrugBank.d276.s0.p2"}
{"sentence": "- Methotrexate (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate", "drug1": "methotrexate", "drug2": "sulfapyridine", "relation": "EFFECT", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s38", "pair_id": "DDI-DrugBank.d179.s38.p7"}
{"sentence": "Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.", "drug1": "amiodarone", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s2", "pair_id": "DDI-DrugBank.d450.s2.p22"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "narcotic analgesics", "drug2": "meperidine", "relation": "NONE", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p17"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "dalfopristin", "drug2": "isoniazid", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p126"}
{"sentence": "Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.", "drug1": "estazolam", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s6", "pair_id": "DDI-DrugBank.d338.s6.p0"}
{"sentence": "Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.", "drug1": "cephalosporins", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Cefepime_ddi.xml", "sentence_id": "DDI-DrugBank.d378.s1", "pair_id": "DDI-DrugBank.d378.s1.p0"}
{"sentence": "Separating the doses of antacid and lomefloxacin minimizes this decrease in bioavailability;", "drug1": "antacid", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s6", "pair_id": "DDI-DrugBank.d516.s6.p0"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "astemizole", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p8"}
{"sentence": "Microdosed minipill progestin preparations are not recommended for use with Soriatane.", "drug1": "progestin", "drug2": "Soriatane", "relation": "ADVISE", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s6", "pair_id": "DDI-DrugBank.d353.s6.p0"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Prolixin", "drug2": "Stelazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p142"}
{"sentence": "Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.", "drug1": "HEXALEN", "drug2": "antidepressants of the MAO inhibitor class", "relation": "EFFECT", "source_file": "Altretamine_ddi.xml", "sentence_id": "DDI-DrugBank.d188.s0", "pair_id": "DDI-DrugBank.d188.s0.p0"}
{"sentence": "Concurrent use of tetracycline may render oral contraceptives less effective.", "drug1": "tetracycline", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s6", "pair_id": "DDI-DrugBank.d500.s6.p0"}
{"sentence": "Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.", "drug1": "nonsteroidal antiinflammatory agents", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s24", "pair_id": "DDI-DrugBank.d314.s24.p9"}
{"sentence": "MAO inhibitors should be used with caution in patients receiving hydralazine.", "drug1": "MAO inhibitors", "drug2": "hydralazine", "relation": "ADVISE", "source_file": "Hydralazine_ddi.xml", "sentence_id": "DDI-DrugBank.d31.s0", "pair_id": "DDI-DrugBank.d31.s0.p0"}
{"sentence": "Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).", "drug1": "Trileptal", "drug2": "contraceptive", "relation": "MECHANISM", "source_file": "Oxcarbazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d307.s40", "pair_id": "DDI-DrugBank.d307.s40.p4"}
{"sentence": "Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.", "drug1": "CMI", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s7", "pair_id": "DDI-DrugBank.d238.s7.p0"}
{"sentence": "Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.", "drug1": "Norepinephrine", "drug2": "Amphetamines", "relation": "NONE", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s18", "pair_id": "DDI-DrugBank.d158.s18.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Nizoral", "drug2": "temazepam", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p580"}
{"sentence": "Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.", "drug1": "Cyclosporine", "drug2": "Itraconazole", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s16", "pair_id": "DDI-DrugBank.d165.s16.p2"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "protease inhibitors", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p18"}
{"sentence": "The beneficial effects on arterial thrombus formation from combined therapy with antiplatelet and anticoagulant medication must be weighed against an increased risk of inducing hemorrhage.", "drug1": "antiplatelet medication", "drug2": "anticoagulant medication", "relation": "ADVISE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s91", "pair_id": "DDI-DrugBank.d64.s91.p0"}
{"sentence": "The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.", "drug1": "dexamethasone", "drug2": "Aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s10", "pair_id": "DDI-DrugBank.d382.s10.p0"}
{"sentence": "Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.", "drug1": "Anticoagulants", "drug2": "anticoagulant", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s43", "pair_id": "DDI-DrugBank.d143.s43.p3"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "haloperidol", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p8"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Felbatol", "drug2": "prednisolone", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p486"}
{"sentence": "This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. ", "drug1": "corticosteroids", "drug2": "methotrexate", "relation": "NONE", "source_file": "7635041.xml", "sentence_id": "DDI-MedLine.d11.s4", "pair_id": "DDI-MedLine.d11.s4.p7"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "alprazolam", "drug2": "diltiazem", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p63"}
{"sentence": "Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.", "drug1": "ZYVOX", "drug2": "vasopressor", "relation": "EFFECT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s2", "pair_id": "DDI-DrugBank.d441.s2.p5"}
{"sentence": "Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.", "drug1": "anti-malarial drugs", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s16", "pair_id": "DDI-DrugBank.d94.s16.p2"}
{"sentence": "Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;", "drug1": "Amphetamines", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s21", "pair_id": "DDI-DrugBank.d158.s21.p2"}
{"sentence": "In vitro, propranolol appears to be displaced from its binding sites by diltiazem.", "drug1": "propranolol", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s9", "pair_id": "DDI-DrugBank.d565.s9.p0"}
{"sentence": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines", "drug1": "Accutane", "drug2": "tetracyclines", "relation": "EFFECT", "source_file": "Isotretinoin_ddi.xml", "sentence_id": "DDI-DrugBank.d163.s2", "pair_id": "DDI-DrugBank.d163.s2.p9"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "antipsychotics", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p7"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "clindamycin", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p21"}
{"sentence": "Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.", "drug1": "Auranofin", "drug2": "penicillamine", "relation": "ADVISE", "source_file": "Auranofin_ddi.xml", "sentence_id": "DDI-DrugBank.d374.s1", "pair_id": "DDI-DrugBank.d374.s1.p0"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "antidepressants", "drug2": "propafenone", "relation": "NONE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p11"}
{"sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ", "drug1": "haloperidol", "drug2": "3H-spiroperidol", "relation": "NONE", "source_file": "2857100.xml", "sentence_id": "DDI-MedLine.d15.s0", "pair_id": "DDI-MedLine.d15.s0.p24"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "disopyramide", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p7"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "desipramine", "drug2": "triazolam", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p502"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "drug1": "thiazides", "drug2": "contraceptives", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s4", "pair_id": "DDI-DrugBank.d245.s4.p4"}
{"sentence": "Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.", "drug1": "phenytoin", "drug2": "ciprofloxacin", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s14", "pair_id": "DDI-DrugBank.d123.s14.p2"}
{"sentence": "Human growth hormone - Concomitant use of L-glutamine and human growth hormone may enhance nutrient absorption in those with severe short bowel syndrome.", "drug1": "L-glutamine", "drug2": "human growth hormone", "relation": "MECHANISM", "source_file": "L-Glutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d66.s0", "pair_id": "DDI-DrugBank.d66.s0.p2"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "androgens", "drug2": "perphenazine", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p28"}
{"sentence": "In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).", "drug1": "corticosteroids", "drug2": "H2 antagonists", "relation": "NONE", "source_file": "Paclitaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d288.s12", "pair_id": "DDI-DrugBank.d288.s12.p6"}
{"sentence": "Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "drug1": "tranquilizers", "drug2": "DILAUDID", "relation": "EFFECT", "source_file": "Hydromorphone_ddi.xml", "sentence_id": "DDI-DrugBank.d26.s0", "pair_id": "DDI-DrugBank.d26.s0.p25"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "terbutaline", "drug2": "thyroid hormones", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p80"}
{"sentence": "Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.", "drug1": "labetalol", "drug2": "calcium antagonist", "relation": "ADVISE", "source_file": "Labetalol_ddi.xml", "sentence_id": "DDI-DrugBank.d412.s11", "pair_id": "DDI-DrugBank.d412.s11.p0"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylurea", "drug2": "coumarins", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p5"}
{"sentence": "Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.", "drug1": "reserpine", "drug2": "beta-blocking agents", "relation": "EFFECT", "source_file": "Acebutolol_ddi.xml", "sentence_id": "DDI-DrugBank.d388.s0", "pair_id": "DDI-DrugBank.d388.s0.p2"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "nefazodone", "drug2": "nelfinavir", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p21"}
{"sentence": "Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.", "drug1": "AEDs", "drug2": "levetiracetam", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s13", "pair_id": "DDI-DrugBank.d212.s13.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "zidovudine", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p14"}
{"sentence": "WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.", "drug1": "WelChol", "drug2": "verapamil", "relation": "MECHANISM", "source_file": "Colesevelam_ddi.xml", "sentence_id": "DDI-DrugBank.d551.s2", "pair_id": "DDI-DrugBank.d551.s2.p0"}
{"sentence": "Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system", "drug1": "ACE inhibitors", "drug2": "beta-adrenergic blockers", "relation": "EFFECT", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s12", "pair_id": "DDI-DrugBank.d561.s12.p2"}
{"sentence": "In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.", "drug1": "VIOXX", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s33", "pair_id": "DDI-DrugBank.d210.s33.p0"}
{"sentence": "Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.", "drug1": "diflunisal", "drug2": "sulindac", "relation": "MECHANISM", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s26", "pair_id": "DDI-DrugBank.d132.s26.p2"}
{"sentence": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "drug1": "clarithromycin", "drug2": "digoxin", "relation": "NONE", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s3", "pair_id": "DDI-DrugBank.d450.s3.p9"}
{"sentence": "Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.", "drug1": "ketoconazole", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s22", "pair_id": "DDI-DrugBank.d458.s22.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "tetracyclines", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p3"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "aminosalicylic acid", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p18"}
{"sentence": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.", "drug1": "Antacids", "drug2": "neomycin", "relation": "NONE", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s6", "pair_id": "DDI-DrugBank.d450.s6.p2"}
{"sentence": "Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.", "drug1": "erythromycin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s20", "pair_id": "DDI-DrugBank.d522.s20.p3"}
{"sentence": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "drug1": "enalapril", "drug2": "diuretic", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s1", "pair_id": "DDI-DrugBank.d107.s1.p1"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "fluvoxamine", "drug2": "quinupristin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p241"}
{"sentence": "Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.", "drug1": "Ketoconazole", "drug2": "TIKOSYN", "relation": "MECHANISM", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s10", "pair_id": "DDI-DrugBank.d558.s10.p0"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "antithyroid drugs", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p235"}
{"sentence": "Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.", "drug1": "BREVIBLOC", "drug2": "succinylcholine", "relation": "ADVISE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s10", "pair_id": "DDI-DrugBank.d422.s10.p2"}
{"sentence": "H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.", "drug1": "omeprazole", "drug2": "dasatinib", "relation": "EFFECT", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s11", "pair_id": "DDI-DrugBank.d48.s11.p20"}
{"sentence": "During controlled hypotensive anesthesia using labetalol HCl in association with halothane, high concentrations (3% or above) of halothane should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure.", "drug1": "labetalol HCl", "drug2": "halothane", "relation": "EFFECT", "source_file": "Labetalol_ddi.xml", "sentence_id": "DDI-DrugBank.d412.s7", "pair_id": "DDI-DrugBank.d412.s7.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ibuprofen", "drug2": "indomethacin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p957"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "sumatriptan", "drug2": "paroxetine", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p3"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "Flupenthixol", "drug2": "MAOI", "relation": "INT", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p1"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "dicumarol", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p5"}
{"sentence": "Tablet If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the effect of clonidine may be reduced, thus necessitating an increase in dosage.", "drug1": "clonidine hydrochloride", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s0", "pair_id": "DDI-DrugBank.d495.s0.p0"}
{"sentence": "Concomitant administration of clarithromycin with pimozide is contraindicated.", "drug1": "clarithromycin", "drug2": "pimozide", "relation": "ADVISE", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s14", "pair_id": "DDI-DrugBank.d29.s14.p0"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "salicylates", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p16"}
{"sentence": "It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. ", "drug1": "3H-spiroperidol", "drug2": "apomorphine", "relation": "NONE", "source_file": "2857100.xml", "sentence_id": "DDI-MedLine.d15.s2", "pair_id": "DDI-MedLine.d15.s2.p0"}
{"sentence": "Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).", "drug1": "WELLBUTRIN", "drug2": "cyclophosphamide", "relation": "INT", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s3", "pair_id": "DDI-DrugBank.d5.s3.p1"}
{"sentence": "Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.", "drug1": "thyroid products", "drug2": "imipramine", "relation": "EFFECT", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s15", "pair_id": "DDI-DrugBank.d54.s15.p3"}
{"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.", "drug1": "dihydroergotamine", "drug2": "naratriptan", "relation": "ADVISE", "source_file": "Naratriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d478.s1", "pair_id": "DDI-DrugBank.d478.s1.p8"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "astemizole", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p12"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylurea", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p6"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "Lorazepam", "drug2": "ethyl alcohol", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p1"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "warfarin", "drug2": "aliskiren", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p29"}
{"sentence": "Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.", "drug1": "Atorvastatin", "drug2": "norethindrone", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s16", "pair_id": "DDI-DrugBank.d485.s16.p3"}
{"sentence": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.", "drug1": "Robinul", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Glycopyrrolate_ddi.xml", "sentence_id": "DDI-DrugBank.d510.s0", "pair_id": "DDI-DrugBank.d510.s0.p1"}
{"sentence": "Magnesium- and aluminum-containing antacids, administered concomitantly with lomefloxacin, significantly decreased the bioavailability (48%) of lomefloxacin.", "drug1": "antacids", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s5", "pair_id": "DDI-DrugBank.d516.s5.p7"}
{"sentence": "Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.", "drug1": "cyclosporin", "drug2": "TAXOL", "relation": "ADVISE", "source_file": "Paclitaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d288.s11", "pair_id": "DDI-DrugBank.d288.s11.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "alcohol", "drug2": "warfarin sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p106"}
{"sentence": "Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.", "drug1": "atorvastatin", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s9", "pair_id": "DDI-DrugBank.d140.s9.p5"}
{"sentence": "Antacids (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "drug1": "cefdinir", "drug2": "Maalox TC", "relation": "MECHANISM", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s0", "pair_id": "DDI-DrugBank.d420.s0.p9"}
{"sentence": "Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.", "drug1": "anticoagulants", "drug2": "thyroid", "relation": "ADVISE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s2", "pair_id": "DDI-DrugBank.d54.s2.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "temazepam", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p40"}
{"sentence": "The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.", "drug1": "methyldopa", "drug2": "sympathomimetics", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s3", "pair_id": "DDI-DrugBank.d448.s3.p3"}
{"sentence": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "drug1": "retinoids", "drug2": "EGF", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s7", "pair_id": "DDI-MedLine.d12.s7.p13"}
{"sentence": "Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "drug1": "NIZORAL", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s12", "pair_id": "DDI-DrugBank.d458.s12.p0"}
{"sentence": "Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John s wort) may significantly decrease exposure to exemestane.", "drug1": "rifampicin", "drug2": "exemestane", "relation": "MECHANISM", "source_file": "Exemestane_ddi.xml", "sentence_id": "DDI-DrugBank.d435.s2", "pair_id": "DDI-DrugBank.d435.s2.p3"}
{"sentence": "Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.", "drug1": "simethicone", "drug2": "antacids", "relation": "NONE", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s9", "pair_id": "DDI-DrugBank.d176.s9.p33"}
{"sentence": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "drug1": "protriptyline", "drug2": "d-amphetamine", "relation": "NONE", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s8", "pair_id": "DDI-DrugBank.d236.s8.p8"}
{"sentence": "Vasopressors: Thyroxine increases the adrenergic effect of catecholamines such as epinephrine and norepinephrine.", "drug1": "Thyroxine", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s21", "pair_id": "DDI-DrugBank.d54.s21.p4"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "alfentanil", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p3"}
{"sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "drug1": "vincristine", "drug2": "antiretroviral", "relation": "NONE", "source_file": "11148572.xml", "sentence_id": "DDI-MedLine.d115.s2", "pair_id": "DDI-MedLine.d115.s2.p53"}
{"sentence": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "drug1": "enflurane", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s6", "pair_id": "DDI-DrugBank.d60.s6.p7"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "fluconazole", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p5"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "methylphenidate", "drug2": "CMI", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p10"}
{"sentence": "The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "drug1": "alcohol", "drug2": "psychotropics", "relation": "NONE", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s0", "pair_id": "DDI-DrugBank.d398.s0.p4"}
{"sentence": "In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.", "drug1": "levodopa", "drug2": "papaverine", "relation": "EFFECT", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s3", "pair_id": "DDI-DrugBank.d47.s3.p1"}
{"sentence": "Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.", "drug1": "CNS depressant drugs", "drug2": "INAPSINE", "relation": "EFFECT", "source_file": "Droperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d254.s0", "pair_id": "DDI-DrugBank.d254.s0.p4"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "imipramine", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p5"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "zileuton", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p25"}
{"sentence": "Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.", "drug1": "Pyrazolone Derivatives", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s3", "pair_id": "DDI-DrugBank.d443.s3.p3"}
{"sentence": "Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.", "drug1": "verapamil", "drug2": "TAMBOCOR", "relation": "ADVISE", "source_file": "Flecainide_ddi.xml", "sentence_id": "DDI-DrugBank.d87.s19", "pair_id": "DDI-DrugBank.d87.s19.p5"}
{"sentence": "therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.", "drug1": "contraceptives", "drug2": "Aprepitant", "relation": "EFFECT", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s20", "pair_id": "DDI-DrugBank.d382.s20.p0"}
{"sentence": "Reported examples of this interaction include the following: Antibiotics: Rifampin is a potent inducer of CYP3A4.", "drug1": "Antibiotics", "drug2": "CYP3A4", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s47", "pair_id": "DDI-DrugBank.d143.s47.p1"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "clofibrate", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p22"}
{"sentence": "Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.", "drug1": "prednisolone", "drug2": "doxycycline", "relation": "NONE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s16", "pair_id": "DDI-DrugBank.d249.s16.p22"}
{"sentence": "Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;", "drug1": "Amphetamines", "drug2": "sympathomimetic agents", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s7", "pair_id": "DDI-DrugBank.d236.s7.p8"}
{"sentence": "Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; ", "drug1": "Theophylline", "drug2": "acetaminophen", "relation": "MECHANISM", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s10", "pair_id": "DDI-MedLine.d111.s10.p0"}
{"sentence": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.", "drug1": "erythromycin", "drug2": "almotriptan", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s11", "pair_id": "DDI-DrugBank.d299.s11.p13"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "itraconazole", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p1"}
{"sentence": "Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.", "drug1": "bromocriptine mesylate", "drug2": "pimozide", "relation": "EFFECT", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s2", "pair_id": "DDI-DrugBank.d272.s2.p3"}
{"sentence": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "drug1": "FLOLAN", "drug2": "digoxin", "relation": "NONE", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s3", "pair_id": "DDI-DrugBank.d241.s3.p0"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "furosemide", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p7"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "erythromycin", "drug2": "disopyramide", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p4"}
{"sentence": "Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.", "drug1": "steroids", "drug2": "beta2-agonists.", "relation": "EFFECT", "source_file": "Formoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d103.s4", "pair_id": "DDI-DrugBank.d103.s4.p19"}
{"sentence": "Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "drug1": "alcohol", "drug2": "insulin", "relation": "EFFECT", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s3", "pair_id": "DDI-DrugBank.d313.s3.p9"}
{"sentence": "Caution should be used if ibuprofen is administered concomitantly with methotrexate.", "drug1": "ibuprofen", "drug2": "methotrexate", "relation": "ADVISE", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s7", "pair_id": "DDI-DrugBank.d415.s7.p0"}
{"sentence": "Both digoxin and COREG slow AV conduction.", "drug1": "digoxin", "drug2": "COREG", "relation": "EFFECT", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s12", "pair_id": "DDI-DrugBank.d269.s12.p0"}
{"sentence": "A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.", "drug1": "FOSCAVIR", "drug2": "pentamidine", "relation": "INT", "source_file": "Foscarnet_ddi.xml", "sentence_id": "DDI-DrugBank.d511.s0", "pair_id": "DDI-DrugBank.d511.s0.p0"}
{"sentence": "The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.", "drug1": "allopurinol", "drug2": "chlorpropamide", "relation": "EFFECT", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s21", "pair_id": "DDI-DrugBank.d413.s21.p0"}
{"sentence": "Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.", "drug1": "Lodine", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s7", "pair_id": "DDI-DrugBank.d219.s7.p1"}
{"sentence": "As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.", "drug1": "nondepolarizing neuromuscular blocking agents", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s6", "pair_id": "DDI-DrugBank.d267.s6.p2"}
{"sentence": "Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.", "drug1": "Aprepitant", "drug2": "tolbutamide", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s4", "pair_id": "DDI-DrugBank.d382.s4.p1"}
{"sentence": "Synergism has been shown between halothane anesthesia and intravenously administered labetalol HCl.", "drug1": "halothane", "drug2": "labetalol HCl", "relation": "EFFECT", "source_file": "Labetalol_ddi.xml", "sentence_id": "DDI-DrugBank.d412.s6", "pair_id": "DDI-DrugBank.d412.s6.p0"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "quinolones", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p11"}
{"sentence": "Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.", "drug1": "anticonvulsant medications", "drug2": "folic acid", "relation": "NONE", "source_file": "Folic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d425.s1", "pair_id": "DDI-DrugBank.d425.s1.p8"}
{"sentence": "Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.", "drug1": "Aprepitant", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s5", "pair_id": "DDI-DrugBank.d382.s5.p0"}
{"sentence": "In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.", "drug1": "platelet inhibitors", "drug2": "digoxin", "relation": "NONE", "source_file": "Fondaparinux sodium_ddi.xml", "sentence_id": "DDI-DrugBank.d15.s0", "pair_id": "DDI-DrugBank.d15.s0.p24"}
{"sentence": "Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and azithromycin.", "drug1": "cetirizine", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Cetirizine_ddi.xml", "sentence_id": "DDI-DrugBank.d393.s0", "pair_id": "DDI-DrugBank.d393.s0.p2"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "atazanavir", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p1"}
{"sentence": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).", "drug1": "ACEI", "drug2": "ARB", "relation": "NONE", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s4", "pair_id": "DDI-DrugBank.d20.s4.p20"}
{"sentence": "When Itraconazole was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.", "drug1": "Itraconazole", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s18", "pair_id": "DDI-DrugBank.d165.s18.p1"}
{"sentence": "Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.", "drug1": "probenecid", "drug2": "nitrofurantoin", "relation": "MECHANISM", "source_file": "Nitrofurantoin_ddi.xml", "sentence_id": "DDI-DrugBank.d276.s2", "pair_id": "DDI-DrugBank.d276.s2.p4"}
{"sentence": "Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.", "drug1": "BEXTRA", "drug2": "lithium", "relation": "ADVISE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s21", "pair_id": "DDI-DrugBank.d328.s21.p2"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "penicillin G", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p6"}
{"sentence": "Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.", "drug1": "reserpine", "drug2": "amphetamines", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s0", "pair_id": "DDI-DrugBank.d236.s0.p17"}
{"sentence": "Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.", "drug1": "imidazoles", "drug2": "amphotericin B", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s8", "pair_id": "DDI-DrugBank.d318.s8.p35"}
{"sentence": "A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.", "drug1": "glyburide", "drug2": "ciprofloxacin", "relation": "INT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s7", "pair_id": "DDI-DrugBank.d178.s7.p0"}
{"sentence": "At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).", "drug1": "methotrexate", "drug2": "rofecoxib", "relation": "MECHANISM", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s21", "pair_id": "DDI-DrugBank.d210.s21.p3"}
{"sentence": "Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.", "drug1": "probenecid", "drug2": "cefditoren pivoxil", "relation": "MECHANISM", "source_file": "Cefditoren_ddi.xml", "sentence_id": "DDI-DrugBank.d550.s4", "pair_id": "DDI-DrugBank.d550.s4.p7"}
{"sentence": "By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.", "drug1": "DIAMOX", "drug2": "primidone", "relation": "MECHANISM", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s3", "pair_id": "DDI-DrugBank.d368.s3.p2"}
{"sentence": "Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. ", "drug1": "Chloral hydrate", "drug2": "anticoagulant agents", "relation": "INT", "source_file": "1109248.xml", "sentence_id": "DDI-MedLine.d106.s8", "pair_id": "DDI-MedLine.d106.s8.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "rifadin", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p38"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "clofibrate", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p3"}
{"sentence": "Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.", "drug1": "diclofenac", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s4", "pair_id": "DDI-DrugBank.d249.s4.p1"}
{"sentence": "Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents. ", "drug1": "antidepressant drugs", "drug2": "hypoglycemic agents", "relation": "INT", "source_file": "11151029.xml", "sentence_id": "DDI-MedLine.d21.s2", "pair_id": "DDI-MedLine.d21.s2.p0"}
{"sentence": "Naproxen: Coadministration (N=18) of naproxen sodium capsules (250 mg) with Neurontin (125 mg) appears to increase the amount of gabapentin absorbed by 12% to 15%.", "drug1": "naproxen sodium", "drug2": "Neurontin", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s15", "pair_id": "DDI-DrugBank.d438.s15.p3"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "Curariform muscle relaxants", "drug2": "Coly-Mycin M", "relation": "EFFECT", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p5"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "monoamine oxidase inhibitors", "drug2": "sertraline", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p6"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "alprazolam", "drug2": "theophylline", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p123"}
{"sentence": "It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. ", "drug1": "HMGCoA reductase inhibitors", "drug2": "pravastatin", "relation": "NONE", "source_file": "19489169.xml", "sentence_id": "DDI-MedLine.d119.s2", "pair_id": "DDI-MedLine.d119.s2.p2"}
{"sentence": "Coadministration of Itraconazole with oral midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "drug1": "midazolam", "drug2": "triazolam", "relation": "NONE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s11", "pair_id": "DDI-DrugBank.d165.s11.p2"}
{"sentence": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.", "drug1": "erythromycin", "drug2": "budesonide", "relation": "ADVISE", "source_file": "Budesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d144.s1", "pair_id": "DDI-DrugBank.d144.s1.p20"}
{"sentence": "In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.", "drug1": "diuretics", "drug2": "anticoagulants", "relation": "NONE", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s3", "pair_id": "DDI-DrugBank.d241.s3.p19"}
{"sentence": "Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.", "drug1": "anticonvulsant agents", "drug2": "cisplatin", "relation": "MECHANISM", "source_file": "Cisplatin_ddi.xml", "sentence_id": "DDI-DrugBank.d145.s0", "pair_id": "DDI-DrugBank.d145.s0.p0"}
{"sentence": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.", "drug1": "phenytoin", "drug2": "clonazepam", "relation": "MECHANISM", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s5", "pair_id": "DDI-DrugBank.d333.s5.p2"}
{"sentence": "PEGASYS contains benzyl alcohol.", "drug1": "PEGASYS", "drug2": "benzyl alcohol", "relation": "NONE", "source_file": "Peginterferon alfa-2a_ddi.xml", "sentence_id": "DDI-DrugBank.d196.s36", "pair_id": "DDI-DrugBank.d196.s36.p0"}
{"sentence": "Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.", "drug1": "descarboethoxyloratadine", "drug2": "loratadine", "relation": "NONE", "source_file": "Loratadine_ddi.xml", "sentence_id": "DDI-DrugBank.d258.s1", "pair_id": "DDI-DrugBank.d258.s1.p3"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "antipsychotic drug", "drug2": "amitriptyline", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p4"}
{"sentence": "It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.", "drug1": "gentamycin", "drug2": "atracurium", "relation": "EFFECT", "source_file": "8542840.xml", "sentence_id": "DDI-MedLine.d90.s11", "pair_id": "DDI-MedLine.d90.s11.p0"}
{"sentence": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "drug1": "phenobarbital", "drug2": "phenobarbital", "relation": "NONE", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s14", "pair_id": "DDI-MedLine.d111.s14.p11"}
{"sentence": "Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "drug1": "phenothiazines", "drug2": "DILAUDID", "relation": "EFFECT", "source_file": "Hydromorphone_ddi.xml", "sentence_id": "DDI-DrugBank.d26.s0", "pair_id": "DDI-DrugBank.d26.s0.p20"}
{"sentence": "Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.", "drug1": "estrogens", "drug2": "salicylates", "relation": "NONE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s24", "pair_id": "DDI-DrugBank.d54.s24.p26"}
{"sentence": "Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine.", "drug1": "STRATTERA", "drug2": "quinidine", "relation": "ADVISE", "source_file": "Atomoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d11.s3", "pair_id": "DDI-DrugBank.d11.s3.p2"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "digitalis", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p11"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "aminoglycosides", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p2"}
{"sentence": "Acitretin: Interferes with the contraceptive effect of microdosed progestin-containing minipill preparations.", "drug1": "Acitretin", "drug2": "progestin", "relation": "EFFECT", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s4", "pair_id": "DDI-DrugBank.d485.s4.p0"}
{"sentence": "Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.", "drug1": "anticoagulants", "drug2": "hypoglycemic agents", "relation": "MECHANISM", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s88", "pair_id": "DDI-DrugBank.d64.s88.p0"}
{"sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "drug1": "ALPHAGAN P", "drug2": "opiates", "relation": "ADVISE", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s0", "pair_id": "DDI-DrugBank.d138.s0.p3"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "ZEBETA", "drug2": "phenylalkylamine", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p2"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "NSAIDs", "drug2": "salicylates", "relation": "NONE", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p6"}
{"sentence": "Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.", "drug1": "dopamine HCl", "drug2": "cyclopropane", "relation": "ADVISE", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s10", "pair_id": "DDI-DrugBank.d325.s10.p0"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "Type 1C antiarrhythmics", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p3"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "buspirone", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p4"}
{"sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "drug1": "Monoamine oxidase (MAO) inhibitors", "drug2": "selegiline", "relation": "NONE", "source_file": "L-Tryptophan_ddi.xml", "sentence_id": "DDI-DrugBank.d63.s0", "pair_id": "DDI-DrugBank.d63.s0.p6"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "nonbarbiturate hypnotics", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p3"}
{"sentence": "Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.", "drug1": "anticoagulants", "drug2": "chlorpropamide", "relation": "MECHANISM", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s88", "pair_id": "DDI-DrugBank.d64.s88.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "diflunisal", "drug2": "prolonged narcotics", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p804"}
{"sentence": "Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide", "drug1": "Hypoglycemic Agents", "drug2": "glipizide", "relation": "NONE", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s22", "pair_id": "DDI-DrugBank.d567.s22.p1"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "verapamil", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p24"}
{"sentence": "Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable", "drug1": "phenytoin", "drug2": "valproate", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s15", "pair_id": "DDI-DrugBank.d40.s15.p2"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "benzodiazepines", "drug2": "diltiazem", "relation": "NONE", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p37"}
{"sentence": "Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.", "drug1": "Carbamazepine", "drug2": "isoniazid", "relation": "ADVISE", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s7", "pair_id": "DDI-DrugBank.d187.s7.p15"}
{"sentence": "Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;", "drug1": "Antihypertensives", "drug2": "verapamil", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s41", "pair_id": "DDI-DrugBank.d143.s41.p5"}
{"sentence": "A clinical interaction study was also conducted with alosetron and the CYP3A4 substrate cisapride.", "drug1": "alosetron", "drug2": "cisapride", "relation": "NONE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s18", "pair_id": "DDI-DrugBank.d364.s18.p0"}
{"sentence": "Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.", "drug1": "antihistamines", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Clemastine_ddi.xml", "sentence_id": "DDI-DrugBank.d309.s0", "pair_id": "DDI-DrugBank.d309.s0.p1"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "epinephrine", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Bupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d153.s0", "pair_id": "DDI-DrugBank.d153.s0.p5"}
{"sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "drug1": "desipramine", "drug2": "diazepam", "relation": "EFFECT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s23", "pair_id": "DDI-DrugBank.d386.s23.p32"}
{"sentence": "Propanolol: The pharmacokinetics of almotriptan were not affected by coadministration of propranolol.", "drug1": "Propanolol", "drug2": "propranolol", "relation": "NONE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s5", "pair_id": "DDI-DrugBank.d299.s5.p1"}
{"sentence": "Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.", "drug1": "beta-blockers", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Betaxolol_ddi.xml", "sentence_id": "DDI-DrugBank.d489.s8", "pair_id": "DDI-DrugBank.d489.s8.p0"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "propranolol", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p4"}
{"sentence": "Flurbiprofen did not affect the pharmacokinetic profile of either drug, and the mechanism under lying the interference with propranolols hypotensive effect is unknown.", "drug1": "Flurbiprofen", "drug2": "propranolol", "relation": "INT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s10", "pair_id": "DDI-DrugBank.d529.s10.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "prolonged narcotics", "drug2": "sulfonamides", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1386"}
{"sentence": "Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.", "drug1": "Fluoxetine", "drug2": "Rifampin", "relation": "NONE", "source_file": "Delavirdine_ddi.xml", "sentence_id": "DDI-DrugBank.d251.s0", "pair_id": "DDI-DrugBank.d251.s0.p28"}
{"sentence": "There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.", "drug1": "theophylline", "drug2": "quinolone", "relation": "EFFECT", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s1", "pair_id": "DDI-DrugBank.d562.s1.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chloral hydrate", "drug2": "metronidazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p424"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "sumatriptan", "drug2": "fluvoxamine", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p2"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "androgens", "drug2": "meclofenamic acid", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p25"}
{"sentence": "In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.", "drug1": "levodopa", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s3", "pair_id": "DDI-DrugBank.d47.s3.p0"}
{"sentence": "Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.", "drug1": "Saquinavir", "drug2": "amprenavir", "relation": "MECHANISM", "source_file": "Amprenavir_ddi.xml", "sentence_id": "DDI-DrugBank.d437.s7", "pair_id": "DDI-DrugBank.d437.s7.p0"}
{"sentence": "Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.", "drug1": "valdecoxib", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s29", "pair_id": "DDI-DrugBank.d328.s29.p1"}
{"sentence": "Aspirin: Animal studies wshow that aspirin given with nonsteroidal anti-inflammatory agents, including ibuprofen, yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug.", "drug1": "aspirin", "drug2": "nonsteroidal anti-inflammatory agents", "relation": "EFFECT", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s2", "pair_id": "DDI-DrugBank.d415.s2.p3"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "Agonist/antagonist analgesics", "drug2": "buprenorphine", "relation": "NONE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p12"}
{"sentence": "The concomitant use of vasopressors, vasoconstricting agents (such as ergonovine) and some oxytocic drugs may result in severe hypertension.", "drug1": "ergonovine", "drug2": "oxytocic drugs", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s12", "pair_id": "DDI-DrugBank.d325.s12.p2"}
{"sentence": "Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;", "drug1": "tricyclic", "drug2": "sympathomimetic agents", "relation": "NONE", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s3", "pair_id": "DDI-DrugBank.d158.s3.p6"}
{"sentence": "Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.", "drug1": "nabumetone", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Nabumetone_ddi.xml", "sentence_id": "DDI-DrugBank.d174.s1", "pair_id": "DDI-DrugBank.d174.s1.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "Antiarrhythmics", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p0"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "tranquilizers", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p17"}
{"sentence": "Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.", "drug1": "phenytoin", "drug2": "bexarotene", "relation": "MECHANISM", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s3", "pair_id": "DDI-DrugBank.d467.s3.p4"}
{"sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "drug1": "PLETAL", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s0", "pair_id": "DDI-DrugBank.d358.s0.p4"}
{"sentence": "DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.", "drug1": "DIAMOX", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s0", "pair_id": "DDI-DrugBank.d368.s0.p1"}
{"sentence": "Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.", "drug1": "IOPIDINE", "drug2": "barbiturates", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s1", "pair_id": "DDI-DrugBank.d224.s1.p2"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "contraceptives", "drug2": "vitamin D", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p71"}
{"sentence": "Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function.", "drug1": "non-steroidal anti-inflammatory drugs", "drug2": "lisinopril", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s5", "pair_id": "DDI-DrugBank.d334.s5.p2"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "clozapine", "drug2": "flecainide", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p5"}
{"sentence": "Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.", "drug1": "dapsone", "drug2": "Lamprene", "relation": "EFFECT", "source_file": "Clofazimine_ddi.xml", "sentence_id": "DDI-DrugBank.d399.s0", "pair_id": "DDI-DrugBank.d399.s0.p0"}
{"sentence": "N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine. ", "drug1": "N-methyllevallorphan", "drug2": "loperamide", "relation": "EFFECT", "source_file": "7625885.xml", "sentence_id": "DDI-MedLine.d128.s15", "pair_id": "DDI-MedLine.d128.s15.p0"}
{"sentence": "With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions", "drug1": "dapsone", "drug2": "folic acid antagonists", "relation": "EFFECT", "source_file": "Dapsone_ddi.xml", "sentence_id": "DDI-DrugBank.d185.s6", "pair_id": "DDI-DrugBank.d185.s6.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "doxycycline", "drug2": "ziprasidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p598"}
{"sentence": "Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.", "drug1": "Ketoconazole", "drug2": "tacrolimus", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s10", "pair_id": "DDI-DrugBank.d458.s10.p1"}
{"sentence": "BREVIBLOC concentrations were equivocally higher when given with warfarin, but this is not likely to be clinically important.", "drug1": "BREVIBLOC", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s3", "pair_id": "DDI-DrugBank.d422.s3.p0"}
{"sentence": "Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, aminopyrine and antipyrine.", "drug1": "warfarin", "drug2": "antipyrine", "relation": "NONE", "source_file": "Famotidine_ddi.xml", "sentence_id": "DDI-DrugBank.d203.s2", "pair_id": "DDI-DrugBank.d203.s2.p4"}
{"sentence": "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "ADVISE", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s9", "pair_id": "DDI-DrugBank.d107.s9.p0"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "Central Nervous System Depressants", "drug2": "tranquilizers", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p6"}
{"sentence": "- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.", "drug1": "non-steroidal anti-inflammatory agent", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s19", "pair_id": "DDI-DrugBank.d46.s19.p6"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Atromid-S", "drug2": "Sandimmune", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p692"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "lamotrigine", "drug2": "methadone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p761"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "dicumarol", "drug2": "succinimides", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p122"}
{"sentence": "Vasoconstrictors: D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.", "drug1": "D.H.E. 45", "drug2": "peripheral vasoconstrictors", "relation": "EFFECT", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s0", "pair_id": "DDI-DrugBank.d410.s0.p4"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "magnesium/choline salicylate", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p2"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Tindal", "drug2": "fluphenazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p49"}
{"sentence": "Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.", "drug1": "indinavir", "drug2": "efavirenz", "relation": "MECHANISM", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s41", "pair_id": "DDI-DrugBank.d97.s41.p2"}
{"sentence": "Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.", "drug1": "Sonata", "drug2": "imipramine", "relation": "EFFECT", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s4", "pair_id": "DDI-DrugBank.d324.s4.p2"}
{"sentence": "Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.", "drug1": "felodipine", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Felodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d316.s14", "pair_id": "DDI-DrugBank.d316.s14.p8"}
{"sentence": "Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;", "drug1": "fluvoxamine maleate", "drug2": "alprazolam", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s14", "pair_id": "DDI-DrugBank.d76.s14.p4"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "choline salicylate", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p6"}
{"sentence": "If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.", "drug1": "dapsone", "drug2": "clofazimine", "relation": "ADVISE", "source_file": "Clofazimine_ddi.xml", "sentence_id": "DDI-DrugBank.d399.s1", "pair_id": "DDI-DrugBank.d399.s1.p0"}
{"sentence": "The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with anesthetics may be potentiated by calcium channel blockers.", "drug1": "anesthetics", "drug2": "calcium channel blockers", "relation": "EFFECT", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s22", "pair_id": "DDI-DrugBank.d565.s22.p0"}
{"sentence": "Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.", "drug1": "Buforin II", "drug2": "azithromycin", "relation": "EFFECT", "source_file": "11152438.xml", "sentence_id": "DDI-MedLine.d47.s4", "pair_id": "DDI-MedLine.d47.s4.p0"}
{"sentence": "Zalcitabine inhibited lamivudine phosphorylation at high concentration ratios (10 and 100);", "drug1": "Zalcitabine", "drug2": "lamivudine", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s5", "pair_id": "DDI-DrugBank.d263.s5.p0"}
{"sentence": "If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.", "drug1": "saquinavir", "drug2": "budesonide", "relation": "ADVISE", "source_file": "Budesonide_ddi.xml", "sentence_id": "DDI-DrugBank.d144.s1", "pair_id": "DDI-DrugBank.d144.s1.p19"}
{"sentence": "Therefore you may need to take a vitamin B12 supplement while taking aminosalicylic acid.", "drug1": "vitamin B12", "drug2": "aminosalicylic acid", "relation": "ADVISE", "source_file": "Aminosalicylic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d22.s3", "pair_id": "DDI-DrugBank.d22.s3.p0"}
{"sentence": "Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.", "drug1": "Grepafloxacin", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s6", "pair_id": "DDI-DrugBank.d78.s6.p2"}
{"sentence": "We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. ", "drug1": "CCNU", "drug2": "misonidazole", "relation": "MECHANISM", "source_file": "3966974.xml", "sentence_id": "DDI-MedLine.d85.s14", "pair_id": "DDI-MedLine.d85.s14.p0"}
{"sentence": "In patients who have received muscle relaxants, doxapram may temporarily mask the residual effects of muscle relaxant drugs.", "drug1": "doxapram", "drug2": "muscle relaxant drugs", "relation": "EFFECT", "source_file": "Doxapram_ddi.xml", "sentence_id": "DDI-DrugBank.d332.s1", "pair_id": "DDI-DrugBank.d332.s1.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "theophylline", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p41"}
{"sentence": "It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.", "drug1": "enalapril", "drug2": "lithium", "relation": "ADVISE", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s17", "pair_id": "DDI-DrugBank.d107.s17.p2"}
{"sentence": "Although no studies have been conducted, concomitant administration of Itraconazole and phenytoin may alter the metabolism of phenytoin;", "drug1": "Itraconazole", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s20", "pair_id": "DDI-DrugBank.d165.s20.p0"}
{"sentence": "Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.", "drug1": "phenobarbital", "drug2": "felbamate", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s33", "pair_id": "DDI-DrugBank.d434.s33.p2"}
{"sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "drug1": "butorphanol", "drug2": "central nervous system depressants", "relation": "EFFECT", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s0", "pair_id": "DDI-DrugBank.d246.s0.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "delavirdine", "drug2": "nicotinamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p171"}
{"sentence": "Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.", "drug1": "ALFENTA", "drug2": "opioids", "relation": "EFFECT", "source_file": "Alfentanil_ddi.xml", "sentence_id": "DDI-DrugBank.d8.s0", "pair_id": "DDI-DrugBank.d8.s0.p3"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "tacrolimus", "drug2": "triazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p98"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "hypnotics", "drug2": "skeletal muscle relaxants", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p61"}
{"sentence": "There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including nortriptyline, when fluoxetine hydrochloride has been administered in combination with these agents.", "drug1": "nortriptyline", "drug2": "fluoxetine hydrochloride", "relation": "MECHANISM", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s6", "pair_id": "DDI-DrugBank.d202.s6.p2"}
{"sentence": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).", "drug1": "caffeine", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Caffeine_ddi.xml", "sentence_id": "DDI-DrugBank.d89.s3", "pair_id": "DDI-DrugBank.d89.s3.p24"}
{"sentence": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.", "drug1": "alcohol", "drug2": "LEXAPRO", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s1", "pair_id": "DDI-DrugBank.d568.s1.p14"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "drug1": "epinephrine", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s0", "pair_id": "DDI-DrugBank.d110.s0.p7"}
{"sentence": "Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.", "drug1": "diazoxide", "drug2": "hydralazine", "relation": "EFFECT", "source_file": "Hydralazine_ddi.xml", "sentence_id": "DDI-DrugBank.d31.s2", "pair_id": "DDI-DrugBank.d31.s2.p0"}
{"sentence": "An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. ", "drug1": "perchlorate", "drug2": "radiopertechnetate", "relation": "NONE", "source_file": "163470.xml", "sentence_id": "DDI-MedLine.d134.s1", "pair_id": "DDI-MedLine.d134.s1.p1"}
{"sentence": "Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.", "drug1": "theophylline", "drug2": "fluvoxamine maleate", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s28", "pair_id": "DDI-DrugBank.d76.s28.p0"}
{"sentence": "Sedatives/Hypnotics: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.", "drug1": "Hypnotics", "drug2": "midazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s23", "pair_id": "DDI-DrugBank.d124.s23.p4"}
{"sentence": "CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. ", "drug1": "diltiazem", "drug2": "sirolimus", "relation": "MECHANISM", "source_file": "11180036.xml", "sentence_id": "DDI-MedLine.d86.s8", "pair_id": "DDI-MedLine.d86.s8.p0"}
{"sentence": "Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.", "drug1": "atorvastatin", "drug2": "norethindrone", "relation": "MECHANISM", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s10", "pair_id": "DDI-DrugBank.d140.s10.p5"}
{"sentence": "Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).", "drug1": "Gleevec", "drug2": "HMG-CoA reductase inhibitors", "relation": "MECHANISM", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s10", "pair_id": "DDI-DrugBank.d115.s10.p2"}
{"sentence": "Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.", "drug1": "cholestyramine", "drug2": "resin", "relation": "NONE", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s2", "pair_id": "DDI-DrugBank.d566.s2.p20"}
{"sentence": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "drug1": "glucocorticoids", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s7", "pair_id": "DDI-MedLine.d12.s7.p10"}
{"sentence": "Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.", "drug1": "leucovorin", "drug2": "fluorouracil", "relation": "EFFECT", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s6", "pair_id": "DDI-DrugBank.d88.s6.p0"}
{"sentence": "Chloral hydrate may cause an increased prothrombin response by displacing the anticoagulant from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction, thus leading to inter-patient variation in ultimate prothrombin effect.", "drug1": "Chloral hydrate", "drug2": "anticoagulant", "relation": "MECHANISM", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s4", "pair_id": "DDI-DrugBank.d64.s4.p0"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylurea", "drug2": "nonsteroidal anti-inflammatory agents", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p0"}
{"sentence": "Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.", "drug1": "norfloxacin", "drug2": "zafirlukast", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s25", "pair_id": "DDI-DrugBank.d558.s25.p69"}
{"sentence": "Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).", "drug1": "ketoconazole", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Caffeine_ddi.xml", "sentence_id": "DDI-DrugBank.d89.s3", "pair_id": "DDI-DrugBank.d89.s3.p20"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.", "drug1": "epinephrine", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Chloroprocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d110.s0", "pair_id": "DDI-DrugBank.d110.s0.p8"}
{"sentence": "The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.", "drug1": "mycophenolate mofetil", "drug2": "muromonab-CD3", "relation": "NONE", "source_file": "Basiliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d544.s5", "pair_id": "DDI-DrugBank.d544.s5.p14"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "clonazepam", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p7"}
{"sentence": "Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.", "drug1": "naproxen", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s6", "pair_id": "DDI-DrugBank.d85.s6.p5"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "dextran", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p27"}
{"sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "drug1": "Matulane", "drug2": "L-tryptophan", "relation": "NONE", "source_file": "L-Tryptophan_ddi.xml", "sentence_id": "DDI-DrugBank.d63.s0", "pair_id": "DDI-DrugBank.d63.s0.p55"}
{"sentence": "Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.", "drug1": "PROLEUKIN", "drug2": "interferon-alfa", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s8", "pair_id": "DDI-DrugBank.d114.s8.p0"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "indinavir", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p3"}
{"sentence": "Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.", "drug1": "psychotropic medications", "drug2": "LEXAPRO", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s1", "pair_id": "DDI-DrugBank.d568.s1.p13"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "alprazolam", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "aminosalicylic acid", "drug2": "chymotrypsin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p165"}
{"sentence": "Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.", "drug1": "PRINIVIL", "drug2": "potassium-sparing diuretics", "relation": "EFFECT", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s15", "pair_id": "DDI-DrugBank.d334.s15.p0"}
{"sentence": "Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil.", "drug1": "neomycin", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Neomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d330.s2", "pair_id": "DDI-DrugBank.d330.s2.p2"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "terfenadine", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p11"}
{"sentence": "Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.", "drug1": "INSPRA", "drug2": "NSAIDs", "relation": "ADVISE", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s12", "pair_id": "DDI-DrugBank.d20.s12.p0"}
{"sentence": "Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.", "drug1": "anileridine", "drug2": "anesthetics", "relation": "ADVISE", "source_file": "Anileridine_ddi.xml", "sentence_id": "DDI-DrugBank.d215.s0", "pair_id": "DDI-DrugBank.d215.s0.p3"}
{"sentence": "Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.", "drug1": "EQUETROTM", "drug2": "Clomipramine HCl", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s13", "pair_id": "DDI-DrugBank.d94.s13.p5"}
{"sentence": "Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.", "drug1": "Ethoxzolamide", "drug2": "procainamide", "relation": "EFFECT", "source_file": "Ethoxzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d286.s0", "pair_id": "DDI-DrugBank.d286.s0.p2"}
{"sentence": "Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.", "drug1": "Immunosuppressive", "drug2": "amiodarone", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s20", "pair_id": "DDI-DrugBank.d143.s20.p2"}
{"sentence": "- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.", "drug1": "insulin", "drug2": "Bezalip", "relation": "EFFECT", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s3", "pair_id": "DDI-DrugBank.d291.s3.p3"}
{"sentence": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.", "drug1": "tricyclic antidepressants", "drug2": "guanethidine", "relation": "EFFECT", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s4", "pair_id": "DDI-DrugBank.d238.s4.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "phenylbutazone", "drug2": "quinidine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1336"}
{"sentence": "Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.", "drug1": "enoxacin", "drug2": "R-warfarin", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s23", "pair_id": "DDI-DrugBank.d395.s23.p7"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "contraceptives", "drug2": "theophylline", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p70"}
{"sentence": "NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.", "drug1": "NSAIDs", "drug2": "cyclosporine", "relation": "ADVISE", "source_file": "Diflunisal_ddi.xml", "sentence_id": "DDI-DrugBank.d132.s19", "pair_id": "DDI-DrugBank.d132.s19.p0"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "beta-blockers", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p11"}
{"sentence": "Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.", "drug1": "valdecoxib", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s13", "pair_id": "DDI-DrugBank.d328.s13.p0"}
{"sentence": "Vitamin D: The coadministration of any of the vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia.", "drug1": "Vitamin D", "drug2": "vitamin D analogues", "relation": "NONE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s13", "pair_id": "DDI-DrugBank.d98.s13.p0"}
{"sentence": "Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.", "drug1": "quinolones", "drug2": "iron", "relation": "MECHANISM", "source_file": "Cinoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d562.s7", "pair_id": "DDI-DrugBank.d562.s7.p0"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p4"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "telithromycin", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p9"}
{"sentence": "Oral Hypoglycemic Agents: In one study, flurbiprofen was given to adult diabetics who were already receiving glyburide (n=4), metformin (n=2) chlorpropamide with phenformin (n= 3) or glyburide with phenformin (n=6).", "drug1": "glyburide", "drug2": "phenformin", "relation": "NONE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s18", "pair_id": "DDI-DrugBank.d529.s18.p17"}
{"sentence": "Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.", "drug1": "Itraconazole", "drug2": "coumarin", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s23", "pair_id": "DDI-DrugBank.d165.s23.p0"}
{"sentence": "Taking amyl nitrite after drinking alcohol may worsen side effects and may cause severe hypotension and cardiovascular collapse.", "drug1": "amyl nitrite", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Amyl Nitrite_ddi.xml", "sentence_id": "DDI-DrugBank.d56.s0", "pair_id": "DDI-DrugBank.d56.s0.p0"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "fluoxetine", "drug2": "paroxetine", "relation": "NONE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s16", "pair_id": "DDI-DrugBank.d238.s16.p10"}
{"sentence": "Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. ", "drug1": "clindamycin", "drug2": "gentamicin", "relation": "EFFECT", "source_file": "15825309.xml", "sentence_id": "DDI-MedLine.d49.s6", "pair_id": "DDI-MedLine.d49.s6.p0"}
{"sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "drug1": "Cisapride", "drug2": "quinidine", "relation": "ADVISE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s14", "pair_id": "DDI-DrugBank.d237.s14.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Trileptal", "drug2": "Sandimmune", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p407"}
{"sentence": "Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.", "drug1": "digoxin", "drug2": "diltiazem hydrochloride", "relation": "ADVISE", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s20", "pair_id": "DDI-DrugBank.d565.s20.p2"}
{"sentence": "Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.", "drug1": "baclofen", "drug2": "morphine", "relation": "EFFECT", "source_file": "Baclofen_ddi.xml", "sentence_id": "DDI-DrugBank.d523.s1", "pair_id": "DDI-DrugBank.d523.s1.p0"}
{"sentence": "Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).", "drug1": "TORADOL", "drug2": "fluoxetine", "relation": "EFFECT", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s19", "pair_id": "DDI-DrugBank.d3.s19.p6"}
{"sentence": "Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.", "drug1": "fluconazole", "drug2": "azithromycin", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s8", "pair_id": "DDI-DrugBank.d53.s8.p2"}
{"sentence": "Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "quinolone antibiotics", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s12", "pair_id": "DDI-DrugBank.d43.s12.p1"}
{"sentence": "However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.", "drug1": "CELEBREX", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s24", "pair_id": "DDI-DrugBank.d172.s24.p0"}
{"sentence": "Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.", "drug1": "chloroquine", "drug2": "ampicillin", "relation": "MECHANISM", "source_file": "Chloroquine_ddi.xml", "sentence_id": "DDI-DrugBank.d429.s4", "pair_id": "DDI-DrugBank.d429.s4.p2"}
{"sentence": "The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of atropine and pralidoxime.", "drug1": "atropine", "drug2": "pralidoxime", "relation": "ADVISE", "source_file": "Atropine_ddi.xml", "sentence_id": "DDI-DrugBank.d222.s1", "pair_id": "DDI-DrugBank.d222.s1.p0"}
{"sentence": "Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "drug1": "BOTOX", "drug2": "aminoglycosides", "relation": "ADVISE", "source_file": "Botulinum Toxin Type A_ddi.xml", "sentence_id": "DDI-DrugBank.d133.s0", "pair_id": "DDI-DrugBank.d133.s0.p0"}
{"sentence": "However, it was observed that the pharmacokinetics of ENBREL  was unaltered by concomitant methotrexate in rheumatoid arthritis patients.", "drug1": "ENBREL", "drug2": "methotrexate", "relation": "NONE", "source_file": "Etanercept_ddi.xml", "sentence_id": "DDI-DrugBank.d341.s1", "pair_id": "DDI-DrugBank.d341.s1.p0"}
{"sentence": "Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.", "drug1": "Simulect", "drug2": "azathioprine", "relation": "MECHANISM", "source_file": "Basiliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d544.s3", "pair_id": "DDI-DrugBank.d544.s3.p0"}
{"sentence": "Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin. ", "drug1": "estradiol", "drug2": "endotoxin", "relation": "EFFECT", "source_file": "7600639.xml", "sentence_id": "DDI-MedLine.d39.s2", "pair_id": "DDI-MedLine.d39.s2.p0"}
{"sentence": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "drug1": "magnesium hydroxide", "drug2": "fluconazole", "relation": "NONE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s14", "pair_id": "DDI-DrugBank.d400.s14.p15"}
{"sentence": "Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.", "drug1": "linezolid", "drug2": "serotonergic agents", "relation": "INT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s1", "pair_id": "DDI-DrugBank.d441.s1.p1"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "selegiline hydrochloride", "drug2": "sertraline", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p19"}
{"sentence": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.", "drug1": "Benzthiazide", "drug2": "Aleve", "relation": "INT", "source_file": "Benzthiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d208.s0", "pair_id": "DDI-DrugBank.d208.s0.p6"}
{"sentence": "Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.", "drug1": "Phenytoin", "drug2": "busulfan", "relation": "MECHANISM", "source_file": "Busulfan_ddi.xml", "sentence_id": "DDI-DrugBank.d72.s2", "pair_id": "DDI-DrugBank.d72.s2.p0"}
{"sentence": "BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.", "drug1": "monoamine oxidase inhibitors", "drug2": "adrenergic agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s6", "pair_id": "DDI-DrugBank.d284.s6.p8"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "phenylbutazone", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p15"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "paroxetine", "drug2": "fluvoxamine", "relation": "NONE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s16", "pair_id": "DDI-DrugBank.d238.s16.p14"}
{"sentence": "Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.", "drug1": "ketoconazole", "drug2": "aripiprazole", "relation": "MECHANISM", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s9", "pair_id": "DDI-DrugBank.d509.s9.p3"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "cimetidine", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p580"}
{"sentence": "Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.", "drug1": "Cyclophosphamide", "drug2": "Cerubidine", "relation": "EFFECT", "source_file": "Daunorubicin_ddi.xml", "sentence_id": "DDI-DrugBank.d69.s2", "pair_id": "DDI-DrugBank.d69.s2.p0"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "non-steroidal anti-inflammatory drugs", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p17"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "fenoprofen", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p19"}
{"sentence": "Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.", "drug1": "lorazepam", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s0", "pair_id": "DDI-DrugBank.d18.s0.p3"}
{"sentence": "No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III).", "drug1": "digoxin", "drug2": "contraceptives", "relation": "NONE", "source_file": "Candesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d547.s0", "pair_id": "DDI-DrugBank.d547.s0.p20"}
{"sentence": "Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.", "drug1": "Allopurinol", "drug2": "azathioprine", "relation": "MECHANISM", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s2", "pair_id": "DDI-DrugBank.d413.s2.p10"}
{"sentence": "Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.", "drug1": "Anabolic steroids", "drug2": "methandrostenolone", "relation": "NONE", "source_file": "Fludrocortisone_ddi.xml", "sentence_id": "DDI-DrugBank.d526.s19", "pair_id": "DDI-DrugBank.d526.s19.p2"}
{"sentence": "Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s16", "pair_id": "DDI-DrugBank.d529.s16.p0"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "phenytoin", "drug2": "estrogens", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p5"}
{"sentence": "The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.", "drug1": "dexamethasone", "drug2": "Aprepitant", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s11", "pair_id": "DDI-DrugBank.d382.s11.p0"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "atazanavir", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p5"}
{"sentence": "It has been reported that results of studies in animals indicate that dopamine-induced ventricular arrhythmias during anesthesia can be reversed by propranolol.", "drug1": "dopamine", "drug2": "propranolol", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s11", "pair_id": "DDI-DrugBank.d325.s11.p0"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "nalbuphine", "drug2": "Levo-Dromoran", "relation": "ADVISE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p25"}
{"sentence": "While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.", "drug1": "carbamazepine", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s14", "pair_id": "DDI-DrugBank.d60.s14.p2"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "ZEBETA", "drug2": "disopyramide", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p7"}
{"sentence": "ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.", "drug1": "NSAIDs", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s4", "pair_id": "DDI-DrugBank.d400.s4.p2"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "Calcidiol", "drug2": "fat soluble vitamins", "relation": "NONE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s0", "pair_id": "DDI-DrugBank.d98.s0.p24"}
{"sentence": "Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.", "drug1": "delavirdine", "drug2": "VIDEX", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s14", "pair_id": "DDI-DrugBank.d43.s14.p4"}
{"sentence": "Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.", "drug1": "beta-adrenergic blockers", "drug2": "calcium channel blockers", "relation": "NONE", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s12", "pair_id": "DDI-DrugBank.d450.s12.p0"}
{"sentence": "Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.", "drug1": "DIAMOX", "drug2": "primidone", "relation": "ADVISE", "source_file": "Acetazolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d368.s4", "pair_id": "DDI-DrugBank.d368.s4.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "pimozide", "drug2": "triazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p119"}
{"sentence": "Example inducers include aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins.", "drug1": "nafcillin", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s22", "pair_id": "DDI-DrugBank.d485.s22.p12"}
{"sentence": "therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.", "drug1": "Aprepitant", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s34", "pair_id": "DDI-DrugBank.d382.s34.p2"}
{"sentence": "Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding.", "drug1": "psychotropic drugs", "drug2": "NSAID", "relation": "EFFECT", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s5", "pair_id": "DDI-DrugBank.d568.s5.p0"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "Magnesium", "drug2": "multivitamin preparations", "relation": "NONE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p4"}
{"sentence": "However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.", "drug1": "aspirin", "drug2": "Ibandronate", "relation": "ADVISE", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s13", "pair_id": "DDI-DrugBank.d440.s13.p13"}
{"sentence": "However, in patients treated with oral carbonic anhydrase inhibitors, rare instances of drug interactions have occurred with high-dose salicylate therapy.", "drug1": "carbonic anhydrase inhibitors", "drug2": "salicylate", "relation": "INT", "source_file": "Brinzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d497.s2", "pair_id": "DDI-DrugBank.d497.s2.p0"}
{"sentence": "Lithium carbonate: The stimulatory effects of amphetamines may be inhibited by lithium carbonate.", "drug1": "amphetamines", "drug2": "lithium carbonate", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s19", "pair_id": "DDI-DrugBank.d236.s19.p2"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "acetaminophen", "drug2": "sedative-hypnotics", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p15"}
{"sentence": "1,25-Dihydroxycholecalciferol D3 (1,25(OH)2D3), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. ", "drug1": "1,25(OH)2D3", "drug2": "vitamin D", "relation": "NONE", "source_file": "7654327.xml", "sentence_id": "DDI-MedLine.d53.s1", "pair_id": "DDI-MedLine.d53.s1.p2"}
{"sentence": "CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ", "drug1": "Macrolide antibiotics", "drug2": "lovastatin", "relation": "MECHANISM", "source_file": "11197581.xml", "sentence_id": "DDI-MedLine.d25.s12", "pair_id": "DDI-MedLine.d25.s12.p3"}
{"sentence": "Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations.", "drug1": "Mineral oil", "drug2": "vitamin D preparations", "relation": "MECHANISM", "source_file": "Ergocalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d471.s0", "pair_id": "DDI-DrugBank.d471.s0.p1"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "cyclosporine", "drug2": "terfenadine", "relation": "NONE", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p34"}
{"sentence": "In vitro, buspirone does not displace tightly bound drugs like phenytoin, propranolol, and warfarin from serum proteins.", "drug1": "buspirone", "drug2": "propranolol", "relation": "NONE", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s5", "pair_id": "DDI-DrugBank.d463.s5.p1"}
{"sentence": "Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.", "drug1": "phenobarbital", "drug2": "calcitriol", "relation": "MECHANISM", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s2", "pair_id": "DDI-DrugBank.d384.s2.p13"}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "NSAIDs", "drug2": "thiazides", "relation": "EFFECT", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s13", "pair_id": "DDI-DrugBank.d210.s13.p4"}
{"sentence": "Propranolol increases hydralazines serum concentrations.", "drug1": "Propranolol", "drug2": "hydralazine", "relation": "MECHANISM", "source_file": "Hydralazine_ddi.xml", "sentence_id": "DDI-DrugBank.d31.s5", "pair_id": "DDI-DrugBank.d31.s5.p0"}
{"sentence": "Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).", "drug1": "Gleevec", "drug2": "dihydropyridine calcium channel blockers", "relation": "MECHANISM", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s10", "pair_id": "DDI-DrugBank.d115.s10.p1"}
{"sentence": "Certain endocrine and liver function tests may be affected by estrogen-containing oral contraceptives.", "drug1": "estrogen", "drug2": "contraceptives", "relation": "NONE", "source_file": "Ethinyl Estradiol_ddi.xml", "sentence_id": "DDI-DrugBank.d152.s0", "pair_id": "DDI-DrugBank.d152.s0.p0"}
{"sentence": "This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. ", "drug1": "phenytoin", "drug2": "quetiapine", "relation": "MECHANISM", "source_file": "11199955.xml", "sentence_id": "DDI-MedLine.d0.s4", "pair_id": "DDI-MedLine.d0.s4.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "quinine", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p57"}
{"sentence": "Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.", "drug1": "Ketoconazole", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s10", "pair_id": "DDI-DrugBank.d458.s10.p0"}
{"sentence": "For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.", "drug1": "lovastatin", "drug2": "fibrate", "relation": "EFFECT", "source_file": "Clofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d12.s7", "pair_id": "DDI-DrugBank.d12.s7.p0"}
{"sentence": "- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine", "drug1": "phenytoin", "drug2": "reserpine", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s12", "pair_id": "DDI-DrugBank.d40.s12.p2"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "quinidine", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p7"}
{"sentence": "It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.", "drug1": "dantrolene sodium", "drug2": "calcium channel blockers", "relation": "ADVISE", "source_file": "Dantrolene_ddi.xml", "sentence_id": "DDI-DrugBank.d305.s6", "pair_id": "DDI-DrugBank.d305.s6.p0"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "celecoxib", "drug2": "valsartan", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p47"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "Antihistamines", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p3"}
{"sentence": "The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.", "drug1": "imipramine", "drug2": "barbiturates", "relation": "MECHANISM", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s5", "pair_id": "DDI-DrugBank.d77.s5.p2"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "Benzodiazepines", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p9"}
{"sentence": "Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.", "drug1": "FACTIVE", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s2", "pair_id": "DDI-DrugBank.d347.s2.p0"}
{"sentence": "Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.", "drug1": "CYP3A4", "drug2": "amiodarone", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s50", "pair_id": "DDI-DrugBank.d143.s50.p3"}
{"sentence": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "drug1": "tranylcypromine", "drug2": "phenelzine", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s4", "pair_id": "DDI-DrugBank.d521.s4.p23"}
{"sentence": "CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.", "drug1": "Sonata", "drug2": "ethanol", "relation": "EFFECT", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s1", "pair_id": "DDI-DrugBank.d324.s1.p4"}
{"sentence": "Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics.", "drug1": "ketoconazole", "drug2": "fluconazole", "relation": "NONE", "source_file": "Eprosartan_ddi.xml", "sentence_id": "DDI-DrugBank.d525.s2", "pair_id": "DDI-DrugBank.d525.s2.p3"}
{"sentence": "Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.", "drug1": "almotriptan", "drug2": "verapamil", "relation": "MECHANISM", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s8", "pair_id": "DDI-DrugBank.d299.s8.p3"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "dantrolene", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p8"}
{"sentence": "It has been reported that Itraconazole enhances the anticoagulant effect of coumarin-like drugs.", "drug1": "Itraconazole", "drug2": "coumarin", "relation": "EFFECT", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s22", "pair_id": "DDI-DrugBank.d165.s22.p0"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "phenobarbital", "drug2": "phenytoin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p533"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "para-aminobenzoic acid", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p7"}
{"sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.", "drug1": "HYDROXYZINE", "drug2": "NON-NARCOTIC ANALGESICS", "relation": "EFFECT", "source_file": "Hydroxyzine_ddi.xml", "sentence_id": "DDI-DrugBank.d308.s0", "pair_id": "DDI-DrugBank.d308.s0.p2"}
{"sentence": "The adverse effects of CAMPTOSAR, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.", "drug1": "CAMPTOSAR", "drug2": "antineoplastic agents", "relation": "EFFECT", "source_file": "Irinotecan_ddi.xml", "sentence_id": "DDI-DrugBank.d279.s0", "pair_id": "DDI-DrugBank.d279.s0.p0"}
{"sentence": "Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect .", "drug1": "doxapram", "drug2": "sympathomimetic", "relation": "EFFECT", "source_file": "Doxapram_ddi.xml", "sentence_id": "DDI-DrugBank.d332.s0", "pair_id": "DDI-DrugBank.d332.s0.p0"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "methylphenidate", "drug2": "cimetidine", "relation": "NONE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p6"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "clonazepam", "drug2": "delavirdine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p334"}
{"sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "drug1": "metoclopramide", "drug2": "APOKYN", "relation": "EFFECT", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s3", "pair_id": "DDI-DrugBank.d357.s3.p44"}
{"sentence": "When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.", "drug1": "indinavir", "drug2": "SUSTIVA", "relation": "MECHANISM", "source_file": "Efavirenz_ddi.xml", "sentence_id": "DDI-DrugBank.d531.s39", "pair_id": "DDI-DrugBank.d531.s39.p0"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p6"}
{"sentence": "Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.", "drug1": "Diuretic", "drug2": "Hydrochlorothiazide", "relation": "NONE", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s10", "pair_id": "DDI-DrugBank.d499.s10.p0"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "cyclosporine", "drug2": "SPRYCEL", "relation": "ADVISE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p54"}
{"sentence": "and phase 3 (days 45-52): cisapride 10 mg 4 times/day (days 45-51) plus fluoxetine 20 mg/day (days 45-52). ", "drug1": "cisapride", "drug2": "fluoxetine", "relation": "NONE", "source_file": "11213850.xml", "sentence_id": "DDI-MedLine.d46.s9", "pair_id": "DDI-MedLine.d46.s9.p0"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "cimetidine", "drug2": "trazodone", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p94"}
{"sentence": "The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.", "drug1": "gemifloxacin", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s6", "pair_id": "DDI-DrugBank.d347.s6.p2"}
{"sentence": "CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.", "drug1": "CELEBREX", "drug2": "fluconazole", "relation": "ADVISE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s18", "pair_id": "DDI-DrugBank.d172.s18.p0"}
{"sentence": "When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ", "drug1": "ofloxacin", "drug2": "KRM-1648", "relation": "EFFECT", "source_file": "11137650.xml", "sentence_id": "DDI-MedLine.d8.s6", "pair_id": "DDI-MedLine.d8.s6.p0"}
{"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "drug1": "heparin", "drug2": "vitamin K antagonists", "relation": "NONE", "source_file": "Alteplase_ddi.xml", "sentence_id": "DDI-DrugBank.d508.s1", "pair_id": "DDI-DrugBank.d508.s1.p0"}
{"sentence": "Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.", "drug1": "Phospholine Iodide", "drug2": "organophosphate insecticide", "relation": "EFFECT", "source_file": "Echothiophate Iodide_ddi.xml", "sentence_id": "DDI-DrugBank.d377.s0", "pair_id": "DDI-DrugBank.d377.s0.p2"}
{"sentence": "Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).", "drug1": "amphotericin B", "drug2": "tubocurarine", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s12", "pair_id": "DDI-DrugBank.d318.s12.p4"}
{"sentence": "Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy. ", "drug1": "cholestyramine", "drug2": "fluvastatin", "relation": "EFFECT", "source_file": "19489169.xml", "sentence_id": "DDI-MedLine.d119.s16", "pair_id": "DDI-MedLine.d119.s16.p0"}
{"sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "ciprofloxacin", "drug2": "calcium", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s8", "pair_id": "DDI-DrugBank.d43.s8.p20"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "zinc", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p17"}
{"sentence": "Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.", "drug1": "propranolol", "drug2": "propranolol", "relation": "NONE", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s8", "pair_id": "DDI-DrugBank.d565.s8.p4"}
{"sentence": "Ascorbic acid: Doses of ascorbic acid (vitamin C) 1 g/day have been reported to increase plasma concentration of synthetic estrogens by ~47%, possibly by inhibiting conjugation;", "drug1": "ascorbic acid", "drug2": "synthetic estrogens", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s14", "pair_id": "DDI-DrugBank.d485.s14.p4"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "aminoglutethimide", "drug2": "ethionamide", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p13"}
{"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.", "drug1": "methysergide", "drug2": "naratriptan", "relation": "ADVISE", "source_file": "Naratriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d478.s1", "pair_id": "DDI-DrugBank.d478.s1.p9"}
{"sentence": "Vecuronium: When used in the perioperative period, piperacillin has been implicated in the prolongation of the neuromuscular blockade of vecuronium.", "drug1": "piperacillin", "drug2": "vecuronium", "relation": "EFFECT", "source_file": "Piperacillin_ddi.xml", "sentence_id": "DDI-DrugBank.d462.s1", "pair_id": "DDI-DrugBank.d462.s1.p2"}
{"sentence": "Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.", "drug1": "Pulmozyme", "drug2": "vitamins", "relation": "NONE", "source_file": "Dornase Alfa_ddi.xml", "sentence_id": "DDI-DrugBank.d93.s0", "pair_id": "DDI-DrugBank.d93.s0.p2"}
{"sentence": "Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.", "drug1": "Clonidine hydrochloride", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s1", "pair_id": "DDI-DrugBank.d495.s1.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "ziprasidone", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p43"}
{"sentence": "Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.", "drug1": "vitamins", "drug2": "corticosteroids", "relation": "NONE", "source_file": "Dornase Alfa_ddi.xml", "sentence_id": "DDI-DrugBank.d93.s0", "pair_id": "DDI-DrugBank.d93.s0.p12"}
{"sentence": "Beta-adrenergic Blocking Agents: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of nifedipine and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina.", "drug1": "nifedipine", "drug2": "beta-blocking agents", "relation": "EFFECT", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s0", "pair_id": "DDI-DrugBank.d373.s0.p2"}
{"sentence": "Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "ketoconazole", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s7", "pair_id": "DDI-DrugBank.d237.s7.p12"}
{"sentence": "Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable", "drug1": "phenytoin", "drug2": "valproic acid", "relation": "EFFECT", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s15", "pair_id": "DDI-DrugBank.d40.s15.p1"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "anesthetics", "drug2": "lidocaine", "relation": "NONE", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p61"}
{"sentence": "Some quinolones have also been shown to interfere with the metabolism of caffeine.", "drug1": "quinolones", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s13", "pair_id": "DDI-DrugBank.d217.s13.p0"}
{"sentence": "Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.", "drug1": "flurbiprofen", "drug2": "beta-blocker", "relation": "ADVISE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s11", "pair_id": "DDI-DrugBank.d529.s11.p0"}
{"sentence": "We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.", "drug1": "ADL 8-2698", "drug2": "morphine", "relation": "EFFECT", "source_file": "11180040.xml", "sentence_id": "DDI-MedLine.d87.s8", "pair_id": "DDI-MedLine.d87.s8.p0"}
{"sentence": "High-dose cisplatin with sodium thiosulfate protection.\r\n", "drug1": "cisplatin", "drug2": "sodium thiosulfate", "relation": "EFFECT", "source_file": "4038510.xml", "sentence_id": "DDI-MedLine.d130.s0", "pair_id": "DDI-MedLine.d130.s0.p0"}
{"sentence": "Methotrexate: Piperacillin sodium may reduce the excretion of methotrexate.", "drug1": "Piperacillin sodium", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Piperacillin_ddi.xml", "sentence_id": "DDI-DrugBank.d462.s7", "pair_id": "DDI-DrugBank.d462.s7.p2"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylurea", "drug2": "beta adrenergic blocking agents", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p7"}
{"sentence": "Rifabutin, another rifamycin, is structurally similar to rifampin and may possibly have some of the same drug interactions as rifampin.", "drug1": "Rifabutin", "drug2": "rifampin", "relation": "NONE", "source_file": "Atovaquone_ddi.xml", "sentence_id": "DDI-DrugBank.d424.s5", "pair_id": "DDI-DrugBank.d424.s5.p1"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p2"}
{"sentence": "- a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil);", "drug1": "isocarboxazid", "drug2": "Marplan", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s4", "pair_id": "DDI-DrugBank.d521.s4.p13"}
{"sentence": "Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.", "drug1": "ketoconazole", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s7", "pair_id": "DDI-DrugBank.d458.s7.p0"}
{"sentence": "Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function.", "drug1": "Furosemide", "drug2": "aminoglycoside antibiotics", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s0", "pair_id": "DDI-DrugBank.d231.s0.p0"}
{"sentence": "Trecator has been found to temporarily raise serum concentrations of isoniazid.", "drug1": "Trecator", "drug2": "isoniazid", "relation": "MECHANISM", "source_file": "Ethionamide_ddi.xml", "sentence_id": "DDI-DrugBank.d166.s0", "pair_id": "DDI-DrugBank.d166.s0.p0"}
{"sentence": "Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "drug1": "narcotic analgesic", "drug2": "DILAUDID", "relation": "EFFECT", "source_file": "Hydromorphone_ddi.xml", "sentence_id": "DDI-DrugBank.d26.s0", "pair_id": "DDI-DrugBank.d26.s0.p7"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "estrogens", "drug2": "levodopa", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p122"}
{"sentence": "Aminoglutethimide diminishes the effect of coumarin and warfarin.", "drug1": "Aminoglutethimide", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Aminoglutethimide_ddi.xml", "sentence_id": "DDI-DrugBank.d372.s2", "pair_id": "DDI-DrugBank.d372.s2.p1"}
{"sentence": "There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;", "drug1": "cetirizine", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Cetirizine_ddi.xml", "sentence_id": "DDI-DrugBank.d393.s5", "pair_id": "DDI-DrugBank.d393.s5.p0"}
{"sentence": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "drug1": "resins", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s7", "pair_id": "DDI-DrugBank.d46.s7.p25"}
{"sentence": "The therapeutic efficacy of tricyclic antidepressants may be compromised in these patients when cimetidine is discontinued.", "drug1": "tricyclic antidepressants", "drug2": "cimetidine", "relation": "EFFECT", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s4", "pair_id": "DDI-DrugBank.d202.s4.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "alcohol", "drug2": "cholestyramine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p51"}
{"sentence": "Thus, the interaction observed between erythromycin and terfenadine is not expected for dirithromycin.", "drug1": "erythromycin", "drug2": "terfenadine", "relation": "INT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s9", "pair_id": "DDI-DrugBank.d522.s9.p0"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "LEVSIN", "drug2": "antimuscarinics", "relation": "EFFECT", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p0"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "norepinephrine", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Lidocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d564.s0", "pair_id": "DDI-DrugBank.d564.s0.p7"}
{"sentence": "Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.", "drug1": "cephalexin", "drug2": "metformin", "relation": "MECHANISM", "source_file": "Cephalexin_ddi.xml", "sentence_id": "DDI-DrugBank.d303.s2", "pair_id": "DDI-DrugBank.d303.s2.p0"}
{"sentence": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "drug1": "Cholestyramine", "drug2": "resins", "relation": "NONE", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s7", "pair_id": "DDI-DrugBank.d46.s7.p1"}
{"sentence": "Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. ", "drug1": "Cytochalasin D", "drug2": "carbachol", "relation": "EFFECT", "source_file": "11121387.xml", "sentence_id": "DDI-MedLine.d59.s4", "pair_id": "DDI-MedLine.d59.s4.p0"}
{"sentence": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "drug1": "verapamil", "drug2": "diltiazem", "relation": "NONE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s17", "pair_id": "DDI-DrugBank.d269.s17.p9"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "benzodiazepines", "drug2": "anticonvulsants", "relation": "EFFECT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p2"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "methsuximide", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p7"}
{"sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetes products, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAO inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "drug1": "ACE inhibitors", "drug2": "salicylates", "relation": "NONE", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s1", "pair_id": "DDI-DrugBank.d527.s1.p5"}
{"sentence": "Although bupropion is not metabolized by this isoenzyme, bupropion and hydroxybupropion are inhibitors of the CYP2D6 isoenzyme in vitro.", "drug1": "bupropion", "drug2": "hydroxybupropion", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s13", "pair_id": "DDI-DrugBank.d5.s13.p1"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "fluoxetine", "drug2": "sertraline", "relation": "NONE", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s8", "pair_id": "DDI-DrugBank.d223.s8.p18"}
{"sentence": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "drug1": "enflurane", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s6", "pair_id": "DDI-DrugBank.d60.s6.p8"}
{"sentence": "Although the mechanism of interaction between fenoprofen and aspirin is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.", "drug1": "fenoprofen", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s1", "pair_id": "DDI-DrugBank.d154.s1.p0"}
{"sentence": "Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ", "drug1": "cocaine", "drug2": "nicotine", "relation": "NONE", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s2", "pair_id": "DDI-MedLine.d110.s2.p13"}
{"sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "drug1": "fentanyl", "drug2": "clarithromycin", "relation": "MECHANISM", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s2", "pair_id": "DDI-DrugBank.d170.s2.p4"}
{"sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "drug1": "CNS depressants", "drug2": "opiates", "relation": "NONE", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s0", "pair_id": "DDI-DrugBank.d138.s0.p8"}
{"sentence": "Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.", "drug1": "rifampicin", "drug2": "isradipine", "relation": "MECHANISM", "source_file": "Isradipine_ddi.xml", "sentence_id": "DDI-DrugBank.d81.s9", "pair_id": "DDI-DrugBank.d81.s9.p3"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "tetracyclines", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p17"}
{"sentence": "Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.", "drug1": "cyclophosphamide", "drug2": "allopurinol", "relation": "EFFECT", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s18", "pair_id": "DDI-DrugBank.d413.s18.p4"}
{"sentence": "Amiodarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased when either amiodarone or verapamil is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class (see WARNINGS, Myopathy/Rhabdomyolysis).", "drug1": "amiodarone", "drug2": "HMG-CoA reductase inhibitor class", "relation": "EFFECT", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s12", "pair_id": "DDI-DrugBank.d567.s12.p8"}
{"sentence": "CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.", "drug1": "CANCIDAS", "drug2": "tacrolimus", "relation": "NONE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s5", "pair_id": "DDI-DrugBank.d350.s5.p1"}
{"sentence": "Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).", "drug1": "TRISENOX", "drug2": "antiarrhythmics", "relation": "ADVISE", "source_file": "Arsenic trioxide_ddi.xml", "sentence_id": "DDI-DrugBank.d470.s1", "pair_id": "DDI-DrugBank.d470.s1.p0"}
{"sentence": "Valproic Acid: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant gabapentin administration (400 mg TID;", "drug1": "valproic acid", "drug2": "gabapentin", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s11", "pair_id": "DDI-DrugBank.d438.s11.p2"}
{"sentence": "Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.", "drug1": "diclofenac", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s18", "pair_id": "DDI-DrugBank.d249.s18.p3"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "glimepiride", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p0"}
{"sentence": "Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.", "drug1": "guanethidine", "drug2": "ZEBETA", "relation": "EFFECT", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s1", "pair_id": "DDI-DrugBank.d476.s1.p2"}
{"sentence": "The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;", "drug1": "hydrochlorothiazide", "drug2": "colestipol hydrochloride", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s11", "pair_id": "DDI-DrugBank.d345.s11.p13"}
{"sentence": "Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.", "drug1": "Diuretic agents", "drug2": "lithium", "relation": "EFFECT", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s10", "pair_id": "DDI-DrugBank.d162.s10.p1"}
{"sentence": "Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.", "drug1": "NSAIDs", "drug2": "ardeparin", "relation": "EFFECT", "source_file": "Ardeparin_ddi.xml", "sentence_id": "DDI-DrugBank.d105.s0", "pair_id": "DDI-DrugBank.d105.s0.p13"}
{"sentence": "Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.", "drug1": "cyclosporine", "drug2": "norfloxacin", "relation": "MECHANISM", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s3", "pair_id": "DDI-DrugBank.d217.s3.p2"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "caffeine", "drug2": "chlordiazepoxide", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p21"}
{"sentence": "In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.", "drug1": "WelChol", "drug2": "simvastatin", "relation": "NONE", "source_file": "Colesevelam_ddi.xml", "sentence_id": "DDI-DrugBank.d551.s4", "pair_id": "DDI-DrugBank.d551.s4.p2"}
{"sentence": "Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).", "drug1": "esomeprazole", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s12", "pair_id": "DDI-DrugBank.d29.s12.p0"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "benzodiazepines", "drug2": "ethanol", "relation": "EFFECT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p4"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "CNS depressants", "drug2": "hypnotics", "relation": "NONE", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p11"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "diazepam", "drug2": "risperidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p529"}
{"sentence": "Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.", "drug1": "barbiturates", "drug2": "INAPSINE", "relation": "EFFECT", "source_file": "Droperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d254.s0", "pair_id": "DDI-DrugBank.d254.s0.p8"}
{"sentence": "Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.", "drug1": "alosetron", "drug2": "procainamide", "relation": "EFFECT", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s15", "pair_id": "DDI-DrugBank.d364.s15.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Topamax", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p10"}
{"sentence": "The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylureas", "drug2": "nonsteroidal anti-inflammatory agents", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s0", "pair_id": "DDI-DrugBank.d178.s0.p0"}
{"sentence": "Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.", "drug1": "Videx", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s7", "pair_id": "DDI-DrugBank.d347.s7.p43"}
{"sentence": "In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. ", "drug1": "(+)-NANM", "drug2": "(-)-NANM", "relation": "NONE", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s6", "pair_id": "DDI-MedLine.d30.s6.p3"}
{"sentence": "Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.", "drug1": "Vardenafil", "drug2": "nitrates", "relation": "ADVISE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s24", "pair_id": "DDI-DrugBank.d198.s24.p2"}
{"sentence": "Amiodarone is known to raise serum digoxin levels. ", "drug1": "Amiodarone", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "3964797.xml", "sentence_id": "DDI-MedLine.d61.s1", "pair_id": "DDI-MedLine.d61.s1.p0"}
{"sentence": "Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.", "drug1": "SSRI", "drug2": "sumatriptan", "relation": "EFFECT", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s16", "pair_id": "DDI-DrugBank.d568.s16.p5"}
{"sentence": "Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;", "drug1": "Antidepressants", "drug2": "tricyclic", "relation": "NONE", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s3", "pair_id": "DDI-DrugBank.d158.s3.p0"}
{"sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "CNS depressants", "drug2": "antihistamines", "relation": "NONE", "source_file": "Diphenylpyraline_ddi.xml", "sentence_id": "DDI-DrugBank.d168.s0", "pair_id": "DDI-DrugBank.d168.s0.p7"}
{"sentence": "The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. ", "drug1": "pulmonary surfactant", "drug2": "Survanta", "relation": "NONE", "source_file": "11064383.xml", "sentence_id": "DDI-MedLine.d18.s1", "pair_id": "DDI-MedLine.d18.s1.p0"}
{"sentence": "Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.", "drug1": "benzodiazepines", "drug2": "antidepressants", "relation": "EFFECT", "source_file": "Lorazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d18.s1", "pair_id": "DDI-DrugBank.d18.s1.p12"}
{"sentence": "Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.", "drug1": "Prednisone", "drug2": "prednisolone", "relation": "NONE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s24", "pair_id": "DDI-DrugBank.d210.s24.p0"}
{"sentence": "Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.", "drug1": "narcotic analgesics", "drug2": "antipsychotics", "relation": "NONE", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s0", "pair_id": "DDI-DrugBank.d396.s0.p0"}
{"sentence": "When therapeutic concentrations of furosemide, propranolol, dipyridamole, warfarin, quinidine, or naproxen were added to human plasma (in vitro), the plasma protein binding of nicardipine HCl was not altered.", "drug1": "dipyridamole", "drug2": "nicardipine HCl", "relation": "NONE", "source_file": "Nicardipine_ddi.xml", "sentence_id": "DDI-DrugBank.d468.s10", "pair_id": "DDI-DrugBank.d468.s10.p14"}
{"sentence": "Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ", "drug1": "Physostigmine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "6536292.xml", "sentence_id": "DDI-MedLine.d54.s8", "pair_id": "DDI-MedLine.d54.s8.p1"}
{"sentence": "Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.", "drug1": "dipyridamole", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s90", "pair_id": "DDI-DrugBank.d64.s90.p21"}
{"sentence": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "drug1": "calcium channel blockers", "drug2": "verapamil", "relation": "NONE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s17", "pair_id": "DDI-DrugBank.d269.s17.p7"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "indinavir", "drug2": "telithromycin", "relation": "NONE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p51"}
{"sentence": "Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;", "drug1": "nelfinavir", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s32", "pair_id": "DDI-DrugBank.d485.s32.p13"}
{"sentence": "- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics", "drug1": "antidiabetics", "drug2": "sulfapyridine", "relation": "EFFECT", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s37", "pair_id": "DDI-DrugBank.d179.s37.p3"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "sucralfate", "drug2": "iron", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p50"}
{"sentence": "Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular organic cation transport, and QTc-prolonging drugs.", "drug1": "loop diuretics", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s35", "pair_id": "DDI-DrugBank.d558.s35.p43"}
{"sentence": "CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.", "drug1": "Ethanol", "drug2": "ethanol", "relation": "NONE", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s0", "pair_id": "DDI-DrugBank.d216.s0.p2"}
{"sentence": "If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "drug1": "sumatriptan", "drug2": "SSRI", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s17", "pair_id": "DDI-DrugBank.d568.s17.p0"}
{"sentence": "In addition, other quinolones have been reported to decrease the CYP3A4-mediated metabolism of cyclosporine.", "drug1": "quinolones", "drug2": "cyclosporine", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s14", "pair_id": "DDI-DrugBank.d78.s14.p0"}
{"sentence": "Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.", "drug1": "Ethoxzolamide", "drug2": "tricyclics", "relation": "EFFECT", "source_file": "Ethoxzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d286.s0", "pair_id": "DDI-DrugBank.d286.s0.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Nizoral", "drug2": "Norvir", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p569"}
{"sentence": "Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.", "drug1": "Aprepitant", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s22", "pair_id": "DDI-DrugBank.d382.s22.p4"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "niacin", "drug2": "salbutamol", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p18"}
{"sentence": "Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.", "drug1": "NSAIDs", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s16", "pair_id": "DDI-DrugBank.d210.s16.p3"}
{"sentence": "The concurrent use of anticholinergics with hydrocodone may produce paralytic ileus.", "drug1": "anticholinergics", "drug2": "hydrocodone", "relation": "EFFECT", "source_file": "Hydrocodone_ddi.xml", "sentence_id": "DDI-DrugBank.d396.s3", "pair_id": "DDI-DrugBank.d396.s3.p0"}
{"sentence": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "drug1": "tolbutamide", "drug2": "tolbutamide", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s18", "pair_id": "DDI-DrugBank.d382.s18.p7"}
{"sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "drug1": "lansoprazole", "drug2": "propranolol", "relation": "NONE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s1", "pair_id": "DDI-DrugBank.d431.s1.p5"}
{"sentence": "Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.", "drug1": "doxycycline", "drug2": "nicardipine", "relation": "NONE", "source_file": "Chlorpheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d235.s4", "pair_id": "DDI-DrugBank.d235.s4.p50"}
{"sentence": "Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.", "drug1": "Geocillin", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Carbenicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d545.s0", "pair_id": "DDI-DrugBank.d545.s0.p1"}
{"sentence": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "drug1": "NSAID", "drug2": "cyclosporine", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s5", "pair_id": "DDI-DrugBank.d249.s5.p11"}
{"sentence": "Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.", "drug1": "CRIXIVAN", "drug2": "delavirdine", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s35", "pair_id": "DDI-DrugBank.d97.s35.p0"}
{"sentence": "Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses. ", "drug1": "RR", "drug2": "InsP(3)", "relation": "EFFECT", "source_file": "11137703.xml", "sentence_id": "DDI-MedLine.d114.s4", "pair_id": "DDI-MedLine.d114.s4.p0"}
{"sentence": "Diphenoxylate HCl and atropine sulfate may interact with MAO inhibitors In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day.", "drug1": "atropine sulfate", "drug2": "MAO inhibitors", "relation": "INT", "source_file": "Diphenoxylate_ddi.xml", "sentence_id": "DDI-DrugBank.d538.s1", "pair_id": "DDI-DrugBank.d538.s1.p3"}
{"sentence": "If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.", "drug1": "frovatriptan", "drug2": "SSRI", "relation": "ADVISE", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s4", "pair_id": "DDI-DrugBank.d426.s4.p0"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "alprazolam", "drug2": "antihistaminics", "relation": "EFFECT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p7"}
{"sentence": "Amiodarone inhibits CYP2D6.", "drug1": "Amiodarone", "drug2": "CYP2D6", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s55", "pair_id": "DDI-DrugBank.d143.s55.p0"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "Central Nervous System Depressants", "drug2": "skeletal muscle relaxants", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p10"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p10"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "TCAs", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p2"}
{"sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "drug1": "barbiturates", "drug2": "barbiturates", "relation": "NONE", "source_file": "Butabarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d184.s0", "pair_id": "DDI-DrugBank.d184.s0.p50"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "ethosuximide", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p8"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "Anticonvulsants", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p5"}
{"sentence": "The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.", "drug1": "lymecycline", "drug2": "zinc", "relation": "MECHANISM", "source_file": "Lymecycline_ddi.xml", "sentence_id": "DDI-DrugBank.d79.s0", "pair_id": "DDI-DrugBank.d79.s0.p1"}
{"sentence": "Beta-adrenergic blocking agents may also interact with sympathomimetics.", "drug1": "Beta-adrenergic blocking agents", "drug2": "sympathomimetics", "relation": "INT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s4", "pair_id": "DDI-DrugBank.d448.s4.p0"}
{"sentence": "In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.", "drug1": "anticonvulsant", "drug2": "phenytoin", "relation": "NONE", "source_file": "Mefloquine_ddi.xml", "sentence_id": "DDI-DrugBank.d220.s11", "pair_id": "DDI-DrugBank.d220.s11.p3"}
{"sentence": "Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.", "drug1": "atorvastatin", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s7", "pair_id": "DDI-DrugBank.d140.s7.p3"}
{"sentence": "These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.", "drug1": "beta-adrenergic receptor blockers", "drug2": "aspirin", "relation": "NONE", "source_file": "Abciximab_ddi.xml", "sentence_id": "DDI-DrugBank.d532.s2", "pair_id": "DDI-DrugBank.d532.s2.p17"}
{"sentence": "Agents Causing Renin Release Captopril's effect will be augmented by antihypertensive agents that cause renin release.", "drug1": "Captopril", "drug2": "antihypertensive agents", "relation": "EFFECT", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s8", "pair_id": "DDI-DrugBank.d175.s8.p0"}
{"sentence": "Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.", "drug1": "Ketoconazole", "drug2": "Ketoconazole", "relation": "NONE", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s8", "pair_id": "DDI-DrugBank.d384.s8.p0"}
{"sentence": "In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.", "drug1": "cimetidine", "drug2": "doxazosin", "relation": "NONE", "source_file": "Doxazosin_ddi.xml", "sentence_id": "DDI-DrugBank.d367.s4", "pair_id": "DDI-DrugBank.d367.s4.p3"}
{"sentence": "Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.", "drug1": "Monoamine oxidase (MAO) inhibitors", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Clemastine_ddi.xml", "sentence_id": "DDI-DrugBank.d309.s2", "pair_id": "DDI-DrugBank.d309.s2.p0"}
{"sentence": "Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)", "drug1": "clonidine", "drug2": "beta-blockers", "relation": "ADVISE", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s7", "pair_id": "DDI-DrugBank.d495.s7.p2"}
{"sentence": "As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.", "drug1": "COREG", "drug2": "verapamil", "relation": "ADVISE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s17", "pair_id": "DDI-DrugBank.d269.s17.p5"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "iron", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p16"}
{"sentence": "The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.", "drug1": "benzodiazepines", "drug2": "antihistaminics", "relation": "EFFECT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s0", "pair_id": "DDI-DrugBank.d131.s0.p3"}
{"sentence": "The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.", "drug1": "thiazide diuretics", "drug2": "beta-agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s4", "pair_id": "DDI-DrugBank.d284.s4.p7"}
{"sentence": "Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.", "drug1": "ACE inhibitor", "drug2": "diuretic", "relation": "ADVISE", "source_file": "Lisinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d334.s4", "pair_id": "DDI-DrugBank.d334.s4.p5"}
{"sentence": "Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.", "drug1": "alprazolam", "drug2": "amiodarone", "relation": "INT", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s10", "pair_id": "DDI-DrugBank.d131.s10.p8"}
{"sentence": "We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.", "drug1": "carbamazepine", "drug2": "tricyclic antidepressants", "relation": "ADVISE", "source_file": "11134454.xml", "sentence_id": "DDI-MedLine.d36.s2", "pair_id": "DDI-MedLine.d36.s2.p5"}
{"sentence": "After prolonged administration of neuroleptics the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. ", "drug1": "cerulein", "drug2": "3H-spiroperidol", "relation": "NONE", "source_file": "2857100.xml", "sentence_id": "DDI-MedLine.d15.s1", "pair_id": "DDI-MedLine.d15.s1.p2"}
{"sentence": "Pyrantel (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of piperazine.", "drug1": "piperazine", "drug2": "pyrantel", "relation": "EFFECT", "source_file": "Piperazine_ddi.xml", "sentence_id": "DDI-DrugBank.d326.s1", "pair_id": "DDI-DrugBank.d326.s1.p7"}
{"sentence": "Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.", "drug1": "isoniazid", "drug2": "acetaminophen", "relation": "MECHANISM", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s5", "pair_id": "DDI-DrugBank.d187.s5.p0"}
{"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "drug1": "phenobarbital", "drug2": "corticosteroid", "relation": "ADVISE", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s1", "pair_id": "DDI-DrugBank.d487.s1.p3"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "quinidine", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p80"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "vitamin D analogues", "drug2": "Cholestyramine", "relation": "NONE", "source_file": "Calcidiol_ddi.xml", "sentence_id": "DDI-DrugBank.d98.s0", "pair_id": "DDI-DrugBank.d98.s0.p5"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "triclofos sodium", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p50"}
{"sentence": "Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.", "drug1": "ABILIFY", "drug2": "centrally acting drugs", "relation": "ADVISE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s0", "pair_id": "DDI-DrugBank.d509.s0.p3"}
{"sentence": "Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.", "drug1": "rifampin", "drug2": "corticosteroid", "relation": "ADVISE", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s1", "pair_id": "DDI-DrugBank.d487.s1.p8"}
{"sentence": "Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.", "drug1": "VIOXX", "drug2": "theophylline", "relation": "ADVISE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s28", "pair_id": "DDI-DrugBank.d210.s28.p2"}
{"sentence": "Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.", "drug1": "irbesartan", "drug2": "aliskiren", "relation": "MECHANISM", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s2", "pair_id": "DDI-DrugBank.d533.s2.p0"}
{"sentence": "After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% (  142 S.D.) and 251% (  68 S.D.), respectively, of those obtained after co-treatment with placebo.", "drug1": "loratadine", "drug2": "loratadine", "relation": "NONE", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s27", "pair_id": "DDI-DrugBank.d458.s27.p2"}
{"sentence": "however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.", "drug1": "ranitidine", "drug2": "ceftibuten", "relation": "MECHANISM", "source_file": "Ceftibuten_ddi.xml", "sentence_id": "DDI-DrugBank.d32.s7", "pair_id": "DDI-DrugBank.d32.s7.p0"}
{"sentence": "With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions", "drug1": "dapsone", "drug2": "pyrimethamine", "relation": "EFFECT", "source_file": "Dapsone_ddi.xml", "sentence_id": "DDI-DrugBank.d185.s6", "pair_id": "DDI-DrugBank.d185.s6.p1"}
{"sentence": "Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.", "drug1": "Duloxetine", "drug2": "Type 1C antiarrhythmics", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s9", "pair_id": "DDI-DrugBank.d548.s9.p7"}
{"sentence": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "drug1": "diuretics", "drug2": "prostaglandin synthetase inhibitors", "relation": "NONE", "source_file": "Finasteride_ddi.xml", "sentence_id": "DDI-DrugBank.d209.s3", "pair_id": "DDI-DrugBank.d209.s3.p107"}
{"sentence": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "drug1": "rifabutin", "drug2": "CRIXIVAN", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s84", "pair_id": "DDI-DrugBank.d97.s84.p5"}
{"sentence": "Sucralfate administered 2 hours before lomefloxacin resulted in a slower absorption (mean C max decreased by 30% and mean T max increased by 1 hour) and a lesser extent of absorption (mean AUC decreased by approximately 25%).", "drug1": "Sucralfate", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s4", "pair_id": "DDI-DrugBank.d516.s4.p0"}
{"sentence": "HMG-CoA Reductase Inhibitor: atorvastatin", "drug1": "HMG-CoA Reductase Inhibitor", "drug2": "atorvastatin", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s70", "pair_id": "DDI-DrugBank.d97.s70.p0"}
{"sentence": "Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).", "drug1": "allopurinol", "drug2": "VIDEX", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s2", "pair_id": "DDI-DrugBank.d43.s2.p5"}
{"sentence": "In patients receiving coumarin-type anticoagulants, the addition of Nalfon to therapy could prolong the prothrombin time.", "drug1": "coumarin-type anticoagulants", "drug2": "Nalfon", "relation": "EFFECT", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s8", "pair_id": "DDI-DrugBank.d154.s8.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "clindamycin", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p6"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "succinylcholine", "drug2": "sodium citrate", "relation": "NONE", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p13"}
{"sentence": "HMG-CoA Reductase Inhibitors: lovastatin, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.", "drug1": "HMG-CoA Reductase Inhibitors", "drug2": "lovastatin", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s22", "pair_id": "DDI-DrugBank.d124.s22.p0"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "Dexbrompheniramine", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "INT", "source_file": "Dexbrompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d62.s0", "pair_id": "DDI-DrugBank.d62.s0.p5"}
{"sentence": "The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.", "drug1": "benzodiazepines", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Estazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d338.s1", "pair_id": "DDI-DrugBank.d338.s1.p1"}
{"sentence": "Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.", "drug1": "alcohol", "drug2": "codeine", "relation": "NONE", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s1", "pair_id": "DDI-DrugBank.d552.s1.p9"}
{"sentence": "Tablets Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide.", "drug1": "sucralfate", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Furosemide_ddi.xml", "sentence_id": "DDI-DrugBank.d231.s10", "pair_id": "DDI-DrugBank.d231.s10.p0"}
{"sentence": "Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.", "drug1": "Nabilone", "drug2": "secobarbitone sodium", "relation": "EFFECT", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s1", "pair_id": "DDI-DrugBank.d552.s1.p1"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "benzodiazepines", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p20"}
{"sentence": "Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.", "drug1": "Aprepitant", "drug2": "tolbutamide", "relation": "NONE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s18", "pair_id": "DDI-DrugBank.d382.s18.p5"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "alprazolam", "drug2": "Phenytoin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p118"}
{"sentence": "Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.", "drug1": "FLOLAN", "drug2": "diuretics", "relation": "EFFECT", "source_file": "Epoprostenol_ddi.xml", "sentence_id": "DDI-DrugBank.d241.s0", "pair_id": "DDI-DrugBank.d241.s0.p0"}
{"sentence": "Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.", "drug1": "fluvoxamine", "drug2": "5-HT1 agonists", "relation": "EFFECT", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s6", "pair_id": "DDI-DrugBank.d299.s6.p24"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "nondepolarizing agents", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p12"}
{"sentence": "The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ", "drug1": "phenobarbital", "drug2": "methaqualone", "relation": "NONE", "source_file": "1109248.xml", "sentence_id": "DDI-MedLine.d106.s1", "pair_id": "DDI-MedLine.d106.s1.p9"}
{"sentence": "Since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions.", "drug1": "barbiturates", "drug2": "anticholinesterases", "relation": "ADVISE", "source_file": "Atropine_ddi.xml", "sentence_id": "DDI-DrugBank.d222.s2", "pair_id": "DDI-DrugBank.d222.s2.p0"}
{"sentence": "Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide.", "drug1": "cimetidine", "drug2": "glyburide", "relation": "NONE", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s13", "pair_id": "DDI-DrugBank.d353.s13.p4"}
{"sentence": "Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).", "drug1": "esomeprazole", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Esomeprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d29.s12", "pair_id": "DDI-DrugBank.d29.s12.p2"}
{"sentence": "Doxorubicin: Doxorubicin caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.", "drug1": "Doxorubicin", "drug2": "zalcitabine", "relation": "EFFECT", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s25", "pair_id": "DDI-DrugBank.d263.s25.p2"}
{"sentence": "Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.", "drug1": "tricyclic antidepressants", "drug2": "DILAUDID", "relation": "EFFECT", "source_file": "Hydromorphone_ddi.xml", "sentence_id": "DDI-DrugBank.d26.s0", "pair_id": "DDI-DrugBank.d26.s0.p32"}
{"sentence": "PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin. ", "drug1": "PGF2alpha", "drug2": "oxytocin", "relation": "EFFECT", "source_file": "1113260.xml", "sentence_id": "DDI-MedLine.d17.s4", "pair_id": "DDI-MedLine.d17.s4.p0"}
{"sentence": "The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;", "drug1": "gemfibrozil", "drug2": "colestipol hydrochloride", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s11", "pair_id": "DDI-DrugBank.d345.s11.p14"}
{"sentence": "Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.", "drug1": "Isoflurane", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s6", "pair_id": "DDI-DrugBank.d60.s6.p4"}
{"sentence": "Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).", "drug1": "Isocarboxazid", "drug2": "Antabuse", "relation": "ADVISE", "source_file": "Isocarboxazid_ddi.xml", "sentence_id": "DDI-DrugBank.d108.s0", "pair_id": "DDI-DrugBank.d108.s0.p0"}
{"sentence": "In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.", "drug1": "verapamil", "drug2": "dofetilide", "relation": "EFFECT", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s8", "pair_id": "DDI-DrugBank.d558.s8.p0"}
{"sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.", "drug1": "SSRI", "drug2": "TCA", "relation": "INT", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s16", "pair_id": "DDI-DrugBank.d77.s16.p0"}
{"sentence": "Median gastric pH was significantly higher when indinavir was taken after didanosine administration; ", "drug1": "indinavir", "drug2": "didanosine", "relation": "MECHANISM", "source_file": "11120981.xml", "sentence_id": "DDI-MedLine.d79.s3", "pair_id": "DDI-MedLine.d79.s3.p0"}
{"sentence": "Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. ", "drug1": "1,25(OH)2D3", "drug2": "TAM", "relation": "EFFECT", "source_file": "7654327.xml", "sentence_id": "DDI-MedLine.d53.s5", "pair_id": "DDI-MedLine.d53.s5.p0"}
{"sentence": "In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.", "drug1": "enoxacin", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s3", "pair_id": "DDI-DrugBank.d395.s3.p0"}
{"sentence": "To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ", "drug1": "vincristine", "drug2": "bleomycin", "relation": "NONE", "source_file": "11148572.xml", "sentence_id": "DDI-MedLine.d115.s2", "pair_id": "DDI-MedLine.d115.s2.p25"}
{"sentence": "Platelet inhibitors: Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.", "drug1": "dipyridamole", "drug2": "heparin sodium", "relation": "EFFECT", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s2", "pair_id": "DDI-DrugBank.d488.s2.p34"}
{"sentence": "Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.", "drug1": "VIRACEPT", "drug2": "OVCON-35", "relation": "MECHANISM", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s35", "pair_id": "DDI-DrugBank.d340.s35.p9"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "glucocorticoids", "drug2": "sulfonamides", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p405"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "praziquantel", "drug2": "topiramate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p961"}
{"sentence": "Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.", "drug1": "Levo-Dromoran", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s0", "pair_id": "DDI-DrugBank.d257.s0.p5"}
{"sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "drug1": "propoxyphene", "drug2": "salicylates", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s1", "pair_id": "DDI-DrugBank.d313.s1.p45"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "polymyxins", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p19"}
{"sentence": "Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.", "drug1": "NSAIDs", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s0", "pair_id": "DDI-DrugBank.d400.s0.p4"}
{"sentence": "Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).", "drug1": "valdecoxib", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s12", "pair_id": "DDI-DrugBank.d328.s12.p5"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "estrogens", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p9"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "felbamate", "drug2": "Phenytoin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p32"}
{"sentence": "Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a  stimulating  effect in some depressed patients.", "drug1": "reserpine", "drug2": "tricyclic antidepressant", "relation": "EFFECT", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s8", "pair_id": "DDI-DrugBank.d202.s8.p0"}
{"sentence": "When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.", "drug1": "anesthetics", "drug2": "calcium channel blockers", "relation": "ADVISE", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s23", "pair_id": "DDI-DrugBank.d565.s23.p0"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "tacrolimus", "drug2": "ergot alkaloids", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p81"}
{"sentence": "Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.", "drug1": "AKINETON", "drug2": "antiarrhythmics", "relation": "EFFECT", "source_file": "Biperiden_ddi.xml", "sentence_id": "DDI-DrugBank.d401.s0", "pair_id": "DDI-DrugBank.d401.s0.p14"}
{"sentence": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "drug1": "miconazole", "drug2": "hypoglycemic agents", "relation": "INT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s9", "pair_id": "DDI-DrugBank.d225.s9.p0"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "voriconazole", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p12"}
{"sentence": "Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.", "drug1": "INDOCIN", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s16", "pair_id": "DDI-DrugBank.d82.s16.p0"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "midazolam", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p10"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "ciprofloxacin", "drug2": "ciprofloxacin", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p18"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "dextrothyroxine", "drug2": "anesthetics", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p714"}
{"sentence": "- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);", "drug1": "Septra", "drug2": "Gantrisin", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s3", "pair_id": "DDI-DrugBank.d521.s3.p19"}
{"sentence": "Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.", "drug1": "Phenobarbital", "drug2": "felbamate", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s28", "pair_id": "DDI-DrugBank.d434.s28.p0"}
{"sentence": "These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.", "drug1": "contraceptive", "drug2": "valdecoxib", "relation": "ADVISE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s46", "pair_id": "DDI-DrugBank.d328.s46.p5"}
{"sentence": "Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.", "drug1": "cypermethrin", "drug2": "Vitamin E", "relation": "EFFECT", "source_file": "11137320.xml", "sentence_id": "DDI-MedLine.d126.s7", "pair_id": "DDI-MedLine.d126.s7.p1"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "norepinephrine", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Bupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d153.s0", "pair_id": "DDI-DrugBank.d153.s0.p8"}
{"sentence": "Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.", "drug1": "clarithromycin", "drug2": "troleandomycin", "relation": "NONE", "source_file": "Eszopiclone_ddi.xml", "sentence_id": "DDI-DrugBank.d216.s9", "pair_id": "DDI-DrugBank.d216.s9.p6"}
{"sentence": "Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.", "drug1": "PRECEDEX", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Dexmedetomidine_ddi.xml", "sentence_id": "DDI-DrugBank.d197.s1", "pair_id": "DDI-DrugBank.d197.s1.p28"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "influenza virus vaccine", "drug2": "sulfinpyrazone", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1041"}
{"sentence": "Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.", "drug1": "oxyphenbutazone", "drug2": "androgens", "relation": "MECHANISM", "source_file": "Dromostanolone_ddi.xml", "sentence_id": "DDI-DrugBank.d129.s2", "pair_id": "DDI-DrugBank.d129.s2.p0"}
{"sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "drug1": "antidepressants", "drug2": "phenothiazines", "relation": "NONE", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s7", "pair_id": "DDI-DrugBank.d99.s7.p5"}
{"sentence": "In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin.", "drug1": "diflunisal", "drug2": "indomethacin", "relation": "MECHANISM", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s0", "pair_id": "DDI-DrugBank.d82.s0.p2"}
{"sentence": "Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.", "drug1": "tricyclic anti-depressants", "drug2": "bepridil hydrochloride", "relation": "EFFECT", "source_file": "Bepridil_ddi.xml", "sentence_id": "DDI-DrugBank.d137.s10", "pair_id": "DDI-DrugBank.d137.s10.p2"}
{"sentence": "If additional adrenergic drugs are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of BROVANA may be potentiated.", "drug1": "adrenergic drugs", "drug2": "BROVANA", "relation": "ADVISE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s0", "pair_id": "DDI-DrugBank.d284.s0.p0"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "terbutaline", "drug2": "estrogens", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p81"}
{"sentence": "In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.", "drug1": "theophylline", "drug2": "erythromycin", "relation": "ADVISE", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s1", "pair_id": "DDI-DrugBank.d397.s1.p5"}
{"sentence": "Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline): Metabolism may be inhibited by combination hormonal contraceptives, increasing plasma levels of antidepressant;", "drug1": "nortriptyline", "drug2": "combination hormonal contraceptives", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s41", "pair_id": "DDI-DrugBank.d485.s41.p12"}
{"sentence": "Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.", "drug1": "Rifampin", "drug2": "carvedilol", "relation": "MECHANISM", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s14", "pair_id": "DDI-DrugBank.d269.s14.p0"}
{"sentence": "The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.", "drug1": "FLUDARA", "drug2": "pentostatin", "relation": "ADVISE", "source_file": "Fludarabine_ddi.xml", "sentence_id": "DDI-DrugBank.d444.s0", "pair_id": "DDI-DrugBank.d444.s0.p0"}
{"sentence": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.", "drug1": "progestin", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Norethindrone_ddi.xml", "sentence_id": "DDI-DrugBank.d306.s0", "pair_id": "DDI-DrugBank.d306.s0.p1"}
{"sentence": "Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.", "drug1": "PLETAL", "drug2": "PLETAL", "relation": "NONE", "source_file": "Cilostazol_ddi.xml", "sentence_id": "DDI-DrugBank.d358.s0", "pair_id": "DDI-DrugBank.d358.s0.p0"}
{"sentence": "Levothyroxine Sodium Absorption: The following agents may bind and decrease absorption of levothyroxine sodium from the gastrointestinal tract: aluminum hydoxide, cholestyramine resin, colestipol hydrochloride, ferrous sulfate, sodium polystyrene sulfonate, soybean flour (e.g., infant formula), sucralfate.", "drug1": "levothyroxine sodium", "drug2": "colestipol hydrochloride", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s2", "pair_id": "DDI-DrugBank.d411.s2.p9"}
{"sentence": "Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "ACE inhibitors", "relation": "INT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s7", "pair_id": "DDI-DrugBank.d172.s7.p2"}
{"sentence": "Effect of Sensipar on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar  is a strong in vitro inhibitor of CYP2D6.", "drug1": "Sensipar", "drug2": "Sensipar", "relation": "NONE", "source_file": "Cinacalcet_ddi.xml", "sentence_id": "DDI-DrugBank.d512.s1", "pair_id": "DDI-DrugBank.d512.s1.p0"}
{"sentence": "- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.", "drug1": "Antihypertensives", "drug2": "Bumetanide", "relation": "NONE", "source_file": "Bumetanide_ddi.xml", "sentence_id": "DDI-DrugBank.d331.s9", "pair_id": "DDI-DrugBank.d331.s9.p0"}
{"sentence": "Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by cocaine and desipramine. ", "drug1": "norepinephrine", "drug2": "desipramine", "relation": "NONE", "source_file": "7798493.xml", "sentence_id": "DDI-MedLine.d94.s17", "pair_id": "DDI-MedLine.d94.s17.p1"}
{"sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "drug1": "butorphanol", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s0", "pair_id": "DDI-DrugBank.d246.s0.p4"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "aluminum", "drug2": "calcium", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p24"}
{"sentence": "Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.", "drug1": "escitalopram", "drug2": "non-selective MAO inhibitor", "relation": "ADVISE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s9", "pair_id": "DDI-DrugBank.d482.s9.p0"}
{"sentence": "Concurrent use of flurbiprofen and aspirin is therefore not recommended.", "drug1": "flurbiprofen", "drug2": "aspirin", "relation": "ADVISE", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s6", "pair_id": "DDI-DrugBank.d529.s6.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "ibuprofen", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p987"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "warfarin-type anticoagulants", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p0"}
{"sentence": "Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;", "drug1": "Sensipar", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Cinacalcet_ddi.xml", "sentence_id": "DDI-DrugBank.d512.s7", "pair_id": "DDI-DrugBank.d512.s7.p0"}
{"sentence": "Aminoglutethimide diminishes the effect of coumarin and warfarin.", "drug1": "Aminoglutethimide", "drug2": "coumarin", "relation": "EFFECT", "source_file": "Aminoglutethimide_ddi.xml", "sentence_id": "DDI-DrugBank.d372.s2", "pair_id": "DDI-DrugBank.d372.s2.p0"}
{"sentence": "Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.", "drug1": "TRICOR", "drug2": "pravastatin", "relation": "MECHANISM", "source_file": "Fenofibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d283.s13", "pair_id": "DDI-DrugBank.d283.s13.p3"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "antipsychotic drug", "drug2": "tricyclic antidepressant", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p3"}
{"sentence": "This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.", "drug1": "probenecid", "drug2": "cloxacillin", "relation": "MECHANISM", "source_file": "15830476.xml", "sentence_id": "DDI-MedLine.d29.s8", "pair_id": "DDI-MedLine.d29.s8.p0"}
{"sentence": "At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin. ", "drug1": "atracurium", "drug2": "gentamycin", "relation": "EFFECT", "source_file": "8542840.xml", "sentence_id": "DDI-MedLine.d90.s9", "pair_id": "DDI-MedLine.d90.s9.p2"}
{"sentence": "Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.", "drug1": "ketoconazole", "drug2": "aripiprazole", "relation": "MECHANISM", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s8", "pair_id": "DDI-DrugBank.d509.s8.p3"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "sodium colistimethate", "drug2": "lithium", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p91"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Agenerase", "drug2": "rifampin", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p814"}
{"sentence": "Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates).", "drug1": "alosetron", "drug2": "levonorgestrel", "relation": "NONE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s17", "pair_id": "DDI-DrugBank.d364.s17.p2"}
{"sentence": "When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.", "drug1": "carbamazepine", "drug2": "aripiprazole", "relation": "ADVISE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s20", "pair_id": "DDI-DrugBank.d509.s20.p0"}
{"sentence": "Fifteen to 30 minutes of exposure to 1.25 MAC isoflurane or enflurane had minimal effects on the duration of action of initial doses of NIMBEX and therefore, no adjustment to the initial dose should be necessary when NIMBEX is administered shortly after initiation of volatile agents.", "drug1": "NIMBEX", "drug2": "NIMBEX", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s8", "pair_id": "DDI-DrugBank.d60.s8.p5"}
{"sentence": "Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.", "drug1": "digoxin", "drug2": "nifedipine", "relation": "ADVISE", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s7", "pair_id": "DDI-DrugBank.d373.s7.p2"}
{"sentence": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. ", "drug1": "3H-spiroperidol", "drug2": "apomorphine", "relation": "NONE", "source_file": "2857100.xml", "sentence_id": "DDI-MedLine.d15.s0", "pair_id": "DDI-MedLine.d15.s0.p14"}
{"sentence": "Concurrent therapy with ORENCIA and TNF antagonists is not recommended.", "drug1": "ORENCIA", "drug2": "TNF antagonists", "relation": "ADVISE", "source_file": "Abatacept_ddi.xml", "sentence_id": "DDI-DrugBank.d297.s4", "pair_id": "DDI-DrugBank.d297.s4.p0"}
{"sentence": "Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.", "drug1": "organophosphate insecticide", "drug2": "carbamate insecticide", "relation": "NONE", "source_file": "Echothiophate Iodide_ddi.xml", "sentence_id": "DDI-DrugBank.d377.s0", "pair_id": "DDI-DrugBank.d377.s0.p9"}
{"sentence": "Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.", "drug1": "valdecoxib", "drug2": "omeprazole", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s39", "pair_id": "DDI-DrugBank.d328.s39.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "antibiotics", "drug2": "fenoprofen", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p322"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "clozapine", "drug2": "propafenone", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p4"}
{"sentence": "Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).", "drug1": "Cimetidine", "drug2": "dofetilide", "relation": "MECHANISM", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s3", "pair_id": "DDI-DrugBank.d558.s3.p0"}
{"sentence": "SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.", "drug1": "SUBOXONE", "drug2": "benzodiazepines", "relation": "ADVISE", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s6", "pair_id": "DDI-DrugBank.d380.s6.p2"}
{"sentence": "Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.", "drug1": "Anafranil", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s24", "pair_id": "DDI-DrugBank.d238.s24.p3"}
{"sentence": "Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.", "drug1": "Acarbose", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s5", "pair_id": "DDI-DrugBank.d536.s5.p0"}
{"sentence": "The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. ", "drug1": "macrolide antibiotics", "drug2": "hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors", "relation": "EFFECT", "source_file": "11197581.xml", "sentence_id": "DDI-MedLine.d25.s10", "pair_id": "DDI-MedLine.d25.s10.p0"}
{"sentence": "Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.", "drug1": "Codeine", "drug2": "narcotic analgesics", "relation": "EFFECT", "source_file": "Codeine_ddi.xml", "sentence_id": "DDI-DrugBank.d464.s0", "pair_id": "DDI-DrugBank.d464.s0.p0"}
{"sentence": "Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.", "drug1": "Uricosuric drugs", "drug2": "nitrofurantoin", "relation": "MECHANISM", "source_file": "Nitrofurantoin_ddi.xml", "sentence_id": "DDI-DrugBank.d276.s2", "pair_id": "DDI-DrugBank.d276.s2.p2"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "Cataflam", "drug2": "etodolac", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p222"}
{"sentence": "Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.", "drug1": "cephalexin", "drug2": "metformin", "relation": "MECHANISM", "source_file": "Cephalexin_ddi.xml", "sentence_id": "DDI-DrugBank.d303.s0", "pair_id": "DDI-DrugBank.d303.s0.p4"}
{"sentence": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.", "drug1": "ketoconazole", "drug2": "gefitinib", "relation": "MECHANISM", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s4", "pair_id": "DDI-DrugBank.d207.s4.p2"}
{"sentence": "In vitro studies evaluating the minimum inhibitory concentration (MIC) of vancomycin, cefazolin, ampicillin, ampicillin/flucoxacillin, ceftazidime, gentamicin, and amphotericin demonstrated no evidence of incompatibility of these antibiotics with EXTRANEAL.", "drug1": "gentamicin", "drug2": "EXTRANEAL", "relation": "NONE", "source_file": "Icodextrin_ddi.xml", "sentence_id": "DDI-DrugBank.d501.s10", "pair_id": "DDI-DrugBank.d501.s10.p32"}
{"sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "ciprofloxacin", "drug2": "calcium", "relation": "NONE", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s8", "pair_id": "DDI-DrugBank.d43.s8.p16"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "cholestyramine", "drug2": "ethchlorvynol", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p173"}
{"sentence": "Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.", "drug1": "flurbiprofen", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s12", "pair_id": "DDI-DrugBank.d529.s12.p20"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "sodium colistimethate", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p8"}
{"sentence": "However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.", "drug1": "clozapine", "drug2": "sertraline", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s22", "pair_id": "DDI-DrugBank.d480.s22.p6"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "gentamicin", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p2"}
{"sentence": "A 30 to 45% increase in AUC and Cmax of nisoldipine was observed with concomitant administration of cimetidine 400 mg twice daily.", "drug1": "nisoldipine", "drug2": "cimetidine 400 mg", "relation": "MECHANISM", "source_file": "Nisoldipine_ddi.xml", "sentence_id": "DDI-DrugBank.d106.s0", "pair_id": "DDI-DrugBank.d106.s0.p0"}
{"sentence": "Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.", "drug1": "anticoagulants", "drug2": "chlordiazepoxide", "relation": "EFFECT", "source_file": "Chlordiazepoxide_ddi.xml", "sentence_id": "DDI-DrugBank.d336.s0", "pair_id": "DDI-DrugBank.d336.s0.p0"}
{"sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "drug1": "hormonal contraceptives", "drug2": "temazepam", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s17", "pair_id": "DDI-DrugBank.d485.s17.p14"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "Tegretol", "drug2": "estrogens", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p89"}
{"sentence": "Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.", "drug1": "Barbiturates", "drug2": "doxycycline", "relation": "MECHANISM", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s4", "pair_id": "DDI-DrugBank.d500.s4.p2"}
{"sentence": "Enhanced theophylline clearance secondary to phenytoin therapy.\r\n", "drug1": "theophylline", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "3967572.xml", "sentence_id": "DDI-MedLine.d7.s0", "pair_id": "DDI-MedLine.d7.s0.p0"}
{"sentence": "These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; ", "drug1": "ethanol", "drug2": "acetaldehyde", "relation": "EFFECT", "source_file": "7653281.xml", "sentence_id": "DDI-MedLine.d107.s9", "pair_id": "DDI-MedLine.d107.s9.p0"}
{"sentence": "Alcohol: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.", "drug1": "Alcohol", "drug2": "vardenafil", "relation": "NONE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s38", "pair_id": "DDI-DrugBank.d198.s38.p1"}
{"sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "drug1": "Rifampin", "drug2": "norethindrone", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s36", "pair_id": "DDI-DrugBank.d485.s36.p6"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "benzodiazepines", "drug2": "diltiazem", "relation": "NONE", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p52"}
{"sentence": "All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.", "drug1": "vasopressors", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "ADVISE", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s1", "pair_id": "DDI-DrugBank.d247.s1.p0"}
{"sentence": "Absorption of tetracycline is impaired by bismuth subsalicylate.", "drug1": "tetracycline", "drug2": "bismuth subsalicylate", "relation": "MECHANISM", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s3", "pair_id": "DDI-DrugBank.d500.s3.p0"}
{"sentence": "Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.", "drug1": "Folic acid", "drug2": "phenobarbital", "relation": "EFFECT", "source_file": "Leucovorin_ddi.xml", "sentence_id": "DDI-DrugBank.d151.s0", "pair_id": "DDI-DrugBank.d151.s0.p0"}
{"sentence": "Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.", "drug1": "dexfenfluramine", "drug2": "MAO inhibitor", "relation": "ADVISE", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s1", "pair_id": "DDI-DrugBank.d423.s1.p2"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "central nervous system depressants", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p13"}
{"sentence": "Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.", "drug1": "Aprepitant", "drug2": "ritonavir", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s31", "pair_id": "DDI-DrugBank.d382.s31.p5"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "clofibrate", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p18"}
{"sentence": "Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ", "drug1": "glutethimide", "drug2": "coumarin drugs", "relation": "ADVISE", "source_file": "1109248.xml", "sentence_id": "DDI-MedLine.d106.s6", "pair_id": "DDI-MedLine.d106.s6.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "allopurinol", "drug2": "dextrothyroxine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p119"}
{"sentence": "Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).", "drug1": "heparin", "drug2": "antithrombin III", "relation": "ADVISE", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s4", "pair_id": "DDI-DrugBank.d488.s4.p0"}
{"sentence": "In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.", "drug1": "metformin", "drug2": "dofetilide", "relation": "ADVISE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s22", "pair_id": "DDI-DrugBank.d558.s22.p4"}
{"sentence": "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.", "drug1": "alprazolam", "drug2": "benzodiazepines", "relation": "NONE", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s8", "pair_id": "DDI-DrugBank.d131.s8.p13"}
{"sentence": "Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;", "drug1": "Amphetamines", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s23", "pair_id": "DDI-DrugBank.d236.s23.p2"}
{"sentence": "Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).", "drug1": "enalapril", "drug2": "antihypertensive agents", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s3", "pair_id": "DDI-DrugBank.d107.s3.p3"}
{"sentence": "Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.", "drug1": "procainamide", "drug2": "amiodarone", "relation": "NONE", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s27", "pair_id": "DDI-DrugBank.d143.s27.p17"}
{"sentence": "Drugs that may have their plasma concentration altered by dasatinib CYP3A4 Substrates: Dasatinib is a time-dependent inhibitor of CYP3A4.", "drug1": "dasatinib", "drug2": "Dasatinib", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s14", "pair_id": "DDI-DrugBank.d48.s14.p0"}
{"sentence": "It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.", "drug1": "Vardenafil", "drug2": "indinavir", "relation": "ADVISE", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s11", "pair_id": "DDI-DrugBank.d198.s11.p0"}
{"sentence": "Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.", "drug1": "barbiturates", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s18", "pair_id": "DDI-DrugBank.d314.s18.p3"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "loratadine", "drug2": "troleandomycin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p292"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "amiodarone", "drug2": "triazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p68"}
{"sentence": "Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; ", "drug1": "secobarbital", "drug2": "glutethimide", "relation": "NONE", "source_file": "1109248.xml", "sentence_id": "DDI-MedLine.d106.s4", "pair_id": "DDI-MedLine.d106.s4.p2"}
{"sentence": "A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.", "drug1": "cimetidine", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s12", "pair_id": "DDI-DrugBank.d565.s12.p2"}
{"sentence": "therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.", "drug1": "nelfinavir", "drug2": "didanosine", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s26", "pair_id": "DDI-DrugBank.d340.s26.p0"}
{"sentence": "Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.", "drug1": "Flurbiprofen", "drug2": "anti-coagulants", "relation": "EFFECT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s2", "pair_id": "DDI-DrugBank.d529.s2.p4"}
{"sentence": "Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.", "drug1": "Isoflurane", "drug2": "enflurane", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s3", "pair_id": "DDI-DrugBank.d267.s3.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "alfentanyl", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p132"}
{"sentence": "If a diuretic is also used, it may increase the risk of lithium toxicity.", "drug1": "diuretic", "drug2": "lithium", "relation": "EFFECT", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s20", "pair_id": "DDI-DrugBank.d175.s20.p0"}
{"sentence": "aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and methadone concurrently, and evidence of decreased plasma concentrations of methadone.", "drug1": "nevirapine", "drug2": "methadone", "relation": "EFFECT", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s58", "pair_id": "DDI-DrugBank.d270.s58.p0"}
{"sentence": "Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.", "drug1": "SPRYCEL", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s1", "pair_id": "DDI-DrugBank.d48.s1.p9"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect of insulin: corticosteroids, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "phenothiazine derivatives", "drug2": "thyroid hormones", "relation": "NONE", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s2", "pair_id": "DDI-DrugBank.d527.s2.p91"}
{"sentence": "Ergotamine: Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.", "drug1": "erythromycin", "drug2": "dihydroergotamine", "relation": "EFFECT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s23", "pair_id": "DDI-DrugBank.d522.s23.p4"}
{"sentence": "Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of grepafloxacin on theophylline indicates that grepafloxacin inhibits theophylline metabolism, which is mediated by CYP1A2.", "drug1": "grepafloxacin", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s11", "pair_id": "DDI-DrugBank.d78.s11.p5"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "terfenadine", "drug2": "Antimycobacterial agents", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p64"}
{"sentence": "Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.", "drug1": "iron", "drug2": "ranitidine", "relation": "NONE", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s2", "pair_id": "DDI-DrugBank.d75.s2.p22"}
{"sentence": "Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.", "drug1": "dirithromycin", "drug2": "antacids", "relation": "MECHANISM", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s15", "pair_id": "DDI-DrugBank.d522.s15.p9"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "Antihistamines", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p3"}
{"sentence": "Fluconazole, and the 5-HT3 antiemetics ondansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX.", "drug1": "Fluconazole", "drug2": "Zofran", "relation": "NONE", "source_file": "Busulfan_ddi.xml", "sentence_id": "DDI-DrugBank.d72.s1", "pair_id": "DDI-DrugBank.d72.s1.p2"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "carbamazepine", "drug2": "sildenafil", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p36"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Tegretol", "drug2": "vitamin C", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p394"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "allopurinol", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1"}
{"sentence": "Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.", "drug1": "butorphanol", "drug2": "barbiturates", "relation": "EFFECT", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s0", "pair_id": "DDI-DrugBank.d246.s0.p2"}
{"sentence": "Patients who are treated with ZYVOX and concomitant serotonergic agents should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).", "drug1": "ZYVOX", "drug2": "serotonergic agents", "relation": "EFFECT", "source_file": "Linezolid_ddi.xml", "sentence_id": "DDI-DrugBank.d441.s7", "pair_id": "DDI-DrugBank.d441.s7.p0"}
{"sentence": "Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.", "drug1": "duloxetine", "drug2": "duloxetine", "relation": "NONE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s3", "pair_id": "DDI-DrugBank.d548.s3.p1"}
{"sentence": "Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.", "drug1": "apraclonidine", "drug2": "beta-blockers", "relation": "ADVISE", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s8", "pair_id": "DDI-DrugBank.d224.s8.p0"}
{"sentence": "Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.", "drug1": "Cephalosporins", "drug2": "cefazolin", "relation": "NONE", "source_file": "Menadione_ddi.xml", "sentence_id": "DDI-DrugBank.d139.s1", "pair_id": "DDI-DrugBank.d139.s1.p12"}
{"sentence": "Antacid: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.", "drug1": "atorvastatin", "drug2": "Maalox TC", "relation": "MECHANISM", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s1", "pair_id": "DDI-DrugBank.d140.s1.p3"}
{"sentence": "Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine. ", "drug1": "trovafloxacin", "drug2": "morphine", "relation": "MECHANISM", "source_file": "11210403.xml", "sentence_id": "DDI-MedLine.d124.s1", "pair_id": "DDI-MedLine.d124.s1.p2"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "phenobarbital", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p7"}
{"sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "drug1": "butyrophenones", "drug2": "APOKYN", "relation": "EFFECT", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s3", "pair_id": "DDI-DrugBank.d357.s3.p41"}
{"sentence": "Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.", "drug1": "itraconazole", "drug2": "almotriptan", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s11", "pair_id": "DDI-DrugBank.d299.s11.p8"}
{"sentence": "Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.", "drug1": "triazolam", "drug2": "tiagabine", "relation": "ADVISE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s23", "pair_id": "DDI-DrugBank.d277.s23.p2"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "magnesium", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p7"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "itraconazole", "drug2": "contraceptives", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p743"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "Flupenthixol", "drug2": "Tricyclic antidepressants", "relation": "EFFECT", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p65"}
{"sentence": "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.", "drug1": "anticholinesterase agents", "drug2": "corticosteroid", "relation": "ADVISE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s5", "pair_id": "DDI-DrugBank.d314.s5.p0"}
{"sentence": "Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.", "drug1": "amphetamines", "drug2": "acidifying agents", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s21", "pair_id": "DDI-DrugBank.d236.s21.p3"}
{"sentence": "When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.", "drug1": "sympathomimetic drugs", "drug2": "monoamine oxidase inhibitors", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s2", "pair_id": "DDI-DrugBank.d448.s2.p0"}
{"sentence": "Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.", "drug1": "b-lactam antibiotics", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Loracarbef_ddi.xml", "sentence_id": "DDI-DrugBank.d351.s0", "pair_id": "DDI-DrugBank.d351.s0.p5"}
{"sentence": "In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.", "drug1": "isoflurane", "drug2": "NIMBEX", "relation": "ADVISE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s9", "pair_id": "DDI-DrugBank.d60.s9.p2"}
{"sentence": "Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, tricyclic antidepressants, phenothiazines.", "drug1": "CNS depressants", "drug2": "tricyclic antidepressants", "relation": "NONE", "source_file": "Chlorpheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d235.s2", "pair_id": "DDI-DrugBank.d235.s2.p1"}
{"sentence": "Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.", "drug1": "ETHYOL", "drug2": "antihypertensive medications", "relation": "ADVISE", "source_file": "Amifostine_ddi.xml", "sentence_id": "DDI-DrugBank.d563.s0", "pair_id": "DDI-DrugBank.d563.s0.p0"}
{"sentence": "These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.", "drug1": "digoxin", "drug2": "amiodarone", "relation": "MECHANISM", "source_file": "3964797.xml", "sentence_id": "DDI-MedLine.d61.s9", "pair_id": "DDI-MedLine.d61.s9.p0"}
{"sentence": "DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.", "drug1": "DOSTINEX", "drug2": "butyrophenones", "relation": "ADVISE", "source_file": "Cabergoline_ddi.xml", "sentence_id": "DDI-DrugBank.d282.s0", "pair_id": "DDI-DrugBank.d282.s0.p1"}
{"sentence": "The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;", "drug1": "penicillin G", "drug2": "colestipol hydrochloride", "relation": "MECHANISM", "source_file": "Colestipol_ddi.xml", "sentence_id": "DDI-DrugBank.d345.s11", "pair_id": "DDI-DrugBank.d345.s11.p11"}
{"sentence": "When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.", "drug1": "idoxuridine", "drug2": "boric acid", "relation": "ADVISE", "source_file": "Idoxuridine_ddi.xml", "sentence_id": "DDI-DrugBank.d91.s2", "pair_id": "DDI-DrugBank.d91.s2.p0"}
{"sentence": "Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.", "drug1": "Clozapine", "drug2": "carbamazepine", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s18", "pair_id": "DDI-DrugBank.d480.s18.p0"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "granisetron", "relation": "NONE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p13"}
{"sentence": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).", "drug1": "Gleevec", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s0", "pair_id": "DDI-DrugBank.d115.s0.p12"}
{"sentence": "Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.", "drug1": "interferon-alfa", "drug2": "PROLEUKIN", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s9", "pair_id": "DDI-DrugBank.d114.s9.p0"}
{"sentence": "There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.", "drug1": "norfloxacin", "drug2": "theophylline", "relation": "EFFECT", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s1", "pair_id": "DDI-DrugBank.d217.s1.p2"}
{"sentence": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.", "drug1": "Intestinal adsorbents", "drug2": "Acarbose", "relation": "MECHANISM", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s4", "pair_id": "DDI-DrugBank.d536.s4.p4"}
{"sentence": "Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.", "drug1": "interleukin-2", "drug2": "radiographic iodinated contrast media", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s11", "pair_id": "DDI-DrugBank.d114.s11.p2"}
{"sentence": "It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. ", "drug1": "magnesium", "drug2": "magnesium", "relation": "NONE", "source_file": "7786695.xml", "sentence_id": "DDI-MedLine.d103.s3", "pair_id": "DDI-MedLine.d103.s3.p5"}
{"sentence": "Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.", "drug1": "chlorprothixene", "drug2": "antiparkinsonian agents", "relation": "ADVISE", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s7", "pair_id": "DDI-DrugBank.d503.s7.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Dilantin", "drug2": "antifungals", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p292"}
{"sentence": "(See CLINICAL PHARMACOLOGY) Coadministration of Femara and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.", "drug1": "Femara", "drug2": "tamoxifen", "relation": "MECHANISM", "source_file": "Letrozole_ddi.xml", "sentence_id": "DDI-DrugBank.d157.s1", "pair_id": "DDI-DrugBank.d157.s1.p0"}
{"sentence": "In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.", "drug1": "ethionamide", "drug2": "cycloserine", "relation": "EFFECT", "source_file": "Ethionamide_ddi.xml", "sentence_id": "DDI-DrugBank.d166.s2", "pair_id": "DDI-DrugBank.d166.s2.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p36"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "didanosine", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p35"}
{"sentence": "Conversely, the coumarin anticoagulants have been reported to increase the serum levels and prolong the serum half-life of phenytoin by inhibiting its metabolism.", "drug1": "coumarin anticoagulants", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Ethotoin_ddi.xml", "sentence_id": "DDI-DrugBank.d359.s4", "pair_id": "DDI-DrugBank.d359.s4.p0"}
{"sentence": "Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied", "drug1": "Antizol", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Fomepizole_ddi.xml", "sentence_id": "DDI-DrugBank.d228.s2", "pair_id": "DDI-DrugBank.d228.s2.p1"}
{"sentence": "- a steroid medicine such as prednisone (Deltasone, Orasone, others), methylprednisolone (Medrol, others), prednisolone (Prelone, Pediapred, others), and others;", "drug1": "steroid medicine", "drug2": "prednisolone", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s7", "pair_id": "DDI-DrugBank.d521.s7.p5"}
{"sentence": "Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.", "drug1": "alfentanil", "drug2": "fentanyl", "relation": "NONE", "source_file": "Dasatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d48.s15", "pair_id": "DDI-DrugBank.d48.s15.p4"}
{"sentence": "Therefore, when EDECRIN and non- steroidal anti- inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.", "drug1": "EDECRIN", "drug2": "non- steroidal anti- inflammatory agents", "relation": "EFFECT", "source_file": "Ethacrynic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d414.s7", "pair_id": "DDI-DrugBank.d414.s7.p0"}
{"sentence": "Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.", "drug1": "ethanol", "drug2": "Antizol", "relation": "MECHANISM", "source_file": "Fomepizole_ddi.xml", "sentence_id": "DDI-DrugBank.d228.s1", "pair_id": "DDI-DrugBank.d228.s1.p0"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "guanethidine", "drug2": "antihistamines", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p75"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "danazol", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p5"}
{"sentence": "the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ", "drug1": "naloxone", "drug2": "morphine", "relation": "EFFECT", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s9", "pair_id": "DDI-MedLine.d30.s9.p1"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "fenoprofen", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p922"}
{"sentence": "Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.", "drug1": "aminoglycosides", "drug2": "MAXIPIME", "relation": "ADVISE", "source_file": "Cefepime_ddi.xml", "sentence_id": "DDI-DrugBank.d378.s0", "pair_id": "DDI-DrugBank.d378.s0.p0"}
{"sentence": "International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking warfarin while on IRESSA therapy.", "drug1": "warfarin", "drug2": "IRESSA", "relation": "EFFECT", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s2", "pair_id": "DDI-DrugBank.d207.s2.p0"}
{"sentence": "Renal clearance measurements of PAH cannot be made with any significant accuracy in patients receiving sulfonamides, procaine, or thiazolesulfone.", "drug1": "PAH", "drug2": "sulfonamides", "relation": "EFFECT", "source_file": "Aminohippurate_ddi.xml", "sentence_id": "DDI-DrugBank.d416.s0", "pair_id": "DDI-DrugBank.d416.s0.p0"}
{"sentence": "Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.", "drug1": "cephalexin", "drug2": "metformin", "relation": "ADVISE", "source_file": "Cephalexin_ddi.xml", "sentence_id": "DDI-DrugBank.d303.s3", "pair_id": "DDI-DrugBank.d303.s3.p2"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "erythromycin", "drug2": "fluoxetine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p198"}
{"sentence": "Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.", "drug1": "phenytoin", "drug2": "doxycycline", "relation": "MECHANISM", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s4", "pair_id": "DDI-DrugBank.d500.s4.p5"}
{"sentence": "The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.", "drug1": "sulfonylurea", "drug2": "chloramphenicol", "relation": "EFFECT", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s0", "pair_id": "DDI-DrugBank.d245.s0.p3"}
{"sentence": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "drug1": "Bezalip", "drug2": "anion-exchange resins", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s9", "pair_id": "DDI-DrugBank.d291.s9.p1"}
{"sentence": "The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ", "drug1": "cocaine", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "7798493.xml", "sentence_id": "DDI-MedLine.d94.s12", "pair_id": "DDI-MedLine.d94.s12.p1"}
{"sentence": "Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.", "drug1": "sodium nitroprusside", "drug2": "INOmax", "relation": "EFFECT", "source_file": "Nitric Oxide_ddi.xml", "sentence_id": "DDI-DrugBank.d183.s2", "pair_id": "DDI-DrugBank.d183.s2.p4"}
{"sentence": "Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.", "drug1": "rifabutin", "drug2": "CRIXIVAN", "relation": "NONE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s84", "pair_id": "DDI-DrugBank.d97.s84.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "oxcarbazepine", "drug2": "quetiapine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p933"}
{"sentence": "Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ", "drug1": "Rifampin", "drug2": "rifampin", "relation": "NONE", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s8", "pair_id": "DDI-MedLine.d3.s8.p2"}
{"sentence": "Catecholamine-depleting drugs, e.g., reserpine, may have an additive effect when given with beta blocking agents.", "drug1": "reserpine", "drug2": "beta blocking agents", "relation": "EFFECT", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s0", "pair_id": "DDI-DrugBank.d422.s0.p0"}
{"sentence": "Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.", "drug1": "Antihistamines", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s0", "pair_id": "DDI-DrugBank.d389.s0.p3"}
{"sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "ciprofloxacin", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s8", "pair_id": "DDI-DrugBank.d43.s8.p21"}
{"sentence": "Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH.", "drug1": "antacids", "drug2": "lactulose", "relation": "MECHANISM", "source_file": "Lactulose_ddi.xml", "sentence_id": "DDI-DrugBank.d206.s0", "pair_id": "DDI-DrugBank.d206.s0.p0"}
{"sentence": "Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.", "drug1": "bosentan", "drug2": "R-warfarin", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s30", "pair_id": "DDI-DrugBank.d289.s30.p4"}
{"sentence": "Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ", "drug1": "Ibogaine", "drug2": "morphine", "relation": "EFFECT", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s9", "pair_id": "DDI-MedLine.d110.s9.p1"}
{"sentence": "Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.", "drug1": "digoxin", "drug2": "Itraconazole", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s16", "pair_id": "DDI-DrugBank.d165.s16.p5"}
{"sentence": "no change in pravastatin AUC and Cmax was observed during diltiazem coadministration.", "drug1": "pravastatin", "drug2": "diltiazem", "relation": "NONE", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s38", "pair_id": "DDI-DrugBank.d565.s38.p0"}
{"sentence": "Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.", "drug1": "tiagabine", "drug2": "carbamazepine", "relation": "MECHANISM", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s10", "pair_id": "DDI-DrugBank.d277.s10.p12"}
{"sentence": "The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).", "drug1": "niacin", "drug2": "estrogens", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s2", "pair_id": "DDI-DrugBank.d313.s2.p24"}
{"sentence": "Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.", "drug1": "antidiabetic agents", "drug2": "VELCADE", "relation": "ADVISE", "source_file": "Bortezomib_ddi.xml", "sentence_id": "DDI-DrugBank.d571.s4", "pair_id": "DDI-DrugBank.d571.s4.p0"}
{"sentence": "Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.", "drug1": "BREVIBLOC", "drug2": "verapamil", "relation": "ADVISE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s13", "pair_id": "DDI-DrugBank.d422.s13.p0"}
{"sentence": "If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.", "drug1": "desipramine hydrochloride", "drug2": "hypnotics", "relation": "EFFECT", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s23", "pair_id": "DDI-DrugBank.d386.s23.p3"}
{"sentence": "It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "drug1": "thiazide diuretics", "drug2": "LEVULAN KERASTICK", "relation": "EFFECT", "source_file": "Aminolevulinic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d379.s1", "pair_id": "DDI-DrugBank.d379.s1.p17"}
{"sentence": "Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "drug1": "lithium", "drug2": "insulin", "relation": "EFFECT", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s3", "pair_id": "DDI-DrugBank.d313.s3.p8"}
{"sentence": "Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. ", "drug1": "Rifampin", "drug2": "warfarin", "relation": "MECHANISM", "source_file": "1115445.xml", "sentence_id": "DDI-MedLine.d116.s2", "pair_id": "DDI-MedLine.d116.s2.p0"}
{"sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "drug1": "Beta Blockers", "drug2": "ergotamine", "relation": "NONE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s3", "pair_id": "DDI-DrugBank.d410.s3.p4"}
{"sentence": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.", "drug1": "progestin", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Norethindrone_ddi.xml", "sentence_id": "DDI-DrugBank.d306.s0", "pair_id": "DDI-DrugBank.d306.s0.p2"}
{"sentence": "Although beta-adrenergic blockers or calcium channel blockers and digoxin may be useful in combination to control atrial fibrillation, their additive effects on AV node conduction can result in advanced or complete heart block.", "drug1": "beta-adrenergic blockers", "drug2": "digoxin", "relation": "EFFECT", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s12", "pair_id": "DDI-DrugBank.d450.s12.p1"}
{"sentence": "Aminoglycosides: The mixing of piperacillin with an aminoglycoside in vitro can result in substantial inactivation of the aminoglycoside.", "drug1": "piperacillin", "drug2": "aminoglycoside", "relation": "EFFECT", "source_file": "Piperacillin_ddi.xml", "sentence_id": "DDI-DrugBank.d462.s0", "pair_id": "DDI-DrugBank.d462.s0.p3"}
{"sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).", "drug1": "foscarnet", "drug2": "zalcitabine", "relation": "MECHANISM", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s18", "pair_id": "DDI-DrugBank.d263.s18.p24"}
{"sentence": "Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).", "drug1": "cimetidine", "drug2": "Xanax", "relation": "ADVISE", "source_file": "Adinazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d449.s1", "pair_id": "DDI-DrugBank.d449.s1.p5"}
{"sentence": "Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.", "drug1": "Lamivudine", "drug2": "zalcitabine", "relation": "EFFECT", "source_file": "Lamivudine_ddi.xml", "sentence_id": "DDI-DrugBank.d71.s5", "pair_id": "DDI-DrugBank.d71.s5.p0"}
{"sentence": "Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.", "drug1": "dicyclomine", "drug2": "cisapride", "relation": "EFFECT", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s3", "pair_id": "DDI-DrugBank.d237.s3.p9"}
{"sentence": "The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.", "drug1": "non-potassium sparing diuretics", "drug2": "beta-agonists", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s4", "pair_id": "DDI-DrugBank.d284.s4.p2"}
{"sentence": "Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.", "drug1": "ergot-type medications", "drug2": "AXERT", "relation": "ADVISE", "source_file": "Almotriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d299.s1", "pair_id": "DDI-DrugBank.d299.s1.p6"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "pertechnetate", "drug2": "mitotane", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p200"}
{"sentence": "At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.", "drug1": "VIOXX", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s20", "pair_id": "DDI-DrugBank.d210.s20.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "antifungals", "drug2": "phenylbutazone", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p516"}
{"sentence": "Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.", "drug1": "indomethacin", "drug2": "potassium-sparing diuretics", "relation": "EFFECT", "source_file": "Amiloride_ddi.xml", "sentence_id": "DDI-DrugBank.d356.s6", "pair_id": "DDI-DrugBank.d356.s6.p0"}
{"sentence": "The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.", "drug1": "beta-adrenergic blocking agents", "drug2": "calcium antagonist", "relation": "EFFECT", "source_file": "Levobunolol_ddi.xml", "sentence_id": "DDI-DrugBank.d252.s4", "pair_id": "DDI-DrugBank.d252.s4.p1"}
{"sentence": "Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.", "drug1": "Potassium-Sparing Diuretics", "drug2": "thiazide diuretics", "relation": "EFFECT", "source_file": "Benazepril_ddi.xml", "sentence_id": "DDI-DrugBank.d561.s3", "pair_id": "DDI-DrugBank.d561.s3.p2"}
{"sentence": "Synergism between xanthine bronchodilators (e.g., theophylline), ephedrine, and other sympathomimetic bronchodilators has been reported.", "drug1": "theophylline", "drug2": "sympathomimetic bronchodilators", "relation": "EFFECT", "source_file": "Dyphylline_ddi.xml", "sentence_id": "DDI-DrugBank.d4.s0", "pair_id": "DDI-DrugBank.d4.s0.p4"}
{"sentence": "Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.", "drug1": "Enoxacin", "drug2": "methylxanthines", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s20", "pair_id": "DDI-DrugBank.d395.s20.p2"}
{"sentence": "Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.", "drug1": "acitretin", "drug2": "ethanol", "relation": "MECHANISM", "source_file": "Acitretin_ddi.xml", "sentence_id": "DDI-DrugBank.d353.s0", "pair_id": "DDI-DrugBank.d353.s0.p5"}
{"sentence": "Imipramine hydrochloride may potentiate the effects of CNS depressant drugs.", "drug1": "Imipramine hydrochloride", "drug2": "CNS depressant drugs", "relation": "EFFECT", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s4", "pair_id": "DDI-DrugBank.d77.s4.p0"}
{"sentence": "Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.", "drug1": "valdecoxib", "drug2": "dextromethorphan", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s18", "pair_id": "DDI-DrugBank.d328.s18.p0"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "epinephrine", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Lidocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d564.s0", "pair_id": "DDI-DrugBank.d564.s0.p6"}
{"sentence": "However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.", "drug1": "clozapine", "drug2": "fluoxetine", "relation": "NONE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s22", "pair_id": "DDI-DrugBank.d480.s22.p2"}
{"sentence": "When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ", "drug1": "rifabutin", "drug2": "ofloxacin", "relation": "EFFECT", "source_file": "11137650.xml", "sentence_id": "DDI-MedLine.d8.s6", "pair_id": "DDI-MedLine.d8.s6.p9"}
{"sentence": "Oral Contraceptives: The effect of oral contraceptives on the pharmacokinetics of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP has not been studied.", "drug1": "Contraceptives", "drug2": "D.H.E. 45", "relation": "NONE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s10", "pair_id": "DDI-DrugBank.d410.s10.p1"}
{"sentence": "Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.", "drug1": "Clozapine", "drug2": "antihypertensive drugs", "relation": "EFFECT", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s9", "pair_id": "DDI-DrugBank.d480.s9.p0"}
{"sentence": "Selegiline - L-phenylalanine and the selective MAO inhibitor selegiline may have synergistic antidepressant activity if used concomitantly.", "drug1": "L-phenylalanine", "drug2": "selegiline", "relation": "EFFECT", "source_file": "L-Phenylalanine_ddi.xml", "sentence_id": "DDI-DrugBank.d530.s2", "pair_id": "DDI-DrugBank.d530.s2.p4"}
{"sentence": "If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.", "drug1": "chlorprothixene", "drug2": "opioids", "relation": "ADVISE", "source_file": "Chlorprothixene_ddi.xml", "sentence_id": "DDI-DrugBank.d503.s2", "pair_id": "DDI-DrugBank.d503.s2.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NUROMAX", "drug2": "tetracyclines", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p2"}
{"sentence": "Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ", "drug1": "phenobarbital", "drug2": "acetaminophen", "relation": "EFFECT", "source_file": "11206047.xml", "sentence_id": "DDI-MedLine.d111.s14", "pair_id": "DDI-MedLine.d111.s14.p9"}
{"sentence": "Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.", "drug1": "LEVSIN", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s0", "pair_id": "DDI-DrugBank.d142.s0.p6"}
{"sentence": "The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.", "drug1": "benzodiazepines", "drug2": "narcotics", "relation": "EFFECT", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s3", "pair_id": "DDI-DrugBank.d335.s3.p1"}
{"sentence": "Antidepressants, tricyclic: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;", "drug1": "tricyclic", "drug2": "sympathomimetic agents", "relation": "NONE", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s7", "pair_id": "DDI-DrugBank.d236.s7.p9"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "5-fluorouracil", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p6"}
{"sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "drug1": "terfenadine", "drug2": "astemizole", "relation": "NONE", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s10", "pair_id": "DDI-DrugBank.d397.s10.p5"}
{"sentence": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "drug1": "diclofenac", "drug2": "aspirin", "relation": "NONE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s0", "pair_id": "DDI-DrugBank.d249.s0.p6"}
{"sentence": "When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.", "drug1": "phenobarbital", "drug2": "Nalfon", "relation": "ADVISE", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s4", "pair_id": "DDI-DrugBank.d154.s4.p0"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "Bentiromide", "drug2": "acetaminophen", "relation": "INT", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p0"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "Sucralfate", "drug2": "didanosine", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p19"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "cimetidine", "drug2": "dextrothyroxine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p542"}
{"sentence": "Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.", "drug1": "verapamil", "drug2": "dofetilide", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s7", "pair_id": "DDI-DrugBank.d558.s7.p4"}
{"sentence": "In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. ", "drug1": "temazepam", "drug2": "ethanol", "relation": "MECHANISM", "source_file": "9120829.xml", "sentence_id": "DDI-MedLine.d113.s3", "pair_id": "DDI-MedLine.d113.s3.p1"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "felodipine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p17"}
{"sentence": "Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.", "drug1": "Videx", "drug2": "norfloxacin", "relation": "ADVISE", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s12", "pair_id": "DDI-DrugBank.d217.s12.p1"}
{"sentence": "Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "drug1": "alcohol", "drug2": "insulin", "relation": "EFFECT", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s3", "pair_id": "DDI-DrugBank.d527.s3.p9"}
{"sentence": "Therefore, concomitant use of TORADOL and probenecid is contraindicated.", "drug1": "TORADOL", "drug2": "probenecid", "relation": "ADVISE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s10", "pair_id": "DDI-DrugBank.d3.s10.p0"}
{"sentence": "We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. ", "drug1": "8-phenyltheophylline", "drug2": "8-cyclopentyl-1,3-dipropylxanthine", "relation": "NONE", "source_file": "7746025.xml", "sentence_id": "DDI-MedLine.d51.s1", "pair_id": "DDI-MedLine.d51.s1.p7"}
{"sentence": "Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.", "drug1": "amantadine", "drug2": "central nervous system stimulants", "relation": "ADVISE", "source_file": "Amantadine_ddi.xml", "sentence_id": "DDI-DrugBank.d116.s0", "pair_id": "DDI-DrugBank.d116.s0.p0"}
{"sentence": "Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.", "drug1": "temazepam", "drug2": "ethanol", "relation": "MECHANISM", "source_file": "9120829.xml", "sentence_id": "DDI-MedLine.d113.s0", "pair_id": "DDI-MedLine.d113.s0.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "mirtazapine", "drug2": "ziprasidone", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p880"}
{"sentence": "Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.", "drug1": "naltrexone", "drug2": "Acamprosate", "relation": "MECHANISM", "source_file": "Acamprosate_ddi.xml", "sentence_id": "DDI-DrugBank.d0.s2", "pair_id": "DDI-DrugBank.d0.s2.p0"}
{"sentence": "- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.", "drug1": "sulphonylureas", "drug2": "Bezalip", "relation": "EFFECT", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s3", "pair_id": "DDI-DrugBank.d291.s3.p1"}
{"sentence": "Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.", "drug1": "Probenecid", "drug2": "cephalosporins", "relation": "MECHANISM", "source_file": "Cefazolin_ddi.xml", "sentence_id": "DDI-DrugBank.d281.s0", "pair_id": "DDI-DrugBank.d281.s0.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Invirase", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p27"}
{"sentence": "Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.", "drug1": "Bosentan", "drug2": "atorvastatin", "relation": "MECHANISM", "source_file": "Bosentan_ddi.xml", "sentence_id": "DDI-DrugBank.d289.s27", "pair_id": "DDI-DrugBank.d289.s27.p2"}
{"sentence": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "drug1": "EPA", "drug2": "Ginkgo biloba", "relation": "INT", "source_file": "Icosapent_ddi.xml", "sentence_id": "DDI-DrugBank.d35.s0", "pair_id": "DDI-DrugBank.d35.s0.p3"}
{"sentence": "Diuretics: Studies in normal volunteers have shown that flurbiprofen like other nonsteroidal anti-inflammatory drugs, can interfere with the effects of furosemide.", "drug1": "flurbiprofen", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s14", "pair_id": "DDI-DrugBank.d529.s14.p4"}
{"sentence": "Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.", "drug1": "Anticoagulants", "drug2": "cefixime", "relation": "EFFECT", "source_file": "Cefixime_ddi.xml", "sentence_id": "DDI-DrugBank.d339.s2", "pair_id": "DDI-DrugBank.d339.s2.p2"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "troleandomycin", "drug2": "valproate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p345"}
{"sentence": "H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.", "drug1": "Cimetidine", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s10", "pair_id": "DDI-DrugBank.d237.s10.p4"}
{"sentence": "INDOCIN given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.", "drug1": "INDOCIN", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s21", "pair_id": "DDI-DrugBank.d82.s21.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "valproate", "drug2": "verapamil", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p348"}
{"sentence": "May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).", "drug1": "famotidine", "drug2": "lansoprazole", "relation": "NONE", "source_file": "Diatrizoate_ddi.xml", "sentence_id": "DDI-DrugBank.d293.s0", "pair_id": "DDI-DrugBank.d293.s0.p28"}
{"sentence": "Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.", "drug1": "beta-adrenoceptor blocking agents", "drug2": "nonsteroidal anti-inflammatory drugs", "relation": "EFFECT", "source_file": "Acebutolol_ddi.xml", "sentence_id": "DDI-DrugBank.d388.s4", "pair_id": "DDI-DrugBank.d388.s4.p0"}
{"sentence": "The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.", "drug1": "quinolones", "drug2": "glyburide", "relation": "EFFECT", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s7", "pair_id": "DDI-DrugBank.d217.s7.p1"}
{"sentence": "- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives", "drug1": "Lofexidine", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Lofexidine_ddi.xml", "sentence_id": "DDI-DrugBank.d454.s0", "pair_id": "DDI-DrugBank.d454.s0.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "clonazepam", "drug2": "glucocorticoids", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p342"}
{"sentence": "Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ", "drug1": "Rifampin", "drug2": "amprenavir", "relation": "MECHANISM", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s8", "pair_id": "DDI-MedLine.d3.s8.p0"}
{"sentence": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "drug1": "methotrexate", "drug2": "methotrexate", "relation": "NONE", "source_file": "L-Methionine_ddi.xml", "sentence_id": "DDI-DrugBank.d528.s0", "pair_id": "DDI-DrugBank.d528.s0.p6"}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "NSAIDs", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s6", "pair_id": "DDI-DrugBank.d400.s6.p3"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "didanosine", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p10"}
{"sentence": "Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).", "drug1": "EPA", "drug2": "ginkgo", "relation": "INT", "source_file": "Icosapent_ddi.xml", "sentence_id": "DDI-DrugBank.d35.s0", "pair_id": "DDI-DrugBank.d35.s0.p2"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "polymyxins", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p5"}
{"sentence": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.", "drug1": "disopyramide", "drug2": "fibrates", "relation": "NONE", "source_file": "Insulin recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d313.s1", "pair_id": "DDI-DrugBank.d313.s1.p19"}
{"sentence": "Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.", "drug1": "EULEXIN", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Flutamide_ddi.xml", "sentence_id": "DDI-DrugBank.d442.s1", "pair_id": "DDI-DrugBank.d442.s1.p2"}
{"sentence": "Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing AEDs.", "drug1": "levetiracetam", "drug2": "AEDs", "relation": "MECHANISM", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s13", "pair_id": "DDI-DrugBank.d212.s13.p2"}
{"sentence": "The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.", "drug1": "sodium nitroprusside", "drug2": "hypotensive drugs", "relation": "EFFECT", "source_file": "Nitroprusside_ddi.xml", "sentence_id": "DDI-DrugBank.d394.s0", "pair_id": "DDI-DrugBank.d394.s0.p0"}
{"sentence": "Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.", "drug1": "L-methionine", "drug2": "methotrexate", "relation": "EFFECT", "source_file": "L-Methionine_ddi.xml", "sentence_id": "DDI-DrugBank.d528.s0", "pair_id": "DDI-DrugBank.d528.s0.p8"}
{"sentence": "Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;", "drug1": "Phenobarbital", "drug2": "Amphetamines", "relation": "NONE", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s23", "pair_id": "DDI-DrugBank.d236.s23.p0"}
{"sentence": "Concomitant treatment with thrombolytics (eg, rt-PA or streptokinase) may: - increase the risk of bleeding complications - considerably enhance the effect of REFLUDAN on aPTT prolongation", "drug1": "thrombolytics", "drug2": "REFLUDAN", "relation": "NONE", "source_file": "Lepirudin_ddi.xml", "sentence_id": "DDI-DrugBank.d52.s0", "pair_id": "DDI-DrugBank.d52.s0.p1"}
{"sentence": "WelChol  was found to have no significant effect on the bioavailability of digoxin, lovastatin, metoprolol, quinidine, valproic acid, and warfarin.", "drug1": "metoprolol", "drug2": "quinidine", "relation": "NONE", "source_file": "Colesevelam_ddi.xml", "sentence_id": "DDI-DrugBank.d551.s1", "pair_id": "DDI-DrugBank.d551.s1.p15"}
{"sentence": "Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.", "drug1": "ciprofloxacin", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s16", "pair_id": "DDI-DrugBank.d123.s16.p7"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "angiotensin-converting enzyme inhibitors", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p17"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "disulfiram", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p17"}
{"sentence": "However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. ", "drug1": "theophylline", "drug2": "CGS21680", "relation": "EFFECT", "source_file": "7746025.xml", "sentence_id": "DDI-MedLine.d51.s4", "pair_id": "DDI-MedLine.d51.s4.p0"}
{"sentence": "CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ", "drug1": "HMG-CoA reductase inhibitors", "drug2": "simvastatin", "relation": "NONE", "source_file": "11197581.xml", "sentence_id": "DDI-MedLine.d25.s12", "pair_id": "DDI-MedLine.d25.s12.p8"}
{"sentence": "Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).", "drug1": "Nafazodone", "drug2": "Xanax", "relation": "ADVISE", "source_file": "Adinazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d449.s1", "pair_id": "DDI-DrugBank.d449.s1.p2"}
{"sentence": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "drug1": "aspirin", "drug2": "Nalfon", "relation": "MECHANISM", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s2", "pair_id": "DDI-DrugBank.d154.s2.p9"}
{"sentence": "Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.", "drug1": "diazepam", "drug2": "Valium", "relation": "NONE", "source_file": "Heroin_ddi.xml", "sentence_id": "DDI-DrugBank.d514.s2", "pair_id": "DDI-DrugBank.d514.s2.p18"}
{"sentence": "This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. ", "drug1": "theophylline", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "3967572.xml", "sentence_id": "DDI-MedLine.d7.s1", "pair_id": "DDI-MedLine.d7.s1.p0"}
{"sentence": "A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported.", "drug1": "miconazole", "drug2": "hypoglycemic agents", "relation": "EFFECT", "source_file": "Glibenclamide_ddi.xml", "sentence_id": "DDI-DrugBank.d178.s9", "pair_id": "DDI-DrugBank.d178.s9.p0"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "Antacids", "drug2": "aluminum", "relation": "NONE", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p4"}
{"sentence": "For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral anticoagulants and vitamin K, the net effects are unpredictable.", "drug1": "anticoagulants", "drug2": "vitamin K", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s3", "pair_id": "DDI-DrugBank.d64.s3.p2"}
{"sentence": "Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.", "drug1": "Quinolones", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s24", "pair_id": "DDI-DrugBank.d516.s24.p4"}
{"sentence": "Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.", "drug1": "Amphetamines", "drug2": "antihypertensives", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s11", "pair_id": "DDI-DrugBank.d158.s11.p2"}
{"sentence": "Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.", "drug1": "magnesium", "drug2": "Ibandronate", "relation": "MECHANISM", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s1", "pair_id": "DDI-DrugBank.d440.s1.p8"}
{"sentence": "Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.", "drug1": "diltiazem", "drug2": "rifampin", "relation": "ADVISE", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s42", "pair_id": "DDI-DrugBank.d565.s42.p0"}
{"sentence": "In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives", "drug1": "broad-spectrum antibiotics", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Clavulanate_ddi.xml", "sentence_id": "DDI-DrugBank.d419.s5", "pair_id": "DDI-DrugBank.d419.s5.p1"}
{"sentence": "Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.", "drug1": "Aripiprazole", "drug2": "aripiprazole", "relation": "NONE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s16", "pair_id": "DDI-DrugBank.d509.s16.p1"}
{"sentence": "Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.", "drug1": "macrolide antibiotics", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s3", "pair_id": "DDI-DrugBank.d450.s3.p12"}
{"sentence": "Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.", "drug1": "ethchlorvynol", "drug2": "amitriptyline HCl", "relation": "EFFECT", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s26", "pair_id": "DDI-DrugBank.d99.s26.p0"}
{"sentence": "ETHANOL / NUTRITION / HERB INTERACTIONS: Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine.", "drug1": "caffeine", "drug2": "combination hormonal contraceptives", "relation": "NONE", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s43", "pair_id": "DDI-DrugBank.d485.s43.p3"}
{"sentence": "In general, most patients treated with dirithromycin who are receiving concomitant theophylline therapy may not require empiric adjustment of theophylline dosage or monitoring of theophylline plasma concentrations.", "drug1": "dirithromycin", "drug2": "theophylline", "relation": "NONE", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s13", "pair_id": "DDI-DrugBank.d522.s13.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "sulfamethoxazole", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p52"}
{"sentence": "Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.", "drug1": "ketoconazole", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s7", "pair_id": "DDI-DrugBank.d165.s7.p0"}
{"sentence": "Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.", "drug1": "BREVIBLOC", "drug2": "norepinephrine", "relation": "ADVISE", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s15", "pair_id": "DDI-DrugBank.d422.s15.p2"}
{"sentence": "Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.", "drug1": "thiazides", "drug2": "vitamin D", "relation": "EFFECT", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s5", "pair_id": "DDI-DrugBank.d404.s5.p0"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "cimetidine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p2"}
{"sentence": "These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ", "drug1": "nimodipine", "drug2": "omega-agatoxin VIA", "relation": "NONE", "source_file": "11137351.xml", "sentence_id": "DDI-MedLine.d58.s7", "pair_id": "DDI-MedLine.d58.s7.p13"}
{"sentence": "Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .", "drug1": "TARCEVA", "drug2": "saquinavir", "relation": "ADVISE", "source_file": "Erlotinib_ddi.xml", "sentence_id": "DDI-DrugBank.d456.s1", "pair_id": "DDI-DrugBank.d456.s1.p8"}
{"sentence": "Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.", "drug1": "NSAID", "drug2": "methotrexate", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s5", "pair_id": "DDI-DrugBank.d249.s5.p10"}
{"sentence": "Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.", "drug1": "PROLEUKIN", "drug2": "dacarbazine", "relation": "EFFECT", "source_file": "Aldesleukin_ddi.xml", "sentence_id": "DDI-DrugBank.d114.s5", "pair_id": "DDI-DrugBank.d114.s5.p1"}
{"sentence": "Phenothiazines - Taking piperazine and a phenothiazine together may increase the risk of convulsions (seizures).", "drug1": "piperazine", "drug2": "phenothiazine", "relation": "EFFECT", "source_file": "Piperazine_ddi.xml", "sentence_id": "DDI-DrugBank.d326.s0", "pair_id": "DDI-DrugBank.d326.s0.p2"}
{"sentence": "Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.", "drug1": "Erythromycin", "drug2": "astemizole", "relation": "MECHANISM", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s10", "pair_id": "DDI-DrugBank.d397.s10.p2"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "antihistamines", "drug2": "Tegretol", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p63"}
{"sentence": "Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.", "drug1": "tricyclic antidepressants", "drug2": "anticholinergic", "relation": "EFFECT", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s20", "pair_id": "DDI-DrugBank.d99.s20.p0"}
{"sentence": "The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "drug1": "codeine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s0", "pair_id": "DDI-DrugBank.d398.s0.p0"}
{"sentence": "Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.", "drug1": "hydrochlorothiazide", "drug2": "anionic exchange resins", "relation": "MECHANISM", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s4", "pair_id": "DDI-DrugBank.d162.s4.p9"}
{"sentence": "- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "drug1": "Oruvail", "drug2": "nabumetone", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s2", "pair_id": "DDI-DrugBank.d521.s2.p187"}
{"sentence": "Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.", "drug1": "anesthetics", "drug2": "INAPSINE", "relation": "EFFECT", "source_file": "Droperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d254.s0", "pair_id": "DDI-DrugBank.d254.s0.p14"}
{"sentence": "Clonidine hydrochloride may enhance the CNS-depressive effects of alcohol, barbiturates or other sedatives.", "drug1": "Clonidine hydrochloride", "drug2": "sedatives", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s1", "pair_id": "DDI-DrugBank.d495.s1.p2"}
{"sentence": "In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.", "drug1": "warfarin", "drug2": "Aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s17", "pair_id": "DDI-DrugBank.d382.s17.p0"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "fentanyl", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p29"}
{"sentence": "If you are also using a steroid inhaler, take bitolterol first and then wait about 15 minutes before using the steroid inhaler.", "drug1": "bitolterol", "drug2": "steroid", "relation": "ADVISE", "source_file": "Bitolterol_ddi.xml", "sentence_id": "DDI-DrugBank.d560.s1", "pair_id": "DDI-DrugBank.d560.s1.p2"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "cinchophen", "drug2": "influenza virus vaccine", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p593"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "antibiotics", "drug2": "colistin", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p35"}
{"sentence": "Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy.", "drug1": "steroids", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Fludrocortisone_ddi.xml", "sentence_id": "DDI-DrugBank.d526.s14", "pair_id": "DDI-DrugBank.d526.s14.p2"}
{"sentence": "The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.", "drug1": "tetracycline", "drug2": "methoxyflurane", "relation": "EFFECT", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s5", "pair_id": "DDI-DrugBank.d500.s5.p1"}
{"sentence": "Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.", "drug1": "Clidinium", "drug2": "phenothiazines", "relation": "EFFECT", "source_file": "Clidinium_ddi.xml", "sentence_id": "DDI-DrugBank.d322.s1", "pair_id": "DDI-DrugBank.d322.s1.p0"}
{"sentence": "Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.", "drug1": "bromocriptine mesylate", "drug2": "haloperidol", "relation": "EFFECT", "source_file": "Bromocriptine_ddi.xml", "sentence_id": "DDI-DrugBank.d272.s2", "pair_id": "DDI-DrugBank.d272.s2.p1"}
{"sentence": "Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.", "drug1": "amprenavir", "drug2": "methadone", "relation": "MECHANISM", "source_file": "Amprenavir_ddi.xml", "sentence_id": "DDI-DrugBank.d437.s10", "pair_id": "DDI-DrugBank.d437.s10.p0"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "aminoglycosides", "drug2": "sodium colistimethate", "relation": "NONE", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s5", "pair_id": "DDI-DrugBank.d267.s5.p33"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "Chlorotrianisene", "drug2": "aspirin", "relation": "INT", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p1"}
{"sentence": "Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.", "drug1": "HMG-CoA reductase inhibitor", "drug2": "spironolactone", "relation": "ADVISE", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s17", "pair_id": "DDI-DrugBank.d140.s17.p1"}
{"sentence": "- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.", "drug1": "coumarin", "drug2": "digitoxin", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s19", "pair_id": "DDI-DrugBank.d40.s19.p33"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "clofibrate", "drug2": "methyldopa", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p637"}
{"sentence": "In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.", "drug1": "heparin", "drug2": "Activase", "relation": "EFFECT", "source_file": "Alteplase_ddi.xml", "sentence_id": "DDI-DrugBank.d508.s1", "pair_id": "DDI-DrugBank.d508.s1.p4"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, seriraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "SSRIs", "drug2": "fluoxetine", "relation": "NONE", "source_file": "Desipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d386.s10", "pair_id": "DDI-DrugBank.d386.s10.p3"}
{"sentence": "Medroxyprogesterone Acetate - L-histidine was observed to enhance (in tissue culture) the effect of medroxyprogesterone acetate in reducing the number of human breast cancer cells that were in the S phase.", "drug1": "L-histidine", "drug2": "medroxyprogesterone acetate", "relation": "EFFECT", "source_file": "L-Histidine_ddi.xml", "sentence_id": "DDI-DrugBank.d365.s0", "pair_id": "DDI-DrugBank.d365.s0.p2"}
{"sentence": "Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.", "drug1": "aprepitant", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s41", "pair_id": "DDI-DrugBank.d382.s41.p4"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "haloperidol", "drug2": "tramadol", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p729"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Theo-Dur", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p42"}
{"sentence": "Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.", "drug1": "eplerenone", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s3", "pair_id": "DDI-DrugBank.d20.s3.p0"}
{"sentence": "Aminoglutethimide: May increase CYP metabolism of progestins leading to possible decrease in contraceptive effectiveness.", "drug1": "Aminoglutethimide", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s6", "pair_id": "DDI-DrugBank.d485.s6.p0"}
{"sentence": "Heparin Sodium Injection should not be mixed with doxorubicin, droperidol, ciprofloxacin, or mitoxantrone, since it has been reported that these drugs are incompatible with heparin and a precipitate may form.", "drug1": "Heparin Sodium", "drug2": "droperidol", "relation": "NONE", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s7", "pair_id": "DDI-DrugBank.d488.s7.p1"}
{"sentence": "When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "drug1": "CANCIDAS", "drug2": "efavirenz", "relation": "ADVISE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s14", "pair_id": "DDI-DrugBank.d350.s14.p0"}
{"sentence": "Valproate: Felbatol  causes an increase in steady-state valproate concentrations.", "drug1": "Felbatol", "drug2": "valproate", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s22", "pair_id": "DDI-DrugBank.d434.s22.p2"}
{"sentence": "Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.", "drug1": "atorvastatin", "drug2": "ethinyl estradiol", "relation": "MECHANISM", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s10", "pair_id": "DDI-DrugBank.d140.s10.p6"}
{"sentence": "Elevated plasma levels of theophylline have been reported with concomitant quinolone use.", "drug1": "theophylline", "drug2": "quinolone", "relation": "MECHANISM", "source_file": "Nalidixic Acid_ddi.xml", "sentence_id": "DDI-DrugBank.d427.s0", "pair_id": "DDI-DrugBank.d427.s0.p0"}
{"sentence": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.", "drug1": "progestin", "drug2": "rifampin", "relation": "EFFECT", "source_file": "Norethindrone_ddi.xml", "sentence_id": "DDI-DrugBank.d306.s0", "pair_id": "DDI-DrugBank.d306.s0.p5"}
{"sentence": "Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "indinavir", "drug2": "cisapride", "relation": "NONE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s12", "pair_id": "DDI-DrugBank.d237.s12.p6"}
{"sentence": "Cimetidine: Cimetidine increases nicardipine HCl plasma levels.", "drug1": "Cimetidine", "drug2": "nicardipine HCl", "relation": "MECHANISM", "source_file": "Nicardipine_ddi.xml", "sentence_id": "DDI-DrugBank.d468.s2", "pair_id": "DDI-DrugBank.d468.s2.p2"}
{"sentence": "While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).", "drug1": "cyclosporine", "drug2": "cyclosporine", "relation": "NONE", "source_file": "16649344.xml", "sentence_id": "DDI-MedLine.d118.s3", "pair_id": "DDI-MedLine.d118.s3.p5"}
{"sentence": "Ketoconazole: Concomitant use of ketoconazole is contraindicated.", "drug1": "Ketoconazole", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s9", "pair_id": "DDI-DrugBank.d558.s9.p0"}
{"sentence": "Tricyclic Antidepressants: Use of thyroid products with imipramine and other tricyclic antidepressants may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed.", "drug1": "thyroid products", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s15", "pair_id": "DDI-DrugBank.d54.s15.p4"}
{"sentence": "Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.", "drug1": "clozapine", "drug2": "antidepressants", "relation": "ADVISE", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s30", "pair_id": "DDI-DrugBank.d480.s30.p0"}
{"sentence": "Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels.", "drug1": "Amphetamines", "drug2": "corticosteroid", "relation": "INT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s29", "pair_id": "DDI-DrugBank.d236.s29.p0"}
{"sentence": "However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.", "drug1": "clozapine", "drug2": "paroxetine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s22", "pair_id": "DDI-DrugBank.d480.s22.p4"}
{"sentence": "Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;", "drug1": "Cholestyramine", "drug2": "fat soluble vitamins", "relation": "MECHANISM", "source_file": "Calcitriol_ddi.xml", "sentence_id": "DDI-DrugBank.d384.s0", "pair_id": "DDI-DrugBank.d384.s0.p27"}
{"sentence": "Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s5", "pair_id": "DDI-DrugBank.d415.s5.p5"}
{"sentence": "However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.", "drug1": "INDOCIN", "drug2": "anticoagulant", "relation": "ADVISE", "source_file": "Indomethacin_ddi.xml", "sentence_id": "DDI-DrugBank.d82.s6", "pair_id": "DDI-DrugBank.d82.s6.p0"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "quinolones", "drug2": "calcium", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p3"}
{"sentence": "However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.", "drug1": "Tagamet", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s4", "pair_id": "DDI-DrugBank.d171.s4.p0"}
{"sentence": "The effect of concomitant administration of fluconazole and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers.", "drug1": "fluconazole", "drug2": "glipizide", "relation": "INT", "source_file": "Glipizide_ddi.xml", "sentence_id": "DDI-DrugBank.d225.s11", "pair_id": "DDI-DrugBank.d225.s11.p0"}
{"sentence": "Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.", "drug1": "CRIXIVAN", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Indinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d97.s78", "pair_id": "DDI-DrugBank.d97.s78.p0"}
{"sentence": "In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.", "drug1": "docetaxel", "drug2": "erythromycin", "relation": "MECHANISM", "source_file": "Docetaxel_ddi.xml", "sentence_id": "DDI-DrugBank.d371.s1", "pair_id": "DDI-DrugBank.d371.s1.p3"}
{"sentence": "A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of selective serotonin reuptake inhibitors (SSRIs) and agents for migraine therapy, such as Imitrex (sumatriptan succinate) and dihydroergotamine.", "drug1": "selective serotonin reuptake inhibitors", "drug2": "sumatriptan succinate", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s4", "pair_id": "DDI-DrugBank.d423.s4.p2"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "procainamide", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p8"}
{"sentence": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "drug1": "Tagamet", "drug2": "lidocaine", "relation": "MECHANISM", "source_file": "Cimetidine_ddi.xml", "sentence_id": "DDI-DrugBank.d171.s0", "pair_id": "DDI-DrugBank.d171.s0.p7"}
{"sentence": "Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.", "drug1": "acetaminophen", "drug2": "caffeine", "relation": "EFFECT", "source_file": "3969689.xml", "sentence_id": "DDI-MedLine.d55.s0", "pair_id": "DDI-MedLine.d55.s0.p0"}
{"sentence": "ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).", "drug1": "INSPRA", "drug2": "ACE inhibitors", "relation": "EFFECT", "source_file": "Eplerenone_ddi.xml", "sentence_id": "DDI-DrugBank.d20.s6", "pair_id": "DDI-DrugBank.d20.s6.p7"}
{"sentence": "Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "drug1": "erythromycin", "drug2": "cisapride", "relation": "MECHANISM", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s2", "pair_id": "DDI-DrugBank.d237.s2.p10"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "rifampin", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p39"}
{"sentence": "Antacids may interfere with the absorption of LEVSIN.", "drug1": "Antacids", "drug2": "LEVSIN", "relation": "MECHANISM", "source_file": "Hyoscyamine_ddi.xml", "sentence_id": "DDI-DrugBank.d142.s1", "pair_id": "DDI-DrugBank.d142.s1.p0"}
{"sentence": "Probenecid: As with other b-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.", "drug1": "probenecid", "drug2": "cefdinir", "relation": "NONE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s4", "pair_id": "DDI-DrugBank.d420.s4.p8"}
{"sentence": "Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.", "drug1": "Nabilone", "drug2": "diazepam", "relation": "EFFECT", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s1", "pair_id": "DDI-DrugBank.d552.s1.p0"}
{"sentence": "Other TNFa-blocking agents (including REMICADE) used in combination with anakinra may also result in similar toxicities.", "drug1": "REMICADE", "drug2": "anakinra", "relation": "EFFECT", "source_file": "Infliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d45.s1", "pair_id": "DDI-DrugBank.d45.s1.p2"}
{"sentence": "However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.", "drug1": "quinolone antimicrobial", "drug2": "warfarin", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s4", "pair_id": "DDI-DrugBank.d347.s4.p5"}
{"sentence": "Corticotropin may accentuate the electrolyte loss associated with diuretic therapy.", "drug1": "Corticotropin", "drug2": "diuretic", "relation": "EFFECT", "source_file": "Cosyntropin_ddi.xml", "sentence_id": "DDI-DrugBank.d439.s0", "pair_id": "DDI-DrugBank.d439.s0.p0"}
{"sentence": "Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.", "drug1": "quinolones", "drug2": "caffeine", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s3", "pair_id": "DDI-DrugBank.d78.s3.p12"}
{"sentence": "In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.", "drug1": "allopurinol", "drug2": "azathioprine", "relation": "ADVISE", "source_file": "Allopurinol_ddi.xml", "sentence_id": "DDI-DrugBank.d413.s4", "pair_id": "DDI-DrugBank.d413.s4.p19"}
{"sentence": "Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.", "drug1": "Diuretic agents", "drug2": "epinephrine", "relation": "EFFECT", "source_file": "Epinephrine_ddi.xml", "sentence_id": "DDI-DrugBank.d247.s8", "pair_id": "DDI-DrugBank.d247.s8.p0"}
{"sentence": "As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.", "drug1": "HALDOL", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s3", "pair_id": "DDI-DrugBank.d186.s3.p8"}
{"sentence": "If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.", "drug1": "phenytoin", "drug2": "Norpace CR", "relation": "MECHANISM", "source_file": "Disopyramide_ddi.xml", "sentence_id": "DDI-DrugBank.d506.s0", "pair_id": "DDI-DrugBank.d506.s0.p1"}
{"sentence": "Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.", "drug1": "Ketoconazole", "drug2": "methylprednisolone", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s10", "pair_id": "DDI-DrugBank.d458.s10.p2"}
{"sentence": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications", "drug1": "fluoxetine", "drug2": "ketoconazole", "relation": "NONE", "source_file": "Fluoxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d482.s14", "pair_id": "DDI-DrugBank.d482.s14.p127"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "clozapine", "drug2": "Phenytoin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p391"}
{"sentence": "- Cholestyramine and colestipol resins: Cholestytamine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract", "drug1": "Cholestyramine", "drug2": "colestipol", "relation": "NONE", "source_file": "Chlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d46.s7", "pair_id": "DDI-DrugBank.d46.s7.p3"}
{"sentence": "plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.", "drug1": "cimetidine", "drug2": "CMI", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s6", "pair_id": "DDI-DrugBank.d238.s6.p14"}
{"sentence": "Taking a rauwolfia alkaloid while you are taking or within 2 weeks of taking MAO inhibitors may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.", "drug1": "rauwolfia alkaloid", "drug2": "MAO inhibitors", "relation": "EFFECT", "source_file": "Deserpidine_ddi.xml", "sentence_id": "DDI-DrugBank.d311.s0", "pair_id": "DDI-DrugBank.d311.s0.p0"}
{"sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).", "drug1": "TORADOL", "drug2": "antiepileptic drugs", "relation": "EFFECT", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s18", "pair_id": "DDI-DrugBank.d3.s18.p4"}
{"sentence": "Antihistamines: Amphetamines may counteract the sedative effect of antihistamines.", "drug1": "Amphetamines", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s10", "pair_id": "DDI-DrugBank.d158.s10.p2"}
{"sentence": "Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.", "drug1": "Cyclopropane", "drug2": "dopamine", "relation": "EFFECT", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s8", "pair_id": "DDI-DrugBank.d325.s8.p2"}
{"sentence": "In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.", "drug1": "amphotericin B", "drug2": "hydrocortisone", "relation": "EFFECT", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s2", "pair_id": "DDI-DrugBank.d314.s2.p0"}
{"sentence": "MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics", "drug1": "DURAGESIC", "drug2": "MAOI", "relation": "ADVISE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s7", "pair_id": "DDI-DrugBank.d170.s7.p4"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "cisapride", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p6"}
{"sentence": "Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.", "drug1": "erythromycin", "drug2": "corticosteroids", "relation": "MECHANISM", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s19", "pair_id": "DDI-DrugBank.d314.s19.p5"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "dalfopristin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p4"}
{"sentence": "Warfarin: Quinolones may enhance the effects of the oral anticoagulant, warfarin, or its derivatives.", "drug1": "Quinolones", "drug2": "anticoagulant", "relation": "EFFECT", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s24", "pair_id": "DDI-DrugBank.d516.s24.p3"}
{"sentence": "Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.", "drug1": "amphotericin B", "drug2": "digitalis", "relation": "EFFECT", "source_file": "Amphotericin B_ddi.xml", "sentence_id": "DDI-DrugBank.d318.s5", "pair_id": "DDI-DrugBank.d318.s5.p2"}
{"sentence": "- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics", "drug1": "sulfapyridine", "drug2": "antidiabetics", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s37", "pair_id": "DDI-DrugBank.d179.s37.p5"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "doxycycline", "drug2": "glucocorticoids", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p573"}
{"sentence": "However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.", "drug1": "STADOL NS", "drug2": "sumatriptan", "relation": "MECHANISM", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s3", "pair_id": "DDI-DrugBank.d246.s3.p2"}
{"sentence": "Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.", "drug1": "acetaminophen", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Butalbital_ddi.xml", "sentence_id": "DDI-DrugBank.d559.s1", "pair_id": "DDI-DrugBank.d559.s1.p16"}
{"sentence": "Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.", "drug1": "antacids", "drug2": "aluminum", "relation": "NONE", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s1", "pair_id": "DDI-DrugBank.d78.s1.p12"}
{"sentence": "Oral contraceptives may be less effective while you are taking lymecycline.", "drug1": "contraceptives", "drug2": "lymecycline", "relation": "EFFECT", "source_file": "Lymecycline_ddi.xml", "sentence_id": "DDI-DrugBank.d79.s1", "pair_id": "DDI-DrugBank.d79.s1.p0"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "tacrolimus", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p99"}
{"sentence": "However, because bleeding has been reported when ibuprofen and other nonsteroidal anti-inflammatory agents have been administered to patients on coumarin-type anticoagulants, the physician should be cautious when administering ibuprofen to patients on anticoagulants.", "drug1": "coumarin-type anticoagulants", "drug2": "anticoagulants", "relation": "NONE", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s1", "pair_id": "DDI-DrugBank.d415.s1.p8"}
{"sentence": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "drug1": "WELLBUTRIN", "drug2": "steroids", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s22", "pair_id": "DDI-DrugBank.d5.s22.p3"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "dalfopristin", "drug2": "fluoxetine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p124"}
{"sentence": "Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.", "drug1": "levothyroxine sodium", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s3", "pair_id": "DDI-DrugBank.d411.s3.p14"}
{"sentence": "The pharmacokinetics of naltrexone and its major metabolite 6-beta-naltrexol were unaffected following co-administration with Acamprosate.", "drug1": "naltrexone", "drug2": "Acamprosate", "relation": "NONE", "source_file": "Acamprosate_ddi.xml", "sentence_id": "DDI-DrugBank.d0.s4", "pair_id": "DDI-DrugBank.d0.s4.p1"}
{"sentence": "Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.", "drug1": "chloroquine", "drug2": "cyclosporin", "relation": "MECHANISM", "source_file": "Chloroquine_ddi.xml", "sentence_id": "DDI-DrugBank.d429.s6", "pair_id": "DDI-DrugBank.d429.s6.p2"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "anti-anxiety drugs", "drug2": "sparfloxacin", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p16"}
{"sentence": "Carbamazepine: Carbamazepine causes an approximate 50% increase in the clearance of Felbatol  at steady state and, therefore, the addition of carbamazepine results in an approximate 40% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "Carbamazepine", "drug2": "Felbatol", "relation": "MECHANISM", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s31", "pair_id": "DDI-DrugBank.d434.s31.p5"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "salicylates", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1447"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "Phenytoin", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p5"}
{"sentence": "Sucralfate should not be taken within 2 hours of FACTIVE.", "drug1": "Sucralfate", "drug2": "FACTIVE", "relation": "ADVISE", "source_file": "Gemifloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d347.s8", "pair_id": "DDI-DrugBank.d347.s8.p0"}
{"sentence": "Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "drug1": "MYOBLOC", "drug2": "aminoglycosides", "relation": "ADVISE", "source_file": "Botulinum Toxin Type B_ddi.xml", "sentence_id": "DDI-DrugBank.d323.s0", "pair_id": "DDI-DrugBank.d323.s0.p0"}
{"sentence": "Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.", "drug1": "tricyclic antidepressants", "drug2": "clidinium", "relation": "EFFECT", "source_file": "Clidinium_ddi.xml", "sentence_id": "DDI-DrugBank.d322.s0", "pair_id": "DDI-DrugBank.d322.s0.p4"}
{"sentence": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "drug1": "diazepam", "drug2": "valdecoxib", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s48", "pair_id": "DDI-DrugBank.d328.s48.p0"}
{"sentence": "Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given with levodopa or carbidopa-levodopa combination products.", "drug1": "LODOSYN", "drug2": "carbidopa", "relation": "NONE", "source_file": "Carbidopa_ddi.xml", "sentence_id": "DDI-DrugBank.d47.s0", "pair_id": "DDI-DrugBank.d47.s0.p2"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "carbamazepine", "drug2": "lovastatin", "relation": "NONE", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p33"}
{"sentence": "Ketoconazole - Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.", "drug1": "citalopram", "drug2": "ketoconazole", "relation": "MECHANISM", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s25", "pair_id": "DDI-DrugBank.d568.s25.p4"}
{"sentence": "Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.", "drug1": "NIMBEX", "drug2": "succinylcholine", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s0", "pair_id": "DDI-DrugBank.d60.s0.p0"}
{"sentence": "Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.", "drug1": "ethoxzolamide", "drug2": "corticosteroids", "relation": "EFFECT", "source_file": "Ethoxzolamide_ddi.xml", "sentence_id": "DDI-DrugBank.d286.s2", "pair_id": "DDI-DrugBank.d286.s2.p2"}
{"sentence": "The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied.", "drug1": "iron", "drug2": "cefdinir", "relation": "NONE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s7", "pair_id": "DDI-DrugBank.d420.s7.p1"}
{"sentence": "If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.", "drug1": "beta-blocker", "drug2": "beta blockers", "relation": "NONE", "source_file": "Atenolol_ddi.xml", "sentence_id": "DDI-DrugBank.d73.s5", "pair_id": "DDI-DrugBank.d73.s5.p3"}
{"sentence": "Methotrexate: Ketoprofen, like other NSAIDs, may cause changes in the elimination of methotrexate leading to elevated serum levels of the drug and increased toxicity.", "drug1": "NSAIDs", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s22", "pair_id": "DDI-DrugBank.d499.s22.p5"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "trifluoperazine", "drug2": "triflupromazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p286"}
{"sentence": "There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.", "drug1": "sucralfate", "drug2": "anagrelide", "relation": "MECHANISM", "source_file": "Anagrelide_ddi.xml", "sentence_id": "DDI-DrugBank.d75.s15", "pair_id": "DDI-DrugBank.d75.s15.p0"}
{"sentence": "In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.", "drug1": "digoxin", "drug2": "dofetilide", "relation": "EFFECT", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s28", "pair_id": "DDI-DrugBank.d558.s28.p0"}
{"sentence": "Lithium carbonate: The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate.", "drug1": "amphetamines", "drug2": "lithium carbonate", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s15", "pair_id": "DDI-DrugBank.d158.s15.p2"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "foscarnet", "drug2": "non-steroidal anti-inflammatory agents", "relation": "NONE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p41"}
{"sentence": "Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.", "drug1": "quinolone", "drug2": "iron", "relation": "MECHANISM", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s8", "pair_id": "DDI-DrugBank.d123.s8.p7"}
{"sentence": "Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.", "drug1": "carbenicillin indanyl sodium", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Carbenicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d545.s0", "pair_id": "DDI-DrugBank.d545.s0.p2"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "atorvastatin", "drug2": "trimethoprim", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p26"}
{"sentence": "Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.", "drug1": "Promethazine", "drug2": "promethazine", "relation": "NONE", "source_file": "Zaleplon_ddi.xml", "sentence_id": "DDI-DrugBank.d324.s12", "pair_id": "DDI-DrugBank.d324.s12.p1"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Viracept", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p30"}
{"sentence": "These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.", "drug1": "contraceptive", "drug2": "atorvastatin", "relation": "ADVISE", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s11", "pair_id": "DDI-DrugBank.d140.s11.p0"}
{"sentence": "Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.", "drug1": "carbamazepine", "drug2": "lamotrigine", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s14", "pair_id": "DDI-DrugBank.d212.s14.p6"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p25"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "antibiotics", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p2"}
{"sentence": "Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "quinolone antibiotics", "drug2": "aluminum", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s12", "pair_id": "DDI-DrugBank.d43.s12.p3"}
{"sentence": "In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23 day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady state conditions to normal healthy male and female volunteers.", "drug1": "fluoxetine", "drug2": "cimetidine", "relation": "NONE", "source_file": "Desloratadine_ddi.xml", "sentence_id": "DDI-DrugBank.d67.s1", "pair_id": "DDI-DrugBank.d67.s1.p8"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "risperidone", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p9"}
{"sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "drug1": "troleandomycin", "drug2": "clarithromycin", "relation": "NONE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s2", "pair_id": "DDI-DrugBank.d170.s2.p22"}
{"sentence": "Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)", "drug1": "Ketoconazole", "drug2": "Nefazodone", "relation": "NONE", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s5", "pair_id": "DDI-DrugBank.d567.s5.p11"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "chlordiazepoxide", "drug2": "vitamin C", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p169"}
{"sentence": "In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.", "drug1": "cyclosporine", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "Diltiazem_ddi.xml", "sentence_id": "DDI-DrugBank.d565.s26", "pair_id": "DDI-DrugBank.d565.s26.p1"}
{"sentence": "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.", "drug1": "selective serotonin reuptake inhibitors", "drug2": "sertraline", "relation": "NONE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s16", "pair_id": "DDI-DrugBank.d238.s16.p2"}
{"sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).", "drug1": "dihydroergotamine", "drug2": "FROVA", "relation": "ADVISE", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s1", "pair_id": "DDI-DrugBank.d426.s1.p8"}
{"sentence": "The effect of corticosteroids on oral anticoagulants is variable.", "drug1": "corticosteroids", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s7", "pair_id": "DDI-DrugBank.d487.s7.p0"}
{"sentence": "If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.", "drug1": "enoxacin", "drug2": "digoxin", "relation": "EFFECT", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s8", "pair_id": "DDI-DrugBank.d395.s8.p4"}
{"sentence": "It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.", "drug1": "butorphanol", "drug2": "erythromycin", "relation": "ADVISE", "source_file": "Butorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d246.s12", "pair_id": "DDI-DrugBank.d246.s12.p0"}
{"sentence": "Other nonsteroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide diuretics in some studies and with potassium-sparing diuretics.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "potassium-sparing diuretics", "relation": "EFFECT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s16", "pair_id": "DDI-DrugBank.d529.s16.p1"}
{"sentence": "Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.", "drug1": "Amphetamines", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s22", "pair_id": "DDI-DrugBank.d236.s22.p2"}
{"sentence": "Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.", "drug1": "Vardenafil", "drug2": "ritonavir", "relation": "MECHANISM", "source_file": "Vardenafil_ddi.xml", "sentence_id": "DDI-DrugBank.d198.s36", "pair_id": "DDI-DrugBank.d198.s36.p7"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "delavirdine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p10"}
{"sentence": "Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.", "drug1": "opiates", "drug2": "sedatives", "relation": "NONE", "source_file": "Brimonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d138.s0", "pair_id": "DDI-DrugBank.d138.s0.p18"}
{"sentence": "The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.", "drug1": "phenytoin", "drug2": "warfarin", "relation": "NONE", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s8", "pair_id": "DDI-DrugBank.d172.s8.p19"}
{"sentence": "A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.", "drug1": "amiodarone", "drug2": "indinavir", "relation": "MECHANISM", "source_file": "Amiodarone_ddi.xml", "sentence_id": "DDI-DrugBank.d143.s10", "pair_id": "DDI-DrugBank.d143.s10.p0"}
{"sentence": "MAO inhibitors MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.", "drug1": "MAO inhibitors", "drug2": "furazolidone", "relation": "NONE", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s6", "pair_id": "DDI-DrugBank.d158.s6.p1"}
{"sentence": "H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.", "drug1": "famotidine", "drug2": "cefditoren pivoxil", "relation": "MECHANISM", "source_file": "Cefditoren_ddi.xml", "sentence_id": "DDI-DrugBank.d550.s2", "pair_id": "DDI-DrugBank.d550.s2.p2"}
{"sentence": "Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride", "drug1": "VIRACEPT", "drug2": "ergot derivatives", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s6", "pair_id": "DDI-DrugBank.d340.s6.p6"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "anticonvulsants", "drug2": "Tegretol", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p251"}
{"sentence": "Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations and the numerous preparations containing salicylates.", "drug1": "estrogens", "drug2": "contraceptives", "relation": "NONE", "source_file": "Liothyronine_ddi.xml", "sentence_id": "DDI-DrugBank.d54.s24", "pair_id": "DDI-DrugBank.d54.s24.p18"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "MAOIs", "drug2": "serotoninergic agents", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p9"}
{"sentence": "Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.", "drug1": "WELLBUTRIN", "drug2": "antipsychotics", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s22", "pair_id": "DDI-DrugBank.d5.s22.p0"}
{"sentence": "- Lofexidine may enhance the CNS depressive effects of alcohol, barbiturates and other sedatives", "drug1": "Lofexidine", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Lofexidine_ddi.xml", "sentence_id": "DDI-DrugBank.d454.s0", "pair_id": "DDI-DrugBank.d454.s0.p0"}
{"sentence": "Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.", "drug1": "Acellular vaccines", "drug2": "RAPTIVA", "relation": "ADVISE", "source_file": "Efalizumab_ddi.xml", "sentence_id": "DDI-DrugBank.d44.s2", "pair_id": "DDI-DrugBank.d44.s2.p2"}
{"sentence": "Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.", "drug1": "dantrolene", "drug2": "vecuronium", "relation": "EFFECT", "source_file": "Dantrolene_ddi.xml", "sentence_id": "DDI-DrugBank.d305.s7", "pair_id": "DDI-DrugBank.d305.s7.p0"}
{"sentence": "The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.", "drug1": "SSRI", "drug2": "TCA", "relation": "EFFECT", "source_file": "Amitriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d99.s9", "pair_id": "DDI-DrugBank.d99.s9.p0"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "ethionamide", "drug2": "thiazide diuretics", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p389"}
{"sentence": "Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.", "drug1": "EQUETROTM", "drug2": "primidone", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s8", "pair_id": "DDI-DrugBank.d94.s8.p6"}
{"sentence": "Clarithromycin exposure was significantly decreased by nevirapine;", "drug1": "Clarithromycin", "drug2": "nevirapine", "relation": "MECHANISM", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s18", "pair_id": "DDI-DrugBank.d270.s18.p0"}
{"sentence": "Anticoagulants: Combination hormonal contraceptives may increase or decrease the effects of coumarin derivatives.", "drug1": "hormonal contraceptives", "drug2": "coumarin derivatives", "relation": "EFFECT", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s10", "pair_id": "DDI-DrugBank.d485.s10.p2"}
{"sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "drug1": "thioxanthenes", "drug2": "APOKYN", "relation": "EFFECT", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s3", "pair_id": "DDI-DrugBank.d357.s3.p43"}
{"sentence": "Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.", "drug1": "colestipol", "drug2": "hydrochlorothiazide", "relation": "MECHANISM", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s5", "pair_id": "DDI-DrugBank.d162.s5.p4"}
{"sentence": "Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines", "drug1": "Accutane", "drug2": "tetracyclines", "relation": "ADVISE", "source_file": "Isotretinoin_ddi.xml", "sentence_id": "DDI-DrugBank.d163.s2", "pair_id": "DDI-DrugBank.d163.s2.p4"}
{"sentence": "In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.", "drug1": "felbamate", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s15", "pair_id": "DDI-DrugBank.d434.s15.p2"}
{"sentence": "Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.", "drug1": "live vaccines", "drug2": "RAPTIVA", "relation": "ADVISE", "source_file": "Efalizumab_ddi.xml", "sentence_id": "DDI-DrugBank.d44.s2", "pair_id": "DDI-DrugBank.d44.s2.p4"}
{"sentence": "ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.", "drug1": "ketoconazole", "drug2": "indinavir", "relation": "NONE", "source_file": "Buprenorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d380.s2", "pair_id": "DDI-DrugBank.d380.s2.p4"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "anticonvulsants", "drug2": "Sporanox", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p258"}
{"sentence": "FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.", "drug1": "alcohol", "drug2": "CNS depressants", "relation": "NONE", "source_file": "Cyclobenzaprine_ddi.xml", "sentence_id": "DDI-DrugBank.d150.s1", "pair_id": "DDI-DrugBank.d150.s1.p4"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "quinine", "drug2": "warfarin sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p1429"}
{"sentence": "When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.", "drug1": "digoxin", "drug2": "BREVIBLOC", "relation": "MECHANISM", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s4", "pair_id": "DDI-DrugBank.d422.s4.p0"}
{"sentence": "DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.", "drug1": "DOSTINEX", "drug2": "thioxanthines", "relation": "ADVISE", "source_file": "Cabergoline_ddi.xml", "sentence_id": "DDI-DrugBank.d282.s0", "pair_id": "DDI-DrugBank.d282.s0.p2"}
{"sentence": "Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h).", "drug1": "Simulect", "drug2": "mycophenolate mofetil", "relation": "NONE", "source_file": "Basiliximab_ddi.xml", "sentence_id": "DDI-DrugBank.d544.s4", "pair_id": "DDI-DrugBank.d544.s4.p1"}
{"sentence": "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.", "drug1": "corticosteroids", "drug2": "diuretics", "relation": "ADVISE", "source_file": "Dexamethasone_ddi.xml", "sentence_id": "DDI-DrugBank.d314.s1", "pair_id": "DDI-DrugBank.d314.s1.p4"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "felodipine", "drug2": "mirtazapine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p665"}
{"sentence": "Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);", "drug1": "magnesium salicylate", "drug2": "bismuth subsalicylate", "relation": "NONE", "source_file": "Glimepiride_ddi.xml", "sentence_id": "DDI-DrugBank.d521.s1", "pair_id": "DDI-DrugBank.d521.s1.p73"}
{"sentence": "Quinidine at 648 mg bid decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration.", "drug1": "Quinidine", "drug2": "nisoldipine", "relation": "MECHANISM", "source_file": "Nisoldipine_ddi.xml", "sentence_id": "DDI-DrugBank.d106.s8", "pair_id": "DDI-DrugBank.d106.s8.p0"}
{"sentence": "Antibiotics (e.g., erythromycin, trimethoprim and sulfamethoxazole, amoxicillin).", "drug1": "Antibiotics", "drug2": "amoxicillin", "relation": "NONE", "source_file": "Doxazosin_ddi.xml", "sentence_id": "DDI-DrugBank.d367.s11", "pair_id": "DDI-DrugBank.d367.s11.p3"}
{"sentence": "Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.", "drug1": "erythromycins", "drug2": "penicillins", "relation": "EFFECT", "source_file": "Ampicillin_ddi.xml", "sentence_id": "DDI-DrugBank.d211.s2", "pair_id": "DDI-DrugBank.d211.s2.p11"}
{"sentence": "Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of diclofenac therapy.", "drug1": "phenobarbital", "drug2": "diclofenac", "relation": "EFFECT", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s17", "pair_id": "DDI-DrugBank.d249.s17.p2"}
{"sentence": "Based on total ertapenem concentrations, probenecid increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.", "drug1": "ertapenem", "drug2": "probenecid", "relation": "MECHANISM", "source_file": "Ertapenem_ddi.xml", "sentence_id": "DDI-DrugBank.d329.s1", "pair_id": "DDI-DrugBank.d329.s1.p0"}
{"sentence": "Antihypertensives: Amphetamines may antagonize the hypotensive effects of antihypertensives.", "drug1": "Amphetamines", "drug2": "antihypertensives", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s15", "pair_id": "DDI-DrugBank.d236.s15.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "felbamate", "drug2": "haloperidol", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p631"}
{"sentence": "Meperidine: Amphetamines potentiate the analgesic effect of meperidine.", "drug1": "Amphetamines", "drug2": "meperidine", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s20", "pair_id": "DDI-DrugBank.d236.s20.p2"}
{"sentence": "Caution is advised in patients receiving concomitant high-dose aspirin and carbonic anhydrase inhibitors, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.", "drug1": "aspirin", "drug2": "carbonic anhydrase inhibitors", "relation": "ADVISE", "source_file": "Dichlorphenamide_ddi.xml", "sentence_id": "DDI-DrugBank.d36.s0", "pair_id": "DDI-DrugBank.d36.s0.p0"}
{"sentence": "Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "NSAIDs", "drug2": "furosemide", "relation": "EFFECT", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s13", "pair_id": "DDI-DrugBank.d210.s13.p3"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "clofibrate", "drug2": "Atromid-S", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p665"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "salicylates", "drug2": "Starlix", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p13"}
{"sentence": "Corticosteroids may increase the clearance of chronic high dose aspirin.", "drug1": "Corticosteroids", "drug2": "aspirin", "relation": "EFFECT", "source_file": "Cortisone acetate_ddi.xml", "sentence_id": "DDI-DrugBank.d487.s4", "pair_id": "DDI-DrugBank.d487.s4.p0"}
{"sentence": "Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.", "drug1": "bromocriptine", "drug2": "lovastatin", "relation": "NONE", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s24", "pair_id": "DDI-DrugBank.d522.s24.p51"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "nicotinamide", "drug2": "quinupristin", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p318"}
{"sentence": "Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ", "drug1": "18-MC", "drug2": "nicotine", "relation": "EFFECT", "source_file": "11085336.xml", "sentence_id": "DDI-MedLine.d110.s6", "pair_id": "DDI-MedLine.d110.s6.p4"}
{"sentence": "Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. ", "drug1": "magnesium", "drug2": "magnesium", "relation": "NONE", "source_file": "7786695.xml", "sentence_id": "DDI-MedLine.d103.s1", "pair_id": "DDI-MedLine.d103.s1.p10"}
{"sentence": "Antagonism between lincomycin and erythromycin in vitro has been demonstrated.", "drug1": "lincomycin", "drug2": "erythromycin", "relation": "EFFECT", "source_file": "Lincomycin_ddi.xml", "sentence_id": "DDI-DrugBank.d130.s2", "pair_id": "DDI-DrugBank.d130.s2.p0"}
{"sentence": "Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "monoamine oxidase inhibitors", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s14", "pair_id": "DDI-DrugBank.d460.s14.p17"}
{"sentence": "Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.", "drug1": "REVIA", "drug2": "opioid analgesics", "relation": "EFFECT", "source_file": "Naltrexone_ddi.xml", "sentence_id": "DDI-DrugBank.d346.s4", "pair_id": "DDI-DrugBank.d346.s4.p1"}
{"sentence": "Hydrocodone increases gabapentin AUC values by 14%.", "drug1": "Hydrocodone", "drug2": "gabapentin", "relation": "MECHANISM", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s24", "pair_id": "DDI-DrugBank.d438.s24.p0"}
{"sentence": "Analgesic/anti-inflammatory (e.g., acetaminophen, aspirin, codeine and codeine combinations, ibuprofen, indomethacin).", "drug1": "anti-inflammatory", "drug2": "ibuprofen", "relation": "NONE", "source_file": "Doxazosin_ddi.xml", "sentence_id": "DDI-DrugBank.d367.s9", "pair_id": "DDI-DrugBank.d367.s9.p11"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "ethosuximide", "drug2": "fluoxetine", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p153"}
{"sentence": "Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.", "drug1": "dexamethasone", "drug2": "albendazole", "relation": "MECHANISM", "source_file": "Albendazole_ddi.xml", "sentence_id": "DDI-DrugBank.d321.s0", "pair_id": "DDI-DrugBank.d321.s0.p5"}
{"sentence": "Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.", "drug1": "Tricyclic antidepressants", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Apraclonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d224.s2", "pair_id": "DDI-DrugBank.d224.s2.p0"}
{"sentence": "Other depressasnts such as alcohol, barbiturates, and MAOIs may enhance CNS depression when administered with ethchlorvynol.", "drug1": "barbiturates", "drug2": "ethchlorvynol", "relation": "EFFECT", "source_file": "Ethchlorvynol_ddi.xml", "sentence_id": "DDI-DrugBank.d405.s1", "pair_id": "DDI-DrugBank.d405.s1.p4"}
{"sentence": "Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.", "drug1": "Nelfinavir", "drug2": "amprenavir", "relation": "MECHANISM", "source_file": "Amprenavir_ddi.xml", "sentence_id": "DDI-DrugBank.d437.s8", "pair_id": "DDI-DrugBank.d437.s8.p0"}
{"sentence": "Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "drug1": "NIZORAL", "drug2": "triazolam", "relation": "MECHANISM", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s12", "pair_id": "DDI-DrugBank.d458.s12.p1"}
{"sentence": "Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. ", "drug1": "Diazepam", "drug2": "morphine", "relation": "EFFECT", "source_file": "11210678.xml", "sentence_id": "DDI-MedLine.d67.s5", "pair_id": "DDI-MedLine.d67.s5.p0"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "Prolixin", "drug2": "trimeprazine", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p145"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "procainamide", "drug2": "quinidine", "relation": "NONE", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p119"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "indinavir", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p6"}
{"sentence": "or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.", "drug1": "zinc", "drug2": "quinolone", "relation": "MECHANISM", "source_file": "Enoxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d395.s16", "pair_id": "DDI-DrugBank.d395.s16.p2"}
{"sentence": "Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.", "drug1": "Quinolones", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Norfloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d217.s5", "pair_id": "DDI-DrugBank.d217.s5.p2"}
{"sentence": "Combination hormonal contraceptives may also decrease the plasma concentration of acetaminophen.", "drug1": "hormonal contraceptives", "drug2": "acetaminophen", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s3", "pair_id": "DDI-DrugBank.d485.s3.p0"}
{"sentence": "Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.", "drug1": "Sympathomimetic amines", "drug2": "methyldopa", "relation": "EFFECT", "source_file": "Carbinoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d389.s2", "pair_id": "DDI-DrugBank.d389.s2.p2"}
{"sentence": "Oxytocin or other oxytocics (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;", "drug1": "Oxytocin", "drug2": "dinoprost", "relation": "EFFECT", "source_file": "Dinoprost Tromethamine_ddi.xml", "sentence_id": "DDI-DrugBank.d181.s0", "pair_id": "DDI-DrugBank.d181.s0.p1"}
{"sentence": "Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.", "drug1": "astemizole", "drug2": "itraconazole", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s6", "pair_id": "DDI-DrugBank.d165.s6.p5"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;", "drug1": "anticoagulant", "drug2": "adrenocortical steroids", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s6", "pair_id": "DDI-DrugBank.d64.s6.p0"}
{"sentence": "Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.", "drug1": "praziquantel", "drug2": "albendazole sulfoxide", "relation": "MECHANISM", "source_file": "Albendazole_ddi.xml", "sentence_id": "DDI-DrugBank.d321.s1", "pair_id": "DDI-DrugBank.d321.s1.p3"}
{"sentence": "Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.", "drug1": "diclofenac", "drug2": "aspirin", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s0", "pair_id": "DDI-DrugBank.d249.s0.p9"}
{"sentence": "Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).", "drug1": "fluvoxamine", "drug2": "Xanax", "relation": "ADVISE", "source_file": "Adinazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d449.s1", "pair_id": "DDI-DrugBank.d449.s1.p4"}
{"sentence": "These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.", "drug1": "dexamethasone", "drug2": "insulin", "relation": "EFFECT", "source_file": "3881461.xml", "sentence_id": "DDI-MedLine.d12.s7", "pair_id": "DDI-MedLine.d12.s7.p3"}
{"sentence": "Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. ", "drug1": "Methamphetamine", "drug2": "pargyline", "relation": "EFFECT", "source_file": "3871245.xml", "sentence_id": "DDI-MedLine.d73.s4", "pair_id": "DDI-MedLine.d73.s4.p1"}
{"sentence": "Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.", "drug1": "diphenoxylate", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s5", "pair_id": "DDI-DrugBank.d450.s5.p2"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "griseofulvin", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p13"}
{"sentence": "Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.", "drug1": "Targretin", "drug2": "gemfibrozil", "relation": "MECHANISM", "source_file": "Bexarotene_ddi.xml", "sentence_id": "DDI-DrugBank.d467.s4", "pair_id": "DDI-DrugBank.d467.s4.p0"}
{"sentence": "However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.", "drug1": "EXTRANEAL", "drug2": "insulin", "relation": "ADVISE", "source_file": "Icodextrin_ddi.xml", "sentence_id": "DDI-DrugBank.d501.s6", "pair_id": "DDI-DrugBank.d501.s6.p0"}
{"sentence": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.", "drug1": "tricyclic antidepressants", "drug2": "carbamazepine", "relation": "ADVISE", "source_file": "Nortriptyline_ddi.xml", "sentence_id": "DDI-DrugBank.d202.s16", "pair_id": "DDI-DrugBank.d202.s16.p2"}
{"sentence": "SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.", "drug1": "RESIN", "drug2": "RESIN", "relation": "NONE", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s5", "pair_id": "DDI-DrugBank.d566.s5.p4"}
{"sentence": "fluoxetine, fluvoxamine, paroxetine, sertraline).", "drug1": "paroxetine", "drug2": "sertraline", "relation": "NONE", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s8", "pair_id": "DDI-DrugBank.d410.s8.p5"}
{"sentence": "Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).", "drug1": "ethosuximide", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Ethosuximide_ddi.xml", "sentence_id": "DDI-DrugBank.d205.s0", "pair_id": "DDI-DrugBank.d205.s0.p15"}
{"sentence": "Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.", "drug1": "propranolol", "drug2": "ergotamine", "relation": "EFFECT", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s3", "pair_id": "DDI-DrugBank.d410.s3.p14"}
{"sentence": "No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin.", "drug1": "chlordiazepoxide", "drug2": "warfarin", "relation": "NONE", "source_file": "Nizatidine_ddi.xml", "sentence_id": "DDI-DrugBank.d475.s0", "pair_id": "DDI-DrugBank.d475.s0.p14"}
{"sentence": "WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.", "drug1": "WelChol", "drug2": "Calan SR", "relation": "MECHANISM", "source_file": "Colesevelam_ddi.xml", "sentence_id": "DDI-DrugBank.d551.s2", "pair_id": "DDI-DrugBank.d551.s2.p1"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "cyclosporine", "drug2": "saquinavir", "relation": "MECHANISM", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p107"}
{"sentence": "Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, carbamazepine).", "drug1": "TORADOL", "drug2": "carbamazepine", "relation": "EFFECT", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s18", "pair_id": "DDI-DrugBank.d3.s18.p6"}
{"sentence": "Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously. ", "drug1": "Echistatin", "drug2": "contortrostatin", "relation": "EFFECT", "source_file": "10978746.xml", "sentence_id": "DDI-MedLine.d69.s3", "pair_id": "DDI-MedLine.d69.s3.p0"}
{"sentence": "Co-administration of lovastatin, atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril, valsartan, metformin and amlodipine did not result in clinically significant increases in aliskiren exposure.", "drug1": "valsartan", "drug2": "amlodipine", "relation": "NONE", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s1", "pair_id": "DDI-DrugBank.d533.s1.p61"}
{"sentence": "Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.", "drug1": "tricyclic antidepressant", "drug2": "cimetidine", "relation": "EFFECT", "source_file": "Doxepin_ddi.xml", "sentence_id": "DDI-DrugBank.d223.s23", "pair_id": "DDI-DrugBank.d223.s23.p0"}
{"sentence": "Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).", "drug1": "lidocaine", "drug2": "multivitamins", "relation": "NONE", "source_file": "Bentiromide_ddi.xml", "sentence_id": "DDI-DrugBank.d537.s0", "pair_id": "DDI-DrugBank.d537.s0.p79"}
{"sentence": "Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.", "drug1": "fluvoxamine", "drug2": "diazepam", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s20", "pair_id": "DDI-DrugBank.d76.s20.p0"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "chlorpromazine", "drug2": "tricyclic antidepressant", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p7"}
{"sentence": "Cyclosporine, hexobarbital and phenytoin concentrations.", "drug1": "Cyclosporine", "drug2": "phenytoin", "relation": "NONE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s15", "pair_id": "DDI-DrugBank.d53.s15.p1"}
{"sentence": "Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.", "drug1": "Amprenavir", "drug2": "ritonavir", "relation": "EFFECT", "source_file": "Amprenavir_ddi.xml", "sentence_id": "DDI-DrugBank.d437.s13", "pair_id": "DDI-DrugBank.d437.s13.p0"}
{"sentence": "If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.", "drug1": "nifedipine", "drug2": "cimetidine", "relation": "ADVISE", "source_file": "Nifedipine_ddi.xml", "sentence_id": "DDI-DrugBank.d373.s14", "pair_id": "DDI-DrugBank.d373.s14.p0"}
{"sentence": "Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.", "drug1": "warfarin", "drug2": "ketorolac tromethamine", "relation": "MECHANISM", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s1", "pair_id": "DDI-DrugBank.d3.s1.p18"}
{"sentence": "Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.", "drug1": "phenobarbital", "drug2": "clonazepam", "relation": "MECHANISM", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s5", "pair_id": "DDI-DrugBank.d333.s5.p7"}
{"sentence": "Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.", "drug1": "FOSCAVIR", "drug2": "amphotericin B", "relation": "ADVISE", "source_file": "Foscarnet_ddi.xml", "sentence_id": "DDI-DrugBank.d511.s4", "pair_id": "DDI-DrugBank.d511.s4.p5"}
{"sentence": "Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.", "drug1": "Diclofenac", "drug2": "lithium", "relation": "MECHANISM", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s8", "pair_id": "DDI-DrugBank.d249.s8.p3"}
{"sentence": "Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.", "drug1": "TCA", "drug2": "Duloxetine", "relation": "ADVISE", "source_file": "Duloxetine_ddi.xml", "sentence_id": "DDI-DrugBank.d548.s10", "pair_id": "DDI-DrugBank.d548.s10.p5"}
{"sentence": "Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.", "drug1": "dihydroergotamine mesylate", "drug2": "macrolide class", "relation": "MECHANISM", "source_file": "Dihydroergotamine_ddi.xml", "sentence_id": "DDI-DrugBank.d410.s5", "pair_id": "DDI-DrugBank.d410.s5.p26"}
{"sentence": "In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.", "drug1": "quinidine", "drug2": "tricyclic anti-depressants", "relation": "NONE", "source_file": "Bepridil_ddi.xml", "sentence_id": "DDI-DrugBank.d137.s9", "pair_id": "DDI-DrugBank.d137.s9.p11"}
{"sentence": "Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.", "drug1": "calcium", "drug2": "iron", "relation": "NONE", "source_file": "Ibandronate_ddi.xml", "sentence_id": "DDI-DrugBank.d440.s1", "pair_id": "DDI-DrugBank.d440.s1.p2"}
{"sentence": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "drug1": "NIMBEX", "drug2": "aminoglycosides", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s12", "pair_id": "DDI-DrugBank.d60.s12.p16"}
{"sentence": "In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. ", "drug1": "(-)-NANM", "drug2": "morphine", "relation": "EFFECT", "source_file": "3968644.xml", "sentence_id": "DDI-MedLine.d30.s7", "pair_id": "DDI-MedLine.d30.s7.p1"}
{"sentence": "The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when prochlorperazine was administered on the same day as CAMPTOSAR than when these drugs were given on separate days (1.3%, 1/80 patients).", "drug1": "prochlorperazine", "drug2": "CAMPTOSAR", "relation": "EFFECT", "source_file": "Irinotecan_ddi.xml", "sentence_id": "DDI-DrugBank.d279.s8", "pair_id": "DDI-DrugBank.d279.s8.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p10"}
{"sentence": "Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCAmetabolism.", "drug1": "Fluvoxamine", "drug2": "TCA", "relation": "MECHANISM", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s17", "pair_id": "DDI-DrugBank.d238.s17.p0"}
{"sentence": "The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.", "drug1": "methylprednisolone", "drug2": "Aprepitant", "relation": "ADVISE", "source_file": "Aprepitant_ddi.xml", "sentence_id": "DDI-DrugBank.d382.s14", "pair_id": "DDI-DrugBank.d382.s14.p4"}
{"sentence": "High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.", "drug1": "etoposide", "drug2": "etoposide", "relation": "NONE", "source_file": "Etoposide_ddi.xml", "sentence_id": "DDI-DrugBank.d194.s1", "pair_id": "DDI-DrugBank.d194.s1.p7"}
{"sentence": "Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.", "drug1": "anileridine", "drug2": "phenothiazines", "relation": "ADVISE", "source_file": "Anileridine_ddi.xml", "sentence_id": "DDI-DrugBank.d215.s0", "pair_id": "DDI-DrugBank.d215.s0.p2"}
{"sentence": "Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.", "drug1": "Clindamycin", "drug2": "neuromuscular blocking agents", "relation": "EFFECT", "source_file": "Clindamycin_ddi.xml", "sentence_id": "DDI-DrugBank.d256.s0", "pair_id": "DDI-DrugBank.d256.s0.p0"}
{"sentence": "Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.", "drug1": "Amprenavir", "drug2": "ritonavir", "relation": "ADVISE", "source_file": "Amprenavir_ddi.xml", "sentence_id": "DDI-DrugBank.d437.s14", "pair_id": "DDI-DrugBank.d437.s14.p0"}
{"sentence": "Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.", "drug1": "cholestyramine", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Digoxin_ddi.xml", "sentence_id": "DDI-DrugBank.d450.s6", "pair_id": "DDI-DrugBank.d450.s6.p19"}
{"sentence": "[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ", "drug1": "picrotoxin", "drug2": "phentolamine", "relation": "EFFECT", "source_file": "2857099.xml", "sentence_id": "DDI-MedLine.d27.s0", "pair_id": "DDI-MedLine.d27.s0.p4"}
{"sentence": "Anticoagulants: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.", "drug1": "nonsteroidal anti-inflammatory drugs", "drug2": "anti-coagulants", "relation": "EFFECT", "source_file": "Flurbiprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d529.s2", "pair_id": "DDI-DrugBank.d529.s2.p5"}
{"sentence": "[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ", "drug1": "picrotoxin", "drug2": "phenibut", "relation": "EFFECT", "source_file": "2857099.xml", "sentence_id": "DDI-MedLine.d27.s0", "pair_id": "DDI-MedLine.d27.s0.p2"}
{"sentence": "- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "drug1": "acetophenazine", "drug2": "Tindal", "relation": "NONE", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s21", "pair_id": "DDI-DrugBank.d179.s21.p24"}
{"sentence": "Coadministration of NIZORAL  Tablets with midazolam or triazolam has resulted in elevated plasma concentrations of the latter two drugs.", "drug1": "midazolam", "drug2": "triazolam", "relation": "NONE", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s12", "pair_id": "DDI-DrugBank.d458.s12.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "EQUETROTM", "drug2": "clozapine", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p8"}
{"sentence": "Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "antihistamines", "drug2": "monoamine oxidase (MAO) inhibitors", "relation": "NONE", "source_file": "Brompheniramine_ddi.xml", "sentence_id": "DDI-DrugBank.d192.s0", "pair_id": "DDI-DrugBank.d192.s0.p30"}
{"sentence": "DIDREX should not be used concomitantly with other CNS stimulants.", "drug1": "DIDREX", "drug2": "CNS stimulants", "relation": "ADVISE", "source_file": "Benzphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d477.s1", "pair_id": "DDI-DrugBank.d477.s1.p0"}
{"sentence": "The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ", "drug1": "MPTP", "drug2": "amphetamine", "relation": "EFFECT", "source_file": "3871245.xml", "sentence_id": "DDI-MedLine.d73.s3", "pair_id": "DDI-MedLine.d73.s3.p0"}
{"sentence": "Amphotericin B or Corticosteroids or Corticotropin (ACTH)", "drug1": "Amphotericin B", "drug2": "Corticosteroids", "relation": "NONE", "source_file": "Hydroflumethiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d17.s9", "pair_id": "DDI-DrugBank.d17.s9.p0"}
{"sentence": "Paroxetine produced only minor changes in the levels of clozapine and its metabolites.", "drug1": "Paroxetine", "drug2": "clozapine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s21", "pair_id": "DDI-DrugBank.d480.s21.p0"}
{"sentence": "5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .", "drug1": "apomorphine", "drug2": "palonosetron", "relation": "ADVISE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s0", "pair_id": "DDI-DrugBank.d357.s0.p28"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "ethosuximide", "drug2": "haloperidol", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p603"}
{"sentence": "Beta blockers may exacerbate the hypertensive response seen with clonidine withdrawl.", "drug1": "Beta blockers", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s6", "pair_id": "DDI-DrugBank.d495.s6.p0"}
{"sentence": "Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.", "drug1": "Isoproterenol hydrochloride", "drug2": "epinephrine", "relation": "ADVISE", "source_file": "Isoproterenol_ddi.xml", "sentence_id": "DDI-DrugBank.d55.s0", "pair_id": "DDI-DrugBank.d55.s0.p0"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "succinylcholine", "drug2": "Coly-Mycin M", "relation": "EFFECT", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p14"}
{"sentence": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "drug1": "d-amphetamine", "drug2": "tricyclics", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s8", "pair_id": "DDI-DrugBank.d236.s8.p2"}
{"sentence": "Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.", "drug1": "NSAIDs", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s7", "pair_id": "DDI-DrugBank.d219.s7.p5"}
{"sentence": "The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators.", "drug1": "isosorbide dinitrate", "drug2": "vasodilators", "relation": "EFFECT", "source_file": "Isosorbide Dinitrate_ddi.xml", "sentence_id": "DDI-DrugBank.d465.s0", "pair_id": "DDI-DrugBank.d465.s0.p0"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "phenobarbital", "drug2": "phenytoin", "relation": "NONE", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p18"}
{"sentence": "Also, due to the potential for additive effects such as bradycardia and AV block, caution is warranted in patients receiving clonidine with agents known to affect sinus node function or AV nodal conduction (e.g., digitalis, calcium channel blockers, and beta-blockers.)", "drug1": "clonidine", "drug2": "digitalis", "relation": "ADVISE", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s7", "pair_id": "DDI-DrugBank.d495.s7.p0"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "bupropion", "drug2": "desipramine", "relation": "ADVISE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p3"}
{"sentence": "- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.", "drug1": "MAO-inhibitors", "drug2": "Bezalip retard", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s11", "pair_id": "DDI-DrugBank.d291.s11.p4"}
{"sentence": "Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).", "drug1": "psychoactive drugs", "drug2": "barbiturates", "relation": "NONE", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s0", "pair_id": "DDI-DrugBank.d552.s0.p7"}
{"sentence": "Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.", "drug1": "warfarin", "drug2": "etodolac", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s23", "pair_id": "DDI-DrugBank.d219.s23.p1"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "antidepressants", "drug2": "nicotine", "relation": "NONE", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p21"}
{"sentence": "The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.", "drug1": "ORENCIA", "drug2": "azathioprine", "relation": "NONE", "source_file": "Abatacept_ddi.xml", "sentence_id": "DDI-DrugBank.d297.s2", "pair_id": "DDI-DrugBank.d297.s2.p4"}
{"sentence": "- Phenytoin (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin", "drug1": "phenytoin", "drug2": "sulfapyridine", "relation": "EFFECT", "source_file": "Sulfapyridine_ddi.xml", "sentence_id": "DDI-DrugBank.d179.s40", "pair_id": "DDI-DrugBank.d179.s40.p7"}
{"sentence": "Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.", "drug1": "Gleevec", "drug2": "simvastatin", "relation": "MECHANISM", "source_file": "Imatinib_ddi.xml", "sentence_id": "DDI-DrugBank.d115.s8", "pair_id": "DDI-DrugBank.d115.s8.p3"}
{"sentence": "Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).", "drug1": "amphotericin", "drug2": "zalcitabine", "relation": "MECHANISM", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s18", "pair_id": "DDI-DrugBank.d263.s18.p21"}
{"sentence": "The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.", "drug1": "veratrum alkaloids", "drug2": "sympathomimetics", "relation": "EFFECT", "source_file": "Azatadine_ddi.xml", "sentence_id": "DDI-DrugBank.d448.s3", "pair_id": "DDI-DrugBank.d448.s3.p9"}
{"sentence": "Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).", "drug1": "Nabilone", "drug2": "barbiturates", "relation": "ADVISE", "source_file": "Nabilone_ddi.xml", "sentence_id": "DDI-DrugBank.d552.s0", "pair_id": "DDI-DrugBank.d552.s0.p3"}
{"sentence": "Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.", "drug1": "Beta-blockers", "drug2": "insulin", "relation": "EFFECT", "source_file": "Insulin Glargine recombinant_ddi.xml", "sentence_id": "DDI-DrugBank.d527.s3", "pair_id": "DDI-DrugBank.d527.s3.p3"}
{"sentence": "As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.", "drug1": "nondepolarizing neuromuscular blocking agents", "drug2": "phenytoin", "relation": "EFFECT", "source_file": "Doxacurium chloride_ddi.xml", "sentence_id": "DDI-DrugBank.d267.s6", "pair_id": "DDI-DrugBank.d267.s6.p1"}
{"sentence": "Effects of Erythromycin on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.", "drug1": "Erythromycin", "drug2": "erythromycin", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s36", "pair_id": "DDI-DrugBank.d434.s36.p1"}
{"sentence": "Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).", "drug1": "ergot-type medications", "drug2": "FROVA", "relation": "ADVISE", "source_file": "Frovatriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d426.s1", "pair_id": "DDI-DrugBank.d426.s1.p6"}
{"sentence": "Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.", "drug1": "Propranolol", "drug2": "aspirins", "relation": "EFFECT", "source_file": "Aspirin_ddi.xml", "sentence_id": "DDI-DrugBank.d443.s8", "pair_id": "DDI-DrugBank.d443.s8.p0"}
{"sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "drug1": "barbiturates", "drug2": "estrogens", "relation": "NONE", "source_file": "Butabarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d184.s0", "pair_id": "DDI-DrugBank.d184.s0.p67"}
{"sentence": "Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.", "drug1": "digoxin", "drug2": "warfarin", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s5", "pair_id": "DDI-DrugBank.d212.s5.p12"}
{"sentence": "Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and thiazides in some patients.", "drug1": "ibuprofen", "drug2": "thiazides", "relation": "EFFECT", "source_file": "Ibuprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d415.s9", "pair_id": "DDI-DrugBank.d415.s9.p4"}
{"sentence": "Anticoagulants: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly.", "drug1": "erythromycin", "drug2": "anticoagulants", "relation": "EFFECT", "source_file": "Dirithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d522.s21", "pair_id": "DDI-DrugBank.d522.s21.p2"}
{"sentence": "Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.", "drug1": "NSAIDs", "drug2": "propranolol", "relation": "EFFECT", "source_file": "Naproxen_ddi.xml", "sentence_id": "DDI-DrugBank.d85.s9", "pair_id": "DDI-DrugBank.d85.s9.p3"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "chlorpropamide", "drug2": "triclofos sodium", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p491"}
{"sentence": "Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.", "drug1": "amylase", "drug2": "Acarbose", "relation": "MECHANISM", "source_file": "Acarbose_ddi.xml", "sentence_id": "DDI-DrugBank.d536.s4", "pair_id": "DDI-DrugBank.d536.s4.p13"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "midazolam", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p7"}
{"sentence": "No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.", "drug1": "felodipine", "drug2": "digoxin", "relation": "NONE", "source_file": "Levosimendan_ddi.xml", "sentence_id": "DDI-DrugBank.d189.s0", "pair_id": "DDI-DrugBank.d189.s0.p24"}
{"sentence": "In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.", "drug1": "irbesartan", "drug2": "warfarin", "relation": "NONE", "source_file": "Irbesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d27.s4", "pair_id": "DDI-DrugBank.d27.s4.p12"}
{"sentence": "Acetaminophen: May increase plasma concentration of synthetic estrogens, possibly by inhibiting conjugation.", "drug1": "Acetaminophen", "drug2": "synthetic estrogens", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s2", "pair_id": "DDI-DrugBank.d485.s2.p0"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "anticoagulant", "drug2": "antihistamines", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p3"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "bupropion", "drug2": "zonisamide", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p214"}
{"sentence": "Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. ", "drug1": "Amprenavir", "drug2": "rifabutin", "relation": "EFFECT", "source_file": "11158747.xml", "sentence_id": "DDI-MedLine.d3.s12", "pair_id": "DDI-MedLine.d3.s12.p0"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "delavirdine", "drug2": "lamotrigine", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p450"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "EQUETROTM", "drug2": "isoniazid", "relation": "MECHANISM", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p11"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "Cholestyramine", "drug2": "thiazide diuretics", "relation": "MECHANISM", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p3"}
{"sentence": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "drug1": "Digoxin", "drug2": "citalopram", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s9", "pair_id": "DDI-DrugBank.d568.s9.p3"}
{"sentence": "Propoxyphene: In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.", "drug1": "propoxyphene", "drug2": "amphetamine", "relation": "EFFECT", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s27", "pair_id": "DDI-DrugBank.d236.s27.p2"}
{"sentence": "In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ", "drug1": "Innovar Vet", "drug2": "ouabain", "relation": "EFFECT", "source_file": "1167743.xml", "sentence_id": "DDI-MedLine.d23.s1", "pair_id": "DDI-MedLine.d23.s1.p16"}
{"sentence": "Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).", "drug1": "Probenecid", "drug2": "famotidine", "relation": "MECHANISM", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s0", "pair_id": "DDI-DrugBank.d260.s0.p24"}
{"sentence": "Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.", "drug1": "diazepam", "drug2": "diazepam", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s48", "pair_id": "DDI-DrugBank.d328.s48.p2"}
{"sentence": "Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.", "drug1": "Proquin XR", "drug2": "Proquin XR", "relation": "NONE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s12", "pair_id": "DDI-DrugBank.d123.s12.p7"}
{"sentence": "When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.", "drug1": "ketoconazole", "drug2": "aripiprazole", "relation": "ADVISE", "source_file": "Aripiprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d509.s11", "pair_id": "DDI-DrugBank.d509.s11.p0"}
{"sentence": "Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.", "drug1": "corticosteroids", "drug2": "antidiabetic drugs", "relation": "EFFECT", "source_file": "Nateglinide_ddi.xml", "sentence_id": "DDI-DrugBank.d460.s15", "pair_id": "DDI-DrugBank.d460.s15.p8"}
{"sentence": "The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.", "drug1": "norepinephrine", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Lidocaine_ddi.xml", "sentence_id": "DDI-DrugBank.d564.s0", "pair_id": "DDI-DrugBank.d564.s0.p8"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "erythromycin", "drug2": "carbamazepine", "relation": "INT", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p0"}
{"sentence": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "drug1": "DURAGESIC", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s5", "pair_id": "DDI-DrugBank.d170.s5.p19"}
{"sentence": "Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.", "drug1": "Fenfluramine", "drug2": "reserpine", "relation": "EFFECT", "source_file": "Fenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d104.s0", "pair_id": "DDI-DrugBank.d104.s0.p3"}
{"sentence": "Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.", "drug1": "Tiagabine", "drug2": "valproate", "relation": "MECHANISM", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s7", "pair_id": "DDI-DrugBank.d277.s7.p2"}
{"sentence": "Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.\r\n", "drug1": "neurotensin", "drug2": "tuftsin", "relation": "EFFECT", "source_file": "6545985.xml", "sentence_id": "DDI-MedLine.d131.s0", "pair_id": "DDI-MedLine.d131.s0.p1"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "ZEBETA", "drug2": "diltiazem", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p5"}
{"sentence": "Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.", "drug1": "escitalopram", "drug2": "LEXAPRO", "relation": "NONE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s12", "pair_id": "DDI-DrugBank.d568.s12.p3"}
{"sentence": "In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives", "drug1": "AUGMENTIN XR", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Clavulanate_ddi.xml", "sentence_id": "DDI-DrugBank.d419.s5", "pair_id": "DDI-DrugBank.d419.s5.p2"}
{"sentence": "Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.", "drug1": "cimetidine", "drug2": "felodipine", "relation": "NONE", "source_file": "Felodipine_ddi.xml", "sentence_id": "DDI-DrugBank.d316.s1", "pair_id": "DDI-DrugBank.d316.s1.p13"}
{"sentence": "Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.", "drug1": "hexobarbital", "drug2": "chlorpromazine", "relation": "NONE", "source_file": "Clorazepate_ddi.xml", "sentence_id": "DDI-DrugBank.d335.s1", "pair_id": "DDI-DrugBank.d335.s1.p4"}
{"sentence": "An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.", "drug1": "lithium", "drug2": "HALDOL", "relation": "EFFECT", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s0", "pair_id": "DDI-DrugBank.d186.s0.p0"}
{"sentence": "conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa).", "drug1": "diethylpropion", "drug2": "a-methyldopa", "relation": "INT", "source_file": "Diethylpropion_ddi.xml", "sentence_id": "DDI-DrugBank.d352.s3", "pair_id": "DDI-DrugBank.d352.s3.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Tylenol", "drug2": "Astramorph", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p117"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "antibiotics", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p3"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "resin", "drug2": "phenobarbital", "relation": "NONE", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p18"}
{"sentence": "The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.", "drug1": "barbiturates", "drug2": "imipramine", "relation": "NONE", "source_file": "Imipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d77.s5", "pair_id": "DDI-DrugBank.d77.s5.p13"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "alcohol", "drug2": "salicylates", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p97"}
{"sentence": "Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.", "drug1": "ciprofloxacin", "drug2": "magnesium", "relation": "MECHANISM", "source_file": "Didanosine_ddi.xml", "sentence_id": "DDI-DrugBank.d43.s8", "pair_id": "DDI-DrugBank.d43.s8.p19"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "androgens", "drug2": "perchlorate", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p97"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Etonogestrel", "drug2": "Crixivan", "relation": "INT", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p25"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Topamax", "drug2": "Gris-PEG", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p431"}
{"sentence": "When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered", "drug1": "CANCIDAS", "drug2": "nevirapine", "relation": "ADVISE", "source_file": "Caspofungin_ddi.xml", "sentence_id": "DDI-DrugBank.d350.s14", "pair_id": "DDI-DrugBank.d350.s14.p1"}
{"sentence": "Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.", "drug1": "estrogens", "drug2": "progestins", "relation": "NONE", "source_file": "Cholestyramine_ddi.xml", "sentence_id": "DDI-DrugBank.d566.s0", "pair_id": "DDI-DrugBank.d566.s0.p75"}
{"sentence": "Diuretic: Hydrochlorothiazide, given concomitantly with ketoprofen, produces a reduction in urinary potassium and chloride excretion compared to hydrochlorothiazide alone.", "drug1": "Hydrochlorothiazide", "drug2": "ketoprofen", "relation": "EFFECT", "source_file": "Ketoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d499.s10", "pair_id": "DDI-DrugBank.d499.s10.p3"}
{"sentence": "Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.", "drug1": "isoniazid", "drug2": "theophylline", "relation": "MECHANISM", "source_file": "Isoniazid_ddi.xml", "sentence_id": "DDI-DrugBank.d187.s11", "pair_id": "DDI-DrugBank.d187.s11.p0"}
{"sentence": "Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.", "drug1": "digoxin", "drug2": "COREG", "relation": "ADVISE", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s13", "pair_id": "DDI-DrugBank.d269.s13.p0"}
{"sentence": "Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.", "drug1": "BOTOX", "drug2": "curare-like compounds", "relation": "ADVISE", "source_file": "Botulinum Toxin Type A_ddi.xml", "sentence_id": "DDI-DrugBank.d133.s0", "pair_id": "DDI-DrugBank.d133.s0.p1"}
{"sentence": "Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.", "drug1": "tetracyclines", "drug2": "anticoagulant", "relation": "ADVISE", "source_file": "Doxycycline_ddi.xml", "sentence_id": "DDI-DrugBank.d500.s0", "pair_id": "DDI-DrugBank.d500.s0.p0"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "butorphanol", "drug2": "Levo-Dromoran", "relation": "ADVISE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p29"}
{"sentence": "Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, reserpine.", "drug1": "Fenfluramine", "drug2": "antihypertensive drugs", "relation": "EFFECT", "source_file": "Fenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d104.s0", "pair_id": "DDI-DrugBank.d104.s0.p0"}
{"sentence": "If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.", "drug1": "naratriptan", "drug2": "SSRI", "relation": "ADVISE", "source_file": "Naratriptan_ddi.xml", "sentence_id": "DDI-DrugBank.d478.s5", "pair_id": "DDI-DrugBank.d478.s5.p0"}
{"sentence": "Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found.", "drug1": "Cardiac Glycosides", "drug2": "digoxin", "relation": "NONE", "source_file": "Captopril_ddi.xml", "sentence_id": "DDI-DrugBank.d175.s21", "pair_id": "DDI-DrugBank.d175.s21.p1"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "phenytoin", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p24"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "clarithromycin", "drug2": "itraconazole", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p106"}
{"sentence": "Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.", "drug1": "phenytoin", "drug2": "terfenadine", "relation": "NONE", "source_file": "Lansoprazole_ddi.xml", "sentence_id": "DDI-DrugBank.d431.s1", "pair_id": "DDI-DrugBank.d431.s1.p44"}
{"sentence": "Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered.", "drug1": "colestipol", "drug2": "atorvastatin", "relation": "MECHANISM", "source_file": "Atorvastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d140.s4", "pair_id": "DDI-DrugBank.d140.s4.p5"}
{"sentence": "The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.", "drug1": "TORADOL", "drug2": "lithium", "relation": "NONE", "source_file": "Ketorolac_ddi.xml", "sentence_id": "DDI-DrugBank.d3.s12", "pair_id": "DDI-DrugBank.d3.s12.p1"}
{"sentence": "Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.", "drug1": "heparin sodium", "drug2": "warfarin sodium", "relation": "ADVISE", "source_file": "Heparin_ddi.xml", "sentence_id": "DDI-DrugBank.d488.s1", "pair_id": "DDI-DrugBank.d488.s1.p1"}
{"sentence": "Effects of Other Antiepileptic Drugs on Felbatol  Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol  (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol  as compared to the same dose of Felbatol  given as monotherapy.", "drug1": "Phenytoin", "drug2": "Phenytoin", "relation": "NONE", "source_file": "Felbamate_ddi.xml", "sentence_id": "DDI-DrugBank.d434.s30", "pair_id": "DDI-DrugBank.d434.s30.p15"}
{"sentence": "Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.", "drug1": "lithium", "drug2": "angiotensin II receptor antagonists", "relation": "MECHANISM", "source_file": "Candesartan_ddi.xml", "sentence_id": "DDI-DrugBank.d547.s2", "pair_id": "DDI-DrugBank.d547.s2.p8"}
{"sentence": "Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.", "drug1": "isocarboxazid", "drug2": "tranylcypromine", "relation": "NONE", "source_file": "L-Tryptophan_ddi.xml", "sentence_id": "DDI-DrugBank.d63.s0", "pair_id": "DDI-DrugBank.d63.s0.p18"}
{"sentence": "RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ", "drug1": "sirolimus", "drug2": "diltiazem", "relation": "MECHANISM", "source_file": "11180036.xml", "sentence_id": "DDI-MedLine.d86.s5", "pair_id": "DDI-MedLine.d86.s5.p0"}
{"sentence": "There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.", "drug1": "isosorbide dinitrate", "drug2": "protamine", "relation": "NONE", "source_file": "Dobutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d274.s3", "pair_id": "DDI-DrugBank.d274.s3.p66"}
{"sentence": "Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.", "drug1": "Itraconazole", "drug2": "isoniazid", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s25", "pair_id": "DDI-DrugBank.d165.s25.p2"}
{"sentence": "Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);", "drug1": "Cisapride", "drug2": "procainamide", "relation": "ADVISE", "source_file": "Cisapride_ddi.xml", "sentence_id": "DDI-DrugBank.d237.s14", "pair_id": "DDI-DrugBank.d237.s14.p2"}
{"sentence": "Concomitant use of HIVID with didanosine is not recommended.", "drug1": "HIVID", "drug2": "didanosine", "relation": "ADVISE", "source_file": "Zalcitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d263.s14", "pair_id": "DDI-DrugBank.d263.s14.p0"}
{"sentence": "Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or lamotrigine.", "drug1": "carbamazepine", "drug2": "topiramate", "relation": "NONE", "source_file": "Levetiracetam_ddi.xml", "sentence_id": "DDI-DrugBank.d212.s14", "pair_id": "DDI-DrugBank.d212.s14.p5"}
{"sentence": "Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.", "drug1": "macrolides", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s5", "pair_id": "DDI-DrugBank.d53.s5.p0"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "tubocurarine", "drug2": "succinylcholine", "relation": "NONE", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p6"}
{"sentence": "Caution should be used when alosetron and ketoconazole are administered concomitantly.", "drug1": "alosetron", "drug2": "ketoconazole", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s9", "pair_id": "DDI-DrugBank.d364.s9.p0"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "amiodarone", "drug2": "phenytoin", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p244"}
{"sentence": "Therefore, use of lamivudine in combination with zalcitabine is not recommended", "drug1": "lamivudine", "drug2": "zalcitabine", "relation": "ADVISE", "source_file": "Lamivudine_ddi.xml", "sentence_id": "DDI-DrugBank.d71.s6", "pair_id": "DDI-DrugBank.d71.s6.p0"}
{"sentence": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.", "drug1": "benzodiazepine class", "drug2": "narcotics", "relation": "EFFECT", "source_file": "Clonazepam_ddi.xml", "sentence_id": "DDI-DrugBank.d333.s7", "pair_id": "DDI-DrugBank.d333.s7.p1"}
{"sentence": "Antacids: In a single dose study (n=6), ingestion of an antacid containing 1.7-gram of magnesium hydroxide with 500-mg of mefenamic acid increased the Cmax and AUC of mefenamic acid by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including fluconazole, lovastatin and trimethoprim.", "drug1": "magnesium hydroxide", "drug2": "mefenamic acid", "relation": "MECHANISM", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s14", "pair_id": "DDI-DrugBank.d400.s14.p13"}
{"sentence": "Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.", "drug1": "LEXAPRO", "drug2": "lithium", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s12", "pair_id": "DDI-DrugBank.d568.s12.p5"}
{"sentence": "Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.", "drug1": "Iron", "drug2": "iron supplement", "relation": "NONE", "source_file": "Cefdinir_ddi.xml", "sentence_id": "DDI-DrugBank.d420.s5", "pair_id": "DDI-DrugBank.d420.s5.p7"}
{"sentence": "Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ", "drug1": "insulin", "drug2": "NaCMC", "relation": "NONE", "source_file": "11154900.xml", "sentence_id": "DDI-MedLine.d76.s9", "pair_id": "DDI-MedLine.d76.s9.p3"}
{"sentence": "After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.", "drug1": "Fluvoxamine", "drug2": "MAOI", "relation": "ADVISE", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s5", "pair_id": "DDI-DrugBank.d76.s5.p0"}
{"sentence": "- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving immuno-suppressant therapy and concomitant bezafibrate.", "drug1": "immuno-suppressant", "drug2": "bezafibrate", "relation": "EFFECT", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s6", "pair_id": "DDI-DrugBank.d291.s6.p0"}
{"sentence": "The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.", "drug1": "diltiazem", "drug2": "fentanyl", "relation": "MECHANISM", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s3", "pair_id": "DDI-DrugBank.d170.s3.p1"}
{"sentence": "Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.", "drug1": "carbamazepine", "drug2": "SUPRAX", "relation": "MECHANISM", "source_file": "Cefixime_ddi.xml", "sentence_id": "DDI-DrugBank.d339.s0", "pair_id": "DDI-DrugBank.d339.s0.p2"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "alcohol", "drug2": "dicumarol", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p25"}
{"sentence": "Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.", "drug1": "aluminum", "drug2": "lomefloxacin", "relation": "MECHANISM", "source_file": "Lomefloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d516.s3", "pair_id": "DDI-DrugBank.d516.s3.p32"}
{"sentence": "Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.", "drug1": "tamoxifen", "drug2": "warfarin", "relation": "NONE", "source_file": "Chlorotrianisene_ddi.xml", "sentence_id": "DDI-DrugBank.d446.s0", "pair_id": "DDI-DrugBank.d446.s0.p90"}
{"sentence": "Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;", "drug1": "levobupivacaine", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Levobupivacaine_ddi.xml", "sentence_id": "DDI-DrugBank.d320.s3", "pair_id": "DDI-DrugBank.d320.s3.p2"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "narcotic", "drug2": "codeine", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p99"}
{"sentence": "Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.", "drug1": "aspirin", "drug2": "Nalfon", "relation": "NONE", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s2", "pair_id": "DDI-DrugBank.d154.s2.p7"}
{"sentence": "There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.", "drug1": "Desyrel", "drug2": "buspirone HCl", "relation": "EFFECT", "source_file": "Buspirone_ddi.xml", "sentence_id": "DDI-DrugBank.d463.s1", "pair_id": "DDI-DrugBank.d463.s1.p2"}
{"sentence": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "drug1": "desipramine", "drug2": "topiramate", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s11", "pair_id": "DDI-DrugBank.d94.s11.p499"}
{"sentence": "Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.", "drug1": "ketoconazole", "drug2": "aliskiren", "relation": "MECHANISM", "source_file": "Aliskiren_ddi.xml", "sentence_id": "DDI-DrugBank.d533.s4", "pair_id": "DDI-DrugBank.d533.s4.p3"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "phenytoin", "drug2": "methylphenidate", "relation": "MECHANISM", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p13"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "MAOIs", "drug2": "sertraline", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p13"}
{"sentence": "There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.", "drug1": "tacrolimus", "drug2": "valproate", "relation": "NONE", "source_file": "Erythromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d397.s8", "pair_id": "DDI-DrugBank.d397.s8.p43"}
{"sentence": "When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.", "drug1": "warfarin", "drug2": "nevirapine", "relation": "ADVISE", "source_file": "Nevirapine_ddi.xml", "sentence_id": "DDI-DrugBank.d270.s11", "pair_id": "DDI-DrugBank.d270.s11.p0"}
{"sentence": "Oral Contraceptive: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of tablets containing 2.5 mg of norethindrone acetate and 50 mcg of ethinyl estradiol were similar with and without coadministration of gabapentin (400 mg TID;", "drug1": "Contraceptive", "drug2": "ethinyl estradiol", "relation": "NONE", "source_file": "Gabapentin_ddi.xml", "sentence_id": "DDI-DrugBank.d438.s33", "pair_id": "DDI-DrugBank.d438.s33.p1"}
{"sentence": "These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.", "drug1": "thiazides", "drug2": "nicotinic acid", "relation": "NONE", "source_file": "Chlorpropamide_ddi.xml", "sentence_id": "DDI-DrugBank.d245.s4", "pair_id": "DDI-DrugBank.d245.s4.p6"}
{"sentence": "Cyclopentolate may interfere with the anti-glaucoma action of carbachol or pilocarpine;", "drug1": "Cyclopentolate", "drug2": "pilocarpine", "relation": "EFFECT", "source_file": "Cyclopentolate_ddi.xml", "sentence_id": "DDI-DrugBank.d298.s0", "pair_id": "DDI-DrugBank.d298.s0.p1"}
{"sentence": "Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.", "drug1": "lithium", "drug2": "Hydrochlorothiazide", "relation": "ADVISE", "source_file": "Hydrochlorothiazide_ddi.xml", "sentence_id": "DDI-DrugBank.d162.s11", "pair_id": "DDI-DrugBank.d162.s11.p0"}
{"sentence": "Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.", "drug1": "VIRACEPT", "drug2": "sulfamethoxazole", "relation": "NONE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s5", "pair_id": "DDI-DrugBank.d340.s5.p2"}
{"sentence": "Norepinephrine: Amphetamines enhance the adrenergic effect of norepinephrine.", "drug1": "Amphetamines", "drug2": "norepinephrine", "relation": "EFFECT", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s18", "pair_id": "DDI-DrugBank.d158.s18.p2"}
{"sentence": "Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.", "drug1": "ammonium chloride", "drug2": "amphetamine", "relation": "MECHANISM", "source_file": "Dextroamphetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d236.s1", "pair_id": "DDI-DrugBank.d236.s1.p4"}
{"sentence": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "drug1": "hormonal contraceptives", "drug2": "alprazolam", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s17", "pair_id": "DDI-DrugBank.d485.s17.p9"}
{"sentence": "Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.", "drug1": "diclofenac", "drug2": "NSAIDs", "relation": "ADVISE", "source_file": "Diclofenac_ddi.xml", "sentence_id": "DDI-DrugBank.d249.s1", "pair_id": "DDI-DrugBank.d249.s1.p4"}
{"sentence": "Patients who are applying Panretin gel should not concurrently use products that contain DEET (N, N-diethyl-m-toluamide), a common component of insect repellent products.", "drug1": "Panretin", "drug2": "N-diethyl-m-toluamide", "relation": "ADVISE", "source_file": "Alitretinoin_ddi.xml", "sentence_id": "DDI-DrugBank.d392.s0", "pair_id": "DDI-DrugBank.d392.s0.p1"}
{"sentence": "The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.", "drug1": "sodium cephalothin", "drug2": "Coly-Mycin M", "relation": "ADVISE", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s4", "pair_id": "DDI-DrugBank.d250.s4.p0"}
{"sentence": "Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.", "drug1": "NSAIDs", "drug2": "methotrexate", "relation": "MECHANISM", "source_file": "Etodolac_ddi.xml", "sentence_id": "DDI-DrugBank.d219.s7", "pair_id": "DDI-DrugBank.d219.s7.p6"}
{"sentence": "While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.", "drug1": "phenytoin", "drug2": "NIMBEX", "relation": "EFFECT", "source_file": "Cisatracurium Besylate_ddi.xml", "sentence_id": "DDI-DrugBank.d60.s14", "pair_id": "DDI-DrugBank.d60.s14.p1"}
{"sentence": "ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.", "drug1": "ZEBETA", "drug2": "antiarrhythmic agents", "relation": "ADVISE", "source_file": "Bisoprolol_ddi.xml", "sentence_id": "DDI-DrugBank.d476.s3", "pair_id": "DDI-DrugBank.d476.s3.p6"}
{"sentence": "May interact with the following: beta-adrenergic blocking agents (these medicines may make your condition worse and prevent the adrenergic bronchodilators from working properly) and disopyramide, quinidine, phenothiazines, and procainamide (these medicines may increase the risk of heart problems).", "drug1": "phenothiazines", "drug2": "procainamide", "relation": "NONE", "source_file": "Isoetharine_ddi.xml", "sentence_id": "DDI-DrugBank.d541.s0", "pair_id": "DDI-DrugBank.d541.s0.p14"}
{"sentence": "- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired", "drug1": "Bezalip retard", "drug2": "anion-exchange resins", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s9", "pair_id": "DDI-DrugBank.d291.s9.p5"}
{"sentence": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.", "drug1": "grepafloxacin", "drug2": "antihistamines", "relation": "NONE", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s1", "pair_id": "DDI-DrugBank.d86.s1.p67"}
{"sentence": "Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants", "drug1": "Monoamine oxidase inhibitors", "drug2": "Flupenthixol", "relation": "NONE", "source_file": "Flupenthixol_ddi.xml", "sentence_id": "DDI-DrugBank.d13.s0", "pair_id": "DDI-DrugBank.d13.s0.p16"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Kaletra", "drug2": "Kadian", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p874"}
{"sentence": "Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.", "drug1": "Rifampin", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s36", "pair_id": "DDI-DrugBank.d485.s36.p5"}
{"sentence": "therefore concomitant administration of Itraconazole with cisapride is contraindicated.", "drug1": "Itraconazole", "drug2": "cisapride", "relation": "ADVISE", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s10", "pair_id": "DDI-DrugBank.d165.s10.p0"}
{"sentence": "However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.", "drug1": "HMG-CoA reductase inhibitor", "drug2": "warfarin", "relation": "EFFECT", "source_file": "Lovastatin_ddi.xml", "sentence_id": "DDI-DrugBank.d567.s14", "pair_id": "DDI-DrugBank.d567.s14.p0"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "Antihistamines", "drug2": "alcohol", "relation": "EFFECT", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p0"}
{"sentence": "DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING PHENYTOIN AND ITS CONGENERS.", "drug1": "DISULFIRAM", "drug2": "PHENYTOIN", "relation": "ADVISE", "source_file": "Disulfiram_ddi.xml", "sentence_id": "DDI-DrugBank.d19.s1", "pair_id": "DDI-DrugBank.d19.s1.p0"}
{"sentence": "The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.", "drug1": "anticonvulsants", "drug2": "antituberculosis drug", "relation": "NONE", "source_file": "Norethindrone_ddi.xml", "sentence_id": "DDI-DrugBank.d306.s0", "pair_id": "DDI-DrugBank.d306.s0.p9"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "anticoagulant", "drug2": "metronidazole", "relation": "EFFECT", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p28"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "warfarin", "drug2": "alprazolam", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p88"}
{"sentence": "Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.", "drug1": "Acetazolamide", "drug2": "isoniazid", "relation": "NONE", "source_file": "Carbamazepine_ddi.xml", "sentence_id": "DDI-DrugBank.d94.s4", "pair_id": "DDI-DrugBank.d94.s4.p36"}
{"sentence": "There is one reported case of a patient with acute delirium associated with the simultaneous use of fluphenazine and oral clonidine.", "drug1": "fluphenazine", "drug2": "clonidine", "relation": "EFFECT", "source_file": "Clonidine_ddi.xml", "sentence_id": "DDI-DrugBank.d495.s8", "pair_id": "DDI-DrugBank.d495.s8.p0"}
{"sentence": "Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.", "drug1": "antidepressants", "drug2": "beta-blockers", "relation": "NONE", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s17", "pair_id": "DDI-DrugBank.d5.s17.p26"}
{"sentence": "Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.", "drug1": "Ethanol", "drug2": "Triazolam", "relation": "NONE", "source_file": "Tiagabine_ddi.xml", "sentence_id": "DDI-DrugBank.d277.s20", "pair_id": "DDI-DrugBank.d277.s20.p0"}
{"sentence": "Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.", "drug1": "topiramate", "drug2": "progestins", "relation": "MECHANISM", "source_file": "Ethynodiol Diacetate_ddi.xml", "sentence_id": "DDI-DrugBank.d485.s12", "pair_id": "DDI-DrugBank.d485.s12.p26"}
{"sentence": "This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "drug1": "monoamine oxidase (MAO) inhibitors", "drug2": "antihistamines", "relation": "NONE", "source_file": "Buclizine_ddi.xml", "sentence_id": "DDI-DrugBank.d342.s0", "pair_id": "DDI-DrugBank.d342.s0.p26"}
{"sentence": "d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;", "drug1": "d-amphetamine", "drug2": "protriptyline", "relation": "MECHANISM", "source_file": "Lisdexamfetamine_ddi.xml", "sentence_id": "DDI-DrugBank.d158.s4", "pair_id": "DDI-DrugBank.d158.s4.p1"}
{"sentence": "The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.", "drug1": "dopamine", "drug2": "Bretylium Tosylate", "relation": "EFFECT", "source_file": "Bretylium_ddi.xml", "sentence_id": "DDI-DrugBank.d180.s1", "pair_id": "DDI-DrugBank.d180.s1.p4"}
{"sentence": "The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.", "drug1": "enalaprilat", "drug2": "diuretic", "relation": "EFFECT", "source_file": "Enalapril_ddi.xml", "sentence_id": "DDI-DrugBank.d107.s1", "pair_id": "DDI-DrugBank.d107.s1.p4"}
{"sentence": "In a study of 12 schizophrenic patients coadministered oral haloperidol and rifampin, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.", "drug1": "haloperidol", "drug2": "rifampin", "relation": "MECHANISM", "source_file": "Haloperidol_ddi.xml", "sentence_id": "DDI-DrugBank.d186.s4", "pair_id": "DDI-DrugBank.d186.s4.p0"}
{"sentence": "MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics", "drug1": "MAO inhibitors", "drug2": "opioid analgesics", "relation": "ADVISE", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s7", "pair_id": "DDI-DrugBank.d170.s7.p9"}
{"sentence": "Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.", "drug1": "dopamine agonist", "drug2": "APOKYN", "relation": "NONE", "source_file": "Apomorphine_ddi.xml", "sentence_id": "DDI-DrugBank.d357.s3", "pair_id": "DDI-DrugBank.d357.s3.p23"}
{"sentence": "Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.", "drug1": "digoxin", "drug2": "carvedilol", "relation": "MECHANISM", "source_file": "Carvedilol_ddi.xml", "sentence_id": "DDI-DrugBank.d269.s11", "pair_id": "DDI-DrugBank.d269.s11.p5"}
{"sentence": "Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.", "drug1": "caffeine", "drug2": "Clozapine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s17", "pair_id": "DDI-DrugBank.d480.s17.p4"}
{"sentence": "Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.", "drug1": "Itraconazole", "drug2": "digoxin", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s15", "pair_id": "DDI-DrugBank.d165.s15.p2"}
{"sentence": "Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin", "drug1": "VIRACEPT", "drug2": "rifabutin", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s7", "pair_id": "DDI-DrugBank.d340.s7.p1"}
{"sentence": "Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.", "drug1": "antihistamines", "drug2": "CNS depressants", "relation": "EFFECT", "source_file": "Clemastine_ddi.xml", "sentence_id": "DDI-DrugBank.d309.s0", "pair_id": "DDI-DrugBank.d309.s0.p0"}
{"sentence": "This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.", "drug1": "VIOXX", "drug2": "ACE inhibitors", "relation": "ADVISE", "source_file": "Rofecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d210.s2", "pair_id": "DDI-DrugBank.d210.s2.p0"}
{"sentence": "Coadministration of oral contraceptives increased the maximum plasma concentration of alprazolam by 18%, decreased clearance by 22%, and increased half-life by 29%.", "drug1": "contraceptives", "drug2": "alprazolam", "relation": "MECHANISM", "source_file": "Alprazolam_ddi.xml", "sentence_id": "DDI-DrugBank.d131.s7", "pair_id": "DDI-DrugBank.d131.s7.p0"}
{"sentence": "Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).", "drug1": "barbiturates", "drug2": "contraceptives", "relation": "EFFECT", "source_file": "Butabarbital_ddi.xml", "sentence_id": "DDI-DrugBank.d184.s0", "pair_id": "DDI-DrugBank.d184.s0.p90"}
{"sentence": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "drug1": "amiodarone", "drug2": "pimozide", "relation": "NONE", "source_file": "Saquinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d124.s26", "pair_id": "DDI-DrugBank.d124.s26.p63"}
{"sentence": "Caution should be used when NSAIDs are administered concomitantly with methotrexate.", "drug1": "NSAIDs", "drug2": "methotrexate", "relation": "ADVISE", "source_file": "Mefenamic acid_ddi.xml", "sentence_id": "DDI-DrugBank.d400.s3", "pair_id": "DDI-DrugBank.d400.s3.p0"}
{"sentence": "Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.", "drug1": "erythromycin", "drug2": "loratadine", "relation": "MECHANISM", "source_file": "Loratadine_ddi.xml", "sentence_id": "DDI-DrugBank.d258.s4", "pair_id": "DDI-DrugBank.d258.s4.p0"}
{"sentence": "Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.", "drug1": "Magnesium", "drug2": "vitamin D", "relation": "EFFECT", "source_file": "Cholecalciferol_ddi.xml", "sentence_id": "DDI-DrugBank.d404.s15", "pair_id": "DDI-DrugBank.d404.s15.p4"}
{"sentence": "Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.", "drug1": "Monoamine Oxidase Inhibitors", "drug2": "monoamine oxidase inhibitors", "relation": "NONE", "source_file": "Formoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d103.s3", "pair_id": "DDI-DrugBank.d103.s3.p2"}
{"sentence": "The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.", "drug1": "fentanyl", "drug2": "troleandomycin", "relation": "MECHANISM", "source_file": "Fentanyl_ddi.xml", "sentence_id": "DDI-DrugBank.d170.s2", "pair_id": "DDI-DrugBank.d170.s2.p3"}
{"sentence": "Antihistamines may have additive effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, tranquilizers, antianxiety agents.", "drug1": "tranquilizers", "drug2": "antianxiety agents", "relation": "NONE", "source_file": "Cyproheptadine_ddi.xml", "sentence_id": "DDI-DrugBank.d492.s1", "pair_id": "DDI-DrugBank.d492.s1.p20"}
{"sentence": "cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).", "drug1": "cimetidine", "drug2": "propafenone", "relation": "NONE", "source_file": "Clomipramine_ddi.xml", "sentence_id": "DDI-DrugBank.d238.s15", "pair_id": "DDI-DrugBank.d238.s15.p3"}
{"sentence": "Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.", "drug1": "Agonist/antagonist analgesics", "drug2": "Levo-Dromoran", "relation": "ADVISE", "source_file": "Levorphanol_ddi.xml", "sentence_id": "DDI-DrugBank.d257.s6", "pair_id": "DDI-DrugBank.d257.s6.p14"}
{"sentence": "The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone", "drug1": "halothane", "drug2": "phenothiazines", "relation": "NONE", "source_file": "Fosphenytoin_ddi.xml", "sentence_id": "DDI-DrugBank.d40.s10", "pair_id": "DDI-DrugBank.d40.s10.p188"}
{"sentence": "Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.", "drug1": "Cerubidine", "drug2": "doxorubicin", "relation": "ADVISE", "source_file": "Daunorubicin_ddi.xml", "sentence_id": "DDI-DrugBank.d69.s1", "pair_id": "DDI-DrugBank.d69.s1.p0"}
{"sentence": "After multiple dosing, interferon beta-1a (AVONEX  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.", "drug1": "AVONEX", "drug2": "TYSABRI", "relation": "MECHANISM", "source_file": "Natalizumab_ddi.xml", "sentence_id": "DDI-DrugBank.d232.s0", "pair_id": "DDI-DrugBank.d232.s0.p2"}
{"sentence": "The use of codeine may result in additive CNS depressant effects when coadministered with alcohol, antihistamines, psychotropics or other drugs that produce CNS depression.", "drug1": "codeine", "drug2": "psychotropics", "relation": "EFFECT", "source_file": "Guaifenesin_ddi.xml", "sentence_id": "DDI-DrugBank.d398.s0", "pair_id": "DDI-DrugBank.d398.s0.p2"}
{"sentence": "Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.", "drug1": "valdecoxib", "drug2": "glyburide", "relation": "NONE", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s32", "pair_id": "DDI-DrugBank.d328.s32.p1"}
{"sentence": "In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.", "drug1": "selegiline hydrochloride", "drug2": "paroxetine", "relation": "EFFECT", "source_file": "Dexfenfluramine_ddi.xml", "sentence_id": "DDI-DrugBank.d423.s0", "pair_id": "DDI-DrugBank.d423.s0.p18"}
{"sentence": "THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.", "drug1": "HYDROXYZINE", "drug2": "CENTRAL NERVOUS SYSTEM DEPRESSANTS", "relation": "EFFECT", "source_file": "Hydroxyzine_ddi.xml", "sentence_id": "DDI-DrugBank.d308.s0", "pair_id": "DDI-DrugBank.d308.s0.p0"}
{"sentence": "Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.", "drug1": "aspirin", "drug2": "nicotinic acid", "relation": "MECHANISM", "source_file": "Niacin_ddi.xml", "sentence_id": "DDI-DrugBank.d542.s1", "pair_id": "DDI-DrugBank.d542.s1.p2"}
{"sentence": "Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.", "drug1": "glutethimide", "drug2": "haloperidol", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s29", "pair_id": "DDI-DrugBank.d64.s29.p222"}
{"sentence": "Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.", "drug1": "NSAIDs", "drug2": "furosemide", "relation": "INT", "source_file": "Celecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d172.s7", "pair_id": "DDI-DrugBank.d172.s7.p3"}
{"sentence": "It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.", "drug1": "dopamine HCl", "drug2": "phenytoin", "relation": "ADVISE", "source_file": "Dopamine_ddi.xml", "sentence_id": "DDI-DrugBank.d325.s14", "pair_id": "DDI-DrugBank.d325.s14.p0"}
{"sentence": "Caution should be observed when anileridine is coadministered with other opioids, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.", "drug1": "anileridine", "drug2": "opioids", "relation": "ADVISE", "source_file": "Anileridine_ddi.xml", "sentence_id": "DDI-DrugBank.d215.s0", "pair_id": "DDI-DrugBank.d215.s0.p0"}
{"sentence": "Coadministration of Itraconazole and cyclosporine, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.", "drug1": "Itraconazole", "drug2": "tacrolimus", "relation": "MECHANISM", "source_file": "Itraconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d165.s15", "pair_id": "DDI-DrugBank.d165.s15.p1"}
{"sentence": "Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.", "drug1": "escitalopram", "drug2": "citalopram", "relation": "ADVISE", "source_file": "Escitalopram_ddi.xml", "sentence_id": "DDI-DrugBank.d568.s39", "pair_id": "DDI-DrugBank.d568.s39.p7"}
{"sentence": "It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.", "drug1": "rifabutin", "drug2": "VIRACEPT", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s31", "pair_id": "DDI-DrugBank.d340.s31.p0"}
{"sentence": "Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease gefitinib metabolism and increase gefitinib plasma concentrations.", "drug1": "itraconazole", "drug2": "gefitinib", "relation": "MECHANISM", "source_file": "Gefitinib_ddi.xml", "sentence_id": "DDI-DrugBank.d207.s4", "pair_id": "DDI-DrugBank.d207.s4.p4"}
{"sentence": "Labetalol HCl blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effect.", "drug1": "Labetalol HCl", "drug2": "nitroglycerin", "relation": "EFFECT", "source_file": "Labetalol_ddi.xml", "sentence_id": "DDI-DrugBank.d412.s9", "pair_id": "DDI-DrugBank.d412.s9.p0"}
{"sentence": "Because severe hypoglycemia has been reported in patients concomitantly receiving oral miconazole (an imidazole) and oral hypoglycemic agents, such a potential interaction involving the latter agents when used concomitantly with ketoconazole tablets (an imidazole) can not be ruled out.", "drug1": "miconazole", "drug2": "hypoglycemic agents", "relation": "EFFECT", "source_file": "Ketoconazole_ddi.xml", "sentence_id": "DDI-DrugBank.d458.s21", "pair_id": "DDI-DrugBank.d458.s21.p1"}
{"sentence": "Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.", "drug1": "Cimetidine", "drug2": "Clozapine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s17", "pair_id": "DDI-DrugBank.d480.s17.p2"}
{"sentence": "Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.", "drug1": "Cimetidine", "drug2": "TIKOSYN", "relation": "MECHANISM", "source_file": "Dofetilide_ddi.xml", "sentence_id": "DDI-DrugBank.d558.s2", "pair_id": "DDI-DrugBank.d558.s2.p0"}
{"sentence": "When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.", "drug1": "azithromycin", "drug2": "didanosine", "relation": "MECHANISM", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s7", "pair_id": "DDI-DrugBank.d53.s7.p3"}
{"sentence": "Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.", "drug1": "alosetron", "drug2": "quinolone antibiotics", "relation": "ADVISE", "source_file": "Alosetron_ddi.xml", "sentence_id": "DDI-DrugBank.d364.s5", "pair_id": "DDI-DrugBank.d364.s5.p0"}
{"sentence": "While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).", "drug1": "bupropion", "drug2": "phenytoin", "relation": "MECHANISM", "source_file": "Bupropion_ddi.xml", "sentence_id": "DDI-DrugBank.d5.s8", "pair_id": "DDI-DrugBank.d5.s8.p2"}
{"sentence": "Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.", "drug1": "erythromycin", "drug2": "Clozapine", "relation": "MECHANISM", "source_file": "Clozapine_ddi.xml", "sentence_id": "DDI-DrugBank.d480.s17", "pair_id": "DDI-DrugBank.d480.s17.p5"}
{"sentence": "Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.\r\n", "drug1": "coumaphos", "drug2": "trichlorfon", "relation": "NONE", "source_file": "46730.xml", "sentence_id": "DDI-MedLine.d5.s0", "pair_id": "DDI-MedLine.d5.s0.p2"}
{"sentence": "The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.", "drug1": "trihexyphenidyl", "drug2": "tricyclic antidepressant", "relation": "EFFECT", "source_file": "Chlorpromazine_ddi.xml", "sentence_id": "DDI-DrugBank.d86.s0", "pair_id": "DDI-DrugBank.d86.s0.p12"}
{"sentence": "Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.", "drug1": "nitric oxide donor compounds", "drug2": "INOmax", "relation": "EFFECT", "source_file": "Nitric Oxide_ddi.xml", "sentence_id": "DDI-DrugBank.d183.s2", "pair_id": "DDI-DrugBank.d183.s2.p2"}
{"sentence": "The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.", "drug1": "succinylcholine", "drug2": "BREVIBLOC", "relation": "EFFECT", "source_file": "Esmolol_ddi.xml", "sentence_id": "DDI-DrugBank.d422.s9", "pair_id": "DDI-DrugBank.d422.s9.p0"}
{"sentence": "Antacid: The effect of an aluminum hydroxide- and magnesium hydroxide-containing antacid (Maalox)* on the pharmacokinetics of capecitabine was investigated in 12 cancer patients.", "drug1": "aluminum hydroxide", "drug2": "antacid", "relation": "NONE", "source_file": "Capecitabine_ddi.xml", "sentence_id": "DDI-DrugBank.d88.s0", "pair_id": "DDI-DrugBank.d88.s0.p6"}
{"sentence": "In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.", "drug1": "steroid", "drug2": "steroid", "relation": "NONE", "source_file": "Fenoprofen_ddi.xml", "sentence_id": "DDI-DrugBank.d154.s11", "pair_id": "DDI-DrugBank.d154.s11.p3"}
{"sentence": "Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.", "drug1": "TRACRIUM", "drug2": "halothane", "relation": "EFFECT", "source_file": "Atracurium_ddi.xml", "sentence_id": "DDI-DrugBank.d469.s7", "pair_id": "DDI-DrugBank.d469.s7.p2"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "rifampin", "drug2": "vitamin C", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p983"}
{"sentence": "The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.", "drug1": "Robinul", "drug2": "tricyclic antidepressants", "relation": "EFFECT", "source_file": "Glycopyrrolate_ddi.xml", "sentence_id": "DDI-DrugBank.d510.s0", "pair_id": "DDI-DrugBank.d510.s0.p3"}
{"sentence": "A daily dose of 2 mg of coumaphos/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of bishydroxy-coumarin in wethers. ", "drug1": "coumaphos", "drug2": "bishydroxy-coumarin", "relation": "NONE", "source_file": "46730.xml", "sentence_id": "DDI-MedLine.d5.s2", "pair_id": "DDI-MedLine.d5.s2.p0"}
{"sentence": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "drug1": "Tylenol", "drug2": "Atromid-S", "relation": "NONE", "source_file": "Etonogestrel_ddi.xml", "sentence_id": "DDI-DrugBank.d484.s0", "pair_id": "DDI-DrugBank.d484.s0.p104"}
{"sentence": "Beta-adrenergic receptor antagonists (beta-blockers) and BROVANA may interfere with the effect of each other when administered concurrently.", "drug1": "beta-blockers", "drug2": "BROVANA", "relation": "EFFECT", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s12", "pair_id": "DDI-DrugBank.d284.s12.p2"}
{"sentence": "For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters", "drug1": "anticoagulant", "drug2": "Bezalip", "relation": "ADVISE", "source_file": "Bezafibrate_ddi.xml", "sentence_id": "DDI-DrugBank.d291.s1", "pair_id": "DDI-DrugBank.d291.s1.p1"}
{"sentence": "The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.", "drug1": "sodium nitroprusside", "drug2": "anesthetics", "relation": "EFFECT", "source_file": "Nitroprusside_ddi.xml", "sentence_id": "DDI-DrugBank.d394.s0", "pair_id": "DDI-DrugBank.d394.s0.p2"}
{"sentence": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.", "drug1": "ACE inhibitors", "drug2": "lithium", "relation": "EFFECT", "source_file": "Fosinopril_ddi.xml", "sentence_id": "DDI-DrugBank.d176.s6", "pair_id": "DDI-DrugBank.d176.s6.p9"}
{"sentence": "Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.", "drug1": "sodium citrate", "drug2": "Coly-Mycin M", "relation": "EFFECT", "source_file": "Colistimethate_ddi.xml", "sentence_id": "DDI-DrugBank.d250.s2", "pair_id": "DDI-DrugBank.d250.s2.p20"}
{"sentence": "Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.", "drug1": "azithromycin", "drug2": "nelfinavir", "relation": "ADVISE", "source_file": "Azithromycin_ddi.xml", "sentence_id": "DDI-DrugBank.d53.s2", "pair_id": "DDI-DrugBank.d53.s2.p0"}
{"sentence": "Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.", "drug1": "Probenecid", "drug2": "ciprofloxacin", "relation": "NONE", "source_file": "Ciprofloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d123.s15", "pair_id": "DDI-DrugBank.d123.s15.p1"}
{"sentence": "Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.", "drug1": "VISTIDE", "drug2": "foscarnet", "relation": "ADVISE", "source_file": "Cidofovir_ddi.xml", "sentence_id": "DDI-DrugBank.d260.s3", "pair_id": "DDI-DrugBank.d260.s3.p5"}
{"sentence": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "drug1": "diflunisal", "drug2": "disulfiram", "relation": "NONE", "source_file": "Anisindione_ddi.xml", "sentence_id": "DDI-DrugBank.d64.s87", "pair_id": "DDI-DrugBank.d64.s87.p782"}
{"sentence": "When paroxetine, a potent inhibitor of CYP2D6, was co-administered with BROVANA at steady-state, exposure to either drug was not altered.", "drug1": "paroxetine", "drug2": "BROVANA", "relation": "NONE", "source_file": "Arformoterol_ddi.xml", "sentence_id": "DDI-DrugBank.d284.s1", "pair_id": "DDI-DrugBank.d284.s1.p0"}
{"sentence": "VIRACEPT and rifampin should not be coadministered.", "drug1": "VIRACEPT", "drug2": "rifampin", "relation": "ADVISE", "source_file": "Nelfinavir_ddi.xml", "sentence_id": "DDI-DrugBank.d340.s33", "pair_id": "DDI-DrugBank.d340.s33.p0"}
{"sentence": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.", "drug1": "midazolam", "drug2": "fluvoxamine", "relation": "MECHANISM", "source_file": "Fluvoxamine_ddi.xml", "sentence_id": "DDI-DrugBank.d76.s12", "pair_id": "DDI-DrugBank.d76.s12.p13"}
{"sentence": "Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.", "drug1": "ELLENCE", "drug2": "calcium channel blockers", "relation": "ADVISE", "source_file": "Epirubicin_ddi.xml", "sentence_id": "DDI-DrugBank.d428.s1", "pair_id": "DDI-DrugBank.d428.s1.p0"}
{"sentence": "SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.", "drug1": "DISULFIRAM", "drug2": "PHENYTOIN", "relation": "EFFECT", "source_file": "Disulfiram_ddi.xml", "sentence_id": "DDI-DrugBank.d19.s2", "pair_id": "DDI-DrugBank.d19.s2.p3"}
{"sentence": "Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.", "drug1": "Valdecoxib", "drug2": "R-warfarin", "relation": "MECHANISM", "source_file": "Valdecoxib_ddi.xml", "sentence_id": "DDI-DrugBank.d328.s24", "pair_id": "DDI-DrugBank.d328.s24.p0"}
{"sentence": "Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.", "drug1": "quinolones", "drug2": "theobromine", "relation": "MECHANISM", "source_file": "Grepafloxacin_ddi.xml", "sentence_id": "DDI-DrugBank.d78.s3", "pair_id": "DDI-DrugBank.d78.s3.p13"}
{"sentence": "Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.", "drug1": "L-glutamine", "drug2": "paclitaxel", "relation": "EFFECT", "source_file": "L-Glutamine_ddi.xml", "sentence_id": "DDI-DrugBank.d66.s7", "pair_id": "DDI-DrugBank.d66.s7.p3"}
{"sentence": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "drug1": "antithyroid drugs", "drug2": "insulin", "relation": "NONE", "source_file": "Levothyroxine_ddi.xml", "sentence_id": "DDI-DrugBank.d411.s4", "pair_id": "DDI-DrugBank.d411.s4.p219"}